Unit_Id,Is_Unit_Ambiguous,Is_Unit_State_Finalized,Trusted_Judgements,Last_Judgement_Date,Judgement_Remarks,Patient_Relation_Type,Percent_Patient_Relation_Type,Chemical_Id,Chemical_Name,Disease_Id,Disease_Name,Form_Sentence,Sentence_Id,Relation_Pair_Id,Patient_Relation_Type_Verification,Patient_Relation_Type_Verification_Reason
770955372,true,false,9,,,Direct,0.4463,D012701,5-HT,D011605,psychotic disorders,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,20705401_D012701_D011605,No Relation,"The receptors to 5-HT6 are related to psychotic disorders, not 5-HT itself."
770955373,true,false,11,,,No Relation,0.9181,D010396,D-penicillamine,D012594,localized scleroderma,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,2334179_D010396_D012594,No Relation,D-penicillamine was used to treat the patients.
770955374,true,false,12,,,No Relation,1,D015016,yohimbine,D019964,affective disorders,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.",1535072_4,1535072_D015016_D019964,No Relation,"The sentence says the affective disorders were caused by ""serotonin reuptake blockers"". Yohimbine was used to try and treat the patients."
770955375,true,false,11,,,No Relation,1,D002118,calcium,D013035,muscle spasms,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,8492347_D002118_D013035,No Relation,The sentence says calcium supplementation cannot be used to treat muscle spasms and tetany.
770955376,true,false,9,,,No Relation,0.8905,D064730,dexrazoxane,D006402,hematologic toxicity,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,15897593_D064730_D006402,No Relation,Dexrazoxane is being used to try and make the patients better without making hematologic toxicity worse. The sentence does not say that dexrazoxane causes hematologic toxicity.
770955377,true,false,15,,,No Relation,1,D003404,creatinine,D006973,hypertension,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_7,10539815_D003404_D006973,No Relation,Creatinine and hypertension were studied as potential predictors of decreased renal (kidney) function.
770955378,true,false,14,,,No Relation,1,C071741,remifentanil,D010146,pain,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,18006530_C071741_D010146,No Relation,Remifentanil reduces the pain caused by propofol.
770955379,true,false,11,,,Direct,0.828,C012052,amisulpride,D006973,hypertensive,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,15811908_C012052_D006973,Direct,This sentence talks about the first case of amisulpride induced hypertensive crisis.
770955380,true,false,10,,,Direct,0.6143,D002211,capsaicin,D010146,painful,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,9514561_D002211_D010146,Direct,"Capsaicin (the chemical that makes chilis spicy), when put under your skin, causes pain."
770955381,true,false,16,,,No Relation,1,D003630,daunorubicin,D000163,AIDS,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,8305357_D003630_D000163,No Relation,Daunorubicin is being studied as a way to treat AIDS related Kaposi's sarcoma.
770955382,true,false,10,,,No Relation,1,D000241,adenosine,D059787|D059350,acute and chronic pain,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,11752998_D000241_D059787|D059350,No Relation,Adenosine might be able to treat acute and chronic pain.
770955383,true,false,9,,,Direct,0.8953,D010830,eserine,D015878,mydriasis,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D010830_D015878,Direct,Eserine and carbachol cause mydriasis.
770955384,true,false,12,,,No Relation,1,C084178,telmisartan,D006973,hypertension,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,18201582_C084178_D006973,No Relation,Telmisartan is being used in patients with stage II hypertension. It seems it is being tested as a treatment.
770955385,true,false,10,,,Direct,0.6858,D004329,droperidol,D004342,drug allergies,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,8599504_D004329_D004342,No Relation,"Droperidol causes angioedema and tongue swelling, but the patient had no prior drug allergies."
770955386,true,false,11,,,Direct,0.63,D006493,heparin,D006470,hemorrhage,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,6615052_D006493_D006470,Direct,"The sentence does not follow the ""[chemical]-induced [other disease] causes [highlighted disease]"" structure, so  heparin-induced [other disease] causes hemorrhage is wrong. Patients developed hemorrhage after receiving heparin, so the correct choice is ""heparin directly contributes to or causes hemorrhage."""
770955387,true,false,14,,,Direct,1,D014700,Verapamil,D001281,AF,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,11282081_D014700_D001281,Direct,
770955388,true,false,20,,,Direct,1,D004298,dopamine,D002389,catatonia,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,6540303_D004298_D002389,Direct,"Dopamine made the duration of catatonia longer, which means dopamine made catatonia worse."
770955389,true,false,11,,,Direct,0.7389,D000082,acetaminophen,D064420,toxicity,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,9067481_D000082_D064420,Direct,"Five chemicals, including acetaminophen, induced (caused) toxicity."
770955390,true,false,8,,,Direct,1,D016861,cyclooxygenase inhibitors,D020521,stroke,"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_1,16586083_D016861_D020521,Direct,Cyclooxygenase inhibitors cause four diseases including stroke.
770955391,true,false,14,,,No Relation,0.9297,D000109,acetylcholine,D023921,coronary artery stenosis,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,11078231_D000109_D023921,No Relation,No fixed coronary artery stenosis was observed in patients who were injected with acetylcholine.
770955392,true,false,10,,,Direct,0.6957,D014147,tramadol,D006212,hallucinations,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,8766220_D014147_D006212,Direct,The hallucinations only went away after psycho-active drugs and tramadol were taken away.
770955393,true,false,14,,,Direct,1,D000638,Amiodarone,D011014,pneumonitis,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,1595783_D000638_D011014,Direct,Pneumonitis is a side effect of amiodarone.
770955394,true,false,14,,,No Relation,1,D017374,paroxetine,D059350,chronic pain,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,8766220_D017374_D059350,No Relation,"A patient with chronic pain was given paroxetine, but the sentence does not say paroxetine caused the pain."
770955395,true,false,5,,,Direct,1,D002945,cisplatin,D058186,acute renal injury,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg).,20510337_1,20510337_D002945_D058186,Direct,Acute renal injury was induced by cisplatin injection.
770955396,true,false,14,,,Direct,1,D010878,piperacillin,D006311,Ototoxicity,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,3535719_D010878_D006311,Direct,Some of the patients receiving piperacillin developed ototoxicity.
770955397,true,false,12,,,No Relation,0.8426,D010665,PPA,D006973,hypertensive,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,6695415_D010665_D006973,No Relation,"The ""previously"" implies that the animals already had hypertension before they were given PPA."
770955398,true,false,13,,,No Relation,0.5225,D000666,amphotericin B,D007008,hypokalemia,Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?,11868798_0,11868798_D000666_D007008,Direct,
770955399,true,false,10,,'was assessed' could mean that they reached the conclution either way.,No Relation,0.7009,C034753,benzylacyclouridine/BAU,D007970,leukopenia,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,2257294_C034753_D007970,No Relation,"Leukopenia was caused by ""AZT""."
770955400,true,false,9,,,Direct,0.7841,D002083,BHA,D010212,squamous cell papilloma,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,3131282_D002083_D010212,Direct,"Giving BHA together with RA caused squamous cell papillomas. Remember if a chemical only works in combination with other chemicals, then the correct choice is that the chemical can cause the disease."
770955401,true,false,11,,,No Relation,0.911,D013835,TPP,D014899,Wernicke's encephalopathy,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,3762968_D013835_D014899,No Relation,
770955402,true,false,10,,,No Relation,0.5825,D004110,diltiazem,D062787,overdose,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,12101159_D004110_D062787,Direct,You can overdose on the drug diltiazem.
770955403,true,false,14,,,Direct,1,D012110,Reserpine,D014202,tremor,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,11999899_D012110_D014202,Direct,
770955404,true,false,9,,,No Relation,0.785,C018370,PREGS,D000647,amnesia,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,11860495_C018370_D000647,No Relation,The amnesia was caused by scopolamine.
770955405,true,false,14,,,No Relation,1,D001590,benztropine,D010302,parkinsonism,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,33969_D001590_D010302,No Relation,Benztropine is being studied as a treatment for parkinsonism.
770955406,true,false,9,,,No Relation,0.8881,D015119,epsilon-aminocaproic acid,D012851,cerebral sinus thrombosis,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,2339463_D015119_D012851,No Relation,"The sentence says no known cases of epsilon-aminocaproic acid causing cerebral sinus thrombosis existed before. Although we might want to say that this sentence is reporting the first case, the relation between epsilon-aminocaproic acid and cerebral sinus thrombosis is not explicit here."
770955407,true,false,12,,,No Relation,1,D010878,piperacillin sodium,D007239,infections,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,3535719_D010878_D007239,No Relation,The text seems to say that piperacillin sodium was being tested as a treatment.
770955408,true,false,13,,,Direct,0.8612,D004317,ADR/adriamycin,D002318,cardiovascular toxicity,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,9952311_D004317_D002318,Direct,
770955409,true,false,10,,,Direct,0.6912,D013467,sulindac,D007681,renal papillary necrosis/RPN,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,6699841_D013467_D007681,No Relation,"The patient developed renal papillary necrosis only after starting naproxen therapy. The sentence says the man was ""previously treated with sulindac"", which implies that sulindac was not taken at the same time as naproxen."
770955410,true,false,4,,,Direct,0.7687,D010862,pilocarpine,D012640,seizures,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,9121607_D010862_D012640,Direct,
770955411,true,false,16,,,No Relation,0.9386,D000082,paracetamol,D006525,viral hepatitis,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,7007443_D000082_D006525,No Relation,Paracetamol overdose causes fulminant hepatic (liver) failure. The text does not say what caused the viral hepatitis.
770955412,true,false,9,,,No Relation,0.5319,D016202,NMDA/N-methyl-D-aspartate,D012559,schizophrenia,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,20727411_D016202_D012559,No Relation,"The NMDA receptor is involved in schizophrenia, not the chemical NMDA."
770955413,true,false,14,,,No Relation,0.935,D010396,D-penicillamine,D008105,primary biliary cirrhosis,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,8268147_D010396_D008105,No Relation,D-penicillamine seems to have been used to treat primary biliary cirrhosis.
770955414,true,false,23,,,Direct,0.8279,D011692,puromycin aminonucleoside/PAN,D058186,Acute experimental models of renal damage,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,3653576_D011692_D058186,Direct,Three chemicals all produced acute experimental models of renal damage.
770955415,true,false,18,,,Direct,0.9467,D013619,Tacrine,D012640,seizures,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_3,19944736_D013619_D012640,Direct,
770955416,true,false,4,,,No Relation,0.768,D020123,sirolimus,D011565,psoriasis,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,10328196_D020123_D011565,No Relation,"Sirolimus made T cells undergo apoptosis (cell death) faster, but sirolimus is not stated to have caused psoriasis."
770955417,true,false,12,,,No Relation,1,C107135,everolimus,D009190,MDS/myelodysplastic syndrome,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,19135948_C107135_D009190,No Relation,"Everolimus was used in patients with myelodysplastic syndrome, but the text does not say everolimus caused MDS."
770955418,true,false,3,,,Direct,1,D013390,succinylcholine,D063806,myalgia,"In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.",12760988_9,12760988_D013390_D063806,Direct,"The sentence says that there is no evidence for an ""inflammatory origin"" of myalgia caused by succinylcholine. This does not mean that succinylcholine cannot cause myalgia."
770955419,true,false,7,,,No Relation,0.7214,D000809,angiotensin,D009404,NS/nephrotic syndrome,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,9154656_D000809_D009404,No Relation,The renin-angiotensin system protein levels were different in rats with nephrotic syndrome.
770955420,true,false,8,,,No Relation,1,C024224,naloxazone,D007035,hypothermia,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,6308526_C024224_D007035,No Relation,Naloxazone made hypothermia better.
770955421,true,false,9,,,No Relation,0.7725,C005618,benzoylecgonine,D003693,EDDs,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,8988571_C005618_D003693,No Relation,
770955422,true,false,7,,,No Relation,1,D008625,Tiopronin,D001172,RA,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_3,3084782_D008625_D001172,No Relation,
770955423,true,false,15,,,No Relation,0.804,D008094,lithium,D014262,tricuspid regurgitation,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,6794356_D008094_D014262,No Relation,"Although the newborn had both tricuspid regurgitation and high blood lithium levels, the sentence does not say that the lithium is what caused the tricuspid regurgitation."
770955424,true,false,12,,,Direct,1,C020976,azelastine,D013651,altered taste perception,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,3057041_C020976_D013651,Direct,Azelastine caused drowsiness and altered taste perception whereas the placebo (no chemical given) did not.
770955425,true,false,10,,,Direct,0.8018,D011433,propranolol,D011928,Raynaud's phenomenon,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_5,6115999_D011433_D011928,Direct,Raynaud's phenomenon is given as an example of an adverse reaction linked with drugs (in this case propranolol).
770955426,true,false,14,,,Direct,0.722,D004837,adrenaline,D001919,bradycardia,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,2894433_D004837_D001919,Direct,
770955427,true,false,11,,,No Relation,0.5457,D000431,alcohol,D000437,alcohol abuse,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_6,11573852_D000431_D000437,No Relation,Alcohol is mentioned as something that might cause seizures. The sentence does not say that alcohol causes alcohol abuse!
770955428,true,false,16,,,Direct,0.9383,C047426,venlafaxine,D020230,Serotonin syndrome,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,8888541_C047426_D020230,Direct,
770955429,true,false,16,,,No Relation,1,D013438,thiol,D008175,lung cancer,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,6402369_D013438_D008175,No Relation,"The subject of the sentence is sodium 2-mercaptoethane sulphonate, not thiol."
770955430,true,false,14,,,No Relation,0.6576,D006493,heparin,D013923,thromboembolism,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,11827497_D006493_D013923,No Relation,The sentence lists some things that were measured.
770955431,true,false,10,,,No Relation,0.8034,D007980,L-dihydroxyphenylalanine,D020258,neurotoxicity,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,20533999_D007980_D020258,No Relation,"Neurotoxicity was induced by ""METH""."
770955432,true,false,13,,,Direct,1,D017963,azithromycin,D006606,hiccups,Possible azithromycin-associated hiccups.,15985056_0,15985056_D017963_D006606,Direct,"The sentence suggests that azithromycin likely causes hiccups through the use of ""possible""."
770955433,true,false,12,,,No Relation,0.8347,D015632,MPTP,D010300,Parkinson's disease,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,20973483_D015632_D010300,No Relation,
770955434,true,false,17,,,No Relation,0.7156,D016642,bupropion,D012892,sleep deprivation,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,12745515_D016642_D012892,No Relation,"The sentence says bupropion causes seizure and sleep deprivation causes seizure, but does not say bupropion causes sleep deprivation."
770955435,true,false,7,,,Direct,0.8519,D011034,epipodophyllotoxin,D066126,cardiac toxicity,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,15897593_D011034_D066126,No Relation,"The chemical ""etoposide"" is a kind of ""epipodophyllotoxin"". The sentence says that etoposide causes cardiac toxicity, but the sentence does not say all epipodophyllotoxins cause cardiac toxicity!"
770955436,true,false,9,,,Direct,1,D002110,caffeine,D001145,ventricular arrhythmias,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,18997632_D002110_D001145,Direct,Serious ventricular arrhythmias can result from taking caffeine.
770955437,true,false,10,,,Direct,0.8918,D008790,metoprolol,D006327,heart block,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_1,7785794_D008790_D006327,Direct,The woman developed a heart block after taking two chemicals together (verapamil and metoprolol).
770955438,true,false,9,,,Direct,1,D004317,doxorubicin,D006333,cardiac failure,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_7,3137399_D004317_D006333,Direct,
770955439,true,false,10,,,No Relation,0.902,D018818,fenoldopam,D009369,tumor,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,12180796_D018818_D009369,No Relation,"Some rats which had been given fenoldopam were examined for a kind of protein (""tumor growth factor-beta1""). Here the word ""tumor"" is not being used to refer to the disease, but is rather part of the name of a protein (""tumor growth factor-beta1"")."
770955440,true,false,12,,,Direct,0.5113,D005047,etoposide,D066126,cardiac toxicity,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,15897593_D005047_D066126,Direct,
770955441,true,false,13,,,Direct,0.9282,D008874,midazolam,D006606,hiccups,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,15985056_D008874_D006606,Direct,"""Benzodiazepines"" are a category of chemicals. Midazolam is mentioned as a specific example of a ""benzodiazepine"" that is known to cause hiccups."
770955442,true,false,9,,,Direct,1,D008775,methylprednisolone,D006323,asystole,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,10074612_D008775_D006323,Direct,Methylprednisolone caused three different diseases in this patient.
770955443,true,false,11,,,No Relation,0.8172,D005045,etomidate,D009207,myoclonus,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,16563323_D005045_D009207,Direct,Remifentanil makes myoclonus caused by etomidate better.
770955444,true,false,13,,,Direct,1,C045645,CLZ,D006261,headache,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,7596955_C045645_D006261,Direct,Eating CLZ caused headaches in 7 of 12 patients.
770955445,true,false,8,,,Direct,1,C037663,ropivacaine,D012640,seizures,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,11524350_C037663_D012640,Direct,
770955446,true,false,13,,,No Relation,1,D013739,testosterone,D006966,hyperprolactinemia,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,20331935_D013739_D006966,No Relation,
770955447,true,false,15,,,No Relation,0.9384,D002794,choline,D000544,AD/Alzheimer's disease,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,16428827_D002794_D000544,No Relation,"The ""choline acetyltransferase activator"" (a protein) and not ""choline"" itself is important to treating Alzheimer's disease."
770955448,true,false,2,,,Direct,1,D004967,oestrogen,D005705,gallbladder disease,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,19370593_D004967_D005705,Direct,Oestrogen increased the risk of gallbladder disease.
770955449,true,false,6,,,Direct,0.8284,D002738,chloroquine,D015354,deterioration of vision,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,1628552_D002738_D015354,Direct,
770955450,true,false,12,,,No Relation,1,D013629,tamoxifen,D001943,breast cancer,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_15,9672273_D013629_D001943,No Relation,Tamoxifen's protective (beneficial) effects on breast cancer are not yet clear according to this sentence.
770955451,true,false,21,,,No Relation,1,D011188,potassium,D007008,hypokalemia,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,6942642_D011188_D007008,No Relation,"Hypokalemia is caused by ""thiazide diuretics""."
770955452,false,false,1,,,Direct,1,D010830,eserine,D015878,mydriasis,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D010830_D015878,No Relation,
770955453,true,false,13,,,No Relation,1,D012293,rifampin,D014376,tuberculosis,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,804391_D012293_D014376,No Relation,"Rifampin was given to patients with tuberculosis, but the sentence does not say rifampin caused their tuberculosis."
770955454,true,false,9,,,No Relation,1,D006024,glycopyrronium,D001919,bradycardias,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,2917114_D006024_D001919,No Relation,Glycopyrronium had a beneficial effect on bradycardias.
770955455,true,false,16,,,No Relation,1,D002998,clonazepam,D009207,myoclonic jerks,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,6118280_D002998_D009207,No Relation,Clonazepam blocked myoclonic jerks.
770955456,true,false,11,,,Direct,0.554,D004317,doxorubicin,D009202,cardiomyopathy,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,7282516_D004317_D009202,Direct,"The ""dose-effect"" and ""structure-function relationships"" refer to that between doxorubicin and cardiomyopathy. Therefore we can conclude that different doses of doxorubicin have different effects on cardiomyopathy, and that therefore doxorubicin causes cardiomyopathy."
770955457,true,false,11,,,Direct,0.8184,D003024,clozapine,D013981,tic-like symptoms,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,16225977_D003024_D013981,Direct,Two reports showed that tic-like symptoms arose during clozapine treatment.
770955458,true,false,9,,,No Relation,1,C059896,SC-48334,D007153,immunodeficiency,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_5,7905523_C059896_D007153,No Relation,"SC-48334 concentration was not high enough to inhibit ""human immunodeficiency virus"". Immunodeficiency is not discussed as a disease here. It is part of ""human immunodeficiency virus""."
770955459,true,false,8,,,Direct,0.8908,D010389,pemoline,D062787,overdose,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,9022662_D010389_D062787,Direct,
770955460,true,false,10,,,Direct,1,C033457,Quinidine phenylethylbarbiturate,D056486,hepatitis,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. A case report.,3411101_0,3411101_C033457_D056486,Direct,Induced means caused.
770955461,true,false,5,,,No Relation,0.8179,D000255,ATP,D009765,obese,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,18674790_D000255_D009765,No Relation,
770955462,true,false,9,,,Direct,0.897,D017374,paroxetine,D009459,neuroleptic malignant syndrome,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,16720068_D017374_D009459,Direct,The sentence says that treatment with paroxetine and alprazolam possibly causes neuroleptic malignant syndrome.
770955463,true,false,7,,,No Relation,0.7103,D003520,Cyclophosphamide,D059265,visceral pain,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,10840460_D003520_D059265,No Relation,
770955464,true,false,11,,,No Relation,0.8362,D005680,gamma-aminobutyric acid/GABA,D007022,hypotension,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,9915601_D005680_D007022,No Relation,"Hypotension is caused by ""vasodilators"" (chemicals that make blood vessels wider) and made worse by the chemical ""isoniazid""."
770955465,true,false,12,,,Direct,0.7582,D000319,beta-adrenergic blocking drugs,D001919,bradycardia,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D000319_D001919,Direct,
770955466,true,false,10,,,No Relation,1,D010068,oxacillin,D013203|D016470,Staphylococcus aureus bacteremia,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,11337188_D010068_D013203|D016470,No Relation,Oxacillin was used to treat staphylococcus aureus bacteremia.
770955467,true,false,13,,"Gold thiosulphate though, not just gold... but right still",Direct,0.6089,D006046,gold,D003872,dermatitis,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_2,3084782_D006046_D003872,No Relation,"""Gold"" is part of ""gold thiosulphate"", which is a very different chemical than ""gold""! Dermatitis is caused by ""gold thiosulphate"", not ""gold""."
770955468,true,false,12,,,No Relation,0.7384,D008094,Li,D001480,EPS,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,17042884_D008094_D001480,No Relation,The EPS related events are no different when chemical QTP is given and when PBO is given. The sentence does not contain enough information to say that lithium (Li) causes EPS related adverse events.
770955469,true,false,8,,,Direct,0.8714,D012110,reserpine,D014202,tremor,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,11999899_D012110_D014202,Direct,Giving reserpine 24 hours prior caused tremor.
770955470,true,false,12,,,No Relation,1,D014810,Vitamin E,D009203,MI,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_5,16584858_D014810_D009203,No Relation,Vitamin E levels were changed in MI rats.
770955471,true,false,9,,,No Relation,1,D005839,gentamicin,D009956,tubular necrosis,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,2709684_D005839_D009956,No Relation,"The ""tubular necrosis score"" was a measurement used to quantify whether ""P"" prevented ""gentamicin-ARF"". The text never says ""gentamicin"" is related to ""tubular necrosis""."
770955473,true,false,8,,,Direct,0.7612,D043343,TP,D011471,prostate cancer,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,3461217_D043343_D011471,Direct,"TP enhances tumors, especially the development of prostate cancer. Therefore we can conclude that TP can cause prostate cancer."
770955474,true,false,9,,,Direct,0.5827,D010672,phenytoin,D011605,psychosis,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,,14698717_D010672_D011605,Direct,The patient developed psychosis after receiving phenytoin.
770955475,true,false,10,,,No Relation,1,D001379,azathioprine,D009369,cancers,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,,3970039_D001379_D009369,No Relation,Azathioprine had no effect on cancer prevalence in the patients.
770955476,true,false,9,,,No Relation,1,D011433,propranolol,D016584,panic disorders,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",,6387529_D011433_D016584,No Relation,The sentence says that the effects of diazepam and propranolol on patients was investigated. The sentence does not state what the effect was.
770955477,true,false,13,,,Direct,0.4668,D004837,adrenaline,D001281,atrial fibrillation,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",,9698967_D004837_D001281,Direct,Giving mepivacaine and adrenaline together caused the male patient to experience atrial fibrillation.
770955478,true,false,10,,,Direct,0.9,D007654,ketoconazole,D006973,hypertension,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",,2632720_D007654_D006973,Direct,Long-term patient monitoring showed that both patients had hypertension after receiving ketoconazole therapy.
770955479,true,false,11,,,No Relation,0.9065,D002945,cisplatin,D064420,toxicity,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,,8643971_D002945_D064420,No Relation,"The sentence says that the response and toxicity of paclitaxel with cisplatin was studied, but does not say what the result was."
770955480,true,false,13,,,No Relation,1,D012964,na,D012640,Seizure,METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.,,12198388_D012964_D012640,No Relation,"""na"" does not represent a chemical in this context. There seems to be an error with ""alcohol-na ve"" since ""ve"" is not a word."
770955481,true,false,8,,,Direct,0.7679,D014031,tobramycin sulfate,D006311,ototoxicity,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,,7420681_D014031_D006311,Direct,Tobramycin sulfate causes ototoxicity in animals and humans.
770955482,true,false,9,,,No Relation,0.8969,D014700,Verapamil,D006973,hypertensive,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,,3173179_D014700_D006973,No Relation,"Verapamil was used by a woman with hypertension, but the sentence does not say that verapamil causes hypertension."
770955483,true,false,12,,,Direct,0.9164,D002110,caffeine,D014693,ventricular fibrillation,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",,11419773_D002110_D014693,Direct,She developed ventricular fibrillation after consuming the health drink containing caffeine.
770955484,true,false,9,,,Direct,0.5372,D000082,acetaminophen,D007676,ESRD,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",,8669433_D000082_D007676,No Relation,"The sentence says that it is not known whether acetaminophen causes ESRD, but that it is also not impossible. Therefore we do not know whether acetaminophen causes ESRD, and therefore the answer is that ""the sentence does not say that acetaminophen contributes to or causes ESRD""."
770955485,true,false,13,,,Indirect,0.7891,D010862,pilocarpine,D002544,Infarcts in substantia nigra pars reticulata,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,,8410052_D010862_D002544,Indirect,"This sentence follows the structure of ""[chemical]-induced [other disease] causes [highlighted disease]"". Status epilepticus is what is actually causing ""infarcts in substantia nigra pars reticulata""."
770955486,true,false,15,,,No Relation,0.8156,D000628,aminophylline,D012131,respiratory failure,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,,234669_D000628_D012131,No Relation,"The sentence says that the effects were studied, but does not say if there were any effects."
770955487,true,false,14,,,No Relation,1,C027260,4'-0-tetrahydropyranyladriamycin/Pirarubicin,D009369,tumors,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,,2224762_C027260_D009369,No Relation,"The study of Pirarubicin was done in patients with existing tumors, but there is no stated link between Pirarubicin and tumors."
770955488,true,false,15,,,Direct,0.547,C558899,lopinavir/ritonavir,D001919,bradycardia,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",,19820426_C558899_D001919,Direct,The second twin developed bradycardia as a result of lopinavir/ritonavir.
770955489,true,false,10,,,No Relation,0.8957,D011346,prochlorperazine,D017109,akathisia,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",,11679859_D011346_D017109,No Relation,Prochlorperazine has no effect on akathisia.
770955490,true,false,14,,,Direct,0.7179,D005283,Fentanyl,D001919,bradycardia,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",,18544179_D005283_D001919,Direct,Fentanyl increased bradycardia.
770955491,true,false,10,,,No Relation,1,D003042,cocaine,D005921,glomerulonephritis,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",,11391224_D003042_D005921,No Relation,"Cocaine is causing ""acute renal failure"", not glomerulonephritis."
770955492,true,false,4,,,No Relation,1,D015740,CGRP,D008881,migraine,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,,14659530_D015740_D008881,No Relation,"Here ""CGRP"" is part of ""Plasma CGRP concentration"". The migraine seemed to cause the increase in CGRP levels, and not the other way around."
770955493,true,false,13,,,Direct,1,C106791,telithromycin,D056486,toxic hepatitis/hepatitis,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",,17919553_C106791_D056486,Direct,Telithromycin was the likely cause of hepatitis in the patient.
770955494,true,false,8,,,No Relation,0.8783,D001920,bradykinin,D006973,hypertension,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,,8955532_D001920_D006973,No Relation,"Here ""bradykinin"" is part of ""bradykinin B2 receptors"", because the activated receptors are disrupting the blood-brain barrier somehow."
770955495,true,false,10,,,Direct,0.6119,D013390,suxamethonium,D001919,bradycardia,Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,,6466532_D013390_D001919,Direct,"Suxamethonium causes bradycardia, and the sentence says two other chemicals (glycopyrrolate and atropine) are being used to try and prevent the bradycardia."
770955496,true,false,16,,,No Relation,0.8239,C060802,fangchinoline,D013927,thrombosis,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,,10193204_C060802_D013927,No Relation,"The sentence is a fragment, and does not explicitly say that negative effects of fangchinoline exist, rather that the effects were tested."
770955497,true,false,15,,,Direct,0.9457,D004164,bisphosphonate,D058186,acute renal failure,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,,18754075_D004164_D058186,Direct,Patient developed acute renal failure after taking bisphosphonate.
770955498,true,false,9,,,Direct,1,D000082,acetaminophen,D007676,chronic renal failure/ESRD,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",,8669433_D000082_D007676,Direct,Habitual use of acetaminophen causes chronic renal failure.
770955499,true,false,11,,,No Relation,1,D009569,NO,D009437,neuropathic pain,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",,19300402_D009569_D009437,No Relation,"The sentence says small doses of ""NO synthase inhibitors"" (a category of chemicals) removes neuropathic pain."
770955500,true,false,14,,,No Relation,0.9245,D003520,cyclophosphamide,D006973,hypertension,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",,15325671_D003520_D006973,No Relation,"An analysis was done to see if congestive heart failure had anything to do with some pretreatment characteristics, including hypertension. The sentence never says what the conclusions of the analysis were, or whether cyclophosphamide causes hypertension."
770955501,true,false,10,,,No Relation,0.918,C524754,maltolyl p-coumarate,D009410,neuronal death,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",,17600377_C524754_D009410,No Relation,"Maltolyl p-coumarate is treating Alzheimer's disease, and not causing one of the symptoms (""neuronal death"") of Alzheimer's disease."
770955502,true,false,11,,it's 'nicotinic acetylcholine receptors' and not acetylcholine.,Direct,0.5251,D000109,acetylcholine,D014202,tremors,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",,15275829_D000109_D014202,No Relation,"Here ""acetylcholine"" is part of ""nicotinic acetylcholine receptors"". Nicotine binding to these receptors causes tremors, but acetylcholine itself does not."
770955503,true,false,11,,,No Relation,1,D012964,na,D006509,HBV infected/HBV mono-infected,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,,17854040_D012964_D006509,No Relation,"""na"" is not being used as a chemical in this context, because ""ve"" is not a word. There seems to be a missing letter between ""na"" and ""ve""."
770955504,true,false,14,,,Direct,0.8613,D004837,epinephrine/EP,D013927,thrombosis,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",,10193204_D004837_D013927,Direct,"Thrombosis was ""induced by"" (caused by) collagen and epinephrine."
770955505,true,false,14,,,No Relation,0.7929,D006854,hydrocortisone,D009202,myocardial injury,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",,983936_D006854_D009202,No Relation,"Myocardial injury is caused by ""epinephrine"". We do not know what the effect of hydrocortisone on myocardial injury is."
770955506,true,false,11,,,No Relation,0.8137,D002784,cholesterol,D003072,cognitive dysfunctions,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",,16755009_D002784_D003072,No Relation,"The sentence lists some ""beneficial effects"" of DCE, such as ""cholesterol lowering property"". The sentence does not say cholesterol causes cognitive dysfunctions."
770955507,true,false,8,,,No Relation,0.8756,D012964,sodium,D016055,volume retention,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,,18768591_D012964_D016055,No Relation,"The sentence says nephropathy caused by doxorubicin leads to volume retention that is dependent on ""epithelial sodium channels"", a kind of protein. It does not say sodium causes volume retention."
770955508,true,false,16,,,Indirect,0.5817,D002945,cisplatin,D028361,mitochondrial toxicity,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,,18809400_D002945_D028361,Indirect,"This sentence follows the ""[chemical]-induced [other disease] causes [highlighted disease]"" structure. Therefore the correct answer is ""cisplatin-induced [neurotoxicity] causes mitochondrial toxicity""."
770955509,true,false,7,,,No Relation,1,D009020,morphine,D059787,acute pain,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",,18221780_D009020_D059787,No Relation,The effect was enhanced by dextromethorphan in a model of acute pain. The sentence does not say morphine causes acute pain. Fun fact: morphine is actually a very strong painkiller that is similar to opium and heroin.
770955510,true,false,9,,,No Relation,0.7793,D016202,NMDA,D059787,acute pain,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,,18221780_D016202_D059787,No Relation,"""NMDA antagonists"" are interacting with morphine. The study is done in a ""acute pain"" model, but the sentence does not say that NMDA causes acute pain."
770955511,true,false,10,,,Direct,0.9053,D000431,alcohol,D005483,flushing of the face,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",,19657887_D000431_D005483,Direct,Ingesting alcohol causes your face to flush (but you already knew that!).
770955512,true,false,6,,,No Relation,0.8397,D004298,dopamine,D001919,bradycardia,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",,10721819_D004298_D001919,No Relation,"Here ""dopamine"" is part of ""dopamine D2 receptors"", which is a kind of protein."
770955513,true,false,14,,,No Relation,1,D006220,haloperidol,D011595,psychomotor agitation,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",,9812111_D006220_D011595,No Relation,Haloperidol seemed to have a positive effect on psychomotor agitation.
770955514,true,false,12,,,No Relation,0.9264,D005283,fentanyl,D010149,postoperative pain,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",,18544179_D005283_D010149,No Relation,"Fentanyl made postoperative nausea and vomiting worse, but did not improve postoperative pain. The sentence does not say that fentanyl originally caused the postoperative pain!"
770955515,true,false,13,,,Direct,1,D009582,Nitrofurantoins,D000853,anophthalmia,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",,19884587_D009582_D000853,Direct,Nitrofurantoins cause anophthalmia.
770955516,true,false,10,,,No Relation,1,D004177,metamizol,D059350,chronic pain,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",,12063090_D004177_D059350,No Relation,Metamizol is said to be useful for treating chronic pain.
770955517,true,false,11,,,Indirect,0.5533,D007608,kainic acid,D001930,hippocampal injury,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,,12757899_D007608_D001930,Indirect,"This follows the ""[chemical]-induced [other disease] caused [highlighted disease]"" format, so the correct answer is ""kainic acid-induced [status epilepticus] causes hippocampal injury""."
770955518,true,false,12,,,Direct,1,D008775,methylprednisolone,D020250,"nausea, vomiting","CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",,17466854_D008775_D020250,Direct,Methylprednisolone causes nausea and vomiting as a side effect.
770955519,true,false,9,,Only in this patient with hypersensitivity.,Direct,0.789,D002220,carbamazepine,D051437,renal failure,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",,2522601_D002220_D051437,Direct,Carbamazepine caused many diseases in this patient.
770955520,true,false,9,,,Direct,1,D019386,alendronate,D011507,proteinuria,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,,18754075_D019386_D011507,Direct,Patient developed proteinuria after taking alendronate.
770955521,true,false,13,,,Direct,1,D002443,ceftriaxone,D056486,hepatitis,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",,9625142_D002443_D056486,Direct,Induced means caused by.
770955522,true,false,11,,,No Relation,1,D009568,nitrendipine,D006978,renovascular hypertension,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",,1639466_D009568_D006978,No Relation,The sentence gives no conclusion regarding the result of the study.
770955523,true,false,11,,,No Relation,1,C030852,vinorelbine,D002289,nonsmall cell lung carcinoma,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.,,10526274_C030852_D002289,No Relation,"The sentence says vinorelbine was used in patients with lung carcinoma, but does not say whether vinorelbine is treating or causing the cancer."
770955524,true,false,16,,,Direct,0.9364,D005283,fentanyl,D016055,retention of urine,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,,11581460_D005283_D016055,Direct,Using fentanyl caused retention or urine.
770955525,true,false,7,,,Direct,0.8569,D018817,MDMA,D003072,impaired social and emotional judgement processes,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,,16574712_D018817_D003072,Direct,People who take MDMA (and other drugs) develop impaired social and emotional judgement processes.
770955526,true,false,7,,,Direct,0.8665,D007980,Levodopa,D004421,dystonia,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,12691807_D007980_D004421,Direct,
770955527,true,false,8,,,Direct,0.8818,D008619,mepivacaine,D009135,muscle damage,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_5,4038130_D008619_D009135,Direct,
770955528,true,false,6,,,Direct,0.8451,D004917,erythromycin,D008133,Prolongation of QT interval,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,9545159_D004917_D008133,Direct,
770955529,true,false,10,,,Direct,1,D002217,carbachol,D014202,tremor,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D002217_D014202,Direct,
770955530,true,false,9,,,Direct,0.9007,D017035,pravastatin,D009220,inflammatory myopathy,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_1,7604176_D017035_D009220,Direct,
770955531,true,false,13,,,Direct,1,D002119,calcium carbon-ate,D053040,nephrolithiasis,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,625456_D002119_D053040,Direct,
770955532,true,false,9,,,Direct,1,D004317,adriamycin,D015470,acute myeloblastic leukemia,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_4,6769133_D004317_D015470,Direct,
770955533,true,false,16,,,Direct,0.8778,D001971,bromocriptine,D011605,psychosis,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,3686155_D001971_D011605,Direct,
770955534,true,false,11,,,Direct,0.5612,D006221,halothane,D056486,hepatitis,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,7647582_D006221_D056486,Direct,
770955535,true,false,14,,,Direct,0.7288,D003520,Cyclophosphamide,D001749,bladder tumor,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,8911359_D003520_D001749,Direct,
770955536,true,false,7,,,Direct,1,D008713,methimazole,D011537,itching,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,14982270_D008713_D011537,Direct,
770955537,true,false,16,,,Direct,0.8075,D010830,eserine,D014202,tremor,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D010830_D014202,Direct,
770955538,true,false,14,,That's a no-brainer.,Direct,0.7941,D011441,PTU/propylthiouracil,D014657,vasculitis,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,16418614_D011441_D014657,Direct,
770955539,true,false,7,,,Direct,0.5738,D004837,epinephrine,D017202,myocardial ischemia,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,3413271_D004837_D017202,Direct,
770955540,true,false,10,,,Direct,0.7043,C047781,Lamotrigine,D009207,myoclonus,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,16157917_C047781_D009207,Direct,
770955541,true,false,8,,,Direct,1,D002110,caffeine,D017180,ventricular tachycardia,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,18997632_D002110_D017180,Direct,
770955542,true,false,12,,,Direct,0.9256,D014700,verapamil,D007022,hypotension,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D014700_D007022,Direct,
770955543,true,false,10,,,Direct,1,D005473,fluoxetine,D062788,adenomyosis,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,9098464_D005473_D062788,Direct,
770955544,true,false,11,,,Direct,0.8453,D004656,enalapril,D051437,decreased renal function,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_10,10539815_D004656_D051437,Direct,
770955545,true,false,12,,,Direct,0.828,D017693,sodium bicarbonate,D006934,hypercalcaemia,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,625456_D017693_D006934,Direct,
770955546,true,false,13,,,Direct,0.7819,C014282,cirazoline,D001919,bradycardia,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_15,1355091_C014282_D001919,Direct,
770955547,true,false,13,,,Direct,0.7762,D000583,amikacin,D007674,nephrotoxicity,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,18356633_D000583_D007674,Direct,
770955548,true,false,6,,,Direct,0.6826,D010042,ouabain,D001145,arrhythmia,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,19721134_D010042_D001145,Direct,"Two animal models were used in this study. One was a rat model where arrhythmia was induced by ""aconitine"". The second was a guinea pig model induced by ""ouabain""."
770955549,true,false,8,,,Direct,1,C019248,Pamidronate,D006996,hypocalcemia,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,16006300_C019248_D006996,Direct,
770955550,true,false,10,,,Direct,0.9015,D004977,ethambutol,D009901,Bilateral optic neuropathy,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,384871_D004977_D009901,Direct,
770955551,true,false,12,,,Direct,0.9252,D002110,caffeine,D017180,ventricular tachycardia,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,18997632_D002110_D017180,Direct,
770955552,true,false,14,,,No Relation,0.5434,D008727,methotrexate,D056784,leukoencephalopathy,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,17682013_D008727_D056784,Direct,
770955553,true,false,17,,,Direct,0.8845,C534628,SCH 23390,D002375,catalepsy,"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_8,1687392_C534628_D002375,Direct,
770955554,true,false,13,,,Direct,0.7746,D003630,daunorubicin,D015431,weight loss,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,15897593_D003630_D015431,Direct,
770955555,true,false,9,,,Direct,0.6644,D009020,morphine,D002375,cataleptic,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,2716967_D009020_D002375,Direct,
770955556,true,false,12,,,Direct,1,C033457,Quinidine phenylethylbarbiturate,D056486,hepatitis,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. A case report.,3411101_0,3411101_C033457_D056486,Direct,
770955557,true,false,11,,,Direct,0.8171,D015742,propofol,D010146,pain,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,18006530_D015742_D010146,Direct,
770955558,true,false,17,,,Direct,0.767,D013619,Tacrine,D001930,hippocampal damage,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_3,19944736_D013619_D001930,Direct,
770955559,true,false,9,,,Direct,1,D009543,nifedipine/Adalat,D013684,telangiectasia,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,8251368_D009543_D013684,Direct,
770955560,true,false,7,,,Direct,0.5931,D014859,warfarin,D018366,LV Cutaneous lesions,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,16047871_D014859_D018366,Direct,
770955561,true,false,7,,,Direct,1,D004837,epinephrine,D017202,myocardial ischemia,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,3413271_D004837_D017202,Direct,
770955562,true,false,11,,'Involved' being the key word.,Direct,1,D009569,nitric oxide/NO,D020326,migraine without aura,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,10524660_D009569_D020326,Direct,
770955563,true,false,12,,,Direct,1,D001971,bromocriptine,D011605,psychosis,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,3686155_D001971_D011605,Direct,
770955564,true,false,11,,,Direct,1,C092292,ziprasidone,D009459,NMS,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,17366349_C092292_D009459,Direct,
770955565,true,false,9,,,Direct,1,D003915,DM,D003072,cognitive deterioration,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,7803371_D003915_D003072,Direct,
770955566,true,false,9,,,Direct,1,D016861,cyclooxygenase inhibitors,D006973,hypertension,"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_1,16586083_D016861_D006973,Direct,
770955567,true,false,5,,,Direct,1,D002217,carbachol,D004830,clonic-tonic convulsions,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002217_D004830,Direct,
770955568,true,false,12,,,Direct,0.9119,D007649,ketamine,D002375,catalepsy,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,2716967_D007649_D002375,Direct,
770955569,true,false,10,,,Direct,0.8979,D010830,eserine,D015878,mydriasis,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D010830_D015878,Direct,
770955570,true,false,3,,,Direct,1,D014147,tramadol,D006212,hallucinations,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,8766220_D014147_D006212,Direct,
770955571,true,false,11,,,Direct,0.9124,D000638,amiodarone,D008103,cirrhosis of the liver,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,3962737_D000638_D008103,Direct,
770955572,true,false,14,,,Direct,0.6423,D001556,alpha-benzene hexachloride,D006528,hepatomas,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,85485_D001556_D006528,Direct,
770955573,true,false,6,,,Direct,1,D005283,fentanyl,D009127,rigidity,Post-operative rigidity after fentanyl administration.,3780697_0,3780697_D005283_D009127,Direct,
770955574,true,false,6,,,Direct,0.8478,D005472,5-fluorouracil,D056784,leukoencephalopathy,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,17682013_D005472_D056784,Direct,
770955575,true,false,10,,,Direct,0.8045,D010830,eserine,D014202,tremor,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D010830_D014202,Direct,
770955576,true,false,13,,,Direct,1,D012293,rifampicin,D058186,Acute renal failure,Acute renal failure subsequent to the administration of rifampicin. A follow-up study of cases reported earlier.,982002_0,982002_D012293_D058186,Direct,
770955577,true,false,5,,,Direct,1,D010830,eserine,D014202,tremor,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D010830_D014202,Direct,
770955578,true,false,15,,,Direct,1,D003276,oral contraceptives,D008113,liver tumors,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,188339_D003276_D008113,Direct,
770955579,true,false,8,,,Direct,1,D004737,enflurane,D056486,hepatic injury,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,7647582_D004737_D056486,Direct,
770955580,true,false,13,,,Direct,1,D003975,diazepam,D001259,incoordination,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,6323692_D003975_D001259,Direct,
770955581,true,false,14,,,Direct,0.9314,D004837,epinephrine,D017202,myocardial ischemia,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,3413271_D004837_D017202,Direct,
770955582,true,false,7,,,Direct,1,D007649,Ketamine,D011605,psychosis,Ketamine elicited psychosis like psychopathology.,20727411_7,20727411_D007649_D011605,Direct,
770955583,true,false,8,,,Direct,1,D015215,AZT,D002311,cardiac dilation,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,17943461_D015215_D002311,Direct,
770955584,true,false,10,,,Direct,0.9194,D010068,oxacillin,D018366,Cutaneous leucocytoclastic vasculitis,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,11337188_D010068_D018366,Direct,
770955585,true,false,10,,,Direct,0.726,D004317,doxorubicin/DXR/Adriamycin,D009202,cardiomyopathy/myocardial disease/CM,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,7282516_D004317_D009202,Direct,
770955586,true,false,8,,,Direct,1,D003915,dextromethorphan,D003072,Cognitive deterioration,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,7803371_D003915_D003072,Direct,
770955587,true,false,18,,,Direct,0.8436,C047426,venlafaxine,D020230,Serotonin syndrome,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,8888541_C047426_D020230,Direct,
770955588,true,false,12,,,Direct,0.9201,D009288,naproxen,D007681,renal papillary necrosis/RPN,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,6699841_D009288_D007681,Direct,
770955589,true,false,12,,'Hypomania-like syndrome' and not just 'Hypomania',Direct,0.9178,C076029,olanzapine,D001714,Hypomania,Hypomania-like syndrome induced by olanzapine.,10565806_0,10565806_C076029_D001714,Direct,
770955590,true,false,12,,,Direct,1,D000728,androgen,D020181,obstructive sleep apnea syndrome,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,6732043_D000728_D020181,Direct,
770955591,true,false,14,,,Direct,1,D005473,fluoxetine hydrochloride,D006966,hyperprolactinemia,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,9098464_D005473_D006966,Direct,
770955592,true,false,11,,,Direct,0.6438,D018967,Risperidone,D010468,visual disturbances,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,12013711_D018967_D010468,Direct,
770955593,true,false,11,,,Direct,0.8349,D005283,fentanyl,D009127,rigidity,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,3780697_D005283_D009127,Direct,
770955594,true,false,13,,,Direct,0.8484,D013619,Tacrine,D012640,seizures,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_3,19944736_D013619_D012640,Direct,
770955595,true,false,15,,,Direct,1,D004837,epinephrine,D017202,myocardial ischemia,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,3413271_D004837_D017202,Direct,
770955596,true,false,11,,This is true.,Direct,0.8178,D004977,Ethambutol,D014786,visual loss,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,16710500_D004977_D014786,Direct,
770955597,true,false,7,,,Direct,0.8546,D005047,Etoposide,D009203,myocardial infarction,Etoposide-related myocardial infarction.,7619765_0,7619765_D005047_D009203,Direct,
770955598,true,false,13,,,Direct,0.6961,D014191,tranylcypromine,D020230,serotonin syndrome,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,8888541_D014191_D020230,Direct,
770955599,true,false,14,,,Direct,0.8545,D018817,MDMA,D008569,impaired memory functioning/memory impairments,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_10,16574713_D018817_D008569,Direct,
770955600,true,false,12,,,Direct,0.9193,D008012,lidocaine,D012640,seizures,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,2790457_D008012_D012640,Direct,
770955601,true,false,7,,,Direct,1,D008625,Tiopronin,D009393,nephritis,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_2,3084782_D008625_D009393,Direct,
770955602,true,false,15,,,Direct,0.8652,D000643,NH4CL,D003128,coma,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,761833_D000643_D003128,Direct,
770955603,true,false,8,,,Direct,1,D017963,azithromycin,D006606,hiccups,Possible azithromycin-associated hiccups.,15985056_0,15985056_D017963_D006606,Direct,
770955604,true,false,8,,,Direct,0.7541,D013390,succinylcholine,D001049,apnoea,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,871943_D013390_D001049,Direct,
770955605,true,false,9,,,Direct,1,D000319,beta-adrenergic blocking drugs,D006333,cardiac failure,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D000319_D006333,Direct,
770955606,true,false,15,,,Direct,0.8676,C047426,venlafaxine,D020230,serotonin syndrome,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,8888541_C047426_D020230,Direct,
770955607,true,false,13,,,Direct,0.9231,D006220,Haloperidol,D003072,cognitive impairment,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,8617710_D006220_D003072,Direct,
770955608,true,false,9,,,Direct,1,D010830,eserine,D004830,clonic-tonic convulsions,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D010830_D004830,Direct,
770955609,true,false,10,,,Direct,1,D004917,erythromycin,D016171,torsades de pointes,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,9545159_D004917_D016171,Direct,
770955610,true,false,10,,,Direct,0.901,D004041,fat,D009765,obesity,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,18674790_D004041_D009765,Direct,
770955611,true,false,7,,,Direct,1,D001971,Bromocriptine,D011605,psychosis,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,3686155_D001971_D011605,Direct,
770955612,true,false,11,,,Direct,0.8318,D007538,isoniazid,D009901,Bilateral optic neuropathy,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,384871_D007538_D009901,Direct,
770955613,true,false,11,,,Direct,0.914,D004917,erythromycin,D016757,sudden cardiac death,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,9545159_D004917_D016757,Direct,
770955614,true,false,5,,,Direct,0.63,D016685,Mitomycin C,D006463,Hemolytic Uremic Syndrome/HUS,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,3108839_D016685_D006463,Direct,
770955615,true,false,8,,,Direct,1,D008775,methylprednisolone,D006323,asystole,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,10074612_D008775_D006323,Direct,
770955616,true,false,12,,,Direct,0.9258,D014635,sodium valproate/VPA,D007177,SIADH/syndrome of inappropriate secretion of antidiuretic hormone,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,11195262_D014635_D007177,Direct,
770955617,true,false,7,,,Direct,0.8723,D014700,verapamil,D001919,bradycardia,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D014700_D001919,Direct,
770955618,true,false,11,,,Direct,1,D001556,alpha-benzene hexachloride,D006528,hepatoma,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,85485_D001556_D006528,Direct,
770955619,true,false,9,,,Direct,0.8949,D013866,6-thioguanine,D006504,veno-occlusive disease of the liver,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,7053705_D013866_D006504,Direct,
770955620,true,false,10,,,Direct,1,D010672,diphenylhydantoin/DPH,D002526,cerebellar dysfunction,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_1,430165_D010672_D002526,Direct,
770955621,true,false,11,,,Direct,0.823,C092292,ziprasidone,D009459,NMS,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,17366349_C092292_D009459,Direct,
770955622,true,false,10,,,Direct,0.9096,D004317,doxorubicin,D006331,cardiac dysfunction,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,18674790_D004317_D006331,Direct,
770955623,true,false,11,,,Direct,1,D010672,DPH,D010291,hemiparesis,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_3,430165_D010672_D010291,Direct,
770955624,true,false,12,,,Direct,0.92,C092292,ziprasidone,D009459,NMS,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,17366349_C092292_D009459,Direct,
770955625,true,false,14,,,Direct,1,D007530,Isoflurane,D002779|D056486,cholestatic hepatitis,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_9,11847945_D007530_D002779|D056486,Direct,
770955626,true,false,7,,,Direct,1,D000728,androgen,D020181,obstructive sleep apnea,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,6732043_D000728_D020181,Direct,
770955627,true,false,12,,,Direct,1,D016861,cyclooxygenase inhibitors,D009203,myocardial infarction,"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_1,16586083_D016861_D009203,Direct,
770955628,true,false,12,,,Direct,0.8455,D010830,eserine,D015878,mydriasis,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D010830_D015878,Direct,
770955629,true,false,8,,,Direct,1,D011718,pyrazinamide,D000857,dysosmia,Recurrent dysosmia induced by pyrazinamide.,19674115_0,19674115_D011718_D000857,Direct,
770955630,true,false,8,,,Direct,1,D002701,chloramphenicol,D000741,aplastic anemia,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,7072798_D002701_D000741,Direct,
770955631,true,false,9,,,Direct,1,D010634,PB,D008107,liver damage,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,17574447_D010634_D008107,Direct,
770955632,true,false,13,,,Direct,0.6918,D014191,tranylcypromine,D020230,Serotonin syndrome,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,8888541_D014191_D020230,Direct,
770955633,true,false,9,,,Direct,0.6596,D005476,fluphenazine,D002375,catalepsy,"Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_4,1687392_D005476_D002375,Direct,
770955634,true,false,8,,,Direct,1,D011718,pyrazinamide,D000857,olfactory disorder,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,19674115_D011718_D000857,Direct,
770955635,true,false,13,,,Direct,1,D010665,Phenylpropanolamine/Dexatrim,D009203,myocardial infarction,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,12734532_D010665_D009203,Direct,
770955636,true,false,13,,,Direct,0.9274,D002217,carbachol,D004830,clonic-tonic convulsions,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D002217_D004830,Direct,
770955637,true,false,12,,Oral Contraception is not a Chemical.,Direct,0.9191,D003276,oral contraception,D002819,Chorea,Chorea associated with oral contraception.,3123611_0,3123611_D003276_D002819,Direct,
770955638,true,false,13,,,Direct,0.9267,D018967,risperidone,D010468,visual disturbances,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,12013711_D018967_D010468,Direct,
770955639,true,false,12,,,Direct,0.842,C047781,LTG,D009207,MJ,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,16157917_C047781_D009207,Direct,
770955640,true,false,11,,,Direct,0.8167,C047781,LTG,D009207,myoclonic status/MJ,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,16157917_C047781_D009207,Direct,
770955641,true,false,8,,,Direct,1,D003520,Cyclophosphamide,D001749,bladder cancer,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,8911359_D003520_D001749,Direct,
770955642,true,false,17,,,Direct,0.8799,D002217,carbachol,D014202,tremor,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002217_D014202,Direct,
770955643,true,false,9,,,Direct,0.8824,D010396,D-penicillamine,D017285,polymyositis,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,8268147_D010396_D017285,Direct,
770955644,true,false,10,,,Direct,0.9049,D002701,chloramphenicol,D000741,aplastic anemia,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,7072798_D002701_D000741,Direct,
770955645,true,false,11,,,Direct,1,D001393,azole,D016757,sudden cardiac death,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,9545159_D001393_D016757,Direct,
770955646,true,false,10,,,Direct,0.6087,D008094,lithium,D054537,atrioventricular (AV) block,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,18441470_D008094_D054537,Direct,
770955647,true,false,6,,,Direct,1,D003907,dexamethasone,D009422,neurological dysfunctions,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,15814210_D003907_D009422,Direct,
770955648,true,false,4,,,Direct,1,D016861,cyclooxygenase inhibitors,D006333,heart failure,"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_1,16586083_D016861_D006333,Direct,
770955649,true,false,10,,,Direct,0.8996,D005839,gentamicin,D058186,acute renal failure,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,19893084_D005839_D058186,Direct,
770955650,true,false,9,,,Direct,0.785,D000324,ACTH,D004421,dystonia,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,2840807_D000324_D004421,Direct,
770955651,true,false,16,,,Direct,0.8124,D000728,androgens,D020181,syndrome of obstructive sleep apnea,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,6732043_D000728_D020181,Direct,
770955652,true,false,11,,,Direct,0.8239,D006220,haloperidol,D003072,Impairment of cognitive function,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,8617710_D006220_D003072,Direct,
770955653,true,false,11,,,Direct,1,D008094,lithium,D012804,Sinus node dysfunction,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,18441470_D008094_D012804,Direct,
770955654,true,false,8,,,Direct,0.8828,D014635,sodium valproate,D007177,syndrome of inappropriate secretion of antidiuretic hormone,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,11195262_D014635_D007177,Direct,
770955655,true,false,9,,,Direct,0.8951,D008012,lidocaine,D009135,muscle damage,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_5,4038130_D008012_D009135,Direct,
770955656,true,false,7,,,Direct,0.8684,D010396,D-penicillamine,D005921,glomerulonephritis/RPGN,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,8267029_D010396_D005921,Direct,
770955657,true,false,12,,,Direct,1,D014700,verapamil,D006333,cardiac failure,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D014700_D006333,Direct,
770955658,true,false,8,,,Direct,1,D007530,isoflurane,D002779|D056486,cholestatic hepatitis,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,11847945_D007530_D002779|D056486,Direct,
770955659,true,false,5,,,Direct,1,D015119,epsilon-aminocaproic acid,D020225|D020227,sagittal and left transverse sinus thrombosis,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,2339463_D015119_D020225|D020227,Direct,
770955660,true,false,12,,,Direct,0.8399,D002217,carbachol,D015878,mydriasis,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D002217_D015878,Direct,
770955661,true,false,9,,,Direct,0.903,D014640,vancomycin,D006311,ototoxicity,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,3934126_D014640_D006311,Direct,
770955662,true,false,9,,,Direct,1,D002752,chlorthalidone,D018879,ventricular ectopic beats,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,3732088_D002752_D018879,Direct,
770955663,true,false,11,,Side effect,Direct,1,D002927,cimetidine,D007172,impotence,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,6150641_D002927_D007172,Direct,
770955664,true,false,9,,,Direct,0.8917,D016685,MMC,D006333,cardiac failure,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_7,3137399_D016685_D006333,Direct,
770955665,true,false,10,,,Direct,1,D009288,naproxen,D007681,Renal papillary necrosis,Renal papillary necrosis due to naproxen.,6699841_0,6699841_D009288_D007681,Direct,
770955666,true,false,13,,,Direct,1,C019248,pamidronate,D006996,hypocalcemia,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,16006300_C019248_D006996,Direct,
770955667,true,false,13,,,Direct,1,D000638,amiodarone,D056486,hepatic injury,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,3962737_D000638_D056486,Direct,
770955668,true,false,13,,,Direct,0.7661,D009074,MSH,D004421,dystonia,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,2840807_D009074_D004421,Direct,
770955669,true,false,12,,,Direct,0.7497,D004456,echothiophate iodide,D018908,muscle weakness,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,7650771_D004456_D018908,Direct,
770955670,true,false,6,,,Direct,1,D002217,carbachol,D004830,clonic-tonic convulsions,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D002217_D004830,Direct,
770955671,true,false,9,,,Direct,1,D010068,oxacillin,D051437,renal failure,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,11337188_D010068_D051437,Direct,
770955672,true,false,14,,,Direct,0.9314,D013874,thiopental,D012133,respiratory paralysis,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,2893236_D013874_D012133,Direct,
770955673,true,false,7,,,Direct,1,D008775,methylprednisolone,D001919,bradycardia,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,10074612_D008775_D001919,Direct,
770955674,true,false,8,,,Direct,0.8784,D011692,PAN,D034141,hypoalbuminemia,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,15075188_D011692_D034141,Direct,
770955675,true,false,17,,,Direct,0.8432,C017367,carmofur,D056784,leukoencephalopathy,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,17682013_C017367_D056784,Direct,
770955676,true,false,5,,,Direct,1,D017693,sodium bicarbonate,D053040,nephrolithiasis,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,625456_D017693_D053040,Direct,
770955677,true,false,11,,,Direct,1,D005476,fluphenazine,D002375,catalepsy,"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_8,1687392_D005476_D002375,Direct,
770955678,true,false,11,,,Direct,1,D005047,etoposide,D009203,myocardial infarction,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,7619765_D005047_D009203,Direct,
770955679,true,false,15,,,Direct,0.9387,D010068,Oxacillin,D018366,leucocytoclastic vasculitis,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,11337188_D010068_D018366,Direct,
770955680,true,false,8,,,Direct,0.7597,D010396,Penicillamine,D005921,glomerulonephritis,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,8267029_D010396_D005921,Direct,
770955681,true,false,7,,,Direct,1,D016685,Mitomycin C,D006463,hemolytic uremic syndrome,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,3108839_D016685_D006463,Direct,
770955682,true,false,8,,,Direct,1,D002217,carbachol,D015878,mydriasis,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002217_D015878,Direct,
770955683,true,false,17,,,Direct,0.9463,D005473,Fluoxetine,D006966,hyperprolactinemia,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,9098464_D005473_D006966,Direct,
770955684,true,false,9,,,No Relation,0.5549,C056299,Abbott-53693,D001919,bradycardia,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_16,1355091_C056299_D001919,Direct,
770955685,true,false,7,,,Direct,1,D001971,bromocriptine,D011605,psychosis,Postpartum psychosis induced by bromocriptine.,3686155_0,3686155_D001971_D011605,Direct,
770955686,true,false,14,,,Direct,0.9354,D004317,doxorubicin,D006333,cardiac failure,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_7,3137399_D004317_D006333,Direct,
770955687,true,false,10,,,Direct,1,D008727,methotrexate,D056784,leukoencephalopathy,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,17682013_D008727_D056784,Direct,
770955688,true,false,10,,,Direct,1,D013866,6-thioguanine,D006504,Hepatic veno-occlusive disease,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,7053705_D013866_D006504,Direct,
770955689,true,false,13,,,Direct,1,D015742,propofol,D010146,pain,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,18006530_D015742_D010146,Direct,
770955690,true,false,9,,,Direct,0.8914,D007530,isoflurane,D002779|D056486,cholestatic hepatitis,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,11847945_D007530_D002779|D056486,Direct,
770955691,true,false,14,,,Direct,0.9276,D002217,carbachol,D014202,tremor,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D002217_D014202,Direct,
770955692,true,false,8,,,Direct,0.7587,D017963,azithromycin,D006606,hiccups,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,15985056_D017963_D006606,Direct,
770955693,true,false,17,,,Direct,0.8899,D015632,MPTP,D020734,parkinsonian,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,8106150_D015632_D020734,Direct,
770955694,true,false,7,,,Direct,1,D002217,carbachol,D015878,mydriasis,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D002217_D015878,Direct,
770955695,true,false,14,,,Direct,0.859,D003276,Oral Contraceptives,D008113,Liver Tumors,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,188339_D003276_D008113,Direct,
770955696,true,false,10,,,Direct,1,D004298,dopamine,D002389,catatonia,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,6540303_D004298_D002389,Direct,
770955697,true,false,11,,,Direct,0.8262,D005472,5-FU/5-fluorouracil,D002637,chest pain,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_1,3952818_D005472_D002637,Direct,
770955698,true,false,6,,,Direct,0.8466,D014635,VPA,D007177,SIADH,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,11195262_D014635_D007177,Direct,
770955699,true,false,9,,,Direct,1,D013629,tamoxifen,D015228,hypertriglyceridaemia,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_14,9672273_D013629_D015228,Direct,
770955700,true,false,9,,,Direct,0.7775,D008012,lidocaine,D012640,seizures,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,2790457_D008012_D012640,Direct,
770955701,true,false,11,,,Direct,0.7269,D008094,Lithium,D011141,polyuria,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,9226773_D008094_D011141,Direct,
770955702,true,false,18,,,Direct,0.838,D009543,nifedipine,D013684,telangiectasia,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,8251368_D009543_D013684,Direct,
770955703,true,false,12,,,Direct,0.7515,D004656,enalapril,D051437,decreased renal function,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_11,10539815_D004656_D051437,Direct,
770955704,true,false,8,,,Direct,1,D016861,cyclooxygenase inhibitors,D020521,stroke,"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_1,16586083_D016861_D020521,Direct,
770955705,true,false,8,,,Direct,1,D005996,Glyceryl trinitrate,D020326,migraine without aura,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,10524660_D005996_D020326,Direct,
770955706,true,false,9,,,Direct,1,D014282,trihexyphenidyl hydrochloride,D001919,Bradycardia,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,3769769_D014282_D001919,Direct,
770955707,true,false,14,,,Direct,0.9313,D016685,mitomycin C,D051437,renal failure,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,3108839_D016685_D051437,Direct,
770955708,true,false,16,,,Direct,0.7553,D011441,PTU,D014657,vasculitis,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,16418614_D011441_D014657,Direct,
770955709,true,false,4,,,Direct,1,D000638,amiodarone,D002779|D056486,cholestatic hepatitis,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,3962737_D000638_D002779|D056486,Direct,
770955710,true,false,12,,,Direct,0.7552,D004317,ADR,D028361,mitochondrial structural and functional impairment,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,9952311_D004317_D028361,Direct,
770955711,true,false,11,,,Direct,1,D007069,ifosfamide,D001002,anuria,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,2320800_D007069_D001002,Direct,
770955712,true,false,12,,,Direct,0.9227,D000319,beta-adrenergic blocking drugs,D001919,bradycardia,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D000319_D001919,Direct,
770955713,true,false,10,,,Direct,1,D008775,methylprednisolone,D006323,asystole,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,10074612_D008775_D006323,Direct,
770955714,true,false,12,,,Direct,0.9191,D000082,paracetamol,D017114,fulminant hepatic failure,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,7007443_D000082_D017114,Direct,
770955715,true,false,9,,,Direct,0.8965,D001393,azole,D008133,Prolongation of QT interval,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,9545159_D001393_D008133,Direct,
770955716,true,false,10,,,Direct,1,D000420,Salbutamol,D013617,SIAT,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,20552622_D000420_D013617,Direct,
770955717,true,false,11,,,Direct,1,C092292,ziprasidone,D009459,Neuroleptic malignant syndrome,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,17366349_C092292_D009459,Direct,
770955718,true,false,18,,,Direct,0.8874,D007069,ifosfamide,D001002,anuria,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,2320800_D007069_D001002,Direct,
770955719,true,false,14,,,Direct,0.929,D013874,thiopental,D012133,respiratory paralysis,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,2893236_D013874_D012133,Direct,
770955720,true,false,9,,,No Relation,0.6479,C056299,Abbott-53693,D001919,bradycardia,"The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_14,1355091_C056299_D001919,Direct,
770955721,true,false,13,,,Direct,0.9274,D000319,beta-adrenergic blocking drugs,D007022,hypotension,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,6127992_D000319_D007022,Direct,
770955722,true,false,13,,,Direct,1,D004977,ethambutol,D009901,optic neuropathy,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,16710500_D004977_D009901,Direct,
770955723,true,false,13,,,Direct,0.7758,D002110,caffeine,D018879,ventricular ectopy,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,18997632_D002110_D018879,Direct,
770955724,true,false,11,,'Induced' being the key term.,Direct,1,D009627,nomifensine,D006948,hyperactivity,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,2576810_D009627_D006948,Direct,
770955725,true,false,13,,,Direct,1,D010396,D-penicillamine,D017285,Polymyositis,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,8268147_D010396_D017285,Direct,
770955726,true,false,8,,,No Relation,1,D007660,Ketoprofen,D013345,SAH,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,10414674_D007660_D013345,No Relation,
770955727,true,false,10,,,No Relation,0.9061,C012655,nimesulide,D014581,urticaria,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,11694026_C012655_D014581,No Relation,
770955728,true,false,18,,,No Relation,0.7843,D000082,paracetamol,D001744,bladder calculi,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_6,4090988_D000082_D001744,No Relation,
770955729,true,false,11,,'Reduced' is the key word.,No Relation,1,D010830,physostigmine,D004409,dyskinetic,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,8106150_D010830_D004409,No Relation,
770955730,true,false,11,,,No Relation,1,D004317,doxorubicin,D001943,breast cancer,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,11230490_D004317_D001943,No Relation,
770955731,true,false,8,,,No Relation,1,D014147,Tramadol,D009369,cancer,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,8766220_D014147_D009369,No Relation,
770955732,true,false,11,,,No Relation,1,D004008,diclofenac sodium,D001172,rheumatoid arthritis,Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).,17965424_0,17965424_D004008_D001172,No Relation,
770955733,true,false,12,,,No Relation,1,D011188,potassium,D003327,coronary disease,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,3732088_D011188_D003327,No Relation,
770955734,true,false,13,,,No Relation,0.925,C422649,etoricoxib,D001172,RA,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_2,17965424_C422649_D001172,No Relation,
770955735,true,false,13,,,No Relation,1,C004742,daidzein,D000647,amnesia,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,16428827_C004742_D000647,No Relation,
770955736,true,false,17,,,No Relation,0.95,D015647,SKF 38393,D002375,catalepsy,"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_8,1687392_D015647_D002375,No Relation,
770955737,true,false,17,,,No Relation,1,D003520,cyclophosphamide,D001943,MBC,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,11230490_D003520_D001943,No Relation,
770955738,true,false,14,,,No Relation,1,D015215,AZT,D000163,AIDS,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,2004015_D015215_D000163,No Relation,
770955739,true,false,9,,,No Relation,1,D007660,ketoprofen,D013345,aneurysmal subarachnoid hemorrhage/SAH,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,10414674_D007660_D013345,No Relation,
770955740,true,false,11,,,No Relation,1,C065179,Atorvastatin,D006973,hypertension,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,16820346_C065179_D006973,No Relation,
770955741,true,false,13,,,No Relation,0.9322,D000082,paracetamol,D006525,viral hepatitis,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,7007443_D000082_D006525,No Relation,
770955742,true,false,8,,,No Relation,1,D002118,calcium,D003866,depression,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,6323692_D002118_D003866,No Relation,
770955743,true,false,13,,,No Relation,1,D005680,GABA,D012133,respiratory paralysis,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,2893236_D005680_D012133,No Relation,
770955744,true,false,9,,,No Relation,1,D017311,amlodipine,D006973,hypertension,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,18201582_D017311_D006973,No Relation,
770955745,true,false,14,,,No Relation,0.942,D001058,Apomorphine,D010300,Parkinson's disease,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,11009181_D001058_D010300,No Relation,
770955746,true,false,13,,,No Relation,0.8457,C012655,nimesulide,D014581,urticaria,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,11694026_C012655_D014581,No Relation,
770955747,true,false,12,,,No Relation,1,D011224,prazosin,D001919,bradycardia,"The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_14,1355091_D011224_D001919,No Relation,
770955748,true,false,9,,,No Relation,0.8909,D002216,captopril,D011507,proteinuria,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,6454943_D002216_D011507,No Relation,
770955749,true,false,11,,,No Relation,1,D002220,CBZ,D012640,seizure,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,2790457_D002220_D012640,No Relation,
770955750,true,false,13,,,No Relation,1,D012964,sodium,D034141,hypoalbuminemia,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,15075188_D012964_D034141,No Relation,
770955751,true,false,18,,,No Relation,1,D012254,ribavirin,D000257,adenovirus disease,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_23,12093990_D012254_D000257,No Relation,
770955752,true,false,17,,,No Relation,0.8878,D013629,tamoxifen,D001943,breast cancer,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_15,9672273_D013629_D001943,No Relation,
770955753,true,false,6,,,No Relation,1,D007980,L-dopa,D003128,coma,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,761833_D007980_D003128,No Relation,
770955754,true,false,10,,,No Relation,0.831,D009020,Morphine,D001523,behavioral disorders,Morphine dose-dependently reversed these behavioral disorders.,10840460_11,10840460_D009020_D001523,No Relation,
770955755,true,false,11,,,No Relation,1,D008687,metformin,D014652,vascular dysfunction,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,20164825_D008687_D014652,No Relation,
770955756,true,false,15,,,No Relation,0.9285,D017374,paroxetine,D059350,chronic pain,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,8766220_D017374_D059350,No Relation,
770955757,true,false,9,,Used as treatment.,No Relation,1,D003520,cyclophosphamide,D066126,cardiotoxicity,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,11230490_D003520_D066126,No Relation,
770955758,true,false,8,,,No Relation,1,C032151,cibenzoline,D001145,ventricular arrhythmias,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,2435991_C032151_D001145,No Relation,
770955759,true,false,17,,,No Relation,1,D002220,CBZ,D012640,seizures,Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_5,2790457_D002220_D012640,No Relation,
770955760,true,false,13,,,No Relation,0.8526,D011224,prazosin,D009127,muscular rigidity,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,2564649_D011224_D009127,No Relation,
770955761,true,false,5,,,No Relation,0.7829,D010433,metrazol,D000699,analgesia,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,6323692_D010433_D000699,No Relation,
770955762,true,false,9,,,No Relation,1,D001262,atenolol,D001145,arrhythmia,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,20552622_D001262_D001145,No Relation,
770955763,true,false,10,,,No Relation,1,D006493,Unfractionated heparin sodium/UFH,D013927,thrombosis,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,18589141_D006493_D013927,No Relation,
770955764,true,false,15,,,No Relation,1,D008687,metformin,D007674,nephrotoxicity,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,20164825_D008687_D007674,No Relation,
770955765,true,false,10,,,No Relation,1,D004052,diethylnitrosamine,D063646,carcinogenic,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,3780814_D004052_D063646,No Relation,
770955766,true,false,13,,,No Relation,0.8558,D000086,acetazolamide,D007674,renal impairment,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,10692744_D000086_D007674,No Relation,
770955767,true,false,13,,,No Relation,0.921,D004298,dopamine,D003128,coma,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,761833_D004298_D003128,No Relation,
770955768,true,false,13,,,No Relation,1,D012254,ribavirin,D006482,infection with hemorrhagic fever viruses,Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.,12093990_8,12093990_D012254_D006482,No Relation,
770955769,true,false,15,,,No Relation,0.8116,D015725,fluconazole,D001145,ventricular arrhythmias,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,11302406_D015725_D001145,No Relation,
770955770,true,false,9,,,No Relation,1,D000082,acetaminophen,D013345,SAH,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,10414674_D000082_D013345,No Relation,
770955771,true,false,15,,,No Relation,1,D017035,pravastatin,D006937,hypercholesterolemia,He assumed pravastatin (20 mg/day) because of hypercholesterolemia.,7604176_3,7604176_D017035_D006937,No Relation,
770955772,true,false,9,,,No Relation,1,D013792,thalidomide,D002292,renal cell carcinoma,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,12448656_D013792_D002292,No Relation,
770955773,true,false,8,,,No Relation,1,C018370,pregnenolone sulphate,D000647,amnesic,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,11860495_C018370_D000647,No Relation,
770955774,true,false,16,,,No Relation,1,D007980,levodopa,D010300,idiopathic Parkinson's disease,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,458486_D007980_D010300,No Relation,
770955775,true,false,11,,,No Relation,0.9171,D014269,trifluoroacetyl,D056486,hepatitis,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,7647582_D014269_D056486,No Relation,
770955776,true,false,10,,,No Relation,1,D003520,cyclophosphamide,D007674,renal involvement,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,12739036_D003520_D007674,No Relation,
770955777,true,false,5,,,No Relation,0.8033,D004052,diethylnitrosamine/DEN,D063646,carcinogenesis,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,3780814_D004052_D063646,No Relation,
770955778,true,false,12,,,No Relation,1,D005492,folic acid,D064420,toxicity,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,8958188_D005492_D064420,No Relation,
770955779,true,false,10,,,No Relation,0.9061,C095756,AIDA,D009127,muscle rigidity,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,12231232_C095756_D009127,No Relation,
770955780,true,false,12,,,No Relation,1,C507346,AMN082,D018476,akinetic,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,19940105_C507346_D018476,No Relation,
770955781,true,false,6,,,No Relation,0.6858,D006046,gold,D009393,nephritis,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_2,3084782_D006046_D009393,No Relation,
770955782,true,false,5,,,No Relation,1,D007649,Ketamine,D012559,schizophrenia,"Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.",20727411_10,20727411_D007649_D012559,No Relation,
770955783,true,false,9,,,No Relation,1,D010634,PB,D009369,tumor,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,3780814_D010634_D009369,No Relation,
770955784,true,false,14,,,No Relation,0.933,D007650,Ketanserin,D009127,muscle rigidity,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,3115150_D007650_D009127,No Relation,
770955785,true,false,15,,,No Relation,0.9383,D009270,Naloxone,D012133,respiratory paralysis,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,2893236_D009270_D012133,No Relation,
770955786,true,false,9,,,No Relation,0.7794,D001379,azathioprine,D007674,renal involvement,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,12739036_D001379_D007674,No Relation,
770955787,true,false,6,,,No Relation,0.8321,D014031,tobramicyn,D064420,toxicity,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,9875685_D014031_D064420,No Relation,
770955788,true,false,10,,,No Relation,1,D005492,folic acid,D064420,toxicity,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,8958188_D005492_D064420,No Relation,
770955789,true,false,13,,,No Relation,0.9328,D002216,captopril,D006973,hypertensive,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,8586822_D002216_D006973,No Relation,
770955790,true,false,16,,,No Relation,0.8813,D013467,sulindac,D001172,rheumatoid arthritis,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,6699841_D013467_D001172,No Relation,
770955791,true,false,14,,,No Relation,0.9308,D000638,amiodarone,D017180,VT,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,6637851_D000638_D017180,No Relation,
770955792,true,false,10,,,No Relation,1,D014635,VPA,D004830,tonic-clonic convulsions,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,11195262_D014635_D004830,No Relation,
770955793,true,false,9,,,No Relation,1,D000617,aminoglycoside,D006402|D009369,hematologic/oncologic disorder,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,18356633_D000617_D006402|D009369,No Relation,
770955794,true,false,7,,,No Relation,0.8507,D003630,daunorubicin,D001855,myelosuppression,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,15897593_D003630_D001855,Direct,Daunorubicin causes weight loss and myelosuppression. Dexrazoxane made the myelosuppression and weight loss better.
770955795,true,false,10,,,No Relation,1,D064730,dexrazoxane,D009362,metastases,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,15897593_D064730_D009362,No Relation,
770955796,true,false,12,,,No Relation,0.5919,D002122,calcium chloride,D014202,tremor,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002122_D014202,No Relation,
770955797,true,false,14,,,No Relation,1,D000583,Amikacin,D009503,febrile neutropenia,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,18356633_D000583_D009503,No Relation,
770955798,true,false,11,,Used as treatment.,No Relation,0.9104,D014282,trihexyphenidyl hydrochloride,D012559,schizophrenic,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,3769769_D014282_D012559,No Relation,
770955799,false,false,2,,,Direct,1,D002122,calcium chloride,D004830,clonic-tonic convulsions,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002122_D004830,No Relation,
770955800,true,false,10,,,No Relation,1,D003520,cyclophosphamide,D008180,systemic lupus erythematosus/SLE,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,12739036_D003520_D008180,No Relation,
770955801,true,false,9,,,No Relation,0.6702,D005557,formalin,D010146,pain,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,15974569_D005557_D010146,No Relation,
770955802,true,false,9,,,No Relation,0.5529,D002110,caffeine,D006331,cardiac disease,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,18997632_D002110_D006331,No Relation,
770955803,true,false,15,,,No Relation,1,C400082,bortezomib,D009101,MM,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,19274460_C400082_D009101,No Relation,
770955804,true,false,17,,,No Relation,1,D007980,L-dopa,D003128,coma,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,761833_D007980_D003128,No Relation,
770955805,true,false,14,,,No Relation,1,D011899,ranitidine,D007172,impotence,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,6150641_D011899_D007172,No Relation,
770955806,true,false,9,,,No Relation,0.8937,D005996,Glyceryl trinitrate,D020325,migraine with aura,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,10524660_D005996_D020325,No Relation,
770955807,true,false,10,,,No Relation,1,C018370,PREGS,D000647,amnesic,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,11860495_C018370_D000647,No Relation,
770955808,true,false,10,,,No Relation,0.6116,D005472,5-FU/5-fluorouracil,D009362,metastasis,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_1,3952818_D005472_D009362,No Relation,
770955809,true,false,9,,,No Relation,1,D002122,calcium chloride,D015878,mydriasis,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D002122_D015878,No Relation,
770955810,true,false,13,,,No Relation,1,D003520,cyclophosphamide,D001943,breast cancer,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,11230490_D003520_D001943,No Relation,
770955811,true,false,10,,al simplificar las palabras es mas entendible para uno que no es medico en este tipo de tarea...thanksss,No Relation,1,D000638,Amiodarone,D017180,VT/ventricular tachycardia,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,6637851_D000638_D017180,No Relation,
770955812,true,false,12,,,No Relation,1,C047781,LTG/lamotrigine,C562694,IGE/idiopathic generalized epilepsies,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,16157917_C047781_C562694,No Relation,
770955813,true,false,12,,,No Relation,0.831,D008713,methimazole,D006980,hyperthyroidism,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,14982270_D008713_D006980,No Relation,
770955814,true,false,5,,,No Relation,0.8017,C004742,Daidzein,D000647,amnesia,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,16428827_C004742_D000647,No Relation,
770955815,true,false,13,,,No Relation,1,D005557,formalin,D006930,thermal hyperalgesia/mechanical hyperalgesia,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,15974569_D005557_D006930,No Relation,
770955816,true,false,8,,,No Relation,1,D020117,Cisapride,D015835,gastrointestinal motility disorders,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,9545159_D020117_D015835,No Relation,
770955817,true,false,10,,,No Relation,0.8957,D015215,AZT,D000163,AIDS,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,9209318_D015215_D000163,No Relation,
770955818,true,false,8,,,No Relation,1,D013835,thiamine pyrophosphate/TPP,D003920,diabetic,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,3762968_D013835_D003920,No Relation,
770955819,true,false,11,,,No Relation,0.5445,C009166,retinyl acetate,D013274,forestomach carcinogenesis,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,3131282_C009166_D013274,No Relation,
770955820,true,false,6,,,No Relation,1,C097949,"1,25-dihydroxyvitamin D",D058186,acute renal insufficiency,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,16006300_C097949_D058186,No Relation,
770955821,true,false,9,,,No Relation,1,C071741,Remifentanil,D010146,pain,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,18006530_C071741_D010146,No Relation,
770955822,true,false,12,,,No Relation,1,D000617,aminoglycoside,D009503,febrile neutropenia,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,18356633_D000617_D009503,No Relation,
770955823,true,false,17,,,No Relation,1,D002122,calcium chloride,D004830,clonic-tonic convulsions,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,6892185_D002122_D004830,No Relation,
770955824,true,false,9,,,No Relation,0.8932,D008687,Metformin,D058186,acute renal failure,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,20164825_D008687_D058186,No Relation,
770955825,true,false,8,,,No Relation,1,C037689,benzamide,D010300,idiopathic Parkinson's disease,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,458486_C037689_D010300,No Relation,
770955826,true,false,10,,,No Relation,1,D006046,gold,D001172,rheumatoid arthritis,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,6699841_D006046_D001172,No Relation,
770955827,true,false,11,,,No Relation,1,D018967,risperidone,D001480,EPS,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,12013711_D018967_D001480,No Relation,
770955828,true,false,12,,,No Relation,0.9206,D002752,chlorthalidone,D003324,coronary artery disease,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,3732088_D002752_D003324,No Relation,
770955829,true,false,9,,,No Relation,0.8848,D003345,corticosterone,D009422,neuropathy,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,3961813_D003345_D009422,No Relation,
770955830,true,false,11,,,No Relation,1,D009543,nifedipine,D000788,Prinzmetal's angina,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_2,3952818_D009543_D000788,No Relation,
770955831,true,false,7,,,No Relation,1,C507346,AMN082,D010300,PD,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,19940105_C507346_D010300,No Relation,
770955832,true,false,9,,,No Relation,0.8851,C422649,etoricoxib,D005767,GI AEs,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_8,17965424_C422649_D005767,No Relation,
770955833,true,false,5,,,No Relation,1,D009599,nitroprusside,D007511,ischemia,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,7710775_D009599_D007511,No Relation,
770955834,true,false,10,,'Reduced cardiotoxicity' being the key term.,No Relation,1,D004317,doxorubicin,D066126,cardiotoxicity,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,11230490_D004317_D066126,No Relation,
770955835,true,false,17,,,No Relation,0.9361,D001262,atenolol,D001145,arrhythmia,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,20552622_D001262_D001145,No Relation,
770955836,true,false,9,,,No Relation,1,D007980,L-dopa,D020734,parkinsonian,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,9549528_D007980_D020734,No Relation,
770955837,true,false,6,,,No Relation,1,D064704,levofloxacin,D012852,sinusitis,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,9564988_D064704_D012852,No Relation,
770955838,true,false,7,,,No Relation,1,D002945,cisplatin,D001943,breast cancer,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,2320800_D002945_D001943,No Relation,
770955839,true,false,10,,,No Relation,0.8068,D063325,Tiapride,D004409,involuntary movements,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,458486_D063325_D004409,No Relation,
770955840,true,false,11,,Used as treatment.,No Relation,1,D003520,cyclophosphamide,D009101,myeloma,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,19274460_D003520_D009101,No Relation,
770955841,true,false,11,,,No Relation,0.9202,D018698,glutamate,D020336,spastic paraparesis,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,15673851_D018698_D020336,No Relation,
770955842,true,false,10,,,No Relation,1,D008790,metoprolol,D017202,myocardial ischemia,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,11079278_D008790_D017202,No Relation,
770955843,true,false,9,,,No Relation,1,D012254,ribavirin,D007239,infection,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_23,12093990_D012254_D007239,No Relation,
770955844,true,false,10,,,No Relation,0.71,D007980,Levodopa,D010300,Parkinson's disease,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,12691807_D007980_D010300,No Relation,
770955845,true,false,12,,,No Relation,1,C032151,Cibenzoline,D001145,arrhythmias,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,2435991_C032151_D001145,No Relation,
770955846,true,false,10,,,No Relation,1,D007660,ketoprofen,D017542,aneurysmal,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,10414674_D007660_D017542,No Relation,
770955847,true,false,8,,,No Relation,0.8757,D008687,Metformin,D007674,nephropathy,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,20164825_D008687_D007674,No Relation,
770955848,true,false,11,,,No Relation,0.9049,D020117,cisapride,D006973,hypertension,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,9545159_D020117_D006973,No Relation,
770955849,true,false,10,,,No Relation,0.7972,D002939,ciprofloxacin,D009369,cancer,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,8494478_D002939_D009369,No Relation,
770955850,true,false,19,,,No Relation,1,D016291,MK-801,D004409,dyskinetic,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,8106150_D016291_D004409,No Relation,
770955851,true,false,12,,,No Relation,0.7402,D004317,doxorubicin,D009765,obese,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,18674790_D004317_D009765,No Relation,
770955852,true,false,9,,,No Relation,1,D002927,cimetidine,D056486|D006402,hepatic or hematologic toxicity,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,6150641_D002927_D056486|D006402,No Relation,
770955853,true,false,7,,,No Relation,1,D014147,Tramadol,D010146,pain,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,8766220_D014147_D010146,No Relation,
770955854,true,false,8,,,No Relation,1,D015647,SKF 38393,D002375,catalepsy,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_10,1687392_D015647_D002375,No Relation,
770955855,true,false,8,,,No Relation,0.8784,D000082,paracetamol,D014581,urticaria,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,11694026_D000082_D014581,No Relation,
770955856,true,false,14,,,No Relation,0.925,D005492,folic acid,D064420,toxicity,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,8958188_D005492_D064420,No Relation,
770955857,true,false,7,,,No Relation,1,D004317,Doxorubicin,D009765,OB,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,18674790_D004317_D009765,No Relation,
770955858,true,false,19,,,No Relation,1,C053571,iopentol,D014693,ventricular fibrillation,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_3,2980315_C053571_D014693,No Relation,
770955859,true,false,8,,,No Relation,1,D064730,dexrazoxane,D015431,weight loss,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,15897593_D064730_D015431,No Relation,
770955860,true,false,10,,,No Relation,1,D008774,methylphenidate,D000544,Alzheimer's disease,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,12907924_D008774_D000544,No Relation,
770955861,true,false,12,,,No Relation,1,D004656,enalapril,D018487,Left Ventricular Dysfunction,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_4,10539815_D004656_D018487,No Relation,
770955862,true,false,10,,,No Relation,1,C400082,bortezomib,D009101,MM/multiple myeloma,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,19274460_C400082_D009101,No Relation,
770955863,true,false,13,,,No Relation,0.855,D009288,naproxen,D001172,rheumatoid arthritis,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,6699841_D009288_D001172,No Relation,
770955864,true,false,10,,,No Relation,1,D013629,tamoxifen,D001943,breast cancer,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_3,9672273_D013629_D001943,No Relation,
770955865,true,false,15,,,No Relation,0.8645,D004008,diclofenac,D004487,oedema,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_9,17965424_D004008_D004487,No Relation,
770955866,true,false,7,,,No Relation,1,D001379,azathioprine,D008180,systemic lupus erythematosus/SLE,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,12739036_D001379_D008180,No Relation,
770955867,true,false,9,,,No Relation,0.889,D008238,LSD,D001480,EPS,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,12013711_D008238_D001480,No Relation,
770955868,true,false,8,,,No Relation,1,D004317,ADR/adriamycin,D009369,cancer,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,9952311_D004317_D009369,No Relation,
770955869,true,false,12,,'produced by carbachol' being the key term.,No Relation,0.6808,D002122,calcium chloride,D015878,mydriasis,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,6892185_D002122_D015878,No Relation,
770955870,true,false,10,,,No Relation,1,D009270,naloxone,D002375,catalepsy,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,2716967_D009270_D002375,No Relation,
770955871,true,false,17,,,No Relation,0.8921,D015119,epsilon-aminocaproic acid,D008595,menorrhagia,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,2339463_D015119_D008595,No Relation,
770955872,true,false,4,,,No Relation,1,D013467,sulindac,D007674,renal toxicity,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,6699841_D013467_D007674,No Relation,
770955873,true,false,11,,,No Relation,0.8275,D009270,naloxone,D012133,respiratory paralysis,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,2893236_D009270_D012133,No Relation,
770955874,true,false,12,,,No Relation,0.7534,D002794,choline,D000647,amnesia,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,16428827_D002794_D000647,No Relation,
770955875,true,false,9,,,Direct,0.5603,D017373,CPA/cyproterone acetate,D054556,venous thromboembolism/VTE,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,12851669_D017373_D054556,No Relation,
770955876,true,false,11,,,No Relation,1,D000662,amphetamines,D012640,seizure,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,11185967_D000662_D012640,No Relation,
770955877,true,false,16,,Used as treatment.,No Relation,1,D000638,amiodarone,D014693,ventricular fibrillation/VF,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,6637851_D000638_D014693,No Relation,
770955878,true,false,8,,,No Relation,1,D002701,chloramphenicol,D002386,cataract,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,7072798_D002701_D002386,No Relation,
770955879,true,false,12,,,No Relation,0.9234,D007530,isoflurane,D004342,hypersensitivity,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,7647582_D007530_D004342,No Relation,
770955880,true,false,13,,,No Relation,1,D004656,enalapril,D006333,CHF,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_4,10539815_D004656_D006333,No Relation,
770955881,true,false,16,,,No Relation,0.8881,D009270,naloxone,D012133,respiratory paralysis,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,2893236_D009270_D012133,No Relation,
770955882,true,false,11,,,No Relation,1,D011441,PTU,D014424,Turner Syndrome,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,16418614_D011441_D014424,No Relation,
770955883,true,false,11,,,No Relation,1,C065179,atorvastatin,D006973,hypertension,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,16820346_C065179_D006973,No Relation,
770955884,true,false,11,,,No Relation,0.8259,D002216,captopril,D011507,proteinuria,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,6454943_D002216_D011507,No Relation,
770955885,true,false,6,,,No Relation,0.8368,C059262,cidofovir,D000257,adenovirus infection,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_10,12093990_C059262_D000257,No Relation,
770955886,true,false,11,,,No Relation,1,D004308,dosulepine hydrochloride,D059350,chronic pain,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,8766220_D004308_D059350,No Relation,
770955887,true,false,9,,,No Relation,1,D000109,ACh/acetylcholine,D000544,AD/Alzheimer's disease,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,16428827_D000109_D000544,No Relation,
770955888,true,false,11,,,No Relation,1,D013629,tamoxifen,D001943,breast cancer,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_13,9672273_D013629_D001943,No Relation,
770955889,true,false,9,,,No Relation,1,D004052,DEN,D009369,tumor,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,3780814_D004052_D009369,No Relation,
770955890,true,false,8,,,No Relation,1,D013629,tamoxifen,D001943,breast cancer,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.,9672273_0,9672273_D013629_D001943,No Relation,
770955891,true,false,7,,,No Relation,0.8579,C012655,nimesulide,D014581,urticaria,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,11694026_C012655_D014581,No Relation,
770955892,true,false,8,,,No Relation,1,D000638,amiodarone,D017180,VT,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,6637851_D000638_D017180,No Relation,
770955893,true,false,17,,,No Relation,1,D001058,Apomorphine,D010300,Parkinson's disease,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,11009181_D001058_D010300,No Relation,
770955894,true,false,10,,,No Relation,1,D014443,tyrosine,D009410,degeneration of dopaminergic neurons,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,17490790_D014443_D009410,No Relation,
770955895,true,false,13,,,No Relation,1,D002216,captopril,D011507,proteinuria,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,6454943_D002216_D011507,No Relation,
770955896,true,false,6,,,No Relation,0.8487,D013835,thiamine pyrophosphate/TPP,D014899,Wernicke's encephalopathy,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,3762968_D013835_D014899,No Relation,
770955897,true,false,12,,,No Relation,0.9189,D003975,Diazepam,D006212,hallucinations,"Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.",12091028_5,12091028_D003975_D006212,No Relation,
770955898,true,false,18,,'Correction' being the key term.,No Relation,1,D008687,metformin,D007674,kidney dysfunction,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,20164825_D008687_D007674,No Relation,
770955899,true,false,10,,Used as treatment.,No Relation,0.9044,D013629,Tamoxifen,D001943,breast cancer,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_1,9672273_D013629_D001943,No Relation,
770955900,true,false,13,,,No Relation,0.7779,D012254,ribavirin,D000257,adenovirus disease,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_12,12093990_D012254_D000257,No Relation,
770955901,true,false,10,,,No Relation,0.9075,D014191,tranylcypromine,D003866,depression,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,8888541_D014191_D003866,No Relation,
770955902,true,false,11,,,No Relation,1,D004656,enalapril,D003920,diabetes,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_9,10539815_D004656_D003920,No Relation,
770955903,true,false,13,,,No Relation,0.7182,D010396,D-penicillamine,D001172,rheumatoid arthritis,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,8267029_D010396_D001172,No Relation,
770955904,true,false,14,,,No Relation,1,D002122,calcium chloride,D015878,mydriasis,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,6892185_D002122_D015878,No Relation,
770955905,true,false,15,,,No Relation,1,D014635,Valproate,D006423,homonymous hemianopsia,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,19234905_D014635_D006423,No Relation,
770955906,true,false,11,,,No Relation,1,D015215,azidothymidine,C565469,immunodeficient,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,2004015_D015215_C565469,No Relation,
770955907,true,false,9,,,No Relation,0.8964,D009270,naloxone,D007022,hypotension,Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.,1928887_5,1928887_D009270_D007022,No Relation,
770955908,true,false,13,,,No Relation,0.6245,D000617,aminoglycoside,D013924,Thrombophlebitis,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,3934126_D000617_D013924,No Relation,
770955909,true,false,8,,,No Relation,0.8679,D008727,methotrexate,D007938,leukaemia,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,17682013_D008727_D007938,No Relation,
770955910,true,false,17,,,No Relation,1,D013999,timolol,D007008,hypokalemia,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,326460_D013999_D007008,No Relation,
770955911,true,false,9,,,No Relation,1,D004110,diltiazem,D005764,gastroesophageal reflux disorder,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,9545159_D004110_D005764,No Relation,
770955912,true,false,9,,,No Relation,1,D009270,naloxone,D012133,respiratory paralysis,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,2893236_D009270_D012133,No Relation,
770955913,true,false,10,,,No Relation,0.8003,D005680,GABA,D012133,respiratory paralysis,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,2893236_D005680_D012133,No Relation,
770955914,true,false,11,,,No Relation,1,D015742,propofol,D008305,malignant hyperthermia,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,15893386_D015742_D008305,No Relation,
770955915,true,false,10,,,No Relation,0.899,C422649,Etoricoxib,D005767,GI AEs,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_11,17965424_C422649_D005767,No Relation,
770955916,true,false,15,,,No Relation,0.8851,D008094,lithium,D001714,bipolar disorder,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,10354657_D008094_D001714,No Relation,
770955917,true,false,8,,,No Relation,0.8892,D008774,methylphenidate,D061218,treatment-resistant depression,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,12907924_D008774_D061218,No Relation,
770955918,true,false,4,,,No Relation,1,D011224,prazosin,D001919,bradycardia,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_17,1355091_D011224_D001919,No Relation,
770955919,true,false,15,,,No Relation,0.8748,D007980,levodopa,D018476,bradykinesia,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_6,15096016_D007980_D018476,No Relation,
770955920,true,false,9,,,No Relation,0.8941,D010396,Penicillamine,D001172,rheumatoid arthritis,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,8267029_D010396_D001172,No Relation,
770955921,true,false,10,,,No Relation,1,D002118,calcium,D003329,coronary spasm,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_3,3952818_D002118_D003329,No Relation,
770955922,true,false,11,,,No Relation,1,C018824,NH4Ac,D003866,depression,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,6323692_C018824_D003866,No Relation,
770955923,true,false,11,,,No Relation,1,D009705,nucleosides,D002545,cerebral ischemia,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,7710775_D009705_D002545,No Relation,
770955924,true,false,17,,,No Relation,0.944,D008784,methysergide,D004409,dyskinetic,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,8106150_D008784_D004409,No Relation,
770955925,true,false,12,,,No Relation,1,D011899,ranitidine,D056486|D006402,hepatic or hematologic toxicity,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,6150641_D011899_D056486|D006402,No Relation,
770955926,false,true,5,2015-08-14T22:22:00,,No Relation,1,D016047,"2',3'-dideoxycytidine",D000744,immunodeficiency,"Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.",1279198_0,1279198_D016047_D000744,,
770955927,false,true,5,2015-08-14T23:14:00,,No Relation,1,D016049,"2',3'-dideoxyinosine",D000744,immunodeficiency,"Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.",1279198_0,1279198_D016049_D000744,,
770955928,false,true,5,2015-08-14T20:43:00,,No Relation,1,D016047,"ddC/2',3'-dideoxycytidine",D000744,immunodeficiency,"We have used the technique of in vitro selection to generate variants of human immunodeficiency virus type 1 (HIV-1) that are resistant to 2',3'-dideoxyinosine (ddI) and cross-resistant to 2',3'-dideoxycytidine (ddC).",1279198_1,1279198_D016047_D000744,,
770955929,false,true,5,2015-08-14T23:18:00,It's 'human immunodeficiency virus type 1' and not just 'Inmunodeficiency',No Relation,1,D016049,"ddI/2',3'-dideoxyinosine",D000744,immunodeficiency,"We have used the technique of in vitro selection to generate variants of human immunodeficiency virus type 1 (HIV-1) that are resistant to 2',3'-dideoxyinosine (ddI) and cross-resistant to 2',3'-dideoxycytidine (ddC).",1279198_1,1279198_D016049_D000744,,
770955930,false,true,5,2015-08-14T22:53:00,,No Relation,0.7893,D008274,magnesium,D009135,muscle damage,"This study examined the effect of magnesium supplementation on muscle magnesium content, on running performance during a 42-km marathon footrace, and on muscle damage and the rate of recovery of muscle function following the race.",1299490_1,1299490_D008274_D009135,,
770955931,false,true,5,2015-08-14T22:21:00,,No Relation,1,D008274,magnesium,D009135,muscle damage,Extra magnesium ingestion also had no influence on the extent of muscle damage or the rate of recovery of muscle function.,1299490_4,1299490_D008274_D009135,,
770955932,false,true,5,2015-08-15T01:57:00,,No Relation,1,D008274,magnesium,D009135,muscle damage,"Thus, magnesium supplementation in magnesium-replete subjects did not enhance performance or increase resistance to muscle damage during the race, or the rate of recovery of muscle function following the race.",1299490_6,1299490_D008274_D009135,,
770955933,false,true,5,2015-08-15T01:53:00,,Direct,0.5999,D004837,epinephrine,D011655,pulmonary thromboembolism,"Compound 7e, which has a comparable level of TXA2 synthase (IC50 1.2 microM) and human platelet cAMP PDE (IC50 6.4 microM) inhibitory activities, was found to be orally bioavailable with a long duration of action and offered effective protection against mortality in a collagen-epinephrine-induced pulmonary thromboembolism model in mice.",1311763_8,1311763_D004837_D011655,,
770955934,false,true,5,2015-08-15T01:38:00,,No Relation,1,D000242,cAMP,D011655,pulmonary thromboembolism,"Compound 7e, which has a comparable level of TXA2 synthase (IC50 1.2 microM) and human platelet cAMP PDE (IC50 6.4 microM) inhibitory activities, was found to be orally bioavailable with a long duration of action and offered effective protection against mortality in a collagen-epinephrine-induced pulmonary thromboembolism model in mice.",1311763_8,1311763_D000242_D011655,,
770955935,false,true,5,2015-08-14T20:42:00,,No Relation,1,D016190,carboplatin,D002289,non-small-cell lung cancer,Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer.,1326224_0,1326224_D016190_D002289,,
770955936,false,true,5,2015-08-15T01:15:00,,No Relation,1,D016190,carboplatin,D007938,Leukemia,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D016190_D007938,,
770955937,false,true,5,2015-08-14T20:19:00,,No Relation,1,D005047,etoposide,D009369,Cancer,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D005047_D009369,,
770955938,false,true,5,2015-08-14T20:38:00,,No Relation,1,D016190,carboplatin,D009369,Cancer,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D016190_D009369,,
770955939,false,true,5,2015-08-15T02:00:00,,No Relation,1,D005047,etoposide,D007938,Leukemia,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D005047_D007938,,
770955940,false,true,5,2015-08-14T20:34:00,,No Relation,1,D016190,carboplatin,D002289,non-small-cell lung cancer/NSCLC,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D016190_D002289,,
770955941,false,true,5,2015-08-14T20:41:00,,No Relation,1,D005047,etoposide,D002289,non-small-cell lung cancer/NSCLC,"From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2.",1326224_2,1326224_D005047_D002289,,
770955942,false,true,5,2015-08-15T00:25:00,,No Relation,1,D002784,cholesterol,D007673,glomerular diseases,"After a baseline control period of 8 weeks on their usual diets, 20 untreated patients with chronic glomerular diseases, stable long-lasting severe proteinuria (5.9 [SD 3.4] g/24 h) and hyperlipidaemia (mean serum cholesterol 8.69 [3.34] mmol/l) ate a vegetarian soy diet for 8 weeks.",1349366_3,1349366_D002784_D007673,,
770955943,false,true,5,2015-08-14T21:02:00,,No Relation,1,D002784,cholesterol,D011507,proteinuria,"After a baseline control period of 8 weeks on their usual diets, 20 untreated patients with chronic glomerular diseases, stable long-lasting severe proteinuria (5.9 [SD 3.4] g/24 h) and hyperlipidaemia (mean serum cholesterol 8.69 [3.34] mmol/l) ate a vegetarian soy diet for 8 weeks.",1349366_3,1349366_D002784_D011507,,
770955944,false,true,5,2015-08-15T01:58:00,,Direct,0.5819,D017258,medroxyprogesterone acetate,D002769,Cholelithiasis,Cholelithiasis associated with medroxyprogesterone acetate therapy in men.,1385654_0,1385654_D017258_D002769,,
770955945,false,true,5,2015-08-15T00:20:00,,Direct,0.8042,D017258,medroxyprogesterone acetate/MPA,D002769,cholelithiasis,"Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera) IM, 200-400 mg/week, for prevention of sex-offending or genital-mutilating behavior developed symptomatic cholelithiasis.",1385654_1,1385654_D017258_D002769,,
770955946,false,true,5,2015-08-15T00:09:00,"The stone had high cholesterol, but it wasn't caused by it.",Direct,0.5893,D002784,cholesterol,D042882,Gallstones,"Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile.",1385654_3,1385654_D002784_D042882,,
770955947,false,true,5,2015-08-14T22:19:00,,Direct,0.7987,D011374,progesterone,D005705,gallbladder disease,These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis.,1385654_4,1385654_D011374_D005705,,
770955948,false,true,5,2015-08-14T22:24:00,,No Relation,1,D011374,progesterone,D002769,cholelithiasis,These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis.,1385654_4,1385654_D011374_D002769,,
770955949,false,true,5,2015-08-15T00:15:00,,Direct,1,D017258,MPA,D002769,cholelithiasis,These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis.,1385654_4,1385654_D017258_D002769,,
770955950,false,true,5,2015-08-15T02:18:00,,No Relation,0.5996,D017258,MPA,D005705,gallbladder disease,These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis.,1385654_4,1385654_D017258_D005705,,
770955951,false,true,5,2015-08-14T23:24:00,,No Relation,1,D008727,methotrexate,D001172,rheumatoid arthritis,Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis.,1404122_0,1404122_D008727_D001172,,
770955952,false,true,5,2015-08-14T20:17:00,,Direct,0.8267,D008727,methotrexate,D003072,Accelerated nodulosis,Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis.,1404122_0,1404122_D008727_D003072,,
770955953,false,true,5,2015-08-15T02:22:00,,No Relation,1,D008727,methotrexate/MTX,D001172,rheumatoid arthritis/RA,"To obtain information on the occurrence of accelerated nodulosis during methotrexate (MTX) for rheumatoid arthritis (RA), localization, size and presence in heart and lungs of these nodules, predisposing factors, relationship with other extraarticular manifestations (EAM) and their histological features.",1404122_2,1404122_D008727_D001172,,
770955954,false,true,5,2015-08-14T20:25:00,,Direct,1,D008727,MTX,D003072,Accelerated nodulosis,Accelerated nodulosis occurred exclusively during treatment with MTX in our double blind study.,1404122_7,1404122_D008727_D003072,,
770955955,false,true,5,2015-08-14T22:10:00,,No Relation,1,D008727,MTX,D001172,RA,"Accelerated nodulosis during MTX for RA is not rare, and occurs despite good clinical response of polyarthritis.",1404122_18,1404122_D008727_D001172,,
770955956,false,true,5,2015-08-14T20:55:00,,Direct,1,D008727,MTX,D003072,Accelerated nodulosis,"Accelerated nodulosis during MTX for RA is not rare, and occurs despite good clinical response of polyarthritis.",1404122_18,1404122_D008727_D003072,,
770955957,false,true,5,2015-08-15T00:20:00,,No Relation,1,D008727,MTX,D001168,polyarthritis,"Accelerated nodulosis during MTX for RA is not rare, and occurs despite good clinical response of polyarthritis.",1404122_18,1404122_D008727_D001168,,
770955958,false,true,5,2015-08-15T01:23:00,,No Relation,1,D009705,nucleoside,D015658,human immunodeficiency virus,"The objective of this study was to determine the population pharmacokinetic parameters and the extent of absorption of 2',3'-dideoxyinosine, a nucleoside analog with activity against human immunodeficiency virus in vitro and in vivo, after oral and intravenous administration through the use of NON-linear Mixed Effects Modeling.",1416828_1,1416828_D009705_D015658,,
770955959,false,true,5,2015-08-14T23:38:00,,No Relation,1,D016049,"2',3'-dideoxyinosine",D015658,human immunodeficiency virus,"The objective of this study was to determine the population pharmacokinetic parameters and the extent of absorption of 2',3'-dideoxyinosine, a nucleoside analog with activity against human immunodeficiency virus in vitro and in vivo, after oral and intravenous administration through the use of NON-linear Mixed Effects Modeling.",1416828_1,1416828_D016049_D015658,,
770955960,false,true,5,2015-08-15T02:05:00,,No Relation,0.8055,D001839,Bombesin,D015408,gastrinoma,"Bombesin, the equivalent of the mammalian gastrin-releasing peptide, has trophic effects on normal and neoplastic tissues of the gastrointestinal tract; the effects of gut hormones on the growth of gastrinoma are not known.",1455308_2,1455308_D001839_D015408,,
770955961,false,true,5,2015-08-14T20:17:00,,Direct,1,D001839,Bombesin,D009369,tumors,Bombesin significantly stimulated growth of PT tumors from day 18 until mice were sacrificed (day 28).,1455308_9,1455308_D001839_D009369,,
770955962,false,true,5,2015-08-14T20:56:00,,Direct,0.613,D001839,bombesin,D015408,gastrinoma,We have demonstrated for the first time that bombesin is a trophic hormone for gastrinoma.,1455308_11,1455308_D001839_D015408,,
770955963,false,true,5,2015-08-15T00:35:00,,No Relation,1,D020280,sertraline,D003866,depression,"One hundred patients with major depression who had discontinued fluoxetine because of side effects were enrolled in a multicenter, open, 8-week study of sertraline.",1480728_1,1480728_D020280_D003866,,
770955964,false,true,5,2015-08-15T00:54:00,,No Relation,0.7864,D005473,fluoxetine,D003866,depression,"One hundred patients with major depression who had discontinued fluoxetine because of side effects were enrolled in a multicenter, open, 8-week study of sertraline.",1480728_1,1480728_D005473_D003866,,
770955965,false,true,5,2015-08-14T21:47:00,,No Relation,0.5925,D020280,sertraline,D003866,Depressive symptoms,The maximum daily dose of sertraline was 200 mg. Depressive symptoms and adverse events were assessed weekly.,1480728_4,1480728_D020280_D003866,,
770955966,false,true,5,2015-08-14T20:43:00,,No Relation,0.8112,D020280,sertraline,D003866,depression,"Of 91 evaluable patients, 69 sertraline-treated patients (75.8%) experienced significant improvement in depression.",1480728_6,1480728_D020280_D003866,,
770955967,false,true,5,2015-08-14T20:29:00,,No Relation,0.8114,D007069,ifosfamide,D009369,tumors,Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.,1485174_0,1485174_D007069_D009369,,
770955968,false,true,5,2015-08-14T20:17:00,,No Relation,1,D007069,ifosfamide,D007938,leukemia,Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.,1485174_0,1485174_D007069_D007938,,
770955969,false,true,5,2015-08-15T01:09:00,,No Relation,1,D007069,ifosfamide,D016609,malignancies,This paper reviews current approaches to the use of ifosfamide/mesna alone or in combination with other agents or modalities in the treatment of pediatric malignancies.,1485174_1,1485174_D007069_D016609,,
770955970,false,true,5,2015-08-15T01:47:00,,No Relation,1,D015080,mesna,D016609,malignancies,This paper reviews current approaches to the use of ifosfamide/mesna alone or in combination with other agents or modalities in the treatment of pediatric malignancies.,1485174_1,1485174_D015080_D016609,,
770955971,false,true,5,2015-08-15T01:35:00,,No Relation,1,D003520,cyclophosphamide,D016609,malignancies,Randomized trials to determine the relative efficacy of ifosfamide and cyclophosphamide in various childhood malignancies are under way.,1485174_4,1485174_D003520_D016609,,
770955972,false,true,5,2015-08-15T01:54:00,,No Relation,1,D007069,ifosfamide,D016609,malignancies,Randomized trials to determine the relative efficacy of ifosfamide and cyclophosphamide in various childhood malignancies are under way.,1485174_4,1485174_D007069_D016609,,
770955973,false,true,5,2015-08-14T22:22:00,,No Relation,0.8005,D007069,ifosfamide,D001749,bladder cancer,"The long-term consequences of ifosfamide in survivors of childhood cancer, in terms of development of bladder cancer or other malignancies thought to be associated with alkylating agents, are not known, and will only be determined through follow-up studies of adult survivors.",1485174_5,1485174_D007069_D001749,,
770955974,false,true,5,2015-08-15T02:04:00,,No Relation,0.8065,D007069,ifosfamide,D009369,cancer,"The long-term consequences of ifosfamide in survivors of childhood cancer, in terms of development of bladder cancer or other malignancies thought to be associated with alkylating agents, are not known, and will only be determined through follow-up studies of adult survivors.",1485174_5,1485174_D007069_D009369,,
770955975,false,true,5,2015-08-14T20:38:00,,No Relation,0.7925,D007069,ifosfamide,D016609,malignancies,"The long-term consequences of ifosfamide in survivors of childhood cancer, in terms of development of bladder cancer or other malignancies thought to be associated with alkylating agents, are not known, and will only be determined through follow-up studies of adult survivors.",1485174_5,1485174_D007069_D016609,,
770955976,false,true,5,2015-08-14T20:23:00,,No Relation,0.5917,D007069,Ifosfamide,D064420,toxicity,Ifosfamide's future role in pediatric oncology will depend on evaluation of its therapeutic benefits against long-term toxicity.,1485174_6,1485174_D007069_D064420,,
770955977,false,true,5,2015-08-15T00:36:00,,No Relation,1,D010844,OK-432,D009369,tumor,Thirty KE of OK-432 was injected into the tumor per week (total 90-KE) and 5 KE of OK-432 was inoculated into the intracutaneous space per week (total 125 KE).,1498496_2,1498496_D010844_D009369,,
770955978,false,true,5,2015-08-14T22:07:00,,No Relation,1,C062940,RP 59500,D012174,RP,"The in vitro antistaphylococcal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teicoplanin against Staphylococcus aureus, and RP 59500 was the most active agent against coagulase-negative staphylococci.",1503448_1,1503448_C062940_D012174,,
770955979,false,true,5,2015-08-14T20:05:00,,No Relation,1,D014640,vancomycin,D012174,RP,"The in vitro antistaphylococcal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teicoplanin against Staphylococcus aureus, and RP 59500 was the most active agent against coagulase-negative staphylococci.",1503448_1,1503448_D014640_D012174,,
770955980,false,true,5,2015-08-14T22:14:00,,No Relation,1,D008550,melatonin,D009369,tumor,"While the in vivo tumor-inhibiting activity of melatonin is established, observations on its in vitro effects have been contradictory.",1542489_2,1542489_D008550_D009369,,
770955981,false,true,5,2015-08-14T20:29:00,,No Relation,1,D008550,melatonin,D009369,cancer,"The effect of this substance was investigated on six human cancer cell lines and compared to the activity of a partially purified, melatonin-free low molecular weight pineal extract (UMO5R).",1542489_3,1542489_D008550_D009369,,
770955982,false,true,5,2015-08-14T23:16:00,,No Relation,1,D008550,melatonin,D009369,tumor,It is therefore concluded that a direct inhibiting action on tumor cells is not a general physiological role of melatonin as opposed to UMO5R.,1542489_5,1542489_D008550_D009369,,
770955983,false,true,5,2015-08-14T23:53:00,,No Relation,0.7932,D015649,pentostatin,D007943,hairy cell leukemia,"Similar to interferon alpha, pentostatin is highly effective in hairy cell leukemia and moderately active in other chronic lymphoid malignancies.",1564958_1,1564958_D015649_D007943,,
770955984,false,true,5,2015-08-14T20:40:00,,No Relation,1,D015649,pentostatin,D007945,lymphoid malignancies,"Similar to interferon alpha, pentostatin is highly effective in hairy cell leukemia and moderately active in other chronic lymphoid malignancies.",1564958_1,1564958_D015649_D007945,,
770955985,false,true,5,2015-08-15T00:35:00,,No Relation,1,D015649,pentostatin,D015451,chronic leukemias,"In ten patients with hairy cell leukemia (HCL) and seven patients with other B-cell chronic leukemias (BCL), we have studied the intracellular 2',5'-oligoadenylate synthetase (2,5OAS) activity of the mononuclear cells before, 4 h, 24 h, and 48 h after pentostatin administration.",1564958_2,1564958_D015649_D015451,,
770955986,false,true,5,2015-08-14T22:09:00,,No Relation,1,D015649,pentostatin,D007943,HCL/hairy cell leukemia,"In ten patients with hairy cell leukemia (HCL) and seven patients with other B-cell chronic leukemias (BCL), we have studied the intracellular 2',5'-oligoadenylate synthetase (2,5OAS) activity of the mononuclear cells before, 4 h, 24 h, and 48 h after pentostatin administration.",1564958_2,1564958_D015649_D007943,,
770955987,false,true,5,2015-08-14T20:29:00,,No Relation,1,C023505,"2',5'-oligoadenylate",D007943,HCL/hairy cell leukemia,"In ten patients with hairy cell leukemia (HCL) and seven patients with other B-cell chronic leukemias (BCL), we have studied the intracellular 2',5'-oligoadenylate synthetase (2,5OAS) activity of the mononuclear cells before, 4 h, 24 h, and 48 h after pentostatin administration.",1564958_2,1564958_C023505_D007943,,
770955988,false,true,5,2015-08-15T00:05:00,,No Relation,1,C023505,"2',5'-oligoadenylate",D015451,chronic leukemias,"In ten patients with hairy cell leukemia (HCL) and seven patients with other B-cell chronic leukemias (BCL), we have studied the intracellular 2',5'-oligoadenylate synthetase (2,5OAS) activity of the mononuclear cells before, 4 h, 24 h, and 48 h after pentostatin administration.",1564958_2,1564958_C023505_D015451,,
770955989,false,true,5,2015-08-15T01:17:00,,No Relation,1,D015649,pentostatin,D007943,HCL,Eleven patients (eight with HCL and two with BCL) responded to pentostatin.,1564958_5,1564958_D015649_D007943,,
770955990,false,true,5,2015-08-15T01:45:00,,Direct,0.3992,D015649,pentostatin,D004487,cytotoxicity,"Thus, response to pentostatin correlates with induction of 2,5OAS directly and the 2',5'-oligoadenylate system seems to be involved in cytotoxicity.",1564958_11,1564958_D015649_D004487,,
770955991,false,true,5,2015-08-15T00:48:00,,No Relation,0.7854,D007213,indomethacin,D020521,stroke,"Using Doppler technology, we determined cardiac output, stroke volume, and total peripheral resistance before and after three 25-mg doses of indomethacin.",1565345_5,1565345_D007213_D020521,,
770955992,false,true,5,2015-08-15T00:27:00,,No Relation,0.7922,D007213,indomethacin,D020521,stroke,"Although blood pressure did not change, peripheral resistance rose and stroke volume fell following indomethacin administration.",1565345_6,1565345_D007213_D020521,,
770955993,false,true,5,2015-08-15T01:39:00,,Direct,0.5911,D000666,amphotericin B,D064420,toxicity,Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.,1590686_0,1590686_D000666_D064420,,
770955994,false,true,5,2015-08-14T23:14:00,,No Relation,0.5894,D000666,amphotericin B,D008172,fungal infection,Results of a double-blind randomized non-crossover study of rapid (45 min) versus slow (4 h) infusion of amphotericin B administered to 20 patients with proven or suspected fungal infection are reported.,1590686_1,1590686_D000666_D008172,,
770955995,false,true,5,2015-08-14T22:23:00,,Direct,0.5742,D008614,meperidine,D064420,Toxicity,"Toxicity was higher in the rapid infusion group than it was in the slow infusion group (mean total 7-day chill score, 173 +/- 276 versus 20 +/- 30 [P less than 0.01]; mean total 7-day dosage of meperidine required to abate rigors, 180 +/- 133 versus 58 +/- 78 mg [P less than 0.05]; and mean maximum total 7-day pulse rise, 225 +/- 64 versus 135 +/- 56 beats per min [P less than 0.02], respectively).",1590686_2,1590686_D008614_D064420,,
770955996,false,true,5,2015-08-14T20:21:00,,Direct,1,D000666,amphotericin B,D009325,nausea,"When analyzed on a daily basis, the mean chill score, meperidine dosage, and pulse rise were also higher; and in addition, nausea and vomiting (5 of 11 patients who received a rapid infusion versus 0 of 9 patients who received a slow infusion [P less than 0.01]) appeared to be more common in those who received amphotericin B rapidly.",1590686_3,1590686_D000666_D009325,,
770955997,false,true,5,2015-08-15T01:59:00,,No Relation,0.6072,D000666,amphotericin B,D014839,vomiting,"When analyzed on a daily basis, the mean chill score, meperidine dosage, and pulse rise were also higher; and in addition, nausea and vomiting (5 of 11 patients who received a rapid infusion versus 0 of 9 patients who received a slow infusion [P less than 0.01]) appeared to be more common in those who received amphotericin B rapidly.",1590686_3,1590686_D000666_D014839,,
770955998,false,true,5,2015-08-15T01:23:00,,No Relation,0.5906,D008614,meperidine,D009325,nausea,"When analyzed on a daily basis, the mean chill score, meperidine dosage, and pulse rise were also higher; and in addition, nausea and vomiting (5 of 11 patients who received a rapid infusion versus 0 of 9 patients who received a slow infusion [P less than 0.01]) appeared to be more common in those who received amphotericin B rapidly.",1590686_3,1590686_D008614_D009325,,
770955999,false,true,5,2015-08-14T22:24:00,,Direct,0.5938,D008614,meperidine,D014839,vomiting,"When analyzed on a daily basis, the mean chill score, meperidine dosage, and pulse rise were also higher; and in addition, nausea and vomiting (5 of 11 patients who received a rapid infusion versus 0 of 9 patients who received a slow infusion [P less than 0.01]) appeared to be more common in those who received amphotericin B rapidly.",1590686_3,1590686_D008614_D014839,,
770956000,false,true,5,2015-08-15T00:58:00,,No Relation,0.8087,D008788,metolazone,D001997,bronchopulmonary dysplasia,Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia.,1593359_0,1593359_D008788_D001997,,
770956001,false,true,5,2015-08-14T20:34:00,,No Relation,1,D005665,furosemide,D001997,bronchopulmonary dysplasia,Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia.,1593359_0,1593359_D005665_D001997,,
770956002,false,true,5,2015-08-14T23:30:00,The disease is a pre-existing condition.,No Relation,1,D012964,sodium,D001997,bronchopulmonary dysplasia,"We conclude that the administration of metolazone with furosemide enhances diuresis, natriuresis, and chloruresis and overcomes the rapid development of tolerance to furosemide in infants with bronchopulmonary dysplasia by blocking the compensatory increase in renal sodium and chloride absorption.",1593359_12,1593359_D012964_D001997,,
770956003,false,true,5,2015-08-15T01:14:00,,No Relation,1,D008788,metolazone,D001997,bronchopulmonary dysplasia,"We conclude that the administration of metolazone with furosemide enhances diuresis, natriuresis, and chloruresis and overcomes the rapid development of tolerance to furosemide in infants with bronchopulmonary dysplasia by blocking the compensatory increase in renal sodium and chloride absorption.",1593359_12,1593359_D008788_D001997,,
770956004,false,true,5,2015-08-14T23:45:00,Disease is a pre-existing condition.,No Relation,1,D005665,furosemide,D001997,bronchopulmonary dysplasia,"We conclude that the administration of metolazone with furosemide enhances diuresis, natriuresis, and chloruresis and overcomes the rapid development of tolerance to furosemide in infants with bronchopulmonary dysplasia by blocking the compensatory increase in renal sodium and chloride absorption.",1593359_12,1593359_D005665_D001997,,
770956005,false,true,5,2015-08-14T23:43:00,,No Relation,1,D002712,chloride,D001997,bronchopulmonary dysplasia,"We conclude that the administration of metolazone with furosemide enhances diuresis, natriuresis, and chloruresis and overcomes the rapid development of tolerance to furosemide in infants with bronchopulmonary dysplasia by blocking the compensatory increase in renal sodium and chloride absorption.",1593359_12,1593359_D002712_D001997,,
770956006,false,true,5,2015-08-15T01:03:00,,No Relation,1,D013256,steroids,D006509,hepatitis B,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D013256_D006509,,
770956007,false,true,5,2015-08-15T01:49:00,,Direct,0.6112,D013256,steroids,D017093,liver failure,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D013256_D017093,,
770956008,false,true,5,2015-08-15T01:52:00,,No Relation,0.5787,D000305,corticosteroids,D017093,liver failure,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D000305_D017093,,
770956009,false,true,5,2015-08-14T20:28:00,,No Relation,1,D000305,corticosteroids,D006509,hepatitis B,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D000305_D006509,,
770956010,false,true,5,2015-08-14T21:48:00,,No Relation,1,D013256,steroids,D013224,asthmatic,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D013256_D013224,,
770956011,false,true,5,2015-08-14T22:16:00,,No Relation,1,D000305,corticosteroids,D013224,asthmatic,We report two hepatitis B virus (HBV) carriers who had liver failure after withdrawal of corticosteroids (steroids) administered for treatment of serious asthmatic attacks.,1600269_1,1600269_D000305_D013224,,
770956012,false,true,5,2015-08-14T23:59:00,,No Relation,0.5969,D013256,steroid,D017093,liver failure,Liver functions deteriorated 1 to 2 wk after withdrawal of the steroid therapy and liver failure occurred.,1600269_2,1600269_D013256_D017093,,
770956013,false,true,5,2015-08-15T00:58:00,,No Relation,1,D013256,Steroid,D017093,liver failure,Steroid readministration and intensive therapy for liver failure did not prevent death.,1600269_3,1600269_D013256_D017093,,
770956014,false,true,5,2015-08-14T20:52:00,,No Relation,1,D013256,Steroid,D003643,death,Steroid readministration and intensive therapy for liver failure did not prevent death.,1600269_3,1600269_D013256_D003643,,
770956015,false,true,5,2015-08-14T21:46:00,,No Relation,0.7904,D013256,steroid,D008107,liver disease,An excessive immune response provoked by steroid withdrawal and decreased reserve capacity due to underlying chronic liver disease were thought to be factors in the liver failure.,1600269_4,1600269_D013256_D008107,,
770956016,false,true,5,2015-08-14T20:24:00,,No Relation,0.6153,D013256,steroid,D017093,liver failure,An excessive immune response provoked by steroid withdrawal and decreased reserve capacity due to underlying chronic liver disease were thought to be factors in the liver failure.,1600269_4,1600269_D013256_D017093,,
770956017,false,true,5,2015-08-14T20:43:00,,No Relation,1,D013256,steroids,D006509,HBV infection,Caution must be exercised in the administration of steroids to patients with underlying chronic HBV infection to prevent exacerbation of hepatitis.,1600269_5,1600269_D013256_D006509,,
770956018,false,true,5,2015-08-14T20:38:00,,Direct,0.8009,D013256,steroids,D006505,hepatitis,Caution must be exercised in the administration of steroids to patients with underlying chronic HBV infection to prevent exacerbation of hepatitis.,1600269_5,1600269_D013256_D006505,,
770956019,false,true,5,2015-08-14T20:06:00,,No Relation,1,D013256,steroids,D017093,liver failure,Prompt readministration of steroids is indicated if evidence of liver failure develops.,1600269_6,1600269_D013256_D017093,,
770956020,false,true,5,2015-08-14T22:31:00,,No Relation,1,D008715,methionine,D055752,SCLC,"In summary, BN analogues which lack a C-terminal methionine may function as useful SCLC BN receptor antagonists.",1646997_6,1646997_D008715_D055752,,
770956021,false,true,5,2015-08-14T23:21:00,,No Relation,0.7925,D001839,BN,D055752,SCLC,"In summary, BN analogues which lack a C-terminal methionine may function as useful SCLC BN receptor antagonists.",1646997_6,1646997_D001839_D055752,,
770956022,false,true,5,2015-08-14T20:38:00,,No Relation,0.824,D013629,tamoxifen,D009447,neuroblastoma,"Non-myelotoxic antitumour effects of L-dopa, buthionine sulphoximine and tamoxifen on neuroblastoma cells in vitro and in vivo.",1653780_0,1653780_D013629_D009447,,
770956023,false,true,5,2015-08-15T00:25:00,,No Relation,1,D007980,L-dopa,D008545,melanoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D007980_D008545,,
770956024,false,true,5,2015-08-14T22:21:00,,No Relation,1,D013629,tamoxifen,D008545,melanoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D013629_D008545,,
770956025,false,true,5,2015-08-14T20:49:00,,Direct,0.5949,D004295,dihydroxyphenylalanine,D064420,toxicity,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D004295_D064420,,
770956026,false,true,5,2015-08-14T23:45:00,,No Relation,1,D013629,tamoxifen,D064420,toxicity,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D013629_D064420,,
770956027,false,true,5,2015-08-14T22:31:00,,No Relation,1,D004295,dihydroxyphenylalanine,D001943,human mammary carcinoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D004295_D001943,,
770956028,false,true,5,2015-08-14T20:06:00,,No Relation,1,D007980,L-dopa,D001943,human mammary carcinoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D007980_D001943,,
770956029,false,true,5,2015-08-15T00:11:00,,No Relation,1,D007980,L-dopa,D009447,neuroblastoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D007980_D009447,,
770956030,false,true,5,2015-08-14T22:15:00,,No Relation,0.5749,D007980,L-dopa,D064420,toxicity,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D007980_D064420,,
770956031,false,true,5,2015-08-14T22:16:00,,No Relation,1,D013629,tamoxifen,D009447,neuroblastoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D013629_D009447,,
770956032,false,true,5,2015-08-15T00:07:00,,No Relation,1,D013629,tamoxifen,D001943,human mammary carcinoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D013629_D001943,,
770956033,false,true,5,2015-08-14T20:54:00,,No Relation,1,D004295,dihydroxyphenylalanine,D009447,neuroblastoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D004295_D009447,,
770956034,false,true,5,2015-08-14T23:16:00,,No Relation,0.8046,D004295,dihydroxyphenylalanine,D008545,melanoma,"The effects of three non-myelotoxic cancer drugs on the growth of neuroblastoma cells were investigated in vitro and in vivo: dihydroxyphenylalanine (L-dopa, a drug with selective toxicity for melanoma cells), DL-buthionine sulphoximine (BSO, a drug with radiosensitizing effects), and tamoxifen (a drug used in the treatment of human mammary carcinoma).",1653780_1,1653780_D004295_D008545,,
770956035,false,true,5,2015-08-15T02:17:00,,No Relation,1,D004298,dopamine,D009369,neuroblastoma tumours,"The growth of neuroblastoma tumours was inhibited by different mechanisms: L-dopa and its metabolite dopamine reduced the activity of tyrosinase, BSO reduced glutathione levels, and L-dopa and tamoxifen raised cAMP concentrations.",1653780_5,1653780_D004298_D009369,,
770956036,false,true,5,2015-08-14T22:52:00,,No Relation,1,D005978,glutathione,D009369,neuroblastoma tumours,"The growth of neuroblastoma tumours was inhibited by different mechanisms: L-dopa and its metabolite dopamine reduced the activity of tyrosinase, BSO reduced glutathione levels, and L-dopa and tamoxifen raised cAMP concentrations.",1653780_5,1653780_D005978_D009369,,
770956037,false,true,5,2015-08-14T20:32:00,,No Relation,0.7976,D000242,cAMP,D009369,neuroblastoma tumours,"The growth of neuroblastoma tumours was inhibited by different mechanisms: L-dopa and its metabolite dopamine reduced the activity of tyrosinase, BSO reduced glutathione levels, and L-dopa and tamoxifen raised cAMP concentrations.",1653780_5,1653780_D000242_D009369,,
770956038,false,true,5,2015-08-15T00:44:00,,No Relation,1,D007980,L-dopa,D009369,neuroblastoma tumours,"The growth of neuroblastoma tumours was inhibited by different mechanisms: L-dopa and its metabolite dopamine reduced the activity of tyrosinase, BSO reduced glutathione levels, and L-dopa and tamoxifen raised cAMP concentrations.",1653780_5,1653780_D007980_D009369,,
770956039,false,true,5,2015-08-15T00:42:00,,No Relation,1,D013629,tamoxifen,D009369,neuroblastoma tumours,"The growth of neuroblastoma tumours was inhibited by different mechanisms: L-dopa and its metabolite dopamine reduced the activity of tyrosinase, BSO reduced glutathione levels, and L-dopa and tamoxifen raised cAMP concentrations.",1653780_5,1653780_D013629_D009369,,
770956040,false,true,5,2015-08-15T02:13:00,,No Relation,1,D016210,methacholine,D013224,asthmatic,"Ten asthmatic subjects were studied on three occasions after bronchial challenges with aerosolized PAF, methacholine, or isotonic saline.",1661723_3,1661723_D016210_D013224,,
770956041,false,true,5,2015-08-15T00:21:00,,No Relation,1,D010100,oxygen,C531854,retinoic acid/RA,We have investigated the effect of retinoic acid (RA) and retinyl acetate (RAc) on the production of reactive oxygen metabolites and the release of lysosomal enzymes by human polymorphonuclear leukocytes (PMN).,1667243_2,1667243_D010100_C531854,,
770956042,false,true,5,2015-08-15T00:12:00,,No Relation,1,C009166,retinyl acetate,C531854,retinoic acid/RA,We have investigated the effect of retinoic acid (RA) and retinyl acetate (RAc) on the production of reactive oxygen metabolites and the release of lysosomal enzymes by human polymorphonuclear leukocytes (PMN).,1667243_2,1667243_C009166_C531854,,
770956043,false,true,5,2015-08-15T00:10:00,,No Relation,1,D014212,retinoic acid,C531854,retinoic acid/RA,We have investigated the effect of retinoic acid (RA) and retinyl acetate (RAc) on the production of reactive oxygen metabolites and the release of lysosomal enzymes by human polymorphonuclear leukocytes (PMN).,1667243_2,1667243_D014212_C531854,,
770956044,false,true,5,2015-08-15T01:39:00,,No Relation,1,D000001,A23187,C531854,RA,"Incubation of PMN with RAc or RA (1-100 microM) caused a dose-dependent inhibition (upto 90%) in O2- production and chemiluminescence induced by phorbol myristate acetate (PMA), N-formyl-methionyl-leucyl-phenylanaline (fMLP), opsonized zymosan or ionophore A23187.",1667243_3,1667243_D000001_C531854,,
770956045,false,true,5,2015-08-15T01:50:00,,No Relation,1,D013481,O2,C531854,RA,"Incubation of PMN with RAc or RA (1-100 microM) caused a dose-dependent inhibition (upto 90%) in O2- production and chemiluminescence induced by phorbol myristate acetate (PMA), N-formyl-methionyl-leucyl-phenylanaline (fMLP), opsonized zymosan or ionophore A23187.",1667243_3,1667243_D013481_C531854,,
770956046,false,true,5,2015-08-15T02:25:00,,No Relation,0.6306,D013755,phorbol myristate acetate/PMA,C531854,RA,"Incubation of PMN with RAc or RA (1-100 microM) caused a dose-dependent inhibition (upto 90%) in O2- production and chemiluminescence induced by phorbol myristate acetate (PMA), N-formyl-methionyl-leucyl-phenylanaline (fMLP), opsonized zymosan or ionophore A23187.",1667243_3,1667243_D013755_C531854,,
770956047,false,true,5,2015-08-15T00:18:00,,No Relation,0.8049,D012176,retinoids,C531854,RA,"Both retinoids (1-100 microM) also inhibited, in a dose-dependent way, degranulation induced by fMLP (upto 85% at the highest concentration of RA).",1667243_4,1667243_D012176_C531854,,
770956048,false,true,5,2015-08-14T20:05:00,,No Relation,1,D015215,zidovudine,D000163,AIDS,Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.,1671651_0,1671651_D015215_D000163,,
770956049,false,true,5,2015-08-14T22:21:00,,No Relation,1,D015215,zidovudine,D000163,AIDS,"To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta 2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex.",1671651_1,1671651_D015215_D000163,,
770956050,false,true,5,2015-08-15T01:29:00,,No Relation,1,D019798,neopterin,D000163,AIDS,"To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta 2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex.",1671651_1,1671651_D019798_D000163,,
770956051,false,true,5,2015-08-15T01:35:00,,No Relation,1,D019798,neopterin,D000163,AIDS,"The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards model: a diagnosis of AIDS (v AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration.",1671651_8,1671651_D019798_D000163,,
770956052,false,true,5,2015-08-14T20:38:00,,No Relation,1,D049971,Thiazide,D006973,hypertensive/hypertension,Thiazide diuretics remain the drugs of first choice for treating hypertension in the African-American hypertensive.,1687447_4,1687447_D049971_D006973,,
770956053,false,true,5,2015-08-15T02:18:00,,No Relation,0.8137,D002118,calcium,D054144,diastolic dysfunction,"The calcium channel blockers (CCBs) are attractive alternatives to thiazides in patients uncontrolled by or intolerant of thiazides or who have specific indications for these agents (eg, angina, severe diastolic dysfunction).",1687447_5,1687447_D002118_D054144,,
770956054,false,true,5,2015-08-15T01:22:00,,No Relation,0.7992,D049971,thiazides,D017566,angina,"The calcium channel blockers (CCBs) are attractive alternatives to thiazides in patients uncontrolled by or intolerant of thiazides or who have specific indications for these agents (eg, angina, severe diastolic dysfunction).",1687447_5,1687447_D049971_D017566,,
770956055,false,true,5,2015-08-14T20:55:00,,No Relation,1,D002118,calcium,D017566,angina,"The calcium channel blockers (CCBs) are attractive alternatives to thiazides in patients uncontrolled by or intolerant of thiazides or who have specific indications for these agents (eg, angina, severe diastolic dysfunction).",1687447_5,1687447_D002118_D017566,,
770956056,false,true,5,2015-08-15T01:11:00,,No Relation,1,D049971,thiazides,D054144,diastolic dysfunction,"The calcium channel blockers (CCBs) are attractive alternatives to thiazides in patients uncontrolled by or intolerant of thiazides or who have specific indications for these agents (eg, angina, severe diastolic dysfunction).",1687447_5,1687447_D049971_D054144,,
770956057,false,true,5,2015-08-15T02:34:00,,No Relation,1,D000431,alcohol,D006525,viral hepatitis,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000431_D006525,,
770956058,false,true,5,2015-08-14T23:11:00,,No Relation,0.6061,D000431,alcohol,D006526,hepatitis C,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000431_D006526,,
770956059,false,true,5,2015-08-15T01:45:00,,Direct,1,D000431,alcohol,D008107,liver diseases/liver disease,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000431_D008107,,
770956060,false,true,5,2015-08-15T00:31:00,,No Relation,1,D000409,alanine,D006526,hepatitis C,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000409_D006526,,
770956061,false,true,5,2015-08-14T22:16:00,,No Relation,1,D001224,aspartate,D006525,viral hepatitis,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D001224_D006525,,
770956062,false,true,5,2015-08-15T01:47:00,,No Relation,1,D000409,alanine,D006525,viral hepatitis,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000409_D006525,,
770956063,false,true,5,2015-08-14T20:21:00,,No Relation,1,D000409,alanine,D008107,liver diseases/liver disease,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D000409_D008107,,
770956064,false,true,5,2015-08-14T20:43:00,,No Relation,1,D001224,aspartate,D006526,hepatitis C,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D001224_D006526,,
770956065,false,true,5,2015-08-15T01:06:00,,No Relation,1,D001224,aspartate,D008107,liver diseases/liver disease,"These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of ""unexplained chronic aminotransferase elevations"" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.",1701367_2,1701367_D001224_D008107,,
770956066,false,true,5,2015-08-15T01:09:00,,No Relation,1,D010426,PPS,D009369,tumor,Daily intraperitoneal injections of PPS were tolerated well by athymic nude mice and prevented growth of subcutaneous SW-13/K-fgf tumor xenografts.,1708834_9,1708834_D010426_D009369,,
770956067,false,true,5,2015-08-14T23:34:00,,No Relation,1,D003520,cyclophosphamide,D015267,granulomatosis,The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids.,1739240_16,1739240_D003520_D015267,,
770956068,false,true,5,2015-08-14T23:40:00,,Direct,1,D003520,cyclophosphamide,D064420,toxicity,"Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.",1739240_19,1739240_D003520_D064420,,
770956069,false,true,5,2015-08-14T20:56:00,,No Relation,0.6112,D003520,cyclophosphamide,D015267,granulomatosis,"Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.",1739240_19,1739240_D003520_D015267,,
770956070,false,true,5,2015-08-14T20:41:00,,No Relation,1,D000596,amino acid,D016638,critically ill,The effect of fuel source on amino acid metabolism in critically ill patients.,1740940_0,1740940_D000596_D016638,,
770956071,false,true,5,2015-08-15T00:39:00,,No Relation,1,D005947,glucose,D016638,critically ill,"While glucose has been proved to have nitrogen sparing properties in postoperative patients, critically ill patients tolerate glucose loads poorly and fat appears to be an obligatory fuel in sepsis.",1740940_2,1740940_D005947_D016638,,
770956072,false,true,5,2015-08-14T23:26:00,,No Relation,1,D009584,nitrogen,D016638,critically ill,"While glucose has been proved to have nitrogen sparing properties in postoperative patients, critically ill patients tolerate glucose loads poorly and fat appears to be an obligatory fuel in sepsis.",1740940_2,1740940_D009584_D016638,,
770956073,false,true,5,2015-08-15T02:09:00,,No Relation,0.8263,D005947,glucose,D018805,sepsis,"While glucose has been proved to have nitrogen sparing properties in postoperative patients, critically ill patients tolerate glucose loads poorly and fat appears to be an obligatory fuel in sepsis.",1740940_2,1740940_D005947_D018805,,
770956074,false,true,5,2015-08-14T20:27:00,,No Relation,0.795,D009584,nitrogen,D018805,sepsis,"While glucose has been proved to have nitrogen sparing properties in postoperative patients, critically ill patients tolerate glucose loads poorly and fat appears to be an obligatory fuel in sepsis.",1740940_2,1740940_D009584_D018805,,
770956075,false,true,5,2015-08-14T20:47:00,,No Relation,0.8091,D005947,glucose,D018149,glucose intolerance,Four patients on the G regimen were withdrawn due to glucose intolerance while none of the patients on GF developed glucose intolerance or hyperlipidaemia.,1740940_14,1740940_D005947_D018149,,
770956076,false,true,5,2015-08-15T00:43:00,,No Relation,1,D006493,Heparin,D006620,fractured hip,Heparin and graduated compression stockings in patients undergoing fractured hip surgery.,1761997_0,1761997_D006493_D006620,,
770956077,false,true,5,2015-08-15T00:38:00,,No Relation,1,D006493,heparin,D006620,fractured hip,"This study confirms that therapy with heparin and graduated compression stockings is effective, inexpensive, and convenient for the prevention of venous thrombosis in fractured hip patients and is associated with a low bleeding risk.",1761997_9,1761997_D006493_D006620,,
770956078,false,true,5,2015-08-14T22:23:00,,No Relation,0.8107,D006493,heparin,D006470,bleeding,"This study confirms that therapy with heparin and graduated compression stockings is effective, inexpensive, and convenient for the prevention of venous thrombosis in fractured hip patients and is associated with a low bleeding risk.",1761997_9,1761997_D006493_D006470,,
770956079,false,true,5,2015-08-15T00:12:00,,No Relation,1,D006493,heparin,D019851,venous thrombosis,"This study confirms that therapy with heparin and graduated compression stockings is effective, inexpensive, and convenient for the prevention of venous thrombosis in fractured hip patients and is associated with a low bleeding risk.",1761997_9,1761997_D006493_D019851,,
770956080,false,true,5,2015-08-15T02:21:00,,No Relation,0.8339,D004176,dipyridamole,D001778,hemorrheologic and blood coagulation,"Effect of buflomedil, dipyridamole and indobufene on hemorrheologic and blood coagulation parameters in patients who underwent vascular surgery for severe atherosclerosis.",1770324_0,1770324_D004176_D001778,,
770956081,false,true,5,2015-08-14T20:34:00,,No Relation,0.8034,D004176,dipyridamole,D050197,atherosclerosis,"Effect of buflomedil, dipyridamole and indobufene on hemorrheologic and blood coagulation parameters in patients who underwent vascular surgery for severe atherosclerosis.",1770324_0,1770324_D004176_D050197,,
770956082,false,true,5,2015-08-15T00:52:00,,No Relation,0.7933,D016572,cyclosporin A,D011565,psoriasis,Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.,1864010_0,1864010_D016572_D011565,,
770956083,false,true,5,2015-08-14T20:33:00,,No Relation,0.7893,D016572,cyclosporin A/CsA,D011565,psoriasis,A study was conducted to quantify soluble IL-2 receptor (sIL-2R) levels in sera of 57 chronic plaque psoriasis patients and correlate these measurements with disease activity and the number of IL-2R-positive (CD25+) lymphocytes in lesional biopsies of 11 cyclosporin A (CsA) and 13 psoralen plus ultraviolet radiation (PUVA) treated patients.,1864010_1,1864010_D016572_D011565,,
770956084,false,true,5,2015-08-14T20:55:00,,No Relation,1,D013256,steroids,D004487,edema,Many facial plastic surgeons use perioperative steroids to reduce postoperative edema and morbidity.,1910730_2,1910730_D013256_D004487,,
770956085,false,true,5,2015-08-15T01:56:00,,No Relation,1,D013256,steroids,D004487,edema,We found significantly less postoperative eyelid and paranasal edema in those patients receiving steroids.,1910730_5,1910730_D013256_D004487,,
770956086,false,true,5,2015-08-14T22:05:00,,No Relation,0.8117,D013256,steroids,D004487,edema,"In addition, trends toward less ecchymosis, less intranasal edema, and less discomfort in the patients receiving steroids were noted.",1910730_6,1910730_D013256_D004487,,
770956087,false,true,5,2015-08-15T02:19:00,,No Relation,1,D004077,digoxin,D001281,atrial fibrillation,Our data indicate that patients who develop spontaneous postoperative atrial fibrillation should be treated with digoxin for 3 weeks following operation and then drug therapy may be discontinued indefinitely.,1910852_7,1910852_D004077_D001281,,
770956088,false,true,5,2015-08-14T23:56:00,,No Relation,1,D002511,cephalosporins,D044504,neutropenic,Third-generation cephalosporins are an important part of the therapeutic armamentarium for the empiric management of neutropenic patients.,1918211_5,1918211_D002511_D044504,,
770956089,false,true,5,2015-08-15T00:13:00,,No Relation,1,D002443,ceftriaxone,D044504,neutropenic,"But even when combined with an aminoglycoside, ceftriaxone would not be a good choice for neutropenic patients.",1918211_8,1918211_D002443_D044504,,
770956090,false,true,5,2015-08-15T01:20:00,,No Relation,1,D000617,aminoglycoside,D044504,neutropenic,"But even when combined with an aminoglycoside, ceftriaxone would not be a good choice for neutropenic patients.",1918211_8,1918211_D000617_D044504,,
770956091,false,true,5,2015-08-14T22:55:00,,No Relation,0.8031,D005947,glucose,D003929,diabetes,Effect of Konjac food on blood glucose level in patients with diabetes.,1966003_0,1966003_D005947_D003929,,
770956092,false,true,5,2015-08-14T20:53:00,,No Relation,1,D005947,glucose,D006402,blood glucose,Effect of Konjac food on blood glucose level in patients with diabetes.,1966003_0,1966003_D005947_D006402,,
770956093,false,true,5,2015-08-14T22:20:00,,No Relation,1,D005947,glucose,D006402,blood glucose,"The data analyzed by multiple F test indicate that the fasting blood glucose (FBG) and the 2-h postprandial blood glucose (PBG) on the 30th and the 65th days after the food was ingested were significantly reduced (P = 0.001, P less than 0.001, respectively), as was the glycosylated hemoglobin level at the end of the trial (P less than 0.05).",1966003_2,1966003_D005947_D006402,,
770956094,false,true,5,2015-08-14T20:28:00,,No Relation,0.8047,D009553,Nimodipine,D014581,urticaria,Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria.,1968727_0,1968727_D009553_D014581,,
770956095,false,true,5,2015-08-14T22:01:00,,No Relation,1,D016593,terfenadine,D014581,urticaria,Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria.,1968727_0,1968727_D016593_D014581,,
770956096,false,true,5,2015-08-14T20:06:00,,No Relation,0.6024,C038806,dihydropyridine,D014581,urticaria,"The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy.",1968727_4,1968727_C038806_D014581,,
770956097,false,true,5,2015-08-15T00:34:00,,No Relation,1,D009553,nimodipine,D014581,urticaria,"The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy.",1968727_4,1968727_D009553_D014581,,
770956098,false,true,5,2015-08-15T02:42:00,,No Relation,1,D002118,calcium,D014581,urticaria,"The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy.",1968727_4,1968727_D002118_D014581,,
770956099,false,true,5,2015-08-15T00:51:00,,No Relation,1,D009553,nimodipine,D014581,urticaria,"The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg.",1968727_5,1968727_D009553_D014581,,
770956100,false,true,5,2015-08-15T00:45:00,,No Relation,0.8075,D016593,terfenadine,D014581,urticaria,"The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg.",1968727_5,1968727_D016593_D014581,,
770956101,false,true,5,2015-08-14T20:45:00,,Direct,0.615,D017640,silicate,D008171,lung disease,Hypothesis: is lung disease after silicate inhalation caused by oxidant generation?,1977006_0,1977006_D017640_D008171,,
770956102,false,true,5,2015-08-15T01:59:00,,Direct,1,D017640,silicate,D008171,lung disease,Inhaled silicate dusts may cause lung disease through their surface coordination of iron with subsequent oxidant generation via the Fenton reaction.,1977006_1,1977006_D017640_D008171,,
770956103,false,true,5,2015-08-14T20:40:00,,Direct,0.7903,D007501,iron,D008171,lung disease,Inhaled silicate dusts may cause lung disease through their surface coordination of iron with subsequent oxidant generation via the Fenton reaction.,1977006_1,1977006_D007501_D008171,,
770956104,false,true,5,2015-08-14T20:38:00,,Direct,0.6123,D017640,silicate,D014376,tuberculosis,The increased incidence of tuberculosis observed among silicate workers could be explained by accumulation of iron complexed by dust particles in the lung and made available to dormant mycobacteria as a virulence factor.,1977006_3,1977006_D017640_D014376,,
770956105,false,true,5,2015-08-14T22:39:00,,Direct,1,D007501,iron,D014376,tuberculosis,The increased incidence of tuberculosis observed among silicate workers could be explained by accumulation of iron complexed by dust particles in the lung and made available to dormant mycobacteria as a virulence factor.,1977006_3,1977006_D007501_D014376,,
770956106,false,true,5,2015-08-14T20:06:00,,No Relation,0.8082,D002118,calcium,D006973,hypertension,"Effect of a calcium-entry blocker, nicardipine, on intrarenal hemodynamics in essential hypertension.",1986570_0,1986570_D002118_D006973,,
770956107,false,true,5,2015-08-14T22:27:00,,No Relation,0.7898,D009529,nicardipine,D006973,hypertension,"Effect of a calcium-entry blocker, nicardipine, on intrarenal hemodynamics in essential hypertension.",1986570_0,1986570_D009529_D006973,,
770956108,false,true,5,2015-08-15T01:58:00,,No Relation,0.8089,D002118,calcium,D006973,hypertension,"The effects of a calcium-entry blocker, nicardipine, on intrarenal hemodynamics were studied in essential hypertension.",1986570_1,1986570_D002118_D006973,,
770956109,false,true,5,2015-08-15T02:10:00,,No Relation,0.8302,D009529,nicardipine,D006973,hypertension,"The effects of a calcium-entry blocker, nicardipine, on intrarenal hemodynamics were studied in essential hypertension.",1986570_1,1986570_D009529_D006973,,
770956110,false,true,5,2015-08-15T02:06:00,,No Relation,1,D012964,sodium,D006973,hypertension,"A 4-week study was performed in eight patients with essential hypertension who were given a regular sodium diet in the first and third weeks, and a sodium-restricted diet in the second and fourth weeks.",1986570_2,1986570_D012964_D006973,,
770956111,false,true,5,2015-08-14T20:16:00,,No Relation,1,D002118,Ca,D006973,hypertension,This Ca-entry blocker worked to normalize intrarenal hemodynamics in essential hypertension by dilating afferent arterioles alone.,1986570_9,1986570_D002118_D006973,,
770956112,false,true,5,2015-08-14T20:05:00,,Direct,0.5928,D003345,corticosterone,D006994,hypoaldosteronism,Severe hypoaldosteronism due to corticosterone methyl oxidase type II deficiency in two boys: metabolic and gas chromatography-mass spectrometry studies.,2044581_0,2044581_D003345_D006994,,
770956113,false,true,5,2015-08-15T01:45:00,,No Relation,0.6394,D003345,corticosterone,D007020,II deficiency,Severe hypoaldosteronism due to corticosterone methyl oxidase type II deficiency in two boys: metabolic and gas chromatography-mass spectrometry studies.,2044581_0,2044581_D003345_D007020,,
770956114,false,true,5,2015-08-14T23:43:00,,No Relation,0.8205,D000450,aldosterone,D019282,wasting,"Infection-triggered, life-threatening salt-loss and hyperkalaemia developed in two male infants with wasting, inappropriately low plasma aldosterone concentrations and elevated plasma renin activity.",2044581_1,2044581_D000450_D019282,,
770956115,false,true,5,2015-08-15T00:03:00,,No Relation,1,D013256,Steroid,D014456,ulcer,Steroid therapy and duodenal ulcer in infants.,2051278_0,2051278_D013256_D014456,,
770956116,false,true,5,2015-08-14T20:53:00,,Direct,1,D013256,steroid,D014456,ulcer,Two infants with acute life-threatening complications of duodenal ulcer following steroid administration are described.,2051278_1,2051278_D013256_D014456,,
770956117,false,true,5,2015-08-14T22:19:00,,Direct,0.8132,D013256,steroid,D014456,ulcer disease/ulcer,"Although the possible association between steroid therapy and peptic ulcer disease is well known, the need for ulcer prophylaxis during such therapy in infants is not unanimously accepted.",2051278_2,2051278_D013256_D014456,,
770956118,false,true,5,2015-08-14T20:23:00,,Direct,0.6308,D000617,aminoglycoside,D064420,toxicity,Haemofiltration is indicated particularly for aminoglycoside toxicity.,2056948_4,2056948_D000617_D064420,,
770956119,false,true,5,2015-08-15T00:17:00,,Direct,1,D008727,methotrexate,D010198,pancytopenia,Severe pancytopenia in a patient taking low dose methotrexate and probenecid.,2066953_0,2066953_D008727_D010198,,
770956120,false,true,5,2015-08-14T20:23:00,,Direct,1,D011339,probenecid,D010198,pancytopenia,Severe pancytopenia in a patient taking low dose methotrexate and probenecid.,2066953_0,2066953_D011339_D010198,,
770956121,false,true,5,2015-08-15T00:23:00,,No Relation,1,D008727,methotrexate/MTX,D001172,rheumatoid arthritis,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D008727_D001172,,
770956122,false,true,5,2015-08-14T22:19:00,,No Relation,0.5891,D008727,methotrexate/MTX,D064420,toxicity,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D008727_D064420,,
770956123,false,true,5,2015-08-15T01:19:00,,Direct,0.7919,D011339,probenecid,D010198,pancytopenia,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D011339_D010198,,
770956124,false,true,5,2015-08-15T00:42:00,,Direct,1,D011339,probenecid,D064420,toxicity,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D011339_D064420,,
770956125,false,true,5,2015-08-14T20:50:00,,Direct,0.7792,D008727,methotrexate/MTX,D010198,pancytopenia,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D008727_D010198,,
770956126,false,true,5,2015-08-15T01:51:00,,No Relation,0.6151,D011339,probenecid,D001172,rheumatoid arthritis,A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid.,2066953_1,2066953_D011339_D001172,,
770956127,false,true,5,2015-08-14T20:26:00,,Direct,0.6087,D008727,MTX,D064420,toxicity,Clinically significant drug interactions are not frequently cited as risk factors for MTX hematologic toxicity.,2066953_2,2066953_D008727_D064420,,
770956128,false,true,5,2015-08-14T20:17:00,,No Relation,1,D015738,Famotidine,D005764,reflux oesophagitis,Famotidine in the management of acid-reflux oesophagitis: a multicentre study.,2083926_0,2083926_D015738_D005764,,
770956129,false,true,5,2015-08-14T23:30:00,Probably used as treatment.,No Relation,1,D015738,famotidine,D005764,reflux oesophagitis/gastro-oesophageal reflux,"In this study, we tested the response to treatment with famotidine for 8 weeks in patients with reflux oesophagitis, taking into consideration, however, only cases with pathological gastro-oesophageal reflux of the acidic type.",2083926_2,2083926_D015738_D005764,,
770956130,false,true,5,2015-08-15T01:19:00,,No Relation,1,D009257,naftidrofuryl,D057066,normal tension glaucoma,Double-blind study in the treatment of normal tension glaucoma with naftidrofuryl.,2089356_0,2089356_D009257_D057066,,
770956131,false,true,5,2015-08-14T22:21:00,,No Relation,1,D009257,naftidrofuryl,D006311,visual acuity and the visual field,"The administration of 2 x 200 mg/day of naftidrofuryl during 6 weeks to 12 patients with normal tension glaucoma has shown an improvement of the visual acuity and the visual field compared with a 6-week period of placebo administration, with a double-blind study method.",2089356_3,2089356_D009257_D006311,,
770956132,false,true,5,2015-08-14T23:57:00,'Improvement' being the key term.,No Relation,1,D009257,naftidrofuryl,D057066,normal tension glaucoma,"The administration of 2 x 200 mg/day of naftidrofuryl during 6 weeks to 12 patients with normal tension glaucoma has shown an improvement of the visual acuity and the visual field compared with a 6-week period of placebo administration, with a double-blind study method.",2089356_3,2089356_D009257_D057066,,
770956133,false,true,5,2015-08-14T23:17:00,,No Relation,1,D009257,naftidrofuryl,D007022,hypotensive,"It suggested that naftidrofuryl might be administered as a useful complement to conventional hypotensive therapy, since it acts positively on the glaucomatous optic nerve damage.",2089356_4,2089356_D009257_D007022,,
770956134,false,true,5,2015-08-15T00:13:00,,No Relation,1,D009257,naftidrofuryl,D006177,optic nerve damage,"It suggested that naftidrofuryl might be administered as a useful complement to conventional hypotensive therapy, since it acts positively on the glaucomatous optic nerve damage.",2089356_4,2089356_D009257_D006177,,
770956135,false,true,5,2015-08-14T22:04:00,,No Relation,1,D011464,prostacyclin,D009503,neutropenia,Effects of prostacyclin on bronchoconstriction and neutropenia induced by inhaled platelet-activating factor in man.,2109002_0,2109002_D011464_D009503,,
770956136,false,true,5,2015-08-14T23:43:00,,No Relation,0.7957,D011464,PGI2,C566800,platelet aggregation,Ex vivo platelet aggregation to PAF (10(-9) to 10(-7) mol/L) was significantly inhibited by PGI2.,2109002_7,2109002_D011464_C566800,,
770956137,false,true,5,2015-08-14T23:26:00,,No Relation,0.5935,D011464,PGI2,C566800,platelet aggregation,"Thus, PGI2 does not influence PAF-induced bronchoconstriction in man despite causing marked inhibition of ex vivo PAF-induced platelet aggregation and preventing the fall of neutrophils.",2109002_9,2109002_D011464_C566800,,
770956138,false,true,5,2015-08-14T23:40:00,,No Relation,1,D017334,teicoplanin,D018805,septicaemia,A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.,2149049_0,2149049_D017334_D018805,,
770956139,false,true,5,2015-08-15T01:15:00,,No Relation,0.7929,D001398,aztreonam,D018805,septicaemia,A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.,2149049_0,2149049_D001398_D018805,,
770956140,false,true,5,2015-08-14T22:26:00,,No Relation,1,D005839,gentamicin,D018805,septicaemia,A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.,2149049_0,2149049_D005839_D018805,,
770956141,false,true,5,2015-08-15T00:14:00,,No Relation,1,D010878,piperacillin,D018805,septicaemia,A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.,2149049_0,2149049_D010878_D018805,,
770956142,false,true,5,2015-08-15T01:23:00,,No Relation,0.7979,D001398,aztreonam,D018805,septicaemia,A randomized comparative evaluation of teicoplanin plus aztreonam versus gentamicin plus piperacillin in leukaemic patients with a clinical diagnosis of septicaemia was undertaken.,2149049_3,2149049_D001398_D018805,,
770956143,false,true,5,2015-08-15T01:15:00,,No Relation,1,D005839,gentamicin,D018805,septicaemia,A randomized comparative evaluation of teicoplanin plus aztreonam versus gentamicin plus piperacillin in leukaemic patients with a clinical diagnosis of septicaemia was undertaken.,2149049_3,2149049_D005839_D018805,,
770956144,false,true,5,2015-08-14T22:02:00,,No Relation,1,D010878,piperacillin,D018805,septicaemia,A randomized comparative evaluation of teicoplanin plus aztreonam versus gentamicin plus piperacillin in leukaemic patients with a clinical diagnosis of septicaemia was undertaken.,2149049_3,2149049_D010878_D018805,,
770956145,false,true,5,2015-08-14T20:23:00,,No Relation,1,C029063,"fructose 1,6-diphosphate",D016491,peripheral vascular disease,"Effect of fructose 1,6-diphosphate on exercise capacity in patients with peripheral vascular disease.",2172175_0,2172175_C029063_D016491,,
770956146,false,true,5,2015-08-15T02:30:00,,No Relation,1,D010100,oxygen,D016491,peripheral vascular disease,The present study was undertaken to determine whether FDP could enhance oxygen supply and thus improve exercise performance in patients with peripheral vascular disease.,2172175_3,2172175_D010100_D016491,,
770956147,false,true,5,2015-08-15T01:00:00,,No Relation,1,D019794,"2,3 diphosphoglycerate",D007383,claudication or peak exercise,"No differences were observed in heart rate, blood pressure, gas exchange data, time to the onset of claudication or peak exercise, or lactate and 2,3 diphosphoglycerate levels.",2172175_6,2172175_D019794_D007383,,
770956148,false,true,5,2015-08-15T02:12:00,,No Relation,1,D019344,lactate,D007383,claudication or peak exercise,"No differences were observed in heart rate, blood pressure, gas exchange data, time to the onset of claudication or peak exercise, or lactate and 2,3 diphosphoglycerate levels.",2172175_6,2172175_D019344_D007383,,
770956149,false,true,5,2015-08-15T00:03:00,,No Relation,1,C029063,FDP,D000860,hypoxic,"In contrast to previous studies performed among patients with peripheral vascular disease and other studies using more severe hypoxic conditions, FDP did not affect the respiratory gas exchange or exercise capacity of patients with exertional claudication.",2172175_7,2172175_C029063_D000860,,
770956150,false,true,5,2015-08-14T22:24:00,,No Relation,1,C029063,FDP,D007383,exertional claudication,"In contrast to previous studies performed among patients with peripheral vascular disease and other studies using more severe hypoxic conditions, FDP did not affect the respiratory gas exchange or exercise capacity of patients with exertional claudication.",2172175_7,2172175_C029063_D007383,,
770956151,false,true,5,2015-08-14T20:43:00,,No Relation,1,C029063,FDP,D016491,peripheral vascular disease,"In contrast to previous studies performed among patients with peripheral vascular disease and other studies using more severe hypoxic conditions, FDP did not affect the respiratory gas exchange or exercise capacity of patients with exertional claudication.",2172175_7,2172175_C029063_D016491,,
770956152,false,true,5,2015-08-14T22:43:00,,No Relation,1,D006820,sodium hyaluronate/SH,D065306,cornea,The aim of the present study was to quantify in man the distribution and clearance of two aqueous sodium hyaluronate (SH) solutions of 0.125% and 0.250% after the administration of 25 microliters onto the cornea.,2176168_1,2176168_D006820_D065306,,
770956153,false,true,5,2015-08-15T00:15:00,,No Relation,1,D006820,SH,D065306,cornea,"Actually, 53% of the radiolabelled 0.250% SH solution remained on the cornea as compared with 30% for the 0.125% SH solution and 18.3% for the PB solution.",2176168_8,2176168_D006820_D065306,,
770956154,false,true,5,2015-08-15T01:25:00,,No Relation,1,D007213,indomethacin,D006831,polyhydramnios,Maternal indomethacin therapy in the treatment of polyhydramnios.,2187352_0,2187352_D007213_D006831,,
770956155,false,true,5,2015-08-15T01:10:00,,No Relation,1,D007213,indomethacin,D006831,polyhydramnios,Fifteen patients with polyhydramnios and clinical symptoms related to excess amniotic fluid volume were treated with indomethacin therapy that was started at a mean gestational age of 27.4 +/- 2.79 weeks and discontinued at a mean gestational age of 32.9 +/- 1.83 weeks.,2187352_1,2187352_D007213_D006831,,
770956156,false,true,5,2015-08-15T01:35:00,,No Relation,1,D007559,ivermectin,D005128,ocular onchocercal disease,"Community trials were started to address questions concerning the safety of ivermectin during large scale treatment, its potential for transmission control, its effect in preventing ocular onchocercal disease, its acceptability and the organization of large scale treatment.",2198750_1,2198750_D007559_D005128,,
770956157,false,true,5,2015-08-14T20:23:00,,No Relation,1,D007559,ivermectin,D009855,Onchocerciasis,"A summary is presented of the major, latest results on the short-term epidemiological impact of large scale ivermectin treatment, as observed in eight community trials undertaken in the Onchocerciasis Control Programme in West Africa (OCP).",2198750_2,2198750_D007559_D009855,,
770956158,false,true,5,2015-08-14T22:29:00,,No Relation,1,D007559,Ivermectin,D007239,infection,"Ivermectin treatment appears to be the most appropriate method for control of recrudescence of infection in an area where the parasite reservoir has been virtually eliminated by vector control, such as in the core area of the OCP.",2198750_9,2198750_D007559_D007239,,
770956159,false,true,5,2015-08-14T22:03:00,,No Relation,1,D002784,cholesterol,D003929,diabetic,The aim of this study was to examine the effect of Max EPA (a commercially available fish oil preparation) on serum cholesterol lipoproteins and apolipoproteins in insulin-dependent diabetic (IDDM) men with dosages that were likely to be acceptable to patients.,2201495_1,2201495_D002784_D003929,,
770956160,false,true,5,2015-08-15T01:02:00,,No Relation,1,D002784,cholesterol,D003922,IDDM,The aim of this study was to examine the effect of Max EPA (a commercially available fish oil preparation) on serum cholesterol lipoproteins and apolipoproteins in insulin-dependent diabetic (IDDM) men with dosages that were likely to be acceptable to patients.,2201495_1,2201495_D002784_D003922,,
770956161,false,true,5,2015-08-14T20:49:00,,No Relation,1,D002118,calcium,D010024,osteoporosis,"Aging is characterized, besides other changes, by a progressive increase in calcium content in the arterial wall, which is enhanced by diabetes mellitus, osteoporosis, arterial hypertension, and tabagism.",2226675_1,2226675_D002118_D010024,,
770956162,false,true,5,2015-08-15T00:57:00,,No Relation,0.8374,D002118,calcium,D003920,diabetes mellitus,"Aging is characterized, besides other changes, by a progressive increase in calcium content in the arterial wall, which is enhanced by diabetes mellitus, osteoporosis, arterial hypertension, and tabagism.",2226675_1,2226675_D002118_D003920,,
770956163,false,true,5,2015-08-15T02:15:00,,No Relation,1,D002118,calcium,D065627,arterial hypertension,"Aging is characterized, besides other changes, by a progressive increase in calcium content in the arterial wall, which is enhanced by diabetes mellitus, osteoporosis, arterial hypertension, and tabagism.",2226675_1,2226675_D002118_D065627,,
770956164,false,true,5,2015-08-15T00:25:00,,No Relation,1,D002118,calcium,C562794,hypocalcemizing,"In order to study the role of calcium ions in the pathogenesis of the vasoconstrictive lesions caused by ""acute"" smoking, the author has studied the peripheral vascular effects of the calcium-channel antagonist nifedipine, a dihydropyridine derivative, and calcitonin, a hypocalcemizing hormone which possess vasoactive actions on 12 elderly regular smokers (mean age 65.8 years).",2226675_3,2226675_D002118_C562794,,
770956165,false,true,5,2015-08-14T22:21:00,,No Relation,1,C038806,dihydropyridine,C562794,hypocalcemizing,"In order to study the role of calcium ions in the pathogenesis of the vasoconstrictive lesions caused by ""acute"" smoking, the author has studied the peripheral vascular effects of the calcium-channel antagonist nifedipine, a dihydropyridine derivative, and calcitonin, a hypocalcemizing hormone which possess vasoactive actions on 12 elderly regular smokers (mean age 65.8 years).",2226675_3,2226675_C038806_C562794,,
770956166,false,true,5,2015-08-15T00:11:00,,No Relation,1,D009543,nifedipine,C562794,hypocalcemizing,"In order to study the role of calcium ions in the pathogenesis of the vasoconstrictive lesions caused by ""acute"" smoking, the author has studied the peripheral vascular effects of the calcium-channel antagonist nifedipine, a dihydropyridine derivative, and calcitonin, a hypocalcemizing hormone which possess vasoactive actions on 12 elderly regular smokers (mean age 65.8 years).",2226675_3,2226675_D009543_C562794,,
770956167,false,true,5,2015-08-15T01:59:00,,No Relation,0.6321,D002116,calcitonin,C562794,hypocalcemizing,"In order to study the role of calcium ions in the pathogenesis of the vasoconstrictive lesions caused by ""acute"" smoking, the author has studied the peripheral vascular effects of the calcium-channel antagonist nifedipine, a dihydropyridine derivative, and calcitonin, a hypocalcemizing hormone which possess vasoactive actions on 12 elderly regular smokers (mean age 65.8 years).",2226675_3,2226675_D002116_C562794,,
770956168,false,true,5,2015-08-14T23:36:00,,No Relation,0.803,D010100,oxygen,D009202,myocardial dysfunction,"The ""stunned myocardium"" is a syndrome of reversible myocardial dysfunction that may be mediated by oxygen-derived free radicals.",2252128_1,2252128_D010100_D009202,,
770956169,false,true,5,2015-08-15T01:35:00,,No Relation,1,D010100,oxygen,D017682,stunned myocardium,"The ""stunned myocardium"" is a syndrome of reversible myocardial dysfunction that may be mediated by oxygen-derived free radicals.",2252128_1,2252128_D010100_D017682,,
770956170,false,true,5,2015-08-14T20:28:00,,No Relation,1,D010100,oxygen,D017682,stunned myocardium,These data suggest that oxygen-derived free radicals may not cause the stunned myocardium seen in neonates undergoing extracorporeal membrane oxygenation.,2252128_6,2252128_D010100_D017682,,
770956171,false,true,5,2015-08-14T21:44:00,,No Relation,0.8204,C092985,calcium pidolate,D010024,involutional osteoporosis,Effect of calcium pidolate on biochemical and hormonal parameters in involutional osteoporosis.,2255262_0,2255262_C092985_D010024,,
770956172,false,true,5,2015-08-14T22:02:00,,No Relation,1,C092985,calcium pidolate,D010024,involutional osteoporosis,The purpose of this study was to determine the value of calcium pidolate in the treatment of involutional osteoporosis.,2255262_1,2255262_C092985_D010024,,
770956173,false,true,5,2015-08-15T00:38:00,,No Relation,1,D002118,calcium,D010024,involutional osteoporosis,We accordingly treated one group of 10 women suffering from involutional osteoporosis with the equivalent of 1 g elemental calcium and administered a placebo to a second group of 10 osteoporotic women whose mean age and body surface area were comparable.,2255262_3,2255262_D002118_D010024,,
770956174,false,true,5,2015-08-14T20:06:00,,No Relation,1,D015725,fluconazole,D002177,candidiasis,"Clinical trials and reports support the use of fluconazole in treatment of candidiasis, particularly oropharyngeal and esophageal infections in immunocompromised hosts.",2260347_8,2260347_D015725_D002177,,
770956175,false,true,5,2015-08-14T20:05:00,,No Relation,1,D015725,fluconazole,D007239,infections,"Clinical trials and reports support the use of fluconazole in treatment of candidiasis, particularly oropharyngeal and esophageal infections in immunocompromised hosts.",2260347_8,2260347_D015725_D007239,,
770956176,false,true,5,2015-08-14T20:34:00,,No Relation,1,D015725,Fluconazole,D016919,cryptococcal meningitis,Fluconazole is also approved for initial and suppressive therapy of cryptococcal meningitis.,2260347_9,2260347_D015725_D016919,,
770956177,false,true,5,2015-08-14T20:25:00,,No Relation,0.6057,D002395,catecholamines,D005334,hyperthermia,Urinary catecholamines in hyperthermia-related deaths.,2279717_0,2279717_D002395_D005334,,
770956178,false,true,5,2015-08-14T20:41:00,,Direct,0.5723,D002395,catecholamines,D003643,deaths,Urinary catecholamines in hyperthermia-related deaths.,2279717_0,2279717_D002395_D003643,,
770956179,false,true,5,2015-08-14T23:25:00,'hyperthermia-related deaths' 'urinary noradrenaline (NA) concentrations' and 'rapid violent deaths' :),Direct,0.587,D009638,noradrenaline,D003643,deaths,A group of five hyperthermia-related deaths is presented in which urinary noradrenaline (NA) concentrations were elevated (172.1 +/- 119.4 ng/ml) compared with a control group of rapid violent deaths (43.7 +/- 26.1 ng/ml).,2279717_1,2279717_D009638_D003643,,
770956180,false,true,5,2015-08-15T01:52:00,,No Relation,0.6065,D009638,noradrenaline,D005334,hyperthermia,A group of five hyperthermia-related deaths is presented in which urinary noradrenaline (NA) concentrations were elevated (172.1 +/- 119.4 ng/ml) compared with a control group of rapid violent deaths (43.7 +/- 26.1 ng/ml).,2279717_1,2279717_D009638_D005334,,
770956181,false,true,5,2015-08-14T22:28:00,,No Relation,1,D004837,adrenaline,D005334,hyperthermia,"Urinary adrenaline (A) concentrations were not elevated in the hyperthermia cases, nor were there any significant differences in urinary dopamine (DA) concentrations between the two groups.",2279717_2,2279717_D004837_D005334,,
770956182,false,true,5,2015-08-15T00:59:00,,No Relation,1,D004298,dopamine,D005334,hyperthermia,"Urinary adrenaline (A) concentrations were not elevated in the hyperthermia cases, nor were there any significant differences in urinary dopamine (DA) concentrations between the two groups.",2279717_2,2279717_D004298_D005334,,
770956183,false,true,5,2015-08-15T01:22:00,,Direct,0.7836,D000431,ethanol,D005334,hyperthermia,All except one of the hyperthermia victims were under the influence of ethanol.,2279717_3,2279717_D000431_D005334,,
770956184,false,true,5,2015-08-15T02:27:00,,No Relation,0.8194,D000431,ethanol,D005334,hyperthermia,"It is suggested that a combination of heat stress and ethanol consumption was responsible for the elevated urinary NA in the hyperthermia cases, reflecting increased sympathetic nervous system activity.",2279717_4,2279717_D000431_D005334,,
770956185,false,true,5,2015-08-14T23:29:00,,No Relation,1,D013015,sotalol,D054141,flutter,"One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred.",2303641_1,2303641_D013015_D054141,,
770956186,false,true,5,2015-08-14T22:47:00,,No Relation,1,D011405,propafenone,D054141,flutter,"One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred.",2303641_1,2303641_D011405_D054141,,
770956187,false,true,5,2015-08-14T20:51:00,,No Relation,1,D011405,propafenone,D001281,atrial fibrillation,"One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred.",2303641_1,2303641_D011405_D001281,,
770956188,false,true,5,2015-08-14T20:31:00,,No Relation,1,D013015,sotalol,D001281,atrial fibrillation,"One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred.",2303641_1,2303641_D013015_D001281,,
770956189,false,true,5,2015-08-15T01:28:00,,No Relation,1,D013015,sotalol,D001145,arrhythmia,The percent of patients free of recurrent symptomatic arrhythmia at 6 months was 39% for propafenone and 50% for sotalol.,2303641_6,2303641_D013015_D001145,,
770956190,false,true,5,2015-08-15T02:00:00,,No Relation,0.7968,D011405,propafenone,D001145,arrhythmia,The percent of patients free of recurrent symptomatic arrhythmia at 6 months was 39% for propafenone and 50% for sotalol.,2303641_6,2303641_D011405_D001145,,
770956191,false,true,5,2015-08-14T20:52:00,,No Relation,1,C050504,Tianeptine,D007022,orthostatic hypotension,Tianeptine did not produce orthostatic hypotension or increase heart rate.,2306747_5,2306747_C050504_D007022,,
770956192,false,true,5,2015-08-15T02:00:00,,Direct,0.6165,C050504,tianeptine,D064420,cardiac toxicity,The present study suggests that tianeptine is a tricyclic antidepressant endowed with less cardiac toxicity than classical tricyclic antidepressants.,2306747_9,2306747_C050504_D064420,,
770956193,false,true,5,2015-08-14T20:33:00,"""An underappreciated relationship""...  hm, puzzling and unorthodox  qualification.",No Relation,0.7895,D000305,corticosteroid,D004241,colonic diverticula,An underappreciated relationship is that of perforation of colonic diverticula and corticosteroid therapy.,2353866_3,2353866_D000305_D004241,,
770956194,false,true,5,2015-08-15T00:58:00,,Direct,1,D000305,corticosteroid,D004241,colonic diverticula,This report describes the course of three patients who developed perforations of colonic diverticula that were temporally related to corticosteroid use.,2353866_4,2353866_D000305_D004241,,
770956195,false,true,5,2015-08-14T20:16:00,,No Relation,1,D000667,ampicillin,D011704,pyelonephritis,"Therefore, we conclude that a limited-spectrum cephalosporin is more appropriate than ampicillin for empirical therapy of pyelonephritis in pregnancy.",2371028_7,2371028_D000667_D011704,,
770956196,false,true,5,2015-08-15T00:55:00,,No Relation,1,D002511,cephalosporin,D011704,pyelonephritis,"Therefore, we conclude that a limited-spectrum cephalosporin is more appropriate than ampicillin for empirical therapy of pyelonephritis in pregnancy.",2371028_7,2371028_D002511_D011704,,
770956197,false,true,5,2015-08-14T22:19:00,,No Relation,1,D000617,aminoglycoside,D011552,Pseudomonas aeruginosa,Mortality due to left-sided endocarditis caused by Pseudomonas aeruginosa remains high despite the therapeutic regimen of high doses of an aminoglycoside plus a beta-lactam antibiotic.,2385771_1,2385771_D000617_D011552,,
770956198,false,true,5,2015-08-14T20:17:00,,No Relation,1,D000617,aminoglycoside,D004696,endocarditis,Mortality due to left-sided endocarditis caused by Pseudomonas aeruginosa remains high despite the therapeutic regimen of high doses of an aminoglycoside plus a beta-lactam antibiotic.,2385771_1,2385771_D000617_D004696,,
770956199,false,true,5,2015-08-14T22:24:00,,No Relation,1,D015525,omega-3 fatty acids,D009369,pancreatic cancer,"No association was found between pancreatic cancer risk and the intake of total fat, saturated fat, cholesterol, omega-3 fatty acids, or vitamins A and C. There was an unexpected inverse association between calcium intake and pancreatic cancer risk in these data.",2389747_9,2389747_D015525_D009369,,
770956200,false,true,5,2015-08-15T00:24:00,,No Relation,0.8119,D002118,calcium,D009369,pancreatic cancer,"No association was found between pancreatic cancer risk and the intake of total fat, saturated fat, cholesterol, omega-3 fatty acids, or vitamins A and C. There was an unexpected inverse association between calcium intake and pancreatic cancer risk in these data.",2389747_9,2389747_D002118_D009369,,
770956201,false,true,5,2015-08-14T20:05:00,,No Relation,1,D002784,cholesterol,D009369,pancreatic cancer,"No association was found between pancreatic cancer risk and the intake of total fat, saturated fat, cholesterol, omega-3 fatty acids, or vitamins A and C. There was an unexpected inverse association between calcium intake and pancreatic cancer risk in these data.",2389747_9,2389747_D002784_D009369,,
770956202,false,true,5,2015-08-14T22:16:00,,Direct,0.814,D009532,Nickel,D003872,dermatitis,Nickel dermatitis.,2406062_0,2406062_D009532_D003872,,
770956203,false,true,5,2015-08-15T02:00:00,,Direct,0.7991,D009532,nickel,D004342,hypersensitivity,It has been claimed that there is such a high correlation between a positive history of nickel hypersensitivity and patch-test results that testing is unnecessary if there is a history of hypersensitivity.,2406062_3,2406062_D009532_D004342,,
770956204,false,true,5,2015-08-14T23:39:00,,No Relation,0.5832,D009532,Nickel,D004342,hypersensitivity,Nickel hypersensitivity itself is not a serious health problem for the individual.,2406062_5,2406062_D009532_D004342,,
770956205,false,true,5,2015-08-14T20:50:00,,Direct,0.5894,D009532,nickel,D004342,hypersensitivity,It seems important to introduce safe methods of ear piercing (a primary source of nickel hypersensitivity) and to spread information about the health hazard potential of the seemingly harmless sensitivity to nickel.,2406062_9,2406062_D009532_D004342,,
770956206,false,true,5,2015-08-14T20:58:00,,No Relation,1,D006221,halothane,D008107,liver disease,"Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion).",7506644_4,7506644_D006221_D008107,,
770956207,false,true,5,2015-08-14T22:31:00,"The first highlighting is erroneous (""hepatitis because the icterus""); it should be just ""hepatitis"" which in this case is directly induced by halothane.",No Relation,0.791,D006221,halothane,D007565,jaundice/hepatitis because the icterus,"Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion).",7506644_4,7506644_D006221_D007565,,
770956208,false,true,5,2015-08-14T20:49:00,,Direct,0.5905,D006221,halothane,D006505,hepatitis,"Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion).",7506644_4,7506644_D006221_D006505,,
770956209,false,true,5,2015-08-14T20:52:00,,No Relation,1,D006221,halothane,D000743,hemolytic anemia,"Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion).",7506644_4,7506644_D006221_D000743,,
770956210,false,true,5,2015-08-15T01:57:00,,No Relation,0.8288,D016729,leuprolide,D011470,prostatic hyperplasia,"Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia.",7516978_0,7516978_D016729_D011470,,
770956211,false,true,5,2015-08-14T23:23:00,Used as treatment.,No Relation,1,D016729,leuprolide,D011470,prostatic hyperplasia,"The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.",7516978_1,7516978_D016729_D011470,,
770956212,false,true,5,2015-08-15T01:47:00,,Direct,1,D016729,leuprolide,D015430,weight gain,Of 26 patients receiving leuprolide 5 had a weight gain of more than 3 kg.,7516978_6,7516978_D016729_D015430,,
770956213,false,true,5,2015-08-15T00:59:00,,No Relation,1,D017265,procaterol,D013224,asthmatic,"Effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing response caused by inflammatory mediators in asthmatic children.",7544228_0,7544228_D017265_D013224,,
770956214,false,true,5,2015-08-14T21:50:00,,No Relation,1,D001920,bradykinin,D013224,asthmatic,"We examined the effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing responses to histamine, platelet-activating factor (PAF), substance P, or bradykinin in eight asthmatic children in a double-blind, randomized, cross-over study.",7544228_3,7544228_D001920_D013224,,
770956215,false,true,5,2015-08-15T00:07:00,,No Relation,1,D017265,procaterol,D013224,asthmatic,"We examined the effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing responses to histamine, platelet-activating factor (PAF), substance P, or bradykinin in eight asthmatic children in a double-blind, randomized, cross-over study.",7544228_3,7544228_D017265_D013224,,
770956216,false,true,5,2015-08-15T01:34:00,,No Relation,1,D006632,histamine,D013224,asthmatic,"We examined the effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing responses to histamine, platelet-activating factor (PAF), substance P, or bradykinin in eight asthmatic children in a double-blind, randomized, cross-over study.",7544228_3,7544228_D006632_D013224,,
770956217,false,true,5,2015-08-14T20:34:00,,No Relation,1,D002939,Ciprofloxacin,D002771,cholera,"Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults.",7548496_0,7548496_D002939_D002771,,
770956218,false,true,5,2015-08-15T00:18:00,,No Relation,1,D002939,ciprofloxacin,D002771,cholera,"We conducted a randomized, double-blind clinical trial to compare ciprofloxacin (250 mg once a day for 3 days) with tetracycline (500 mg four times a day for 3 days) in terms of efficacy and safety in the treatment of moderate-to-severe cholera in Peruvian adults.",7548496_1,7548496_D002939_D002771,,
770956219,false,true,5,2015-08-14T20:34:00,,No Relation,1,D013752,tetracycline,D002771,cholera,"We conducted a randomized, double-blind clinical trial to compare ciprofloxacin (250 mg once a day for 3 days) with tetracycline (500 mg four times a day for 3 days) in terms of efficacy and safety in the treatment of moderate-to-severe cholera in Peruvian adults.",7548496_1,7548496_D013752_D002771,,
770956220,false,true,5,2015-08-15T01:13:00,,No Relation,1,D002939,ciprofloxacin,D002771,cholera,We conclude that ciprofloxacin given once a day is as effective as the standard tetracycline regimen for the treatment of cholera in adults.,7548496_6,7548496_D002939_D002771,,
770956221,false,true,5,2015-08-15T01:26:00,,No Relation,1,D013752,tetracycline,D002771,cholera,We conclude that ciprofloxacin given once a day is as effective as the standard tetracycline regimen for the treatment of cholera in adults.,7548496_6,7548496_D013752_D002771,,
770956222,false,true,5,2015-08-15T00:01:00,,No Relation,1,D003894,desmopressin,D009103,multiple sclerosis,"An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia.",7551881_0,7551881_D003894_D009103,,
770956223,false,true,5,2015-08-15T00:38:00,,No Relation,0.8042,D003894,desmopressin,D053158,nocturia,"An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia.",7551881_0,7551881_D003894_D053158,,
770956224,false,true,5,2015-08-15T02:00:00,,No Relation,1,D003894,desmopressin,D009103,multiple sclerosis,To examine the safety and efficacy of desmopressin in three doses given to women with multiple sclerosis to treat nocturia with or without enuresis.,7551881_1,7551881_D003894_D009103,,
770956225,false,true,5,2015-08-14T20:19:00,,No Relation,1,D003894,desmopressin,D053158,nocturia,To examine the safety and efficacy of desmopressin in three doses given to women with multiple sclerosis to treat nocturia with or without enuresis.,7551881_1,7551881_D003894_D053158,,
770956226,false,true,5,2015-08-15T00:32:00,Used as treatment of another disease.,No Relation,1,D003894,desmopressin,D004775,enuresis,To examine the safety and efficacy of desmopressin in three doses given to women with multiple sclerosis to treat nocturia with or without enuresis.,7551881_1,7551881_D003894_D004775,,
770956227,false,true,5,2015-08-15T02:10:00,,No Relation,1,C080985,Batimastat,D009369,cancer,Batimastat (BB-94) is the first inhibitor of this class to enter clinical trial in cancer patients.,7572350_6,7572350_C080985_D009369,,
770956228,false,true,5,2015-08-15T00:13:00,,No Relation,1,C080985,batimastat,D001201,malignant ascites,In a phase I/II trial in patients with malignant ascites batimastat was well tolerated and there were preliminary signs of efficacy.,7572350_7,7572350_C080985_D001201,,
770956229,false,true,5,2015-08-14T20:48:00,,No Relation,0.6013,D005280,fenoterol,D004417,breathlessness,"The response to regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer, and to regular nebulized salbutamol and ipratropium bromide was assessed by home peak flow recordings, spirometry and two subjective scores: (a) rating of breathlessness on a simple four-point scale, and (b) activity score of the St George's Respiratory Questionnaire.",7597269_7,7597269_D005280_D004417,,
770956230,false,true,5,2015-08-14T22:00:00,,No Relation,0.7932,D009241,ipratropium bromide,D004417,breathlessness,"The response to regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer, and to regular nebulized salbutamol and ipratropium bromide was assessed by home peak flow recordings, spirometry and two subjective scores: (a) rating of breathlessness on a simple four-point scale, and (b) activity score of the St George's Respiratory Questionnaire.",7597269_7,7597269_D009241_D004417,,
770956231,false,true,5,2015-08-14T23:03:00,,No Relation,1,D000420,salbutamol,D004417,breathlessness,"The response to regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer, and to regular nebulized salbutamol and ipratropium bromide was assessed by home peak flow recordings, spirometry and two subjective scores: (a) rating of breathlessness on a simple four-point scale, and (b) activity score of the St George's Respiratory Questionnaire.",7597269_7,7597269_D000420_D004417,,
770956232,false,true,5,2015-08-15T00:28:00,,No Relation,0.5904,D000728,androgen,D011471,prostate cancer,Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients.,7630245_0,7630245_D000728_D011471,,
770956233,false,true,5,2015-08-14T20:57:00,,No Relation,1,D005485,flutamide,D011471,prostate cancer,"A systematic overview, or meta-analysis, of the randomised evidence on maximum androgen blockade (MAB) in advanced prostate cancer identified 25 trials that compared conventional castration (surgical or medical) versus MAB (castration plus prolonged use of an antiandrogen such as flutamide, cyproterone acetate, or nilutamide).",7630245_2,7630245_D005485_D011471,,
770956234,false,true,5,2015-08-15T01:09:00,,No Relation,1,D017373,cyproterone acetate,D011471,prostate cancer,"A systematic overview, or meta-analysis, of the randomised evidence on maximum androgen blockade (MAB) in advanced prostate cancer identified 25 trials that compared conventional castration (surgical or medical) versus MAB (castration plus prolonged use of an antiandrogen such as flutamide, cyproterone acetate, or nilutamide).",7630245_2,7630245_D017373_D011471,,
770956235,false,true,5,2015-08-14T20:33:00,,No Relation,1,C021277,nilutamide,D011471,prostate cancer,"A systematic overview, or meta-analysis, of the randomised evidence on maximum androgen blockade (MAB) in advanced prostate cancer identified 25 trials that compared conventional castration (surgical or medical) versus MAB (castration plus prolonged use of an antiandrogen such as flutamide, cyproterone acetate, or nilutamide).",7630245_2,7630245_C021277_D011471,,
770956236,false,true,5,2015-08-15T02:10:00,,No Relation,0.5897,D002996,CC/clomiphene citrate,D016471,ovarian hyperstimulation,Controlled ovarian hyperstimulation was achieved using three types of ovarian stimulation protocols: clomiphene citrate (CC) and hMG (n = 35). hMG alone (n = 35) or GnRH agonist and FSH and hMG (n = 30).,7641902_5,7641902_D002996_D016471,,
770956237,false,true,5,2015-08-15T00:33:00,,No Relation,1,C040791,8-hydroxydeoxyguanosine,D009369,cancer,Determination of urinary 8-hydroxydeoxyguanosine by automated coupled-column high performance liquid chromatography: a powerful technique for assaying in vivo oxidative DNA damage in cancer patients.,7646926_0,7646926_C040791_D009369,,
770956238,false,true,5,2015-08-14T20:45:00,,No Relation,1,D003404,creatinine,D009369,cancer,"Normal healthy individuals were found to excrete 14.9 +/- 7.8 nmol 8OHdG/24 h, or 1.11 +/- 0.62 mumol 8OHdG per mol creatinine, in their urine, whereas increased levels of 8OHdG were found in 24 h collections from a variety of cancer patients, both in samples taken before onset of oncological therapy (1.84 +/- 1.12 mumol/mol creatinine, P < 0.01 versus healthy individuals) and after therapy onset (2.18 +/- 1.44 mumol/mol creatinine, P < 0.001 versus healthy individuals).",7646926_6,7646926_D003404_D009369,,
770956239,false,true,5,2015-08-15T00:26:00,,No Relation,1,C040791,8OHdG,D009369,cancer,"Normal healthy individuals were found to excrete 14.9 +/- 7.8 nmol 8OHdG/24 h, or 1.11 +/- 0.62 mumol 8OHdG per mol creatinine, in their urine, whereas increased levels of 8OHdG were found in 24 h collections from a variety of cancer patients, both in samples taken before onset of oncological therapy (1.84 +/- 1.12 mumol/mol creatinine, P < 0.01 versus healthy individuals) and after therapy onset (2.18 +/- 1.44 mumol/mol creatinine, P < 0.001 versus healthy individuals).",7646926_6,7646926_C040791_D009369,,
770956240,false,true,5,2015-08-14T20:16:00,,No Relation,0.8167,D003404,creatinine,D009369,cancer,"Moreover, mean values of 8OHdG in random urinary samples from cancer patients were significantly higher than from healthy individuals (2.42 +/- 2.28 versus 1.19 +/- 0.48 mumol/mol creatinine, P < 0.001), both in samples taken before therapy onset (1.91 +/- 0.96, P < 0.001 versus healthy individuals) and after (2.57 +/- 2.46, P < 0.001 versus healthy individuals).",7646926_7,7646926_D003404_D009369,,
770956241,false,true,5,2015-08-15T02:13:00,,No Relation,1,C040791,8OHdG,D009369,cancer,"Moreover, mean values of 8OHdG in random urinary samples from cancer patients were significantly higher than from healthy individuals (2.42 +/- 2.28 versus 1.19 +/- 0.48 mumol/mol creatinine, P < 0.001), both in samples taken before therapy onset (1.91 +/- 0.96, P < 0.001 versus healthy individuals) and after (2.57 +/- 2.46, P < 0.001 versus healthy individuals).",7646926_7,7646926_C040791_D009369,,
770956242,false,true,5,2015-08-14T22:19:00,,Direct,0.5973,D019796,U-46619,C566800,platelet aggregation,"In human platelets in vitro, daltroban (10 nM-100 microM; n = 6 per group) concentration-dependently induced shape change, attaining at 50 microM, a maximum amplitude of 0.83 +/- 0.09 mV representing 46.4 +/- 4.8% of that evoked by U-46619 (1.78 +/- 0.20 mV at 0.2 microM; n = 9); and inhibited U-46619-induced platelet aggregation with an IC50 of 77 (41-161)nM.",7647979_4,7647979_D019796_C566800,,
770956243,false,true,5,2015-08-15T01:29:00,,No Relation,0.5876,D019796,U-46619,C566800,platelet aggregation,"SQ 29,548 (10 nM-100 microM; n = 6 per group) failed to evoke any platelet shape change, but potently inhibited U-46619-induced platelet aggregation with an IC50 < 10 nM.",7647979_5,7647979_D019796_C566800,,
770956244,false,true,5,2015-08-15T00:16:00,,No Relation,1,D005467,floxuridine,D009369,tumour,Effect of aberrant hepatic arterial anatomy on tumour response to hepatic artery infusion of floxuridine for colorectal liver metastases.,7648164_0,7648164_D005467_D009369,,
770956245,false,true,5,2015-08-14T23:27:00,,No Relation,0.8014,D005467,floxuridine,D009362,metastases,Effect of aberrant hepatic arterial anatomy on tumour response to hepatic artery infusion of floxuridine for colorectal liver metastases.,7648164_0,7648164_D005467_D009362,,
770956246,false,true,5,2015-08-15T01:16:00,,Direct,0.5933,D005467,floxuridine,D009369,tumour,The effect of variation in hepatic artery anatomy on tumour response to regional floxuridine (FUdR) was studied.,7648164_2,7648164_D005467_D009369,,
770956247,false,true,5,2015-08-14T23:44:00,,No Relation,1,D020280,sertraline,D003866,depression,Outpatients receiving fluoxetine were switched to sertraline therapy without a loss of control of depression and without substantial adverse effects.,7656119_10,7656119_D020280_D003866,,
770956248,false,true,5,2015-08-14T23:42:00,'without a loss of control of depression' being the key term.,No Relation,1,D005473,fluoxetine,D003866,depression,Outpatients receiving fluoxetine were switched to sertraline therapy without a loss of control of depression and without substantial adverse effects.,7656119_10,7656119_D005473_D003866,,
770956249,false,true,5,2015-08-14T23:16:00,It's a suspected connection.,Direct,0.6101,D007980,levodopa,D001008,anxiety,"Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.",7675241_0,7675241_D007980_D001008,,
770956250,false,true,5,2015-08-14T23:24:00,,No Relation,0.8103,D007980,levodopa,D010300,Parkinson's disease,"Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.",7675241_0,7675241_D007980_D010300,,
770956251,false,true,5,2015-08-15T00:22:00,,No Relation,1,D007980,levodopa,D001008,anxiety,We investigated the effect of levodopa on mood and anxiety in eight Parkinson's disease patients with motor fluctuations.,7675241_1,7675241_D007980_D001008,,
770956252,false,true,5,2015-08-15T00:05:00,,No Relation,1,D007980,levodopa,D010300,Parkinson's disease,We investigated the effect of levodopa on mood and anxiety in eight Parkinson's disease patients with motor fluctuations.,7675241_1,7675241_D007980_D010300,,
770956253,false,true,5,2015-08-15T01:13:00,,Direct,1,D007980,levodopa,D001008,anxiety,"We conclude that mood and anxiety fluctuations related to levodopa dosing are robust pharmacologic, and not placebo, effects.",7675241_6,7675241_D007980_D001008,,
770956254,false,true,5,2015-08-15T00:31:00,,No Relation,1,D015311,cefmetazole,D016063,surgical incision,Administration of cefmetazole immediately prior to surgical incision should be effective prophylaxis for surgical wound infections.,7694975_8,7694975_D015311_D016063,,
770956255,false,true,5,2015-08-14T20:32:00,,No Relation,1,D015311,cefmetazole,D007239,infections,Administration of cefmetazole immediately prior to surgical incision should be effective prophylaxis for surgical wound infections.,7694975_8,7694975_D015311_D007239,,
770956256,false,true,5,2015-08-14T22:22:00,,No Relation,1,D018170,sumatriptan,D008881,migraine,"Since the vasoconstrictor response of sumatriptan is reproducible outside the migraine attack, this action appears to be a direct vascular effect and not indirectly mediated via neural mechanisms.",7697699_5,7697699_D018170_D008881,,
770956257,false,true,5,2015-08-14T20:53:00,,No Relation,1,D018170,sumatriptan,D008881,migraine,This finding is further supported by the clinical observation that sumatriptan reduces the plasma levels of calcitonin gene-related peptide which are raised during a migraine attack.,7697699_12,7697699_D018170_D008881,,
770956258,false,true,5,2015-08-15T02:15:00,,Direct,0.8018,D015127,DMBA,D001943,mammary carcinoma,"Vorozole, like ovariectomy, almost completely reduces tumor growth in the DMBA-induced mammary carcinoma model in the rat.",7726994_6,7726994_D015127_D001943,,
770956259,false,true,5,2015-08-14T22:50:00,,No Relation,1,C060523,Vorozole,D009369,tumor,"Vorozole, like ovariectomy, almost completely reduces tumor growth in the DMBA-induced mammary carcinoma model in the rat.",7726994_6,7726994_C060523_D009369,,
770956260,false,true,5,2015-08-15T00:20:00,,No Relation,1,C060523,Vorozole,D001943,mammary carcinoma,"Vorozole, like ovariectomy, almost completely reduces tumor growth in the DMBA-induced mammary carcinoma model in the rat.",7726994_6,7726994_C060523_D001943,,
770956261,false,true,5,2015-08-14T23:14:00,,No Relation,0.6016,D015127,DMBA,D009369,tumor,"Vorozole, like ovariectomy, almost completely reduces tumor growth in the DMBA-induced mammary carcinoma model in the rat.",7726994_6,7726994_D015127_D009369,,
770956262,false,true,5,2015-08-14T20:57:00,al simplificar las palabras es mas entendible para uno que no es medico en este tipo de tarea...thanksss,No Relation,1,D015742,propofol,D013224,asthmatic,Both asthmatic and nonasthmatic patients who received a thiobarbiturate for induction had a greater incidence of wheezing than did patients receiving propofol.,7741285_9,7741285_D015742_D013224,,
770956263,false,true,5,2015-08-15T00:28:00,,No Relation,0.7987,C029684,thiobarbiturate,D013224,asthmatic,Both asthmatic and nonasthmatic patients who received a thiobarbiturate for induction had a greater incidence of wheezing than did patients receiving propofol.,7741285_9,7741285_C029684_D013224,,
770956264,false,true,5,2015-08-14T22:11:00,,No Relation,1,D015742,propofol,D013224,asthmatic,"In asthmatic patients, 45% (23, 67) (mean and 95% confidence interval) who received a thiobarbiturate, 26% (8, 44) who received an oxybarbiturate, and none (0, 17) who received propofol wheezed after intubation.",7741285_10,7741285_D015742_D013224,,
770956265,false,true,5,2015-08-15T01:47:00,,No Relation,1,C029684,thiobarbiturate,D013224,asthmatic,"In asthmatic patients, 45% (23, 67) (mean and 95% confidence interval) who received a thiobarbiturate, 26% (8, 44) who received an oxybarbiturate, and none (0, 17) who received propofol wheezed after intubation.",7741285_10,7741285_C029684_D013224,,
770956266,false,true,5,2015-08-14T23:05:00,Beneficial,No Relation,1,D015742,propofol,D001249,asthma,"This study suggests that propofol should be considered for induction of anesthesia in patients, particularly those with asthma, who require timely intubation.",7741285_12,7741285_D015742_D001249,,
770956267,false,true,5,2015-08-15T02:39:00,,No Relation,1,D014859,coumadin,D020521,cardioembolic stroke,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D014859_D020521,,
770956268,false,true,5,2015-08-15T00:03:00,Used as a preventive measure.,No Relation,1,D001241,aspirin,D008946,rheumatic mitral stenosis,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D001241_D008946,,
770956269,false,true,5,2015-08-15T00:20:00,,No Relation,1,D014859,coumadin,D013923,thromboembolic,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D014859_D013923,,
770956270,false,true,5,2015-08-14T22:14:00,,No Relation,1,D014859,coumadin,D008946,rheumatic mitral stenosis,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D014859_D008946,,
770956271,false,true,5,2015-08-14T20:33:00,,No Relation,1,D001241,aspirin,D001281,atrial fibrillation,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D001241_D001281,,
770956272,false,true,5,2015-08-15T02:23:00,,No Relation,1,D014859,coumadin,D001281,atrial fibrillation,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D014859_D001281,,
770956273,false,true,5,2015-08-14T22:27:00,,No Relation,1,D001241,aspirin,D013923,thromboembolic,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D001241_D013923,,
770956274,false,true,5,2015-08-15T01:00:00,,No Relation,0.7976,D001241,aspirin,D020521,cardioembolic stroke,A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.,7798824_0,7798824_D001241_D020521,,
770956275,false,true,5,2015-08-14T20:25:00,,No Relation,1,D014859,coumadin,D020521,cardioembolic stroke,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D014859_D020521,,
770956276,false,true,5,2015-08-15T00:21:00,,No Relation,1,D001241,aspirin,D008946,mitral stenosis,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D001241_D008946,,
770956277,false,true,5,2015-08-14T22:34:00,,No Relation,1,D014859,coumadin,D008946,mitral stenosis,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D014859_D008946,,
770956278,false,true,5,2015-08-14T22:23:00,,No Relation,1,D001241,aspirin,D001281,atrial fibrillation,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D001241_D001281,,
770956279,false,true,5,2015-08-14T20:45:00,,No Relation,1,D014859,coumadin,D012214,rheumatic heart disease,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D014859_D012214,,
770956280,false,true,5,2015-08-15T01:56:00,,No Relation,1,D014859,coumadin,D001281,atrial fibrillation,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D014859_D001281,,
770956281,false,true,5,2015-08-14T20:17:00,,No Relation,1,D001241,aspirin,D020521,cardioembolic stroke,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D001241_D020521,,
770956282,false,true,5,2015-08-15T01:47:00,,No Relation,1,D001241,aspirin,D012214,rheumatic heart disease,"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.",7798824_1,7798824_D001241_D012214,,
770956283,false,true,5,2015-08-15T02:14:00,,No Relation,1,D014859,coumadin,D020521,cardioembolic stroke,There were three patients with nonfatal cardioembolic stroke in the aspirin group but none in the coumadin group after three years of follow-up.,7798824_7,7798824_D014859_D020521,,
770956284,false,true,5,2015-08-14T20:42:00,,No Relation,0.5988,D001241,aspirin,D020521,cardioembolic stroke,There were three patients with nonfatal cardioembolic stroke in the aspirin group but none in the coumadin group after three years of follow-up.,7798824_7,7798824_D001241_D020521,,
770956285,false,true,5,2015-08-15T02:01:00,,Direct,0.8012,D014859,coumadin,D006470,bleeding,The complications in coumadin group were minor bleeding over the thigh in one patient and generalised ecchymosis over the whole body in one other.,7798824_10,7798824_D014859_D006470,,
770956286,false,true,5,2015-08-14T22:07:00,,No Relation,1,D001241,aspirin,D006470,bleeding,"In the aspirin group, the complication was gastrointestional symptoms, mainly epigastric pain, but no frank bleeding was observed.",7798824_11,7798824_D001241_D006470,,
770956287,false,true,5,2015-08-14T20:28:00,,Direct,1,D001241,aspirin,D010146,epigastric pain,"In the aspirin group, the complication was gastrointestional symptoms, mainly epigastric pain, but no frank bleeding was observed.",7798824_11,7798824_D001241_D010146,,
770956288,false,true,5,2015-08-15T01:09:00,,No Relation,1,D014859,coumadin,D020521,cardioembolic stroke,Primary prevention of cardioembolic stroke in chronic rheumatic heart disease was found to be more effective with coumadin than aspirin.,7798824_12,7798824_D014859_D020521,,
770956289,false,true,5,2015-08-15T00:31:00,,No Relation,1,D014859,coumadin,D012214,rheumatic heart disease,Primary prevention of cardioembolic stroke in chronic rheumatic heart disease was found to be more effective with coumadin than aspirin.,7798824_12,7798824_D014859_D012214,,
770956290,false,true,5,2015-08-14T20:10:00,,No Relation,1,D001241,aspirin,D020521,cardioembolic stroke,Primary prevention of cardioembolic stroke in chronic rheumatic heart disease was found to be more effective with coumadin than aspirin.,7798824_12,7798824_D001241_D020521,,
770956291,false,true,5,2015-08-15T01:48:00,,No Relation,1,D001241,aspirin,D012214,rheumatic heart disease,Primary prevention of cardioembolic stroke in chronic rheumatic heart disease was found to be more effective with coumadin than aspirin.,7798824_12,7798824_D001241_D012214,,
770956292,false,true,5,2015-08-14T22:39:00,,No Relation,1,D001241,aspirin,D004617,cardiac embolism,Our study does not support the use of aspirin in primary prevention of cardiac embolism in chronic rheumatic heart disease.,7798824_13,7798824_D001241_D004617,,
770956293,false,true,5,2015-08-14T23:28:00,,No Relation,0.8197,D001241,aspirin,D012214,rheumatic heart disease,Our study does not support the use of aspirin in primary prevention of cardiac embolism in chronic rheumatic heart disease.,7798824_13,7798824_D001241_D012214,,
770956294,false,true,5,2015-08-14T22:00:00,,No Relation,1,D015215,AZT,D015658,HIV infection,A mathematical model of CD4+ lymphocyte depletion in HIV infection is used to simulate and analyse the effect of AZT treatment.,7805931_1,7805931_D015215_D015658,,
770956295,false,true,5,2015-08-15T01:48:00,,No Relation,1,D015215,AZT,D007239,infection,"Interestingly, the survival prolongation is greater, if the treatment is started at five than at two years after the infection and there is no striking increase in survival time if a dose of AZT inhibiting 75% of HIV proliferation is used instead of a lower one inducing 25% inhibition only.",7805931_7,7805931_D015215_D007239,,
770956296,false,true,5,2015-08-15T00:41:00,,Direct,0.6159,D005907,gliclazide,D003925,diabetic vascular disease,From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease.,7833498_0,7833498_D005907_D003925,,
770956297,false,true,5,2015-08-14T23:35:00,,No Relation,0.6228,D005907,gliclazide,D014652,vascular disease,From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease.,7833498_0,7833498_D005907_D014652,,
770956298,false,true,5,2015-08-14T23:53:00,,No Relation,1,D005947,glucose,D003929,diabetes,"The process of vascular damage is accelerated by diabetes, often due to co-existing disease and aging, although it is not clear that improvement in long-term glycemic control by lowering blood glucose levels to near to the nondiabetic state reduces the development of small and large vessel disease.",7833498_9,7833498_D005947_D003929,,
770956299,false,true,5,2015-08-14T20:34:00,,No Relation,0.7911,D005947,glucose,D006177,vascular damage,"The process of vascular damage is accelerated by diabetes, often due to co-existing disease and aging, although it is not clear that improvement in long-term glycemic control by lowering blood glucose levels to near to the nondiabetic state reduces the development of small and large vessel disease.",7833498_9,7833498_D005947_D006177,,
770956300,false,true,5,2015-08-15T00:18:00,,No Relation,0.8225,D016718,arachidonic acid,D003925,diabetic vascular disease,"Increased oxidative stress due to excess free-radical activity may be central to diabetic vascular disease as endothelial cell damage, lipoprotein oxidation, modification of both platelet reactivity and arachidonic acid cascade are all properties of free radicals and their reaction products lipid peroxides.",7833498_11,7833498_D016718_D003925,,
770956301,false,true,5,2015-08-14T22:23:00,,No Relation,0.5954,D010545,peroxides,D003925,diabetic vascular disease,"Increased oxidative stress due to excess free-radical activity may be central to diabetic vascular disease as endothelial cell damage, lipoprotein oxidation, modification of both platelet reactivity and arachidonic acid cascade are all properties of free radicals and their reaction products lipid peroxides.",7833498_11,7833498_D010545_D003925,,
770956302,false,true,5,2015-08-15T00:28:00,,No Relation,0.5953,C077908,BW2258U89,D055752,small cell lung cancer,BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth.,7869832_0,7869832_C077908_D055752,,
770956303,false,true,5,2015-08-14T20:16:00,,No Relation,0.8167,D005755,gastrin,D055752,SCLC/small cell lung cancer,The ability of reduced peptide bond analogues of gastrin releasing peptide (GRP) to antagonize small cell lung cancer (SCLC) GRP receptors was investigated.,7869832_1,7869832_D005755_D055752,,
770956304,false,true,5,2015-08-14T22:21:00,,No Relation,1,D001279,atracurium,D003866,depression,"Once the adductor pollicis response has returned to normal values after a single intubating dose of atracurium or vecuronium, the risk of residual depression of the TH of the geniohyoid muscle, one of the principal muscles contributing to airway patency, appears unlikely.",7879933_9,7879933_D001279_D003866,,
770956305,false,true,5,2015-08-15T01:35:00,,No Relation,1,D014673,vecuronium,D003866,depression,"Once the adductor pollicis response has returned to normal values after a single intubating dose of atracurium or vecuronium, the risk of residual depression of the TH of the geniohyoid muscle, one of the principal muscles contributing to airway patency, appears unlikely.",7879933_9,7879933_D014673_D003866,,
770956306,false,true,5,2015-08-14T20:19:00,,Direct,0.7919,D010416,pentachlorophenol,D011041,poisoning,Human pentachlorophenol poisoning.,7904464_0,7904464_D010416_D011041,,
770956307,false,true,5,2015-08-14T20:48:00,,Direct,1,D010416,PCP,D011041,Chronic poisoning,Chronic poisoning occurs mainly in sawmill workers or people living in log homes treated with PCP-containing wood protecting formulations.,7904464_4,7904464_D010416_D011041,,
770956308,false,true,5,2015-08-14T20:32:00,,Direct,0.6209,D010416,PCP,D011041,poisoning,"The clinical features of acute and chronic PCP poisoning can be classified systematically into effects on the skin, metabolism (fever), the haematopoietic tissue, the respiratory system, the central and peripheral nervous system, the kidney and the gastrointestinal tract.",7904464_6,7904464_D010416_D011041,,
770956309,false,true,5,2015-08-14T20:28:00,,Direct,1,D010416,PCP,D012509,sarcoma,"Although PCP is not classified as a human carcinogen, some epidemiological observations suggest that exposure to chlorophenols in general and PCP solutions in particular may result in an increased risk for certain malignant disorders such as nasal carcinoma and soft tissue sarcoma.",7904464_7,7904464_D010416_D012509,,
770956310,false,true,5,2015-08-14T20:33:00,,Direct,1,D002733,chlorophenols,D009668,nasal carcinoma,"Although PCP is not classified as a human carcinogen, some epidemiological observations suggest that exposure to chlorophenols in general and PCP solutions in particular may result in an increased risk for certain malignant disorders such as nasal carcinoma and soft tissue sarcoma.",7904464_7,7904464_D002733_D009668,,
770956311,false,true,5,2015-08-14T20:40:00,,Direct,1,D010416,PCP,D009668,nasal carcinoma,"Although PCP is not classified as a human carcinogen, some epidemiological observations suggest that exposure to chlorophenols in general and PCP solutions in particular may result in an increased risk for certain malignant disorders such as nasal carcinoma and soft tissue sarcoma.",7904464_7,7904464_D010416_D009668,,
770956312,false,true,5,2015-08-14T23:56:00,,Direct,1,D002733,chlorophenols,D012509,sarcoma,"Although PCP is not classified as a human carcinogen, some epidemiological observations suggest that exposure to chlorophenols in general and PCP solutions in particular may result in an increased risk for certain malignant disorders such as nasal carcinoma and soft tissue sarcoma.",7904464_7,7904464_D002733_D012509,,
770956313,false,true,5,2015-08-14T23:02:00,PCP overdose causes poisoning and not on its own.,No Relation,0.5704,D010416,PCP,D011041,poisoning,No specific antidote exists for the treatment of (acute) PCP poisoning.,7904464_9,7904464_D010416_D011041,,
770956314,false,true,5,2015-08-14T21:49:00,,No Relation,1,D000242,cAMP,D001249,asthma,A variety of drugs known to act via increasing intracellular cAMP are used in the treatment of asthma.,7908546_1,7908546_D000242_D001249,,
770956315,false,true,5,2015-08-15T02:11:00,,No Relation,0.8372,C041226,terazosin,D006973,hypertension,Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.,7923316_0,7923316_C041226_D006973,,
770956316,false,true,5,2015-08-15T01:09:00,,No Relation,1,C041226,terazosin,D006973,hypertension,"The purpose of this study was to evaluate the effects of the alpha 1-blocking agent terazosin on blood pressure (BP) and blood lipids in a large, variant population of patients with hypertension.",7923316_1,7923316_C041226_D006973,,
770956317,false,true,5,2015-08-14T20:21:00,,No Relation,1,C041226,terazosin,D006973,hypertension,"A total of 16,917 patients with hypertension were evaluated at 2214 primary and community care facilities; 7808 of these patients had not been treated previously for hypertension; 3928 were switched to terazosin from another antihypertensive agent; and 5181 received terazosin in addition to an agent that had not controlled their hypertension.",7923316_2,7923316_C041226_D006973,,
770956318,false,true,5,2015-08-14T21:48:00,,No Relation,1,D002784,cholesterol,D006949,hyperlipidemia,The greatest reductions in blood cholesterol (-9.2%) were observed among patients with hyperlipidemia (total cholesterol > or = 240 mg/dL).,7923316_8,7923316_D002784_D006949,,
770956319,false,true,5,2015-08-15T01:11:00,,No Relation,1,C041226,Terazosin,D004194,concomitant diseases,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D004194,,
770956320,false,true,5,2015-08-14T22:22:00,,No Relation,0.6035,C041226,Terazosin,D006333,congestive heart failure,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D006333,,
770956321,false,true,5,2015-08-14T23:50:00,,No Relation,1,C041226,Terazosin,D029424,chronic obstructive pulmonary disease,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D029424,,
770956322,false,true,5,2015-08-14T20:49:00,,No Relation,1,C041226,Terazosin,D016491,peripheral vascular disease,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D016491,,
770956323,false,true,5,2015-08-15T02:04:00,,No Relation,1,C041226,Terazosin,D011470,prostatic hyperplasia,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D011470,,
770956324,false,true,5,2015-08-15T01:08:00,,No Relation,1,C041226,Terazosin,D009765,obesity,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D009765,,
770956325,false,true,5,2015-08-14T20:50:00,,No Relation,1,C041226,Terazosin,D003929,diabetes,"Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity.",7923316_9,7923316_C041226_D003929,,
770956326,false,true,5,2015-08-14T22:26:00,,No Relation,1,C041226,terazosin,D006973,hypertension,These data demonstrate the usefulness of terazosin as monotherapy or add-on therapy for treatment of hypertension.,7923316_13,7923316_C041226_D006973,,
770956327,false,true,5,2015-08-15T01:58:00,,Direct,0.6209,D002330,carmustine,D064420,Ocular toxicity,Ocular toxicity of systemic chemotherapy with megadoses of carmustine and mitomycin.,7944163_0,7944163_D002330_D064420,,
770956328,false,true,5,2015-08-15T00:26:00,,Direct,0.6139,D016685,mitomycin,D064420,Ocular toxicity,Ocular toxicity of systemic chemotherapy with megadoses of carmustine and mitomycin.,7944163_0,7944163_D016685_D064420,,
770956329,false,true,5,2015-08-15T02:22:00,,Direct,0.6116,D002330,carmustine,D064420,ocular toxicity,"In this article, we discuss the ocular toxicity in six patients with advanced nonpretreated colorectal cancer who received megadoses of carmustine and mitomycin with the support of autologous bone marrow transplantation.",7944163_2,7944163_D002330_D064420,,
770956330,false,true,5,2015-08-14T23:12:00,,No Relation,0.6118,D016685,mitomycin,D015179,colorectal cancer,"In this article, we discuss the ocular toxicity in six patients with advanced nonpretreated colorectal cancer who received megadoses of carmustine and mitomycin with the support of autologous bone marrow transplantation.",7944163_2,7944163_D016685_D015179,,
770956331,false,true,5,2015-08-14T23:13:00,"Its a mere discussion on whether mitomycin contributes to ocular toxicity, on basis of six patients which concluded in negative effect, so mitomycin don't contribute or causes cular toxicity.",No Relation,0.7997,D016685,mitomycin,D064420,ocular toxicity,"In this article, we discuss the ocular toxicity in six patients with advanced nonpretreated colorectal cancer who received megadoses of carmustine and mitomycin with the support of autologous bone marrow transplantation.",7944163_2,7944163_D016685_D064420,,
770956332,false,true,5,2015-08-15T01:11:00,,No Relation,0.8,D002330,carmustine,D015179,colorectal cancer,"In this article, we discuss the ocular toxicity in six patients with advanced nonpretreated colorectal cancer who received megadoses of carmustine and mitomycin with the support of autologous bone marrow transplantation.",7944163_2,7944163_D002330_D015179,,
770956333,false,true,5,2015-08-14T20:23:00,,No Relation,1,D005978,glutathione,D007511,ischemic renal injury,Previous reports have suggested beneficial effects of exogenous glutathione for preservation of renal function after ischemic renal injury.,7952483_2,7952483_D005978_D007511,,
770956334,false,true,5,2015-08-15T01:43:00,,No Relation,1,D005047,etoposide,D002289,non-small-cell lung cancer/NSCLC,"Patients with non-small-cell lung cancer (NSCLC) were treated with ICE chemotherapy (ifosfamide 2000 mg/m2, days 1-3; carboplatin 300 mg/m2, day 1; etoposide 75 mg/m2, days 1-3) intravenously (i.v.) during the first 3 d of a maximum of four 28 d treatment cycles.",7986706_1,7986706_D005047_D002289,,
770956335,false,true,5,2015-08-14T23:58:00,Used as treatment.,No Relation,1,D016190,carboplatin,D002289,non-small-cell lung cancer/NSCLC,"Patients with non-small-cell lung cancer (NSCLC) were treated with ICE chemotherapy (ifosfamide 2000 mg/m2, days 1-3; carboplatin 300 mg/m2, day 1; etoposide 75 mg/m2, days 1-3) intravenously (i.v.) during the first 3 d of a maximum of four 28 d treatment cycles.",7986706_1,7986706_D016190_D002289,,
770956336,false,true,5,2015-08-15T01:52:00,,No Relation,1,D007069,ifosfamide,D002289,non-small-cell lung cancer/NSCLC,"Patients with non-small-cell lung cancer (NSCLC) were treated with ICE chemotherapy (ifosfamide 2000 mg/m2, days 1-3; carboplatin 300 mg/m2, day 1; etoposide 75 mg/m2, days 1-3) intravenously (i.v.) during the first 3 d of a maximum of four 28 d treatment cycles.",7986706_1,7986706_D007069_D002289,,
770956337,false,true,5,2015-08-14T20:22:00,,No Relation,1,D010100,oxygen,D016638,critically ill,Elevation of systemic oxygen delivery in the treatment of critically ill patients.,7993413_0,7993413_D010100_D016638,,
770956338,false,true,5,2015-08-14T22:16:00,,No Relation,1,D010100,oxygen,D016638,critically ill,Elevation of systemic oxygen delivery and consumption has been associated with an improved outcome in critically ill patients.,7993413_1,7993413_D010100_D016638,,
770956339,false,true,5,2015-08-14T20:19:00,,No Relation,1,D010100,oxygen,D016638,critically ill,The use of dobutamine to boost the cardiac index and systemic oxygen delivery failed to improve the outcome in this heterogeneous group of critically ill patients.,7993413_12,7993413_D010100_D016638,,
770956340,false,true,5,2015-08-14T20:56:00,,No Relation,1,D004280,dobutamine,D016638,critically ill,The use of dobutamine to boost the cardiac index and systemic oxygen delivery failed to improve the outcome in this heterogeneous group of critically ill patients.,7993413_12,7993413_D004280_D016638,,
770956341,false,true,5,2015-08-15T00:11:00,,No Relation,1,D010100,oxygen,D018222,aggressive,"Contrary to what might have been expected, our results suggest that in some cases aggressive efforts to increase oxygen consumption may have been detrimental.",7993413_13,7993413_D010100_D018222,,
770956342,false,true,5,2015-08-15T01:42:00,,No Relation,1,D017035,pravastatin,D006937,hypercholesterolemia,A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia.,8001304_0,8001304_D017035_D006937,,
770956343,false,true,5,2015-08-15T01:34:00,,No Relation,1,D017035,pravastatin,D003924,non-insulin-dependent diabetes mellitus,A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia.,8001304_0,8001304_D017035_D003924,,
770956344,false,true,5,2015-08-14T20:28:00,,No Relation,1,D017035,pravastatin,D006937,hypercholesterolemia,"This multinational, 16-week, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of low-dose pravastatin in 325 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia [serum total cholesterol concentrations of 5.2-7.8 mmol/l (200 to 300 mg/dl)].",8001304_2,8001304_D017035_D006937,,
770956345,false,true,5,2015-08-14T22:19:00,,No Relation,1,D017035,pravastatin,D003924,non-insulin-dependent diabetes mellitus/NIDDM,"This multinational, 16-week, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of low-dose pravastatin in 325 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia [serum total cholesterol concentrations of 5.2-7.8 mmol/l (200 to 300 mg/dl)].",8001304_2,8001304_D017035_D003924,,
770956346,false,true,5,2015-08-14T22:26:00,,No Relation,0.7917,D002784,cholesterol,D006937,hypercholesterolemia,"This multinational, 16-week, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of low-dose pravastatin in 325 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia [serum total cholesterol concentrations of 5.2-7.8 mmol/l (200 to 300 mg/dl)].",8001304_2,8001304_D002784_D006937,,
770956347,false,true,5,2015-08-14T22:09:00,,No Relation,1,D002784,cholesterol,D003924,non-insulin-dependent diabetes mellitus/NIDDM,"This multinational, 16-week, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of low-dose pravastatin in 325 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia [serum total cholesterol concentrations of 5.2-7.8 mmol/l (200 to 300 mg/dl)].",8001304_2,8001304_D002784_D003924,,
770956348,false,true,5,2015-08-14T22:10:00,,Direct,0.5844,D017035,pravastatin,D007757,laboratory test abnormalities,Adverse events and laboratory test abnormalities were similar among patients treated with pravastatin or placebo.,8001304_6,8001304_D017035_D007757,,
770956349,false,true,5,2015-08-14T23:36:00,,No Relation,1,D017035,pravastatin,D006937,hypercholesterolemia,The results of this study demonstrate that low-dose pravastatin is effective and well tolerated for lowering elevated cholesterol concentrations during short-term treatment of patients with NIDDM and hypercholesterolemia.,8001304_8,8001304_D017035_D006937,,
770956350,false,true,5,2015-08-14T20:52:00,,No Relation,1,D017035,pravastatin,D003924,NIDDM,The results of this study demonstrate that low-dose pravastatin is effective and well tolerated for lowering elevated cholesterol concentrations during short-term treatment of patients with NIDDM and hypercholesterolemia.,8001304_8,8001304_D017035_D003924,,
770956351,false,true,5,2015-08-14T21:59:00,,No Relation,0.599,D002784,cholesterol,D006937,hypercholesterolemia,The results of this study demonstrate that low-dose pravastatin is effective and well tolerated for lowering elevated cholesterol concentrations during short-term treatment of patients with NIDDM and hypercholesterolemia.,8001304_8,8001304_D002784_D006937,,
770956352,false,true,5,2015-08-15T01:03:00,,No Relation,0.804,D002784,cholesterol,D003924,NIDDM,The results of this study demonstrate that low-dose pravastatin is effective and well tolerated for lowering elevated cholesterol concentrations during short-term treatment of patients with NIDDM and hypercholesterolemia.,8001304_8,8001304_D002784_D003924,,
770956353,false,true,5,2015-08-14T20:23:00,,No Relation,1,D012176,Retinoids,D015473,acute promyelocytic leukemia,Retinoids can differentiate leukemic cell lines in vitro and induce clinically complete remissions in patients with acute promyelocytic leukemia.,8025272_3,8025272_D012176_D015473,,
770956354,false,true,5,2015-08-14T23:37:00,,No Relation,1,D000242,cAMP,D006463,cholera toxin,Potent cAMP inducers like cholera toxin are also growth promoters for neonatal melanocytes but only transient growth stimulators for cells derived from adults.,8054689_3,8054689_D000242_D006463,,
770956355,false,true,5,2015-08-15T00:04:00,,No Relation,1,D010703,phorbol esters,D006463,cholera toxin,The simultaneous addition of phorbol esters and cholera toxin did not prevent cells from reaching terminal differentiation.,8054689_7,8054689_D010703_D006463,,
770956356,false,true,5,2015-08-15T01:26:00,,No Relation,0.8088,D010703,phorbol esters,D020151,PKC/protein kinase C,"Identified targets for phorbol esters are protein kinase C (PKC) and the mitogen-activated kinases (MAPKs), also called extracellular signal-regulated kinases (ERKs).",8054689_8,8054689_D010703_D020151,,
770956357,false,true,5,2015-08-15T01:15:00,,No Relation,0.8174,D015282,octreotide,D012891,sleep apnea,"Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.",8067645_0,8067645_D015282_D012891,,
770956358,false,true,5,2015-08-14T20:21:00,,No Relation,1,D015282,octreotide,D000172,acromegaly,"Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.",8067645_0,8067645_D015282_D000172,,
770956359,false,true,5,2015-08-14T22:13:00,,No Relation,1,D013004,somatostatin,D000172,acromegaly,"Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.",8067645_0,8067645_D013004_D000172,,
770956360,false,true,5,2015-08-14T22:27:00,,No Relation,0.8042,D013004,somatostatin,D012891,sleep apnea,"Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.",8067645_0,8067645_D013004_D012891,,
770956361,false,true,5,2015-08-14T22:48:00,,No Relation,1,D015282,octreotide,D012891,sleep apnea,"To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly.",8067645_1,8067645_D015282_D012891,,
770956362,false,true,5,2015-08-15T00:12:00,,No Relation,1,D015282,octreotide,D000172,acromegaly,"To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly.",8067645_1,8067645_D015282_D000172,,
770956363,false,true,5,2015-08-14T20:20:00,,No Relation,1,D013004,somatostatin,D000172,acromegaly,"To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly.",8067645_1,8067645_D013004_D000172,,
770956364,false,true,5,2015-08-14T20:41:00,,No Relation,1,D013004,somatostatin,D012891,sleep apnea,"To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly.",8067645_1,8067645_D013004_D012891,,
770956365,false,true,5,2015-08-14T23:43:00,,No Relation,1,D010100,oxygen,D012893,sleepiness improved,"Indices of oxygen desaturation, sleep quality, and subjective sleepiness improved after 6 months of octreotide.",8067645_8,8067645_D010100_D012893,,
770956366,false,true,5,2015-08-15T01:57:00,,Direct,0.6083,D015282,octreotide,D012893,sleepiness improved,"Indices of oxygen desaturation, sleep quality, and subjective sleepiness improved after 6 months of octreotide.",8067645_8,8067645_D015282_D012893,,
770956367,false,true,5,2015-08-15T01:02:00,,No Relation,0.8059,D015282,octreotide,D012891,sleep apnea,Improvement in indices of sleep apnea severity occurs in association with octreotide treatment in patients with sleep apnea and acromegaly.,8067645_12,8067645_D015282_D012891,,
770956368,false,true,5,2015-08-14T23:46:00,,No Relation,1,D015282,octreotide,D000172,acromegaly,Improvement in indices of sleep apnea severity occurs in association with octreotide treatment in patients with sleep apnea and acromegaly.,8067645_12,8067645_D015282_D000172,,
770956369,false,true,5,2015-08-14T21:45:00,,No Relation,1,D015251,Epirubicin,D006528,Epirubicin in hepatocellular carcinoma,Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.,8070007_0,8070007_D015251_D006528,,
770956370,false,true,5,2015-08-14T22:10:00,,No Relation,1,D015251,epirubicin,D006528,HCC/hepatocellular carcinoma,The pharmacokinetics and clinical activity of epirubicin were investigated in 16 patients with hepatocellular carcinoma (HCC) who received epirubicin at 75 mg/m2; the drug was given intravenously to 7 patients and via the hepatic artery to 9 patients (7 of whom also underwent embolisation).,8070007_1,8070007_D015251_D006528,,
770956371,false,true,5,2015-08-15T02:32:00,,No Relation,1,D015251,epirubicin,D006528,HCC,"However, at this dose and schedule, epirubicin has only modest activity against HCC.",8070007_9,8070007_D015251_D006528,,
770956372,false,true,5,2015-08-14T20:32:00,,No Relation,1,D001241,aspirin,D006935,hypercapnia,"Therefore, the nonsteroidal anti-inflammatory drugs and aspirin, which inhibit cyclooxygenase, might be expected to reduce cerebral blood flow and the response to hypercapnia.",8073456_2,8073456_D001241_D006935,,
770956373,false,true,5,2015-08-15T01:47:00,,No Relation,1,D005472,5-fluorouracil,D009369,tumor,Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue.,8074466_0,8074466_D005472_D009369,,
770956374,false,true,5,2015-08-14T22:21:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D002277,carcinoma,The modulating effect of recombinant human interferon alpha (IFN-alpha) on the antitumor efficacy of 5-fluorouracil (5-FU) against human carcinoma cell lines was investigated in vitro and in vivo.,8074466_1,8074466_D005472_D002277,,
770956375,false,true,5,2015-08-14T20:22:00,,No Relation,1,D005472,5-FU,D009369,colon tumor,"5-FU, fluorouridine (FUR) or fluoro-5'-deoxyuridine (FUdR) were tested against cultured human colon tumor C-1 cells with or without IFN-alpha.",8074466_2,8074466_D005472_D009369,,
770956376,false,true,5,2015-08-14T22:08:00,,No Relation,1,D005472,5-FU,D003108,colon carcinoma,"The in vivo antitumor activity of 5-FU with or without IFN-alpha was assessed using Co-4, a human colon carcinoma xenograft, in nude mice.",8074466_4,8074466_D005472_D003108,,
770956377,false,true,5,2015-08-15T01:06:00,,No Relation,1,D005472,5-FU,D015431,weight loss,"A synergistic effect of 5-FU and IFN-alpha was observed on Co-4 in nude mice, and this in vivo synergism was obtained without any increment of thymidylate synthetase inhibition or side effects in terms of death rate and body weight loss.",8074466_6,8074466_D005472_D015431,,
770956378,false,true,5,2015-08-14T20:10:00,,No Relation,0.5891,D005472,5-FU,D009369,tumor,The intratumoral concentration of FUR was significantly increased by the addition of IFN-alpha in Co-4 tumor tissue treated with 5-FU.,8074466_7,8074466_D005472_D009369,,
770956379,false,true,5,2015-08-15T00:59:00,,No Relation,1,D005472,5-FU,D009369,target tumor,"These results suggest that the mechanism of the combined effect of 5-FU and IFN-alpha is not related to enhancement of thymidylate synthetase inhibition, but to an increase of FUR concentration in the target tumor tissue.",8074466_8,8074466_D005472_D009369,,
770956380,false,true,5,2015-08-15T01:15:00,,Direct,0.4054,D006861,H2O2,D005921,glomerulonephritis,"Brouwer et al. reported pauci-immune glomerulonephritis in rats immunized with human MPO followed by perfusion of kidneys with lysosomal enzyme extract combined with H2O2, and suggested that this could serve as a model of ANCA-induced disease.",8082301_3,8082301_D006861_D005921,,
770956381,false,true,5,2015-08-14T20:43:00,,Direct,0.6139,D006861,H2O2,D004108,Pathological lesions,"Pathological lesions and deposits of IgG, C3, and MPO were found in immunized rats perfused with MPO + H2O2 with or without neutral protease, or MPO alone, in both rat strains and on both day 4 and day 10.",8082301_8,8082301_D006861_D004108,,
770956382,false,true,5,2015-08-15T00:26:00,,No Relation,1,C071192,entacapone,D010300,Parkinson's disease,"Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.",8112370_0,8112370_C071192_D010300,,
770956383,false,true,5,2015-08-14T20:29:00,,No Relation,1,D007980,levodopa,D010300,Parkinson's disease,"Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.",8112370_0,8112370_D007980_D010300,,
770956384,false,true,5,2015-08-14T20:17:00,,No Relation,1,C034221,catechol,D020734,parkinsonian,"In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.",8112370_1,8112370_C034221_D020734,,
770956385,false,true,5,2015-08-14T23:47:00,,No Relation,1,D007980,levodopa,D020734,parkinsonian,"In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.",8112370_1,8112370_D007980_D020734,,
770956386,false,true,5,2015-08-14T22:23:00,,No Relation,1,D002230,carbidopa,D020734,parkinsonian,"In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.",8112370_1,8112370_D002230_D020734,,
770956387,false,true,5,2015-08-15T00:06:00,,No Relation,1,C071192,entacapone,D020734,parkinsonian,"In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.",8112370_1,8112370_C071192_D020734,,
770956388,false,true,5,2015-08-15T00:10:00,,Direct,1,D000431,alcohol,D006177,brain damage,"Because drinking patterns can include periods of alcohol consumption followed by abstinence, binge drinking may enhance the possibility of brain damage.",8123218_2,8123218_D000431_D006177,,
770956389,false,true,5,2015-08-15T00:02:00,,Direct,1,D016202,NMDA,D006177,brain damage,NMDA-mediated mechanisms and glucocorticoid actions on the hippocampus are associated with brain damage.,8123218_4,8123218_D016202_D006177,,
770956390,false,true,5,2015-08-14T22:28:00,,No Relation,1,D016202,NMDA,D000437,alcoholism,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D016202_D000437,,
770956391,false,true,5,2015-08-14T23:18:00,,No Relation,0.7844,D000431,ethanol,D006177,brain damage,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D000431_D006177,,
770956392,false,true,5,2015-08-14T20:31:00,,No Relation,1,D000431,ethanol,D000437,alcoholism,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D000431_D000437,,
770956393,false,true,5,2015-08-14T22:22:00,,No Relation,1,D002118,calcium,D006177,brain damage,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D002118_D006177,,
770956394,false,true,5,2015-08-14T23:33:00,,No Relation,1,D002118,calcium,D000437,alcoholism,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D002118_D000437,,
770956395,false,true,5,2015-08-14T20:53:00,,No Relation,1,D016202,NMDA,D006177,brain damage,"Therapeutic adjuncts for treating ethanol withdrawal, including NMDA, calcium, and glucocorticoid antagonists, may eventually prove useful in preventing further brain damage in alcoholism.",8123218_6,8123218_D016202_D006177,,
770956396,false,true,5,2015-08-14T20:55:00,,No Relation,1,C022192,alinidine,D009203,AMI,"We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo.",8124790_2,8124790_C022192_D009203,,
770956397,false,true,5,2015-08-14T22:21:00,,No Relation,1,D001262,atenolol,D009203,AMI,"We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo.",8124790_2,8124790_D001262_D009203,,
770956398,false,true,5,2015-08-14T23:38:00,,No Relation,0.6059,C022192,alinidine,D001145,arrhythmia,"We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo.",8124790_2,8124790_C022192_D001145,,
770956399,false,true,5,2015-08-15T02:13:00,,No Relation,0.803,D001262,atenolol,D001145,arrhythmia,"We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo.",8124790_2,8124790_D001262_D001145,,
770956400,false,true,5,2015-08-14T20:30:00,,No Relation,1,C022192,alinidine,D054537,atrioventricular block,Atenolol and alinidine significantly decreased the basic heart rate without causing more sinus arrest or higher-degree atrioventricular block.,8124790_6,8124790_C022192_D054537,,
770956401,false,true,5,2015-08-15T01:24:00,,No Relation,1,D001262,Atenolol,D054537,atrioventricular block,Atenolol and alinidine significantly decreased the basic heart rate without causing more sinus arrest or higher-degree atrioventricular block.,8124790_6,8124790_D001262_D054537,,
770956402,false,true,5,2015-08-14T23:34:00,,No Relation,1,D001262,Atenolol,D054138,sinus arrest,Atenolol and alinidine significantly decreased the basic heart rate without causing more sinus arrest or higher-degree atrioventricular block.,8124790_6,8124790_D001262_D054138,,
770956403,false,true,5,2015-08-14T22:29:00,,No Relation,1,C022192,alinidine,D054138,sinus arrest,Atenolol and alinidine significantly decreased the basic heart rate without causing more sinus arrest or higher-degree atrioventricular block.,8124790_6,8124790_C022192_D054138,,
770956404,false,true,5,2015-08-14T20:22:00,,No Relation,0.6182,D001262,atenolol,D001281,atrial fibrillation,The prevalence of atrial fibrillation in alinidine patients was lower than in the atenolol patients (P = .007) but not lower than in placebo patients (P = .11).,8124790_7,8124790_D001262_D001281,,
770956405,false,true,5,2015-08-15T01:06:00,,No Relation,0.6027,C022192,alinidine,D001281,atrial fibrillation,The prevalence of atrial fibrillation in alinidine patients was lower than in the atenolol patients (P = .007) but not lower than in placebo patients (P = .11).,8124790_7,8124790_C022192_D001281,,
770956406,false,true,5,2015-08-14T22:14:00,,No Relation,0.8217,D013498,Suramin,D009369,metastatic cancer,Suramin and serum insulin-like growth factor levels in metastatic cancer patients.,8135485_0,8135485_D013498_D009369,,
770956407,false,true,5,2015-08-15T00:59:00,,No Relation,1,D013498,Suramin,D009369,tumors,"Suramin, a polysulphonated naphthylurea, inhibits the activity of several growth factors in in vitro experiments and clinical responses have been reported in human solid tumors.",8135485_1,8135485_D013498_D009369,,
770956408,false,true,5,2015-08-14T20:47:00,,No Relation,1,D013498,suramin,D008175,lung cancer,"We decided to investigate the relationship between suramin treatment and serum levels of insulin-like growth factor I (IGF-I) and II (IGF-II) in advanced breast, prostate and lung cancer patients.",8135485_2,8135485_D013498_D008175,,
770956409,false,true,5,2015-08-14T20:47:00,,No Relation,1,D013498,suramin,C564816,IGF,"We decided to investigate the relationship between suramin treatment and serum levels of insulin-like growth factor I (IGF-I) and II (IGF-II) in advanced breast, prostate and lung cancer patients.",8135485_2,8135485_D013498_C564816,,
770956410,false,true,5,2015-08-15T02:02:00,,No Relation,1,D013498,suramin,C564816,IGF,A significant decline of IGF-I and IGF-II serum levels was demonstrated in suramin treated patients.,8135485_4,8135485_D013498_C564816,,
770956411,false,true,5,2015-08-14T23:19:00,,Direct,0.6052,D013498,suramin,C564816,IGF,Our results suggest that suramin-induced IGF suppression could be one of the possible mechanisms of suramin action.,8135485_5,8135485_D013498_C564816,,
770956412,false,true,5,2015-08-14T20:29:00,,No Relation,0.6199,D006513,HBeAg,D012075,Remission,Remission occurred within 6 months of clearing the antigen (HBeAg) in the majority of cases.,8142208_7,8142208_D006513_D012075,,
770956413,false,true,5,2015-08-14T20:57:00,,No Relation,1,D006513,HBeAg,D011507,proteinuria,One had a reduction of proteinuria but remained HBeAg positive.,8142208_11,8142208_D006513_D011507,,
770956414,false,true,5,2015-08-14T21:48:00,,No Relation,1,D014807,vitamin D,D051436,chronic renal diseases,The influence of UV irradiation on vitamin D metabolism in children with chronic renal diseases.,8175280_0,8175280_D014807_D051436,,
770956415,false,true,5,2015-08-14T23:38:00,,Direct,0.6118,D014807,vitamin D,D002114,calcinosis,"One can obtain the same results also by oral vitamin D therapy, although we have to point out the danger of calcinosis and stone formation which the author could frequently demonstrate, but never after UV treatment.",8175280_5,8175280_D014807_D002114,,
770956416,false,true,5,2015-08-14T23:47:00,,No Relation,1,D010716,phosphatidylinositol,D009101,MM,The MM cell lines contained significantly more hormone-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity than the B-lymphoblastoid cell lines.,8205537_10,8205537_D010716_D009101,,
770956417,false,true,5,2015-08-15T00:42:00,,No Relation,1,D005947,glucose,D009101,MM,Hormone-responsive glucose metabolism was also greater in the MM cell lines.,8205537_12,8205537_D005947_D009101,,
770956418,false,true,5,2015-08-15T00:58:00,,No Relation,1,D013755,phorbol myristate acetate/PMA,D000163,AIDS/ARC/acquired immunodeficiency syndrome/AIDS-related complex,"Peripheral blood mononuclear cells from patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), and heterosexual controls were stimulated with anti-CD3 monoclonal antibody, phorbol myristate acetate (PMA), or both and 3H thymidine incorporation and IL-2 receptor (IL-2R alpha; CD25; Tac antigen) expression were measured.",8209399_1,8209399_D013755_D000163,,
770956419,false,true,5,2015-08-14T22:43:00,,No Relation,1,D013755,PMA,D000163,AIDS/ARC,A significantly reduced DNA synthesis and CD25 expression was observed in both AIDS and ARC upon stimulation with anti-CD3 or PMA.,8209399_3,8209399_D013755_D000163,,
770956420,false,true,5,2015-08-14T23:45:00,It's 'anti-CD3 plus PMA stimulation' and not just 'PMA',No Relation,1,D013755,PMA,D000163,AIDS/ARC,"Although, a significant synergism was observed with anti-CD3 plus PMA stimulation in both AIDS and ARC, and the responses were normalized to the levels of anti-CD3 or PMA response in normal control, the levels were significantly lower than those observed with anti-CD3 plus PMA in controls.",8209399_4,8209399_D013755_D000163,,
770956421,false,true,5,2015-08-15T00:39:00,,No Relation,0.7975,D005947,glucose,D003924,NIDDM,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D005947_D003924,,
770956422,false,true,5,2015-08-14T20:16:00,,No Relation,1,D008687,metformin,D003924,NIDDM,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D008687_D003924,,
770956423,false,true,5,2015-08-14T20:28:00,,No Relation,1,D005947,glucose,D003929,diabetic,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D005947_D003929,,
770956424,false,true,5,2015-08-14T23:48:00,,No Relation,0.788,D002241,carbohydrates,D003929,diabetic,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D002241_D003929,,
770956425,false,true,5,2015-08-14T20:10:00,,No Relation,1,D013395,sucrose,D003929,diabetic,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D013395_D003929,,
770956426,false,true,5,2015-08-15T02:39:00,,No Relation,1,D013395,sucrose,D003924,NIDDM,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D013395_D003924,,
770956427,false,true,5,2015-08-15T02:03:00,,No Relation,1,D002241,carbohydrates,D003924,NIDDM,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D002241_D003924,,
770956428,false,true,5,2015-08-15T00:03:00,,No Relation,1,D008687,metformin,D003929,diabetic,"The rationale for combining insulin and oral drug therapy derives from a better understanding of the pathophysiology of NIDDM and of the mechanisms of action of the oral drugs available: 1) type 2 diabetic patients are both insulin-deficient and insulin-resistant, thus requiring quite high doses of exogenous insulin; 2) peripheral insulin delivery leads to hyperinsulinaemia which could play a role in the pathogenesis of late diabetic complications; 3) sulphonylureas stimulate insulin release directly into the portal vein and could also potentiate peripheral insulin action; and 4) metformin (by improving glucose metabolism and insulin sensitivity) and alpha-glucosidase inhibitors (by slowing down the digestion of complex carbohydrates and sucrose) are able to reduce the amounts of insulin needed to control postprandial hyperglycaemia.",8212978_6,8212978_D008687_D003929,,
770956429,false,true,5,2015-08-14T20:47:00,,No Relation,1,D005947,glucose,D003924,NIDDM,"Numerous studies have shown that a combination of insulin and sulphonylurea is more effective than insulin alone in the treatment of patients with NIDDM after secondary failure to oral drugs, leading to better glucose profiles and/or decreased insulin needs.",8212978_7,8212978_D005947_D003924,,
770956430,false,true,5,2015-08-15T01:26:00,,No Relation,1,D008687,metformin,D009765,obesity,Preliminary results suggested that insulin-metformin (when obesity is present) or insulin-acarbose (when post-prandial hyperglycaemia occurs) combinations might offer some favourable features for the treatment of NIDDM patients although these therapeutical approaches still require adequate evaluation in further controlled studies.,8212978_9,8212978_D008687_D009765,,
770956431,false,true,5,2015-08-14T23:16:00,,No Relation,1,D020909,acarbose,D009765,obesity,Preliminary results suggested that insulin-metformin (when obesity is present) or insulin-acarbose (when post-prandial hyperglycaemia occurs) combinations might offer some favourable features for the treatment of NIDDM patients although these therapeutical approaches still require adequate evaluation in further controlled studies.,8212978_9,8212978_D020909_D009765,,
770956432,false,true,5,2015-08-15T00:51:00,,No Relation,1,D020909,acarbose,D003924,NIDDM,Preliminary results suggested that insulin-metformin (when obesity is present) or insulin-acarbose (when post-prandial hyperglycaemia occurs) combinations might offer some favourable features for the treatment of NIDDM patients although these therapeutical approaches still require adequate evaluation in further controlled studies.,8212978_9,8212978_D020909_D003924,,
770956433,false,true,5,2015-08-15T02:12:00,,No Relation,1,D008687,metformin,D003924,NIDDM,Preliminary results suggested that insulin-metformin (when obesity is present) or insulin-acarbose (when post-prandial hyperglycaemia occurs) combinations might offer some favourable features for the treatment of NIDDM patients although these therapeutical approaches still require adequate evaluation in further controlled studies.,8212978_9,8212978_D008687_D003924,,
770956434,false,true,5,2015-08-15T00:07:00,,No Relation,1,D000212,acyclovir,D020804,varicella-zoster virus infections,Previous studies in immunocompetent hosts and normal adults have demonstrated the value of intravenous acyclovir in the treatment of varicella-zoster virus infections.,8245900_2,8245900_D000212_D020804,,
770956435,false,true,5,2015-08-14T20:16:00,,No Relation,1,D000212,acyclovir,D002644,varicella,Oral acyclovir has also shown efficacy in both normal adults with zoster (shingles) and immunocompetent children with varicella.,8245900_3,8245900_D000212_D002644,,
770956436,false,true,5,2015-08-14T20:13:00,,No Relation,1,D000212,acyclovir,D006562,shingles,Oral acyclovir has also shown efficacy in both normal adults with zoster (shingles) and immunocompetent children with varicella.,8245900_3,8245900_D000212_D006562,,
770956437,false,true,5,2015-08-14T22:28:00,,No Relation,1,D000212,acyclovir,D002644,varicella,A recently completed double-blind placebo-controlled study of oral acyclovir in immunocompetent adults with uncomplicated varicella also demonstrated efficacy.,8245900_4,8245900_D000212_D002644,,
770956438,false,true,5,2015-08-15T02:31:00,,No Relation,1,D000212,acyclovir,D002644,varicella pneumonia/varicella,Adults with complicated varicella (usually symptomatic varicella pneumonia) should receive intravenous acyclovir.,8245900_8,8245900_D000212_D002644,,
770956439,false,true,5,2015-08-15T01:27:00,,No Relation,1,C031368,brovavir,D002644,varicella,Several new agents for varicella-zoster therapy are being evaluated; brovavir is a new agent currently being compared to placebo in the treatment of adult varicella.,8245900_9,8245900_C031368_D002644,,
770956440,false,true,5,2015-08-15T00:03:00,,No Relation,0.793,D000082,paracetamol,D001172,rheumatoid arthritis,Additive effect of combined naproxen and paracetamol in rheumatoid arthritis.,8252318_0,8252318_D000082_D001172,,
770956441,false,true,5,2015-08-14T23:19:00,,No Relation,0.626,D009288,naproxen,D001172,rheumatoid arthritis,Additive effect of combined naproxen and paracetamol in rheumatoid arthritis.,8252318_0,8252318_D009288_D001172,,
770956442,false,true,5,2015-08-14T22:26:00,,No Relation,1,D000082,paracetamol/acetaminophen,D001172,RA,"The clinical effect and plasma naproxen levels were studied in 20 patients with RA receiving three doses of naproxen and two naproxen doses combined with paracetamol (acetaminophen) in a randomized, double-blind, comparison in five 2-wk treatment periods.",8252318_1,8252318_D000082_D001172,,
770956443,false,true,5,2015-08-15T00:35:00,,No Relation,1,D009288,naproxen,D001172,RA,"The clinical effect and plasma naproxen levels were studied in 20 patients with RA receiving three doses of naproxen and two naproxen doses combined with paracetamol (acetaminophen) in a randomized, double-blind, comparison in five 2-wk treatment periods.",8252318_1,8252318_D009288_D001172,,
770956444,false,true,5,2015-08-15T01:02:00,,No Relation,0.818,D000082,paracetamol,D001172,RA,The results show that the clinical effect of naproxen in RA may be significantly increased by concomitant paracetamol administration.,8252318_6,8252318_D000082_D001172,,
770956445,false,true,5,2015-08-14T23:37:00,,No Relation,1,D009288,naproxen,D001172,RA,The results show that the clinical effect of naproxen in RA may be significantly increased by concomitant paracetamol administration.,8252318_6,8252318_D009288_D001172,,
770956446,false,true,5,2015-08-15T02:06:00,,No Relation,1,D003401,creatine,D009203,acute myocardial infarction,"The latter complex, creatine kinase and cardiac troponin T, were measured in peripheral venous blood samples serially drawn in 39 patients with acute myocardial infarction.",8259712_2,8259712_D003401_D009203,,
770956447,false,true,5,2015-08-15T00:36:00,,No Relation,1,D003401,Creatine,D009202,myocardial tissue injury,Creatine kinase activities and cardiac troponin T concentrations were used as markers of myocardial tissue injury.,8259712_4,8259712_D003401_D009202,,
770956448,false,true,5,2015-08-15T00:59:00,,Direct,0.6029,D009638,norepinephrine,D006323,asystole,A 36-year-old male who experienced postexercise bradycardia and asystole had higher basal plasma norepinephrine (120 versus 68 +/- 6 pg/ml) and epinephrine (18 versus less than 10 pg/ml) but a similar vagal tone (vagal tone index of 5.44 versus 5.81 +/- 1.00 U) when compared with 6 closely matched subjects who underwent an uneventful stress test.,8261477_2,8261477_D009638_D006323,,
770956449,false,true,5,2015-08-14T20:23:00,,No Relation,0.7838,D004837,epinephrine,D006323,asystole,A 36-year-old male who experienced postexercise bradycardia and asystole had higher basal plasma norepinephrine (120 versus 68 +/- 6 pg/ml) and epinephrine (18 versus less than 10 pg/ml) but a similar vagal tone (vagal tone index of 5.44 versus 5.81 +/- 1.00 U) when compared with 6 closely matched subjects who underwent an uneventful stress test.,8261477_2,8261477_D004837_D006323,,
770956450,false,true,5,2015-08-14T21:55:00,,No Relation,0.4181,D009638,norepinephrine,D001919,bradycardia,A 36-year-old male who experienced postexercise bradycardia and asystole had higher basal plasma norepinephrine (120 versus 68 +/- 6 pg/ml) and epinephrine (18 versus less than 10 pg/ml) but a similar vagal tone (vagal tone index of 5.44 versus 5.81 +/- 1.00 U) when compared with 6 closely matched subjects who underwent an uneventful stress test.,8261477_2,8261477_D009638_D001919,,
770956451,false,true,5,2015-08-14T20:51:00,,No Relation,0.5815,D004837,epinephrine,D001919,bradycardia,A 36-year-old male who experienced postexercise bradycardia and asystole had higher basal plasma norepinephrine (120 versus 68 +/- 6 pg/ml) and epinephrine (18 versus less than 10 pg/ml) but a similar vagal tone (vagal tone index of 5.44 versus 5.81 +/- 1.00 U) when compared with 6 closely matched subjects who underwent an uneventful stress test.,8261477_2,8261477_D004837_D001919,,
770956452,false,true,5,2015-08-14T22:09:00,,No Relation,0.806,D011092,Polyethylene glycol,D002292,renal cell carcinoma,Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma.,8262734_0,8262734_D011092_D002292,,
770956453,false,true,5,2015-08-15T01:31:00,,No Relation,1,C028210,monomethoxypolyethylene glycol,D002292,renal cell carcinoma,Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials.,8262734_1,8262734_C028210_D002292,,
770956454,false,true,5,2015-08-15T00:15:00,,No Relation,1,D000728,Androgens,D011471,prostate cancer,Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor.,8263129_0,8263129_D000728_D011471,,
770956455,false,true,5,2015-08-15T01:49:00,,Direct,0.8154,D000728,Androgens,D011471,prostate cancers,Androgens affect growth of the prostate gland and many prostate cancers.,8263129_1,8263129_D000728_D011471,,
770956456,false,true,5,2015-08-15T02:04:00,,No Relation,1,D013739,testosterone,D011471,prostate cancer,"We examined the effects of 5 alpha-dihydrotestosterone (DHT) and testosterone (T), EGF, and EGF-alpha on cell proliferation and 3H-thymidine incorporation in an androgen-dependent human prostate cancer cell line, ALVA101, in serum-free medium.",8263129_3,8263129_D013739_D011471,,
770956457,false,true,5,2015-08-14T20:42:00,,No Relation,0.7906,D000728,androgen,D011471,prostate cancer,"We examined the effects of 5 alpha-dihydrotestosterone (DHT) and testosterone (T), EGF, and EGF-alpha on cell proliferation and 3H-thymidine incorporation in an androgen-dependent human prostate cancer cell line, ALVA101, in serum-free medium.",8263129_3,8263129_D000728_D011471,,
770956458,false,true,5,2015-08-14T20:53:00,,No Relation,1,D013196,5 alpha-dihydrotestosterone,D011471,prostate cancer,"We examined the effects of 5 alpha-dihydrotestosterone (DHT) and testosterone (T), EGF, and EGF-alpha on cell proliferation and 3H-thymidine incorporation in an androgen-dependent human prostate cancer cell line, ALVA101, in serum-free medium.",8263129_3,8263129_D013196_D011471,,
770956459,false,true,5,2015-08-15T01:58:00,,No Relation,1,C055305,ginsenoside Rh2,D009369,ovarian cancer,Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice.,8270603_0,8270603_C055305_D009369,,
770956460,false,true,5,2015-08-14T22:22:00,,No Relation,1,D002945,cisplatin/cis-diamminedichloroplatinum(II),D009369,tumor,After 7 days of tumor inoculation 2 mg/kg cis-diamminedichloroplatinum(II) (cisplatin) was administered intraperitoneally once a week for 5 weeks.,8270603_5,8270603_D002945_D009369,,
770956461,false,true,5,2015-08-14T20:44:00,,No Relation,1,D000431,ethanol,D009369,tumor,"Rh2 was dissolved in absolute ethanol, adjusted with distilled water to 1, 15, and 120 microM, and 0.4 ml of each concentration was administered orally by canula every day for 90 days, from the next day of tumor inoculation.",8270603_7,8270603_D000431_D009369,,
770956462,false,true,5,2015-08-15T00:30:00,,No Relation,0.8103,D000431,ethanol,D009369,tumor,"On days 56 and 63 after tumor inoculation, the tumor volumes in all groups treated with Rh2 were significantly less than those in an ethanol-treated control group and also in cisplatin treated group.",8270603_9,8270603_D000431_D009369,,
770956463,false,true,5,2015-08-14T23:24:00,,No Relation,0.8103,D002945,cisplatin,D009369,tumor,"On days 56 and 63 after tumor inoculation, the tumor volumes in all groups treated with Rh2 were significantly less than those in an ethanol-treated control group and also in cisplatin treated group.",8270603_9,8270603_D002945_D009369,,
770956464,false,true,5,2015-08-14T23:40:00,,No Relation,1,D002945,cisplatin,D009369,tumor,"After 70 days, the tumor growth in nude mice treated with 15 microM and 120 microM Rh2 was significantly inhibited compared to that in a cisplatin treated group as well as a control group.",8270603_10,8270603_D002945_D009369,,
770956465,false,true,5,2015-08-14T22:28:00,,No Relation,1,D005473,fluoxetine,D009771,compulsive behavior disorder,Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation.,8292312_0,8292312_D005473_D009771,,
770956466,false,true,5,2015-08-15T00:36:00,,No Relation,1,D005473,fluoxetine,D008607,mental retardation,Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation.,8292312_0,8292312_D005473_D008607,,
770956467,false,true,5,2015-08-15T02:47:00,,No Relation,1,D005473,fluoxetine,D009771,compulsive behavior disorder,The behavior disorders of 10 subjects who met criteria for compulsive behavior disorder and 6 subjects who did not (comparison subjects) were treated using the medication fluoxetine.,8292312_2,8292312_D005473_D009771,,
770956468,false,true,5,2015-08-15T00:58:00,,No Relation,1,D005473,fluoxetine,D009771,compulsive behavior disorder,Seven of the 10 subjects with compulsive behavior disorder responded favorably to fluoxetine treatment; none of the comparison subjects responded favorably to this medication.,8292312_4,8292312_D005473_D009771,,
770956469,false,true,5,2015-08-15T00:42:00,,Direct,0.5798,D005473,fluoxetine,D009771,compulsive behaviors,"Further, there appeared to be a relation between manifest motor stereotypies, compulsive behaviors, and response to fluoxetine.",8292312_5,8292312_D005473_D009771,,
770956470,false,true,5,2015-08-15T01:20:00,,No Relation,0.7865,D003891,desipramine,D061218,desipramine-refractory depression,Characteristics of desipramine-refractory depression.,8294386_0,8294386_D003891_D061218,,
770956471,false,true,5,2015-08-14T20:20:00,,No Relation,1,D003891,desipramine,D003865,major depression,"To determine the predictors of desipramine-refractory depression, the authors examined the outcome in patients with major depression who were admitted to a general hospital and treated with desipramine adjusted to an adequate blood level.",8294386_1,8294386_D003891_D003865,,
770956472,false,true,5,2015-08-14T20:13:00,,No Relation,0.5955,D003891,desipramine,D061218,desipramine-refractory depression,"To determine the predictors of desipramine-refractory depression, the authors examined the outcome in patients with major depression who were admitted to a general hospital and treated with desipramine adjusted to an adequate blood level.",8294386_1,8294386_D003891_D061218,,
770956473,false,true,5,2015-08-14T22:20:00,,No Relation,1,D003891,desipramine,D003866,Depression,Outcome was assessed with the Yale Depression Inventory after a 4-week desipramine trial in which 24-hour plasma concentrations were used to rapidly achieve a therapeutic desipramine level.,8294386_3,8294386_D003891_D003866,,
770956474,false,true,5,2015-08-15T02:21:00,,No Relation,0.6027,D003891,desipramine,D003866,depressive episode/depression,"Poor response to a therapeutic desipramine trial, which occurred in 15 of 50 patients, was significantly associated with definite personality disorder, prior treatment failure, near delusional status, age < or = 35 years, duration of depressive episode, recurrence of depression, dysthymia, and secondary depression.",8294386_4,8294386_D003891_D003866,,
770956475,false,true,5,2015-08-15T00:19:00,,No Relation,0.62,D003891,desipramine,D010554,personality disorder,"Poor response to a therapeutic desipramine trial, which occurred in 15 of 50 patients, was significantly associated with definite personality disorder, prior treatment failure, near delusional status, age < or = 35 years, duration of depressive episode, recurrence of depression, dysthymia, and secondary depression.",8294386_4,8294386_D003891_D010554,,
770956476,false,true,5,2015-08-15T00:51:00,,No Relation,1,C071363,RC-3095,D009369,breast cancer,Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.,8313327_0,8313327_C071363_D009369,,
770956477,false,true,5,2015-08-15T01:16:00,,Direct,0.5989,C062876,SB-75,D009369,breast cancer,Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.,8313327_0,8313327_C062876_D009369,,
770956478,false,true,5,2015-08-15T01:44:00,,No Relation,0.8335,D001839,bombesin,D009369,breast cancer,Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.,8313327_0,8313327_D001839_D009369,,
770956479,false,true,5,2015-08-14T22:17:00,,Direct,0.6062,D004967,estrogen,D009369,breast cancers,"However, only about 30% of breast cancers are estrogen-dependent and can be treated by hormonal manipulation.",8313327_2,8313327_D004967_D009369,,
770956480,false,true,5,2015-08-14T23:08:00,,Direct,1,D001839,bombesin,D009369,cancers,"Various studies suggest that bombesin or gastrin-releasing peptide acts as an autocrine growth factor and may play a role in the initiation and progression of some cancers, including that of the breast.",8313327_4,8313327_D001839_D009369,,
770956481,false,true,5,2015-08-15T00:36:00,,No Relation,1,D001839,bombesin,D009369,breast cancer,"Female athymic nude mice bearing xenografts of the MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/gastrin-releasing peptide antagonist (D-Tpi6, Leu13 psi[CH2NH]-Leu14) bombesin(6-14) (RC-3095) injected subcutaneously daily at a dose of 20 micrograms and luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) administered biweekly in the form of microgranules releasing 45 micrograms/day.",8313327_5,8313327_D001839_D009369,,
770956482,false,true,5,2015-08-14T23:21:00,'Inhibition' being the key term.,No Relation,1,C062876,SB-75,D009369,tumor,"After 2 weeks of treatment, a significant inhibition of tumor volume was observed in the groups treated with RC-3095 alone or in combination with SB-75 but not in those treated with SB-75 as a single agent.",8313327_6,8313327_C062876_D009369,,
770956483,false,true,5,2015-08-14T22:19:00,,No Relation,1,C024352,Fludarabine,D008258,macroglobulinemia,Fludarabine therapy in Waldenstrm's macroglobulinemia.,8328496_0,8328496_C024352_D008258,,
770956484,false,true,5,2015-08-14T20:45:00,,No Relation,1,C024352,fludarabine,D008258,macroglobulinemia,"To assess the response rate, remission duration, and survival of patients with Waldenstrm's macroglobulinemia treated with the adenine nucleoside analogue fludarabine.",8328496_1,8328496_C024352_D008258,,
770956485,false,true,5,2015-08-15T00:16:00,,No Relation,1,C024352,fludarabine,D008258,macroglobulinemia,"Twenty-eight patients with Waldenstrm's macroglobulinemia, of whom only 2 were previously untreated, received fludarabine at a dose of 20 to 30 mg/m2 intravenously daily for 5 days (20 patients) or 30 mg/m2 intravenously daily for 3 days (8 patients).",8328496_2,8328496_C024352_D008258,,
770956486,false,true,5,2015-08-14T23:42:00,,No Relation,1,C024352,Fludarabine,D008258,macroglobulinemia,Fludarabine is an effective salvage agent for the treatment of patients with resistant Waldenstrm's macroglobulinemia.,8328496_9,8328496_C024352_D008258,,
770956487,false,true,5,2015-08-15T02:17:00,,No Relation,1,D000617,aminoglycoside,D059413,intraabdominal infections,Effect of peritoneal fluid pH on outcome of aminoglycoside treatment of intraabdominal infections.,8337887_0,8337887_D000617_D059413,,
770956488,false,true,5,2015-08-14T23:08:00,,No Relation,1,D002981,clindamycin,D059413,intraabdominal infection,Netilmicin and clindamycin were administered to 47 patients with an intraabdominal infection who underwent emergency laparotomy.,8337887_1,8337887_D002981_D059413,,
770956489,false,true,5,2015-08-15T00:33:00,,No Relation,1,D009428,Netilmicin,D059413,intraabdominal infection,Netilmicin and clindamycin were administered to 47 patients with an intraabdominal infection who underwent emergency laparotomy.,8337887_1,8337887_D009428_D059413,,
770956490,false,true,5,2015-08-14T21:00:00,,No Relation,1,D000617,aminoglycoside,D004927,Escherichia,Reduction of pH antagonized aminoglycoside activity in vitro against clinical isolates of Escherichia coli.,8337887_8,8337887_D000617_D004927,,
770956491,false,true,5,2015-08-14T22:17:00,,No Relation,1,D000305,corticosteroid,D000402,obstructive airways disease,"Although most patients with obstructive airways disease show some amelioration with long-term inhaled corticosteroid therapy, the extent of improvement may vary considerably between patients.",8339808_2,8339808_D000305_D000402,,
770956492,false,true,5,2015-08-14T20:16:00,,No Relation,1,D020682,cefixime,D006069,gonorrhea,"Single-dose oral treatment with cefixime (Suprax) or a quinolone appears to be effective, safe, and practical for patients with uncomplicated gonorrhea.",8341619_6,8341619_D020682_D006069,,
770956493,false,true,5,2015-08-14T20:25:00,,No Relation,1,D002443,Rocephin/ceftriaxone sodium,D007239,infections,"Because disseminated infections can be fatal, hospitalization and treatment with intravenous antibiotics such as ceftriaxone sodium (Rocephin) or cefotaxime sodium (Claforan) are required.",8341619_8,8341619_D002443_D007239,,
770956494,false,true,5,2015-08-14T23:35:00,,No Relation,1,D002439,cefotaxime sodium,D007239,infections,"Because disseminated infections can be fatal, hospitalization and treatment with intravenous antibiotics such as ceftriaxone sodium (Rocephin) or cefotaxime sodium (Claforan) are required.",8341619_8,8341619_D002439_D007239,,
770956495,false,true,5,2015-08-14T22:43:00,,No Relation,0.8017,D004298,dopamine,D012559,schizophrenic,"Homovanillic acid (HVA), an oxidative metabolite of dopamine, has been shown in a number of studies to reflect severity of symptoms and to predict response to neuroleptic treatment in schizophrenic patients.",8341767_1,8341767_D004298_D012559,,
770956496,false,true,5,2015-08-15T00:18:00,,No Relation,1,D006719,HVA/Homovanillic acid,D012559,schizophrenic,"Homovanillic acid (HVA), an oxidative metabolite of dopamine, has been shown in a number of studies to reflect severity of symptoms and to predict response to neuroleptic treatment in schizophrenic patients.",8341767_1,8341767_D006719_D012559,,
770956497,false,true,5,2015-08-14T22:28:00,,No Relation,1,D004298,dopamine,D009207,drug action,"However, administration of dopamine postsynaptic antagonists should be expected to increase synaptic dopamine availability, thereby increasing HVA concentrations, according to traditional models of drug action.",8341767_4,8341767_D004298_D009207,,
770956498,false,true,5,2015-08-14T20:23:00,,No Relation,1,D006719,HVA,D009207,drug action,"However, administration of dopamine postsynaptic antagonists should be expected to increase synaptic dopamine availability, thereby increasing HVA concentrations, according to traditional models of drug action.",8341767_4,8341767_D006719_D009207,,
770956499,false,true,5,2015-08-14T20:29:00,,Direct,1,D002104,cadmium,D042882,renal stones,Incidence of renal stones among cadmium exposed battery workers.,8343420_0,8343420_D002104_D042882,,
770956500,false,true,5,2015-08-14T23:34:00,,No Relation,1,D003404,creatinine,D011507,proteinuria,"The IRRs were 1.0, 1.6 [95% confidence interval (95% CI) 0.7-3.4], and 3.0 (95% CI 1.3-6.8) respectively. beta 2 Microglobulin measurements were available for 33 workers who formed stones; 13 of these workers had tubular proteinuria (beta 2 microglobulin > or = 34 micrograms/mmole creatinine)--that is, a prevalence of 39%.",8343420_8,8343420_D003404_D011507,,
770956501,false,true,5,2015-08-14T20:43:00,,No Relation,0.7936,D013004,somatostatin,D007027,hypothalamic,"To clarify the pathogenesis underlying these alterations, in six obese patients (3 males and 3 females, age 20-44 yrs, BMI = 42.1 +/- 2.2) on unrestricted diet we studied the effect of 8 day GHRH pretreatment (1 micrograms/kg iv each day) on the acute somatotropic response to the neurohormone administered both alone and combined with arginine (ARG, 0.5 g/kg iv infused from 0 to 30 min) which likely inhibits the release of hypothalamic somatostatin.",8344645_3,8344645_D013004_D007027,,
770956502,false,true,5,2015-08-14T20:45:00,,No Relation,0.7956,D013004,somatostatin,D009765,obese,"To clarify the pathogenesis underlying these alterations, in six obese patients (3 males and 3 females, age 20-44 yrs, BMI = 42.1 +/- 2.2) on unrestricted diet we studied the effect of 8 day GHRH pretreatment (1 micrograms/kg iv each day) on the acute somatotropic response to the neurohormone administered both alone and combined with arginine (ARG, 0.5 g/kg iv infused from 0 to 30 min) which likely inhibits the release of hypothalamic somatostatin.",8344645_3,8344645_D013004_D009765,,
770956503,false,true,5,2015-08-15T02:06:00,,No Relation,0.6272,D000728,androgens,D011471,prostatic cancer,"Although all androgens have an effect on prostatic cells, it is believed that dihydrotestosterone (DHT) is the active metabolite primarily utilized by prostatic cancer cells for growth and division.",8358057_2,8358057_D000728_D011471,,
770956504,false,true,5,2015-08-14T20:57:00,,Direct,1,D013196,dihydrotestosterone/DHT,D011471,prostatic cancer,"Although all androgens have an effect on prostatic cells, it is believed that dihydrotestosterone (DHT) is the active metabolite primarily utilized by prostatic cancer cells for growth and division.",8358057_2,8358057_D013196_D011471,,
770956505,false,true,5,2015-08-15T00:25:00,,No Relation,0.803,D013196,DHT,D011471,prostatic cancer,Hormonal therapies are therefore designed to lower tissue levels of DHT or prevent its binding to receptors on prostatic cancer cells.,8358057_3,8358057_D013196_D011471,,
770956506,false,true,5,2015-08-14T20:28:00,,No Relation,1,D013739,testosterone,D006521,chronic viral hepatitis,"The effect of long-term treatment with recombinant interferon-alpha 2b (IFN-alpha 2b) on luteinizing hormone (LH), testosterone, free testosterone, and sex hormone-binding globulin (SHBG) was evaluated in 7 male patients suffering from chronic viral hepatitis.",8366286_1,8366286_D013739_D006521,,
770956507,false,true,5,2015-08-14T22:12:00,,No Relation,1,D005047,etoposide,D064420,toxicity,"Although the optimal chemotherapy regimen for combined-modality treatment has not yet been established, use of cisplatin and etoposide combinations, which do not promote pulmonary, cardiac, or esophageal toxicity, have been particularly appropriate in patients with small-cell lung cancer.",8380135_7,8380135_D005047_D064420,,
770956508,false,true,5,2015-08-14T22:22:00,,No Relation,1,D002945,cisplatin,D008175,lung cancer,"Although the optimal chemotherapy regimen for combined-modality treatment has not yet been established, use of cisplatin and etoposide combinations, which do not promote pulmonary, cardiac, or esophageal toxicity, have been particularly appropriate in patients with small-cell lung cancer.",8380135_7,8380135_D002945_D008175,,
770956509,false,true,5,2015-08-15T00:03:00,,No Relation,1,D005047,etoposide,D008175,lung cancer,"Although the optimal chemotherapy regimen for combined-modality treatment has not yet been established, use of cisplatin and etoposide combinations, which do not promote pulmonary, cardiac, or esophageal toxicity, have been particularly appropriate in patients with small-cell lung cancer.",8380135_7,8380135_D005047_D008175,,
770956510,false,true,5,2015-08-14T23:14:00,,No Relation,1,D002945,cisplatin,D064420,toxicity,"Although the optimal chemotherapy regimen for combined-modality treatment has not yet been established, use of cisplatin and etoposide combinations, which do not promote pulmonary, cardiac, or esophageal toxicity, have been particularly appropriate in patients with small-cell lung cancer.",8380135_7,8380135_D002945_D064420,,
770956511,false,true,5,2015-08-15T01:51:00,,No Relation,1,D017963,azithromycin,D002690,Chlamydia trachomatis infected,"In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells.",8383102_0,8383102_D017963_D002690,,
770956512,false,true,5,2015-08-15T00:58:00,,No Relation,1,D017963,azithromycin,D002690,Chlamydia trachomatis infected,"The in-vitro activity of azithromycin on Chlamydia trachomatis infected human endometrial epithelial cells, both primary and transformed cells growing in a polarized and non-polarized orientation, was analyzed.",8383102_1,8383102_D017963_D002690,,
770956513,false,true,5,2015-08-14T23:53:00,,No Relation,1,C059499,"9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine",D015658,human immunodeficiency virus (HIV) replication,"9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), a potent inhibitor of human immunodeficiency virus (HIV) replication, was evaluated for its activity against human cytomegalovirus (HCMV) in vitro, and murine cytomegalovirus (MCMV) and rat CMV (RCMV) in vivo.",8395382_1,8395382_C059499_D015658,,
770956514,false,true,5,2015-08-14T21:23:00,,No Relation,0.5766,D006495,LMWH,D013927,thrombosis,There were 21 cases of thrombosis in the group without prophylaxis (16.5%) and only six cases of thrombosis (4.8%) with LMWH.,8395716_6,8395716_D006495_D013927,,
770956515,false,true,5,2015-08-14T23:24:00,,No Relation,0.8067,D004967,Oestrogen,D016889,endometrial cancer,Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates.,8398274_0,8398274_D004967_D016889,,
770956516,false,true,5,2015-08-15T02:15:00,,No Relation,0.8187,D004967,oestrogen,D016889,endometrial cancer,"The relationship between oestrogen replacement treatment and the risk of endometrial cancer was analysed in a case-control study of 158 histologically confirmed incident cases below the age of 75 and 468 controls in hospital for acute, non-neoplastic, non-hormone-related conditions conducted in the Swiss Canton of Vaud in 1988-1992.",8398274_1,8398274_D004967_D016889,,
770956517,false,true,5,2015-08-15T02:13:00,,No Relation,0.5934,D004967,oestrogen,D016889,endometrial cancer,"Thus, this study confirms the presence of a strong association between oestrogen replacement treatment and endometrial cancer risk, since in the late 1980s or early 1990s about 25% of cases could be attributed to oestrogen replacement treatment in this Swiss population.",8398274_8,8398274_D004967_D016889,,
770956518,false,true,5,2015-08-14T20:31:00,,Direct,0.5923,D004967,oestrogen,D009765,obesity,"Further, it confirms the presence of significant negative interactions of oestrogen use with obesity, and, possibly, with OC as well.",8398274_9,8398274_D004967_D009765,,
770956519,false,true,5,2015-08-14T20:49:00,,No Relation,0.825,D017835,Nedocromil sodium,D001986,bronchospasm,Nedocromil sodium in the prevention of exercise-induced bronchospasm in athletes with asthma.,8412049_0,8412049_D017835_D001986,,
770956520,false,true,5,2015-08-15T02:14:00,,No Relation,1,D017835,Nedocromil sodium,D001249,asthma,Nedocromil sodium in the prevention of exercise-induced bronchospasm in athletes with asthma.,8412049_0,8412049_D017835_D001249,,
770956521,false,true,5,2015-08-14T20:48:00,,No Relation,0.8173,D012964,sodium,D001986,bronchospasm,The aim of this study was to determine the efficacy of nedocromil sodium in the prevention of exercise-induced bronchospasm (EIB) in 13 top athletes affected by bronchial asthma.,8412049_1,8412049_D012964_D001986,,
770956522,false,true,5,2015-08-14T23:57:00,It's 'nedocromil sodium' and not just 'Na',No Relation,1,D012964,sodium,D001249,bronchial asthma,The aim of this study was to determine the efficacy of nedocromil sodium in the prevention of exercise-induced bronchospasm (EIB) in 13 top athletes affected by bronchial asthma.,8412049_1,8412049_D012964_D001249,,
770956523,false,true,5,2015-08-15T00:46:00,,No Relation,0.8081,D012964,sodium,D016535,bronchial hyperreactivity,"In conclusion, the effect of nedocromil sodium in the prevention of EIB may be dose-dependent in relation to the degree of bronchial hyperreactivity or to interference of other factors.",8412049_5,8412049_D012964_D016535,,
770956524,false,true,5,2015-08-15T00:21:00,,No Relation,0.8065,D013420,sulfamethoxazole,D014890,Wegener's granulomatosis,Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis.,8417733_0,8417733_D013420_D014890,,
770956525,false,true,5,2015-08-14T20:27:00,,No Relation,0.8123,D014295,trimethoprim,D014890,Wegener's granulomatosis,Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis.,8417733_0,8417733_D014295_D014890,,
770956526,false,true,5,2015-08-14T20:56:00,,No Relation,1,D013420,sulfamethoxazole,D014890,Wegener's granulomatosis,"Since 1985, a number of reports have highlighted the effectiveness of a short course of sulfamethoxazole-trimethoprim as an adjuvant to immunosuppressive drugs in the treatment of Wegener's granulomatosis.",8417733_1,8417733_D013420_D014890,,
770956527,false,true,5,2015-08-14T23:27:00,,No Relation,1,D014295,trimethoprim,D014890,Wegener's granulomatosis,"Since 1985, a number of reports have highlighted the effectiveness of a short course of sulfamethoxazole-trimethoprim as an adjuvant to immunosuppressive drugs in the treatment of Wegener's granulomatosis.",8417733_1,8417733_D014295_D014890,,
770956528,false,true,5,2015-08-14T20:48:00,,No Relation,1,D013420,sulfamethoxazole,D014890,Wegener's granulomatosis,We report our experience with long-term sulfamethoxazole-trimethoprim therapy in patients with Wegener's granulomatosis.,8417733_2,8417733_D013420_D014890,,
770956529,false,true,5,2015-08-14T21:51:00,,No Relation,1,D014295,trimethoprim,D014890,Wegener's granulomatosis,We report our experience with long-term sulfamethoxazole-trimethoprim therapy in patients with Wegener's granulomatosis.,8417733_2,8417733_D014295_D014890,,
770956530,false,true,5,2015-08-15T02:24:00,,No Relation,1,D013420,sulfamethoxazole,D014890,Wegener's granulomatosis,"We describe recent advances in the pathogenesis of Wegener's granulomatosis, suggest a complementary mechanism of action of sulfamethoxazole-trimethoprim, and advocate long-term sulfamethoxazole-trimethoprim therapy as a treatment option in Wegener's granulomatosis.",8417733_3,8417733_D013420_D014890,,
770956531,false,true,5,2015-08-15T02:12:00,,No Relation,1,D014295,trimethoprim,D014890,Wegener's granulomatosis,"We describe recent advances in the pathogenesis of Wegener's granulomatosis, suggest a complementary mechanism of action of sulfamethoxazole-trimethoprim, and advocate long-term sulfamethoxazole-trimethoprim therapy as a treatment option in Wegener's granulomatosis.",8417733_3,8417733_D014295_D014890,,
770956532,false,true,5,2015-08-14T20:51:00,,No Relation,1,D002511,cephalosporin,D008581,meningitis,Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.,8451095_0,8451095_D002511_D008581,,
770956533,false,true,5,2015-08-14T21:45:00,,No Relation,1,D002443,ceftriaxone,D008581,meningitis,We recently managed an infant with meningitis caused by Streptococcus pneumoniae in whom ceftriaxone failed to sterilize the cerebrospinal fluid after 6 days of therapy.,8451095_1,8451095_D002443_D008581,,
770956534,false,true,5,2015-08-15T02:13:00,,No Relation,0.8063,D002443,ceftriaxone,D008581,meningitis,Furthermore ceftriaxone therapy of meningitis induced with this strain in a rabbit model was ineffective.,8451095_3,8451095_D002443_D008581,,
770956535,false,true,5,2015-08-14T22:20:00,,No Relation,1,D002511,cephalosporin/cephalosporins,D008581,meningitis,The definition of cephalosporin resistance for pneumococci requires modification and further studies of the antibiotic management of meningitis caused by such strains are needed because resistance to cephalosporins is increasing and the extended spectrum cephalosporins may be ineffective as sole therapy.,8451095_6,8451095_D002511_D008581,,
770956536,false,true,5,2015-08-15T00:15:00,,Direct,0.6051,C011272,4-hydroperoxycyclophosphamide,D002869,Chromosome abnormalities,Chromosome abnormalities in patients treated with 4-hydroperoxycyclophosphamide-purged autologous bone marrow transplantation.,8453599_0,8453599_C011272_D002869,,
770956537,false,true,5,2015-08-14T23:56:00,,No Relation,1,D002066,busulfan,D015470,ANLL,"ANLL patients received busulfan and cytoxan, and the others received cytoxan and total body irradiation as their preparative regimen before transplant.",8453599_4,8453599_D002066_D015470,,
770956538,false,true,5,2015-08-14T21:59:00,,No Relation,1,C011272,4-hydroperoxycyclophosphamide/4-HC,D009369,tumor,BM was purged ex vivo with 4-hydroperoxycyclophosphamide (4-HC) at 30-100 micrograms/ml before reinfusion to kill tumor cells.,8453599_5,8453599_C011272_D009369,,
770956539,false,true,5,2015-08-15T01:46:00,,No Relation,1,C011272,4-HC,D009369,tumor,Our data suggest that clonal abnormalities observed posttransplant are best explained by clinical relapse of tumor and that ex vivo marrow purging with 4-HC is not likely to induce clonal chromosome abnormalities in normal cells.,8453599_12,8453599_C011272_D009369,,
770956540,false,true,5,2015-08-15T00:06:00,,No Relation,0.5804,C011272,4-HC,D001855,marrow purging,Our data suggest that clonal abnormalities observed posttransplant are best explained by clinical relapse of tumor and that ex vivo marrow purging with 4-HC is not likely to induce clonal chromosome abnormalities in normal cells.,8453599_12,8453599_C011272_D001855,,
770956541,false,true,5,2015-08-15T01:03:00,,No Relation,1,C011272,4-HC,C580365,clonal abnormalities,Our data suggest that clonal abnormalities observed posttransplant are best explained by clinical relapse of tumor and that ex vivo marrow purging with 4-HC is not likely to induce clonal chromosome abnormalities in normal cells.,8453599_12,8453599_C011272_C580365,,
770956542,false,true,5,2015-08-14T20:58:00,,No Relation,1,C011272,4-HC,D002869,clonal chromosome abnormalities,Our data suggest that clonal abnormalities observed posttransplant are best explained by clinical relapse of tumor and that ex vivo marrow purging with 4-HC is not likely to induce clonal chromosome abnormalities in normal cells.,8453599_12,8453599_C011272_D002869,,
770956543,false,true,5,2015-08-14T20:16:00,,No Relation,1,D024841,Fluoroquinolone,D007239,infection,"Fluoroquinolone antimicrobials meet Joint Commission criteria for targeting for DUE: the drugs are used in populations at high risk for adverse drug reactions, quality assurance or infection control committees target them for DUE, the drugs are costly, they may be suspected or known to be used inappropriately, and they are prescribed frequently.",8474940_3,8474940_D024841_D007239,,
770956544,false,true,5,2015-08-15T01:39:00,,No Relation,0.8129,D024841,fluoroquinolone,D007239,infections,"Suggested criteria include use in patients who would otherwise be candidates for oral fluoroquinolone therapy (for which published criteria exist) but who cannot use the oral route of administration due to gastrointestinal conditions predisposing to malabsorption or unavailability of the oral route; for severe infections due to gram-negative pathogens; as a replacement for aminoglycosides when ototoxicity or nephrotoxicity is a substantial risk; targeting to resistant pathogens (i.e., not as empiric therapy); and targeting to therapeutic use only (not for prophylaxis).",8474940_5,8474940_D024841_D007239,,
770956545,false,true,5,2015-08-15T00:22:00,,No Relation,1,D024841,fluoroquinolone,C564013,ototoxicity,"Suggested criteria include use in patients who would otherwise be candidates for oral fluoroquinolone therapy (for which published criteria exist) but who cannot use the oral route of administration due to gastrointestinal conditions predisposing to malabsorption or unavailability of the oral route; for severe infections due to gram-negative pathogens; as a replacement for aminoglycosides when ototoxicity or nephrotoxicity is a substantial risk; targeting to resistant pathogens (i.e., not as empiric therapy); and targeting to therapeutic use only (not for prophylaxis).",8474940_5,8474940_D024841_C564013,,
770956546,false,true,5,2015-08-14T20:22:00,,Direct,0.5857,D000617,aminoglycosides,C564013,ototoxicity,"Suggested criteria include use in patients who would otherwise be candidates for oral fluoroquinolone therapy (for which published criteria exist) but who cannot use the oral route of administration due to gastrointestinal conditions predisposing to malabsorption or unavailability of the oral route; for severe infections due to gram-negative pathogens; as a replacement for aminoglycosides when ototoxicity or nephrotoxicity is a substantial risk; targeting to resistant pathogens (i.e., not as empiric therapy); and targeting to therapeutic use only (not for prophylaxis).",8474940_5,8474940_D000617_C564013,,
770956547,false,true,5,2015-08-14T23:14:00,,No Relation,0.809,D000617,aminoglycosides,D007239,infections,"Suggested criteria include use in patients who would otherwise be candidates for oral fluoroquinolone therapy (for which published criteria exist) but who cannot use the oral route of administration due to gastrointestinal conditions predisposing to malabsorption or unavailability of the oral route; for severe infections due to gram-negative pathogens; as a replacement for aminoglycosides when ototoxicity or nephrotoxicity is a substantial risk; targeting to resistant pathogens (i.e., not as empiric therapy); and targeting to therapeutic use only (not for prophylaxis).",8474940_5,8474940_D000617_D007239,,
770956548,false,true,5,2015-08-15T01:34:00,,No Relation,1,D001241,aspirin,D000783,aneurysm,This series represents a minimum number of cases for this period and illustrates an association of aneurysm-risk with prolonged fever; improved defervescence with the combination of intravenous gamma-globulin (IVGG) and aspirin compared with aspirin alone; and a more severe disease process in the very young.,8489792_7,8489792_D001241_D000783,,
770956549,false,true,5,2015-08-14T20:28:00,,No Relation,0.6021,D001241,aspirin,D005334,fever,This series represents a minimum number of cases for this period and illustrates an association of aneurysm-risk with prolonged fever; improved defervescence with the combination of intravenous gamma-globulin (IVGG) and aspirin compared with aspirin alone; and a more severe disease process in the very young.,8489792_7,8489792_D001241_D005334,,
770956550,false,true,5,2015-08-15T00:55:00,,No Relation,1,D003613,danazol,D004715,endometriosis,Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study.,8495764_0,8495764_D003613_D004715,,
770956551,false,true,5,2015-08-14T20:17:00,,No Relation,1,D002064,buserelin acetate,D004715,endometriosis,Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study.,8495764_0,8495764_D002064_D004715,,
770956552,false,true,5,2015-08-14T20:47:00,,No Relation,1,D003613,danazol,D004715,endometriosis,To evaluate histologic and ultrastructural changes of the vaginal mucosa in patients given buserelin acetate or danazol treatment for endometriosis.,8495764_1,8495764_D003613_D004715,,
770956553,false,true,5,2015-08-14T22:29:00,,No Relation,1,D002064,buserelin acetate,D004715,endometriosis,To evaluate histologic and ultrastructural changes of the vaginal mucosa in patients given buserelin acetate or danazol treatment for endometriosis.,8495764_1,8495764_D002064_D004715,,
770956554,false,true,5,2015-08-15T01:13:00,,No Relation,0.8078,D002064,buserelin acetate,D007246,Infertile,Infertile women with endometriosis randomized to receive buserelin acetate or danazol and undergoing vaginal biopsies during treatment were selected.,8495764_4,8495764_D002064_D007246,,
770956555,false,true,5,2015-08-15T00:29:00,,No Relation,1,D003613,danazol,D004715,endometriosis,Infertile women with endometriosis randomized to receive buserelin acetate or danazol and undergoing vaginal biopsies during treatment were selected.,8495764_4,8495764_D003613_D004715,,
770956556,false,true,5,2015-08-15T01:26:00,,No Relation,1,D002064,buserelin acetate,D004715,endometriosis,Infertile women with endometriosis randomized to receive buserelin acetate or danazol and undergoing vaginal biopsies during treatment were selected.,8495764_4,8495764_D002064_D004715,,
770956557,false,true,5,2015-08-14T20:16:00,,No Relation,1,D003613,danazol,D007246,Infertile,Infertile women with endometriosis randomized to receive buserelin acetate or danazol and undergoing vaginal biopsies during treatment were selected.,8495764_4,8495764_D003613_D007246,,
770956558,false,true,5,2015-08-14T23:32:00,,No Relation,0.7945,D003613,danazol,D004715,endometriosis,Vaginal mucosa undergoes constant and well-defined modifications during both buserelin acetate and danazol treatment for endometriosis.,8495764_11,8495764_D003613_D004715,,
770956559,false,true,5,2015-08-15T02:02:00,,No Relation,1,D002064,buserelin acetate,D004715,endometriosis,Vaginal mucosa undergoes constant and well-defined modifications during both buserelin acetate and danazol treatment for endometriosis.,8495764_11,8495764_D002064_D004715,,
770956560,false,true,5,2015-08-14T23:35:00,,No Relation,1,D007741,labetalol,D002637,chest pain,"Although labetalol is sometimes given to patients with cocaine-associated chest pain, its influence on cocaine-induced coronary vasoconstriction is unknown.",8506886_1,8506886_D007741_D002637,,
770956561,false,true,5,2015-08-14T23:31:00,,Direct,0.8066,D003042,cocaine,D002637,chest pain,"Although labetalol is sometimes given to patients with cocaine-associated chest pain, its influence on cocaine-induced coronary vasoconstriction is unknown.",8506886_1,8506886_D003042_D002637,,
770956562,false,true,5,2015-08-14T23:28:00,,Direct,0.5858,D003042,cocaine,D002637,chest pain,"In 15 patients (7 men, 8 women, aged 40 to 79 years) undergoing catheterization for chest pain, heart rate, mean arterial pressure, and coronary arterial area (by computer-assisted quantitative angiography) were measured (1) at baseline, (2) 15 minutes after intranasal cocaine, 2 mg/kg, then (3) 5 minutes after intravenous saline (n = 6) or labetalol, 0.25 mg/kg (n = 9).",8506886_2,8506886_D003042_D002637,,
770956563,false,true,5,2015-08-14T22:19:00,,No Relation,1,D007741,labetalol,D002637,chest pain,"In 15 patients (7 men, 8 women, aged 40 to 79 years) undergoing catheterization for chest pain, heart rate, mean arterial pressure, and coronary arterial area (by computer-assisted quantitative angiography) were measured (1) at baseline, (2) 15 minutes after intranasal cocaine, 2 mg/kg, then (3) 5 minutes after intravenous saline (n = 6) or labetalol, 0.25 mg/kg (n = 9).",8506886_2,8506886_D007741_D002637,,
770956564,false,true,5,2015-08-14T20:26:00,,No Relation,1,D013793,thallium,D002037,left bundle branch block,"Twelve patients with exercise-induced ST-segment elevation without prior myocardial infarction, electrocardiographic evidence of left ventricular hypertrophy or left bundle branch block underwent thallium-201 tomography immediately after exercise and 4 hours later.",8517412_1,8517412_D013793_D002037,,
770956565,false,true,5,2015-08-15T02:21:00,,No Relation,1,D013793,thallium,D006984,ventricular hypertrophy,"Twelve patients with exercise-induced ST-segment elevation without prior myocardial infarction, electrocardiographic evidence of left ventricular hypertrophy or left bundle branch block underwent thallium-201 tomography immediately after exercise and 4 hours later.",8517412_1,8517412_D013793_D006984,,
770956566,false,true,5,2015-08-15T01:21:00,,No Relation,1,D013793,thallium,D009203,myocardial infarction,"Twelve patients with exercise-induced ST-segment elevation without prior myocardial infarction, electrocardiographic evidence of left ventricular hypertrophy or left bundle branch block underwent thallium-201 tomography immediately after exercise and 4 hours later.",8517412_1,8517412_D013793_D009203,,
770956567,false,true,5,2015-08-14T20:17:00,,No Relation,1,D004986,ether,D005910,glioma,Effects of structural modifications of ether lipids on antiproliferative activity against human glioma cell lines.,8517654_0,8517654_D004986_D005910,,
770956568,false,true,5,2015-08-14T22:28:00,,No Relation,1,D004986,ether,D005910,glioma,The effect of structural modifications of ether lipids on antiproliferative activity was studied in four human glioma cell lines.,8517654_1,8517654_D004986_D005910,,
770956569,false,true,5,2015-08-14T20:51:00,,No Relation,1,D011034,podophyllotoxin,D003218,condylomata,To evaluate the clinical efficacy of a 0.15% and a 0.3% cream formulation of podophyllotoxin in comparison with the 0.5% solution in the treatment of condylomata acuminata and to compare the treatment modalities regarding side effects.,8566979_1,8566979_D011034_D003218,,
770956570,false,true,5,2015-08-14T22:52:00,,No Relation,1,D010100,oxygen,D008171,chronic lung disease,"We studied pulmonary protein oxidation and its association with the development of chronic lung disease in 61 newborn infants (mean gestational age 31.1 +/- 4.0, range 24-41 weeks) requiring intensive care with oxygen therapy.",8580630_2,8580630_D010100_D008171,,
770956571,false,true,5,2015-08-15T00:43:00,,No Relation,1,D010100,oxygen,D001997,bronchopulmonary dysplasia,"In multiple regression analysis explaining bronchopulmonary dysplasia, using gestational age, inspired oxygen on days 1-3 and protein carbonylation on day 3 as independent variables, only protein carbonylation remained significant.",8580630_7,8580630_D010100_D001997,,
770956572,false,true,5,2015-08-14T22:25:00,,No Relation,1,D000111,N-acetylcysteine,C565846,toxicosis,"Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats.",8585668_0,8585668_D000111_C565846,,
770956573,false,true,5,2015-08-15T01:51:00,,No Relation,1,D008751,methylene blue,C565846,toxicosis,"Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats.",8585668_0,8585668_D008751_C565846,,
770956574,false,true,5,2015-08-14T20:58:00,,No Relation,0.591,D000082,acetaminophen,C565846,toxicosis,"Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats.",8585668_0,8585668_D000082_C565846,,
770956575,false,true,5,2015-08-15T01:33:00,,Direct,1,D000082,Acetaminophen,D011041,poisoning,"Acetaminophen is widely used in human beings for analgesic purposes, but is one of the most frequent causes of poisoning in cats.",8585668_1,8585668_D000082_D011041,,
770956576,false,true,5,2015-08-15T02:18:00,,Direct,1,D000082,Acetaminophen,D008708,methemoglobinemia,Acetaminophen-poisoned cats develop methemoglobinemia and sometimes hepatic failure.,8585668_2,8585668_D000082_D008708,,
770956577,false,true,5,2015-08-14T20:17:00,,Direct,1,D000082,Acetaminophen,D017093,hepatic failure,Acetaminophen-poisoned cats develop methemoglobinemia and sometimes hepatic failure.,8585668_2,8585668_D000082_D017093,,
770956578,false,true,5,2015-08-14T20:13:00,,No Relation,1,D000111,NAC/N-acetylcysteine,D008708,methemoglobinemia,"To determine the benefit of using methylene blue, a treatment for methemoglobinemia, along with N-acetylcysteine (NAC), the recommended treatment for acetaminophen-poisoned cats, groups of 3 male and 3 female cats each were given methylene blue NAC, or both after administration of acetaminophen (120 mg/kg of body weight, PO).",8585668_3,8585668_D000111_D008708,,
770956579,false,true,5,2015-08-15T00:24:00,,No Relation,1,D008751,methylene blue,D008708,methemoglobinemia,"To determine the benefit of using methylene blue, a treatment for methemoglobinemia, along with N-acetylcysteine (NAC), the recommended treatment for acetaminophen-poisoned cats, groups of 3 male and 3 female cats each were given methylene blue NAC, or both after administration of acetaminophen (120 mg/kg of body weight, PO).",8585668_3,8585668_D008751_D008708,,
770956580,false,true,5,2015-08-14T21:53:00,,No Relation,1,D000082,acetaminophen,D008708,methemoglobinemia,"To determine the benefit of using methylene blue, a treatment for methemoglobinemia, along with N-acetylcysteine (NAC), the recommended treatment for acetaminophen-poisoned cats, groups of 3 male and 3 female cats each were given methylene blue NAC, or both after administration of acetaminophen (120 mg/kg of body weight, PO).",8585668_3,8585668_D000082_D008708,,
770956581,false,true,5,2015-08-15T01:58:00,,Direct,0.5873,D000111,NAC,C565846,toxicosis,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D000111_C565846,,
770956582,false,true,5,2015-08-15T02:02:00,,Direct,1,D008751,methylene blue,C565846,toxicosis,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D008751_C565846,,
770956583,false,true,5,2015-08-15T01:18:00,,Direct,1,D000082,acetaminophen,C565846,toxicosis,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D000082_C565846,,
770956584,false,true,5,2015-08-15T01:35:00,,Direct,0.7851,D008751,methylene blue,D017093,hepatic failure,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D008751_D017093,,
770956585,false,true,5,2015-08-14T20:10:00,,Direct,0.8224,D000111,NAC,D017093,hepatic failure,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D000111_D017093,,
770956586,false,true,5,2015-08-14T20:27:00,,Direct,1,D000082,acetaminophen,D017093,hepatic failure,"Male cats seemed more susceptible than female cats to acetaminophen toxicosis, because 3 males died of hepatic failure (2 cats given acetaminophen/methylene blue and 1 given acetaminophen/NAC/methylene blue).",8585668_4,8585668_D000082_D017093,,
770956587,false,true,5,2015-08-15T00:38:00,,No Relation,1,D016685,mitomycin C,D009369,Tumor,Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.,8614004_0,8614004_D016685_D009369,,
770956588,false,true,5,2015-08-14T20:48:00,,No Relation,1,D010710,phosphate,D009369,tumor,"We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.",8614004_4,8614004_D010710_D009369,,
770956589,false,true,5,2015-08-14T20:27:00,,No Relation,1,D009249,NADPH/NAD(P)H,D009369,tumor,"We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.",8614004_4,8614004_D009249_D009369,,
770956590,false,true,5,2015-08-15T01:23:00,,No Relation,1,D016685,mitomycin C,D009369,tumor,"We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.",8614004_4,8614004_D016685_D009369,,
770956591,false,true,5,2015-08-14T23:32:00,,No Relation,1,D009243,nicotinamide adenine dinucleotide/NADH,D009369,tumor,"We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.",8614004_4,8614004_D009243_D009369,,
770956592,false,true,5,2015-08-14T22:00:00,,No Relation,0.7989,C004532,quinone,D009369,tumor,"We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.",8614004_4,8614004_C004532_D009369,,
770956593,false,true,5,2015-08-14T23:20:00,,No Relation,0.5682,D006493,heparin,D006470,haemorrhagic,"The use of heparin for extracorporeal therapies has been problematical due to haemorrhagic complications; as a consequence, heparinase I from Flavobacterium heparinum is used for the determination of plasma heparin and for elimination of heparin from circulation.",8615834_1,8615834_D006493_D006470,,
770956594,false,true,5,2015-08-15T01:13:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.,8636753_0,8636753_D013629_D009369,,
770956595,false,true,5,2015-08-15T02:08:00,,No Relation,1,D017312,toremifene,D009369,breast cancer,Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.,8636753_0,8636753_D017312_D009369,,
770956596,false,true,5,2015-08-15T01:35:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,Forty-nine postmenopausal patients with node-positive breast cancer were randomized in a trial that compared the effects of tamoxifen and toremifene on serum lipoproteins.,8636753_2,8636753_D013629_D009369,,
770956597,false,true,5,2015-08-14T20:17:00,,No Relation,1,D017312,toremifene,D009369,breast cancer,Forty-nine postmenopausal patients with node-positive breast cancer were randomized in a trial that compared the effects of tamoxifen and toremifene on serum lipoproteins.,8636753_2,8636753_D017312_D009369,,
770956598,false,true,5,2015-08-15T02:10:00,,No Relation,1,D017312,toremifene,D003327,CHD/coronary heart disease,These results provide positive evidence that toremifene has antiatherogenic properties with potency to improve all lipoproteins that are associated with increased coronary heart disease (CHD) risk.,8636753_11,8636753_D017312_D003327,,
770956599,false,true,5,2015-08-14T20:32:00,,No Relation,1,D000666,amphotericin B,D058387,candidemia,"During a comparative trial of amphotericin B vs. fluconazole for treatment of candidemia in nonneutropenic patients, data on the management of intravascular catheters were collected.",8645855_2,8645855_D000666_D058387,,
770956600,false,true,5,2015-08-14T20:21:00,,No Relation,1,D015725,fluconazole,D058387,candidemia,"During a comparative trial of amphotericin B vs. fluconazole for treatment of candidemia in nonneutropenic patients, data on the management of intravascular catheters were collected.",8645855_2,8645855_D015725_D058387,,
770956601,false,true,5,2015-08-15T01:53:00,,No Relation,1,D016898,interferon-alpha,D006509,hepatitis B,We investigated the long-term effect of interferon-alpha treatment in patients with chronic hepatitis B with regard to the response status during treatment.,8686350_1,8686350_D016898_D006509,,
770956602,false,true,5,2015-08-14T20:27:00,,Direct,0.5789,D016898,interferon-alpha,D006509,hepatitis B,"97 patients with chronic hepatitis B, including 18 patients with active cirrhosis Child A, were followed for 12-110 months (mean: 40.5 months) after interferon-alpha treatment.",8686350_2,8686350_D016898_D006509,,
770956603,false,true,5,2015-08-14T22:20:00,,No Relation,0.8048,D016898,interferon-alpha,D005355,cirrhosis,"97 patients with chronic hepatitis B, including 18 patients with active cirrhosis Child A, were followed for 12-110 months (mean: 40.5 months) after interferon-alpha treatment.",8686350_2,8686350_D016898_D005355,,
770956604,false,true,5,2015-08-15T01:50:00,,No Relation,1,D006513,HBeAg,D005355,cirrhosis,"Thus, in patients without apparent cirrhosis interferon-alpha treatment has a considerable long-term effect with regard to the enhanced rate of HBsAg and HBeAg clearance during prolonged follow-up.",8686350_12,8686350_D006513_D005355,,
770956605,false,true,5,2015-08-15T02:14:00,,No Relation,0.8082,D007649,ketamine,D010146,terminal cancer pain,Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.,8697554_0,8697554_D007649_D010146,,
770956606,false,true,5,2015-08-14T22:20:00,,No Relation,1,D009020,morphine,D010146,terminal cancer pain,Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.,8697554_0,8697554_D009020_D010146,,
770956607,false,true,5,2015-08-15T02:33:00,,No Relation,1,D007649,Ketamine,D010146,pain,Ketamine has been administered epidurally and intrathecally for operative and post-operative pain control.,8697554_1,8697554_D007649_D010146,,
770956608,false,true,5,2015-08-14T20:25:00,,Direct,1,D009020,morphine,D000699,analgesia,Animal studies showed potentiation of analgesia induced by ketamine and morphine.,8697554_2,8697554_D009020_D000699,,
770956609,false,true,5,2015-08-15T01:42:00,,Direct,0.5764,D007649,ketamine,D000699,analgesia,Animal studies showed potentiation of analgesia induced by ketamine and morphine.,8697554_2,8697554_D007649_D000699,,
770956610,false,true,5,2015-08-15T01:34:00,,No Relation,1,D007649,ketamine,D010146,cancer pain,We hypothesized that intrathecal ketamine would potentiate the effects of intrathecal morphine in the treatment of cancer pain.,8697554_3,8697554_D007649_D010146,,
770956611,false,true,5,2015-08-15T01:35:00,,No Relation,1,D009020,morphine,D010146,cancer pain,We hypothesized that intrathecal ketamine would potentiate the effects of intrathecal morphine in the treatment of cancer pain.,8697554_3,8697554_D009020_D010146,,
770956612,false,true,5,2015-08-15T02:02:00,,No Relation,1,D007649,ketamine,D010146,terminal cancer pain,"A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients.",8697554_4,8697554_D007649_D010146,,
770956613,false,true,5,2015-08-14T22:27:00,,Direct,0.616,D009020,morphine,D000699,analgesia,"A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients.",8697554_4,8697554_D009020_D000699,,
770956614,false,true,5,2015-08-15T02:02:00,,No Relation,1,D009020,morphine,D010146,terminal cancer pain,"A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients.",8697554_4,8697554_D009020_D010146,,
770956615,false,true,5,2015-08-15T00:58:00,,No Relation,0.7963,D007649,ketamine,D000699,analgesia,"A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients.",8697554_4,8697554_D007649_D000699,,
770956616,false,true,5,2015-08-15T01:59:00,,No Relation,1,D009020,morphine,D010146,pain,"The dose of morphine was titrated upwards until acceptable pain relief was achieved, defined by numeric rating scales (0-10) < or = 3, and the rescue dose of morphine was less than 5 mg after each intrathecal administration for two days.",8697554_6,8697554_D009020_D010146,,
770956617,false,true,5,2015-08-14T20:10:00,,No Relation,1,D011188,K,D010146,Pain,Pain scales were decreased to 2.2 +/- 0.17 (P < 0.05) in phase M and 1.95 +/- 0.20 (P < 0.05) in phase M + K after the effective dose of morphine had been reached.,8697554_10,8697554_D011188_D010146,,
770956618,false,true,5,2015-08-15T02:29:00,,No Relation,1,D009020,morphine,D010146,Pain,Pain scales were decreased to 2.2 +/- 0.17 (P < 0.05) in phase M and 1.95 +/- 0.20 (P < 0.05) in phase M + K after the effective dose of morphine had been reached.,8697554_10,8697554_D009020_D010146,,
770956619,false,true,5,2015-08-15T00:27:00,,No Relation,1,D010431,Pentoxifylline,D013927,thrombosis,Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells.,8699848_0,8699848_D010431_D013927,,
770956620,false,true,5,2015-08-15T00:36:00,,No Relation,1,D010431,pentoxifylline/PTX,D009336,necrosis,"In vitro, pentoxifylline (PTX) inhibits monocyte production of TF in response to endotoxin, as well as endothelial cell production of TF in response to tumor necrosis factor-alpha (TNF-alpha).",8699848_5,8699848_D010431_D009336,,
770956621,false,true,5,2015-08-15T01:37:00,,No Relation,1,C047781,Lamotrigine,D020189,nocturnal myoclonus syndrome/NMS,Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.,8739847_0,8739847_C047781_D020189,,
770956622,false,true,5,2015-08-15T02:03:00,,No Relation,0.7879,D004298,dopamine,D020189,nocturnal myoclonus syndrome/NMS,In previous investigations we found an increase of D2 dopamine receptors in the striatum of patients with nocturnal myoclonus syndrome (NMS) after treatment with dopamimetics.,8739847_1,8739847_D004298_D020189,,
770956623,false,true,5,2015-08-14T20:19:00,,No Relation,1,D018698,glutamate,D020189,NMS,The glutamate release inhibitor lamotrigine was tested in up to now two NMS patients.,8739847_3,8739847_D018698_D020189,,
770956624,false,true,5,2015-08-14T23:19:00,Used as treatment.,No Relation,1,C047781,lamotrigine,D020189,NMS,The glutamate release inhibitor lamotrigine was tested in up to now two NMS patients.,8739847_3,8739847_C047781_D020189,,
770956625,false,true,5,2015-08-15T01:25:00,,No Relation,0.7997,D013619,tacrine,D000544,Alzheimer's amyloid,Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine.,8761343_0,8761343_D013619_D000544,,
770956626,false,true,5,2015-08-14T20:42:00,,No Relation,0.8087,D013619,tacrine,D000544,AD,"In addition, zinc or tacrine treatment of AD patients with high dosage or in the long term may have effects on the process of amyloidogensis.",8761343_7,8761343_D013619_D000544,,
770956627,false,true,5,2015-08-14T23:42:00,,No Relation,1,D015032,zinc,D000544,AD,"In addition, zinc or tacrine treatment of AD patients with high dosage or in the long term may have effects on the process of amyloidogensis.",8761343_7,8761343_D015032_D000544,,
770956628,false,true,5,2015-08-14T20:16:00,,Direct,1,D004317,adriamycin,D064420,acute cardiac toxicity,The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice.,8787689_0,8787689_D004317_D064420,,
770956629,false,true,5,2015-08-15T02:27:00,,Direct,1,D004317,ADR/Adriamycin,D064420,cardiac toxicity,Adriamycin (ADR) is a potent anticancer drug known to cause severe cardiac toxicity.,8787689_1,8787689_D004317_D064420,,
770956630,false,true,5,2015-08-14T22:19:00,,Direct,0.5907,D004317,ADR,D064420,cardiac toxicity,"Although ADR generates free radicals, the role of free radicals in the development of cardiac toxicity and the intracellular target for ADR-induced cardiac toxicity are still not well understood.",8787689_2,8787689_D004317_D064420,,
770956631,false,true,5,2015-08-15T01:02:00,,Direct,0.6124,D004317,ADR,D006177,mitochondrial damage,"Electron microscopy revealed dose-dependent ultrastructural alterations with marked mitochondrial damage in nontransgenic mice treated with ADR, but not in the transgenic littermates.",8787689_6,8787689_D004317_D006177,,
770956632,false,true,5,2015-08-14T22:07:00,,Direct,0.8068,D004317,ADR,D064420,toxicity,These results support a major role for free radical generation in ADR toxicity as well as suggesting mitochondria as the critical site of cardiac injury.,8787689_8,8787689_D004317_D064420,,
770956633,false,true,5,2015-08-15T01:14:00,,No Relation,0.7839,D004317,ADR,D014947,cardiac injury,These results support a major role for free radical generation in ADR toxicity as well as suggesting mitochondria as the critical site of cardiac injury.,8787689_8,8787689_D004317_D014947,,
770956634,false,true,5,2015-08-14T23:01:00,,Direct,1,D012701,5-HT,D018229,contractions,Ketanserin (10-1000 nM) antagonized part of the 5-HT-induced contractions.,8789380_7,8789380_D012701_D018229,,
770956635,false,true,5,2015-08-14T22:04:00,,No Relation,0.8188,D007650,Ketanserin,D018229,contractions,Ketanserin (10-1000 nM) antagonized part of the 5-HT-induced contractions.,8789380_7,8789380_D007650_D018229,,
770956636,false,true,5,2015-08-14T22:43:00,,Direct,0.7944,D012701,5-HT,D018229,contractions,"Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M of 6.9 and f1 of 0.17 (100 nM ketanserin) and -log EC50, M of 6.4 and f1 of 0.20 (1000 nM ketanserin).",8789380_8,8789380_D012701_D018229,,
770956637,false,true,5,2015-08-14T22:21:00,,No Relation,0.6231,D007650,Ketanserin,D018229,contractions,"Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M of 6.9 and f1 of 0.17 (100 nM ketanserin) and -log EC50, M of 6.4 and f1 of 0.20 (1000 nM ketanserin).",8789380_8,8789380_D007650_D018229,,
770956638,false,true,5,2015-08-15T00:15:00,,Direct,1,D012701,5-HT,D018229,contractions,"In rings with endothelial function attenuated by enzymatic treatment, 5-HT caused contractions with a -log EC50, M of 7.2 that were partially blocked by ketanserin.",8789380_10,8789380_D012701_D018229,,
770956639,false,true,5,2015-08-14T23:02:00,,No Relation,1,D007650,ketanserin,D018229,contractions,"In rings with endothelial function attenuated by enzymatic treatment, 5-HT caused contractions with a -log EC50, M of 7.2 that were partially blocked by ketanserin.",8789380_10,8789380_D007650_D018229,,
770956640,false,true,5,2015-08-14T20:13:00,al simplificar las palabras es mas entendible para uno que no es medico en este tipo de tarea...thanksss,Direct,0.7972,D012701,5-HT,D018229,contractions,"Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M 7.4 and f1 of 0.16 (100 nM ketanserin) and -log EC50, M of 7.5 and f1 of 0.14 (1000 nM ketanserin).",8789380_11,8789380_D012701_D018229,,
770956641,false,true,5,2015-08-15T02:13:00,,No Relation,0.4106,D007650,Ketanserin,D018229,contractions,"Ketanserin-resistant components of 5-HT-induced contractions were found with -log EC50, M 7.4 and f1 of 0.16 (100 nM ketanserin) and -log EC50, M of 7.5 and f1 of 0.14 (1000 nM ketanserin).",8789380_11,8789380_D007650_D018229,,
770956642,false,true,5,2015-08-15T00:17:00,,Direct,1,D018170,sumatriptan,D018229,contractions,"In rings with intact endothelium the 5-HT1-like-selective agonist, sumatriptan, caused small contractions with a -log EC50, M of 6.5 and intrinsic activity of 0.21 with respect to 5-HT that were resistant to blockade by 1000 nM ketanserin but antagonized by 100 nM methiothepin.",8789380_15,8789380_D018170_D018229,,
770956643,false,true,5,2015-08-14T23:01:00,,No Relation,1,D012701,5-HT,D018229,contractions,"In rings with intact endothelium the 5-HT1-like-selective agonist, sumatriptan, caused small contractions with a -log EC50, M of 6.5 and intrinsic activity of 0.21 with respect to 5-HT that were resistant to blockade by 1000 nM ketanserin but antagonized by 100 nM methiothepin.",8789380_15,8789380_D012701_D018229,,
770956644,false,true,5,2015-08-15T00:01:00,,No Relation,1,D008719,methiothepin,D018229,contractions,"In rings with intact endothelium the 5-HT1-like-selective agonist, sumatriptan, caused small contractions with a -log EC50, M of 6.5 and intrinsic activity of 0.21 with respect to 5-HT that were resistant to blockade by 1000 nM ketanserin but antagonized by 100 nM methiothepin.",8789380_15,8789380_D008719_D018229,,
770956645,false,true,5,2015-08-15T01:06:00,,No Relation,1,D007650,ketanserin,D018229,contractions,"In rings with intact endothelium the 5-HT1-like-selective agonist, sumatriptan, caused small contractions with a -log EC50, M of 6.5 and intrinsic activity of 0.21 with respect to 5-HT that were resistant to blockade by 1000 nM ketanserin but antagonized by 100 nM methiothepin.",8789380_15,8789380_D007650_D018229,,
770956646,false,true,5,2015-08-14T22:46:00,,No Relation,1,D006919,hydroxyzine,D065631,allergic rhinitis,"Fifteen subjects with allergic rhinitis were tested before and 2-2.5 h after administration of diphenhydramine, hydroxyzine, or placebo in a double-blind, single-dose, three-way crossover study.",8792380_4,8792380_D006919_D065631,,
770956647,false,true,5,2015-08-15T01:49:00,,No Relation,0.8026,D004155,diphenhydramine,D065631,allergic rhinitis,"Fifteen subjects with allergic rhinitis were tested before and 2-2.5 h after administration of diphenhydramine, hydroxyzine, or placebo in a double-blind, single-dose, three-way crossover study.",8792380_4,8792380_D004155_D065631,,
770956648,false,true,5,2015-08-14T20:29:00,,Direct,1,D006919,hydroxyzine,D002493,CNS dysfunction,"In children, diphenhydramine and hydroxyzine are effective H1-receptor antagonists, but both these medications cause CNS dysfunction, as evidenced by increased P300 latency, a measure of cognitive function, and by increased subjective somnolence.",8792380_11,8792380_D006919_D002493,,
770956649,false,true,5,2015-08-14T20:31:00,,Direct,1,D004155,diphenhydramine,D002493,CNS dysfunction,"In children, diphenhydramine and hydroxyzine are effective H1-receptor antagonists, but both these medications cause CNS dysfunction, as evidenced by increased P300 latency, a measure of cognitive function, and by increased subjective somnolence.",8792380_11,8792380_D004155_D002493,,
770956650,false,true,5,2015-08-14T22:07:00,,No Relation,1,D006854,cortisol,D007027,hypothalamic,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D006854_D007027,,
770956651,false,true,5,2015-08-14T22:21:00,,No Relation,1,D006854,cortisol,D006259,head injury,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D006854_D006259,,
770956652,false,true,5,2015-08-14T21:03:00,,No Relation,1,D013739,testosterone,D006259,head injury,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D013739_D006259,,
770956653,false,true,5,2015-08-15T00:21:00,,No Relation,1,D007987,GnRH,D007027,hypothalamic,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D007987_D007027,,
770956654,false,true,5,2015-08-14T20:30:00,,No Relation,1,D007987,GnRH,D006259,head injury,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D007987_D006259,,
770956655,false,true,5,2015-08-14T20:22:00,,No Relation,1,D013739,testosterone,D007027,hypothalamic,"Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.",8796342_5,8796342_D013739_D007027,,
770956656,false,true,5,2015-08-15T00:04:00,,No Relation,1,D003000,clonidine,D007003,hypoglycemia,"However, GH response was reduced both to insulin-induced hypoglycemia, clonidine and GHRH tests.",8796342_9,8796342_D003000_D007003,,
770956657,false,true,5,2015-08-15T01:02:00,,No Relation,1,D019319,okadaic acid,C531854,okadaic acid/OA,Human (6.2 +/- 4.5 x 10(-2) mU/10(6) sperm) and monkey (4.3 +/- 0.8 x 10(-2) mU/10(6) sperm) sonicates contained activity tentatively identified as PP1 on the basis of inhibition profiles in okadaic acid (OA) and CA.,8835396_7,8835396_D019319_C531854,,
770956658,false,true,5,2015-08-14T20:23:00,,No Relation,1,D013752,tetracycline,D007239,infection,"The recommended management of this infection consists of drainage and antimicrobial therapy with tetracycline, clindamycin, or a fluoroquinolone.",8852981_5,8852981_D013752_D007239,,
770956659,false,true,5,2015-08-14T23:36:00,,No Relation,1,D024841,fluoroquinolone,D007239,infection,"The recommended management of this infection consists of drainage and antimicrobial therapy with tetracycline, clindamycin, or a fluoroquinolone.",8852981_5,8852981_D024841_D007239,,
770956660,false,true,5,2015-08-15T00:03:00,,No Relation,1,D002981,clindamycin,D007239,infection,"The recommended management of this infection consists of drainage and antimicrobial therapy with tetracycline, clindamycin, or a fluoroquinolone.",8852981_5,8852981_D002981_D007239,,
770956661,false,true,5,2015-08-14T20:16:00,,No Relation,1,D004744,[Met5]enkephalin,D009369,colon cancer,Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer.,8853403_0,8853403_D004744_D009369,,
770956662,false,true,5,2015-08-15T02:19:00,,No Relation,1,D004744,[Met5]enkephalin,D009369,colon cancer,"Daily administration of the native opioid growth factor (OGF), [Met5]enkephalin, at dosages of 0.5, 5, or 25 mg/kg prevented the occurrence of human colon cancer HT-29 xenografts in nude mice.",8853403_3,8853403_D004744_D009369,,
770956663,false,true,5,2015-08-14T20:13:00,,No Relation,1,D016210,methacholine,D001249,asthma,"To evaluate the effects of age, height and prechallenge respiratory system resistance (Rrs) on bronchial responsiveness to methacholine inhalation (BRm) as measured by the oscillation technique in children with mild asthma, we studied BRm in 92 atopic children aged from 8 to 13 years (mean +/- SD, 10.5 +/- 1.7 years).",8856797_1,8856797_D016210_D001249,,
770956664,false,true,5,2015-08-15T01:56:00,,No Relation,0.8035,D008727,methotrexate,D000799,angioedema,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D008727_D000799,,
770956665,false,true,5,2015-08-14T22:35:00,,No Relation,1,D003622,dapsone,D000799,angioedema,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D003622_D000799,,
770956666,false,true,5,2015-08-14T23:53:00,,No Relation,1,D006886,hydroxychloroquine,D000799,angioedema,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D006886_D000799,,
770956667,false,true,5,2015-08-14T23:48:00,Used as a failed treatment.,No Relation,1,D006886,hydroxychloroquine,D014657,urticarial vasculitis,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D006886_D014657,,
770956668,false,true,5,2015-08-15T01:43:00,,No Relation,1,D008727,methotrexate,D014657,urticarial vasculitis,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D008727_D014657,,
770956669,false,true,5,2015-08-14T20:58:00,,No Relation,0.7857,D003622,dapsone,D014657,urticarial vasculitis,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D003622_D014657,,
770956670,false,true,5,2015-08-14T20:50:00,,No Relation,1,D001379,azathioprine,D000799,angioedema,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D001379_D000799,,
770956671,false,true,5,2015-08-14T23:36:00,,No Relation,0.7941,D001379,azathioprine,D014657,urticarial vasculitis,"A 68-year-old woman with a 5 yr history of chronic recurrent urticarial vasculitis with angioedema, refractory to conventional treatment including glucocorticosteroids, H1 and H2 blockers, nonsteroidal antiinflammatory agents, methotrexate, hydroxychloroquine, dapsone, azathioprine, intravenous gamma globulin, and plasma exchange, was successfully treated with interferon alpha 2a.",8882052_1,8882052_D001379_D014657,,
770956672,false,true,5,2015-08-15T02:07:00,,No Relation,1,D005978,glutathione,C535575,head and neck squamous carcinoma,Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion.,8898974_0,8898974_D005978_C535575,,
770956674,false,true,5,2015-08-14T23:21:00,,No Relation,1,D010984,platinum,D009369,tumor,"On the basis of this interaction with both endogenous and synthetic substances, glutathione and the key enzyme for its conjugation, glutathione S-transferase, appear to be critical determinants in tumor cell resistance to several antineoplastic drugs, e.g. platinum analogs.",8898974_2,8898974_D010984_D009369,,
770956675,false,true,5,2015-08-15T02:20:00,,No Relation,1,D005978,glutathione,D009369,tumor,"On the basis of this interaction with both endogenous and synthetic substances, glutathione and the key enzyme for its conjugation, glutathione S-transferase, appear to be critical determinants in tumor cell resistance to several antineoplastic drugs, e.g. platinum analogs.",8898974_2,8898974_D005978_D009369,,
770956676,false,true,5,2015-08-14T20:45:00,,No Relation,1,D002945,cisplatin,D006258,head and neck cancer,"In ten established head and neck cancer cell lines (UM-SCC 10A, 10B, 11B, 14A, 14B, 14C, and 22B, HLac79, 8029NA, and 8029DDP4) chemosensitivity to cisplatin, carboplatin, 5-fluorouracil, and bleomycin, as well as cellular glutathione content and activity of glutathione S-transferase were determined.",8898974_3,8898974_D002945_D006258,,
770956677,false,true,5,2015-08-14T20:52:00,,No Relation,1,D001761,bleomycin,D006258,head and neck cancer,"In ten established head and neck cancer cell lines (UM-SCC 10A, 10B, 11B, 14A, 14B, 14C, and 22B, HLac79, 8029NA, and 8029DDP4) chemosensitivity to cisplatin, carboplatin, 5-fluorouracil, and bleomycin, as well as cellular glutathione content and activity of glutathione S-transferase were determined.",8898974_3,8898974_D001761_D006258,,
770956678,false,true,5,2015-08-14T23:33:00,,No Relation,1,D005472,5-fluorouracil,D006258,head and neck cancer,"In ten established head and neck cancer cell lines (UM-SCC 10A, 10B, 11B, 14A, 14B, 14C, and 22B, HLac79, 8029NA, and 8029DDP4) chemosensitivity to cisplatin, carboplatin, 5-fluorouracil, and bleomycin, as well as cellular glutathione content and activity of glutathione S-transferase were determined.",8898974_3,8898974_D005472_D006258,,
770956679,false,true,5,2015-08-14T22:34:00,,No Relation,0.8022,D016190,carboplatin,D006258,head and neck cancer,"In ten established head and neck cancer cell lines (UM-SCC 10A, 10B, 11B, 14A, 14B, 14C, and 22B, HLac79, 8029NA, and 8029DDP4) chemosensitivity to cisplatin, carboplatin, 5-fluorouracil, and bleomycin, as well as cellular glutathione content and activity of glutathione S-transferase were determined.",8898974_3,8898974_D016190_D006258,,
770956680,false,true,5,2015-08-14T20:27:00,,No Relation,1,D005978,glutathione,D006258,head and neck cancer,"In ten established head and neck cancer cell lines (UM-SCC 10A, 10B, 11B, 14A, 14B, 14C, and 22B, HLac79, 8029NA, and 8029DDP4) chemosensitivity to cisplatin, carboplatin, 5-fluorouracil, and bleomycin, as well as cellular glutathione content and activity of glutathione S-transferase were determined.",8898974_3,8898974_D005978_D006258,,
770956681,false,true,5,2015-08-14T23:57:00,,No Relation,1,D005978,glutathione,D009369,tumor,The results revealed no correlation between the sensitivity of tumor cells to any of the drugs tested and the level of glutathione or the activity of glutathione S-transferase.,8898974_4,8898974_D005978_D009369,,
770956682,false,true,5,2015-08-14T23:48:00,,No Relation,1,D005978,glutathione,C537866,cross-resistance,"However, the cisplatin-resistant subpopulation 8029DDP4 showed the highest glutathione level and marked cross-resistance to bleomycin.",8898974_5,8898974_D005978_C537866,,
770956683,false,true,5,2015-08-15T00:39:00,,No Relation,1,D001761,bleomycin,C537866,cross-resistance,"However, the cisplatin-resistant subpopulation 8029DDP4 showed the highest glutathione level and marked cross-resistance to bleomycin.",8898974_5,8898974_D001761_C537866,,
770956684,false,true,5,2015-08-15T00:08:00,,No Relation,0.8135,D002945,cisplatin,C537866,cross-resistance,"However, the cisplatin-resistant subpopulation 8029DDP4 showed the highest glutathione level and marked cross-resistance to bleomycin.",8898974_5,8898974_D002945_C537866,,
770956685,false,true,5,2015-08-15T00:58:00,,No Relation,1,D005978,glutathione,D002277,carcinoma,These results suggest that the level of glutathione or the activity of glutathione S-transferase is not a suitable parameter for the assessment of chemosensitivity in head and neck squamous-cell carcinoma lines.,8898974_7,8898974_D005978_D002277,,
770956686,false,true,5,2015-08-15T02:05:00,,No Relation,1,C047340,Levocabastine,D003231,conjunctivitis,"Levocabastine is a selective topical H1 antagonist, effective in the treatment of seasonal allergic rhinitis and conjunctivitis.",8911706_1,8911706_C047340_D003231,,
770956687,false,true,5,2015-08-14T20:27:00,,No Relation,1,C047340,Levocabastine,D006255,seasonal allergic rhinitis,"Levocabastine is a selective topical H1 antagonist, effective in the treatment of seasonal allergic rhinitis and conjunctivitis.",8911706_1,8911706_C047340_D006255,,
770956688,false,true,5,2015-08-15T02:07:00,,No Relation,0.8239,C066304,sertindole,D012559,schizophrenia,"A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.",8935813_0,8935813_C066304_D012559,,
770956689,false,true,5,2015-08-14T22:12:00,,No Relation,1,C066304,sertindole,D012559,schizophrenic,"This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n = 205).",8935813_2,8935813_C066304_D012559,,
770956690,false,true,5,2015-08-15T00:45:00,,No Relation,1,C066304,sertindole,D001480,EPS,EPS-related events were comparable in the placebo and sertindole groups.,8935813_8,8935813_C066304_D001480,,
770956691,false,true,5,2015-08-14T22:16:00,,No Relation,1,D000241,adenosine,C566351,various disorders,"Recent data support the evidence that adenosine A2 receptor properties may prove useful in future drug development, and selective manipulation of receptor-associated biologic effects might be relevant in the treatment of various disorders, including psychiatric diseases, hypoxia/ischemia, inflammation or erythrocytosis.",8940747_4,8940747_D000241_C566351,,
770956692,false,true,5,2015-08-15T00:54:00,,No Relation,1,D000241,adenosine,D000860,hypoxia,"Recent data support the evidence that adenosine A2 receptor properties may prove useful in future drug development, and selective manipulation of receptor-associated biologic effects might be relevant in the treatment of various disorders, including psychiatric diseases, hypoxia/ischemia, inflammation or erythrocytosis.",8940747_4,8940747_D000241_D000860,,
770956693,false,true,5,2015-08-15T02:32:00,,No Relation,1,D000241,adenosine,D001523,psychiatric diseases,"Recent data support the evidence that adenosine A2 receptor properties may prove useful in future drug development, and selective manipulation of receptor-associated biologic effects might be relevant in the treatment of various disorders, including psychiatric diseases, hypoxia/ischemia, inflammation or erythrocytosis.",8940747_4,8940747_D000241_D001523,,
770956694,false,true,5,2015-08-15T01:28:00,,No Relation,1,D000241,adenosine,D007511,ischemia,"Recent data support the evidence that adenosine A2 receptor properties may prove useful in future drug development, and selective manipulation of receptor-associated biologic effects might be relevant in the treatment of various disorders, including psychiatric diseases, hypoxia/ischemia, inflammation or erythrocytosis.",8940747_4,8940747_D000241_D007511,,
770956695,false,true,5,2015-08-15T00:15:00,,No Relation,1,D000241,adenosine,D007249,inflammation,"Recent data support the evidence that adenosine A2 receptor properties may prove useful in future drug development, and selective manipulation of receptor-associated biologic effects might be relevant in the treatment of various disorders, including psychiatric diseases, hypoxia/ischemia, inflammation or erythrocytosis.",8940747_4,8940747_D000241_D007249,,
770956696,false,true,5,2015-08-15T01:14:00,,No Relation,1,D018698,Glutamine,D009369,cancer,"Glutamine, cancer, and its therapy.",8942537_1,8942537_D018698_D009369,,
770956697,false,true,5,2015-08-15T00:58:00,,No Relation,1,D018698,glutamine,D009369,tumor/cancer,"This overview on glutamine, cancer and its therapy discusses some of the in vitro and in vivo work on glutamine and tumor growth, and summarizes animal and human data on the potential benefits of glutamine in the tumor-bearing host receiving radiation or chemotherapy.",8942537_2,8942537_D018698_D009369,,
770956698,false,true,5,2015-08-15T02:18:00,,No Relation,0.6202,D018698,glutamine,D002100,cachexia,"A tumor can act as a ""glutamine trap,"" depleting host glutamine stores and resulting in cachexia.",8942537_4,8942537_D018698_D002100,,
770956699,false,true,5,2015-08-15T00:05:00,,No Relation,1,D018698,glutamine,D009369,tumor,"A tumor can act as a ""glutamine trap,"" depleting host glutamine stores and resulting in cachexia.",8942537_4,8942537_D018698_D009369,,
770956700,false,true,5,2015-08-15T00:57:00,,No Relation,0.5787,D018698,glutamine,D019966,dependence,In vitro evidence of the dependence of tumor growth on glutamine has deterred its use in the clinic setting.,8942537_5,8942537_D018698_D019966,,
770956701,false,true,5,2015-08-15T00:47:00,,Direct,0.8076,D018698,glutamine,D009369,tumor,In vitro evidence of the dependence of tumor growth on glutamine has deterred its use in the clinic setting.,8942537_5,8942537_D018698_D009369,,
770956702,false,true,5,2015-08-14T20:40:00,,No Relation,1,D018698,glutamine,D009369,tumor,Data from a variety of investigations studying glutamine's interaction with the tumor-bearing host receiving radiation or chemotherapy were compiled and summarized.,8942537_6,8942537_D018698_D009369,,
770956703,false,true,5,2015-08-15T00:47:00,,No Relation,1,D018698,glutamine,D009369,tumors,A large body of evidence in vivo suggests that supplemental glutamine does not make tumors grow but in fact results in decreased growth through stimulation of the immune system.,8942537_7,8942537_D018698_D009369,,
770956704,false,true,5,2015-08-14T22:48:00,,No Relation,1,D018698,glutamine,D009369,tumor,"When given with radiation or chemotherapy, glutamine protects the host and actually increases the selectivity of therapy for the tumor.",8942537_8,8942537_D018698_D009369,,
770956705,false,true,5,2015-08-14T22:09:00,,No Relation,1,D002166,camptothecin,D008228,non-Hodgkin's lymphoma,"The camptothecin derivative irinotecan (CPT-11) has been shown to possess antitumor activity in phase II trials for patients with carcinoma of the lung, cervix, ovary, colon, or rectum and for patients with non-Hodgkin's lymphoma.",8996518_2,8996518_D002166_D008228,,
770956706,false,true,5,2015-08-14T20:58:00,,No Relation,1,C051890,irinotecan,D008171,carcinoma of the lung,"The camptothecin derivative irinotecan (CPT-11) has been shown to possess antitumor activity in phase II trials for patients with carcinoma of the lung, cervix, ovary, colon, or rectum and for patients with non-Hodgkin's lymphoma.",8996518_2,8996518_C051890_D008171,,
770956707,false,true,5,2015-08-14T23:46:00,,No Relation,1,D002166,camptothecin,D008171,carcinoma of the lung,"The camptothecin derivative irinotecan (CPT-11) has been shown to possess antitumor activity in phase II trials for patients with carcinoma of the lung, cervix, ovary, colon, or rectum and for patients with non-Hodgkin's lymphoma.",8996518_2,8996518_D002166_D008171,,
770956708,false,true,5,2015-08-14T23:59:00,,No Relation,1,C051890,irinotecan,D008228,non-Hodgkin's lymphoma,"The camptothecin derivative irinotecan (CPT-11) has been shown to possess antitumor activity in phase II trials for patients with carcinoma of the lung, cervix, ovary, colon, or rectum and for patients with non-Hodgkin's lymphoma.",8996518_2,8996518_C051890_D008228,,
770956709,false,true,5,2015-08-14T20:45:00,,No Relation,1,D002066,busulfan,D005910,gliomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D002066_D005910,,
770956710,false,true,5,2015-08-14T22:29:00,,No Relation,1,D003520,cyclophosphamide,D005910,gliomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D003520_D005910,,
770956711,false,true,5,2015-08-14T23:38:00,Used as a useless treatment,No Relation,1,D011344,procarbazine,D012208,rhabdomyosarcoma,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D011344_D012208,,
770956712,false,true,5,2015-08-14T20:51:00,,No Relation,1,D008558,melphalan,D012208,rhabdomyosarcoma,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D008558_D012208,,
770956713,false,true,5,2015-08-14T23:43:00,,No Relation,0.8136,D011344,procarbazine,D009369,Tumors,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D011344_D009369,,
770956714,false,true,5,2015-08-15T02:10:00,,No Relation,1,D008558,melphalan,D009369,Tumors,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D008558_D009369,,
770956715,false,true,5,2015-08-14T22:23:00,,No Relation,1,D002066,busulfan,D008527,medulloblastomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D002066_D008527,,
770956716,false,true,5,2015-08-14T20:34:00,,No Relation,1,D002066,busulfan,D004806,ependymomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D002066_D004806,,
770956717,false,true,5,2015-08-14T20:51:00,,No Relation,1,D008558,melphalan,D004806,ependymomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D008558_D004806,,
770956718,false,true,5,2015-08-14T21:46:00,,No Relation,1,D003520,cyclophosphamide,D012208,rhabdomyosarcoma,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D003520_D012208,,
770956719,false,true,5,2015-08-15T00:15:00,,No Relation,1,D002066,busulfan,D009369,Tumors,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D002066_D009369,,
770956720,false,true,5,2015-08-14T20:58:00,,No Relation,1,D011344,procarbazine,D005910,gliomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D011344_D005910,,
770956721,false,true,5,2015-08-14T23:14:00,,No Relation,1,D008558,melphalan,D005910,gliomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D008558_D005910,,
770956722,false,true,5,2015-08-14T20:31:00,,No Relation,1,D011344,procarbazine,D008527,medulloblastomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D011344_D008527,,
770956723,false,true,5,2015-08-15T02:09:00,,No Relation,1,D002066,busulfan,D012208,rhabdomyosarcoma,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D002066_D012208,,
770956724,false,true,5,2015-08-14T23:49:00,,No Relation,1,D011344,procarbazine,D004806,ependymomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D011344_D004806,,
770956725,false,true,5,2015-08-14T20:48:00,al simplificar las palabras es mas entendible para uno que no es medico en este tipo de tarea...thanksss,No Relation,1,D003520,cyclophosphamide,D008527,medulloblastomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D003520_D008527,,
770956726,false,true,5,2015-08-15T02:17:00,,No Relation,1,D008558,melphalan,D008527,medulloblastomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D008558_D008527,,
770956727,false,true,5,2015-08-15T00:59:00,,No Relation,1,D003520,cyclophosphamide,D009369,Tumors,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D003520_D009369,,
770956728,false,true,5,2015-08-15T00:23:00,,No Relation,1,D003520,cyclophosphamide,D004806,ependymomas,"Tumors included childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D341 Med, D487 Med), ependymomas (D528 EP, D612 EP), and a rhabdomyosarcoma (TE-671), as well as sublines with demonstrated resistance to busulfan (D-456 MG (BR)), cyclophosphamide (TE-671 CR), procarbazine (D-245 MG (PR)) or melphalan (TE-671 MR), growing subcutaneously and intracranially in athymic nude mice.",8996518_4,8996518_D003520_D004806,,
770956729,false,true,5,2015-08-15T00:49:00,,No Relation,1,D003520,cyclophosphamide,D009369,tumor,"CPT-11 produced statistically significant (P < 0.001) growth delays in all subcutaneous xenografts tested, including those resistant to busulfan, cyclophosphamide, procarbazine, and melphalan, with growth delays ranging from 21.3 days in D487 Med to 90+ days in several tumor lines.",8996518_6,8996518_D003520_D009369,,
770956730,false,true,5,2015-08-15T01:24:00,,No Relation,1,D002066,busulfan,D009369,tumor,"CPT-11 produced statistically significant (P < 0.001) growth delays in all subcutaneous xenografts tested, including those resistant to busulfan, cyclophosphamide, procarbazine, and melphalan, with growth delays ranging from 21.3 days in D487 Med to 90+ days in several tumor lines.",8996518_6,8996518_D002066_D009369,,
770956731,false,true,5,2015-08-14T22:49:00,,No Relation,1,C051890,CPT-11,D009369,tumor,"CPT-11 produced statistically significant (P < 0.001) growth delays in all subcutaneous xenografts tested, including those resistant to busulfan, cyclophosphamide, procarbazine, and melphalan, with growth delays ranging from 21.3 days in D487 Med to 90+ days in several tumor lines.",8996518_6,8996518_C051890_D009369,,
770956732,false,true,5,2015-08-14T23:03:00,,No Relation,1,D011344,procarbazine,D009369,tumor,"CPT-11 produced statistically significant (P < 0.001) growth delays in all subcutaneous xenografts tested, including those resistant to busulfan, cyclophosphamide, procarbazine, and melphalan, with growth delays ranging from 21.3 days in D487 Med to 90+ days in several tumor lines.",8996518_6,8996518_D011344_D009369,,
770956733,false,true,5,2015-08-14T20:51:00,,No Relation,1,D013806,theophylline,D003680,impaired or difficult deglutition,"Microcapsules of theophylline, administered as a suspension in water, proved to be a suitable dosage form for a clientele with impaired or difficult deglutition.",8996853_2,8996853_D013806_D003680,,
770956734,false,true,5,2015-08-14T20:41:00,,No Relation,1,D013806,theophylline,D001249,asthma,"Maximum serum levels of 9.6 micrograms/ml and 10.0 micrograms/ml were attained 6.6 and 6.1 hours after dosing of T1 and T2, coinciding perfectly with the time of the critical morning dip at 2-4 a.m. With a nocturnal excess of 15.5% (T1) and 17.9% (T2) this circadian-tailored asymmetric dosage regimen proved to take into account the chronopathology of asthma and the chronopharmacokinetics of theophylline sustained-release preparations.",8996853_6,8996853_D013806_D001249,,
770956735,false,true,5,2015-08-14T20:40:00,,No Relation,0.5984,D001285,atropine,D015835,colonic motility,"Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit.",9009112_0,9009112_D001285_D015835,,
770956736,false,true,5,2015-08-14T21:38:00,,No Relation,1,D001285,Atropine,D015835,colonic motility,Atropine was used as control to demonstrate responsiveness of selected parameters of colonic motility.,9009112_4,9009112_D001285_D015835,,
770956737,false,true,5,2015-08-14T20:42:00,,No Relation,0.6081,D015016,yohimbine,D013313,posttraumatic stress disorder,Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder.,9075465_0,9075465_D015016_D013313,,
770956738,false,true,5,2015-08-14T20:39:00,,No Relation,0.591,D009638,norepinephrine,D001008,anxiety,"We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release.",9075465_1,9075465_D009638_D001008,,
770956739,false,true,5,2015-08-14T20:38:00,,Direct,0.5908,D015016,yohimbine,D013313,posttraumatic stress disorder/PTSD,"We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release.",9075465_1,9075465_D015016_D013313,,
770956740,false,true,5,2015-08-14T23:50:00,,No Relation,0.5893,D009638,norepinephrine,D013313,posttraumatic stress disorder/PTSD,"We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release.",9075465_1,9075465_D009638_D013313,,
770956741,false,true,5,2015-08-15T00:27:00,,Direct,1,D015016,yohimbine,D001008,anxiety,"We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release.",9075465_1,9075465_D015016_D001008,,
770956742,false,true,5,2015-08-14T22:23:00,,No Relation,1,D015016,yohimbine,D013313,PTSD,"We used positron emission tomography and fludeoxyglucose F 18 to measure brain metabolism in Vietnam combat veterans with PTSD (n = 10) and healthy age-matched control subjects (n = 10), following administration of yohimbine (0.4 mg/kg) or placebo in a randomized, double-blind fashion.",9075465_3,9075465_D015016_D013313,,
770956743,false,true,5,2015-08-14T20:40:00,,No Relation,0.6319,D015016,Yohimbine,D013313,PTSD,"Yohimbine resulted in a significant increase in anxiety in the patients with PTSD, but not in healthy subjects.",9075465_4,9075465_D015016_D013313,,
770956744,false,true,5,2015-08-14T22:23:00,"Only in PTSD patients, making the third option also technically correct.",Direct,1,D015016,Yohimbine,D001008,anxiety,"Yohimbine resulted in a significant increase in anxiety in the patients with PTSD, but not in healthy subjects.",9075465_4,9075465_D015016_D001008,,
770956745,false,true,5,2015-08-14T23:46:00,,No Relation,1,D015016,yohimbine,D013313,PTSD,"There was a significant difference in brain metabolic response to yohimbine in patients with PTSD compared with healthy subjects in prefrontal, temporal, parietal, and orbitofrontal cortexes.",9075465_5,9075465_D015016_D013313,,
770956746,false,true,5,2015-08-14T22:27:00,,No Relation,1,D015016,yohimbine,D013313,PTSD,Metabolism tended to decrease in patients with PTSD and increase in healthy subjects following administration of yohimbine.,9075465_6,9075465_D015016_D013313,,
770956747,false,true,5,2015-08-14T20:42:00,,No Relation,0.8077,D015016,yohimbine,D013313,PTSD,These findings are consistent with our previous hypothesis of enhanced norepinephrine release in the brain with yohimbine in patients with PTSD.,9075465_7,9075465_D015016_D013313,,
770956748,false,true,5,2015-08-15T00:39:00,,No Relation,0.8198,D009638,norepinephrine,D013313,PTSD,These findings are consistent with our previous hypothesis of enhanced norepinephrine release in the brain with yohimbine in patients with PTSD.,9075465_7,9075465_D009638_D013313,,
770956749,false,true,5,2015-08-14T22:04:00,,No Relation,1,D002701,chloramphenicol,D014435,typhoid fever,"In 28 children, with bacteriologically and/or serologically diagnosed typhoid fever treated at KEM Hospital, Bombay in 1991, initially one of the three recommended drugs (viz. chloramphenicol, amoxycillin or co-trimoxazole) was given for 7 days for defervescence to occur.",9136240_1,9136240_D002701_D014435,,
770956750,false,true,5,2015-08-15T00:18:00,,No Relation,1,D000658,amoxycillin,D014435,typhoid fever,"In 28 children, with bacteriologically and/or serologically diagnosed typhoid fever treated at KEM Hospital, Bombay in 1991, initially one of the three recommended drugs (viz. chloramphenicol, amoxycillin or co-trimoxazole) was given for 7 days for defervescence to occur.",9136240_1,9136240_D000658_D014435,,
770956751,false,true,5,2015-08-14T20:51:00,,No Relation,0.6092,D015662,co-trimoxazole,D014435,typhoid hepatitis,"There were no major complications, except 2 cases with typhoid hepatitis who responded to choramphenicol and co-trimoxazole, respectively.",9136240_7,9136240_D015662_D014435,,
770956752,false,true,5,2015-08-14T23:30:00,,No Relation,1,D014700,verapamil,D006973,hypertension,Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment.,9147707_0,9147707_D014700_D006973,,
770956753,false,true,5,2015-08-14T20:40:00,,No Relation,1,C052035,trandolapril,D006973,hypertension,Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment.,9147707_0,9147707_C052035_D006973,,
770956754,false,true,5,2015-08-14T23:36:00,,No Relation,1,D002118,calcium,D006973,hypertension,"Using ambulatory blood pressure (BP) monitoring, a potent ACE-inhibitor/calcium channel blocker combination was tested in 21 Black patients (age 52 +/- 10 years; 10 males, 11 females) with mild to moderate hypertension (mean 12-hour daytime diastolic BP > or = 90 mmHg and < or = 114 mmHg).",9147707_1,9147707_D002118_D006973,,
770956755,false,true,5,2015-08-14T23:43:00,,No Relation,0.5907,D001971,bromocriptine,D000236,adenoma,Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment.,9151080_0,9151080_D001971_D000236,,
770956756,false,true,5,2015-08-14T20:46:00,,No Relation,1,D010431,Pentoxifylline,D008288,malaria,"Pentoxifylline and the two analogues HWA138 and HWA448, at concentrations exceeding 60 micrograms/ml, inhibited malaria antigen or lipopolysaccharide (LPS) induced TNF-alpha and IL-1 alpha secretion, but not IL-6 secretion, from human peripheral blood mononuclear cells in vitro.",9160101_1,9160101_D010431_D008288,,
770956757,false,true,5,2015-08-14T21:47:00,,No Relation,0.7852,D010431,pentoxifylline,D064420,toxicity,The pentoxifylline analogues may have lower toxicity than pentoxifylline itself and may therefore be useful in future treatment of diseases induced by endotoxic substances.,9160101_8,9160101_D010431_D064420,,
770956758,false,true,5,2015-08-14T22:05:00,,No Relation,1,D010431,pentoxifylline,D012772,endotoxic,The pentoxifylline analogues may have lower toxicity than pentoxifylline itself and may therefore be useful in future treatment of diseases induced by endotoxic substances.,9160101_8,9160101_D010431_D012772,,
770956759,false,true,5,2015-08-14T20:47:00,,No Relation,1,D010431,pentoxifylline,D004194,diseases,The pentoxifylline analogues may have lower toxicity than pentoxifylline itself and may therefore be useful in future treatment of diseases induced by endotoxic substances.,9160101_8,9160101_D010431_D004194,,
770956760,false,true,5,2015-08-15T01:20:00,,No Relation,0.4218,D020106,acrylamide,D001167,neuropathy,"The increase in the rate of tubulin polymerization by acrylamide and carbon disulfide treatment may alter the rate of transport of axonal constituents, including neurofilament, and contribute toward their accumulation in the focal swellings observed in this neuropathy.",9165488_10,9165488_D020106_D001167,,
770956761,false,true,5,2015-08-14T20:49:00,,No Relation,0.7961,D002246,carbon disulfide,D001167,neuropathy,"The increase in the rate of tubulin polymerization by acrylamide and carbon disulfide treatment may alter the rate of transport of axonal constituents, including neurofilament, and contribute toward their accumulation in the focal swellings observed in this neuropathy.",9165488_10,9165488_D002246_D001167,,
770956762,false,true,5,2015-08-15T00:05:00,,No Relation,1,D018967,risperidone,D012559,schizophrenia,Does risperidone improve verbal working memory in treatment-resistant schizophrenia?,9167507_0,9167507_D018967_D012559,,
770956763,false,true,5,2015-08-15T02:29:00,,No Relation,1,D006220,haloperidol,D012559,schizophrenic,"Verbal working memory of 59 treatment-resistant schizophrenic patients was assessed as part of a randomized, double-blind comparison of treatment with risperidone and haloperidol.",9167507_4,9167507_D006220_D012559,,
770956764,false,true,5,2015-08-14T20:38:00,,No Relation,1,D018967,risperidone,D012559,schizophrenic,"Verbal working memory of 59 treatment-resistant schizophrenic patients was assessed as part of a randomized, double-blind comparison of treatment with risperidone and haloperidol.",9167507_4,9167507_D018967_D012559,,
770956765,false,true,5,2015-08-15T00:04:00,,No Relation,0.8032,D001590,benztropine,D000341,psychotic symptoms,"The treatment effect remained significant after the effects of benztropine cotreatment, change in psychotic symptoms, and change in negative symptoms were controlled.",9167507_7,9167507_D001590_D000341,,
770956766,false,true,5,2015-08-14T23:54:00,,No Relation,1,D012828,silicone,D009216,myopia,"We investigated the efficacy, safety, and stability of correction achieved with a silicone posterior chamber intraocular lens used to correct high myopia in phakic eyes.",9183752_1,9183752_D012828_D009216,,
770956767,false,true,5,2015-08-14T23:42:00,,No Relation,1,D012828,silicone,D009216,myopia,"A silicone posterior chamber plate-style intraocular lens (Chiron, Adatomed) was implanted in 38 consecutive phakic eyes with high myopia (-7.00 to -28.00 diopters (D) over a period of 21 months.",9183752_2,9183752_D012828_D009216,,
770956768,false,true,5,2015-08-15T00:46:00,,No Relation,1,D000804,angiotensin II,D006333,heart failure,Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure.,9220306_0,9220306_D000804_D006333,,
770956769,false,true,5,2015-08-14T23:46:00,,No Relation,1,D000804,angiotensin II,D006333,heart failure,"This double-blind, placebo-controlled study investigated whether 12 weeks of treatment with the angiotensin II receptor blocker losartan influenced N-terminal proANF plasma levels in 129 chronic heart failure patients.",9220306_3,9220306_D000804_D006333,,
770956770,false,true,5,2015-08-15T00:27:00,,No Relation,1,D019808,losartan,D006333,heart failure,"This double-blind, placebo-controlled study investigated whether 12 weeks of treatment with the angiotensin II receptor blocker losartan influenced N-terminal proANF plasma levels in 129 chronic heart failure patients.",9220306_3,9220306_D019808_D006333,,
770956771,false,true,5,2015-08-14T23:50:00,,No Relation,1,D017035,pravastatin,D006937,hypercholesterolemia,"Most recently, a positive effect of cholesterol-lowering drugs (pravastatin, lovastatin) on NPT has been observed in middle-aged males with chronic hypercholesterolemia.",9226599_6,9226599_D017035_D006937,,
770956772,false,true,5,2015-08-14T22:16:00,,No Relation,1,D008148,lovastatin,D006937,hypercholesterolemia,"Most recently, a positive effect of cholesterol-lowering drugs (pravastatin, lovastatin) on NPT has been observed in middle-aged males with chronic hypercholesterolemia.",9226599_6,9226599_D008148_D006937,,
770956773,false,true,5,2015-08-14T22:43:00,,No Relation,1,D002784,cholesterol,D006937,hypercholesterolemia,"Most recently, a positive effect of cholesterol-lowering drugs (pravastatin, lovastatin) on NPT has been observed in middle-aged males with chronic hypercholesterolemia.",9226599_6,9226599_D002784_D006937,,
770956774,false,true,5,2015-08-15T02:18:00,,No Relation,1,D017964,Itraconazole,D009062,oral candidosis,Itraconazole for treatment of oral candidosis in pediatric cancer patients.,9240009_0,9240009_D017964_D009062,,
770956775,false,true,5,2015-08-14T21:46:00,,No Relation,1,D017964,Itraconazole,D009369,pediatric cancer,Itraconazole for treatment of oral candidosis in pediatric cancer patients.,9240009_0,9240009_D017964_D009369,,
770956776,false,true,5,2015-08-14T20:46:00,,No Relation,1,D017964,itraconazole,D009062,oral candidosis,The aim of this study is to evaluate the efficacy and side effects of itraconazole on treatment of oral candidosis.,9240009_3,9240009_D017964_D009062,,
770956777,false,true,5,2015-08-14T20:44:00,,No Relation,1,D017964,itraconazole,D009062,oral candidosis,Fourteen children with malignancy undergoing chemotherapy received itraconazole 100-200 mg/day for 10 days to treat oral candidosis.,9240009_4,9240009_D017964_D009062,,
770956778,false,true,5,2015-08-14T22:26:00,,No Relation,1,D017964,itraconazole,D016609,malignancy,Fourteen children with malignancy undergoing chemotherapy received itraconazole 100-200 mg/day for 10 days to treat oral candidosis.,9240009_4,9240009_D017964_D016609,,
770956779,false,true,5,2015-08-14T20:42:00,,No Relation,1,D005363,psoralen,D011565,psoriasis,p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA).,9242514_0,9242514_D005363_D011565,,
770956780,false,true,5,2015-08-14T20:41:00,,No Relation,0.5988,D005363,psoralen,D002294,squamous cell carcinomas,p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA).,9242514_0,9242514_D005363_D002294,,
770956781,false,true,5,2015-08-14T21:00:00,,Direct,1,D011803,quinine,D034381,hearing loss,"Reversible hearing loss is a known complication following the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin.",9270425_2,9270425_D011803_D034381,,
770956782,false,true,5,2015-08-14T20:48:00,,Direct,1,D012459,salicylates,D034381,hearing loss,"Reversible hearing loss is a known complication following the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin.",9270425_2,9270425_D012459_D034381,,
770956783,false,true,5,2015-08-14T20:44:00,,Direct,1,D004917,erythromycin,D034381,hearing loss,"Reversible hearing loss is a known complication following the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin.",9270425_2,9270425_D004917_D034381,,
770956784,false,true,5,2015-08-15T01:25:00,,No Relation,1,D004298,dopamine,D012559,schizophrenia,Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.,9278187_0,9278187_D004298_D012559,,
770956785,false,true,5,2015-08-14T20:49:00,,Direct,0.8022,D004298,dopamine,D012559,schizophrenia,"For the past 20 years the most enduring explanation for schizophrenia has been the dopamine hypothesis, which proposes that the dopaminergic system is overactive in this widespread disease.",9278187_1,9278187_D004298_D012559,,
770956786,false,true,5,2015-08-14T21:23:00,,No Relation,0.6062,D004298,dopamine,D059350,widespread disease,"For the past 20 years the most enduring explanation for schizophrenia has been the dopamine hypothesis, which proposes that the dopaminergic system is overactive in this widespread disease.",9278187_1,9278187_D004298_D059350,,
770956787,false,true,5,2015-08-15T02:18:00,,No Relation,0.5915,D004298,dopamine,D012559,schizophrenic,"Classically, the D2 receptor formed the core of the dopamine hypothesis since there was considerable evidence for elevations of D2 receptor levels in the brains of schizophrenic patients, and because these receptors served as the primary target in mediating antipsychotic effects of most neuroleptics.",9278187_2,9278187_D004298_D012559,,
770956788,false,true,5,2015-08-15T00:38:00,,No Relation,0.8075,D003024,clozapine,D012559,schizophrenia,"The existence of these D4 polymorphisms raises the possibility that structural variations of this receptor may be associated with an increased susceptibility to schizophrenia, or observed variations in individual response to clozapine treatment.",9278187_8,9278187_D003024_D012559,,
770956789,false,true,5,2015-08-14T20:49:00,,No Relation,0.8209,D003024,clozapine,D012559,schizophrenia,"Furthermore, no association was evident between the polymorphic forms of D4 and susceptibility to schizophrenia, or variable clozapine response.",9278187_10,9278187_D003024_D012559,,
770956790,false,true,5,2015-08-14T23:32:00,,No Relation,1,D004298,dopamine,D012559,schizophrenia,"The observations which support the idea that D4 might serve as a target for clozapine have significantly modified and extended our understanding of mechanisms underlying atypical antipsychotic treatment of schizophrenia, as well as the dopamine hypothesis for schizophrenia.",9278187_12,9278187_D004298_D012559,,
770956791,false,true,5,2015-08-15T02:14:00,,No Relation,1,D003024,clozapine,D012559,schizophrenia,"The observations which support the idea that D4 might serve as a target for clozapine have significantly modified and extended our understanding of mechanisms underlying atypical antipsychotic treatment of schizophrenia, as well as the dopamine hypothesis for schizophrenia.",9278187_12,9278187_D003024_D012559,,
770956792,false,true,5,2015-08-14T22:01:00,,No Relation,1,D009020,morphine,D001008,anxiety,"There was no difference in pain intensity after the initial assessment, morphine usage, mood, anxiety, and depression at any other measurement period.",9338905_9,9338905_D009020_D001008,,
770956793,false,true,5,2015-08-14T20:43:00,,No Relation,1,D009020,morphine,D010146,pain,"There was no difference in pain intensity after the initial assessment, morphine usage, mood, anxiety, and depression at any other measurement period.",9338905_9,9338905_D009020_D010146,,
770956794,false,true,5,2015-08-14T22:23:00,,No Relation,1,D009020,morphine,D003866,depression,"There was no difference in pain intensity after the initial assessment, morphine usage, mood, anxiety, and depression at any other measurement period.",9338905_9,9338905_D009020_D003866,,
770956795,false,true,5,2015-08-14T22:26:00,,No Relation,1,D002129,calcium oxalate,D000138,acidosis,"Ingestion of ethylene glycol, either accidentally or in a suicide attempt, is characterized by severe acidosis, calcium oxalate crystal formation and deposition, and a wide variety of end organ effects that may be fatal.",9348055_2,9348055_D002129_D000138,,
770956796,false,true,5,2015-08-15T02:31:00,,Direct,1,D019855,ethylene glycol,D000138,acidosis,"Ingestion of ethylene glycol, either accidentally or in a suicide attempt, is characterized by severe acidosis, calcium oxalate crystal formation and deposition, and a wide variety of end organ effects that may be fatal.",9348055_2,9348055_D019855_D000138,,
770956797,false,true,5,2015-08-14T22:26:00,,No Relation,0.5816,D019855,ethylene glycol,D064420,toxicity,"A comprehensive review of the literature on the pathology and pathophysiology of ethylene glycol toxicity on each organ system is provided, along with information on diagnosis and current treatment recommendations.",9348055_4,9348055_D019855_D064420,,
770956798,false,true,5,2015-08-15T01:26:00,,No Relation,1,D003401,creatine,D009203,myocardial infarction,"By measuring creatine kinase (CK) MB levels preoperatively, at entry to the intensive care unit (ICU), and every 12 h for 48 h; and by obtaining serial 12-lead electrocardiograms (ECG) (preoperatively; 2, 4, 12, 24, and 48 h after ICU admission, 8:00 AM the morning after surgery; and 5 min pre- and postextubation), myocardial infarction was identified.",9356086_6,9356086_D003401_D009203,,
770956799,false,true,5,2015-08-14T21:47:00,,Direct,0.5896,D015742,propofol,D017202,myocardial ischemia,This randomized study of patients after coronary artery bypass surgery examined whether light (versus heavy) sedation with propofol in the intensive care unit was associated with an increased degree of myocardial ischemia.,9356086_16,9356086_D015742_D017202,,
770956800,false,true,5,2015-08-14T23:00:00,,No Relation,1,D005996,glyceryl trinitrate,D005401,chronic anal fissure,A sample of 24 consecutive patients with chronic anal fissure was randomly allocated to treatment with sphincterotomy or local glyceryl trinitrate.,9369106_2,9369106_D005996_D005401,,
770956801,false,true,5,2015-08-15T01:39:00,,No Relation,1,D005996,glyceryl trinitrate,D005401,chronic anal fissure,Local application of glyceryl trinitrate can avoid surgery in more than 80 percent of patients with chronic anal fissure.,9369106_6,9369106_D005996_D005401,,
770956802,false,true,5,2015-08-15T00:34:00,,No Relation,0.7917,D017258,medroxyprogesterone acetate,D009336,necrosis,Effect of high-dose medroxyprogesterone acetate on tumor necrosis factor-alpha release in patients with chemotherapy-induced neutropenia.,9373794_0,9373794_D017258_D009336,,
770956803,false,true,5,2015-08-15T02:12:00,,No Relation,0.8324,D017258,medroxyprogesterone acetate,D009369,tumor,Effect of high-dose medroxyprogesterone acetate on tumor necrosis factor-alpha release in patients with chemotherapy-induced neutropenia.,9373794_0,9373794_D017258_D009369,,
770956804,false,true,5,2015-08-15T01:46:00,,No Relation,1,D017258,medroxyprogesterone acetate,D009503,neutropenia,Effect of high-dose medroxyprogesterone acetate on tumor necrosis factor-alpha release in patients with chemotherapy-induced neutropenia.,9373794_0,9373794_D017258_D009503,,
770956805,false,true,5,2015-08-14T20:40:00,,No Relation,1,D017258,medroxyprogesterone acetate/MPA,D009336,necrosis,The aim of the study was to investigate the effects of high-dose medroxyprogesterone acetate (MPA) on the tumor necrosis factor-alpha (TNF-alpha) release in patients with chemotherapy-induced neutropenia.,9373794_1,9373794_D017258_D009336,,
770956806,false,true,5,2015-08-15T02:10:00,,No Relation,1,D017258,medroxyprogesterone acetate/MPA,D009369,tumor,The aim of the study was to investigate the effects of high-dose medroxyprogesterone acetate (MPA) on the tumor necrosis factor-alpha (TNF-alpha) release in patients with chemotherapy-induced neutropenia.,9373794_1,9373794_D017258_D009369,,
770956807,false,true,5,2015-08-15T02:33:00,,No Relation,0.8087,D017258,medroxyprogesterone acetate/MPA,D009503,neutropenia,The aim of the study was to investigate the effects of high-dose medroxyprogesterone acetate (MPA) on the tumor necrosis factor-alpha (TNF-alpha) release in patients with chemotherapy-induced neutropenia.,9373794_1,9373794_D017258_D009503,,
770956808,false,true,5,2015-08-14T23:49:00,,No Relation,1,D005664,furazolidone,D000163,AIDS,Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone.,9378811_0,9378811_D005664_D000163,,
770956809,false,true,5,2015-08-14T20:40:00,,No Relation,1,D005664,furazolidone,D000163,AIDS,To investigate changes in morphology of the developmental stages of Enterocytozoon bieneusi and symptomatic relief observed in AIDS patients after treatment with furazolidone.,9378811_1,9378811_D005664_D000163,,
770956810,false,true,5,2015-08-15T02:14:00,,No Relation,1,D005664,furazolidone,D000163,AIDS,Six AIDS patients with symptomatic E bieneusi infection of the small intestine were treated with a course of furazolidone.,9378811_2,9378811_D005664_D000163,,
770956811,false,true,5,2015-08-14T22:20:00,,No Relation,1,D005664,furazolidone,D007410,intestinal infection,The clinical benefit seen after treatment with furazolidone in six AIDS patients with E bieneusi intestinal infection may be due to damage to the developmental stages causing a partial inhibition to reproduction of the parasite.,9378811_7,9378811_D005664_D007410,,
770956812,false,true,5,2015-08-14T22:24:00,,No Relation,1,D005664,furazolidone,D000163,AIDS,The clinical benefit seen after treatment with furazolidone in six AIDS patients with E bieneusi intestinal infection may be due to damage to the developmental stages causing a partial inhibition to reproduction of the parasite.,9378811_7,9378811_D005664_D000163,,
770956813,false,true,5,2015-08-14T20:36:00,,No Relation,0.6201,D005557,formaldehyde,D009369,tumor,"Data for one of the most extensively studied chemicals, the weakly genotoxic carcinogen formaldehyde, support the contention that the concentration-response relationship for tumor incidence is a function of formaldehyde-induced target cell proliferation, in addition to other factors including target cell population size.",9385388_4,9385388_D005557_D009369,,
770956814,false,true,5,2015-08-14T22:35:00,,No Relation,0.6076,D007200,Indoxyl sulfate,D051437,renal failure,Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.,9387112_0,9387112_D007200_D051437,,
770956815,false,true,5,2015-08-14T20:41:00,,Direct,0.8122,D007200,indoxyl sulfate,D007673,glomerular sclerosis,We have previously demonstrated that indoxyl sulfate is a stimulating factor for the progression of glomerular sclerosis in uremic rats.,9387112_1,9387112_D007200_D007673,,
770956816,false,true,5,2015-08-15T01:06:00,,No Relation,0.7904,D007200,indoxyl sulfate,D007673,glomerular sclerosis,"In conclusion, a low-protein diet or AST-120 reduced the serum and urine levels of indoxyl sulfate, a stimulating factor for glomerular sclerosis, in both uremic rats and undialyzed uremic patients.",9387112_8,9387112_D007200_D007673,,
770956817,false,true,5,2015-08-15T00:38:00,,No Relation,1,D002045,bupivacaine,D007021,hypospadias,"Ninety boys, aged 13-53 months, undergoing repair of hypospadias, were allocated randomly to receive 0.8 ml kg-1 of one of three solutions into the caudal extradural space: group B received bupivacaine 2 mg kg-1, group T received tramadol 2 mg kg-1 in 0.9% saline and group BT a mixture of both.",9389843_1,9389843_D002045_D007021,,
770956818,false,true,5,2015-08-15T01:51:00,,No Relation,1,D014147,tramadol,D007021,hypospadias,"Ninety boys, aged 13-53 months, undergoing repair of hypospadias, were allocated randomly to receive 0.8 ml kg-1 of one of three solutions into the caudal extradural space: group B received bupivacaine 2 mg kg-1, group T received tramadol 2 mg kg-1 in 0.9% saline and group BT a mixture of both.",9389843_1,9389843_D014147_D007021,,
770956819,false,true,5,2015-08-14T21:52:00,,No Relation,0.6173,D016559,FK506,D006259,sciatic-nerve crush injury,This review focuses on studies showing that systemic administration of FK506 dose-dependently speeds nerve regeneration and functional recovery in rats following a sciatic-nerve crush injury.,9457703_7,9457703_D016559_D006259,,
770956820,false,true,5,2015-08-14T20:36:00,,No Relation,0.8066,D014640,vancomycin,D007239,infection,"In order to determine the extent of vancomycin resistant enterococcus (VRE) colonisation within a paediatric oncology unit, the risk factors for the acquisition of the organism, the molecular epidemiology of the isolates and the impact of infection control measures, extensive patient and environmental surveillance was undertaken with identification, antibiotic susceptibility testing and pulsed-field gel electrophoresis (PFGE) of all VRE isolates.",9461358_1,9461358_D014640_D007239,,
770956821,false,true,5,2015-08-15T01:33:00,,No Relation,1,D000583,amikacin,D009503,neutropenia,"Following comparison of the 14 cases with 41 controls matched for age (+/- 4 years) and cohabitation on the oncology unit, risk factors for colonisation with VRE included duration of neutropenia, (OR, 3.72; 95% CI, 1.0-13.1), and antibiotic therapy, (OR, 4.07; 95% CI, 1.08-15.3), the number of antibiotic agents received, (OR, 8.4; 95% CI, 1.34-34.3) and the duration of therapy with amikacin, (OR, 10.7; 95% CI, 1.4-81.5), ceftazidime, (OR, 11.5; 95% CI, 2.2 59.9) or teicoplanin, (OR, 12.3; 95% CI, 2.25-67.4).",9461358_7,9461358_D000583_D009503,,
770956822,false,true,5,2015-08-14T20:47:00,,No Relation,0.8197,D002442,ceftazidime,D009503,neutropenia,"Following comparison of the 14 cases with 41 controls matched for age (+/- 4 years) and cohabitation on the oncology unit, risk factors for colonisation with VRE included duration of neutropenia, (OR, 3.72; 95% CI, 1.0-13.1), and antibiotic therapy, (OR, 4.07; 95% CI, 1.08-15.3), the number of antibiotic agents received, (OR, 8.4; 95% CI, 1.34-34.3) and the duration of therapy with amikacin, (OR, 10.7; 95% CI, 1.4-81.5), ceftazidime, (OR, 11.5; 95% CI, 2.2 59.9) or teicoplanin, (OR, 12.3; 95% CI, 2.25-67.4).",9461358_7,9461358_D002442_D009503,,
770956823,false,true,5,2015-08-14T20:41:00,,No Relation,0.805,D000583,amikacin,D009503,neutropenia,"Risk factors for VRE colonization in paediatric oncology patients included duration of neutropenia, duration of any antibiotic therapy, exposure to ceftazidime, amikacin or teicoplanin and the number of antibiotics used.",9461358_10,9461358_D000583_D009503,,
770956824,false,true,5,2015-08-15T01:24:00,,No Relation,1,D017334,teicoplanin,D009503,neutropenia,"Risk factors for VRE colonization in paediatric oncology patients included duration of neutropenia, duration of any antibiotic therapy, exposure to ceftazidime, amikacin or teicoplanin and the number of antibiotics used.",9461358_10,9461358_D017334_D009503,,
770956825,false,true,5,2015-08-15T00:26:00,,No Relation,0.8108,D002442,ceftazidime,D009503,neutropenia,"Risk factors for VRE colonization in paediatric oncology patients included duration of neutropenia, duration of any antibiotic therapy, exposure to ceftazidime, amikacin or teicoplanin and the number of antibiotics used.",9461358_10,9461358_D002442_D009503,,
770956826,false,true,5,2015-08-15T00:29:00,,Direct,0.8139,D000431,alcohol,D015356,septal branch occlusion,"As an alternative nonsurgical procedure for reducing the left ventricular outflow tract (LVOT) gradient, PTSMA by alcohol-induced septal branch occlusion was introduced.",9462563_3,9462563_D000431_D015356,,
770956827,false,true,5,2015-08-14T22:05:00,,No Relation,1,D003401,creatine,D017566,angina,"All patients had angina pectoris for 24 h. The maximal creatine kinase increase was 780 +/- 436 U/liter (range 305 to 1,810) after 11.1 +/- 6.0 h (range 4 to 24).",9462563_8,9462563_D003401_D017566,,
770956828,false,true,5,2015-08-15T02:03:00,,No Relation,1,D005045,etomidate,D055090,trachea,The effect of propofol and etomidate was also studied on both [Ca2+]i increase measured by microspectrofluorimetry in isolated myocytes and isometric contraction in the rat trachea.,9477050_4,9477050_D005045_D055090,,
770956829,false,true,5,2015-08-14T22:02:00,,No Relation,1,D015742,propofol,D055090,trachea,The effect of propofol and etomidate was also studied on both [Ca2+]i increase measured by microspectrofluorimetry in isolated myocytes and isometric contraction in the rat trachea.,9477050_4,9477050_D015742_D055090,,
770956830,false,true,5,2015-08-15T01:40:00,,No Relation,1,D015742,propofol,D013224,asthmatic,"Whereas thiopental contracts human isolated bronchi, propofol and etomidate reduce histamine-induced contraction in human isolated airway smooth muscle that were either not sensitized or passively sensitized with asthmatic serum.",9477050_10,9477050_D015742_D013224,,
770956831,false,true,5,2015-08-15T00:34:00,,No Relation,1,D013874,thiopental,D013224,asthmatic,"Whereas thiopental contracts human isolated bronchi, propofol and etomidate reduce histamine-induced contraction in human isolated airway smooth muscle that were either not sensitized or passively sensitized with asthmatic serum.",9477050_10,9477050_D013874_D013224,,
770956832,false,true,5,2015-08-14T20:42:00,,No Relation,0.6129,D006632,histamine,D013224,asthmatic,"Whereas thiopental contracts human isolated bronchi, propofol and etomidate reduce histamine-induced contraction in human isolated airway smooth muscle that were either not sensitized or passively sensitized with asthmatic serum.",9477050_10,9477050_D006632_D013224,,
770956833,false,true,5,2015-08-15T01:15:00,,No Relation,1,D005045,etomidate,D013224,asthmatic,"Whereas thiopental contracts human isolated bronchi, propofol and etomidate reduce histamine-induced contraction in human isolated airway smooth muscle that were either not sensitized or passively sensitized with asthmatic serum.",9477050_10,9477050_D005045_D013224,,
770956834,false,true,5,2015-08-14T21:51:00,,Direct,1,C010745,maltitol,D005414,flatulence,"Relative to ingestion of sucrose, 30 g maltitol caused no significant difference in symptoms, but 40 g resulted in more mild borborygmi (P < 0.05) and mild flatulence (P < 0.01) but not moderate or severe symptoms.",9482768_6,9482768_C010745_D005414,,
770956835,false,true,5,2015-08-15T00:48:00,,No Relation,0.5922,D013395,sucrose,D005414,flatulence,"Relative to ingestion of sucrose, 30 g maltitol caused no significant difference in symptoms, but 40 g resulted in more mild borborygmi (P < 0.05) and mild flatulence (P < 0.01) but not moderate or severe symptoms.",9482768_6,9482768_D013395_D005414,,
770956836,false,true,5,2015-08-15T01:43:00,,No Relation,1,D013256,Steroid,D009135,myopathy,Steroid-responsive myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue.,9484390_0,9484390_D013256_D009135,,
770956837,false,true,5,2015-08-15T00:15:00,,No Relation,0.7888,D002809,chondroitin sulfate C,D009135,myopathy,Steroid-responsive myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue.,9484390_0,9484390_D002809_D009135,,
770956838,false,true,5,2015-08-15T01:31:00,,No Relation,1,D002809,chondroitin sulfate,D001284,atrophy,"A muscle biopsy showed only a moderate degree of type 2 atrophy, but immunocytochemistry showed absence of chondroitin sulfate C glycosaminoglycan in the endomysium.",9484390_2,9484390_D002809_D001284,,
770956839,false,true,5,2015-08-15T02:18:00,,No Relation,0.6,D004128,N-nitrosodimethylamine,D004487,cytotoxicity,Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.,9498284_0,9498284_D004128_D004487,,
770956840,false,true,5,2015-08-14T21:24:00,,No Relation,1,C010238,4-methylpyrazole,D064420,toxicity,"Inhibitors of P450 2E1 activity such as ethanol, 4-methylpyrazole, and isoniazid caused a 90% decrease in the methylation of cellular macromolecules and also completely protected the cells against NDMA-mediated toxicity.",9498284_7,9498284_C010238_D064420,,
770956841,false,true,5,2015-08-14T20:51:00,,No Relation,1,D000431,ethanol,D064420,toxicity,"Inhibitors of P450 2E1 activity such as ethanol, 4-methylpyrazole, and isoniazid caused a 90% decrease in the methylation of cellular macromolecules and also completely protected the cells against NDMA-mediated toxicity.",9498284_7,9498284_D000431_D064420,,
770956842,false,true,5,2015-08-14T22:02:00,,No Relation,1,D007538,isoniazid,D064420,toxicity,"Inhibitors of P450 2E1 activity such as ethanol, 4-methylpyrazole, and isoniazid caused a 90% decrease in the methylation of cellular macromolecules and also completely protected the cells against NDMA-mediated toxicity.",9498284_7,9498284_D007538_D064420,,
770956843,false,true,5,2015-08-14T20:51:00,,Direct,0.5884,D004128,NDMA,D064420,toxicity,"Inhibitors of P450 2E1 activity such as ethanol, 4-methylpyrazole, and isoniazid caused a 90% decrease in the methylation of cellular macromolecules and also completely protected the cells against NDMA-mediated toxicity.",9498284_7,9498284_D004128_D064420,,
770956844,false,true,5,2015-08-15T00:50:00,,No Relation,1,C029217,N-t-butyl-alpha-phenylnitrone,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_C029217_D004487,,
770956845,false,true,5,2015-08-15T02:07:00,,No Relation,0.8248,D002083,butylated hydroxyanisole,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_D002083_D004487,,
770956846,false,true,5,2015-08-15T00:01:00,,No Relation,1,D000111,N-acetylcysteine,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_D000111_D004487,,
770956847,false,true,5,2015-08-14T23:52:00,,No Relation,1,D001205,ascorbic acid,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_D001205_D004487,,
770956848,false,true,5,2015-08-14T20:45:00,,Direct,0.8218,D004128,NDMA,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_D004128_D004487,,
770956849,false,true,5,2015-08-14T23:49:00,,No Relation,1,D005978,glutathione,D004487,cytotoxicity,"The cytotoxicity due to exposure to NDMA was partially inhibited by antioxidants such as N-acetylcysteine, ascorbic acid, butylated hydroxyanisole and N-t-butyl-alpha-phenylnitrone but was not potentiated upon glutathione depletion.",9498284_8,9498284_D005978_D004487,,
770956850,false,true,5,2015-08-14T23:14:00,,No Relation,1,D004128,NDMA,D063646,carcinogenesis,These results document the ability of rat P450 2E1 to metabolize NDMA to toxic reactive intermediates and demonstrate that this cell line provides a useful model for studying the mechanisms of metabolism-mediated toxicity and carcinogenesis.,9498284_9,9498284_D004128_D063646,,
770956851,false,true,5,2015-08-14T23:46:00,,No Relation,0.8074,D004128,NDMA,D064420,toxicity,These results document the ability of rat P450 2E1 to metabolize NDMA to toxic reactive intermediates and demonstrate that this cell line provides a useful model for studying the mechanisms of metabolism-mediated toxicity and carcinogenesis.,9498284_9,9498284_D004128_D064420,,
770956852,false,true,5,2015-08-15T01:43:00,,No Relation,1,D008775,methylprednisolone,D008180,lupus,"Survival was even more prolonged when bindarit (0.5% medicated diet) was combined with a low dose of methylprednisolone (1.5 mg/kg i.p.), which that only partially modifies proteinuria and survival of lupus mice, in an additional group of animals (N = 16).",9507220_10,9507220_D008775_D008180,,
770956853,false,true,5,2015-08-15T01:50:00,,No Relation,1,D008775,methylprednisolone,D011507,proteinuria,"Survival was even more prolonged when bindarit (0.5% medicated diet) was combined with a low dose of methylprednisolone (1.5 mg/kg i.p.), which that only partially modifies proteinuria and survival of lupus mice, in an additional group of animals (N = 16).",9507220_10,9507220_D008775_D011507,,
770956854,false,true,5,2015-08-14T22:48:00,,No Relation,1,D013256,steroid,D008180,lupus,Studies are needed to establish whether bindarit may function as a steroid sparing drug in human lupus.,9507220_12,9507220_D013256_D008180,,
770956855,false,true,5,2015-08-14T23:18:00,,No Relation,1,D000617,aminoglycosides,D005600,tubular marker proteins,"In order to assess the nephrotoxic potential of antibiotics, various aminoglycosides and cephalosporins were tested for their potency to alter the excretion of tubular marker proteins (and brush border antigens) or to change the normal pattern of serumproteinuria as analyzed by SDS polyacrylamidgel gradient electrophoresis.",9562231_1,9562231_D000617_D005600,,
770956856,false,true,5,2015-08-14T20:41:00,,No Relation,0.7959,D002511,cephalosporins,D005600,tubular marker proteins,"In order to assess the nephrotoxic potential of antibiotics, various aminoglycosides and cephalosporins were tested for their potency to alter the excretion of tubular marker proteins (and brush border antigens) or to change the normal pattern of serumproteinuria as analyzed by SDS polyacrylamidgel gradient electrophoresis.",9562231_1,9562231_D002511_D005600,,
770956857,false,true,5,2015-08-14T21:02:00,,No Relation,0.7975,D000617,aminoglycosides/aminoglycoside,D005600,tubular marker proteins,Excretion of tubular marker proteins was enhanced under combined administration of cephalosporins and aminoglycosides mainly due to the aminoglycoside component.,9562231_4,9562231_D000617_D005600,,
770956858,false,true,5,2015-08-15T02:21:00,,No Relation,0.7893,D002511,cephalosporins,D005600,tubular marker proteins,Excretion of tubular marker proteins was enhanced under combined administration of cephalosporins and aminoglycosides mainly due to the aminoglycoside component.,9562231_4,9562231_D002511_D005600,,
770956859,false,true,5,2015-08-15T00:14:00,,Direct,1,C007027,Chloroxylenol,D003872,dermatitis,Chloroxylenol causing hand dermatitis in a plumber.,9601902_0,9601902_C007027_D003872,,
770956860,false,true,5,2015-08-14T21:50:00,,No Relation,1,D010100,oxygen,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D010100_D010146,,
770956861,false,true,5,2015-08-14T23:59:00,,No Relation,1,D004837,epinephrine,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D004837_D010146,,
770956862,false,true,5,2015-08-14T20:45:00,,No Relation,1,D009638,norepinephrine,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D009638_D010146,,
770956863,false,true,5,2015-08-15T01:29:00,,No Relation,1,D019344,lactate,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D019344_D010146,,
770956864,false,true,5,2015-08-14T22:19:00,,No Relation,1,D005230,free fatty acids,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D005230_D010146,,
770956865,false,true,5,2015-08-14T20:51:00,,No Relation,1,D005947,glucose,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D005947_D010146,,
770956866,false,true,5,2015-08-14T22:12:00,,No Relation,1,D006854,cortisol,D010146,pain,"Aural canal (core) and skin surface (15 sites) temperatures; oxygen consumption; pain visual analogue score; and concentrations of epinephrine, norepinephrine, glucose, cortisol, lactate, and free fatty acids in plasma were measured before epidural blockade, 30 min after epidural blockade, at the end of surgery, and for 4 h after surgery.",9605680_8,9605680_D006854_D010146,,
770956867,false,true,5,2015-08-14T21:03:00,,No Relation,1,D010100,oxygen,D010146,pain,"During recovery, there was no difference between the two groups for norepinephrine concentrations in plasma, body weight-adjusted oxygen consumption, pain visual analogue score, and metabolites.",9605680_12,9605680_D010100_D010146,,
770956868,false,true,5,2015-08-15T00:33:00,,No Relation,1,D009638,norepinephrine,D010146,pain,"During recovery, there was no difference between the two groups for norepinephrine concentrations in plasma, body weight-adjusted oxygen consumption, pain visual analogue score, and metabolites.",9605680_12,9605680_D009638_D010146,,
770956869,false,true,5,2015-08-15T02:05:00,,No Relation,1,D004298,dopamine,D004421,dystonia,It has been suggested that tardive cervical dystonia may be clinically indistinguishable from the idiopathic form and that the diagnosis rests solely on documenting an exposure to dopamine antagonist medications.,9613742_1,9613742_D004298_D004421,,
770956870,false,true,5,2015-08-14T20:40:00,,No Relation,0.8018,D004298,dopamine,D004421,dystonia,"These differences may help to distinguish them in the clinical setting, improve diagnostic accuracy, and support the existence of a causal relationship between exposure to dopamine antagonist medications and chronic dystonia.",9613742_10,9613742_D004298_D004421,,
770956871,false,true,5,2015-08-14T23:46:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D006521,chronic hepatic encephalopathy,Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.,9625322_0,9625322_C002939_D006521,,
770956872,false,true,5,2015-08-14T20:40:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D005355,cirrhosis,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_C002939_D005355,,
770956873,false,true,5,2015-08-14T20:46:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D022124,hyperammonemia,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_C002939_D022124,,
770956874,false,true,5,2015-08-15T02:21:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D006521,chronic hepatic encephalopathy,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_C002939_D006521,,
770956875,false,true,5,2015-08-14T23:40:00,,No Relation,0.8031,C002939,L-ornithine-L-aspartate,C538320,impaired ammonia detoxification,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_C002939_C538320,,
770956876,false,true,5,2015-08-14T20:40:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D006501,hepatic encephalopathy,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_C002939_D006501,,
770956877,false,true,5,2015-08-14T20:39:00,,No Relation,1,D000641,ammonia,D005355,cirrhosis,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_D000641_D005355,,
770956878,false,true,5,2015-08-15T02:15:00,,No Relation,1,D000641,ammonia,D006521,chronic hepatic encephalopathy,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_D000641_D006521,,
770956879,false,true,5,2015-08-15T00:10:00,,No Relation,1,D000641,ammonia,D006501,hepatic encephalopathy,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_D000641_D006501,,
770956880,false,true,5,2015-08-14T20:40:00,,No Relation,1,D000641,ammonia,C538320,impaired ammonia detoxification,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_D000641_C538320,,
770956881,false,true,5,2015-08-14T22:05:00,,No Relation,1,D000641,ammonia,D022124,hyperammonemia,"Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.",9625322_2,9625322_D000641_D022124,,
770956882,false,true,5,2015-08-15T02:19:00,,No Relation,1,D000641,ammonia,D001925,Encephalopathy,"Efficacy variables were: fasting and postprandial ammonia concentration, Number-Connection-Test time, mental state grades, and a Portosystemic Encephalopathy Index.",9625322_5,9625322_D000641_D001925,,
770956883,false,true,5,2015-08-14T20:43:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D006501,hepatic encephalopathy,Analyses were based on the total study sample of 32 placebo- and 34 L-ornithine-L-aspartate-treated patients as well as on the subgroup samples in the overt (20 placebo- and 23 L-ornithine-L-aspartate-treated) and subclinical hepatic encephalopathy (12 placebo- and 11 L-ornithine-L-aspartate-treated) patients.,9625322_6,9625322_C002939_D006501,,
770956884,false,true,5,2015-08-14T23:38:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D001925,Encephalopathy,"Also, the mental state grade (p<0.05) and the Portosystemic Encephalopathy Index (p<0.01), improved to a much greater degree in the L-ornithine-L-aspartate group than in the placebo group.",9625322_8,9625322_C002939_D001925,,
770956885,false,true,5,2015-08-15T01:38:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D005355,cirrhosis,"Oral L-ornithine-L-aspartate is a safe, well-tolerated treatment with a good compliance rate and a beneficial therapeutic effect in patients with cirrhosis and stable, overt, chronic hepatic encephalopathy.",9625322_10,9625322_C002939_D005355,,
770956886,false,true,5,2015-08-15T00:58:00,,No Relation,1,C002939,L-ornithine-L-aspartate,D006521,chronic hepatic encephalopathy,"Oral L-ornithine-L-aspartate is a safe, well-tolerated treatment with a good compliance rate and a beneficial therapeutic effect in patients with cirrhosis and stable, overt, chronic hepatic encephalopathy.",9625322_10,9625322_C002939_D006521,,
770956887,false,true,5,2015-08-15T00:54:00,,No Relation,1,D013256,steroids,D019106,aggressive postoperative diuresis,"A protocol emphasizing preoperative placement of the intra-aortic balloon pump, reduced CPB time, early extubation, perioperative steroids, thyroid hormone, and aggressive postoperative diuresis was used.",9635268_4,9635268_D013256_D019106,,
770956888,false,true,5,2015-08-14T22:12:00,,No Relation,0.808,D010100,oxygen,D000787,angina pectoris,"From a therapeutic point of view, angina pectoris is best thought of as an imbalance between oxygen supply and demand.",9642483_1,9642483_D010100_D000787,,
770956889,false,true,5,2015-08-15T02:10:00,,No Relation,0.8189,D010100,oxygen,D007022,decreasing heart rate,"Reduction of oxygen demand is accomplished by decreasing heart rate, blood pressure, heart size, and left ventricular mass.",9642483_5,9642483_D010100_D007022,,
770956890,false,true,5,2015-08-14T23:37:00,Used as treatment.,No Relation,1,D001241,aspirin,D000787,angina pectoris,"Together with reduction of risk factors, this combination therapy plus aspirin provides optimal management of patients with angina pectoris.",9642483_8,9642483_D001241_D000787,,
770956891,false,true,5,2015-08-14T23:16:00,,No Relation,1,D000596,amino acid,D005355,cirrhosis,Effects of branched-chain amino acid-enriched nutrient mixture on natural killer cell activity in viral cirrhosis.,9689432_0,9689432_D000596_D005355,,
770956892,false,true,5,2015-08-15T00:43:00,,No Relation,1,D000596,amino acid,D005355,cirrhosis,"A controlled study was performed in 18 viral cirrhosis patients to evaluate whether immune function, as indicated by natural killer (NK) cell activity, was improved by a branched-chain amino acid-enriched nutrient mixture (nutrient-mixture), Aminoleban EN.",9689432_1,9689432_D000596_D005355,,
770956893,false,true,5,2015-08-14T23:36:00,,No Relation,1,D001663,bilirubin,D008103,liver cirrhosis,"Laboratory data, indicating severity of liver cirrhosis, such as total bilirubin and albumin, showed better values (p < 0.01, p < 0.05 respectively), and baseline NK cell activity was low (8.7 +/- 7.2% vs 33.3 +/- 13.0%, p < 0.05) in the affected group than unaffected group.",9689432_7,9689432_D001663_D008103,,
770956894,false,true,5,2015-08-14T22:03:00,,No Relation,1,D000596,amino acid,D008103,liver cirrhosis,These results suggest that the branched-chain amino acid-enriched nutrient mixture increases NK cell activity moderately in patients who have compensated liver cirrhosis and shows lower values of baseline NK cell activity.,9689432_11,9689432_D000596_D008103,,
770956895,false,true,5,2015-08-15T00:48:00,,No Relation,0.8087,D001241,aspirin,D001281,atrial fibrillation,Cardioversion of patients with nonvalvular atrial fibrillation followed by the use of aspirin alone or with amiodarone has a reasonable marginal cost-effectiveness ratio.,9701102_13,9701102_D001241_D001281,,
770956896,false,true,5,2015-08-15T02:10:00,,No Relation,0.6212,D000638,amiodarone,D001281,atrial fibrillation,Cardioversion of patients with nonvalvular atrial fibrillation followed by the use of aspirin alone or with amiodarone has a reasonable marginal cost-effectiveness ratio.,9701102_13,9701102_D000638_D001281,,
770956897,false,true,5,2015-08-15T00:41:00,,No Relation,0.794,D001241,aspirin,D001281,atrial fibrillation,"Finally, for patients who are bothered little by symptoms of atrial fibrillation, cardioversion followed by either aspirin or warfarin without subsequent antiarrhythmic therapy is the treatment of choice.",9701102_15,9701102_D001241_D001281,,
770956898,false,true,5,2015-08-15T00:21:00,,No Relation,1,D014859,warfarin,D001281,atrial fibrillation,"Finally, for patients who are bothered little by symptoms of atrial fibrillation, cardioversion followed by either aspirin or warfarin without subsequent antiarrhythmic therapy is the treatment of choice.",9701102_15,9701102_D014859_D001281,,
770956899,false,true,5,2015-08-15T01:46:00,,No Relation,1,D013739,Testosterone,D008594,surgical menopause,"Testosterone deficiency in menopausal women is more common than appreciated, particularly in patients on hormone replacement or with surgical menopause.",9711681_2,9711681_D013739_D008594,,
770956900,false,true,5,2015-08-14T21:52:00,,No Relation,1,D013739,Testosterone,D003677,Testosterone deficiency,"Testosterone deficiency in menopausal women is more common than appreciated, particularly in patients on hormone replacement or with surgical menopause.",9711681_2,9711681_D013739_D003677,,
770956901,false,true,5,2015-08-15T00:36:00,,No Relation,1,D002118,calcium,D010024,osteoporosis,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D002118_D010024,,
770956902,false,true,5,2015-08-14T20:47:00,,No Relation,1,D002118,calcium,D003645,sudden death,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D002118_D003645,,
770956903,false,true,5,2015-08-15T02:05:00,,No Relation,1,D002118,calcium,D006973,hypertension,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D002118_D006973,,
770956904,false,true,5,2015-08-15T02:00:00,,No Relation,1,D012964,sodium,D010024,osteoporosis,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D012964_D010024,,
770956905,false,true,5,2015-08-14T22:20:00,,No Relation,1,D012964,sodium,D003645,sudden death,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D012964_D003645,,
770956906,false,true,5,2015-08-14T23:47:00,,No Relation,1,D008274,magnesium,D003645,sudden death,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D008274_D003645,,
770956907,false,true,5,2015-08-14T22:05:00,,No Relation,1,D008274,magnesium,D010024,osteoporosis,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D008274_D010024,,
770956908,false,true,5,2015-08-14T23:08:00,,No Relation,1,D008274,magnesium,D006973,hypertension,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D008274_D006973,,
770956909,false,true,5,2015-08-14T23:36:00,,Direct,1,D012964,sodium,D006973,hypertension,"Epidemiologic and clinical studies suggest that magnesium may reduce the frequency of sudden death, that sodium contributes to the occurrence of hypertension, and that calcium may help prevent osteoporosis.",9727819_7,9727819_D012964_D006973,,
770956910,false,true,5,2015-08-15T02:05:00,,No Relation,0.8047,D000431,alcohol,D002318,cardiovascular disease,"In the presence of cardiovascular disease, however, even such small quantities of alcohol might result in transient unfavorable hemodynamic changes.",9751945_3,9751945_D000431_D002318,,
770956911,false,true,5,2015-08-14T20:39:00,,Direct,1,D000431,alcohol,D003645,sudden death,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D003645,,
770956912,false,true,5,2015-08-14T23:10:00,,Direct,1,D000431,alcohol,D020521,stroke,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D020521,,
770956913,false,true,5,2015-08-15T01:14:00,,Direct,1,D000431,alcohol,D006973,hypertension,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D006973,,
770956914,false,true,5,2015-08-15T02:17:00,,No Relation,1,D000431,alcohol,D000437,alcohol abuse,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D000437,,
770956915,false,true,5,2015-08-14T22:29:00,,Direct,1,D000431,alcohol,D009202,cardiomyopathy,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D009202,,
770956916,false,true,5,2015-08-14T22:20:00,,Direct,1,D000431,alcohol,D001145,cardiac arrhythmias,"Moreover, alcohol abuse can produce cardiac arrhythmias, hypertension, cardiomyopathy, stroke, and even sudden death.",9751945_4,9751945_D000431_D001145,,
770956917,false,true,5,2015-08-15T01:16:00,,No Relation,1,D000431,alcohol,D014652,vascular diseases,"In contrast, moderate alcohol use produces changes that have an overall favorable effect on atherosclerotic-related vascular diseases.",9751945_5,9751945_D000431_D014652,,
770956918,false,true,5,2015-08-15T02:12:00,,No Relation,1,D000431,alcohol,D050197,atherosclerosis,"Because cardiovascular disease due to atherosclerosis is the leading cause of death in Western society, this desirable effect of alcohol use outweighs its detrimental actions, resulting in favorable findings in population studies.",9751945_6,9751945_D000431_D050197,,
770956919,false,true,5,2015-08-14T20:42:00,,No Relation,0.8087,D000431,alcohol,D002318,cardiovascular disease,"Because cardiovascular disease due to atherosclerosis is the leading cause of death in Western society, this desirable effect of alcohol use outweighs its detrimental actions, resulting in favorable findings in population studies.",9751945_6,9751945_D000431_D002318,,
770956920,false,true,5,2015-08-15T00:48:00,,No Relation,0.817,D000431,alcohol,D003643,death,"Because cardiovascular disease due to atherosclerosis is the leading cause of death in Western society, this desirable effect of alcohol use outweighs its detrimental actions, resulting in favorable findings in population studies.",9751945_6,9751945_D000431_D003643,,
770956921,false,true,5,2015-08-14T21:02:00,,No Relation,1,D005947,glucose,D003920,diabetes mellitus,"Cross-sectional analysis of data for 1567 participants in The Gubbio Population Study (677 men and 890 women), aged 45 to 64 years, without macroalbuminuria, without diabetes mellitus, and with fasting plasma glucose levels of less than 7.8 mmol/L (140 mg/ dL).",9759691_3,9759691_D005947_D003920,,
770956922,false,true,5,2015-08-14T22:09:00,,Direct,0.5908,C043562,flavone,C538231,A549 lung adenocarcinoma,Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells.,9804172_0,9804172_C043562_C538231,,
770956923,false,true,5,2015-08-15T02:30:00,,No Relation,0.8255,C043562,Flavone,D009369,cancer,"Flavone is a well known flavonoid, and many of its derivatives have been shown to have anti-proliferative effects on several cancer cells.",9804172_3,9804172_C043562_D009369,,
770956924,false,true,5,2015-08-14T21:02:00,,No Relation,1,C043562,flavone,C538231,lung adenocarcinoma,"We report here that flavone can effectively inhibit the cell growth of human lung adenocarcinoma A549 cells in a dose-dependent manner, and 100 microM flavone causes cell cycle arrest at the G1 phase.",9804172_4,9804172_C043562_C538231,,
770956925,false,true,5,2015-08-14T20:40:00,,No Relation,1,C043562,flavone,D012175,RB/retinoblastoma,"As a mechanism underlying the cell cycle arrest, flavone markedly increases the mRNA and protein levels of a universal inhibitor of cyclin-dependent kinase, p21/WAF1, and inhibits phosphorylation of retinoblastoma (RB) protein.",9804172_5,9804172_C043562_D012175,,
770956926,false,true,5,2015-08-14T23:54:00,,No Relation,1,C043562,flavone,D012175,RB,These results suggest that the G1 phase arrest by flavone is due to p53-independent transcriptional induction of the p21/WAF1 gene and the subsequent dephosphorylation of RB protein.,9804172_8,9804172_C043562_D012175,,
770956927,false,true,5,2015-08-14T20:43:00,,Direct,0.8035,D020123,sirolimus,D064420,toxicities,"After a phase I trial in stable renal transplant recipients documented that cyclosporine and sirolimus have few overlapping toxicities, we conducted an open-label, single-center, phase I/II dose-escalation trial to examine the safety and efficacy of this drug combination.",9808489_2,9808489_D020123_D064420,,
770956928,false,true,5,2015-08-15T01:53:00,,No Relation,0.6175,D016572,cyclosporine,D064420,toxicities,"After a phase I trial in stable renal transplant recipients documented that cyclosporine and sirolimus have few overlapping toxicities, we conducted an open-label, single-center, phase I/II dose-escalation trial to examine the safety and efficacy of this drug combination.",9808489_2,9808489_D016572_D064420,,
770956929,false,true,5,2015-08-15T00:29:00,,No Relation,1,D020123,sirolimus,D006973,hypertensive,"Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine.",9808489_7,9808489_D020123_D006973,,
770956930,false,true,5,2015-08-14T20:40:00,,No Relation,1,D014280,triglycerides,D006973,hypertensive,"Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine.",9808489_7,9808489_D014280_D006973,,
770956931,false,true,5,2015-08-15T00:18:00,,No Relation,1,D002784,cholesterol,D006973,hypertensive,"Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine.",9808489_7,9808489_D002784_D006973,,
770956932,false,true,5,2015-08-14T23:37:00,,No Relation,0.7947,D016572,cyclosporine,D006973,hypertensive,"Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine.",9808489_7,9808489_D016572_D006973,,
770956933,false,true,5,2015-08-14T20:53:00,,No Relation,0.8145,D004967,estrogens,D009369,breast cancer,Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.,9816328_0,9816328_D004967_D009369,,
770956934,false,true,5,2015-08-15T01:58:00,,No Relation,1,D019290,megestrol acetate,D009369,breast cancer,Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.,9816328_0,9816328_D019290_D009369,,
770956935,false,true,5,2015-08-14T20:44:00,,No Relation,0.7939,D006854,cortisol,D009369,breast cancer,"Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg.",9816328_1,9816328_D006854_D009369,,
770956936,false,true,5,2015-08-15T00:38:00,,No Relation,1,D004967,estrogens,D009369,breast cancer,"Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg.",9816328_1,9816328_D004967_D009369,,
770956937,false,true,5,2015-08-14T23:03:00,,No Relation,0.8101,D000728,androgens,D009369,breast cancer,"Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg.",9816328_1,9816328_D000728_D009369,,
770956938,false,true,5,2015-08-14T21:24:00,,No Relation,1,D019290,megestrol acetate,D009369,breast cancer,"Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg.",9816328_1,9816328_D019290_D009369,,
770956939,false,true,5,2015-08-15T01:41:00,,No Relation,1,D000728,androgens,D009369,breast cancer,Our findings indicate that MA causes profound suppression of adrenal steroid production but in addition suppresses ovarian secretion of androgens in postmenopausal breast cancer patients.,9816328_6,9816328_D000728_D009369,,
770956940,false,true,5,2015-08-15T00:58:00,,No Relation,1,D013256,steroid,D009369,breast cancer,Our findings indicate that MA causes profound suppression of adrenal steroid production but in addition suppresses ovarian secretion of androgens in postmenopausal breast cancer patients.,9816328_6,9816328_D013256_D009369,,
770956941,false,true,5,2015-08-14T23:39:00,,No Relation,1,D004967,estrogens,D009369,breast cancer,The reduction in plasma estrogens is comparable to values obtained with commonly used aromatase inhibitors and may be responsible for its antitumor effects in breast cancer.,9816328_7,9816328_D004967_D009369,,
770956942,false,true,5,2015-08-15T00:36:00,,No Relation,1,D008274,Mg/magnesium,D018476,hypokinesia,The aim of this study was to evaluate the effect of magnesium (Mg) loading (10.0 mg Mg/kg body wt) and daily Mg supplements (5.0 mg Mg/kg body wt) on Mg deficiency shown by increased and not by decreased serum Mg concentration during hypokinesia (decreased km number/d).,9823441_1,9823441_D008274_D018476,,
770956943,false,true,5,2015-08-14T23:41:00,,No Relation,1,D008274,Mg,D014717,SACS,The SHKS and SACS groups took daily 5.0 mg elemental Mg/kg body wt and subjected to Mg loading (10.0 mg Mg/kg body wt).,9823441_12,9823441_D008274_D014717,,
770956944,false,true,5,2015-08-14T22:11:00,,No Relation,1,D008274,Mg,C536231,hypokinetic,"During the prehypokinetic and hypokinetic periods, excretion of Mg in feces and urine, concentration of Mg in serum, and Mg balance were measured.",9823441_14,9823441_D008274_C536231,,
770956945,false,true,5,2015-08-15T00:26:00,,No Relation,1,D008274,Mg,D014717,SACS,"In both SHKS and UHKS groups, fecal Mg loss, urinary excretion of electrolytes, and serum concentrations of electrolytes increased significantly (p < or = 0.05) when compared with the SACS and UACS groups.",9823441_16,9823441_D008274_D014717,,
770956946,false,true,5,2015-08-15T02:14:00,,No Relation,1,D008274,Mg,D014717,SACS,"During Mg loading tests, urinary and fecal Mg excretion was also greater in the SHKS and UHKS groups than in the SACS and UACS groups.",9823441_17,9823441_D008274_D014717,,
770956947,false,true,5,2015-08-14T22:08:00,,No Relation,1,D008274,Mg,D014717,SACS,"Throughout the study, Mg balance was negative in the SHKS and UHKS groups, whereas in the SACS and UACS groups, Mg balance was positive.",9823441_18,9823441_D008274_D014717,,
770956948,false,true,5,2015-08-14T20:45:00,,No Relation,0.8207,D008274,Mg,D018476,HK,"It was concluded that significant losses of Mg occurred in the presence of negative Mg balance and Mg deficiency in endurance-trained subjects during prolonged exposure to HK, daily mg supplements, and Mg loading tests.",9823441_19,9823441_D008274_D018476,,
770956949,false,true,5,2015-08-14T23:50:00,,Direct,0.815,D017367,SSRI,D012735,sexual dysfunction,Management of SSRI-induced sexual dysfunction.,9825088_0,9825088_D017367_D012735,,
770956950,false,true,5,2015-08-14T20:38:00,,Direct,0.5968,D012701,serotonin,D012735,sexual dysfunction,"To describe the occurrence and management of sexual dysfunction induced by selective serotonin-reuptake inhibitors (SSRIs), to provide an overview of sexual dysfunction, reports of SSRI-induced sexual dysfunction, and management strategies.",9825088_1,9825088_D012701_D012735,,
770956951,false,true,5,2015-08-14T20:40:00,,Direct,0.7994,D017367,SSRI,D012735,sexual dysfunction,"To describe the occurrence and management of sexual dysfunction induced by selective serotonin-reuptake inhibitors (SSRIs), to provide an overview of sexual dysfunction, reports of SSRI-induced sexual dysfunction, and management strategies.",9825088_1,9825088_D017367_D012735,,
770956952,false,true,5,2015-08-14T20:46:00,,No Relation,0.7897,C051752,nefazodone,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_C051752_D012735,,
770956953,false,true,5,2015-08-15T00:49:00,,No Relation,1,D005473,fluoxetine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D005473_D012735,,
770956954,false,true,5,2015-08-14T21:55:00,,No Relation,0.7899,D016642,bupropion,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D016642_D012735,,
770956955,false,true,5,2015-08-15T02:12:00,,No Relation,1,D003533,cyproheptadine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D003533_D012735,,
770956956,false,true,5,2015-08-15T02:31:00,,No Relation,0.7938,D015016,yohimbine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D015016_D012735,,
770956957,false,true,5,2015-08-14T20:40:00,,No Relation,1,D002997,clomipramine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D002997_D012735,,
770956958,false,true,5,2015-08-14T20:40:00,,No Relation,1,D020280,sertraline,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D020280_D012735,,
770956959,false,true,5,2015-08-15T01:58:00,,No Relation,1,D000547,amantadine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D000547_D012735,,
770956960,false,true,5,2015-08-15T02:12:00,,No Relation,1,D002065,buspirone,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D002065_D012735,,
770956961,false,true,5,2015-08-14T21:47:00,,No Relation,0.7996,D017374,paroxetine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D017374_D012735,,
770956962,false,true,5,2015-08-14T21:47:00,,No Relation,0.7899,D016666,fluvoxamine,D012735,sexual dysfunction,"Indexing terms included sexual dysfunction, antidepressants, selective serotonergic reuptake inhibitors, fluoxetine, sertraline, paroxetine, fluvoxamine, clomipramine, buspirone, nefazodone, bupropion, cyproheptadine, amantadine, yohimbine, and central nervous system stimulants.",9825088_3,9825088_D016666_D012735,,
770956963,false,true,5,2015-08-14T23:03:00,,No Relation,0.5815,D017367,SSRI,D012735,sexual dysfunction,There are no controlled studies describing SSRI-induced sexual dysfunction or its management.,9825088_4,9825088_D017367_D012735,,
770956964,false,true,5,2015-08-14T22:00:00,,Direct,0.8106,D005473,fluoxetine,D012735,sexual dysfunction,"SSRI-induced sexual dysfunction is described with fluoxetine, paroxetine, sertraline, and fluvoxamine for 3-24 weeks of therapy.",9825088_6,9825088_D005473_D012735,,
770956965,false,true,5,2015-08-14T22:19:00,,Direct,0.7906,D017374,paroxetine,D012735,sexual dysfunction,"SSRI-induced sexual dysfunction is described with fluoxetine, paroxetine, sertraline, and fluvoxamine for 3-24 weeks of therapy.",9825088_6,9825088_D017374_D012735,,
770956966,false,true,5,2015-08-15T00:04:00,,No Relation,0.5885,D016666,fluvoxamine,D012735,sexual dysfunction,"SSRI-induced sexual dysfunction is described with fluoxetine, paroxetine, sertraline, and fluvoxamine for 3-24 weeks of therapy.",9825088_6,9825088_D016666_D012735,,
770956967,false,true,5,2015-08-15T00:12:00,,Direct,0.7997,D020280,sertraline,D012735,sexual dysfunction,"SSRI-induced sexual dysfunction is described with fluoxetine, paroxetine, sertraline, and fluvoxamine for 3-24 weeks of therapy.",9825088_6,9825088_D020280_D012735,,
770956968,false,true,5,2015-08-14T21:36:00,,Direct,1,D017367,SSRI,D012735,sexual dysfunction,"SSRI-induced sexual dysfunction is described with fluoxetine, paroxetine, sertraline, and fluvoxamine for 3-24 weeks of therapy.",9825088_6,9825088_D017367_D012735,,
770956969,false,true,5,2015-08-14T21:54:00,,No Relation,0.6084,D012701,serotonin,D009771,obsessive-compulsive disorder,Role of serotonin in obsessive-compulsive disorder.,9829022_0,9829022_D012701_D009771,,
770956970,false,true,5,2015-08-14T20:51:00,,Direct,0.41,D012701,Serotonin,D009771,obsessive-compulsive disorder/OCD,Serotonin may play a role in the pathophysiology of obsessive-compulsive disorder (OCD) because of the anti-obsessional effect of selective serotonin reuptake inhibitors (SSRIs).,9829022_1,9829022_D012701_D009771,,
770956971,false,true,5,2015-08-14T21:46:00,,No Relation,1,D006719,homovanillic acid,D009771,OCD,"In most of the OCD cases analysed, CSF 5-hydroxyindoleacetic acid and homovanillic acid concentrations do not significantly differ from age-corrected controls.",9829022_3,9829022_D006719_D009771,,
770956972,false,true,5,2015-08-15T00:08:00,,No Relation,0.7866,D013004,somatostatin,D009771,OCD,"Abnormalities in CSF arginine vasopressin, corticotropin-releasing hormone, oxytocin and somatostatin levels have been reported in OCD.",9829022_5,9829022_D013004_D009771,,
770956973,false,true,5,2015-08-14T22:28:00,,No Relation,0.8103,D001127,arginine vasopressin,D009771,OCD,"Abnormalities in CSF arginine vasopressin, corticotropin-releasing hormone, oxytocin and somatostatin levels have been reported in OCD.",9829022_5,9829022_D001127_D009771,,
770956974,false,true,5,2015-08-15T02:47:00,,No Relation,1,D010121,oxytocin,D009771,OCD,"Abnormalities in CSF arginine vasopressin, corticotropin-releasing hormone, oxytocin and somatostatin levels have been reported in OCD.",9829022_5,9829022_D010121_D009771,,
770956975,false,true,5,2015-08-14T23:32:00,,No Relation,1,D002997,clomipramine,D002869,neuropeptide abnormalities,"Long-term treatment with high-doses of clomipramine, fluvoxamine, and fluoxetine tend to correct these neuropeptide abnormalities.",9829022_6,9829022_D002997_D002869,,
770956976,false,true,5,2015-08-15T01:54:00,,No Relation,1,D005473,fluoxetine,D002869,neuropeptide abnormalities,"Long-term treatment with high-doses of clomipramine, fluvoxamine, and fluoxetine tend to correct these neuropeptide abnormalities.",9829022_6,9829022_D005473_D002869,,
770956977,false,true,5,2015-08-14T20:43:00,,No Relation,1,D016666,fluvoxamine,D002869,neuropeptide abnormalities,"Long-term treatment with high-doses of clomipramine, fluvoxamine, and fluoxetine tend to correct these neuropeptide abnormalities.",9829022_6,9829022_D016666_D002869,,
770956978,false,true,5,2015-08-15T00:04:00,,No Relation,0.8209,D012701,serotonin,D009771,OCD,We hypothesise that continuous treatment with SSRIs alters serotonin turnover and neuropeptide expression patterns in OCD-entertaining functional forebrain/midbrain circuits.,9829022_7,9829022_D012701_D009771,,
770956979,false,true,5,2015-08-15T02:07:00,,No Relation,1,D007501,iron,D007676,ESRD/end-stage renal disease,"The study included 20 end-stage renal disease (ESRD) patients, performing chronic peritoneal or home hemodialysis, with iron deficiency defined as ferritin < 100 ng/mL and/or an iron saturation < 20%.",9848632_4,9848632_D007501_D007676,,
770956980,false,true,5,2015-08-15T00:54:00,,No Relation,1,D007501,iron,D018798,iron deficiency,"The study included 20 end-stage renal disease (ESRD) patients, performing chronic peritoneal or home hemodialysis, with iron deficiency defined as ferritin < 100 ng/mL and/or an iron saturation < 20%.",9848632_4,9848632_D007501_D018798,,
770956981,false,true,5,2015-08-15T00:18:00,,No Relation,1,D007501,iron,D007676,ESRD,Total dose iron is a safe and effective means of restoring iron and erythropoietic response in ESRD patients weighing more than 50 kg who receive their renal replacement therapy at home.,9848632_18,9848632_D007501_D007676,,
770956982,false,true,5,2015-08-15T00:47:00,,No Relation,1,D008751,Methylene blue,D008708,methemoglobinemia,Methylene blue by intraosseous infusion for methemoglobinemia.,9867898_0,9867898_D008751_D008708,,
770956983,false,true,5,2015-08-14T20:47:00,,No Relation,1,D008751,methylene blue,D008708,methemoglobinemia,Intraosseous administration of standard intravenous doses of methylene blue rapidly terminated the effects of acquired methemoglobinemia.,9867898_11,9867898_D008751_D008708,,
770956984,false,true,5,2015-08-14T23:18:00,,No Relation,1,D010406,penicillin,D000039,peritonsillar abscess,These results suggest that intravenous penicillin remains an excellent choice for therapy in cases of peritonsillar abscess requiring parenteral antibiotics after drainage.,9914550_9,9914550_D010406_D000039,,
770956985,false,true,5,2015-08-15T00:58:00,,No Relation,0.5878,D002725,chloroform,D006177,hepatic damage,The contribution of drug-induced hepatic damage to postoperative hepatic dysfunction has remained unsettled since chloroform was first incriminated during the nineteenth century.,9921434_4,9921434_D002725_D006177,,
770956986,false,true,5,2015-08-15T01:54:00,,No Relation,0.5968,D002725,chloroform,D006505,hepatic dysfunction,The contribution of drug-induced hepatic damage to postoperative hepatic dysfunction has remained unsettled since chloroform was first incriminated during the nineteenth century.,9921434_4,9921434_D002725_D006505,,
770956987,false,true,5,2015-08-15T02:14:00,,Direct,0.8072,D002725,chloroform,D011041,poisoning,"The drug was condemned in 1912, without any attempt being made to determine the incidence of the so-called delayed chloroform poisoning, with the result that the drug is still in use and the chloroform controversy remains unsettled to this day.",9921434_5,9921434_D002725_D011041,,
770956988,false,true,5,2015-08-14T20:40:00,,No Relation,0.7771,D002725,chloroform,D009336,necrosis,Babior and Davidson noted that it was the first drug implicated in hepatic necrosis--presumably with the exception of chloroform--the first report appearing in 1922.,9921434_8,9921434_D002725_D009336,,
770956989,false,true,5,2015-08-15T01:23:00,,No Relation,0.7793,D006221,halothane,D006505,hepatitis,"Just as we have conducted the definitive retrospective hypothesis-testing study--the National Halothane Study--demanded by the ""halothane hepatitis"" controversy, so must we now move to the final stage of epidemiological investigation (experimental epidemiology) by investigating the effects of multiple administrations of the drug.",9921434_18,9921434_D006221_D006505,,
770956990,false,true,5,2015-08-14T22:08:00,,No Relation,0.7981,D017239,Paclitaxel,D009369,tumor,Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.,9925253_0,9925253_D017239_D009369,,
770956991,false,true,5,2015-08-15T02:12:00,,No Relation,0.6068,D017239,paclitaxel,D009369,tumor,Low Raf- kinase activity has been reported to be associated with radioresistance in epithelial tumor cell lines and with paclitaxel sensitivity in cervical tumor cells.,9925253_1,9925253_D017239_D009369,,
770956992,false,true,5,2015-08-15T01:33:00,,No Relation,1,D017239,Paclitaxel,D009369,tumors,"Paclitaxel might thus be effective in eliminating radioresistant clones from cervical tumors, even in the absence of synergistic interaction between these therapeutic modalities.",9925253_2,9925253_D017239_D009369,,
770956993,false,true,5,2015-08-15T02:20:00,,No Relation,0.7929,D017239,paclitaxel,D009369,tumor,We thus established the relationship between Raf-1 kinase activity and radiosensitivity in human cervical tumor cells and determined if paclitaxel is preferentially cytotoxic to radio-resistant tumor clones.,9925253_3,9925253_D017239_D009369,,
770956994,false,true,5,2015-08-15T02:16:00,,No Relation,1,D017239,paclitaxel,D009369,tumor,We established and contrasted the radiation and paclitaxel sensitivity of 12 human cervical tumor clones that exhibited a wide range of Raf-1 kinase activity.,9925253_4,9925253_D017239_D009369,,
770956995,false,true,5,2015-08-14T22:52:00,,No Relation,1,D017239,Paclitaxel,D009369,tumor,"Paclitaxel was preferentially cytotoxic to radioresistant tumor clones, with the level of paclitaxel-induced cytotoxicity being significantly (P = 0.0016) influenced by Raf-1 kinase activity levels.",9925253_6,9925253_D017239_D009369,,
770956996,false,true,5,2015-08-14T20:41:00,,Direct,1,D017239,Paclitaxel,D004487,cytotoxicity,"Paclitaxel was preferentially cytotoxic to radioresistant tumor clones, with the level of paclitaxel-induced cytotoxicity being significantly (P = 0.0016) influenced by Raf-1 kinase activity levels.",9925253_6,9925253_D017239_D004487,,
770956997,false,true,5,2015-08-14T21:53:00,,No Relation,0.7893,D017239,paclitaxel,D009369,tumor,"Our in vitro data indicate that there are marked, but completely opposite, Raf-1 kinase dependencies of radiation and paclitaxel cytotoxicity in cervical tumor cells.",9925253_7,9925253_D017239_D009369,,
770956998,false,true,5,2015-08-14T21:02:00,,No Relation,0.7975,D017239,paclitaxel,D004487,cytotoxicity,"Our in vitro data indicate that there are marked, but completely opposite, Raf-1 kinase dependencies of radiation and paclitaxel cytotoxicity in cervical tumor cells.",9925253_7,9925253_D017239_D004487,,
770956999,false,true,5,2015-08-15T02:13:00,,No Relation,1,D017239,paclitaxel,D065309,squamous cell carcinoma of the cervix,The use of combined paclitaxel and radiotherapy treatment may thus lead to higher local control rates for squamous cell carcinoma of the cervix.,9925253_8,9925253_D017239_D065309,,
770957000,false,true,5,2015-08-15T01:00:00,,No Relation,1,D017239,paclitaxel,D009369,tumor,"Circumstantially, our data suggest that the greatest therapeutic gains might accrue if paclitaxel was administered when there is the greatest proportion of tumor clones with low Raf-1 kinase activity.",9925253_9,9925253_D017239_D009369,,
770957001,false,true,5,2015-08-15T00:54:00,,No Relation,1,D005978,glutathione,D009369,tumor,Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells.,9988757_0,9988757_D005978_D009369,,
770957002,false,true,5,2015-08-14T21:02:00,,No Relation,1,D003907,dexamethasone,D009336,necrosis,Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells.,9988757_0,9988757_D003907_D009336,,
770957003,false,true,5,2015-08-15T00:35:00,,No Relation,1,D005978,glutathione,D009336,necrosis,Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells.,9988757_0,9988757_D005978_D009336,,
770957004,false,true,5,2015-08-14T20:42:00,,No Relation,1,D003907,dexamethasone,D009369,tumor,Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells.,9988757_0,9988757_D003907_D009369,,
770957005,false,true,5,2015-08-14T20:44:00,,No Relation,0.8302,D005978,GSH,D009369,tumor,We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549).,9988757_2,9988757_D005978_D009369,,
770957006,false,true,5,2015-08-14T22:10:00,,No Relation,1,D003907,dexamethasone,D009336,necrosis,We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549).,9988757_2,9988757_D003907_D009336,,
770957007,false,true,5,2015-08-14T21:47:00,,No Relation,0.7996,D005978,GSH,D009336,necrosis,We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549).,9988757_2,9988757_D005978_D009336,,
770957008,false,true,5,2015-08-14T20:40:00,,No Relation,1,D003907,dexamethasone,D009369,tumor,We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549).,9988757_2,9988757_D003907_D009369,,
770957009,false,true,5,2015-08-15T00:47:00,,No Relation,1,D011241,prednisone,D006333,heart failure,The 2 patients with active inflammation received prednisone (1 mg. kg-1. d-1 for 4 weeks followed by 0.33 mg. kg-1. d-1 for 5 months) and azathioprine (2 mg. kg-1. d-1 for 5 months) in addition to conventional drug therapy for heart failure.,10077512_6,10077512_D011241_D006333,,
770957010,false,true,5,2015-08-15T02:18:00,,No Relation,1,D001379,azathioprine,D006333,heart failure,The 2 patients with active inflammation received prednisone (1 mg. kg-1. d-1 for 4 weeks followed by 0.33 mg. kg-1. d-1 for 5 months) and azathioprine (2 mg. kg-1. d-1 for 5 months) in addition to conventional drug therapy for heart failure.,10077512_6,10077512_D001379_D006333,,
770957011,false,true,5,2015-08-15T01:23:00,,No Relation,1,D011241,prednisone,D007249,inflammation,The 2 patients with active inflammation received prednisone (1 mg. kg-1. d-1 for 4 weeks followed by 0.33 mg. kg-1. d-1 for 5 months) and azathioprine (2 mg. kg-1. d-1 for 5 months) in addition to conventional drug therapy for heart failure.,10077512_6,10077512_D011241_D007249,,
770957012,false,true,5,2015-08-14T20:49:00,,No Relation,1,D001379,azathioprine,D007249,inflammation,The 2 patients with active inflammation received prednisone (1 mg. kg-1. d-1 for 4 weeks followed by 0.33 mg. kg-1. d-1 for 5 months) and azathioprine (2 mg. kg-1. d-1 for 5 months) in addition to conventional drug therapy for heart failure.,10077512_6,10077512_D001379_D007249,,
770957013,false,true,5,2015-08-14T23:45:00,,No Relation,1,D019797,MIBG,D009369,Carcinoid tumours/breast cancer,Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.,10197087_0,10197087_D019797_D009369,,
770957014,false,true,5,2015-08-15T01:44:00,,No Relation,1,C081788,pentetreotide,D009369,Carcinoid tumours/breast cancer,Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.,10197087_0,10197087_C081788_D009369,,
770957015,false,true,5,2015-08-15T01:49:00,,No Relation,1,D019793,fluorescein,D001237,asphyxia,"Superfusion of PAF over the cortex induced a dose-dependent increase in leukocyte adherence to cerebral venules and leakage of fluorescein; with 1 micromol/L PAF, the magnitude of adherence and BBB breakdown was similar to that seen during reoxygenation after 9 minutes of asphyxia.",10197511_4,10197511_D019793_D001237,,
770957016,false,true,5,2015-08-14T23:17:00,,No Relation,1,D013134,spiperone,D012559,schizophrenia,3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.,10202608_0,10202608_D013134_D012559,,
770957017,false,true,5,2015-08-14T20:46:00,,No Relation,0.5871,D013134,spiperone,D012559,schizophrenic/schizophrenia,The aim of this study was to determine whether spiperone binding to lymphocytes could serve as a biological marker of susceptibility to schizophrenia and schizophrenic spectrum disorders or as a measure of response to neuroleptic treatment.,10202608_1,10202608_D013134_D012559,,
770957018,false,true,5,2015-08-15T00:19:00,,No Relation,1,D013134,spiperone,D012569,schizotypal personality disorder,"Lymphocyte spiperone binding parameters (Bmax, KD) were assessed in 13 patients with schizophrenia and 4 patients with schizotypal personality disorder, all neuroleptic naive, and in 19 age- and sex-matched control subjects.",10202608_2,10202608_D013134_D012569,,
770957019,false,true,5,2015-08-15T00:51:00,,No Relation,0.8121,D013134,spiperone,D012559,schizophrenia,"Lymphocyte spiperone binding parameters (Bmax, KD) were assessed in 13 patients with schizophrenia and 4 patients with schizotypal personality disorder, all neuroleptic naive, and in 19 age- and sex-matched control subjects.",10202608_2,10202608_D013134_D012559,,
770957020,false,true,5,2015-08-14T23:33:00,,No Relation,1,D003609,actinomycin,D004828,localized disease,Seven patients had localized disease (stage I/II) and the six surviving patients received chemotherapy with vincristine and actinomycin; no patient received radiotherapy.,10212915_6,10212915_D003609_D004828,,
770957021,false,true,5,2015-08-15T01:54:00,,No Relation,1,D014750,vincristine,D004828,localized disease,Seven patients had localized disease (stage I/II) and the six surviving patients received chemotherapy with vincristine and actinomycin; no patient received radiotherapy.,10212915_6,10212915_D014750_D004828,,
770957022,false,true,5,2015-08-14T20:36:00,,Direct,0.6225,D000109,ACh/acetylcholine,D000544,AD/Alzheimer's disease,Alzheimer's disease (AD) is associated with a deficiency of acetylcholine (ACh) in the forebrain that correlates with brain pathology and cognitive dysfunction.,10332937_1,10332937_D000109_D000544,,
770957023,false,true,5,2015-08-15T00:31:00,,No Relation,0.5987,D000109,ACh/acetylcholine,D004108,brain pathology,Alzheimer's disease (AD) is associated with a deficiency of acetylcholine (ACh) in the forebrain that correlates with brain pathology and cognitive dysfunction.,10332937_1,10332937_D000109_D004108,,
770957024,false,true,5,2015-08-14T22:02:00,,No Relation,0.4057,D000109,ACh/acetylcholine,D003072,cognitive dysfunction,Alzheimer's disease (AD) is associated with a deficiency of acetylcholine (ACh) in the forebrain that correlates with brain pathology and cognitive dysfunction.,10332937_1,10332937_D000109_D003072,,
770957025,false,true,5,2015-08-15T00:11:00,,No Relation,1,C076946,Donepezil,C535860,HCI,"Donepezil HCI represents a new chemical class of AChE inhibitors, the piperidines.",10332937_4,10332937_C076946_C535860,,
770957026,false,true,5,2015-08-15T02:18:00,,No Relation,1,D010880,piperidines,C535860,HCI,"Donepezil HCI represents a new chemical class of AChE inhibitors, the piperidines.",10332937_4,10332937_D010880_C535860,,
770957027,false,true,5,2015-08-15T00:54:00,,No Relation,1,C076946,donepezil,D000544,AD,"In clinical trials, donepezil has been shown to improve significantly cognition and global function in patients with mild to moderately severe AD, and has demonstrated an excellent tolerability and safety profile.",10332937_5,10332937_C076946_D000544,,
770957028,false,true,5,2015-08-14T20:40:00,,No Relation,1,C076946,donepezil,D000544,AD,"These benefits, as well as a simple, once-daily dosing regimen, make donepezil a viable therapeutic option for AD patients.",10332937_6,10332937_C076946_D000544,,
770957029,false,true,5,2015-08-15T01:40:00,,No Relation,1,D000728,androgen,D011471,prostate cancer,Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer.,10337657_0,10337657_D000728_D011471,,
770957030,false,true,5,2015-08-15T00:54:00,,No Relation,1,D000728,androgen,D011471,PCa/prostate cancer,We undertook the present analysis to evaluate the effect of NHT on pathologic stage of PCa and resection limit status in patients with prostate cancer and treated with total androgen ablation either for three or six months before RP.,10337657_6,10337657_D000728_D011471,,
770957031,false,true,5,2015-08-14T22:38:00,,No Relation,0.8139,D000728,androgen,D009369,tumours,"114 patients were clinical stage B whereas 41 were clinical stage C. After three months of total androgen ablation, pathological stage B was more prevalent among patients with clinical B tumours, compared with untreated patients (57% in treated patients vs. 36% in untreated).",10337657_12,10337657_D000728_D009369,,
770957032,false,true,5,2015-08-14T23:16:00,,No Relation,1,D014443,tyrosine,D009369,tumors,"Northern and Western blots and tyrosine phosphorylation analysis showed that the HGF receptor was overexpressed and functional in all five tumors, as well as in two additional tumors.",10359528_5,10359528_D014443_D009369,,
770957033,false,true,5,2015-08-14T20:40:00,,No Relation,1,D002857,chromium,D003872,dermatitis,Therapeutic review: is ascorbic acid of value in chromium poisoning and chromium dermatitis?,10382555_0,10382555_D002857_D003872,,
770957034,false,true,5,2015-08-14T20:36:00,,Direct,0.602,D002857,chromium,D011041,poisoning,Therapeutic review: is ascorbic acid of value in chromium poisoning and chromium dermatitis?,10382555_0,10382555_D002857_D011041,,
770957035,false,true,5,2015-08-15T02:17:00,,No Relation,0.8053,D001205,ascorbic acid,D003872,dermatitis,Therapeutic review: is ascorbic acid of value in chromium poisoning and chromium dermatitis?,10382555_0,10382555_D001205_D003872,,
770957036,false,true,5,2015-08-14T23:27:00,,No Relation,1,D001205,ascorbic acid,D011041,poisoning,Therapeutic review: is ascorbic acid of value in chromium poisoning and chromium dermatitis?,10382555_0,10382555_D001205_D011041,,
770957037,false,true,5,2015-08-15T02:21:00,,Direct,1,C074702,chromium(VI),D014456,ulcers,Repeated topical exposure to chromium(VI) may cause an allergic contact dermatitis or the formation of chrome ulcers.,10382555_1,10382555_C074702_D014456,,
770957038,false,true,5,2015-08-14T22:23:00,'May' could make the third option right as well.,Direct,1,C074702,chromium(VI),D011695,allergic,Repeated topical exposure to chromium(VI) may cause an allergic contact dermatitis or the formation of chrome ulcers.,10382555_1,10382555_C074702_D011695,,
770957039,false,true,5,2015-08-15T00:33:00,,Direct,1,C074702,chromium(VI),D003872,dermatitis,Repeated topical exposure to chromium(VI) may cause an allergic contact dermatitis or the formation of chrome ulcers.,10382555_1,10382555_C074702_D003872,,
770957040,false,true,5,2015-08-15T02:10:00,,Direct,1,C074702,chromium(VI),D002056,skin burns,"Systemic toxicity may occur following the ingestion of a chromium(VI) salt, from chromium(VI)-induced skin burns, or from inhalation of chromium(VI) occurring occupationally.",10382555_2,10382555_C074702_D002056,,
770957041,false,true,5,2015-08-14T20:43:00,,Direct,1,C074702,chromium(VI),D064420,toxicity,"Systemic toxicity may occur following the ingestion of a chromium(VI) salt, from chromium(VI)-induced skin burns, or from inhalation of chromium(VI) occurring occupationally.",10382555_2,10382555_C074702_D064420,,
770957042,false,true,5,2015-08-15T00:47:00,,No Relation,0.5975,C074702,chromium(VI),D011041,poisoning,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_C074702_D011041,,
770957043,false,true,5,2015-08-14T23:18:00,,No Relation,1,D001205,ascorbic acid,D003872,dermatitis,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_D001205_D003872,,
770957044,false,true,5,2015-08-15T01:59:00,,No Relation,1,D001205,ascorbic acid,D011041,poisoning,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_D001205_D011041,,
770957045,false,true,5,2015-08-15T00:45:00,,No Relation,0.6099,D002857,chromium,D003872,dermatitis,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_D002857_D003872,,
770957046,false,true,5,2015-08-14T20:47:00,,No Relation,0.5914,D002857,chromium,D011041,poisoning,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_D002857_D011041,,
770957047,false,true,5,2015-08-14T20:47:00,,No Relation,1,C074702,chromium(VI),D003872,dermatitis,The administration of exogenous ascorbic acid has been advocated therefore in the treatment of systemic chromium poisoning and chromium dermatitis to enhance the extracellular reduction of chromium(VI) to the less bioavailable chromium(III).,10382555_5,10382555_C074702_D003872,,
770957048,false,true,5,2015-08-15T00:15:00,,Direct,0.7805,D001205,ascorbic acid,D064420,toxicity,"However, the administration of parenteral ascorbic acid more than 2 hours after parenteral chromate in these experimental studies did not protect against renal damage, and parenteral ascorbic acid given 3 hours postparenteral chromate increased toxicity.",10382555_9,10382555_D001205_D064420,,
770957049,false,true,5,2015-08-15T02:02:00,,No Relation,1,D001205,ascorbic acid,D006177,renal damage,"However, the administration of parenteral ascorbic acid more than 2 hours after parenteral chromate in these experimental studies did not protect against renal damage, and parenteral ascorbic acid given 3 hours postparenteral chromate increased toxicity.",10382555_9,10382555_D001205_D006177,,
770957050,false,true,5,2015-08-15T02:57:00,,Direct,0.5978,D002857,chromium,D011041,poisoning,"In addition, there is no confirmed clinical evidence that the administration of ascorbic acid lessens morbidity or mortality in systemic chromium poisoning.",10382555_10,10382555_D002857_D011041,,
770957051,false,true,5,2015-08-14T23:57:00,It's 'chromium poisoning' and not just 'poisoning',No Relation,1,D001205,ascorbic acid,D011041,poisoning,"In addition, there is no confirmed clinical evidence that the administration of ascorbic acid lessens morbidity or mortality in systemic chromium poisoning.",10382555_10,10382555_D001205_D011041,,
770957052,false,true,5,2015-08-14T20:54:00,,No Relation,1,D001205,ascorbic acid,D014456,ulcers,Topical 10% ascorbic acid has been claimed to reduce significantly the healing time of experimentally induced chrome ulcers in guinea pigs.,10382555_12,10382555_D001205_D014456,,
770957053,false,true,5,2015-08-14T22:48:00,,No Relation,1,D001205,ascorbic acid,D003872,dermatitis,"Several case reports suggest that topical ascorbic acid is effective in the management of chromium dermatitis but this has not been confirmed in controlled clinical trials and, moreover, the practical difficulties of frequent application are likely to limit its usefulness.",10382555_14,10382555_D001205_D003872,,
770957054,false,true,5,2015-08-14T23:19:00,,No Relation,1,D001205,ascorbic acid,D064420,toxicity,"Based on experimental studies, substantial amounts of ascorbic acid would need to be administered, preferably parenterally, soon after exposure to prevent systemic toxicity from chromium(VI) in humans.",10382555_15,10382555_D001205_D064420,,
770957055,false,true,5,2015-08-14T20:36:00,,Direct,1,C074702,chromium(VI),D064420,toxicity,"Based on experimental studies, substantial amounts of ascorbic acid would need to be administered, preferably parenterally, soon after exposure to prevent systemic toxicity from chromium(VI) in humans.",10382555_15,10382555_C074702_D064420,,
770957056,false,true,5,2015-08-14T20:39:00,,No Relation,0.6043,D001205,ascorbic acid,D051437,renal failure,"However, as ascorbic acid is a metabolic precursor of oxalate, the administration of ascorbic acid in high dose could lead to acute oxalate nephropathy, particularly in the presence of renal failure.",10382555_16,10382555_D001205_D051437,,
770957057,false,true,5,2015-08-15T01:52:00,,Direct,1,D001205,ascorbic acid,D000208,acute oxalate nephropathy,"However, as ascorbic acid is a metabolic precursor of oxalate, the administration of ascorbic acid in high dose could lead to acute oxalate nephropathy, particularly in the presence of renal failure.",10382555_16,10382555_D001205_D000208,,
770957058,false,true,5,2015-08-14T20:45:00,,Direct,0.6032,D002857,chromium,D011041,poisoning,"While smaller doses of ascorbic acid (e.g., 10 g intravenously) are not toxic, such doses probably will not reduce the mortality from systemic chromium poisoning.",10382555_17,10382555_D002857_D011041,,
770957059,false,true,5,2015-08-14T22:27:00,,No Relation,1,D001205,ascorbic acid,D011041,poisoning,"While smaller doses of ascorbic acid (e.g., 10 g intravenously) are not toxic, such doses probably will not reduce the mortality from systemic chromium poisoning.",10382555_17,10382555_D001205_D011041,,
770957060,false,true,5,2015-08-15T00:38:00,,No Relation,1,D001205,ascorbic acid,D064420,toxicity,There is currently insufficient evidence to advocate the use of ascorbic acid in the management of systemic chromium toxicity.,10382555_18,10382555_D001205_D064420,,
770957061,false,true,5,2015-08-14T22:22:00,,Direct,0.8003,D002857,chromium,D064420,toxicity,There is currently insufficient evidence to advocate the use of ascorbic acid in the management of systemic chromium toxicity.,10382555_18,10382555_D002857_D064420,,
770957062,false,true,5,2015-08-15T00:15:00,,No Relation,0.8136,D002784,cholesterol,D007511,ischemic,"Acute ischemic events during the treatment period and a persistently elevated serum cholesterol thereafter are observations of particular concern in these patients, and the underlying basic mechanisms are unknown to date.",10383804_2,10383804_D002784_D007511,,
770957063,false,true,5,2015-08-15T01:43:00,,No Relation,1,D005047,etoposide,D009369,testicular cancer,"To evaluate etoposide, which is part of the standard treatment for testicular cancer, as a potential cause of atherogenesis in an experimental model.",10383804_3,10383804_D005047_D009369,,
770957064,false,true,5,2015-08-15T02:13:00,,No Relation,1,D019787,linoleic acid,D009369,tumor/cancer,Conjugated linoleic acid inhibits the growth of a number of human cancer cell lines and suppresses chemically-induced tumor development at a number of sites in animal models.,10386321_3,10386321_D019787_D009369,,
770957065,false,true,5,2015-08-14T23:46:00,,No Relation,0.8198,D019787,linoleic acid,D009369,tumors,"As little as 0.1% of dietary conjugated linoleic acid inhibits the development of rat mammary tumors, independent of the amount and type of fat in the diet.",10386321_4,10386321_D019787_D009369,,
770957066,false,true,5,2015-08-14T23:43:00,,No Relation,0.8026,D013110,sphingosine,D063646,suppression of carcinogenesis,"Sphingomyelin, through its metabolites ceramide and sphingosine, participates in multiple antiproliferative pathways associated with suppression of carcinogenesis.",10386321_5,10386321_D013110_D063646,,
770957067,false,true,5,2015-08-14T20:39:00,,No Relation,0.8138,C105791,auristatin PE,D008258,Waldenstrom's macroglobulinemia,"A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.",10402249_0,10402249_C105791_D008258,,
770957068,false,true,5,2015-08-14T20:42:00,,No Relation,0.7976,C105791,auristatin PE,D009369,tumor,"A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.",10402249_0,10402249_C105791_D009369,,
770957069,false,true,5,2015-08-14T21:33:00,,No Relation,1,C105791,auristatin PE,D009369,tumor,"In this study, we investigated the anti-tumor effects of auristatin PE (a structural modification of the marine, shell-less mollusk peptide constituent dolastatin 10).",10402249_3,10402249_C105791_D009369,,
770957070,false,true,5,2015-08-15T00:28:00,,No Relation,1,C105791,Auristatin PE,D008258,WM,"Auristatin PE or dolastatin 10 were added to triplicate wells and cell count and viability were assessed after 24, 48 and 72 h. Results showed that both agents were active against WSU-WM, and were able to induce complete growth inhibition at 100 pg/ml.",10402249_5,10402249_C105791_D008258,,
770957071,false,true,5,2015-08-14T20:49:00,,No Relation,1,C105791,auristatin PE,D009369,Tumor,"Tumor growth inhibition (T/C), tumor growth delay (T-C), and log10 kill for auristatin PE and dolastatin 10 were 0%, 18 days, 2.83 and 67%, 2 days, 0.06, respectively.",10402249_9,10402249_C105791_D009369,,
770957072,false,true,5,2015-08-14T21:24:00,,No Relation,0.805,C105791,auristatin PE,D009369,tumor,The activity of auristatin PE should be evaluated in other tumor types and in clinical trials.,10402249_15,10402249_C105791_D009369,,
770957073,false,true,5,2015-08-14T23:09:00,,No Relation,1,D014810,vitamin E,D002386,cataract,The role of past intake of vitamin E in early cataract changes.,10420210_0,10420210_D014810_D002386,,
770957074,false,true,5,2015-08-14T22:51:00,,No Relation,1,D014810,vitamin E,D002386,cataract,We examined the association between prior supplementation of vitamin E and early cataract changes in volunteers currently enrolled in the cross-sectional VECAT study.,10420210_1,10420210_D014810_D002386,,
770957075,false,true,5,2015-08-15T02:00:00,,No Relation,1,D014810,Vitamin E,D002386,Cataract,"The Vitamin E and Cataract Prevention Study (VECAT) is a clinical trial currently in progress, designed to assess the affect of vitamin E supplementation on the development and progression of cataract and age-related macular degeneration.",10420210_2,10420210_D014810_D002386,,
770957076,false,true,5,2015-08-15T00:54:00,,No Relation,0.8178,D014810,Vitamin E,D008268,macular degeneration,"The Vitamin E and Cataract Prevention Study (VECAT) is a clinical trial currently in progress, designed to assess the affect of vitamin E supplementation on the development and progression of cataract and age-related macular degeneration.",10420210_2,10420210_D014810_D008268,,
770957077,false,true,5,2015-08-14T20:44:00,,No Relation,1,D014810,vitamin E,D003318,nuclear opacity/NO,The levels of nuclear opacity (NO) were not statistically different between those who reported intake and those with no prior vitamin E supplementation.,10420210_8,10420210_D014810_D003318,,
770957078,false,true,5,2015-08-14T22:46:00,,No Relation,1,D014810,vitamin E,D002386,cataracts,Prior vitamin E supplementation may protect VECAT participants from developing at least early cortical cataracts.,10420210_9,10420210_D014810_D002386,,
770957079,false,true,5,2015-08-14T23:32:00,,No Relation,1,D000109,acetylcholine,D055090,trachea,Modulation of acetylcholine release from parasympathetic nerves innervating guinea-pig and human trachea by endomorphin-1 and -2.,10422636_0,10422636_D000109_D055090,,
770957080,false,true,5,2015-08-14T20:40:00,,No Relation,1,D009270,naloxone,D055090,trachea,"Endomorphin-1 and -2 (mu-opioid receptor agonists) produced a concentration-dependent and naloxone-sensitive inhibition of cholinergic contractile responses in guinea-pig trachea (at 10 microM, 46.1 +/- 8.0% and 33.8 +/- 8.6%, respectively).",10422636_1,10422636_D009270_D055090,,
770957081,false,true,5,2015-08-15T00:59:00,,No Relation,1,D000109,acetylcholine,D055090,trachea,"Endomorphin-1 and -2 also inhibited electrically-evoked acetylcholine release from cholinergic nerves innervating guinea-pig (at 0.1 microM, 41.8 +/- 10.9%; at 1 microM 60.1 +/- 6.3%, respectively) and human trachea (at 10 microM, 76.2 +/- 18.1%, and 77.7 +/- 14.3%, respectively).",10422636_2,10422636_D000109_D055090,,
770957082,false,true,5,2015-08-14T22:17:00,,No Relation,1,D009270,Naloxone,D055090,trachea,"Naloxone prevented the inhibition by endomorphin-1 and -2 in both guinea-pig and human trachea, suggesting that these peptides can inhibit cholinergic, parasympathetic neurotransmission to the airways via the activation of classical opioid receptors.",10422636_3,10422636_D009270_D055090,,
770957083,false,true,5,2015-08-14T20:49:00,,Direct,1,D016595,misoprostol,D005316,fetal distress,"Some trials also indicate increased frequencies of meconium passage, neonatal acidemia, and cesarean delivery for fetal distress in women receiving higher doses of misoprostol.",10454679_6,10454679_D016595_D005316,,
770957084,false,true,5,2015-08-14T22:01:00,,Direct,1,D016595,misoprostol,C537358,acidemia,"Some trials also indicate increased frequencies of meconium passage, neonatal acidemia, and cesarean delivery for fetal distress in women receiving higher doses of misoprostol.",10454679_6,10454679_D016595_C537358,,
770957085,false,true,5,2015-08-14T22:02:00,,No Relation,1,D009569,nitric oxide,D001249,asthma,Circadian variation in exhaled nitric oxide in nocturnal asthma.,10461936_0,10461936_D009569_D001249,,
770957086,false,true,5,2015-08-15T00:27:00,,No Relation,1,D009569,nitric oxide,D007249,inflammation,"Because exhaled nitric oxide (ENO) measurement appears to be a noninvasive marker of airway inflammation, we examined the hypothesis that ENO would increase at night.",10461936_2,10461936_D009569_D007249,,
770957087,false,true,5,2015-08-14T21:25:00,,Direct,0.5946,D009569,nitric oxide,D001249,asthma,"The significant decrease in ENO in nocturnal asthma may reflect an important chronobiological defect in the endogenous production and/or increased disposition of nitric oxide, which in view of its bronchodilator action, could play a role in nocturnal exacerbations of asthma.",10461936_9,10461936_D009569_D001249,,
770957088,false,true,5,2015-08-15T00:28:00,,No Relation,1,D016572,cyclosporin,C536463,neurological involvement,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D016572_C536463,,
770957089,false,true,5,2015-08-14T20:44:00,,No Relation,1,D011239,prednisolone,C536463,neurological involvement,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D011239_C536463,,
770957090,false,true,5,2015-08-14T20:49:00,,No Relation,1,D016572,cyclosporin,D055952,Cogan's syndrome,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D016572_D055952,,
770957091,false,true,5,2015-08-15T01:59:00,,No Relation,0.7894,D011239,prednisolone,D007249,inflammation,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D011239_D007249,,
770957092,false,true,5,2015-08-14T23:14:00,,No Relation,1,D011239,prednisolone,D055952,Cogan's syndrome,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D011239_D055952,,
770957093,false,true,5,2015-08-15T02:10:00,,No Relation,1,D016572,cyclosporin,D007249,inflammation,We describe a case of Cogan's syndrome with neurological involvement in which early treatment with combination therapy (prednisolone and cyclosporin) failed to bring ear inflammation under control.,10464564_4,10464564_D016572_D007249,,
770957094,false,true,5,2015-08-14T23:29:00,,No Relation,0.8008,D013739,testosterone,D010024,osteoporosis,The effects of testosterone on osteoporosis in men.,10468898_0,10468898_D013739_D010024,,
770957095,false,true,5,2015-08-15T02:17:00,,No Relation,0.7987,D013739,testosterone,D010024,osteoporosis,"Although the pathogenesis of osteoporosis in men is multi-factorial, testosterone is known to play an important role in the maintenance of the male skeleton.",10468898_1,10468898_D013739_D010024,,
770957096,false,true,5,2015-08-14T20:39:00,,No Relation,1,D013739,Testosterone,D010024,hypogonadal osteoporosis,"Testosterone replacement therapy improves bone density in men with hypogonadal osteoporosis, particularly if the epiphyses are still open.",10468898_3,10468898_D013739_D010024,,
770957097,false,true,5,2015-08-15T02:25:00,,No Relation,1,D013739,testosterone,C537700,idiopathic osteoporosis,"There is no well-established treatment for idiopathic osteoporosis in men, but testosterone supplementation may prove to be useful.",10468898_4,10468898_D013739_C537700,,
770957098,false,true,5,2015-08-14T22:51:00,,No Relation,1,D009569,nitric oxide,D018496,hyperoxia,Effects of exogenous nitric oxide and hyperoxia on lung fibroblast viability and DNA fragmentation.,10471386_0,10471386_D009569_D018496,,
770957099,false,true,5,2015-08-14T20:43:00,,No Relation,1,D009569,NO,D004487,cytotoxicity,"Primary cultures of normal human lung fibroblasts were exposed for 4 h to room air (RA), 80% oxygen, NO (at either 20 or 50 ppm) blended with RA, or NO blended with 80% O(2), then incubated for 24 to 72 h. Cell viability was determined by fluorescence viability/cytotoxicity assay and DNA fragmentation by TUNEL assay.",10471386_4,10471386_D009569_D004487,,
770957100,false,true,5,2015-08-14T23:26:00,,No Relation,1,D010100,oxygen,D004487,cytotoxicity,"Primary cultures of normal human lung fibroblasts were exposed for 4 h to room air (RA), 80% oxygen, NO (at either 20 or 50 ppm) blended with RA, or NO blended with 80% O(2), then incubated for 24 to 72 h. Cell viability was determined by fluorescence viability/cytotoxicity assay and DNA fragmentation by TUNEL assay.",10471386_4,10471386_D010100_D004487,,
770957101,false,true,5,2015-08-14T22:17:00,,No Relation,1,D013481,O(2),D004487,cytotoxicity,"Primary cultures of normal human lung fibroblasts were exposed for 4 h to room air (RA), 80% oxygen, NO (at either 20 or 50 ppm) blended with RA, or NO blended with 80% O(2), then incubated for 24 to 72 h. Cell viability was determined by fluorescence viability/cytotoxicity assay and DNA fragmentation by TUNEL assay.",10471386_4,10471386_D013481_D004487,,
770957102,false,true,5,2015-08-14T22:51:00,,No Relation,1,D000305,corticosteroids,D011020,pneumocystis pneumonia,"The clinical picture was consistent with pneumocystis pneumonia, and antibiotic therapy with corticosteroids was initiated.",10498175_2,10498175_D000305_D011020,,
770957103,false,true,5,2015-08-15T00:47:00,,Direct,0.8059,D013256,steroids,D003453,cryptococcosis,"Sudden, rapid deterioration and death are rare consequences of disseminated cryptococcosis, and steroids may worsen the course of the disease.",10498175_5,10498175_D013256_D003453,,
770957104,false,true,5,2015-08-15T00:27:00,,No Relation,0.8283,D013256,steroids,D003643,death,"Sudden, rapid deterioration and death are rare consequences of disseminated cryptococcosis, and steroids may worsen the course of the disease.",10498175_5,10498175_D013256_D003643,,
770957105,false,true,5,2015-08-15T00:16:00,,No Relation,1,D008874,Midazolam,D013226,status epilepticus,Midazolam treatment of acute and refractory status epilepticus.,10516875_0,10516875_D008874_D013226,,
770957106,false,true,5,2015-08-14T22:18:00,,Direct,1,D001463,barbiturates,D012131,respiratory depression,"Refractory GCSE is often difficult to treat, and traditional therapy with barbiturates induces hypotension and respiratory depression and prolongs recovery.",10516875_3,10516875_D001463_D012131,,
770957107,false,true,5,2015-08-14T23:17:00,,Direct,1,D001463,barbiturates,D007022,hypotension,"Refractory GCSE is often difficult to treat, and traditional therapy with barbiturates induces hypotension and respiratory depression and prolongs recovery.",10516875_3,10516875_D001463_D007022,,
770957108,false,true,5,2015-08-15T00:26:00,,No Relation,1,D001463,barbiturates,D013226,GCSE,"Refractory GCSE is often difficult to treat, and traditional therapy with barbiturates induces hypotension and respiratory depression and prolongs recovery.",10516875_3,10516875_D001463_D013226,,
770957109,false,true,5,2015-08-15T00:36:00,,No Relation,1,D008874,Midazolam,D013226,GCSE,"Midazolam is particularly useful for treating acute GCSE because it has an imidazole ring that is open at low pH, allowing it to be dissolved in aqueous solution for intramuscular injection, but closed at physiologic pH, increasing lipophilicity and rendering good intramuscular absorption, brain penetration, and fast onset of action.",10516875_4,10516875_D008874_D013226,,
770957110,false,true,5,2015-08-14T23:52:00,,No Relation,1,C029899,imidazole,D013226,GCSE,"Midazolam is particularly useful for treating acute GCSE because it has an imidazole ring that is open at low pH, allowing it to be dissolved in aqueous solution for intramuscular injection, but closed at physiologic pH, increasing lipophilicity and rendering good intramuscular absorption, brain penetration, and fast onset of action.",10516875_4,10516875_C029899_D013226,,
770957111,false,true,5,2015-08-15T00:23:00,"Another ambiguous one. The [chemical] does induce less [disease]. Does it mean it causes the disease? Probably, but how much?",Direct,0.7985,D008874,midazolam,D007022,less hypotension,"For refractory GCSE, continuous i.v. midazolam infusion at 0.1-0.6 mg/kg/hr after a 0.2 mg/kg i.v. bolus is effective and has advantages over traditional therapies because it induces less hypotension and cardiorespiratory depression and can be easily titrated.",10516875_7,10516875_D008874_D007022,,
770957112,false,true,5,2015-08-14T23:36:00,,No Relation,1,D008874,midazolam,D013226,GCSE,"For refractory GCSE, continuous i.v. midazolam infusion at 0.1-0.6 mg/kg/hr after a 0.2 mg/kg i.v. bolus is effective and has advantages over traditional therapies because it induces less hypotension and cardiorespiratory depression and can be easily titrated.",10516875_7,10516875_D008874_D013226,,
770957113,false,true,5,2015-08-14T20:45:00,,No Relation,0.8101,D008874,midazolam,D003866,cardiorespiratory depression,"For refractory GCSE, continuous i.v. midazolam infusion at 0.1-0.6 mg/kg/hr after a 0.2 mg/kg i.v. bolus is effective and has advantages over traditional therapies because it induces less hypotension and cardiorespiratory depression and can be easily titrated.",10516875_7,10516875_D008874_D003866,,
770957114,false,true,5,2015-08-14T22:24:00,,No Relation,1,D015474,13-cis-retinoic acid,D009447,high-risk neuroblastoma,"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.",10519894_0,10519894_D015474_D009447,,
770957115,false,true,5,2015-08-14T22:22:00,,No Relation,1,C041359,terbinafine,D014008,tinea pedis,Effectiveness of treatment of severe tinea pedis with 1% terbinafine cream in members of the Japanese self-defense forces.,10546490_0,10546490_C041359_D014008,,
770957116,false,true,5,2015-08-14T23:35:00,,No Relation,1,C041359,terbinafine,D014008,tinea pedis,A clinical study was conducted to determine the efficacy of terbinafine cream in severe cases of tinea pedis.,10546490_1,10546490_C041359_D014008,,
770957117,false,true,5,2015-08-14T22:22:00,,No Relation,1,C041359,terbinafine,D014008,tinea pedis,These results suggested that terbinafine cream is a beneficial topical antifungal cream for severe tinea pedis.,10546490_7,10546490_C041359_D014008,,
770957118,false,true,5,2015-08-14T20:53:00,,Direct,1,D020748,mibefradil,D064420,Tacrolimus toxicity,Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.,10549098_0,10549098_D020748_D064420,,
770957119,false,true,5,2015-08-15T01:19:00,,Direct,0.4119,D016559,Tacrolimus,D064420,Tacrolimus toxicity,Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.,10549098_0,10549098_D016559_D064420,,
770957120,false,true,5,2015-08-14T20:53:00,,No Relation,1,D016572,cyclosporin A,D011565,psoriasis,Effects of cyclosporin A on immune activation markers in patients with active psoriasis.,10559581_0,10559581_D016572_D011565,,
770957121,false,true,5,2015-08-15T01:02:00,,No Relation,1,D016572,cyclosporin A/CsA,D011565,psoriasis,"The objective of this work was to investigate the presence of cellular and soluble activation molecules in the blood of patients with psoriasis, not responding to local treatment and to study the effect of cyclosporin A (CsA) on these markers.",10559581_2,10559581_D016572_D011565,,
770957122,false,true,5,2015-08-15T01:20:00,,No Relation,1,D016572,CsA,D011565,psoriasis,"Although there is evidence for systemic immune activation in psoriasis, sIL-2R is the most consistently increased activation marker, related to the Th1 immune response, that may be used as a marker for monitoring disease activity and response to treatment with CsA in psoriatic patients.",10559581_9,10559581_D016572_D011565,,
770957123,false,true,5,2015-08-14T23:35:00,,No Relation,1,D013004,somatostatin,D006470,bleeding,The efficacy of somatostatin and octreotide have been widely studied in the control of bleeding from oesophageal varices.,10567788_2,10567788_D013004_D006470,,
770957124,false,true,5,2015-08-14T23:48:00,,No Relation,1,D015282,octreotide,D006470,bleeding,The efficacy of somatostatin and octreotide have been widely studied in the control of bleeding from oesophageal varices.,10567788_2,10567788_D015282_D006470,,
770957125,false,true,5,2015-08-15T02:15:00,,No Relation,1,D013004,somatostatin,D006470,bleeding/haemorrhage,"Results from recent studies have indicated that somatostatin is an effective treatment for the control of non-variceal UGI bleeding in high-risk patients, i.e. those in whom haemorrhage does not cease spontaneously or is likely to recur.",10567788_6,10567788_D013004_D006470,,
770957126,false,true,5,2015-08-14T20:48:00,,No Relation,1,D013004,somatostatin,D006470,bleeding,"The efficacy of somatostatin in controlling bleeding in patients with non-variceal UGI bleeding at high risk of mortality upon admission, or rebleeding following endoscopy, coupled with an excellent safety and tolerability profile, suggests it may be a valuable therapeutic option in the management of non-variceal bleeding.",10567788_8,10567788_D013004_D006470,,
770957127,false,true,5,2015-08-14T22:18:00,,No Relation,0.8058,D014280,triglycerides,D006973,Hypertensive,"Hypertensive patients with microalbuminuria manifest greater levels of blood pressure, particularly at night, and higher serum levels of cholesterol, triglycerides, and uric acid than patients with normal UAE.",10585306_3,10585306_D014280_D006973,,
770957128,false,true,5,2015-08-14T20:50:00,,No Relation,1,D002784,cholesterol,D006973,Hypertensive,"Hypertensive patients with microalbuminuria manifest greater levels of blood pressure, particularly at night, and higher serum levels of cholesterol, triglycerides, and uric acid than patients with normal UAE.",10585306_3,10585306_D002784_D006973,,
770957129,false,true,5,2015-08-15T01:40:00,,No Relation,1,D014527,uric acid,D006973,Hypertensive,"Hypertensive patients with microalbuminuria manifest greater levels of blood pressure, particularly at night, and higher serum levels of cholesterol, triglycerides, and uric acid than patients with normal UAE.",10585306_3,10585306_D014527_D006973,,
770957130,false,true,5,2015-08-14T22:28:00,,No Relation,1,C023036,perfluorooctanoic acid,D006528,hepatoma,"Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells.",10590214_0,10590214_C023036_D006528,,
770957131,false,true,5,2015-08-15T01:49:00,,No Relation,1,C023036,PFOA,D018197,hepatoblastoma,"In the present study we demonstrate that treatment of human hepatoblastoma HepG2 cells with PFOA induces apoptosis, as well as perturbs the cell cycle.",10590214_2,10590214_C023036_D018197,,
770957132,false,true,5,2015-08-14T23:26:00,,No Relation,1,D011419,propidium iodide,D012892,typical nucleosomal fragmentation,"This apoptosis was characterized by electron microscopy, which revealed typical nucleosomal fragmentation (also observed as a 'DNA ladder' upon electrophoresis on agarose) and was quantitated using propidium iodide staining of cellular DNA and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay.",10590214_3,10590214_D011419_D012892,,
770957133,false,true,5,2015-08-14T20:57:00,,Direct,0.8026,C023036,PFOA,D009336,necrosis,"These findings indicate that in the presence of high concentrations of PFOA for long times, HepG2 cells undergo primary and secondary necrosis.",10590214_5,10590214_C023036_D009336,,
770957134,false,true,5,2015-08-14T21:57:00,,No Relation,1,D007294,inositol,D016736,APS,"These data suggest that a strategy for development of therapeutic agents for APS may be based on the use of small cyclic, organic oligoanions such as inositol derivatives to act as ligands for lysine residues at the PL binding site of beta 2GPI.",10624568_9,10624568_D007294_D016736,,
770957135,false,true,5,2015-08-14T21:02:00,,No Relation,1,D014443,tyrosine,C536227,hematopoiesis,"A retrospective study was conducted to quantitate plasma levels of 5 cytokines regulating hematopoiesis, namely, 2 stimulatory fms-like tyrosine kinase (FLT3-L) and stem cell factor (SCF) and 3 inhibitory growth factors tumor necrosis factor-alpha (TNFalpha), tumor growth factor-beta, and macrophage inflammatory protein (MIP-1alpha), by immunoassay in 43 patients enrolled in clinical trials at Garden State Cancer Center in Belleville, New Jersey.",10640965_7,10640965_D014443_C536227,,
770957136,false,true,5,2015-08-15T00:21:00,,No Relation,1,D014443,tyrosine,D009336,necrosis,"A retrospective study was conducted to quantitate plasma levels of 5 cytokines regulating hematopoiesis, namely, 2 stimulatory fms-like tyrosine kinase (FLT3-L) and stem cell factor (SCF) and 3 inhibitory growth factors tumor necrosis factor-alpha (TNFalpha), tumor growth factor-beta, and macrophage inflammatory protein (MIP-1alpha), by immunoassay in 43 patients enrolled in clinical trials at Garden State Cancer Center in Belleville, New Jersey.",10640965_7,10640965_D014443_D009336,,
770957137,false,true,5,2015-08-14T21:06:00,,No Relation,1,D014443,tyrosine,D009369,tumor,"A retrospective study was conducted to quantitate plasma levels of 5 cytokines regulating hematopoiesis, namely, 2 stimulatory fms-like tyrosine kinase (FLT3-L) and stem cell factor (SCF) and 3 inhibitory growth factors tumor necrosis factor-alpha (TNFalpha), tumor growth factor-beta, and macrophage inflammatory protein (MIP-1alpha), by immunoassay in 43 patients enrolled in clinical trials at Garden State Cancer Center in Belleville, New Jersey.",10640965_7,10640965_D014443_D009369,,
770957138,false,true,5,2015-08-15T01:03:00,,Indirect,0.4119,D017953,isocyanates,D001249,asthma,Animal studies have suggested that skin exposure to isocyanates may be an important risk factor for respiratory sensitization leading to asthma.,10642416_2,10642416_D017953_D001249,,
770957139,false,true,5,2015-08-15T01:02:00,,No Relation,1,D013256,steroids,D006177,structural damage,"Following steroids and hydroxyurea administration, the lesions on MRI disappeared, suggesting that the pathogenetic mechanism was reversible and did not cause significant structural damage.",10646028_2,10646028_D013256_D006177,,
770957140,false,true,5,2015-08-14T23:56:00,,No Relation,1,D006918,hydroxyurea,D006177,structural damage,"Following steroids and hydroxyurea administration, the lesions on MRI disappeared, suggesting that the pathogenetic mechanism was reversible and did not cause significant structural damage.",10646028_2,10646028_D006918_D006177,,
770957141,false,true,5,2015-08-15T02:31:00,,No Relation,1,C071315,Ramosetron,D020250,postoperative nausea and vomiting,Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery.,10648342_0,10648342_C071315_D020250,,
770957142,false,true,5,2015-08-14T23:43:00,,No Relation,1,C071315,ramosetron,D020250,PONV/prevention of postoperative nausea and vomiting,"In a prospective, randomized, double-blinded, placebo-controlled trial, we evaluated the efficacy of ramosetron at three different doses (0.15, 0.3, and 0.6 mg) for the prevention of postoperative nausea and vomiting (PONV) after gynecological surgery.",10648342_1,10648342_C071315_D020250,,
770957143,false,true,5,2015-08-14T20:53:00,,No Relation,1,C071315,ramosetron,D020250,PONV,"In conclusion, ramosetron 0.3 mg is an effective antiemetic for preventing PONV during 0-48 h after anesthesia in female patients undergoing gynecological surgery.",10648342_8,10648342_C071315_D020250,,
770957144,false,true,5,2015-08-15T01:54:00,,No Relation,1,C071315,ramosetron,D020250,postoperative nausea and vomiting,"This randomized, double-blinded, placebo-controlled trial in 120 women found the effective dose of ramosetron for preventing postoperative nausea and vomiting after gynecological surgery to be 0.3 mg.",10648342_10,10648342_C071315_D020250,,
770957145,false,true,5,2015-08-14T21:00:00,,No Relation,1,D000305,corticosteroids,D001249,bronchial asthma,Study of fluticasone propionate efficacy in the treatment of patients with bronchial asthma not controlled by other inhaled corticosteroids.,10660975_0,10660975_D000305_D001249,,
770957146,false,true,5,2015-08-15T00:00:00,,No Relation,1,C065382,fluticasone propionate,D001249,bronchial asthma,Study of fluticasone propionate efficacy in the treatment of patients with bronchial asthma not controlled by other inhaled corticosteroids.,10660975_0,10660975_C065382_D001249,,
770957147,false,true,5,2015-08-14T23:26:00,,No Relation,0.8156,D000305,corticosteroids,D001249,bronchial asthma/BA,"The aim of the study was to test the fluticasone propionate (FP) efficacy in the treatment of patients with bronchial asthma (BA), not controlled by high doses (more than 1 mg) of other inhaled corticosteroids.",10660975_1,10660975_D000305_D001249,,
770957148,false,true,5,2015-08-14T20:57:00,,No Relation,1,C065382,fluticasone propionate,D001249,bronchial asthma/BA,"The aim of the study was to test the fluticasone propionate (FP) efficacy in the treatment of patients with bronchial asthma (BA), not controlled by high doses (more than 1 mg) of other inhaled corticosteroids.",10660975_1,10660975_C065382_D001249,,
770957149,false,true,5,2015-08-15T01:31:00,,No Relation,1,D000305,corticosteroids,D001249,BA,Our results demonstrate improved efficacy of FP vs high doses of other inhaled corticosteroids in the treatment of moderate persistent and severe forms of BA.,10660975_14,10660975_D000305_D001249,,
770957150,false,true,5,2015-08-14T21:00:00,,No Relation,0.598,D002110,Caffeine,D007040,hypoventilation,"Caffeine can affect velocity in the middle cerebral artery during hyperventilation, hypoventilation, and thinking: a transcranial Doppler study.",10666980_0,10666980_D002110_D007040,,
770957151,false,true,5,2015-08-15T01:04:00,,No Relation,1,D002110,caffeine,D007040,hypoventilation,"Time-course analyses showed that VMCA (1) followed a triphasic pattern to increase over baselines during hypoventilation regardless of caffeine condition, (2) slowed below baselines during hyperventilation (with the degree of slowing attenuated under caffeine), and (3) increased over baselines during all cognitive activities (ranges 3.8-6.9%).",10666980_5,10666980_D002110_D007040,,
770957152,false,true,5,2015-08-15T01:03:00,,No Relation,1,D000242,cAMP,D020335,hypotonic challenge,"A hypotonic challenge, but not cAMP stimulation, was found to induce release of ATP measured by the luciferin-luciferase assay from both the murine mammary carcinoma cell line C127i and C127 cells stably transfected with the cDNA for human cystic fibrosis transmembrane conductance regulator (CFTR) protein (C127/CFTR).",10673540_2,10673540_D000242_D020335,,
770957153,false,true,5,2015-08-14T22:03:00,,No Relation,1,D000242,cAMP,D002277,carcinoma,"A hypotonic challenge, but not cAMP stimulation, was found to induce release of ATP measured by the luciferin-luciferase assay from both the murine mammary carcinoma cell line C127i and C127 cells stably transfected with the cDNA for human cystic fibrosis transmembrane conductance regulator (CFTR) protein (C127/CFTR).",10673540_2,10673540_D000242_D002277,,
770957154,false,true,5,2015-08-15T00:25:00,,No Relation,0.8065,D000255,ATP,D020335,hypotonic challenge,"A hypotonic challenge, but not cAMP stimulation, was found to induce release of ATP measured by the luciferin-luciferase assay from both the murine mammary carcinoma cell line C127i and C127 cells stably transfected with the cDNA for human cystic fibrosis transmembrane conductance regulator (CFTR) protein (C127/CFTR).",10673540_2,10673540_D000255_D020335,,
770957155,false,true,5,2015-08-15T02:03:00,,No Relation,1,D000255,ATP,D002277,carcinoma,"A hypotonic challenge, but not cAMP stimulation, was found to induce release of ATP measured by the luciferin-luciferase assay from both the murine mammary carcinoma cell line C127i and C127 cells stably transfected with the cDNA for human cystic fibrosis transmembrane conductance regulator (CFTR) protein (C127/CFTR).",10673540_2,10673540_D000255_D002277,,
770957156,false,true,5,2015-08-14T20:56:00,,No Relation,1,D000255,ATP,D020335,hypotonic,CFTR expression augmented swelling-induced ATP release by 10-20 times under hypotonic conditions (< or = 80 % osmolality).,10673540_3,10673540_D000255_D020335,,
770957157,false,true,5,2015-08-14T21:51:00,,No Relation,1,D020849,Raloxifene,D014082,Fracture,"Two randomized, double-blind, placebo-controlled trials in 11 US clinical research centers for the Fracture Intervention Trial and 180 centers in the United States and other countries for the Multiple Outcomes of Raloxifene Evaluation Trial.",10714731_4,10714731_D020849_D014082,,
770957158,false,true,5,2015-08-15T02:26:00,,No Relation,1,D020849,Raloxifene/raloxifene hydrochloride,D014082,Fracture,"Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).",10714731_5,10714731_D020849_D014082,,
770957159,false,true,5,2015-08-15T02:09:00,,No Relation,1,D020849,Raloxifene/raloxifene hydrochloride,D010024,BMD/osteoporosis,"Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).",10714731_5,10714731_D020849_D010024,,
770957160,false,true,5,2015-08-15T02:01:00,,No Relation,1,D019386,alendronate sodium,D010024,BMD/osteoporosis,"Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).",10714731_5,10714731_D019386_D010024,,
770957161,false,true,5,2015-08-15T01:44:00,,No Relation,1,D019386,alendronate sodium,D014082,Fracture,"Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).",10714731_5,10714731_D019386_D014082,,
770957162,false,true,5,2015-08-14T20:56:00,,No Relation,0.5971,D019386,alendronate,D010024,BMD,"Specifically, among women taking alendronate whose hip BMD decreased by more than 4% during the first year, 83% (95% confidence interval [CI], 82%-84%)had increases in hip BMD during the second year, with an overall mean increase of 4.7%.",10714731_8,10714731_D019386_D010024,,
770957163,false,true,5,2015-08-15T00:58:00,,No Relation,0.789,D020849,raloxifene,D010024,BMD,Our data suggest that most women who lose BMD during the first year of treatment with alendronate or raloxifene will gain BMD if the same treatment is continued for a second year.,10714731_11,10714731_D020849_D010024,,
770957164,false,true,5,2015-08-15T00:27:00,,No Relation,0.8064,D019386,alendronate,D010024,BMD,Our data suggest that most women who lose BMD during the first year of treatment with alendronate or raloxifene will gain BMD if the same treatment is continued for a second year.,10714731_11,10714731_D019386_D010024,,
770957165,false,true,5,2015-08-15T01:49:00,,Direct,1,D005472,5-fluorouracil,D007767,excessive lacrimation,Ocular side effects of systemic 5-fluorouracil therapy include excessive lacrimation which often resolves on cessation of therapy.,10726804_1,10726804_D005472_D007767,,
770957166,false,true,5,2015-08-14T20:57:00,,Direct,1,D005472,5-fluorouracil,D003251,stenosis,Severe stenosis of puncta and canaliculi may be associated with prolonged systemic 5-fluorouracil therapy.,10726804_5,10726804_D005472_D003251,,
770957167,false,true,5,2015-08-14T22:20:00,,Direct,1,D005472,5-fluorouracil,D064420,ocular toxicity,It is important for both the oncologist and ophthalmologist to be aware of the potential ocular toxicity of 5-fluorouracil.,10726804_6,10726804_D005472_D064420,,
770957168,false,true,5,2015-08-14T20:56:00,,No Relation,1,D002857,Cr,D009369,tumor,"In our improved model, tumor angiogenesis is determined by measuring the blood volume in an area of skin held in contact with a tumor cell-containing chamber, using 51Cr-labeled red blood cells (RBC).",10757446_2,10757446_D002857_D009369,,
770957169,false,true,5,2015-08-14T21:23:00,,No Relation,1,D002857,Cr,D016510,angiogenesis,"In our improved model, tumor angiogenesis is determined by measuring the blood volume in an area of skin held in contact with a tumor cell-containing chamber, using 51Cr-labeled red blood cells (RBC).",10757446_2,10757446_D002857_D016510,,
770957170,false,true,5,2015-08-15T01:47:00,,No Relation,1,C005066,borrelidin,D016510,angiogenesis,"Using the improved model, it was confirmed that TNP-470, a well-known inhibitor, and borrelidin, an antibiotic from Streptomyces rochei, significantly inhibited the WiDr cell-induced angiogenesis.",10757446_6,10757446_C005066_D016510,,
770957171,false,true,5,2015-08-14T22:24:00,,No Relation,0.7891,C005066,Borrelidin,D016510,angiogenesis,Borrelidin also inhibited spontaneous lung metastasis of B16-BL6 melanoma at the same dose that inhibited angiogenesis.,10757446_7,10757446_C005066_D016510,,
770957172,false,true,5,2015-08-15T01:46:00,,No Relation,0.8037,C005066,Borrelidin,D008545,melanoma,Borrelidin also inhibited spontaneous lung metastasis of B16-BL6 melanoma at the same dose that inhibited angiogenesis.,10757446_7,10757446_C005066_D008545,,
770957173,false,true,5,2015-08-14T20:55:00,,No Relation,0.8019,D020123,rapamycin,C580075,AML,"While inhibition of p70S6-kinase with rapamycin did not increase drug-induced apoptosis, PI3-kinase inhibition resulted in notable dephosphorylation of PKB, suggesting that the PI3-kinase/PKB survival pathway may play a major role in chemoresistance in AML.",10764145_6,10764145_D020123_C580075,,
770957174,false,true,5,2015-08-14T20:57:00,,No Relation,1,C014347,5-azadeoxycytidine/5-aza-dC,D011218,PWS,"Furthermore, treatment of PWS cells with the DNA methyltransferase inhibitor 5-azadeoxycytidine (5-aza-dC) induced demethylation of the SNURF-SNRPN CpG island and restoration of gene expression on the maternal allele.",10775525_4,10775525_C014347_D011218,,
770957175,false,true,5,2015-08-15T00:26:00,,No Relation,1,D059808,polyphenols,D009369,Cancer,Cancer chemoprevention by tea polyphenols.,10786933_0,10786933_D059808_D009369,,
770957176,false,true,5,2015-08-14T23:22:00,'Against' being the key term.,No Relation,0.7879,D059808,polyphenol,D063646,carcinogenesis,The inhibitory effects of tea against carcinogenesis have been attributed to the biologic activities of the polyphenol fraction in tea.,10786933_3,10786933_D059808_D063646,,
770957177,false,true,5,2015-08-14T23:18:00,,No Relation,1,D059808,polyphenols,D009369,tumor,This review summarizes experimental data on chemopreventive effects of tea polyphenols in various tumor bioassay systems.,10786933_4,10786933_D059808_D009369,,
770957178,false,true,5,2015-08-14T20:57:00,,No Relation,1,C045651,(-)-epigallocatechin-3-gallate/EGCG,D063646,carcinogenesis,"Many laboratory studies have demonstrated the inhibitory effects of green tea polyphenols, especially (-)-epigallocatechin-3-gallate (EGCG), on carcinogenesis in animals models.",10786933_5,10786933_C045651_D063646,,
770957179,false,true,5,2015-08-14T22:42:00,,No Relation,1,D059808,polyphenols,D063646,carcinogenesis,"Many laboratory studies have demonstrated the inhibitory effects of green tea polyphenols, especially (-)-epigallocatechin-3-gallate (EGCG), on carcinogenesis in animals models.",10786933_5,10786933_D059808_D063646,,
770957180,false,true,5,2015-08-14T20:53:00,,No Relation,0.8133,D059808,polyphenols,D009369,skin tumor,"The majority of these studies have been conducted in mouse skin tumor models, where tea polyphenols were used either as oral feeding in drinking water or in direct local application.",10786933_6,10786933_D059808_D009369,,
770957181,false,true,5,2015-08-15T01:46:00,,No Relation,0.8241,D059808,polyphenols,D009369,tumor,Most studies used 12-O-tetradecanoylphorbol-13-acetate (TPA) or ultraviolet (UV) radiation as the tumor promoter and found anticarcinogenic effects caused by green tea polyphenols.,10786933_7,10786933_D059808_D009369,,
770957182,false,true,5,2015-08-14T23:33:00,,No Relation,0.7967,C554292|D013755,12-O-tetradecanoylphorbol-13-acetate/TPA,D009369,tumor,Most studies used 12-O-tetradecanoylphorbol-13-acetate (TPA) or ultraviolet (UV) radiation as the tumor promoter and found anticarcinogenic effects caused by green tea polyphenols.,10786933_7,10786933_C554292|D013755_D009369,,
770957183,false,true,5,2015-08-14T20:54:00,,No Relation,1,D002110,Caffeine,D063646,tumorigenesis,Caffeine in tea was also important for tea to prevent tumorigenesis.,10786933_10,10786933_D002110_D063646,,
770957184,false,true,5,2015-08-14T20:57:00,,No Relation,0.6,D059808,polyphenols,D009369,cancer,The molecular mechanisms of the cancer chemopreventive effects of tea polyphenols are not completely understood.,10786933_11,10786933_D059808_D009369,,
770957185,false,true,5,2015-08-14T22:20:00,,No Relation,0.6086,D059808,polyphenols,D009369,tumor,"They are most likely related to the mechanisms of biochemical actions of tea polyphenols, which include antioxidative activities, modulation of xenobiotic metabolite enzymes and inhibition of tumor promotion.",10786933_12,10786933_D059808_D009369,,
770957186,false,true,5,2015-08-14T23:46:00,,No Relation,0.8044,D059808,polyphenols,D009369,cancer,"In addition, we have also proposed that tea polyphenols function as cancer chemopreventive agents through modulation of mitotic signal transduction.",10786933_13,10786933_D059808_D009369,,
770957187,false,true,5,2015-08-15T02:22:00,,No Relation,1,D005472,5-fluorouracil,D003108,colon carcinoma,"Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.",10791849_0,10791849_D005472_D003108,,
770957188,false,true,5,2015-08-15T01:35:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D015179,colorectal carcinoma,Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma.,10791849_1,10791849_D005472_D015179,,
770957189,false,true,5,2015-08-15T00:52:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D020159,Thymidylate synthase/TS,Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma.,10791849_1,10791849_D005472_D020159,,
770957190,false,true,5,2015-08-14T21:56:00,,No Relation,1,D005472,5-FU,D015179,colorectal carcinoma,Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS.,10791849_2,10791849_D005472_D015179,,
770957191,false,true,5,2015-08-15T01:17:00,,No Relation,1,D005472,5-FU,D009369,tumors,Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS.,10791849_2,10791849_D005472_D009369,,
770957192,false,true,5,2015-08-15T02:57:00,,No Relation,0.808,D005472,5-FU,D020159,TS,Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS.,10791849_2,10791849_D005472_D020159,,
770957193,false,true,5,2015-08-14T23:38:00,Used as treatment.,No Relation,1,D005472,5-FU,D003108,colon carcinoma,"TS, itself, may be a prognostic factor for colon carcinoma; and 5-FU adjuvant chemotherapy may be appropriate for colon carcinoma with high expression of TS.",10791849_11,10791849_D005472_D003108,,
770957194,false,true,5,2015-08-14T23:24:00,,No Relation,1,D005472,5-FU,D020159,TS,"TS, itself, may be a prognostic factor for colon carcinoma; and 5-FU adjuvant chemotherapy may be appropriate for colon carcinoma with high expression of TS.",10791849_11,10791849_D005472_D020159,,
770957195,false,true,5,2015-08-14T21:00:00,,No Relation,1,D013256,steroids,D001987,bronchiectasis,Inhaled steroids for bronchiectasis.,10796575_0,10796575_D013256_D001987,,
770957196,false,true,5,2015-08-14T23:03:00,,No Relation,1,D000305,corticosteroid,D001987,bronchiectasis,The Cochrane Airways Group RCT register and Cochrane Controlled Clinical Trials Register were searched using the following search terms; bronchiectasis AND [corticosteroid* OR beclomethasone OR budesonide OR fluticasone OR triamcinolone OR flunisolide].,10796575_4,10796575_D000305_D001987,,
770957197,false,true,5,2015-08-14T21:24:00,,No Relation,1,C065382,fluticasone,D001987,bronchiectasis,The Cochrane Airways Group RCT register and Cochrane Controlled Clinical Trials Register were searched using the following search terms; bronchiectasis AND [corticosteroid* OR beclomethasone OR budesonide OR fluticasone OR triamcinolone OR flunisolide].,10796575_4,10796575_C065382_D001987,,
770957198,false,true,5,2015-08-14T20:51:00,,No Relation,1,D014221,triamcinolone,D001987,bronchiectasis,The Cochrane Airways Group RCT register and Cochrane Controlled Clinical Trials Register were searched using the following search terms; bronchiectasis AND [corticosteroid* OR beclomethasone OR budesonide OR fluticasone OR triamcinolone OR flunisolide].,10796575_4,10796575_D014221_D001987,,
770957199,false,true,5,2015-08-15T00:43:00,,No Relation,1,C007734,flunisolide,D001987,bronchiectasis,The Cochrane Airways Group RCT register and Cochrane Controlled Clinical Trials Register were searched using the following search terms; bronchiectasis AND [corticosteroid* OR beclomethasone OR budesonide OR fluticasone OR triamcinolone OR flunisolide].,10796575_4,10796575_C007734_D001987,,
770957200,false,true,5,2015-08-14T20:55:00,,No Relation,1,D000305,corticosteroids,D001987,bronchiectasis,"In bronchiectasis, regular use of inhaled corticosteroids may improve lung function.",10796575_14,10796575_D000305_D001987,,
770957201,false,true,5,2015-08-15T00:54:00,,Direct,0.8233,D000305,corticosteroids,D002386,cataract,Risk of cataract among users of intranasal corticosteroids.,10808171_0,10808171_D000305_D002386,,
770957202,false,true,5,2015-08-14T23:53:00,,Direct,1,D000305,corticosteroid/corticosteroids,D002386,cataract,"Oral corticosteroid users are at increased risk of cataract, but the risk among intranasal corticosteroids users is unknown.",10808171_1,10808171_D000305_D002386,,
770957203,false,true,5,2015-08-14T23:57:00,It's 'intranasal steroids' and not just 'Steroids',No Relation,0.6194,D013256,steroids,D002386,cataract,Our purpose was to describe the risk of cataract among users of intranasal steroids.,10808171_2,10808171_D013256_D002386,,
770957204,false,true,5,2015-08-14T20:57:00,,Direct,0.6114,D013256,steroids,D002386,cataract,A retrospective observational cohort study of cataract incidence was conducted among users of oral and intranasal steroids identified from the United Kingdom-based General Practice Research Database with a nested case-control analysis to control for confounding factors.,10808171_3,10808171_D013256_D002386,,
770957205,false,true,5,2015-08-14T21:03:00,,No Relation,0.8256,D000305,corticosteroids,D002386,cataract,The incidence rate of cataract (1.0/1000 person-years) among users of intranasal corticosteroids was similar to the incidence rate among nonusers.,10808171_8,10808171_D000305_D002386,,
770957206,false,true,5,2015-08-14T21:47:00,,Direct,1,D000305,corticosteroid,D002386,cataract,"However, oral corticosteroid users were at higher risk of cataract (2.2/1000 person-years).",10808171_9,10808171_D000305_D002386,,
770957207,false,true,5,2015-08-14T21:48:00,,No Relation,1,D000305,corticosteroids,D002386,Cataract,Cataract risk did not increase with the number of prior prescriptions for intranasal corticosteroids.,10808171_11,10808171_D000305_D002386,,
770957208,false,true,5,2015-08-15T00:27:00,,No Relation,1,D000305,corticosteroids,D002386,cataracts,The use of intranasal corticosteroids was not associated with an increased risk of cataracts in this study population.,10808171_12,10808171_D000305_D002386,,
770957209,false,true,5,2015-08-14T23:49:00,,No Relation,0.5956,D014443,tyrosine,D003929,diabetes,"Expression of pancreatic islet MHC class I, insulin, and ICA 512 tyrosine phosphatase in low-dose streptozotocin-induced diabetes in mice.",10820150_0,10820150_D014443_D003929,,
770957210,false,true,5,2015-08-14T21:06:00,,Direct,0.8054,D013311,streptozotocin,D003929,diabetes,"Expression of pancreatic islet MHC class I, insulin, and ICA 512 tyrosine phosphatase in low-dose streptozotocin-induced diabetes in mice.",10820150_0,10820150_D013311_D003929,,
770957211,false,true,5,2015-08-14T22:39:00,,Direct,0.6053,D013311,streptozotocin,D003920,diabetes mellitus,Activated immune cells contribute to the development of diabetes mellitus in multiple low-dose streptozotocin-treated mice.,10820150_1,10820150_D013311_D003920,,
770957212,false,true,5,2015-08-14T20:53:00,,No Relation,0.7983,D004967,oestrogen,D009369,breast cancer,Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line.,10823131_0,10823131_D004967_D009369,,
770957213,false,true,5,2015-08-15T01:32:00,,Direct,0.6079,D004967,oestrogens,D009369,breast cancer,"In addition, oestrogens play an important role in breast cancer development, and oestrone sulphate (E1S) might be the main source of active oestrogens in the breast.",10823131_3,10823131_D004967_D009369,,
770957214,false,true,5,2015-08-15T00:55:00,,Direct,0.402,C017296,oestrone sulphate,D009369,breast cancer,"In addition, oestrogens play an important role in breast cancer development, and oestrone sulphate (E1S) might be the main source of active oestrogens in the breast.",10823131_3,10823131_C017296_D009369,,
770957215,false,true,5,2015-08-15T02:07:00,,No Relation,1,D004967,oestrogen,D009369,breast cancer,The aim of this study was to assess the effect of TGF-beta 2 on oestrogen synthesis in an attempt to understand the mechanism by which TGF-beta 2 may exert a protective effect in breast cancer.,10823131_4,10823131_D004967_D009369,,
770957216,false,true,5,2015-08-14T23:16:00,,Direct,0.5712,D004967,oestrogens,D009369,breast cancer,"In conclusion, TGF-beta 2 might exert a protective role in breast cancer by reducing the amount of active oestrogens present in the breast.",10823131_7,10823131_D004967_D009369,,
770957217,false,true,5,2015-08-14T20:47:00,,No Relation,1,C076029,olanzapine,D012559,schizophrenia,Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.,10831481_0,10831481_C076029_D012559,,
770957218,false,true,5,2015-08-15T01:16:00,,No Relation,1,C076029,olanzapine,D009461,deficit syndrome,The authors examined the effects of olanzapine on primary and secondary negative symptoms for patients with severe negative symptoms who did or did not have the deficit syndrome.,10831481_3,10831481_C076029_D009461,,
770957219,false,true,5,2015-08-15T01:19:00,,No Relation,1,C076029,olanzapine,D009461,deficit syndrome,"Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine.",10831481_4,10831481_C076029_D009461,,
770957220,false,true,5,2015-08-14T21:00:00,,No Relation,1,C076029,olanzapine,D012559,schizophrenia,"Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine.",10831481_4,10831481_C076029_D012559,,
770957221,false,true,5,2015-08-14T22:02:00,,No Relation,0.8076,C076029,olanzapine,D012559,schizophrenia,The results of this study suggest that olanzapine is efficacious for secondary negative symptoms in schizophrenia but fail to support the contention that olanzapine has a direct beneficial effect on primary negative symptoms.,10831481_9,10831481_C076029_D012559,,
770957222,false,true,5,2015-08-15T00:20:00,,No Relation,0.7928,D020888,vigabatrin,D004827,epilepsy,Visual impairment in children with epilepsy treated with vigabatrin.,10894216_0,10894216_D020888_D004827,,
770957223,false,true,5,2015-08-15T00:54:00,,No Relation,0.5941,D020888,vigabatrin,D006311,Visual impairment,Visual impairment in children with epilepsy treated with vigabatrin.,10894216_0,10894216_D020888_D006311,,
770957224,false,true,5,2015-08-14T20:47:00,,No Relation,0.7957,D020888,Vigabatrin,D012640,seizures,Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms.,10894216_1,10894216_D020888_D012640,,
770957225,false,true,5,2015-08-14T21:24:00,,No Relation,1,D020888,Vigabatrin,D004827,epileptic,Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms.,10894216_1,10894216_D020888_D004827,,
770957226,false,true,5,2015-08-15T02:15:00,,No Relation,1,D020888,Vigabatrin,D013035,spasms,Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms.,10894216_1,10894216_D020888_D013035,,
770957227,false,true,5,2015-08-14T23:14:00,,Direct,0.6074,D020888,vigabatrin,D006311,visual field constriction/VFC,"Recently, vigabatrin-induced visual field constriction (VFC) and abnormal ocular electrophysiological studies were reported.",10894216_2,10894216_D020888_D006311,,
770957228,false,true,5,2015-08-14T20:53:00,,Direct,0.8214,D020888,vigabatrin,D006311,VFC,"In summary, over half of the children treated with vigabatrin demonstrated VFC or abnormal ocular electrophysiological studies.",10894216_9,10894216_D020888_D006311,,
770957229,false,true,5,2015-08-15T01:45:00,,Direct,0.579,D020888,vigabatrin,D064420,toxicity,Perimetry seemed to be the most sensitive modality for identifying vigabatrin toxicity.,10894216_10,10894216_D020888_D064420,,
770957230,false,true,5,2015-08-15T00:02:00,,No Relation,0.5964,D020888,vigabatrin,D012640,seizures,"Although the incidence of vigabatrin-induced VFC is worrisome, in the context of intractable seizures or infantile spasms, therapeutic benefits must be weighed against risks.",10894216_12,10894216_D020888_D012640,,
770957231,false,true,5,2015-08-14T21:00:00,,Direct,0.6106,D020888,vigabatrin,D006311,VFC,"Although the incidence of vigabatrin-induced VFC is worrisome, in the context of intractable seizures or infantile spasms, therapeutic benefits must be weighed against risks.",10894216_12,10894216_D020888_D006311,,
770957232,false,true,5,2015-08-15T01:51:00,,No Relation,0.6194,D020888,vigabatrin,D013035,spasms,"Although the incidence of vigabatrin-induced VFC is worrisome, in the context of intractable seizures or infantile spasms, therapeutic benefits must be weighed against risks.",10894216_12,10894216_D020888_D013035,,
770957233,false,true,5,2015-08-15T02:42:00,,No Relation,0.805,D010622,PCP,D010623,PCP,Primary or secondary P. carinii pneumonia prophylaxis was discontinued in 43 patients: 1 first episode of PCP occurred after 2 months but no other episode was recorded after a median follow-up of 16 months.,10896967_6,10896967_D010622_D010623,,
770957234,false,true,5,2015-08-14T23:03:00,,No Relation,1,D010622,PCP,D011014,pneumonia,Primary or secondary P. carinii pneumonia prophylaxis was discontinued in 43 patients: 1 first episode of PCP occurred after 2 months but no other episode was recorded after a median follow-up of 16 months.,10896967_6,10896967_D010622_D011014,,
770957235,false,true,5,2015-08-14T22:02:00,,No Relation,1,D005641,tegafur,D064420,toxicity,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_D005641_D064420,,
770957236,false,true,5,2015-08-14T23:50:00,No toxicity is actaully claimed.,No Relation,0.7952,C104201,"5-chloro-2,4-dihydroxypyridine",D064420,toxicity,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_C104201_D064420,,
770957237,false,true,5,2015-08-15T01:15:00,,No Relation,0.602,C489337,potassium oxonate,D064420,toxicity,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_C489337_D064420,,
770957238,false,true,5,2015-08-14T20:57:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D064420,toxicity,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_D005472_D064420,,
770957239,false,true,5,2015-08-14T21:03:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D015179,colorectal carcinoma,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_D005472_D015179,,
770957240,false,true,5,2015-08-14T23:48:00,Used as possible treatment.,No Relation,1,C104201,"5-chloro-2,4-dihydroxypyridine",D015179,colorectal carcinoma,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_C104201_D015179,,
770957241,false,true,5,2015-08-15T02:14:00,,No Relation,1,C489337,potassium oxonate,D015179,colorectal carcinoma,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_C489337_D015179,,
770957242,false,true,5,2015-08-15T00:04:00,,No Relation,0.6111,D005641,tegafur,D015179,colorectal carcinoma,"This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD).",10901361_2,10901361_D005641_D015179,,
770957243,false,true,5,2015-08-15T00:15:00,,No Relation,1,D002955,leucovorin,D064420,toxicity,None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.,10901361_11,10901361_D002955_D064420,,
770957244,false,true,5,2015-08-14T20:53:00,,No Relation,0.7979,D005472,5-FU,D064420,toxicity,None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.,10901361_11,10901361_D005472_D064420,,
770957245,false,true,5,2015-08-15T00:20:00,,No Relation,1,D010862,pilocarpine,D009798,ocular hypertension,"The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study.",10901475_0,10901475_D010862_D009798,,
770957246,false,true,5,2015-08-15T02:02:00,,No Relation,1,D010862,pilocarpine,D005902,open-angle glaucoma,"The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study.",10901475_0,10901475_D010862_D005902,,
770957247,false,true,5,2015-08-15T00:45:00,,No Relation,1,D010862,pilocarpine,D009798,ocular hypertension,To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.,10901475_2,10901475_D010862_D009798,,
770957248,false,true,5,2015-08-14T23:51:00,,No Relation,1,D013999,timolol,D005902,open-angle glaucoma,To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.,10901475_2,10901475_D013999_D005902,,
770957249,false,true,5,2015-08-15T00:11:00,,No Relation,1,D013999,timolol,D009798,ocular hypertension,To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.,10901475_2,10901475_D013999_D009798,,
770957250,false,true,5,2015-08-14T23:10:00,,No Relation,1,D010862,pilocarpine,D005902,open-angle glaucoma,To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.,10901475_2,10901475_D010862_D005902,,
770957251,false,true,5,2015-08-15T02:08:00,,No Relation,1,C031356,OH,C562750,POAG,"In a 6-month, multicenter, randomized, open-label study 242 patients with POAG or OH whose IOP was not controlled with timolol 0.5% b.i.d. were enrolled.",10901475_3,10901475_C031356_C562750,,
770957252,false,true,5,2015-08-15T00:13:00,,No Relation,1,D013999,timolol,C562750,POAG,"In a 6-month, multicenter, randomized, open-label study 242 patients with POAG or OH whose IOP was not controlled with timolol 0.5% b.i.d. were enrolled.",10901475_3,10901475_D013999_C562750,,
770957253,false,true,5,2015-08-15T01:29:00,,No Relation,0.827,C012629,formoterol fumarate,D013224,asthmatic,Bronchodilatation effects of dry powder formoterol fumarate in asthmatic patients.,10904569_0,10904569_C012629_D013224,,
770957254,false,true,5,2015-08-14T23:26:00,,No Relation,1,C012629,formoterol fumarate,D013224,asthmatic,Ten asthmatic patients were enrolled in our study of the effects of dry powder formoterol fumarate.,10904569_1,10904569_C012629_D013224,,
770957255,false,true,5,2015-08-15T01:52:00,,No Relation,0.7914,D011241,Prednisone,D020773,daily headache,Prednisone as initial treatment of analgesic-induced daily headache.,10961766_0,10961766_D011241_D020773,,
770957256,false,true,5,2015-08-14T21:56:00,,No Relation,0.808,D011241,prednisone,D020773,daily headache,This study aimed to analyse the possibility of using a short course of oral prednisone for detoxifying patients with chronic daily headache due to medication overuse in an out-patient setting.,10961766_2,10961766_D011241_D020773,,
770957257,false,true,5,2015-08-14T20:53:00,,No Relation,1,D011241,prednisone,D006261,rebound headaches,"This study demonstrates that it is possible to detoxify patients suffering from rebound headaches, using oral prednisone during the first days of withdrawal, in an out-patient setting.",10961766_10,10961766_D011241_D006261,,
770957258,false,true,5,2015-08-15T01:49:00,,No Relation,1,D017963,Azithromycin,D001991,bronchitis,"Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study.",10983860_0,10983860_D017963_D001991,,
770957259,false,true,5,2015-08-14T20:51:00,,No Relation,1,D010917,pivampicillin,D001991,bronchitis,"Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study.",10983860_0,10983860_D010917_D001991,,
770957260,false,true,5,2015-08-15T01:59:00,,No Relation,1,D017963,azithromycin,D001991,bronchitis,"This single-blind, double-dummy, multicentre study compared oral azithromycin, administered as tablets, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in adults with acute exacerbations of chronic bronchitis (not needing parenteral antibiotic therapy, hospitalization or oxygen support).",10983860_1,10983860_D017963_D001991,,
770957261,false,true,5,2015-08-15T01:29:00,,No Relation,0.7956,D010917,pivampicillin,D001991,bronchitis,"This single-blind, double-dummy, multicentre study compared oral azithromycin, administered as tablets, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in adults with acute exacerbations of chronic bronchitis (not needing parenteral antibiotic therapy, hospitalization or oxygen support).",10983860_1,10983860_D010917_D001991,,
770957262,false,true,5,2015-08-15T01:49:00,,No Relation,0.8068,D010100,oxygen,D001991,bronchitis,"This single-blind, double-dummy, multicentre study compared oral azithromycin, administered as tablets, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in adults with acute exacerbations of chronic bronchitis (not needing parenteral antibiotic therapy, hospitalization or oxygen support).",10983860_1,10983860_D010100_D001991,,
770957263,false,true,5,2015-08-15T00:03:00,,No Relation,1,D017963,azithromycin,D001991,bronchitis,"This oral azithromycin regime is an effective treatment for acute exacerbations of chronic bronchitis, similar in efficacy to the longer pivampicillin regime and may offer superior patient compliance.",10983860_6,10983860_D017963_D001991,,
770957264,false,true,5,2015-08-14T20:58:00,,No Relation,1,D010917,pivampicillin,D001991,bronchitis,"This oral azithromycin regime is an effective treatment for acute exacerbations of chronic bronchitis, similar in efficacy to the longer pivampicillin regime and may offer superior patient compliance.",10983860_6,10983860_D010917_D001991,,
770957265,false,true,5,2015-08-14T20:57:00,,Direct,0.5991,D008727,methotrexate,D015212,IBD,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D008727_D015212,,
770957266,false,true,5,2015-08-14T22:24:00,,No Relation,0.5774,D016572,cyclosporin,D008228,NHL,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D016572_D008228,,
770957267,false,true,5,2015-08-15T02:57:00,,No Relation,0.784,D001379,azathioprine,D008228,NHL,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D001379_D008228,,
770957268,false,true,5,2015-08-15T01:54:00,,No Relation,0.5976,D008727,methotrexate,D008228,NHL,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D008727_D008228,,
770957269,false,true,5,2015-08-14T21:06:00,,Direct,0.6236,D001379,azathioprine,D015212,IBD,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D001379_D015212,,
770957270,false,true,5,2015-08-15T01:45:00,,No Relation,0.8062,D016572,cyclosporin,D015212,IBD,"There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).",10986211_6,10986211_D016572_D015212,,
770957271,false,true,5,2015-08-15T00:22:00,,No Relation,1,C085665,Zaleplon,D007319,insomnia,Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia.,11060714_0,11060714_C085665_D007319,,
770957272,false,true,5,2015-08-14T21:00:00,,Direct,0.8034,D013331,strychnine,D012640,convulsions,"The compound is also reported to be active against convulsions induced by bicuculline, picrotoxin and strychnine.",11060714_8,11060714_D013331_D012640,,
770957273,false,true,5,2015-08-14T20:58:00,,Direct,1,D010852,picrotoxin,D012640,convulsions,"The compound is also reported to be active against convulsions induced by bicuculline, picrotoxin and strychnine.",11060714_8,11060714_D010852_D012640,,
770957274,false,true,5,2015-08-15T01:03:00,,Direct,1,D001640,bicuculline,D012640,convulsions,"The compound is also reported to be active against convulsions induced by bicuculline, picrotoxin and strychnine.",11060714_8,11060714_D001640_D012640,,
770957275,false,true,5,2015-08-14T20:57:00,,Direct,1,C085665,zaleplon,D012893,reduction in sleep latency,Results from Phase II/III studies suggest that zaleplon (5 - 20 mg) produces a dose-dependent reduction in sleep latency in patients suffering from primary insomnia.,11060714_18,11060714_C085665_D012893,,
770957276,false,true,5,2015-08-14T21:24:00,,No Relation,0.8125,C085665,zaleplon,D007319,primary insomnia,Results from Phase II/III studies suggest that zaleplon (5 - 20 mg) produces a dose-dependent reduction in sleep latency in patients suffering from primary insomnia.,11060714_18,11060714_C085665_D007319,,
770957277,false,true,5,2015-08-15T00:54:00,,No Relation,0.8178,D014229,triazolam,D019966,drug abuse,The clinical efficacy of zaleplon persists for at least four weeks at doses of 10 mg and 20 mg. Studies in patients with a history of drug abuse suggest that the abuse potential of zaleplon (at doses above the therapeutic dose range) is similar to that seen with the benzodiazepine triazolam.,11060714_19,11060714_D014229_D019966,,
770957278,false,true,5,2015-08-14T22:56:00,,No Relation,0.6286,D001569,benzodiazepine,D019966,drug abuse,The clinical efficacy of zaleplon persists for at least four weeks at doses of 10 mg and 20 mg. Studies in patients with a history of drug abuse suggest that the abuse potential of zaleplon (at doses above the therapeutic dose range) is similar to that seen with the benzodiazepine triazolam.,11060714_19,11060714_D001569_D019966,,
770957279,false,true,5,2015-08-14T22:18:00,,No Relation,0.5763,C085665,zaleplon,D019966,drug abuse,The clinical efficacy of zaleplon persists for at least four weeks at doses of 10 mg and 20 mg. Studies in patients with a history of drug abuse suggest that the abuse potential of zaleplon (at doses above the therapeutic dose range) is similar to that seen with the benzodiazepine triazolam.,11060714_19,11060714_C085665_D019966,,
770957280,false,true,5,2015-08-15T01:47:00,,Direct,0.8095,D000109,acetylcholine,D013035,spasm,Major complications during spasm provocation tests with an intracoronary injection of acetylcholine.,11078314_0,11078314_D000109_D013035,,
770957281,false,true,5,2015-08-14T20:57:00,,Direct,1,D000109,acetylcholine,D013035,spasm,"The spasm provocation test using acetylcholine should be performed carefully, although it is considered a safe and reliable method.",11078314_3,11078314_D000109_D013035,,
770957282,false,true,5,2015-08-14T23:35:00,,No Relation,1,D000305,corticosteroids,D003876,atopic dermatitis,The number of patients with atopic dermatitis who refuse to use topical corticosteroids because of personal fears seems to be increasing.,11096196_1,11096196_D000305_D003876,,
770957283,false,true,5,2015-08-14T20:54:00,,No Relation,1,D004656,enalapril,D006333,congestive heart failure,Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study.,11127445_0,11127445_D004656_D006333,,
770957284,false,true,5,2015-08-14T20:57:00,,No Relation,0.8123,D004656,enalapril,D006333,CHF/congestive heart failure,We sought to prospectively and randomly compare survival with clinical and hemodynamic variables in patients with congestive heart failure (CHF) treated with standard versus high doses of enalapril.,11127445_2,11127445_D004656_D006333,,
770957285,false,true,5,2015-08-15T00:43:00,,No Relation,1,D000809,Angiotensin,D006333,CHF,"Angiotensin-converting enzyme (ACE) inhibitors produce hemodynamic and symptomatic benefits in patients with CHF, but there is still controversy about the optimal dose in this clinical setting.",11127445_3,11127445_D000809_D006333,,
770957286,false,true,5,2015-08-15T02:18:00,,No Relation,1,D004656,enalapril,D006333,CHF,"Two hundred and forty-eight patients with advanced CHF (age 56.3+/-12 years) were randomized to receive a maximal tolerated dose of enalapril, up to 20 mg/day in group 1 (mean dose achieved 17.9+/-4.3 mg/day, n = 122) and 60 mg/day in group 2 (mean dose achieved 42+/-19.3 mg/day, n = 126).",11127445_4,11127445_D004656_D006333,,
770957287,false,true,5,2015-08-14T22:00:00,,No Relation,1,D000961,antithymocyte globulin,D000741,aplastic anemia,Four patients with aplastic anemia received intravenous antithymocyte globulin (ATG) or antilymphocyte globulin (ALG).,11144443_12,11144443_D000961_D000741,,
770957288,false,true,5,2015-08-14T21:03:00,,No Relation,0.8138,D000961,ATG,D000741,aplastic anemia,"Four did not receive ATG/ALG, two had aplastic anemia, and two had bone marrow suppression.",11144443_15,11144443_D000961_D000741,,
770957289,false,true,5,2015-08-15T00:55:00,,No Relation,0.8043,D000961,ATG,D001855,bone marrow suppression,"Four did not receive ATG/ALG, two had aplastic anemia, and two had bone marrow suppression.",11144443_15,11144443_D000961_D001855,,
770957290,false,true,5,2015-08-14T22:23:00,,No Relation,1,D016572,cyclosporine,D064420,toxicity,"Although one large randomized study has demonstrated a proven survival advantage without increased toxicity using cyclosporine, the inconsistent results with other modulators raise doubt as to the utility and overall strategy of using drug efflux blockers in patients with established Pgp overexpression.",11148681_8,11148681_D016572_D064420,,
770957291,false,true,5,2015-08-14T20:47:00,,No Relation,1,D014807,vitamin D,D009369,breast cancer,"Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis.",11165041_0,11165041_D014807_D009369,,
770957292,false,true,5,2015-08-15T00:59:00,,No Relation,0.807,C103436,CB1093,D009369,breast cancer,"Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis.",11165041_0,11165041_C103436_D009369,,
770957293,false,true,5,2015-08-14T21:08:00,,No Relation,0.8255,D014807,vitamin D,D009369,tumour,Mechanisms by which vitamin D analogues promote apoptosis in tumour cells are unclear.,11165041_1,11165041_D014807_D009369,,
770957294,false,true,5,2015-08-15T01:44:00,,No Relation,1,D014807,vitamin D,D009369,breast cancer,"In this study we have examined possible interactions between the synthetic vitamin D analogue CB1093 and two other known mediators of apoptosis, TNFalpha and ceramide, in MCF-7, T47D and Hs578T breast cancer cells.",11165041_2,11165041_D014807_D009369,,
770957295,false,true,5,2015-08-15T02:12:00,,No Relation,0.8065,C103436,CB1093,D009369,breast cancer,"In this study we have examined possible interactions between the synthetic vitamin D analogue CB1093 and two other known mediators of apoptosis, TNFalpha and ceramide, in MCF-7, T47D and Hs578T breast cancer cells.",11165041_2,11165041_C103436_D009369,,
770957296,false,true,5,2015-08-14T20:47:00,,No Relation,1,D014807,vitamin D,D009369,breast cancer,These results indicate that CB1093 potentiates responsiveness of breast cancer cells to TNFalpha and suggest that ceramide and/or cPLA(2) might be involved as downstream effectors in vitamin D-mediated caspase-independent cell death.,11165041_10,11165041_D014807_D009369,,
770957297,false,true,5,2015-08-14T21:00:00,,Direct,0.6309,C103436,CB1093,D009369,breast cancer,These results indicate that CB1093 potentiates responsiveness of breast cancer cells to TNFalpha and suggest that ceramide and/or cPLA(2) might be involved as downstream effectors in vitamin D-mediated caspase-independent cell death.,11165041_10,11165041_C103436_D009369,,
770957298,false,true,5,2015-08-15T02:01:00,,No Relation,1,D002701,chloramphenicol,D007239,infections,Sometimes penicillin G and chloramphenicol were used successfully in some anaerobic infections.,11178339_2,11178339_D002701_D007239,,
770957299,false,true,5,2015-08-14T20:58:00,,No Relation,1,D010400,penicillin G,D007239,infections,Sometimes penicillin G and chloramphenicol were used successfully in some anaerobic infections.,11178339_2,11178339_D010400_D007239,,
770957300,false,true,5,2015-08-14T23:31:00,,No Relation,1,D007501,Iron,D001265,athletes,Iron status in female endurance athletes and in non-athletes.,11183845_0,11183845_D007501_D001265,,
770957301,false,true,5,2015-08-15T00:13:00,,No Relation,1,D007501,Iron,D001265,athletes,"Iron status was studied in 126 female endurance athletes and 52 control subjects, all aged 16-20 years.",11183845_1,11183845_D007501_D001265,,
770957302,false,true,5,2015-08-14T23:19:00,Iron cures iron-deficiency.,No Relation,1,D007501,iron,D018798,iron deficiency,The study aimed at identifying factors responsible for iron deficiency.,11183845_2,11183845_D007501_D018798,,
770957303,false,true,5,2015-08-15T02:21:00,,No Relation,0.8,D007501,iron,D000740,anemia,Twenty-six percent of athletes and 50% of controls had latent iron-deficiency without anemia symptoms.,11183845_3,11183845_D007501_D000740,,
770957304,false,true,5,2015-08-15T00:46:00,Athletes is not a Disease.,No Relation,1,D007501,iron,D001265,athletes,Twenty-six percent of athletes and 50% of controls had latent iron-deficiency without anemia symptoms.,11183845_3,11183845_D007501_D001265,,
770957305,false,true,5,2015-08-14T22:17:00,,No Relation,1,D007501,iron,D018798,iron-deficiency,Twenty-six percent of athletes and 50% of controls had latent iron-deficiency without anemia symptoms.,11183845_3,11183845_D007501_D018798,,
770957306,false,true,5,2015-08-14T23:14:00,,Direct,0.5925,D007501,iron,D018798,iron deficiency,"A too low intake of iron (especially heme iron: 0.3 mg daily), and of nutrients influencing iron metabolism, were identified as main causes of iron deficiency in control subjects.",11183845_4,11183845_D007501_D018798,,
770957307,false,true,5,2015-08-14T20:58:00,,No Relation,0.619,D006418,heme,D018798,iron deficiency,"A too low intake of iron (especially heme iron: 0.3 mg daily), and of nutrients influencing iron metabolism, were identified as main causes of iron deficiency in control subjects.",11183845_4,11183845_D006418_D018798,,
770957308,false,true,5,2015-08-15T00:26:00,,No Relation,1,D007501,iron,D018798,iron deficiency,"In athletes, whose iron intake was sufficient (14.6 mg), the principal cause of iron deficiency were blood losses due to menstruation.",11183845_5,11183845_D007501_D018798,,
770957309,false,true,5,2015-08-14T21:54:00,,No Relation,1,D007501,iron,D001265,athletes,"In athletes, whose iron intake was sufficient (14.6 mg), the principal cause of iron deficiency were blood losses due to menstruation.",11183845_5,11183845_D007501_D001265,,
770957310,false,true,5,2015-08-14T23:11:00,,No Relation,1,D007501,iron,D019106,blood losses,"In athletes, whose iron intake was sufficient (14.6 mg), the principal cause of iron deficiency were blood losses due to menstruation.",11183845_5,11183845_D007501_D019106,,
770957311,false,true,5,2015-08-15T01:39:00,,No Relation,1,D007501,iron,D018798,iron deficiency,"High level of physical activity, expressed as training volume and experience, did not adversely affect iron stores, as these were higher than in control subjects and the incidence of iron deficiency was much lower than in the control group.",11183845_6,11183845_D007501_D018798,,
770957312,false,true,5,2015-08-14T21:56:00,,No Relation,1,D007501,iron,D001265,athletes,It was concluded that an increased intake of iron and of dietary factors involved in iron metabolism prevented possible exercise-induced losses of iron in young athletes.,11183845_7,11183845_D007501_D001265,,
770957313,false,true,5,2015-08-15T00:12:00,,Direct,1,D004155,diphenhydramine,D064420,toxicity,Dose-dependent toxicity of diphenhydramine overdose.,11204550_0,11204550_D004155_D064420,,
770957314,false,true,5,2015-08-14T22:00:00,,No Relation,0.5773,D004155,diphenhydramine,D062787,overdose,Dose-dependent toxicity of diphenhydramine overdose.,11204550_0,11204550_D004155_D062787,,
770957315,false,true,5,2015-08-14T23:08:00,,No Relation,0.8143,D004155,Diphenhydramine/DPHM,D062787,overdose,Diphenhydramine (DPHM) overdose is a frequent cause of acute poisoning.,11204550_1,11204550_D004155_D062787,,
770957316,false,true,5,2015-08-14T21:02:00,,Direct,1,D004155,Diphenhydramine/DPHM,D011041,poisoning,Diphenhydramine (DPHM) overdose is a frequent cause of acute poisoning.,11204550_1,11204550_D004155_D011041,,
770957317,false,true,5,2015-08-14T21:08:00,,No Relation,0.5971,D004155,DPHM,D064420,toxicity,"Although its clinical features are well known, information about the dose-dependent toxicity of DPHM is still scarce.",11204550_2,11204550_D004155_D064420,,
770957318,false,true,5,2015-08-14T21:00:00,,No Relation,0.5825,D004155,DPHM,D064420,toxicity,The objective of this study was to investigate the dose-dependent toxicity of DPHM in patients with acute DPHM poisoning.,11204550_3,11204550_D004155_D064420,,
770957319,false,true,5,2015-08-14T23:02:00,,Direct,0.6121,D004155,DPHM,D011041,poisoning,The objective of this study was to investigate the dose-dependent toxicity of DPHM in patients with acute DPHM poisoning.,11204550_3,11204550_D004155_D011041,,
770957320,false,true,5,2015-08-15T02:25:00,,Direct,0.7873,D004155,DPHM,D064420,toxicity,These data demonstrate a clear dose-dependent acute toxicity of DPHM.,11204550_11,11204550_D004155_D064420,,
770957321,false,true,5,2015-08-14T21:08:00,,Direct,0.6046,D004155,DPHM,D062787,overdose,"Thus, the results contribute to the data basis required for a cost effective management of patients with DPHM overdose.",11204550_13,11204550_D004155_D062787,,
770957322,false,true,5,2015-08-15T00:58:00,,No Relation,1,C089995,Glatiramer acetate,D009103,MS,Glatiramer acetate is a drug recently approved for the treatment of MS. We therefore investigated the effect of glatiramer acetate on RANTES expression in glial cells in vitro.,11223159_2,11223159_C089995_D009103,,
770957323,false,true,5,2015-08-15T00:52:00,,No Relation,0.812,C089995,glatiramer acetate,D004194,diseases,"Our results suggest that glatiramer acetate may inhibit IL-1beta-stimulated RANTES expression in human glial cells by blocking NF-kappaB activation, thus identifying part of the molecular basis for its anti-inflammatory and immunosuppressive effects in demyelinating diseases.",11223159_9,11223159_C089995_D004194,,
770957324,false,true,5,2015-08-14T22:00:00,,No Relation,1,D002945,cisplatin,D002289,non-small-cell lung cancer,"Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.",11230476_0,11230476_D002945_D002289,,
770957325,false,true,5,2015-08-14T22:27:00,,No Relation,1,D016685,mitomycin,D002289,non-small-cell lung cancer,"Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.",11230476_0,11230476_D016685_D002289,,
770957326,false,true,5,2015-08-15T01:33:00,,No Relation,1,D014747,vinblastine,D002289,non-small-cell lung cancer,"Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.",11230476_0,11230476_D014747_D002289,,
770957327,false,true,5,2015-08-15T01:39:00,,No Relation,1,D002945,cisplatin,D002289,NSCLC,"Patients with stage IIIb or IV NSCLC were randomized at start of treatment to receive either three or six courses of mitomycin 8 mg/m(2) (courses 1, 2, 4, and 6), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) (MVP) every 21 days.",11230476_3,11230476_D002945_D002289,,
770957328,false,true,5,2015-08-14T22:58:00,Used as treatment.,No Relation,1,D016685,mitomycin,D002289,NSCLC,"Patients with stage IIIb or IV NSCLC were randomized at start of treatment to receive either three or six courses of mitomycin 8 mg/m(2) (courses 1, 2, 4, and 6), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) (MVP) every 21 days.",11230476_3,11230476_D016685_D002289,,
770957329,false,true,5,2015-08-14T23:30:00,,No Relation,1,D014747,vinblastine,D002289,NSCLC,"Patients with stage IIIb or IV NSCLC were randomized at start of treatment to receive either three or six courses of mitomycin 8 mg/m(2) (courses 1, 2, 4, and 6), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) (MVP) every 21 days.",11230476_3,11230476_D014747_D002289,,
770957330,false,true,5,2015-08-14T21:00:00,,No Relation,0.5988,C108830,Y-27632,D009362,metastasis,Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.,11230737_0,11230737_C108830_D009362,,
770957331,false,true,5,2015-08-14T21:44:00,,No Relation,0.601,C108830,Y-27632,D006528,hepatocellular carcinoma,Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.,11230737_0,11230737_C108830_D006528,,
770957332,false,true,5,2015-08-15T00:38:00,,No Relation,1,C108830,Y-27632,D009362,metastasis,"To investigate whether the specific p160ROCK inhibitor, Y-27632, could also inhibit intrahepatic metastasis, the effect of Y-27632 on the cell motility and intrahepatic metastasis of Li7 was investigated.",11230737_4,11230737_C108830_D009362,,
770957333,false,true,5,2015-08-14T21:24:00,,No Relation,1,C108830,Y-27632,D016511,SCID,"Y-27632 was administered continuously into the peritoneal cavity using a micro-osmotic pump, together with orthotopic implantation of Li7 cells into the liver of SCID mice.",11230737_6,11230737_C108830_D016511,,
770957334,false,true,5,2015-08-14T21:06:00,,No Relation,1,C108830,Y-27632,D009369,tumor,"The primary tumor volume at the site of injection was smaller in the Y-27632-treated group compared with the control group, but the difference was not statistically significant.",11230737_9,11230737_C108830_D009369,,
770957335,false,true,5,2015-08-14T21:03:00,,No Relation,0.7969,C108830,Y-27632,D009369,tumor/tumors,"Histologically, control tumors showed infiltrative growth into the sinusoidal area at the tumor boundary, whereas Y-27632-treated tumors showed expansive growth and low invasiveness.",11230737_10,11230737_C108830_D009369,,
770957336,false,true,5,2015-08-15T00:43:00,,No Relation,1,C108830,Y-27632,D009362,metastasis,"These findings confirm the importance of the Rho/p160ROCK signaling pathway in intrahepatic metastasis of human HCC, and indicate that Y-27632 may be useful for the prevention of intrahepatic metastasis of human HCC.",11230737_11,11230737_C108830_D009362,,
770957337,false,true,5,2015-08-15T01:51:00,,No Relation,1,C108830,Y-27632,D006528,HCC,"These findings confirm the importance of the Rho/p160ROCK signaling pathway in intrahepatic metastasis of human HCC, and indicate that Y-27632 may be useful for the prevention of intrahepatic metastasis of human HCC.",11230737_11,11230737_C108830_D006528,,
770957338,false,true,5,2015-08-14T21:03:00,,No Relation,1,D007501,iron,D008545,melanoma,"We investigated survival of two kinds of human embryonic cells (CLV102, Lu106) and human melanoma cells (Mel8) exposed to exogenous iron and copper ions in the absence or in the presence of ascorbic acid, catalase and superoxide dismutase.",11243246_1,11243246_D007501_D008545,,
770957339,false,true,5,2015-08-14T20:58:00,,No Relation,1,D013481,superoxide,D008545,melanoma,"We investigated survival of two kinds of human embryonic cells (CLV102, Lu106) and human melanoma cells (Mel8) exposed to exogenous iron and copper ions in the absence or in the presence of ascorbic acid, catalase and superoxide dismutase.",11243246_1,11243246_D013481_D008545,,
770957340,false,true,5,2015-08-14T23:35:00,,No Relation,0.813,D001205,ascorbic acid,D008545,melanoma,"We investigated survival of two kinds of human embryonic cells (CLV102, Lu106) and human melanoma cells (Mel8) exposed to exogenous iron and copper ions in the absence or in the presence of ascorbic acid, catalase and superoxide dismutase.",11243246_1,11243246_D001205_D008545,,
770957341,false,true,5,2015-08-14T20:56:00,,No Relation,1,D003300,copper,D008545,melanoma,"We investigated survival of two kinds of human embryonic cells (CLV102, Lu106) and human melanoma cells (Mel8) exposed to exogenous iron and copper ions in the absence or in the presence of ascorbic acid, catalase and superoxide dismutase.",11243246_1,11243246_D003300_D008545,,
770957342,false,true,5,2015-08-15T02:05:00,,Direct,1,D007501,Iron,D004487,cytotoxicity,Iron ions produced cytotoxicity towards both kinds of cells dependent on its concentration.,11243246_2,11243246_D007501_D004487,,
770957343,false,true,5,2015-08-15T00:37:00,,Direct,1,D007501,iron,D004487,cytotoxicity,"Catalase suppressed the cytotoxicity induced by iron ions in Lu106 cells. whereas in CLV102 and Mel8 cells, was ineffective.",11243246_3,11243246_D007501_D004487,,
770957344,false,true,5,2015-08-14T23:31:00,,No Relation,0.7962,D013481,superoxide,D004487,cytotoxicity,"By contrast, superoxide dismutase abolished the cytotoxicity of iron ions towards CLV102 cells, whereas in Lu106 and Mel8 cells, was ineffective.",11243246_4,11243246_D013481_D004487,,
770957345,false,true,5,2015-08-15T01:15:00,,No Relation,0.6134,D007501,iron,D004487,cytotoxicity,"By contrast, superoxide dismutase abolished the cytotoxicity of iron ions towards CLV102 cells, whereas in Lu106 and Mel8 cells, was ineffective.",11243246_4,11243246_D007501_D004487,,
770957346,false,true,5,2015-08-14T23:42:00,,No Relation,1,D005665,furosemide,D006973,hypertensives,"Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives.",11250127_0,11250127_D005665_D006973,,
770957347,false,true,5,2015-08-14T23:50:00,,No Relation,1,D005665,furosemide,D006973,hypertensives,"Arterial wall shear rate (ultrasound technique, profilmeter FRP III), the systo-diastolic diameter (echotracking technique) and the mean blood flow velocity and volume of the common carotid artery, the blood viscosity (rotational viscometer) and the finger arterial blood pressure (Finapress Ohmeda) were measured in 12 young volunteers (aged 25+/-2 years) and in 12 elderly hypertensives (aged 80+/-4 years) treated with short-acting calcium antagonists up to 24h before the study, both at baseline and after intravenous furosemide infusion (0.5mg/min), when the haematocrit had increased by at least two percentage points.",11250127_2,11250127_D005665_D006973,,
770957348,false,true,5,2015-08-14T22:29:00,,No Relation,1,D002118,calcium,D006973,hypertensives,"Arterial wall shear rate (ultrasound technique, profilmeter FRP III), the systo-diastolic diameter (echotracking technique) and the mean blood flow velocity and volume of the common carotid artery, the blood viscosity (rotational viscometer) and the finger arterial blood pressure (Finapress Ohmeda) were measured in 12 young volunteers (aged 25+/-2 years) and in 12 elderly hypertensives (aged 80+/-4 years) treated with short-acting calcium antagonists up to 24h before the study, both at baseline and after intravenous furosemide infusion (0.5mg/min), when the haematocrit had increased by at least two percentage points.",11250127_2,11250127_D002118_D006973,,
770957349,false,true,5,2015-08-14T23:33:00,,Direct,0.6041,D005665,furosemide,D007022,decreased and blood viscosity,After furosemide administration the mean arterial blood pressure decreased and blood viscosity and carotid systolic shear stress increased in both groups.,11250127_3,11250127_D005665_D007022,,
770957350,false,true,5,2015-08-14T21:52:00,,No Relation,0.5913,D014700,verapamil,D004487,cytotoxicity,"After treatment of the resistant cells with verapamil, the intracellular levels of doxorubicin were markedly increased and consequent cytotoxicity was improved.",11261883_6,11261883_D014700_D004487,,
770957351,false,true,5,2015-08-14T23:25:00,'Improved' being the key term.,Direct,0.5985,D004317,doxorubicin,D004487,cytotoxicity,"After treatment of the resistant cells with verapamil, the intracellular levels of doxorubicin were markedly increased and consequent cytotoxicity was improved.",11261883_6,11261883_D004317_D004487,,
770957352,false,true,5,2015-08-14T23:49:00,,No Relation,1,D002945,cisplatin,D004938,esophageal cancer,Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.,11295088_0,11295088_D002945_D004938,,
770957353,false,true,5,2015-08-15T00:27:00,,No Relation,1,D002945,cisplatin/CDDP,D009369,cancers,Intraoperative intrapleural (i.pl.) cisplatin (CDDP) treatment during thoracotomy was performed for esophageal cancers.,11295088_1,11295088_D002945_D009369,,
770957354,false,true,5,2015-08-14T22:30:00,,No Relation,0.5805,D002945,CDDP,D020335,Hypotonic,"Hypotonic CDDP treatments with a 154 mOsm/l solution and a 62 mOsm/l solution were administered to 4 and 9 patients, respectively.",11295088_3,11295088_D002945_D020335,,
770957355,false,true,5,2015-08-14T23:43:00,,No Relation,1,D010984,platinum,D020335,hypotonic,The maximum concentrations (Cmax) of both total and filterable platinum in the plasma after injection of the hypotonic solution were significantly higher than those after injection of the isotonic solution.,11295088_4,11295088_D010984_D020335,,
770957356,false,true,5,2015-08-15T01:56:00,,No Relation,1,D010984,platinum,D020335,hypotonic,"Although higher levels of the Cmax may increase side-effects, the hypotonic condition of the i.pl. fluid and increased AUC in the plasma may escalate the accumulation of platinum in i.pl. cancer cells.",11295088_6,11295088_D010984_D020335,,
770957357,false,true,5,2015-08-15T01:57:00,,No Relation,1,D010984,platinum,D009369,cancer,"Although higher levels of the Cmax may increase side-effects, the hypotonic condition of the i.pl. fluid and increased AUC in the plasma may escalate the accumulation of platinum in i.pl. cancer cells.",11295088_6,11295088_D010984_D009369,,
770957358,false,true,5,2015-08-14T23:10:00,,No Relation,1,D002945,CDDP,D002277,pleural carcinomatosis,CDDP is tolerable and may be useful for treatment of the incipient phase of pleural carcinomatosis and for prophylaxis of postoperative recurrence.,11295088_8,11295088_D002945_D002277,,
770957359,false,true,5,2015-08-15T02:11:00,,No Relation,0.804,D008727,methotrexate,D001172,rheumatoid arthritis,"Because of radiographic evidence of progressive bone loss and the inability to eliminate synovial proliferation with methotrexate, it became apparent that therapy for rheumatoid arthritis needed further advancement.",11304108_1,11304108_D008727_D001172,,
770957360,false,true,5,2015-08-15T01:35:00,,No Relation,0.6084,D008727,methotrexate,D016301,bone loss,"Because of radiographic evidence of progressive bone loss and the inability to eliminate synovial proliferation with methotrexate, it became apparent that therapy for rheumatoid arthritis needed further advancement.",11304108_1,11304108_D008727_D016301,,
770957361,false,true,5,2015-08-14T21:03:00,,Direct,1,D008727,Methotrexate,D064420,toxicity,Methotrexate is not a remission-inducing drug and may have dose-limiting toxicity.,11304108_2,11304108_D008727_D064420,,
770957362,false,true,5,2015-08-15T00:59:00,,No Relation,1,C045463,leflunomide,D019966,disease-modifying antirheumatic drugs/DMARDs,"In the past 2 years, three new disease-modifying antirheumatic drugs (DMARDs) have been approved: leflunomide, etanercept, and infliximab.",11304108_3,11304108_C045463_D019966,,
770957363,false,true,5,2015-08-15T01:59:00,,No Relation,1,D006886,hydroxychloroquine,D019966,DMARDs,"Other established DMARDs, such as sulfasalazine and hydroxychloroquine, have also demonstrated efficacy when used together with methotrexate.",11304108_6,11304108_D006886_D019966,,
770957364,false,true,5,2015-08-14T20:47:00,,No Relation,1,D012460,sulfasalazine,D019966,DMARDs,"Other established DMARDs, such as sulfasalazine and hydroxychloroquine, have also demonstrated efficacy when used together with methotrexate.",11304108_6,11304108_D012460_D019966,,
770957365,false,true,5,2015-08-14T23:59:00,,No Relation,1,D008727,methotrexate,D019966,DMARDs,"Other established DMARDs, such as sulfasalazine and hydroxychloroquine, have also demonstrated efficacy when used together with methotrexate.",11304108_6,11304108_D008727_D019966,,
770957366,false,true,5,2015-08-15T00:19:00,,No Relation,1,D008727,methotrexate,D019966,DMARDs,The results of these combination studies clearly demonstrate that clinical responses can be meaningfully improved when new and existing DMARDs are added to methotrexate.,11304108_7,11304108_D008727_D019966,,
770957367,false,true,5,2015-08-14T20:56:00,,No Relation,1,D008727,methotrexate,D019966,DMARDs,It has also become apparent that combinations of new DMARDs and methotrexate virtually halt radiographic progression over 2 years.,11304108_9,11304108_D008727_D019966,,
770957368,false,true,5,2015-08-14T20:57:00,,No Relation,0.812,D016049,didanosine,D015658,HIV-1 infection,The role of didanosine in the management of HIV-1 infection.,11322269_0,11322269_D016049_D015658,,
770957369,false,true,5,2015-08-14T20:56:00,,No Relation,1,D016049,didanosine,D015658,human immunodeficiency virus (HIV) infection,"Large-scale clinical end point studies comparing antiretroviral therapy with zidovudine alone, didanosine alone, and zidovudine combined with didanosine indicate that both didanosine alone and zidovudine/didanosine provide a better clinical outcome than zidovudine alone in patients with human immunodeficiency virus (HIV) infection.",11322269_1,11322269_D016049_D015658,,
770957370,false,true,5,2015-08-15T02:20:00,,No Relation,1,D015215,zidovudine,D015658,human immunodeficiency virus (HIV) infection,"Large-scale clinical end point studies comparing antiretroviral therapy with zidovudine alone, didanosine alone, and zidovudine combined with didanosine indicate that both didanosine alone and zidovudine/didanosine provide a better clinical outcome than zidovudine alone in patients with human immunodeficiency virus (HIV) infection.",11322269_1,11322269_D015215_D015658,,
770957371,false,true,5,2015-08-15T02:33:00,,No Relation,0.5993,D016049,didanosine,D001308,gastrointestinal disturbances,"Apart from mostly mild gastrointestinal disturbances, didanosine alone and in various combination therapies has been generally well tolerated.",11322269_4,11322269_D016049_D001308,,
770957372,false,true,5,2015-08-15T00:25:00,,No Relation,1,D009705,nucleoside,D015658,HIV infection,"Thus, didanosine represents a potent, versatile nucleoside analogue with potential benefits in both current and future antiretroviral regimens for HIV infection.",11322269_5,11322269_D009705_D015658,,
770957373,false,true,5,2015-08-14T22:16:00,,No Relation,1,D016049,didanosine,D015658,HIV infection,"Thus, didanosine represents a potent, versatile nucleoside analogue with potential benefits in both current and future antiretroviral regimens for HIV infection.",11322269_5,11322269_D016049_D015658,,
770957374,false,true,5,2015-08-15T00:15:00,,No Relation,1,D005472,5-FU,D009369,Tumor,"Tumor sensitivities as measured by the IC50 (drug concentration producing 50% growth inhibition) varied largely between drugs, ranging larger than 3 x 10(5) ng/mL for 5-FU, larger than 1.5 x 10(2) ng/mL for MMC, 20 ng/mL to 1.4 x 10(3) ng/mL for ADM, and 80 ng/mL to 2.4 x 10(3) ng/mL for CDDP.",11329936_5,11329936_D005472_D009369,,
770957375,false,true,5,2015-08-14T21:56:00,,No Relation,1,D016685,MMC,D009369,Tumor,"Tumor sensitivities as measured by the IC50 (drug concentration producing 50% growth inhibition) varied largely between drugs, ranging larger than 3 x 10(5) ng/mL for 5-FU, larger than 1.5 x 10(2) ng/mL for MMC, 20 ng/mL to 1.4 x 10(3) ng/mL for ADM, and 80 ng/mL to 2.4 x 10(3) ng/mL for CDDP.",11329936_5,11329936_D016685_D009369,,
770957376,false,true,5,2015-08-15T00:54:00,,No Relation,1,D002945,CDDP,D009369,Tumor,"Tumor sensitivities as measured by the IC50 (drug concentration producing 50% growth inhibition) varied largely between drugs, ranging larger than 3 x 10(5) ng/mL for 5-FU, larger than 1.5 x 10(2) ng/mL for MMC, 20 ng/mL to 1.4 x 10(3) ng/mL for ADM, and 80 ng/mL to 2.4 x 10(3) ng/mL for CDDP.",11329936_5,11329936_D002945_D009369,,
770957377,false,true,5,2015-08-15T02:15:00,,No Relation,1,D005472,5-FU,D000230,adenocarcinomas,"Nine human pancreatic adenocarcinomas varied widely in their sensitivity to chemotherapies, especially for 5-FU.",11329936_10,11329936_D005472_D000230,,
770957378,false,true,5,2015-08-14T23:45:00,,No Relation,1,D010889,piracetam,D020521,stroke,Restitution of alpha-topography by piracetam in post-stroke aphasia.,11332870_0,11332870_D010889_D020521,,
770957379,false,true,5,2015-08-14T23:36:00,,No Relation,1,D010889,piracetam,D001037,aphasia,Restitution of alpha-topography by piracetam in post-stroke aphasia.,11332870_0,11332870_D010889_D001037,,
770957380,false,true,5,2015-08-14T22:50:00,,No Relation,1,D010889,piracetam,D020521,stroke,"Electroencephalographic and clinical effects of piracetam in post-stroke aphasia were evaluated in a prospective, randomized, double-blind, placebo-controlled trial.",11332870_1,11332870_D010889_D020521,,
770957381,false,true,5,2015-08-14T22:10:00,,No Relation,1,D010889,piracetam,D001037,aphasia,"Electroencephalographic and clinical effects of piracetam in post-stroke aphasia were evaluated in a prospective, randomized, double-blind, placebo-controlled trial.",11332870_1,11332870_D010889_D001037,,
770957382,false,true,5,2015-08-14T22:34:00,,No Relation,1,C054218,manidipine,D003929,diabetic,Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria.,11336083_0,11336083_C054218_D003929,,
770957383,false,true,5,2015-08-15T00:18:00,,No Relation,1,D002118,calcium,D003929,diabetic,"This study was designed to investigate the effect of delapril, an ACE inhibitor, and manidipine, a long action calcium antagonist, on persistent microalbuminuria in normotensive type 2 diabetic patients.",11336083_1,11336083_D002118_D003929,,
770957384,false,true,5,2015-08-14T21:52:00,,No Relation,1,C054218,manidipine,D003929,diabetic,"This study was designed to investigate the effect of delapril, an ACE inhibitor, and manidipine, a long action calcium antagonist, on persistent microalbuminuria in normotensive type 2 diabetic patients.",11336083_1,11336083_C054218_D003929,,
770957385,false,true,5,2015-08-14T22:16:00,,No Relation,1,C047759,delapril,D003929,diabetic,"This study was designed to investigate the effect of delapril, an ACE inhibitor, and manidipine, a long action calcium antagonist, on persistent microalbuminuria in normotensive type 2 diabetic patients.",11336083_1,11336083_C047759_D003929,,
770957386,false,true,5,2015-08-14T22:29:00,,No Relation,1,C054218,manidipine,D003929,diabetic,"Sixty type 2 diabetic patients were randomized to take delapril 30 mg/day or manidipine 10 mg/day for 48 weeks, in an open label design.",11336083_2,11336083_C054218_D003929,,
770957387,false,true,5,2015-08-14T22:24:00,,No Relation,1,C047759,delapril,D003929,diabetic,"Sixty type 2 diabetic patients were randomized to take delapril 30 mg/day or manidipine 10 mg/day for 48 weeks, in an open label design.",11336083_2,11336083_C047759_D003929,,
770957388,false,true,5,2015-08-15T02:15:00,,No Relation,0.6043,C047759,delapril,C562889,nephropathy,"After 48 weeks of treatment, two patients in the delapril group and one patient in the manidipine group converted to normoalbuminuria (urinary albumin:creatinine ratio < 30 mg/g) and one patient in each group progressed to overt nephropathy (urinary albumin:creatinine ratio > 300 mg/g).",11336083_6,11336083_C047759_C562889,,
770957389,false,true,5,2015-08-14T20:51:00,,No Relation,0.7952,C054218,manidipine,C562889,nephropathy,"After 48 weeks of treatment, two patients in the delapril group and one patient in the manidipine group converted to normoalbuminuria (urinary albumin:creatinine ratio < 30 mg/g) and one patient in each group progressed to overt nephropathy (urinary albumin:creatinine ratio > 300 mg/g).",11336083_6,11336083_C054218_C562889,,
770957390,false,true,5,2015-08-14T20:56:00,,No Relation,0.8026,D003404,creatinine,C562889,nephropathy,"After 48 weeks of treatment, two patients in the delapril group and one patient in the manidipine group converted to normoalbuminuria (urinary albumin:creatinine ratio < 30 mg/g) and one patient in each group progressed to overt nephropathy (urinary albumin:creatinine ratio > 300 mg/g).",11336083_6,11336083_D003404_C562889,,
770957391,false,true,5,2015-08-14T23:08:00,,No Relation,1,D005947,glucose,D044882,plasma glucose,"There were no significant changes in fasting plasma glucose, HbA1c, serum fructosamine, creatinine, potassium and lipid profiles after 48 weeks of treatment in both groups.",11336083_7,11336083_D005947_D044882,,
770957392,false,true,5,2015-08-15T00:38:00,,No Relation,1,D011188,potassium,D044882,plasma glucose,"There were no significant changes in fasting plasma glucose, HbA1c, serum fructosamine, creatinine, potassium and lipid profiles after 48 weeks of treatment in both groups.",11336083_7,11336083_D011188_D044882,,
770957393,false,true,5,2015-08-15T02:31:00,,No Relation,1,D019270,fructosamine,D044882,plasma glucose,"There were no significant changes in fasting plasma glucose, HbA1c, serum fructosamine, creatinine, potassium and lipid profiles after 48 weeks of treatment in both groups.",11336083_7,11336083_D019270_D044882,,
770957394,false,true,5,2015-08-15T00:54:00,,No Relation,1,D003404,creatinine,D044882,plasma glucose,"There were no significant changes in fasting plasma glucose, HbA1c, serum fructosamine, creatinine, potassium and lipid profiles after 48 weeks of treatment in both groups.",11336083_7,11336083_D003404_D044882,,
770957395,false,true,5,2015-08-14T21:59:00,,No Relation,0.5969,C047759,delapril,D004244,dizziness,Two cases in the delapril group were withdrawn during the study because of an intolerable cough and one case in the manidipine group because of intolerable dizziness and headache.,11336083_8,11336083_C047759_D004244,,
770957396,false,true,5,2015-08-14T20:50:00,,Direct,0.8193,C054218,manidipine,D004244,dizziness,Two cases in the delapril group were withdrawn during the study because of an intolerable cough and one case in the manidipine group because of intolerable dizziness and headache.,11336083_8,11336083_C054218_D004244,,
770957397,false,true,5,2015-08-15T01:57:00,,Direct,0.5905,C047759,delapril,D006261,headache,Two cases in the delapril group were withdrawn during the study because of an intolerable cough and one case in the manidipine group because of intolerable dizziness and headache.,11336083_8,11336083_C047759_D006261,,
770957398,false,true,5,2015-08-14T22:38:00,,Direct,0.7848,C054218,manidipine,D006261,headache,Two cases in the delapril group were withdrawn during the study because of an intolerable cough and one case in the manidipine group because of intolerable dizziness and headache.,11336083_8,11336083_C054218_D006261,,
770957399,false,true,5,2015-08-14T23:53:00,,No Relation,1,C054218,manidipine,D003929,diabetic,"In conclusion, both delapril and manidipine are effective in the reduction of microalbuminuria in normotensive type 2 diabetic patients with persistent microalbuminuria.",11336083_9,11336083_C054218_D003929,,
770957400,false,true,5,2015-08-15T02:47:00,,Direct,0.5968,D000431,ethanol,C567108,testicular atrophy,"The presentations were (1) Alcoholic myopathy: Past, present and future, by Timothy J. Peters and Victor R. Preedy; (2) Protein adducts in the type I and II fiber-predominant muscles of the ethanol-fed rat, by Simon Worrall, Seppo Parkkila, and Onni Niemela; (3) Hydroperoxides and changes in alcoholic myopathy, by Junko Adachi, Migiwa Asamo, and Yasuhino Ueno; and (4) A close association between testicular atrophy, muscle atrophy, and the increase in protein catabolism after chronic ethanol administration, by Kunihiko Takeda, Masayoshi Yamauchi, Kazuhiko Sakamoto, Masaru Takagi, Hisato Nakajima, and Gotaro Toda.",11391050_3,11391050_D000431_C567108,,
770957401,false,true,5,2015-08-14T22:30:00,,Direct,1,D000431,ethanol,D009133,muscle atrophy,"The presentations were (1) Alcoholic myopathy: Past, present and future, by Timothy J. Peters and Victor R. Preedy; (2) Protein adducts in the type I and II fiber-predominant muscles of the ethanol-fed rat, by Simon Worrall, Seppo Parkkila, and Onni Niemela; (3) Hydroperoxides and changes in alcoholic myopathy, by Junko Adachi, Migiwa Asamo, and Yasuhino Ueno; and (4) A close association between testicular atrophy, muscle atrophy, and the increase in protein catabolism after chronic ethanol administration, by Kunihiko Takeda, Masayoshi Yamauchi, Kazuhiko Sakamoto, Masaru Takagi, Hisato Nakajima, and Gotaro Toda.",11391050_3,11391050_D000431_D009133,,
770957402,false,true,5,2015-08-14T22:10:00,,No Relation,0.5999,D000431,ethanol,D000437,Alcoholic myopathy,"The presentations were (1) Alcoholic myopathy: Past, present and future, by Timothy J. Peters and Victor R. Preedy; (2) Protein adducts in the type I and II fiber-predominant muscles of the ethanol-fed rat, by Simon Worrall, Seppo Parkkila, and Onni Niemela; (3) Hydroperoxides and changes in alcoholic myopathy, by Junko Adachi, Migiwa Asamo, and Yasuhino Ueno; and (4) A close association between testicular atrophy, muscle atrophy, and the increase in protein catabolism after chronic ethanol administration, by Kunihiko Takeda, Masayoshi Yamauchi, Kazuhiko Sakamoto, Masaru Takagi, Hisato Nakajima, and Gotaro Toda.",11391050_3,11391050_D000431_D000437,,
770957403,false,true,5,2015-08-14T20:54:00,,No Relation,1,D005473,Fluoxetine,D019052,postnatal depression,"Appleby et al (1997) reported that Fluoxetine was significantly more effective than placebo and, after an initial session of counselling, as effective as a full course of cognitive-behavioural counselling in the treatment of postnatal depression.",11406023_13,11406023_D005473_D019052,,
770957404,false,true,5,2015-08-14T20:56:00,,No Relation,1,D005473,fluoxetine,D019052,postnatal depression,"Women with postnatal depression can be effectively treated with fluoxetine, which is as effective as a course of cognitive-behavioural counselling in the short-term.",11406023_15,11406023_D005473_D019052,,
770957405,false,true,5,2015-08-14T20:52:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D013035,muscle spasms,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D013035,,
770957406,false,true,5,2015-08-14T22:05:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D005901,glaucoma,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D005901,,
770957407,false,true,5,2015-08-15T00:16:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D010146,pain,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D010146,,
770957408,false,true,5,2015-08-15T00:42:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D009325,nausea,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D009325,,
770957409,false,true,5,2015-08-15T00:31:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D001008,anxiety,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D001008,,
770957410,false,true,5,2015-08-15T02:00:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D019282,wasting diseases,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D019282,,
770957411,false,true,5,2015-08-15T01:17:00,,No Relation,1,D013759,Delta(9)-tetrahydrocannabinol/THC,D003699,Delta(9)-tetrahydrocannabinol/THC,"The active principle in marijuana, Delta(9)-tetrahydrocannabinol (THC), has been shown to have wide therapeutic application for a number of important medical conditions, including pain, anxiety, glaucoma, nausea, emesis, muscle spasms, and wasting diseases.",11448725_1,11448725_D013759_D003699,,
770957412,false,true,5,2015-08-14T23:16:00,,Direct,0.8011,D009599,SNP,D013610,tachycardia,"Despite tachycardia and sympathetic activation with both SNP and phentolamine, LF variability in RR, MSNA, and BP increased during SNP and decreased during phentolamine (SNP: RR +20 +/- 6%, MSNA +3 +/- 5%, systolic BP +9 +/- 6%, diastolic BP +7 +/- 5%; phentolamine: RR -2 +/- 7%, MSNA -34 +/- 6%, systolic BP -16 +/- 8%, diastolic BP -13 +/- 4%, P < 0.05 except systolic BP, where P = 0.09).",11454557_4,11454557_D009599_D013610,,
770957413,false,true,5,2015-08-14T20:55:00,,No Relation,0.7769,D010646,phentolamine,D013610,tachycardia,"Despite tachycardia and sympathetic activation with both SNP and phentolamine, LF variability in RR, MSNA, and BP increased during SNP and decreased during phentolamine (SNP: RR +20 +/- 6%, MSNA +3 +/- 5%, systolic BP +9 +/- 6%, diastolic BP +7 +/- 5%; phentolamine: RR -2 +/- 7%, MSNA -34 +/- 6%, systolic BP -16 +/- 8%, diastolic BP -13 +/- 4%, P < 0.05 except systolic BP, where P = 0.09).",11454557_4,11454557_D010646_D013610,,
770957414,false,true,5,2015-08-15T02:33:00,,Direct,1,D009638,noradrenaline,D002561,vascular disorders,"Supersensitivity to noradrenaline contributes to certain vascular disorders (e.g., hypertension) and chronic neuropathic pain conditions (e.g., complex regional pain syndrome).",11474550_1,11474550_D009638_D002561,,
770957415,false,true,5,2015-08-15T01:28:00,,Direct,0.6122,D009638,noradrenaline,D006973,hypertension,"Supersensitivity to noradrenaline contributes to certain vascular disorders (e.g., hypertension) and chronic neuropathic pain conditions (e.g., complex regional pain syndrome).",11474550_1,11474550_D009638_D006973,,
770957416,false,true,5,2015-08-14T22:52:00,,Direct,0.5894,D009638,noradrenaline,D010146,regional pain syndrome/neuropathic pain,"Supersensitivity to noradrenaline contributes to certain vascular disorders (e.g., hypertension) and chronic neuropathic pain conditions (e.g., complex regional pain syndrome).",11474550_1,11474550_D009638_D010146,,
770957417,false,true,5,2015-08-15T01:59:00,,No Relation,1,D006145,guanethidine,D006930,thermal hyperalgesia,To investigate the effect of guanethidine pretreatment on thermal hyperalgesia. the experimental sites were sensitized to heat by the topical application of 0.6% capsaicin.,11474550_7,11474550_D006145_D006930,,
770957418,false,true,5,2015-08-14T22:46:00,,No Relation,0.8179,D002211,capsaicin,D006930,thermal hyperalgesia,To investigate the effect of guanethidine pretreatment on thermal hyperalgesia. the experimental sites were sensitized to heat by the topical application of 0.6% capsaicin.,11474550_7,11474550_D002211_D006930,,
770957419,false,true,5,2015-08-14T22:19:00,,No Relation,1,D002211,capsaicin,D010146,pain,"Both before and after the application of capsaicin, the heat-pain threshold and heat-pain ratings to suprathreshold stimulation were similar at sites pretreated for 2 weeks with guanethidine or saline.",11474550_8,11474550_D002211_D010146,,
770957420,false,true,5,2015-08-15T01:54:00,,No Relation,0.8005,D006145,guanethidine,D010146,pain,"Both before and after the application of capsaicin, the heat-pain threshold and heat-pain ratings to suprathreshold stimulation were similar at sites pretreated for 2 weeks with guanethidine or saline.",11474550_8,11474550_D006145_D010146,,
770957421,false,true,5,2015-08-14T22:12:00,,Direct,1,D006145,guanethidine,D006930,thermal hyperalgesia,"However, after the iontophoresis of noradrenaline, thermal hyperalgesia was greater at the guanethidine-pretreated site than the saline pretreated site.",11474550_9,11474550_D006145_D006930,,
770957422,false,true,5,2015-08-14T22:27:00,,Direct,0.6181,D009638,noradrenaline,D006930,thermal hyperalgesia,"However, after the iontophoresis of noradrenaline, thermal hyperalgesia was greater at the guanethidine-pretreated site than the saline pretreated site.",11474550_9,11474550_D009638_D006930,,
770957423,false,true,5,2015-08-14T22:27:00,,Indirect,1,D006145,guanethidine,D006930,thermal hyperalgesia,"These observations indicate that prolonged depletion of adrenergic stores by guanethidine induces adrenergic supersensitivity in cutaneous vessels, and that adrenergic supersensitivity enhances thermal hyperalgesia in the presence of noradrenaline.",11474550_10,11474550_D006145_D006930,,
770957424,false,true,5,2015-08-15T02:33:00,,Direct,0.7885,D009638,noradrenaline,D006930,thermal hyperalgesia,"These observations indicate that prolonged depletion of adrenergic stores by guanethidine induces adrenergic supersensitivity in cutaneous vessels, and that adrenergic supersensitivity enhances thermal hyperalgesia in the presence of noradrenaline.",11474550_10,11474550_D009638_D006930,,
770957425,false,true,5,2015-08-15T00:59:00,,Direct,1,D013012,sorbitol,D000140,lactic acidosis,Another feature of TURP syndrome: hyperglycaemia and lactic acidosis caused by massive absorption of sorbitol.,11493513_0,11493513_D013012_D000140,,
770957426,false,true,5,2015-08-14T20:51:00,,Direct,0.8006,D013012,sorbitol,D013577,TURP syndrome,Another feature of TURP syndrome: hyperglycaemia and lactic acidosis caused by massive absorption of sorbitol.,11493513_0,11493513_D013012_D013577,,
770957427,false,true,5,2015-08-15T01:47:00,,No Relation,0.6199,D013012,sorbitol,D000140,lactic acidosis,We report a case where hyperglycaemia and lactic acidosis complicated the TURP syndrome caused by the massive absorption (approximately 15 litres) of a sorbitol- mannitol irrigation solution.,11493513_3,11493513_D013012_D000140,,
770957428,false,true,5,2015-08-15T00:00:00,,Direct,1,D013012,sorbitol,D013577,TURP syndrome,We report a case where hyperglycaemia and lactic acidosis complicated the TURP syndrome caused by the massive absorption (approximately 15 litres) of a sorbitol- mannitol irrigation solution.,11493513_3,11493513_D013012_D013577,,
770957429,false,true,5,2015-08-14T23:59:00,,Direct,1,D008353,mannitol,D013577,TURP syndrome,We report a case where hyperglycaemia and lactic acidosis complicated the TURP syndrome caused by the massive absorption (approximately 15 litres) of a sorbitol- mannitol irrigation solution.,11493513_3,11493513_D008353_D013577,,
770957430,false,true,5,2015-08-14T23:42:00,It's 'sorbitol- mannitol irrigation solution' and not just 'Mannitol',No Relation,0.8183,D008353,mannitol,D000140,lactic acidosis,We report a case where hyperglycaemia and lactic acidosis complicated the TURP syndrome caused by the massive absorption (approximately 15 litres) of a sorbitol- mannitol irrigation solution.,11493513_3,11493513_D008353_D000140,,
770957431,false,true,5,2015-08-14T22:19:00,,No Relation,0.6131,D013012,sorbitol,D000140,lactic acidosis,The proposed mechanism is a type B lactic acidosis related to the metabolism of sorbitol.,11493513_4,11493513_D013012_D000140,,
770957432,false,true,5,2015-08-15T01:00:00,,No Relation,1,D014364,tryptophan,C567529,bipolar affective disorder,Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder.,11513817_0,11513817_D014364_C567529,,
770957433,false,true,5,2015-08-14T22:59:00,,No Relation,0.6149,D014364,tryptophan,C564108,manic-depressive illness,The lowering of mood induced by an acute tryptophan depletion (ATD) has been proposed as a candidate endophenotype for the vulnerability to manic-depressive illness.,11513817_1,11513817_D014364_C564108,,
770957434,false,true,5,2015-08-14T20:57:00,,No Relation,1,D014364,tryptophan,C567529,BAD,"At 5 hours after AA drink ingestion, relative to the placebo, ATD resulted in 74% and 84% decreases in total plasma tryptophan concentrations in control subjects and relatives of patients with BAD, respectively.",11513817_5,11513817_D014364_C567529,,
770957435,false,true,5,2015-08-15T01:57:00,,No Relation,1,D014364,tryptophan,C567529,BAD,These results replicate and extend previous findings suggesting that URs of patients with BAD are more susceptible to low tryptophan availability.,11513817_9,11513817_D014364_C567529,,
770957436,false,true,5,2015-08-15T01:19:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.,11556039_0,11556039_D013629_D009369,,
770957437,false,true,5,2015-08-15T00:26:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,Eighty-eight women presenting with locally advanced or metastatic breast cancer were treated with tamoxifen alone.,11556039_1,11556039_D013629_D009369,,
770957438,false,true,5,2015-08-14T22:05:00,,No Relation,1,D004967,Estrogen,D009369,tumour,Estrogen and progesterone receptors (ER and PR) were immunocytochemically analysed in mammary tumour cells obtained by fine needle sampling from 73 patients.,11556039_2,11556039_D004967_D009369,,
770957439,false,true,5,2015-08-15T02:25:00,,No Relation,1,D011374,progesterone,D009369,tumour,Estrogen and progesterone receptors (ER and PR) were immunocytochemically analysed in mammary tumour cells obtained by fine needle sampling from 73 patients.,11556039_2,11556039_D011374_D009369,,
770957440,false,true,5,2015-08-15T01:25:00,,No Relation,1,D013974,levothyroxine,D007037,hypothyroidism,One of my pregnant patients is taking levothyroxine for hypothyroidism.,11561329_1,11561329_D013974_D007037,,
770957441,false,true,5,2015-08-14T21:08:00,,No Relation,0.8072,D000431,alcohol,D000230,adenocarcinomas,"A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States).",11562112_0,11562112_D000431_D000230,,
770957442,false,true,5,2015-08-14T22:22:00,,No Relation,0.8002,D000431,alcohol,D013272,"gastric cardia, and distal gastric adenocarcinomas","We sought to determine the role of smoking, alcohol use, and body size characteristics in the etiology of esophageal, gastric cardia, and distal gastric adenocarcinomas.",11562112_3,11562112_D000431_D013272,,
770957443,false,true,5,2015-08-14T23:38:00,,No Relation,1,D000431,Alcohol,D009369,tumor,Alcohol use was not associated with an increased risk of these tumor types.,11562112_8,11562112_D000431_D009369,,
770957444,false,true,5,2015-08-15T02:05:00,,No Relation,0.8083,D000450,Aldosterone,D051436,renal disease,Aldosterone in progressive renal disease.,11709805_0,11709805_D000450_D051436,,
770957445,false,true,5,2015-08-14T20:53:00,,No Relation,0.8162,D000450,aldosterone,D051436,renal disease,"Blockade of the renin-angiotensin-aldosterone system has proven effective in retarding progression of renal disease in the remnant kidney model, as well as other experimental diseases, and, most importantly, in a range of progressive human renal diseases.",11709805_1,11709805_D000450_D051436,,
770957446,false,true,5,2015-08-15T00:28:00,,No Relation,0.5949,D000450,aldosterone,D015658,human renal diseases,"Blockade of the renin-angiotensin-aldosterone system has proven effective in retarding progression of renal disease in the remnant kidney model, as well as other experimental diseases, and, most importantly, in a range of progressive human renal diseases.",11709805_1,11709805_D000450_D015658,,
770957447,false,true,5,2015-08-14T23:33:00,,No Relation,1,D000450,aldosterone,D004194,diseases,"Blockade of the renin-angiotensin-aldosterone system has proven effective in retarding progression of renal disease in the remnant kidney model, as well as other experimental diseases, and, most importantly, in a range of progressive human renal diseases.",11709805_1,11709805_D000450_D004194,,
770957448,false,true,5,2015-08-14T21:03:00,,No Relation,0.5967,D000450,aldosterone,D006973,hypertension,"Thus, aldosterone, as well as angiotensin II, appears to be instrumental in sustaining the hypertension and fibroproliferative destruction of the residual kidney.",11709805_4,11709805_D000450_D006973,,
770957449,false,true,5,2015-08-15T01:52:00,,No Relation,0.79,D000804,angiotensin II,D006973,hypertension,"Thus, aldosterone, as well as angiotensin II, appears to be instrumental in sustaining the hypertension and fibroproliferative destruction of the residual kidney.",11709805_4,11709805_D000804_D006973,,
770957450,false,true,5,2015-08-14T21:57:00,,No Relation,0.6037,D019256,cadmium chloride,D063646,tumorigenesis,The molecular mechanisms potentially responsible for cadmium-induced cell transformation and tumorigenesis were investigated using Balb/c-3T3 cells transformed with cadmium chloride.,11711542_1,11711542_D019256_D063646,,
770957451,false,true,5,2015-08-14T23:50:00,,No Relation,0.5716,D002104,cadmium,D063646,tumorigenesis,The molecular mechanisms potentially responsible for cadmium-induced cell transformation and tumorigenesis were investigated using Balb/c-3T3 cells transformed with cadmium chloride.,11711542_1,11711542_D002104_D063646,,
770957452,false,true,5,2015-08-14T22:19:00,,No Relation,1,D002104,cadmium,D063646,tumorigenesis,Blocking the translation of TEF-1 delta with antisense TEF-1 delta mRNA resulted in a significant reversal of the oncogenic potential of cadmium-transformed Balb/c-3T3 cells as evidenced from suppression in anchorage-independent growth and tumorigenesis in nude mice.,11711542_8,11711542_D002104_D063646,,
770957453,false,true,5,2015-08-14T22:19:00,,Direct,0.7869,D002104,cadmium,D063646,tumorigenesis,"Our findings demonstrate, for the first time, that the cell transformation and tumorigenesis induced by cadmium are due, at least in part, to the overexpression of TEF-1 delta, a novel cadmium-responsive proto-oncogene.",11711542_9,11711542_D002104_D063646,,
770957454,false,true,5,2015-08-14T21:02:00,,No Relation,0.8137,D004656,Enalapril,D006973,hypertension,Enalapril acts through release of nitric oxide in patients with essential hypertension.,11725911_0,11725911_D004656_D006973,,
770957455,false,true,5,2015-08-15T01:36:00,,No Relation,1,D009569,nitric oxide,D006973,hypertension,Enalapril acts through release of nitric oxide in patients with essential hypertension.,11725911_0,11725911_D009569_D006973,,
770957456,false,true,5,2015-08-14T20:51:00,,No Relation,1,D004656,enalapril,D006973,hypertension,"To study the mechanism of action of enalapril, an ACEI, serum reactive nitrite intermediates (RNI) and citrulline, by products of nitric oxide metabolism were measured before and after treatment with enalapril in 25 consecutive patients of essential hypertension.",11725911_3,11725911_D004656_D006973,,
770957457,false,true,5,2015-08-14T23:04:00,,No Relation,1,D009569,nitric oxide,D006973,hypertension,"To study the mechanism of action of enalapril, an ACEI, serum reactive nitrite intermediates (RNI) and citrulline, by products of nitric oxide metabolism were measured before and after treatment with enalapril in 25 consecutive patients of essential hypertension.",11725911_3,11725911_D009569_D006973,,
770957458,false,true,5,2015-08-15T00:50:00,,No Relation,1,D009573,nitrite,D006973,hypertension,"To study the mechanism of action of enalapril, an ACEI, serum reactive nitrite intermediates (RNI) and citrulline, by products of nitric oxide metabolism were measured before and after treatment with enalapril in 25 consecutive patients of essential hypertension.",11725911_3,11725911_D009573_D006973,,
770957459,false,true,5,2015-08-14T21:08:00,,No Relation,1,D013806,theophylline,D001249,asthma,Effect of theophylline on airway inflammation in asthma.,11743900_0,11743900_D013806_D001249,,
770957460,false,true,5,2015-08-14T20:57:00,,No Relation,1,D013806,theophylline,D001249,asthma,To investigate whether low dose theophylline has an anti-inflammatory effect in asthma.,11743900_1,11743900_D013806_D001249,,
770957461,false,true,5,2015-08-15T02:05:00,,No Relation,1,D013806,theophylline,D013224,asthmatic,Nineteen asthmatic subjects were given 200 mg sustained-release theophylline preparation twice daily for 4 weeks.,11743900_2,11743900_D013806_D013224,,
770957462,false,true,5,2015-08-14T21:23:00,,No Relation,1,D013806,theophylline,D013224,asthmatic,"Before using theophylline, sputum eosinophils, EG2+ eosinophils, and ECP in asthmatic group were much higher than those of healthy group.",11743900_6,11743900_D013806_D013224,,
770957463,false,true,5,2015-08-14T20:54:00,,No Relation,1,D013806,theophylline,D001249,asthma,These results indicated that low dose theophylline had inhibitory action on airway inflammation in asthma with noticeable improvement of the patients' symptoms and lung function.,11743900_11,11743900_D013806_D001249,,
770957464,false,true,5,2015-08-14T23:02:00,,No Relation,1,D013629,tamoxifen,D001943,breast carcinoma,Iodine-labeled tamoxifen uptake in primary human breast carcinoma.,11752079_0,11752079_D013629_D001943,,
770957465,false,true,5,2015-08-15T00:47:00,,No Relation,1,D007455,Iodine,D001943,breast carcinoma,Iodine-labeled tamoxifen uptake in primary human breast carcinoma.,11752079_0,11752079_D007455_D001943,,
770957466,false,true,5,2015-08-14T21:06:00,,No Relation,1,D013629,tamoxifen,D009369,tumor,Assessing tumor uptake and retention of (123)I-labeled tamoxifen (TX) could increase our understanding of TX's action and the mechanisms involved in resistance to the drug.,11752079_1,11752079_D013629_D009369,,
770957467,false,true,5,2015-08-14T22:10:00,,No Relation,0.5886,D004967,estrogen,D009369,Tumor,Tumor-to-normal tissue uptake ratios (T/N) derived from SPECT images were related to estrogen receptor (ER) and progesterone receptor (PR) status.,11752079_3,11752079_D004967_D009369,,
770957468,false,true,5,2015-08-14T22:23:00,,No Relation,0.8065,D011374,progesterone,D009369,Tumor,Tumor-to-normal tissue uptake ratios (T/N) derived from SPECT images were related to estrogen receptor (ER) and progesterone receptor (PR) status.,11752079_3,11752079_D011374_D009369,,
770957469,false,true,5,2015-08-14T22:23:00,,No Relation,1,D012254,ribavirin,D006526,chronic hepatitis C virus,"In 55 patients with chronic hepatitis C virus (HCV), 33 treated with interferon (IFN) and 22 treated with IFN + ribavirin, sera was collected prior to treatment, at 3 + 6 months of therapy and 6 months post-treatment.",11759109_2,11759109_D012254_D006526,,
770957470,false,true,5,2015-08-15T01:52:00,,No Relation,0.8152,D000409,alanine,D005355,fibrosis,"Levels of ICAM-1, VCAM-1 and hyaluronic acid were correlated with alanine aminotransferase levels, HCV-RNA-polymerase chain reaction status and histological fibrosis scoring.",11759109_3,11759109_D000409_D005355,,
770957471,false,true,5,2015-08-14T20:53:00,,No Relation,0.5927,D003024,clozapine,D000380,agranulocytosis,"A number of studies investigating the use of clozapine have been published in children; however, owing to the frequent monitoring required for agranulocytosis, the use of clozapine may be restricted to patients with treatment-refractory disease.",11772153_4,11772153_D003024_D000380,,
770957472,false,true,5,2015-08-15T00:36:00,,No Relation,0.8041,D003024,clozapine,D006402,blood glucose,"With accumulating data on the development of glucose intolerance in adults receiving clozapine, closer monitoring of bodyweight and fasting blood glucose is imperative.",11772153_5,11772153_D003024_D006402,,
770957473,false,true,5,2015-08-15T01:52:00,,No Relation,0.8372,D005947,glucose,D006402,blood glucose,"With accumulating data on the development of glucose intolerance in adults receiving clozapine, closer monitoring of bodyweight and fasting blood glucose is imperative.",11772153_5,11772153_D005947_D006402,,
770957474,false,true,5,2015-08-15T00:50:00,,Direct,0.6056,D003024,clozapine,D018149,glucose intolerance,"With accumulating data on the development of glucose intolerance in adults receiving clozapine, closer monitoring of bodyweight and fasting blood glucose is imperative.",11772153_5,11772153_D003024_D018149,,
770957475,false,true,5,2015-08-15T02:04:00,,No Relation,1,D005947,glucose,D018149,glucose intolerance,"With accumulating data on the development of glucose intolerance in adults receiving clozapine, closer monitoring of bodyweight and fasting blood glucose is imperative.",11772153_5,11772153_D005947_D018149,,
770957476,false,true,5,2015-08-15T01:04:00,,Direct,1,D003024,Clozapine,D012640,seizure,"Clozapine also has an increased seizure risk, therefore a baseline electroencephalogram should be performed, as well as continued vigilance for this adverse effect.",11772153_6,11772153_D003024_D012640,,
770957477,false,true,5,2015-08-14T21:44:00,,No Relation,0.6191,D003024,clozapine,D001480,extrapyramidal symptoms/EPS,"Unlike clozapine, its receptor interaction profile lends itself toward increased risk of extrapyramidal symptoms (EPS) and hyperprolactinaemia.",11772153_8,11772153_D003024_D001480,,
770957478,false,true,5,2015-08-15T02:03:00,,No Relation,0.5967,D003024,clozapine,D006966,hyperprolactinaemia,"Unlike clozapine, its receptor interaction profile lends itself toward increased risk of extrapyramidal symptoms (EPS) and hyperprolactinaemia.",11772153_8,11772153_D003024_D006966,,
770957479,false,true,5,2015-08-15T02:02:00,,Direct,0.6088,C076029,olanzapine,D015430,Bodyweight gain,"Bodyweight gain is a common adverse effect, although somewhat less than that reported with olanzapine.",11772153_9,11772153_C076029_D015430,,
770957480,false,true,5,2015-08-14T21:00:00,,Direct,1,D018967,Risperidone,D001714,mania,"Risperidone-induced mania has been reported in adults and, therefore, increased caution should be used when deciding to treat children and adolescents with risperidone, particularly in those with a predisposition toward mania.",11772153_11,11772153_D018967_D001714,,
770957481,false,true,5,2015-08-15T00:58:00,,Direct,1,C076029,Olanzapine,D001714,mania,"Olanzapine, like risperidone, has also been associated with onset of mania in adults.",11772153_12,11772153_C076029_D001714,,
770957482,false,true,5,2015-08-15T00:26:00,,Direct,1,D018967,risperidone,D001714,mania,"Olanzapine, like risperidone, has also been associated with onset of mania in adults.",11772153_12,11772153_D018967_D001714,,
770957483,false,true,5,2015-08-15T00:55:00,,Direct,1,C076029,Olanzapine,D015430,bodyweight gain,Olanzapine has a receptor profile that results in significant risk for bodyweight gain and sedation.,11772153_13,11772153_C076029_D015430,,
770957484,false,true,5,2015-08-15T02:10:00,,No Relation,0.8093,D005947,glucose,D006402,blood glucose,"Furthermore, this drug has been linked to the development of glucose intolerance; thus, it is important to monitor bodyweight and fasting blood glucose on a frequent basis.",11772153_14,11772153_D005947_D006402,,
770957485,false,true,5,2015-08-15T01:08:00,,No Relation,1,D005947,glucose,D018149,glucose intolerance,"Furthermore, this drug has been linked to the development of glucose intolerance; thus, it is important to monitor bodyweight and fasting blood glucose on a frequent basis.",11772153_14,11772153_D005947_D018149,,
770957486,false,true,5,2015-08-14T21:03:00,,Direct,0.607,C076029,olanzapine,D015430,bodyweight gain,"Quetiapine appears to have increased risk for sedation and bodyweight gain, albeit less than that of olanzapine.",11772153_17,11772153_C076029_D015430,,
770957487,false,true,5,2015-08-14T21:59:00,,Direct,1,C069541,Quetiapine,D015430,bodyweight gain,"Quetiapine appears to have increased risk for sedation and bodyweight gain, albeit less than that of olanzapine.",11772153_17,11772153_C069541_D015430,,
770957488,false,true,5,2015-08-14T23:38:00,,No Relation,1,C092292,ziprasidone,D015430,bodyweight gain,Lack of evidence for bodyweight gain with ziprasidone is a considerable advantage.,11772153_23,11772153_C092292_D015430,,
770957489,false,true,5,2015-08-14T20:54:00,,No Relation,1,D007213,Indomethacin,D006831,polyhydramnios,Indomethacin therapy in the treatment of polyhydramnios due to placental chorioangioma.,11776505_0,11776505_D007213_D006831,,
770957490,false,true,5,2015-08-15T02:07:00,,No Relation,0.8208,D007213,Indomethacin,D006391,placental chorioangioma,Indomethacin therapy in the treatment of polyhydramnios due to placental chorioangioma.,11776505_0,11776505_D007213_D006391,,
770957491,false,true,5,2015-08-15T01:03:00,,No Relation,1,D007213,indomethacin,D012128,respiratory distress,"Preterm labor started with respiratory distress and indomethacin, 25 mg was given every 6 hours.",11776505_4,11776505_D007213_D012128,,
770957492,false,true,5,2015-08-14T21:54:00,,No Relation,1,D007213,indomethacin,D007752,Preterm labor,"Preterm labor started with respiratory distress and indomethacin, 25 mg was given every 6 hours.",11776505_4,11776505_D007213_D007752,,
770957493,false,true,5,2015-08-14T23:56:00,,No Relation,0.7943,D013256,steroid,D003093,ulcerative colitis,Effective maintenance leukocytapheresis for patients with steroid dependent or resistant ulcerative colitis.,11800081_0,11800081_D013256_D003093,,
770957494,false,true,5,2015-08-15T01:35:00,,No Relation,0.8101,D000305,corticosteroid,D003093,ulcerative colitis/UC,We prospectively examined the effect of leukocytapheresis (LA) on the maintenance of remission in 7 patients with ulcerative colitis (UC) who were initially refractory to corticosteroid therapy (steroid resistant or steroid dependent).,11800081_1,11800081_D000305_D003093,,
770957495,false,true,5,2015-08-14T20:56:00,,No Relation,1,D013256,steroid,D003093,ulcerative colitis/UC,We prospectively examined the effect of leukocytapheresis (LA) on the maintenance of remission in 7 patients with ulcerative colitis (UC) who were initially refractory to corticosteroid therapy (steroid resistant or steroid dependent).,11800081_1,11800081_D013256_D003093,,
770957496,false,true,5,2015-08-15T00:50:00,,No Relation,1,D013256,steroid,D003093,UC,The patients with refractory UC had been in remission due to LA (induction LA) in combination with the steroid therapy.,11800081_2,11800081_D013256_D003093,,
770957497,false,true,5,2015-08-15T02:18:00,,No Relation,1,D013256,steroid/steroids,D003093,UC,It is concluded that the maintenance LA therapy might be effective in some patients with steroid dependent or resistant UC for the maintenance of remission without steroids.,11800081_10,11800081_D013256_D003093,,
770957498,false,true,5,2015-08-14T22:42:00,,Direct,1,D006220,haloperidol,D009459,neuroleptic syndrome,A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.,11819156_1,11819156_D006220_D009459,,
770957499,false,true,5,2015-08-14T22:16:00,,No Relation,1,D044062,prostacyclins,D065627,PPH,"Due to the complicated nature of this therapy, inhaled, sc. and oral prostacyclins have also been evaluated for treatment of PPH.",11829729_5,11829729_D044062_D065627,,
770957500,false,true,5,2015-08-15T01:38:00,,Direct,1,D002784,cholesterol,D003324,coronary artery disease/CAD,It is commonly agreed that people with a high blood LDL-cholesterol will have a higher risk of coronary artery disease (CAD) than people with low blood LDL-cholesterol.,11835697_1,11835697_D002784_D003324,,
770957501,false,true,5,2015-08-14T21:02:00,,No Relation,0.8141,C008047,HMG-CoA,D006937,hypercholesterolemia,"Simvastatin, an HMG-CoA reductase inhibitor, is listed as an essential drug for the treatment of hypercholesterolemia.",11835697_4,11835697_C008047_D006937,,
770957502,false,true,5,2015-08-14T22:20:00,,No Relation,1,D019821,Simvastatin,D006937,hypercholesterolemia,"Simvastatin, an HMG-CoA reductase inhibitor, is listed as an essential drug for the treatment of hypercholesterolemia.",11835697_4,11835697_D019821_D006937,,
770957503,false,true,5,2015-08-14T20:55:00,,No Relation,1,C006632,Arsenic trioxide,D007943,leukemic differentiation,Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.,11839383_0,11839383_C006632_D007943,,
770957504,false,true,5,2015-08-14T20:53:00,,No Relation,0.7902,D008775,methylprednisolone,D007943,leukemic differentiation,Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.,11839383_0,11839383_D008775_D007943,,
770957505,false,true,5,2015-08-14T23:00:00,,No Relation,0.4319,D008775,methylprednisolone,D007951,myeloid leukemia,High dose methylprednisolone treatment has been shown to induce in vivo and in vitro differentiation of myeloid leukemia cells to mature granulocytes in patients with acute promyelocytic leukemia (APL) and other subtypes of acute myeloid leukemia (AML).,11839383_2,11839383_D008775_D007951,,
770957506,false,true,5,2015-08-15T00:27:00,,No Relation,1,D008775,methylprednisolone,D015473,APL/acute promyelocytic leukemia,High dose methylprednisolone treatment has been shown to induce in vivo and in vitro differentiation of myeloid leukemia cells to mature granulocytes in patients with acute promyelocytic leukemia (APL) and other subtypes of acute myeloid leukemia (AML).,11839383_2,11839383_D008775_D015473,,
770957507,false,true,5,2015-08-14T21:24:00,,No Relation,0.8125,D008775,methylprednisolone,D015470,acute myeloid leukemia/AML,High dose methylprednisolone treatment has been shown to induce in vivo and in vitro differentiation of myeloid leukemia cells to mature granulocytes in patients with acute promyelocytic leukemia (APL) and other subtypes of acute myeloid leukemia (AML).,11839383_2,11839383_D008775_D015470,,
770957508,false,true,5,2015-08-14T20:58:00,,No Relation,0.5989,C006632,Arsenic trioxide,D015473,APL,Arsenic trioxide (As(2)O(3)) has been confirmed to have remission induction effects on APL.,11839383_3,11839383_C006632_D015473,,
770957509,false,true,5,2015-08-15T01:34:00,,No Relation,1,D008775,methylprednisolone,D007943,leukemic differentiation,"In contrast to methylprednisolone, there was no effect of phosphatase inhibitors on As(2)O(3)-induced leukemic differentiation.",11839383_9,11839383_D008775_D007943,,
770957510,false,true,5,2015-08-14T22:51:00,,No Relation,1,D008775,methylprednisolone,D007943,leukemic differentiation,"Incomplete leukemic differentiation occurred with lower As(2)O(3) concentration as 10(-6)M. Unlike As(2)O(3), methylprednisolone induced complete granulocytic and/or monocytic differentiation of HL 60 and K 562 cells via upregulation of PP2A regulatory subunits.",11839383_10,11839383_D008775_D007943,,
770957511,false,true,5,2015-08-14T20:51:00,,No Relation,1,D008775,methylprednisolone,D007943,leukemic differentiation,"Therefore, As(2)O(3) and methylprednisolone are promising agents that have the potential to be used together in myeloid leukemic differentiation therapy.",11839383_11,11839383_D008775_D007943,,
770957512,false,true,5,2015-08-15T00:27:00,,No Relation,1,D013739,testosterone,D007006,hypogonadotrophic hypogonadism,"These data were consistent with partial hypogonadotrophic hypogonadism of hypothalamic origin, and the patient was treated with testosterone.",11874189_15,11874189_D013739_D007006,,
770957513,false,true,5,2015-08-14T23:02:00,,No Relation,0.794,D009569,nitric oxide,D009336,necrosis,Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.,11875767_0,11875767_D009569_D009336,,
770957514,false,true,5,2015-08-15T01:29:00,,No Relation,1,D009569,nitric oxide,D009369,tumor,Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.,11875767_0,11875767_D009569_D009369,,
770957515,false,true,5,2015-08-14T22:38:00,,No Relation,1,D010431,Pentoxifylline,D009369,tumor,Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.,11875767_0,11875767_D010431_D009369,,
770957516,false,true,5,2015-08-14T20:51:00,,No Relation,1,D010431,Pentoxifylline,D009336,necrosis,Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.,11875767_0,11875767_D010431_D009336,,
770957517,false,true,5,2015-08-14T22:00:00,,No Relation,1,D010431,Pentoxifylline/PTX,D009336,necrosis,"Pentoxifylline (PTX), a phosphodiesterase inhibitor, is known to downregulate tumor necrosis factor-alpha (TNF-alpha) secretion induced by lipopolysacchride (LPS) and gamma interferon (IFN-gamma).",11875767_1,11875767_D010431_D009336,,
770957518,false,true,5,2015-08-14T21:56:00,,No Relation,1,D010431,Pentoxifylline/PTX,D009369,tumor,"Pentoxifylline (PTX), a phosphodiesterase inhibitor, is known to downregulate tumor necrosis factor-alpha (TNF-alpha) secretion induced by lipopolysacchride (LPS) and gamma interferon (IFN-gamma).",11875767_1,11875767_D010431_D009369,,
770957519,false,true,5,2015-08-14T20:56:00,,Direct,1,D014635,sodium valproate,D009395,Tubulo-interstitial nephritis,Tubulo-interstitial nephritis caused by sodium valproate.,11891102_0,11891102_D014635_D009395,,
770957520,false,true,5,2015-08-15T01:25:00,,No Relation,0.7998,D014635,sodium valproate,D004827,epilepsy,A severely handicapped 14-year-old Japanese girl had epilepsy and was treated with sodium valproate (SV) from the age of 7 years.,11891102_1,11891102_D014635_D004827,,
770957521,false,true,5,2015-08-15T01:49:00,,No Relation,1,D002996,clomiphene citrate,D011085,polycystic ovary syndrome/PCOS,"With the availability of laparoscopic ovarian cautery, there has been a resurgence in interest in the surgical treatment of clomiphene citrate-resistant polycystic ovary syndrome (PCOS).",11915582_1,11915582_D002996_D011085,,
770957522,false,true,5,2015-08-14T22:27:00,,No Relation,1,D002996,clomiphene citrate,D011085,PCOS,"Because of the potential advantages of ovarian cautery, we recommend this surgery as the next line of treatment if clomiphene citrate fails to induce ovulation in PCOS patients, before gonadotropins are introduced.",11915582_4,11915582_D002996_D011085,,
770957523,false,true,5,2015-08-15T00:41:00,,No Relation,1,C058218,Duloxetine,D003866,depressive disorder,Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.,11926722_0,11926722_C058218_D003866,,
770957524,false,true,5,2015-08-14T22:23:00,,No Relation,1,C058218,Duloxetine hydrochloride,D003865,major depression,"Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression.",11926722_1,11926722_C058218_D003865,,
770957525,false,true,5,2015-08-14T20:53:00,,No Relation,1,D012701,serotonin,D003865,major depression,"Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression.",11926722_1,11926722_D012701_D003865,,
770957526,false,true,5,2015-08-15T00:49:00,,No Relation,1,D009638,norepinephrine,D003865,major depression,"Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression.",11926722_1,11926722_D009638_D003865,,
770957527,false,true,5,2015-08-14T21:52:00,,No Relation,1,C058218,duloxetine,D003866,depressive disorder,"In an 8-week multicenter, double-blind, placebo-controlled study, 173 patients (aged 18-65 years) with DSM-IV major depressive disorder were randomly allocated to receive placebo (N = 70), duloxetine (N = 70), or fluoxetine, 20 mg q.d.",11926722_2,11926722_C058218_D003866,,
770957528,false,true,5,2015-08-14T22:20:00,,No Relation,0.8002,D005473,fluoxetine,D003866,depressive disorder,"In an 8-week multicenter, double-blind, placebo-controlled study, 173 patients (aged 18-65 years) with DSM-IV major depressive disorder were randomly allocated to receive placebo (N = 70), duloxetine (N = 70), or fluoxetine, 20 mg q.d.",11926722_2,11926722_D005473_D003866,,
770957529,false,true,5,2015-08-15T00:30:00,,Direct,1,C058218,duloxetine,D001247,asthenia,"In general, duloxetine was well tolerated; 76% of patients achieved the maximum dose, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxetine-treated patients compared with placebo-treated patients.",11926722_12,11926722_C058218_D001247,,
770957530,false,true,5,2015-08-15T01:22:00,,Direct,0.6118,C058218,duloxetine,D007319,insomnia,"In general, duloxetine was well tolerated; 76% of patients achieved the maximum dose, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxetine-treated patients compared with placebo-treated patients.",11926722_12,11926722_C058218_D007319,,
770957531,false,true,5,2015-08-14T21:05:00,,No Relation,1,C058218,duloxetine,D003866,depressive disorder,These data indicate that duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe.,11926722_13,11926722_C058218_D003866,,
770957532,false,true,5,2015-08-15T01:56:00,,No Relation,0.6059,D003024,clozapine,D001008,anxiety/depression,"A new 4-factor model (negative symptoms, reality distortion, disorganization, and anxiety/depression) had better fit in both data sets than two commonly used factor models, and also fit better post-clozapine.",11927178_5,11927178_D003024_D001008,,
770957533,false,true,5,2015-08-14T21:03:00,,No Relation,0.8038,D004008,Diclofenac,D000699,analgesia,Diclofenac or paracetamol for analgesia in paediatric myringotomy outpatients.,11939442_0,11939442_D004008_D000699,,
770957534,false,true,5,2015-08-15T00:34:00,,No Relation,0.792,D000082,paracetamol,D000699,analgesia,Diclofenac or paracetamol for analgesia in paediatric myringotomy outpatients.,11939442_0,11939442_D000082_D000699,,
770957535,false,true,5,2015-08-14T23:59:00,,No Relation,1,D000082,paracetamol,D010146,postoperative pain,"This prospective, randomized, double-blind study compared the analgesic efficacy of oral diclofenac resinate 0.5 mg.kg(-1) with paracetamol 15 mg/kg(-1) for control of postoperative pain in paediatric patients for outpatient bilateral myringotomy and tube insertion.",11939442_1,11939442_D000082_D010146,,
770957536,false,true,5,2015-08-14T21:32:00,,No Relation,0.5741,D004008,diclofenac,D000699,analgesia,Twenty per cent of the diclofenac group and 27% of the paracetamol group required rescue analgesia (not statistically significant).,11939442_12,11939442_D004008_D000699,,
770957537,false,true,5,2015-08-14T21:41:00,,No Relation,1,D000082,paracetamol,D000699,analgesia,Twenty per cent of the diclofenac group and 27% of the paracetamol group required rescue analgesia (not statistically significant).,11939442_12,11939442_D000082_D000699,,
770957538,false,true,5,2015-08-14T23:56:00,,Direct,0.6135,C476513,levobupivacaine,D064420,toxicity,Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine.,11945112_0,11945112_C476513_D064420,,
770957539,false,true,5,2015-08-14T21:31:00,,No Relation,1,D002045,bupivacaine,D064420,toxicity,Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine.,11945112_0,11945112_D002045_D064420,,
770957540,false,true,5,2015-08-15T02:01:00,,No Relation,1,C476513,Levobupivacaine,D064420,toxicity,"Levobupivacaine, a single enantiomer of bupivacaine, has recently been introduced as a new long-acting local anaesthetic with a potentially reduced toxicity compared with bupivacaine.",11945112_3,11945112_C476513_D064420,,
770957541,false,true,5,2015-08-15T02:20:00,,No Relation,0.5814,D002045,bupivacaine,D064420,toxicity,"Levobupivacaine, a single enantiomer of bupivacaine, has recently been introduced as a new long-acting local anaesthetic with a potentially reduced toxicity compared with bupivacaine.",11945112_3,11945112_D002045_D064420,,
770957542,false,true,5,2015-08-15T01:03:00,,Direct,0.6035,C476513,levobupivacaine,D003643,death,"In awake sheep, for example, almost 78% more levobupivacaine was required to cause death.",11945112_7,11945112_C476513_D003643,,
770957543,false,true,5,2015-08-14T22:40:00,,No Relation,0.5913,C476513,levobupivacaine,D017180,ventricular tachycardia,"In contrast, in anaesthetised dogs no differences were seen in the incidence of spontaneous or electrical stimulation- induced ventricular tachycardia and fibrillations among animals exposed to levobupivacaine or bupivacaine.",11945112_8,11945112_C476513_D017180,,
770957544,false,true,5,2015-08-14T21:54:00,,No Relation,0.795,C476513,levobupivacaine,D014693,fibrillations,"In contrast, in anaesthetised dogs no differences were seen in the incidence of spontaneous or electrical stimulation- induced ventricular tachycardia and fibrillations among animals exposed to levobupivacaine or bupivacaine.",11945112_8,11945112_C476513_D014693,,
770957545,false,true,5,2015-08-14T21:15:00,,No Relation,0.7936,D002045,bupivacaine,D017180,ventricular tachycardia,"In contrast, in anaesthetised dogs no differences were seen in the incidence of spontaneous or electrical stimulation- induced ventricular tachycardia and fibrillations among animals exposed to levobupivacaine or bupivacaine.",11945112_8,11945112_D002045_D017180,,
770957546,false,true,5,2015-08-14T23:15:00,,No Relation,0.5884,D002045,bupivacaine,D014693,fibrillations,"In contrast, in anaesthetised dogs no differences were seen in the incidence of spontaneous or electrical stimulation- induced ventricular tachycardia and fibrillations among animals exposed to levobupivacaine or bupivacaine.",11945112_8,11945112_D002045_D014693,,
770957547,false,true,5,2015-08-15T02:17:00,,Direct,1,C476513,levobupivacaine,D066126,cardiotoxicity,The reversibility of levobupivacaine-induced cardiotoxicity has also been assessed.,11945112_9,11945112_C476513_D066126,,
770957548,false,true,5,2015-08-15T01:08:00,,No Relation,1,D013256,steroid,D004679,encephalomyelitis,Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis.,11954856_0,11954856_D013256_D004679,,
770957549,false,true,5,2015-08-15T01:21:00,,No Relation,1,D013256,steroid,D004679,encephalomyelitis,"We present here five patients, 3 of them affected by classic disseminated encephalomyelitis and 2 by a post infectious myelitis, which showed a good response to intravenous immunoglobulin (IVIg) after steroid treatment failure.",11954856_4,11954856_D013256_D004679,,
770957550,false,true,5,2015-08-15T01:59:00,,No Relation,1,D013256,steroid,D009187,infectious myelitis,"We present here five patients, 3 of them affected by classic disseminated encephalomyelitis and 2 by a post infectious myelitis, which showed a good response to intravenous immunoglobulin (IVIg) after steroid treatment failure.",11954856_4,11954856_D013256_D009187,,
770957551,false,true,5,2015-08-15T02:23:00,,No Relation,1,D011239,prednisolone,D054198,ALL,"Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL.",11984797_6,11984797_D011239_D054198,,
770957552,false,true,5,2015-08-14T22:00:00,,No Relation,1,D011239,prednisolone,D054198,ALL,"Within Ph+ ALL, in vitro prednisolone resistance increased significantly with age (P = 0.006).",11984797_7,11984797_D011239_D054198,,
770957553,false,true,5,2015-08-14T21:05:00,,No Relation,1,D011239,prednisolone,D054198,ALL,The correlation of prednisolone resistance with age within the Ph+ cases might help explain the poorer prognosis of adult Ph+ ALL.,11984797_11,11984797_D011239_D054198,,
770957554,false,true,5,2015-08-15T01:11:00,,No Relation,1,D008874,midazolam,D013226,status epilepticus,The potential of midazolam given via a nasal spray in the acute treatment of status epilepticus and other seizure disruptions should be evaluated.,11994056_13,11994056_D008874_D013226,,
770957555,false,true,5,2015-08-15T00:13:00,,No Relation,1,D008874,midazolam,D012640,seizure,The potential of midazolam given via a nasal spray in the acute treatment of status epilepticus and other seizure disruptions should be evaluated.,11994056_13,11994056_D008874_D012640,,
770957556,false,true,5,2015-08-15T00:49:00,,No Relation,1,C001758,Bendamustine,D008223,indolent lymphomas,Bendamustine (B) and mitoxantrone (M) have been shown to be potent cytotoxic drugs for the treatment of relapsed or refractory indolent lymphomas.,11999564_1,11999564_C001758_D008223,,
770957557,false,true,5,2015-08-14T22:43:00,,No Relation,1,D008942,mitoxantrone,D008223,indolent lymphomas,Bendamustine (B) and mitoxantrone (M) have been shown to be potent cytotoxic drugs for the treatment of relapsed or refractory indolent lymphomas.,11999564_1,11999564_D008942_D008223,,
770957558,false,true,5,2015-08-15T00:00:00,,No Relation,1,D014801,vitamin A,C538659,rural South,Increased vitamin A intake in children aged 2-5 years through targeted home-gardens in a rural South African community.,12001973_0,12001973_D014801_C538659,,
770957559,false,true,5,2015-08-15T00:58:00,,No Relation,1,D014801,vitamin A,C538659,rural South,To determine vitamin A intake of children aged 2-5 years in a rural South African community one year after the implementation of a home-based food production programme targeting beta-carotene-rich fruits and vegetables.,12001973_1,12001973_D014801_C538659,,
770957560,false,true,5,2015-08-14T22:10:00,,No Relation,1,D019207,beta-carotene,C538659,rural South,To determine vitamin A intake of children aged 2-5 years in a rural South African community one year after the implementation of a home-based food production programme targeting beta-carotene-rich fruits and vegetables.,12001973_1,12001973_D019207_C538659,,
770957561,false,true,5,2015-08-14T21:22:00,,Direct,0.6262,D011803,Quinine,D064420,ocular toxicity,Quinine ocular toxicity: treatment of blindness using therapy for vasospasm.,12002937_0,12002937_D011803_D064420,,
770957562,false,true,5,2015-08-15T02:26:00,,No Relation,0.7906,D011803,Quinine,D001766,blindness,Quinine ocular toxicity: treatment of blindness using therapy for vasospasm.,12002937_0,12002937_D011803_D001766,,
770957563,false,true,5,2015-08-14T21:10:00,,No Relation,1,D011803,Quinine,D020301,vasospasm,Quinine ocular toxicity: treatment of blindness using therapy for vasospasm.,12002937_0,12002937_D011803_D020301,,
770957564,false,true,5,2015-08-14T23:48:00,,Direct,1,D011803,quinine,D064420,ocular toxicity,A case of ocular toxicity with vasospasm secondary to quinine poisoning is described.,12002937_1,12002937_D011803_D064420,,
770957565,false,true,5,2015-08-15T02:12:00,,Direct,0.8033,D011803,quinine,D020301,vasospasm,A case of ocular toxicity with vasospasm secondary to quinine poisoning is described.,12002937_1,12002937_D011803_D020301,,
770957566,false,true,5,2015-08-15T02:06:00,,No Relation,0.6163,D011803,quinine,D011041,poisoning,A case of ocular toxicity with vasospasm secondary to quinine poisoning is described.,12002937_1,12002937_D011803_D011041,,
770957567,false,true,5,2015-08-14T23:30:00,,No Relation,0.7937,D009553,nimodipine,D006973,hypertension,"Therapy for vasospasm using nimodipine, hypertension, haemodilution and hypervolaemia was instituted with subsequent resolution of symptoms.",12002937_2,12002937_D009553_D006973,,
770957568,false,true,5,2015-08-14T22:43:00,,No Relation,1,D009553,nimodipine,D020301,vasospasm,"Therapy for vasospasm using nimodipine, hypertension, haemodilution and hypervolaemia was instituted with subsequent resolution of symptoms.",12002937_2,12002937_D009553_D020301,,
770957569,false,true,5,2015-08-15T00:32:00,,No Relation,1,D000431,alcohol,D006470,bleeding,"Thirty-seven consecutive patients with portal hypertension and endoscopic evidence of isolated GVs, 17 presenting with histories of active bleeding, were randomized to receive endoscopic intervention either with alcohol (n = 17) or with cyanoacrylate glue (n = 20) injection.",12003381_3,12003381_D000431_D006470,,
770957570,false,true,5,2015-08-15T00:48:00,,No Relation,0.6314,D000431,alcohol,D004932,GVs,"Thirty-seven consecutive patients with portal hypertension and endoscopic evidence of isolated GVs, 17 presenting with histories of active bleeding, were randomized to receive endoscopic intervention either with alcohol (n = 17) or with cyanoacrylate glue (n = 20) injection.",12003381_3,12003381_D000431_D004932,,
770957571,false,true,5,2015-08-15T01:26:00,,No Relation,0.7981,D000431,alcohol,D006973,hypertension,"Thirty-seven consecutive patients with portal hypertension and endoscopic evidence of isolated GVs, 17 presenting with histories of active bleeding, were randomized to receive endoscopic intervention either with alcohol (n = 17) or with cyanoacrylate glue (n = 20) injection.",12003381_3,12003381_D000431_D006973,,
770957572,false,true,5,2015-08-15T00:16:00,,No Relation,0.7912,D000431,alcohol,D006470,arrest of acute GV bleeding,"Cyanoacrylate glue injection could achieve arrest of acute GV bleeding more often than alcohol (89% vs 62%), and the need for rescue surgery was less; the difference was, however, not significant.",12003381_7,12003381_D000431_D006470,,
770957573,false,true,5,2015-08-14T21:47:00,,Direct,0.8172,D003487,Cyanoacrylate,D006470,arrest of acute GV bleeding,"Cyanoacrylate glue injection could achieve arrest of acute GV bleeding more often than alcohol (89% vs 62%), and the need for rescue surgery was less; the difference was, however, not significant.",12003381_7,12003381_D003487_D006470,,
770957574,false,true,5,2015-08-14T22:04:00,,Direct,0.5939,D000431,alcohol,D006470,bleeding,"Six patients died from uncontrolled GV bleeding, four being in the alcohol group.",12003381_8,12003381_D000431_D006470,,
770957575,false,true,5,2015-08-14T23:23:00,,Direct,0.581,D008628,Hg,D000419,Albuminuria,Albuminuria significantly correlated with blood and urine Hg.,12018634_11,12018634_D008628_D000419,,
770957576,false,true,5,2015-08-14T21:14:00,,Direct,0.6347,D008628,Hg,D064420,toxicity,"From the nephrotoxicity point of view, dental amalgam is an unsuitable filling material, as it may give rise to Hg toxicity.",12018634_12,12018634_D008628_D064420,,
770957577,false,true,5,2015-08-15T01:19:00,,No Relation,0.607,D008628,Hg,D064420,toxicity,Hg levels in blood and urine are good markers of such toxicity.,12018634_13,12018634_D008628_D064420,,
770957578,false,true,5,2015-08-14T23:19:00,,No Relation,1,D003520,cyclophosphamide,D008181,lupus nephritis,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D003520_D008181,,
770957579,false,true,5,2015-08-14T22:21:00,,No Relation,1,D014580,ursodeoxycholic acid/ursolite,D008181,lupus nephritis,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D014580_D008181,,
770957580,false,true,5,2015-08-15T00:26:00,,Direct,0.612,D014580,ursodeoxycholic acid/ursolite,D007757,laboratory abnormalities,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D014580_D007757,,
770957581,false,true,5,2015-08-15T00:47:00,,No Relation,1,D013256,steroids,D007757,laboratory abnormalities,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D013256_D007757,,
770957582,false,true,5,2015-08-15T00:39:00,,No Relation,0.5994,D003520,cyclophosphamide,D007757,laboratory abnormalities,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D003520_D007757,,
770957583,false,true,5,2015-08-14T23:45:00,,No Relation,1,D013256,steroids,D008181,lupus nephritis,"The patient required steroids and repeated courses of cyclophosphamide for the management of lupus nephritis, and ursodeoxycholic acid (ursolite) administration resulted in amelioration of cholestatic laboratory abnormalities.",12028402_4,12028402_D013256_D008181,,
770957584,false,true,5,2015-08-15T00:20:00,,No Relation,1,D012828,silicone,D009369,breast-cancer,Comparative examination of complaints of patients with breast-cancer with and without silicone implants.,12039092_0,12039092_D012828_D009369,,
770957585,false,true,5,2015-08-15T02:27:00,,No Relation,1,D012828,silicone,D009369,breast-cancer,A matched-pair-analysis of 96 women with breast-cancer (32 with silicone implants (K I); 64 without implants (K II)) was performed with help of a standardized questionnaire in respect to 50 single criteria.,12039092_2,12039092_D012828_D009369,,
770957586,false,true,5,2015-08-15T01:43:00,,Direct,0.6208,D003042,cocaine,D005334,hyperthermia,Mechanism of cocaine-induced hyperthermia in humans.,12044126_0,12044126_D003042_D005334,,
770957587,false,true,5,2015-08-15T00:52:00,,Direct,0.7933,D003042,cocaine,D005334,hyperthermia,The lethal effects of cocaine are unique among those of other illicit drugs because cocaine has the propensity to cause hyperthermia.,12044126_1,12044126_D003042_D005334,,
770957588,false,true,5,2015-08-15T00:01:00,,Direct,1,D003042,cocaine,C565498,hypermetabolic,The traditional view is that cocaine causes a hypermetabolic state with increased heat production.,12044126_2,12044126_D003042_C565498,,
770957589,false,true,5,2015-08-14T22:20:00,,Direct,1,D003042,cocaine,D005334,hyperthermia,"However, because cocaine-induced hyperthermia occurs primarily in hot weather, it is hypothesized that cocaine also impairs thermoregulatory adjustments that mediate heat dissipation.",12044126_3,12044126_D003042_D005334,,
770957590,false,true,5,2015-08-15T01:25:00,,No Relation,0.8068,D008012,lidocaine,D018882,heat stress,"Progressive passive heat stress, during which each participant received intranasal cocaine (2 mg/kg of body weight) or placebo (lidocaine, 2 mg/kg).",12044126_8,12044126_D008012_D018882,,
770957591,false,true,5,2015-08-14T23:30:00,,No Relation,0.5996,D003042,cocaine,D018882,heat stress,"Progressive passive heat stress, during which each participant received intranasal cocaine (2 mg/kg of body weight) or placebo (lidocaine, 2 mg/kg).",12044126_8,12044126_D003042_D018882,,
770957592,false,true,5,2015-08-15T01:09:00,,No Relation,0.6032,D003042,cocaine,D018882,heat stress,"First, cocaine substantially augmented the progressive increase in esophageal temperature during heat stress (P < 0.001).",12044126_11,12044126_D003042_D018882,,
770957593,false,true,5,2015-08-15T00:01:00,,No Relation,0.6233,D003042,cocaine,D018882,heat stress,"Third, cocaine paradoxically impaired the perception of heating by attenuating the progressive increase in thermal discomfort associated with heat stress.",12044126_13,12044126_D003042_D018882,,
770957594,false,true,5,2015-08-14T21:16:00,,No Relation,0.5792,D003042,cocaine,D018883,impaired heat dissipation,"In humans, impaired heat dissipation is a major mechanism by which cocaine elevates body temperature.",12044126_14,12044126_D003042_D018883,,
770957595,false,true,5,2015-08-14T21:40:00,,No Relation,1,D003613,danazol,D000799,angioedema,Autoimmune acquired form of angioedema that responded to danazol therapy.,12058892_0,12058892_D003613_D000799,,
770957596,false,true,5,2015-08-15T01:48:00,,No Relation,1,D003613,danazol,D000799,angioedema,"The danazol treatment relieved the symptoms of angioedema and increased the C1 INH activity and concentration with the normalization of CH50, C1q and C4 levels.",12058892_2,12058892_D003613_D000799,,
770957597,false,true,5,2015-08-14T23:56:00,,No Relation,1,D011223,praziquantel,D012552,schistosomiasis,Reduction in the prevalence and intensity of hookworm infections after praziquantel treatment for schistosomiasis infection.,12062494_0,12062494_D011223_D012552,,
770957598,false,true,5,2015-08-14T21:30:00,,No Relation,0.7987,D011223,praziquantel,D006725,hookworm infections,Reduction in the prevalence and intensity of hookworm infections after praziquantel treatment for schistosomiasis infection.,12062494_0,12062494_D011223_D006725,,
770957599,false,true,5,2015-08-14T21:42:00,,No Relation,1,D011223,Praziquantel,D012552,schistosomiasis,Praziquantel exhibits activity against all major human schistosome parasites and has become the cornerstone for treatment and morbidity control of schistosomiasis.,12062494_1,12062494_D011223_D012552,,
770957600,false,true,5,2015-08-15T00:55:00,,No Relation,1,D011223,Praziquantel,D014201,trematodes,"Praziquantel is also active against a wide range of trematodes, human and veterinary cestodes and displays cysticidal effects.",12062494_2,12062494_D011223_D014201,,
770957601,false,true,5,2015-08-15T00:50:00,,No Relation,1,D011223,praziquantel,D012555,Schistosoma,"Here, we report a study among 96 schoolchildren from an area highly endemic for Schistosoma mansoni and hookworm infection, and place particular emphasis on the effect of praziquantel on the prevalence and intensity of hookworm infections.",12062494_4,12062494_D011223_D012555,,
770957602,false,true,5,2015-08-14T21:27:00,,No Relation,0.607,D011223,praziquantel,D006725,hookworm infection/hookworm infections,"Here, we report a study among 96 schoolchildren from an area highly endemic for Schistosoma mansoni and hookworm infection, and place particular emphasis on the effect of praziquantel on the prevalence and intensity of hookworm infections.",12062494_4,12062494_D011223_D006725,,
770957603,false,true,5,2015-08-14T22:18:00,,No Relation,1,D011223,praziquantel,D012552,schistosomiasis,"In areas where both schistosome and hookworm coexist, and praziquantel is being recommended for schistosomiasis control, large-scale application of this drug might also reduce the burden of hookworms.",12062494_9,12062494_D011223_D012552,,
770957604,false,true,5,2015-08-15T01:28:00,,No Relation,1,D011223,praziquantel,D006725,hookworm coexist,"In areas where both schistosome and hookworm coexist, and praziquantel is being recommended for schistosomiasis control, large-scale application of this drug might also reduce the burden of hookworms.",12062494_9,12062494_D011223_D006725,,
770957605,false,true,5,2015-08-14T21:36:00,,Direct,1,D019819,budesonide,D003872,dermatitis,Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen.,12063485_0,12063485_D019819_D003872,,
770957606,false,true,5,2015-08-14T21:31:00,,No Relation,1,D000305,corticosteroids,D003872,dermatitis,Up to 5% of patients with dermatitis who are consecutively patch tested are allergic to one or more corticosteroids.,12063485_1,12063485_D000305_D003872,,
770957607,false,true,5,2015-08-14T21:27:00,,Direct,0.6096,D019819,budesonide,D004342,hypersensitivity,"Fifteen nonasthmatic patients who were initially given a diagnosis of budesonide hypersensitivity on patch testing from less than 1 up to 8 years before the study were provoked with budesonide or placebo by inhalation 6 weeks after they had been patch tested with budesonide, its R and S diastereomers, and potentially cross-reacting substances.",12063485_5,12063485_D019819_D004342,,
770957608,false,true,5,2015-08-14T22:19:00,,Direct,1,D019819,budesonide,D006967,allergy,This study shows that allergic skin reactions may occur in patients with contact allergy to budesonide when inhaled forms of the drug are used.,12063485_9,12063485_D019819_D006967,,
770957609,false,true,5,2015-08-15T00:25:00,,No Relation,0.5773,D018943,anthracycline,D066126,cardiotoxicity,"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.",12075737_0,12075737_D018943_D066126,,
770957610,false,true,5,2015-08-14T23:30:00,,Direct,1,D018943,anthracycline,D006177,heart damage,With increasing doses the highly tumoricidal anthracycline drugs cause heart damage.,12075737_1,12075737_D018943_D006177,,
770957611,false,true,5,2015-08-14T22:23:00,,No Relation,0.5989,D018943,anthracycline,D006333,CHF,To avoid CHF there is a consensus recommendation that cardiac function should be monitored in close connection with anthracycline administration.,12075737_3,12075737_D018943_D006333,,
770957612,false,true,5,2015-08-15T00:15:00,,No Relation,0.8089,D015251,epirubicin,D009369,breast cancer,"In a prospective, blinded observational study 120 patients with advanced breast cancer were followed before, during, and a median 3 years after treatment with epirubicin.",12075737_5,12075737_D015251_D009369,,
770957613,false,true,5,2015-08-14T22:18:00,,Direct,0.6092,D018943,Anthracycline,D066126,cardiotoxicity,"Anthracycline cardiotoxicity was closely correlated with the cumulative dose, with a great variability in individual susceptibility and a dramatic increase with advancing age.",12075737_7,12075737_D018943_D066126,,
770957614,false,true,5,2015-08-14T22:43:00,,No Relation,0.612,D015251,epirubicin,D006333,CHF,An actuarial estimation of 59% of the patients experienced a 25% relative reduction in LVEF 3 years after 850-1000 mg/m2 of epirubicin and 20% had deteriorated into a CHF.,12075737_9,12075737_D015251_D006333,,
770957615,false,true,5,2015-08-14T22:26:00,,No Relation,0.6055,D018943,anthracycline,D066126,cardiotoxic,"Due to the displaced cardiotoxic manifestation, functional monitoring in close connection with anthracycline administration appears to be a poorly effective method while later monitoring is essential.",12075737_11,12075737_D018943_D066126,,
770957616,false,true,5,2015-08-15T02:12:00,,No Relation,1,D004164,Bisphosphonates,D009369,cancer,"Bisphosphonates for cancer patients: why, how, and when?",12136223_0,12136223_D004164_D009369,,
770957617,false,true,5,2015-08-15T00:33:00,,No Relation,0.6285,D004164,BPs/Bisphosphonates,D009369,tumor/breast cancer/cancer,"Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors.",12136223_1,12136223_D004164_D009369,,
770957618,false,true,5,2015-08-14T22:23:00,,No Relation,0.8062,D004164,BPs/Bisphosphonates,D009101,myeloma,"Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors.",12136223_1,12136223_D004164_D009101,,
770957619,false,true,5,2015-08-14T22:17:00,,No Relation,1,D004164,BPs,D009369,cancer hypercalcemia,"BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of clodronate is recommended; the former compound is more potent and has a longer lasting effect.",12136223_2,12136223_D004164_D009369,,
770957620,false,true,5,2015-08-15T02:22:00,,No Relation,1,C019248,pamidronate,D009369,cancer hypercalcemia,"BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of clodronate is recommended; the former compound is more potent and has a longer lasting effect.",12136223_2,12136223_C019248_D009369,,
770957621,false,true,5,2015-08-14T22:01:00,,No Relation,0.8111,C019248,pamidronate,D010146,bone pain,Repeated pamidronate infusions exert clinically relevant analgesic effects in more than half of patients with metastatic bone pain.,12136223_3,12136223_C019248_D010146,,
770957622,false,true,5,2015-08-14T22:44:00,,No Relation,1,D004002,clodronate,D009369,breast cancer,Lifelong administration of oral clodronate to patients with breast cancer metastatic to bone reduces the frequency of morbid skeletal events by more than one-fourth.,12136223_7,12136223_D004002_D009369,,
770957623,false,true,5,2015-08-15T02:12:00,,No Relation,0.8123,D004164,BPs,D001847,bone disease,"However, preference can be given to the oral route when BPs are started early in the process of metastatic bone disease in a patient receiving hormone therapy.",12136223_10,12136223_D004164_D001847,,
770957624,false,true,5,2015-08-15T02:09:00,,No Relation,1,C019248,pamidronate,D009369,breast cancer,"According to the recently published ASCO guidelines, pamidronate 90 mg i.v. delivered over 2 h every 3-4 weeks can be recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy.",12136223_11,12136223_C019248_D009369,,
770957625,false,true,5,2015-08-15T00:00:00,,No Relation,1,D004164,BPs,D001847,bone disease,"Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should not be stopped when metastatic bone disease is progressing.",12136223_15,12136223_D004164_D001847,,
770957626,false,true,5,2015-08-14T23:46:00,,No Relation,1,D004164,BPs,D004194,lytic disease,"Even better results have been achieved in patients with multiple myeloma, and the general consensus is that BPs should be started as soon as the diagnosis of lytic disease is made in myeloma patients.",12136223_18,12136223_D004164_D004194,,
770957627,false,true,5,2015-08-15T00:14:00,,No Relation,1,D004164,BPs,D009101,myeloma/multiple myeloma,"Even better results have been achieved in patients with multiple myeloma, and the general consensus is that BPs should be started as soon as the diagnosis of lytic disease is made in myeloma patients.",12136223_18,12136223_D004164_D009101,,
770957628,false,true,5,2015-08-15T00:49:00,,No Relation,1,D004164,BPs,D011471,prostate cancer,"On the other hand, data are scanty in prostate cancer, but large-scale trials with potent BPs are ongoing or planned in such patients.",12136223_19,12136223_D004164_D011471,,
770957629,false,true,5,2015-08-14T21:31:00,,No Relation,1,C019248,pamidronate,D009369,breast cancer,Similar results to those achieved with pamidronate have been obtained with monthly 6-mg infusions of the newer BP ibandronate in patients with breast cancer metastatic to bone.,12136223_20,12136223_C019248_D009369,,
770957630,false,true,5,2015-08-14T23:14:00,,No Relation,1,D004164,BPs,D018222,aggressive osteolytic disease,"These newer BPs will simplify the current therapeutic schemes and improve the cost-effectiveness ratio; they also have the potential to improve the therapeutic efficacy, at least in patients with an aggressive osteolytic disease or when given as adjuvant therapy.",12136223_23,12136223_D004164_D018222,,
770957631,false,true,5,2015-08-14T22:28:00,,No Relation,1,D011142,polyvinyl alcohol,C564648,intraosseous lesion,"The patients were embolized with fiber coils through direct puncture, and the coils were placed directly into the center of the intraosseous lesion, in some cases in conjunction with polyvinyl alcohol foam and N-butyl-2-cyanoacrylate through vascular access.",12149733_3,12149733_D011142_C564648,,
770957632,false,true,5,2015-08-15T00:38:00,,No Relation,1,D004659,N-butyl-2-cyanoacrylate,C564648,intraosseous lesion,"The patients were embolized with fiber coils through direct puncture, and the coils were placed directly into the center of the intraosseous lesion, in some cases in conjunction with polyvinyl alcohol foam and N-butyl-2-cyanoacrylate through vascular access.",12149733_3,12149733_D004659_C564648,,
770957633,false,true,5,2015-08-14T22:05:00,,No Relation,0.8266,D013974,levothyroxine,D013964,thyroid cancer,We performed a series of neuropsychological tests in 13 thyroid cancer patients while they continued to take their usual dose of levothyroxine (LT4) and again after discontinuing thyroid hormone.,12186506_2,12186506_D013974_D013964,,
770957634,false,true,5,2015-08-14T21:29:00,,No Relation,0.8039,D015032,zinc,D007239,infection,Supplementation of infant formula with the probiotic lactobacillus reuteri and zinc: impact on enteric infection and nutrition in infant rhesus monkeys.,12187291_0,12187291_D015032_D007239,,
770957635,false,true,5,2015-08-14T21:43:00,,No Relation,1,D015032,zinc,D005767,gastrointestinal infection,"To study effects of probiotic supplementation of infant formula (with or without supplemental zinc) on nutritional status, gut colonization and the ability to resist gastrointestinal infection in an infant rhesus monkey model.",12187291_3,12187291_D015032_D005767,,
770957636,false,true,5,2015-08-14T21:19:00,,No Relation,1,D007501,iron,D007239,infection,#NAME?,12187291_9,12187291_D007501_D007239,,
770957637,false,true,5,2015-08-14T22:31:00,,No Relation,1,D007501,iron,D003967,decreases diarrhea severity,#NAME?,12187291_9,12187291_D007501_D003967,,
770957638,false,true,5,2015-08-15T00:49:00,,No Relation,1,D007501,iron,D044342,nutritional deficiencies,#NAME?,12187291_9,12187291_D007501_D044342,,
770957639,false,true,5,2015-08-14T21:05:00,,No Relation,1,D006493,heparin,D001281,atrial fibrillation,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D006493_D001281,,
770957640,false,true,5,2015-08-14T23:50:00,,No Relation,1,D003404,creatinine,D001281,atrial fibrillation,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D003404_D001281,,
770957641,false,true,5,2015-08-15T01:47:00,,No Relation,1,D006493,heparin,D019106,blood loss,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D006493_D019106,,
770957642,false,true,5,2015-08-15T00:12:00,,No Relation,0.7997,D006493,heparin,D001308,postoperative coagulation disturbances,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D006493_D001308,,
770957643,false,true,5,2015-08-14T23:43:00,,No Relation,1,D003404,creatinine,D001308,postoperative coagulation disturbances,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D003404_D001308,,
770957644,false,true,5,2015-08-15T01:13:00,,No Relation,1,D003404,creatinine,D019106,blood loss,"The use of heparin-coated circuits reduced the mean length of stay in hospital from 7.8 +/- 2.5 to 7.3 +/- 1.8 days (p = 0.040) and postoperative ventilation time from 9.7 +/- 9.2 to 8.2 +/- 8.5 h (p = 0.018), blood loss 8 h post surgery from 676 +/- 385 to 540 +/- 245 ml (p = 0.001), individual perioperative change of haemoglobin loss (p = 0.001), leukocyte count (p = 0.000) and creatinine elevation (p = 0.000), proportion of patients exposed to allogenous blood transfusions 39.2 vs 23.9% (p = 0.001), postoperative coagulation disturbances 4.4 vs 0.4% (p = 0.006), postoperative deviations from the normal postoperative course 47.2 vs 36.7% (p = 0.035), neurological deviations 9.4 vs 3.9% (p = 0.021) and atrial fibrillation 26.4 vs 18.0% (p = 0.041).",12201973_9,12201973_D003404_D019106,,
770957645,false,true,5,2015-08-14T22:19:00,,No Relation,1,C422649,etoricoxib,D010146,postoperative pain,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C422649_D010146,,
770957646,false,true,5,2015-08-14T21:35:00,,No Relation,1,C406224,valdecoxib,D010146,postoperative pain,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C406224_D010146,,
770957647,false,true,5,2015-08-14T21:38:00,,No Relation,0.7998,C406224,valdecoxib,D000699,analgesia,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C406224_D000699,,
770957648,false,true,5,2015-08-15T02:21:00,,No Relation,1,C105934,celecoxib,D000699,analgesia,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C105934_D000699,,
770957649,false,true,5,2015-08-15T00:17:00,,No Relation,1,C116926,rofecoxib,D010146,postoperative pain,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C116926_D010146,,
770957650,false,true,5,2015-08-14T22:12:00,,No Relation,1,C105934,celecoxib,D010146,postoperative pain,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C105934_D010146,,
770957651,false,true,5,2015-08-14T22:00:00,,No Relation,0.7867,C116926,rofecoxib,D000699,analgesia,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C116926_D000699,,
770957652,false,true,5,2015-08-14T23:03:00,,No Relation,0.8079,C422649,etoricoxib,D000699,analgesia,"Clinical trials have demonstrated the efficacy and safety of celecoxib and rofecoxib for postoperative pain and for preemptive analgesia, and newer agents such as valdecoxib and etoricoxib also have demonstrated efficacy in these settings.",12204484_5,12204484_C422649_D000699,,
770957653,false,true,5,2015-08-14T21:58:00,,No Relation,1,D011464,epoprostenol,D065627,primary pulmonary hypertension,Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.,12204511_0,12204511_D011464_D065627,,
770957654,false,true,5,2015-08-14T21:33:00,,No Relation,1,D011464,epoprostenol,D065627,primary pulmonary hypertension/PPH,We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion.,12204511_1,12204511_D011464_D065627,,
770957655,false,true,5,2015-08-14T23:26:00,,No Relation,1,D011464,Epoprostenol,D065627,PPH,Epoprostenol improves survival in patients with PPH in New York Heart Association (NYHA) functional class III or IV.,12204511_2,12204511_D011464_D065627,,
770957656,false,true,5,2015-08-14T22:18:00,,No Relation,0.809,D011464,epoprostenol,D065627,PPH,"Between December 1992 and January 2001, 178 patients with PPH in NYHA functional class III or IV were treated with epoprostenol.",12204511_5,12204511_D011464_D065627,,
770957657,false,true,5,2015-08-14T21:27:00,,No Relation,0.5886,D011464,epoprostenol,D006333,right-sided heart failure,"On multivariate analysis, including both baseline variables and those measured after three months on epoprostenol, a history of right-sided heart failure, persistence of NYHA functional class III or IV at three months, and the absence of a fall in total pulmonary resistance of >30%, relative to baseline, were associated with poor survival.",12204511_9,12204511_D011464_D006333,,
770957658,false,true,5,2015-08-14T22:19:00,,No Relation,1,D011464,epoprostenol,D065627,PPH,"Survival of patients with PPH treated with epoprostenol depends on the severity at baseline, as well as the three-month response to therapy.",12204511_10,12204511_D011464_D065627,,
770957659,false,true,5,2015-08-15T02:23:00,,No Relation,1,C059262,cidofovir/CDV,D000257,adenovirus (Ad) infections,"Although there is currently no FDA approved antiviral treatment for adenovirus (Ad) infections, the broad spectrum antiviral cidofovir (CDV) has demonstrated potent inhibitory activity against many Ad serotypes in vitro and in an in vivo ocular replication model.",12323401_1,12323401_C059262_D000257,,
770957660,false,true,5,2015-08-15T01:09:00,,No Relation,1,C059262,CDV,D007239,infection,"CDV resistance was demonstrated by ability to replicate viral DNA in infected cells at CDV concentrations that inhibit the parental virus, by ability to form plaques in CDV concentrations of >20 microg/ml and by increased progeny release following infection and growth in media containing CDV.",12323401_4,12323401_C059262_D007239,,
770957661,false,true,5,2015-08-14T21:37:00,,No Relation,0.6082,D001647,bile acids,D007410,intestinal atrophy,Dietary bile acids inhibit potentially elemental diet-induced small intestinal atrophy in rats.,12373304_0,12373304_D001647_D007410,,
770957662,false,true,5,2015-08-14T21:27:00,,No Relation,1,D001647,bile acid,D001284,atrophy,"Oral bile acid administration may prevent this atrophy and the elevations in mucosal DAO and ALP activities, which may lead to new therapeutic strategies in patients managed with ED.",12373304_11,12373304_D001647_D001284,,
770957663,false,true,5,2015-08-14T21:47:00,,No Relation,1,D008727,methotrexate,D001172,RA,Eleven RA patients (mean age 46+/-5 years; disease duration 9+/-2 years) with high disease activity despite treatment with stable doses of methotrexate (<or=25 mg/wk) and prednisone (<or=10 mg/d) were investigated.,12390945_5,12390945_D008727_D001172,,
770957664,false,true,5,2015-08-14T23:49:00,,No Relation,1,D011241,prednisone,D001172,RA,Eleven RA patients (mean age 46+/-5 years; disease duration 9+/-2 years) with high disease activity despite treatment with stable doses of methotrexate (<or=25 mg/wk) and prednisone (<or=10 mg/d) were investigated.,12390945_5,12390945_D011241_D001172,,
770957665,false,true,5,2015-08-14T22:23:00,,Direct,0.7912,C030110,Oxaliplatin,D015179,colorectal carcinoma,Oxaliplatin: results in colorectal carcinoma.,12398998_0,12398998_C030110_D015179,,
770957666,false,true,5,2015-08-14T21:23:00,,No Relation,1,C030110,Oxaliplatin,D015179,CRC/colorectal cancer,"Oxaliplatin, a platinum compound characterized by a diaminocyclohexane (DACH) platinum carrier ligand, has proven its efficacy in first- and second-line advanced colorectal cancer (CRC) treatment.",12398998_1,12398998_C030110_D015179,,
770957667,false,true,5,2015-08-14T21:37:00,,No Relation,1,D010984,platinum,D015179,CRC/colorectal cancer,"Oxaliplatin, a platinum compound characterized by a diaminocyclohexane (DACH) platinum carrier ligand, has proven its efficacy in first- and second-line advanced colorectal cancer (CRC) treatment.",12398998_1,12398998_D010984_D015179,,
770957668,false,true,5,2015-08-15T00:59:00,,Direct,0.7983,C030110,oxaliplatin,D010523,peripheral sensory neuropathy,Acute reversible and cumulative peripheral sensory neuropathy has been observed frequently with oxaliplatin treatment and limits its use.,12398998_2,12398998_C030110_D010523,,
770957669,false,true,5,2015-08-14T23:50:00,,No Relation,1,D005472,5-FU,D015179,CRC,"In three prospective randomized phase III studies in advanced CRC, oxaliplatin plus 5-FU/LV improved significantly progression-free survival without a significant increase in median survival time and without affecting quality of life, compared to treatment with 5-FU/LV.",12398998_6,12398998_D005472_D015179,,
770957670,false,true,5,2015-08-14T22:19:00,,No Relation,1,C030110,oxaliplatin,D015179,CRC,"In three prospective randomized phase III studies in advanced CRC, oxaliplatin plus 5-FU/LV improved significantly progression-free survival without a significant increase in median survival time and without affecting quality of life, compared to treatment with 5-FU/LV.",12398998_6,12398998_C030110_D015179,,
770957671,false,true,5,2015-08-14T22:06:00,,Direct,1,D018817,Ecstasy,D007239,infections,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D007239,,
770957672,false,true,5,2015-08-14T21:52:00,,Direct,1,D018817,Ecstasy,D008569,memory problems,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D008569,,
770957673,false,true,5,2015-08-14T22:12:00,,Direct,1,D018817,Ecstasy,D001008,anxiety,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D001008,,
770957674,false,true,5,2015-08-15T00:11:00,,Direct,1,D018817,Ecstasy,D014202,tremors,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D014202,,
770957675,false,true,5,2015-08-15T01:56:00,,Direct,1,D018817,Ecstasy,D015431,weight loss,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D015431,,
770957676,false,true,5,2015-08-15T02:17:00,,Direct,1,D018817,Ecstasy,D003866,Depression,"Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use.",12404677_6,12404677_D018817_D003866,,
770957677,false,true,5,2015-08-14T23:00:00,,Direct,1,D018817,Ecstasy,D008569,memory problems,"Thus memory problems attributed to Ecstasy were reported by 19% of novice users, 52% of heavy users and 73% of heavy users (chi-square 42.74, df=2, p<0.001); many of the other variables showed similar trends.",12404677_7,12404677_D018817_D008569,,
770957678,false,true,5,2015-08-14T22:31:00,,No Relation,1,D005682,gadolinium,D009103,MS,"Four double-blind trials in relapsing-remitting MS have demonstrated that IVIG may reduce the relapse rate, progression and the number of gadolinium-enhancing lesions.",12453069_2,12453069_D005682_D009103,,
770957679,false,true,5,2015-08-15T01:29:00,,No Relation,1,C089995,glatiramer acetate,D009103,multiple sclerosis/MS,"However, these trials were smaller than the pivotal trials of interferon-beta and glatiramer acetate, and therefore, we performed a meta-analysis of the four trials in order to provide an overall assessment of the benefits of IVIG in relapsing-remitting multiple sclerosis in comparison with other drugs currently available for treatment of disease activity in MS.",12453069_3,12453069_C089995_D009103,,
770957680,false,true,5,2015-08-14T21:52:00,,No Relation,1,D001058,apomorphine,D010302,Parkinson,Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.,12460716_0,12460716_D001058_D010302,,
770957681,false,true,5,2015-08-15T01:35:00,,No Relation,1,D004298,dopamine,D010300,Parkinson's disease,Apomorphine is a mixed dopamine D1/D2 receptor agonist which is potentially useful in the treatment of Parkinson's disease.,12460716_1,12460716_D004298_D010300,,
770957682,false,true,5,2015-08-14T22:40:00,,No Relation,1,D001058,Apomorphine,D010300,Parkinson's disease,Apomorphine is a mixed dopamine D1/D2 receptor agonist which is potentially useful in the treatment of Parkinson's disease.,12460716_1,12460716_D001058_D010300,,
770957683,false,true,5,2015-08-15T00:38:00,,No Relation,1,D001058,apomorphine,D010302,Parkinson,The most interesting route for controlled delivery of apomorphine is transdermal iontophoresis because this could enable the Parkinson patient to directly control the needed amount of apomorphine by increasing or decreasing the drug input in order to achieve optimal drug therapy ('on-demand') with a minimum of toxic side effects.,12460716_3,12460716_D001058_D010302,,
770957684,false,true,5,2015-08-14T22:22:00,,No Relation,1,D001058,apomorphine,D010300,Parkinson's disease,Transdermal iontophoretic transport of apomorphine was studied both in vitro with human stratum corneum using a newly developed iontophoretic continuous flow-through transport cell and in vivo in a first exploratory study in patients with Parkinson's disease.,12460716_8,12460716_D001058_D010300,,
770957685,false,true,5,2015-08-14T21:59:00,,No Relation,1,D016572,CsA/cyclosporine,D001168,arthritis,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D016572_D001168,,
770957686,false,true,5,2015-08-14T21:04:00,,No Relation,1,D012460,sulfasalazine/SSZ,D015535,PsA,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D012460_D015535,,
770957687,false,true,5,2015-08-14T21:41:00,,No Relation,1,D008727,Methotrexate/MTX,D015535,PsA,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D008727_D015535,,
770957688,false,true,5,2015-08-14T21:13:00,,No Relation,1,D008727,Methotrexate/MTX,D001168,arthritis,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D008727_D001168,,
770957689,false,true,5,2015-08-14T22:09:00,,No Relation,1,D012460,sulfasalazine/SSZ,D001168,arthritis,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D012460_D001168,,
770957690,false,true,5,2015-08-14T21:30:00,,No Relation,1,D016572,CsA/cyclosporine,D015535,PsA,"Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatment of PsA and are safe and effective in patients with active peripheral arthritis, although they do not appear to be effective on axial manifestations.",12463452_2,12463452_D016572_D015535,,
770957691,false,true,5,2015-08-15T00:04:00,,No Relation,1,C045463,leflunomide,D009369,tumor,It has recently been demonstrated that leflunomide and anti-tumor necrosis factor (TNF) agents are effective in PsA and psoriasis.,12463452_4,12463452_C045463_D009369,,
770957692,false,true,5,2015-08-14T23:37:00,,No Relation,1,C045463,leflunomide,D011565,psoriasis,It has recently been demonstrated that leflunomide and anti-tumor necrosis factor (TNF) agents are effective in PsA and psoriasis.,12463452_4,12463452_C045463_D011565,,
770957693,false,true,5,2015-08-14T22:32:00,It's 'anti-tumor necrosis factor' and not 'necrosis',No Relation,1,C045463,leflunomide,D009336,necrosis,It has recently been demonstrated that leflunomide and anti-tumor necrosis factor (TNF) agents are effective in PsA and psoriasis.,12463452_4,12463452_C045463_D009336,,
770957694,false,true,5,2015-08-15T00:32:00,,No Relation,1,C045463,leflunomide,D015535,PsA,It has recently been demonstrated that leflunomide and anti-tumor necrosis factor (TNF) agents are effective in PsA and psoriasis.,12463452_4,12463452_C045463_D015535,,
770957695,false,true,5,2015-08-14T23:34:00,,No Relation,0.8112,D013629,tamoxifen,D018335,rhabdoid tumor,Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.,12495475_0,12495475_D013629_D018335,,
770957696,false,true,5,2015-08-14T22:05:00,,No Relation,1,D004967,Estrogen,D018335,rhabdoid tumor,Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.,12495475_0,12495475_D004967_D018335,,
770957697,false,true,5,2015-08-14T21:45:00,,No Relation,1,D013629,TAM/tamoxifen,D009369,breast cancer/malignant neoplasms,Recent studies have shown that the antiestrogen tamoxifen (TAM) can be used in the treatment of malignant neoplasms other than breast cancer.,12495475_1,12495475_D013629_D009369,,
770957698,false,true,5,2015-08-14T21:36:00,,No Relation,0.8072,D004967,estrogen,D018335,rhabdoid tumor,"In the present study, we investigated the expression of estrogen receptor (ER) in six malignant rhabdoid tumor (MRT) cell lines.",12495475_2,12495475_D004967_D018335,,
770957699,false,true,5,2015-08-15T01:24:00,,No Relation,1,C097613,Imatinib,D000796,eosinophilic disorders,Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.,12506022_0,12506022_C097613_D000796,,
770957700,false,true,5,2015-08-14T21:24:00,,No Relation,1,C097613,Imatinib,D017681,hypereosinophilic syndrome,Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.,12506022_0,12506022_C097613_D017681,,
770957701,false,true,5,2015-08-15T00:09:00,,No Relation,1,D014443,tyrosine,D017681,hypereosinophilic syndrome/HES,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_D014443_D017681,,
770957702,false,true,5,2015-08-14T22:43:00,,No Relation,1,C097613,Imatinib,D004802,eosinophilia,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_C097613_D004802,,
770957703,false,true,5,2015-08-14T23:04:00,,No Relation,1,D014443,tyrosine,D007951,myeloid disorder,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_D014443_D007951,,
770957704,false,true,5,2015-08-15T01:40:00,,No Relation,1,C097613,Imatinib,C565145,CMD,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_C097613_C565145,,
770957705,false,true,5,2015-08-14T21:16:00,,No Relation,0.8232,C097613,Imatinib,D007951,myeloid disorder,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_C097613_D007951,,
770957706,false,true,5,2015-08-14T21:56:00,,No Relation,1,D014443,tyrosine,D004802,eosinophilia,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_D014443_D004802,,
770957707,false,true,5,2015-08-15T00:40:00,,No Relation,1,D014443,tyrosine,C565145,CMD,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_D014443_C565145,,
770957708,false,true,5,2015-08-15T01:09:00,,No Relation,1,C097613,Imatinib,D017681,hypereosinophilic syndrome/HES,"Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.",12506022_1,12506022_C097613_D017681,,
770957709,false,true,5,2015-08-14T23:46:00,,No Relation,1,C097613,imatinib,D017681,HES,"In the current study, we sought to confirm the preliminary observations in HES as well as evaluate the therapeutic value of imatinib in eos-CMD that is not associated with t(5;12)(q33;p13).",12506022_2,12506022_C097613_D017681,,
770957710,false,true,5,2015-08-14T23:04:00,,No Relation,1,C097613,imatinib,C565145,CMD,"In the current study, we sought to confirm the preliminary observations in HES as well as evaluate the therapeutic value of imatinib in eos-CMD that is not associated with t(5;12)(q33;p13).",12506022_2,12506022_C097613_C565145,,
770957711,false,true,5,2015-08-14T22:17:00,,No Relation,1,C097613,imatinib,D017681,HES,"Five patients with HES (all men, median age = 46 years) and 2 with eos-CMD (both men, aged 45 and 58 years) were treated with imatinib at a starting dose of 100 to 400 mg/day.",12506022_3,12506022_C097613_D017681,,
770957712,false,true,5,2015-08-14T21:01:00,,No Relation,1,C097613,imatinib,C565145,CMD,"Five patients with HES (all men, median age = 46 years) and 2 with eos-CMD (both men, aged 45 and 58 years) were treated with imatinib at a starting dose of 100 to 400 mg/day.",12506022_3,12506022_C097613_C565145,,
770957713,false,true,5,2015-08-15T01:54:00,,No Relation,1,D000305,corticosteroid,D000796,eosinophilic infiltration,"Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy.",12506022_9,12506022_D000305_D000796,,
770957714,false,true,5,2015-08-14T21:22:00,,No Relation,1,D000305,corticosteroid,D012770,cardiogenic shock,"Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy.",12506022_9,12506022_D000305_D012770,,
770957715,false,true,5,2015-08-14T21:19:00,,No Relation,1,D005947,glucose,D001941,breast feeding,To investigate whether breast feeding is effective for pain relief during venepuncture in term neonates and compare any effect with that of oral glucose combined with a pacifier.,12511452_1,12511452_D005947_D001941,,
770957716,false,true,5,2015-08-15T00:43:00,,No Relation,1,D005947,glucose,D010146,pain,To investigate whether breast feeding is effective for pain relief during venepuncture in term neonates and compare any effect with that of oral glucose combined with a pacifier.,12511452_1,12511452_D005947_D010146,,
770957717,false,true,5,2015-08-14T21:43:00,,No Relation,1,D005947,glucose,D001941,breast feeding,"During venepuncture infants were either breast fed (group 1), held in their mother's arms without breast feeding (group 2), given 1 ml of sterile water as placebo (group 3), or given 1 ml of 30% glucose followed by pacifier (group 4).",12511452_4,12511452_D005947_D001941,,
770957718,false,true,5,2015-08-14T23:55:00,,No Relation,1,D005947,glucose,D001941,breast feeding,"Median pain scores (interquartile range) for breast feeding, held in mother's arms, placebo, and 30% glucose plus pacifier groups were 1 (0-3), 10 (8.5-10), 10 (7.5-10), and 3 (0-5) with the Douleur Aigu Nouveau-n scale and 4.5 (2.25-8), 13 (10.5-15), 12 (9-13), and 4 (1-6) with the premature infant pain profile scale.",12511452_7,12511452_D005947_D001941,,
770957719,false,true,5,2015-08-14T21:38:00,,No Relation,1,D005947,glucose,D010146,pain,"Median pain scores (interquartile range) for breast feeding, held in mother's arms, placebo, and 30% glucose plus pacifier groups were 1 (0-3), 10 (8.5-10), 10 (7.5-10), and 3 (0-5) with the Douleur Aigu Nouveau-n scale and 4.5 (2.25-8), 13 (10.5-15), 12 (9-13), and 4 (1-6) with the premature infant pain profile scale.",12511452_7,12511452_D005947_D010146,,
770957720,false,true,5,2015-08-14T21:54:00,,No Relation,1,D005947,glucose,D001941,breast feeding,"There were significant reductions in both scores for the breast feeding and glucose plus pacifier groups compared with the other two groups (P<0.0001, two tailed Mann-Whitney U tests between groups).",12511452_9,12511452_D005947_D001941,,
770957721,false,true,5,2015-08-15T01:49:00,,No Relation,1,D005947,glucose,D001941,breast feeding,The difference in Douleur Aigu Nouveau-n scores between breast feeding and glucose plus pacifier groups was not significant (P=0.16).,12511452_10,12511452_D005947_D001941,,
770957722,false,true,5,2015-08-14T21:43:00,,No Relation,1,C056814,cefdinir,D011472,acute bacterial rhinosinusitis,Management update of acute bacterial rhinosinusitis and the use of cefdinir.,12511857_0,12511857_C056814_D011472,,
770957723,false,true,5,2015-08-15T02:39:00,,No Relation,1,C056814,cefdinir,D011472,ABRS,A clinical trial was reviewed in which cefdinir was effective in treating ABRS.,12511857_8,12511857_C056814_D011472,,
770957724,false,true,5,2015-08-15T01:20:00,,No Relation,1,D000111,N-acetylcysteine,C562889,radiocontrast nephropathy,A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.,12556733_0,12556733_D000111_C562889,,
770957725,false,true,5,2015-08-15T01:47:00,,No Relation,1,D018818,fenoldopam,C562889,radiocontrast nephropathy,A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.,12556733_0,12556733_D018818_C562889,,
770957726,false,true,5,2015-08-15T01:43:00,,No Relation,1,D018818,fenoldopam,C562889,RCN,"The antihypertensive agent fenoldopam has been shown in a canine model, as well as in small, retrospective, prospective, and randomized human evaluations, to be effective for preventing RCN.",12556733_3,12556733_D018818_C562889,,
770957727,false,true,5,2015-08-14T21:05:00,,No Relation,1,D000111,NAC/N-acetylcysteine,C562889,RCN,"In addition, studies have reported the ability of the free radical scavenger N-acetylcysteine (NAC) to prevent RCN.",12556733_4,12556733_D000111_C562889,,
770957728,false,true,5,2015-08-14T21:46:00,,No Relation,1,C088658,zoledronic acid,D011471,prostate cancer,"Adjuvant studies of zoledronic acid in patients with breast and prostate cancer are under development, and the results are eagerly anticipated.",12562049_7,12562049_C088658_D011471,,
770957729,false,true,5,2015-08-15T00:44:00,,No Relation,0.799,D004967,Estrogen,D006973,hypertensive,Estrogen effect on heart rate variability in hypertensive postmenopausal women.,12568734_0,12568734_D004967_D006973,,
770957730,false,true,5,2015-08-15T02:13:00,,No Relation,1,D004967,estrogen,D006973,hypertensive,To examine the heart rate variability (HRV) response to estrogen replacement therapy (ERT) and its association with changes in metabolic variables in hypertensive postmenopausal women.,12568734_2,12568734_D004967_D006973,,
770957731,false,true,5,2015-08-14T23:45:00,,No Relation,1,D014700,verapamil,D006973,hypertensive,"A double-blind, placebo-controlled clinical trial was conducted in 30 hypertensive postmenopausal women receiving 180 mg/day of verapamil.",12568734_3,12568734_D014700_D006973,,
770957732,false,true,5,2015-08-14T21:40:00,,No Relation,1,D004837,Epinephrine,D008133,congenital long-QT syndrome,Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome.,12598076_0,12598076_D004837_D008133,,
770957733,false,true,5,2015-08-15T01:54:00,,No Relation,1,D004837,Epinephrine,D003643,cardiac death,"Epinephrine challenge is a powerful test to establish electrocardiographic diagnosis in silent LQT1 mutation carriers, thus allowing implementation of prophylactic measures aimed at reducing sudden cardiac death.",12598076_8,12598076_D004837_D003643,,
770957734,false,true,5,2015-08-14T21:16:00,,Direct,0.5995,D016202,NMDA,D010146,inflammatory pain,Here we propose the hypothesis that forebrain NMDA receptors play an important role in persistent inflammatory pain by re-enforcing glutamate sensory transmission in the brain.,12598926_4,12598926_D016202_D010146,,
770957735,false,true,5,2015-08-14T22:22:00,,No Relation,0.8013,D018698,glutamate,D010146,inflammatory pain,Here we propose the hypothesis that forebrain NMDA receptors play an important role in persistent inflammatory pain by re-enforcing glutamate sensory transmission in the brain.,12598926_4,12598926_D018698_D010146,,
770957736,false,true,5,2015-08-15T01:19:00,,Direct,0.8011,D016202,NMDA,D006930,allodynia,Mice with enhanced function of forebrain NMDA receptors demonstrate selective enhancement of persistent pain and allodynia.,12598926_5,12598926_D016202_D006930,,
770957737,false,true,5,2015-08-14T21:49:00,,Direct,0.6005,D016202,NMDA,D010146,pain,Mice with enhanced function of forebrain NMDA receptors demonstrate selective enhancement of persistent pain and allodynia.,12598926_5,12598926_D016202_D010146,,
770957738,false,true,5,2015-08-15T02:23:00,,No Relation,1,D016202,NMDA,D010146,pain,Drugs targeting forebrain NMDA NR2B receptors may serve as a new class of medicine to control persistent pain in humans.,12598926_6,12598926_D016202_D010146,,
770957739,false,true,5,2015-08-15T00:58:00,,No Relation,1,D009569,nitric oxide,D020521,stroke,The potential of nitric oxide therapeutics in stroke.,12605567_0,12605567_D009569_D020521,,
770957740,false,true,5,2015-08-14T21:54:00,,No Relation,1,D009569,NO,D020521,stroke,"In stroke, a useful strategy is to increase NO availability and thereby exploit its beneficial antiplatelet, antiatherosclerotic, haemodynamic and neuroprotective properties.",12605567_2,12605567_D009569_D020521,,
770957741,false,true,5,2015-08-15T00:33:00,,No Relation,1,D009569,NO,D020521,stroke,"This article reviews developments in NO-related therapeutics for treatment of stroke, with a particular emphasis on compounds that are in the clinical research and development pipeline.",12605567_5,12605567_D009569_D020521,,
770957742,false,true,5,2015-08-14T22:12:00,,No Relation,1,D009569,NO,D020521,stroke,"Although the routine use of NO therapeutics for the prevention or treatment of stroke cannot currently be recommended, we are evidently at an exciting stage in their pharmacological development.",12605567_6,12605567_D009569_D020521,,
770957743,false,true,5,2015-08-14T21:18:00,,Direct,0.7897,D013629,tamoxifen,D006965,hyperplasia,Simple endometrial hyperplasia was diagnosed in 18 of the 20 samples exposed to tamoxifen compared with only 2 of the 20 controls ( P< 0.0005).,12627041_6,12627041_D013629_D006965,,
770957744,false,true,5,2015-08-14T23:36:00,,No Relation,1,D004967,estrogen,D009375,glandular hyperplasia,"Tamoxifen rapidly up-regulated the cell proliferation markers, an effect that was associated with enhanced growth as confirmed by increased expression of estrogen receptors and Ki-67, in addition to a high incidence of glandular hyperplasia.",12627041_9,12627041_D004967_D009375,,
770957745,false,true,5,2015-08-14T22:21:00,,No Relation,0.5978,D013629,Tamoxifen,D009375,glandular hyperplasia,"Tamoxifen rapidly up-regulated the cell proliferation markers, an effect that was associated with enhanced growth as confirmed by increased expression of estrogen receptors and Ki-67, in addition to a high incidence of glandular hyperplasia.",12627041_9,12627041_D013629_D009375,,
770957746,false,true,5,2015-08-15T01:50:00,,No Relation,0.8131,C043259,gossypolone,D064420,toxicity,"They react easily with electrophiles in aprotic solvents to regenerate gossypolone or to form dehydrogossypoldithianes and dehydrogossypoldithiolanes, which display higher toxicity on KB cells.",12670651_3,12670651_C043259_D064420,,
770957747,false,true,5,2015-08-14T22:09:00,,No Relation,0.7969,D009569,nitric oxide,D064420,toxicity,"In addition, the low toxicity of gossypol thioderivatives was reversed by nitric oxide donors in physiological media.",12670651_4,12670651_D009569_D064420,,
770957748,false,true,5,2015-08-15T01:41:00,,Direct,0.8086,D006072,gossypol,D064420,toxicity,"In addition, the low toxicity of gossypol thioderivatives was reversed by nitric oxide donors in physiological media.",12670651_4,12670651_D006072_D064420,,
770957749,false,true,5,2015-08-14T21:24:00,,No Relation,1,D006072,gossypol,D009369,tumor,These experiments suggest that gossypol and gossypolone dithianes and dithiolanes can be used as prodrugs that target tumor cells surrounded by high concentrations of nitric oxide.,12670651_5,12670651_D006072_D009369,,
770957750,false,true,5,2015-08-14T21:05:00,,No Relation,0.812,D009569,nitric oxide,D009369,tumor,These experiments suggest that gossypol and gossypolone dithianes and dithiolanes can be used as prodrugs that target tumor cells surrounded by high concentrations of nitric oxide.,12670651_5,12670651_D009569_D009369,,
770957751,false,true,5,2015-08-14T22:42:00,,No Relation,1,D001418,baclofen,D009128,spasticity,"To describe the oral motor, communication, and nutritional status of children receiving intrathecal baclofen (ITB) therapy for spasticity of cerebral origin.",12690587_1,12690587_D001418_D009128,,
770957752,false,true,5,2015-08-14T21:20:00,,No Relation,1,D001128,argon,D020256,Choroidal neovascularization,Choroidal neovascularization was treated by argon laser photocoagulation.,12696645_4,12696645_D001128_D020256,,
770957753,false,true,5,2015-08-14T23:33:00,,No Relation,1,D002511,cephalosporins,D008586,pneumococcal meningitis,"In Belgium, high doses of third generation cephalosporins remain effective for the treatment of pneumococcal meningitis.",12723258_9,12723258_D002511_D008586,,
770957754,false,true,5,2015-08-15T01:52:00,,No Relation,1,D024841,fluoroquinolones,D008586,pneumococcal meningitis,The new fluoroquinolones seem the most promising agents for the treatment of pneumococcal meningitis in the future.,12723258_10,12723258_D024841_D008586,,
770957755,false,true,5,2015-08-14T22:40:00,,No Relation,1,D007538,isoniazid,D014376,tuberculosis,"Retrospective prospective analysis involved an outbreak of 94 isoniazid-resistant tuberculosis cases in London, United Kingdom, that began after cases were identified at one hospital in January 2000.",12734218_9,12734218_D007538_D014376,,
770957756,false,true,5,2015-08-14T22:28:00,,No Relation,1,D002220,carbamazepine,D019966,AEDs/antiepileptic drugs,"Ninety percent were on antiepileptic drugs (AEDs), most commonly valproate and carbamazepine.",12763471_7,12763471_D002220_D019966,,
770957757,false,true,5,2015-08-14T21:15:00,,No Relation,1,D014635,valproate,D019966,AEDs/antiepileptic drugs,"Ninety percent were on antiepileptic drugs (AEDs), most commonly valproate and carbamazepine.",12763471_7,12763471_D014635_D019966,,
770957758,false,true,5,2015-08-14T23:16:00,,No Relation,1,D003404,creatinine,D000419,albuminuria,"Characteristics of nephropaths identified by existing screening practice (phase I, albuminuria >20 mg/l in three separate urine samples), were compared with those identified by a nurse-led management program (phase II, in which screening for nephropathy was based on albumin-to-creatinine ratio in a single random urine specimen).",12766114_2,12766114_D003404_D000419,,
770957759,false,true,5,2015-08-14T22:05:00,,No Relation,1,D003404,creatinine,D003554,nephropaths,"Characteristics of nephropaths identified by existing screening practice (phase I, albuminuria >20 mg/l in three separate urine samples), were compared with those identified by a nurse-led management program (phase II, in which screening for nephropathy was based on albumin-to-creatinine ratio in a single random urine specimen).",12766114_2,12766114_D003404_D003554,,
770957760,false,true,5,2015-08-14T21:03:00,,No Relation,1,D003404,creatinine,C562889,nephropathy,"Characteristics of nephropaths identified by existing screening practice (phase I, albuminuria >20 mg/l in three separate urine samples), were compared with those identified by a nurse-led management program (phase II, in which screening for nephropathy was based on albumin-to-creatinine ratio in a single random urine specimen).",12766114_2,12766114_D003404_C562889,,
770957761,false,true,5,2015-08-14T23:24:00,,No Relation,1,D013792,Thalidomide,D007918,leprosy,"Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer.",12803319_1,12803319_D013792_D007918,,
770957762,false,true,5,2015-08-15T00:51:00,,No Relation,1,D013792,Thalidomide,D009369,cancer,"Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer.",12803319_1,12803319_D013792_D009369,,
770957763,false,true,5,2015-08-15T01:58:00,,No Relation,1,D013792,thalidomide,D004409,SelCIDs/selective cytokine inhibitory drugs,"These include selective cytokine inhibitory drugs (SelCIDs), with greatly improved TNF-alpha inhibitory activity, and immunomodulatory drugs (IMiDs) that are structural analogs of thalidomide, with improved properties.",12803319_4,12803319_D013792_D004409,,
770957764,false,true,5,2015-08-14T21:43:00,,No Relation,1,D013792,thalidomide,D007249,inflammatory disease,"This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV.",12803319_6,12803319_D013792_D007249,,
770957765,false,true,5,2015-08-14T21:56:00,,No Relation,1,D013792,thalidomide,D009101,myeloma,"This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV.",12803319_6,12803319_D013792_D009101,,
770957766,false,true,5,2015-08-14T23:50:00,,No Relation,0.7862,D013792,thalidomide,D009369,cancers,"This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV.",12803319_6,12803319_D013792_D009369,,
770957767,false,true,5,2015-08-15T01:35:00,,No Relation,0.815,D013792,thalidomide,D015658,HIV,"This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV.",12803319_6,12803319_D013792_D015658,,
770957768,false,true,5,2015-08-14T23:42:00,,No Relation,1,D013792,thalidomide,D009369,cancers,"Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers.",12803319_8,12803319_D013792_D009369,,
770957769,false,true,5,2015-08-15T00:48:00,,No Relation,1,D010710,phosphate,D007676,ESRD/end-stage renal disease,"More than 60% of patients on chronic haemodialysis (HD) have a serum phosphate level above 5.5 mg/dl (1.75 mmol/l), which recently has been recommended as an appropriate target in patients with end-stage renal disease (ESRD).",12817070_1,12817070_D010710_D007676,,
770957770,false,true,5,2015-08-14T21:04:00,,No Relation,1,D008353,Mannitol,D020521,acute stroke,Mannitol use in acute stroke: case fatality at 30 days and 1 year.,12817105_0,12817105_D008353_D020521,,
770957771,false,true,5,2015-08-14T21:38:00,,No Relation,1,D008353,Mannitol,D020521,acute stroke,"Mannitol is used worldwide to treat acute stroke, although its efficacy and safety have not been proven by randomized trials.",12817105_1,12817105_D008353_D020521,,
770957772,false,true,5,2015-08-14T23:33:00,,No Relation,1,D008353,mannitol,D020521,stroke,"In a tricenter, prospective study, we analyzed the 30-day and 1-year case fatality with respect to mannitol treatment status in 805 patients consecutively admitted within 72 hours of stroke onset.",12817105_2,12817105_D008353_D020521,,
770957773,false,true,5,2015-08-14T21:29:00,,No Relation,0.8084,D008353,Mannitol,D005334,fever,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D008353_D005334,,
770957774,false,true,5,2015-08-15T02:39:00,,No Relation,1,D008353,Mannitol,D020521,stroke,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D008353_D020521,,
770957775,false,true,5,2015-08-14T21:19:00,,No Relation,1,D001241,aspirin,D002544,ischemic strokes,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D001241_D002544,,
770957776,false,true,5,2015-08-14T22:10:00,,No Relation,1,D001241,aspirin,D020521,stroke,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D001241_D020521,,
770957777,false,true,5,2015-08-14T21:56:00,,No Relation,1,D001241,aspirin,D005334,fever,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D001241_D005334,,
770957778,false,true,5,2015-08-15T02:19:00,,No Relation,1,D008353,Mannitol,D002544,ischemic strokes,"Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models.",12817105_6,12817105_D008353_D002544,,
770957779,false,true,5,2015-08-15T01:37:00,,No Relation,1,D008353,mannitol,D020521,acute stroke,"Based on the results of this study, no recommendations can be made on the use of mannitol in acute stroke, and properly randomized, controlled trials should be performed to come to a final conclusion.",12817105_10,12817105_D008353_D020521,,
770957780,false,true,5,2015-08-15T02:15:00,,No Relation,1,C063008,mycophenolate mofetil,C535661,ST,"We investigated in vitro monokine responses in 112 patients with long-term stable kidney graft function (ST patients; n=80, non-mycophenolate mofetil [MMF]; n=32, MMF) and 25 patients with chronic renal transplant rejection (CR patients; non-MMF).",12829918_2,12829918_C063008_C535661,,
770957781,false,true,5,2015-08-15T01:41:00,,No Relation,1,C063008,mycophenolate mofetil,D051436,chronic renal transplant rejection,"We investigated in vitro monokine responses in 112 patients with long-term stable kidney graft function (ST patients; n=80, non-mycophenolate mofetil [MMF]; n=32, MMF) and 25 patients with chronic renal transplant rejection (CR patients; non-MMF).",12829918_2,12829918_C063008_D051436,,
770957782,false,true,5,2015-08-14T22:43:00,,No Relation,1,D013256,steroid,C535661,ST,"Coinciding with a significantly higher steroid dosage in CR patients, IL-6 receptor and TNF-R1 expression on monocytes were down-regulated (P< or =0.02) and AC was suppressed in CR compared with ST (non-MMF) patients (P<0.01, SED; P<0.05, SEE).",12829918_5,12829918_D013256_C535661,,
770957783,false,true,5,2015-08-14T21:14:00,,No Relation,1,D008712,methicillin,D060467,methicillin-resistant,Genetic relationship between methicillin-sensitive and methicillin-resistant Staphylococcus aureus strains from France and from international sources: delineation of genomic groups.,12843025_0,12843025_D008712_D060467,,
770957784,false,true,5,2015-08-15T02:13:00,,No Relation,1,D008712,methicillin,D060467,methicillin-resistant/MRSA,"Cluster analysis of the SmaI patterns, generated by pulsed-field gel electrophoresis, of 44 methicillin-resistant (MRSA) and 118 methicillin-sensitive (MSSA) Staphylococcus aureus strains isolated in various French hospitals and 61 MRSA and 48 MSSA strains from 20 other countries revealed 20 genomic groups distributed into four distantly related phylogenic branches.",12843025_1,12843025_D008712_D060467,,
770957785,false,true,5,2015-08-14T22:17:00,,No Relation,1,D005472,5-fluorouracil,D015179,colorectal cancer,Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.,12886055_0,12886055_D005472_D015179,,
770957786,false,true,5,2015-08-14T21:05:00,,No Relation,1,C030110,Oxaliplatin,D015179,colorectal cancer,Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.,12886055_0,12886055_C030110_D015179,,
770957787,false,true,5,2015-08-14T23:51:00,,No Relation,1,D002955,leucovorin,D015179,colorectal cancer,Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.,12886055_0,12886055_D002955_D015179,,
770957788,false,true,5,2015-08-15T00:10:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D015179,colorectal cancer,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_D005472_D015179,,
770957789,false,true,5,2015-08-14T21:15:00,,No Relation,1,C030110,oxaliplatin,D015179,colorectal cancer,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_C030110_D015179,,
770957790,false,true,5,2015-08-15T02:33:00,,No Relation,0.6036,C030110,oxaliplatin,D064420,toxicity,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_C030110_D064420,,
770957791,false,true,5,2015-08-14T22:21:00,,No Relation,0.7805,D005472,5-FU/5-fluorouracil,D064420,toxicity,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_D005472_D064420,,
770957792,false,true,5,2015-08-14T21:23:00,,No Relation,1,D002955,leucovorin,D064420,toxicity,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_D002955_D064420,,
770957793,false,true,5,2015-08-14T21:01:00,,No Relation,1,D002955,leucovorin,D015179,colorectal cancer,The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer.,12886055_1,12886055_D002955_D015179,,
770957794,false,true,5,2015-08-14T21:59:00,,No Relation,1,D005472,5-FU,D015179,colorectal cancer,A total of 39 patients with documented 5-FU-resistant advanced colorectal cancer were enrolled.,12886055_2,12886055_D005472_D015179,,
770957795,false,true,5,2015-08-14T23:49:00,,No Relation,1,D005472,5-FU,D015179,colorectal cancer,Oxaliplatin in combination with weekly bolus 5-FU/LV is also active in patients with advanced colorectal cancer where first-line treatment has failed.,12886055_11,12886055_D005472_D015179,,
770957796,false,true,5,2015-08-15T00:45:00,,No Relation,1,C030110,Oxaliplatin,D015179,colorectal cancer,Oxaliplatin in combination with weekly bolus 5-FU/LV is also active in patients with advanced colorectal cancer where first-line treatment has failed.,12886055_11,12886055_C030110_D015179,,
770957797,false,true,5,2015-08-14T21:08:00,,No Relation,1,C065179,atorvastatin,D054058,acute coronary syndromes,Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.,12888133_0,12888133_C065179_D054058,,
770957798,false,true,5,2015-08-15T02:21:00,,No Relation,1,C055162,clopidogrel,D054058,acute coronary syndromes,Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.,12888133_0,12888133_C055162_D054058,,
770957799,false,true,5,2015-08-14T21:45:00,,No Relation,1,C065179,atorvastatin,D054058,acute coronary syndromes,"In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy.",12888133_1,12888133_C065179_D054058,,
770957800,false,true,5,2015-08-14T22:19:00,,No Relation,1,C055162,clopidogrel,D054058,acute coronary syndromes,"In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy.",12888133_1,12888133_C055162_D054058,,
770957801,false,true,5,2015-08-15T00:15:00,,No Relation,1,C055162,clopidogrel,D020521,stroke,"In patients receiving atorvastatin therapy, clopidogrel therapy was associated with a significant decrease in mortality and stroke during univariate analysis and a moderate trend of reduced mortality and stroke without statistical significance in the multivariate analysis.",12888133_2,12888133_C055162_D020521,,
770957802,false,true,5,2015-08-14T21:42:00,,No Relation,1,C065179,atorvastatin,D020521,stroke,"In patients receiving atorvastatin therapy, clopidogrel therapy was associated with a significant decrease in mortality and stroke during univariate analysis and a moderate trend of reduced mortality and stroke without statistical significance in the multivariate analysis.",12888133_2,12888133_C065179_D020521,,
770957803,false,true,5,2015-08-14T23:22:00,,No Relation,1,D018698,glutamine,D014947,burn injury,"This research was conducted to evaluate the effect of enterally administered glutamine (gln) dipeptide on metabolic, gastrointestinal, and outcome parameters after severe burn injury.",12903886_1,12903886_D018698_D014947,,
770957804,false,true,5,2015-08-15T00:48:00,,No Relation,1,D008353,mannitol,D014947,burn injury,"Lactulose/mannitol ratios were increased above normal on POD +1 (control, 0.221 +/- 0.169; gln, 0.268 +/- 0.202; not significant), reflecting increased intestinal permeability after burn injury.",12903886_10,12903886_D008353_D014947,,
770957805,false,true,5,2015-08-14T21:22:00,,No Relation,1,D007792,Lactulose,D014947,burn injury,"Lactulose/mannitol ratios were increased above normal on POD +1 (control, 0.221 +/- 0.169; gln, 0.268 +/- 0.202; not significant), reflecting increased intestinal permeability after burn injury.",12903886_10,12903886_D007792_D014947,,
770957806,false,true,5,2015-08-14T22:19:00,,No Relation,1,D000109,acetylcholine,D006973,hypertensive,We compared dose-response curves relating changes in coronary blood flow and epicardial diameter to graded infusions of acetylcholine in 50 African American and 65 white subjects with hypertensive left ventricular hypertrophy (LVH) and normal coronary arteries.,12913059_3,12913059_D000109_D006973,,
770957807,false,true,5,2015-08-14T21:42:00,,No Relation,1,D000109,acetylcholine,D017379,left ventricular hypertrophy/LVH,We compared dose-response curves relating changes in coronary blood flow and epicardial diameter to graded infusions of acetylcholine in 50 African American and 65 white subjects with hypertensive left ventricular hypertrophy (LVH) and normal coronary arteries.,12913059_3,12913059_D000109_D017379,,
770957808,false,true,5,2015-08-15T00:36:00,,No Relation,1,D000241,Adenosine,D017379,LVH,"Adenosine responses, a measure of endothelium-independent function, were similar after partitioning by LVH.",12913059_10,12913059_D000241_D017379,,
770957809,false,true,5,2015-08-14T23:30:00,,No Relation,1,D000109,acetylcholine,D017379,LVH,Our study demonstrates that there are racial differences in sensitivity of coronary arteries to acetylcholine-stimulated relaxation among those with LVH.,12913059_11,12913059_D000109_D017379,,
770957810,false,true,5,2015-08-14T21:01:00,,No Relation,0.5786,D009532,nickel,D003872,dermatitis,"Recently, several studies reported that patients affected by cutaneous diseases (i.e. dermatitis, eczema and urticaria) with positive patch test to nickel have a positive oral nickel challenge.",12915773_2,12915773_D009532_D003872,,
770957811,false,true,5,2015-08-15T01:46:00,,No Relation,0.8073,D009532,nickel,D004485,eczema,"Recently, several studies reported that patients affected by cutaneous diseases (i.e. dermatitis, eczema and urticaria) with positive patch test to nickel have a positive oral nickel challenge.",12915773_2,12915773_D009532_D004485,,
770957812,false,true,5,2015-08-15T00:37:00,,Direct,0.6107,D009532,nickel,D014581,urticaria,"Recently, several studies reported that patients affected by cutaneous diseases (i.e. dermatitis, eczema and urticaria) with positive patch test to nickel have a positive oral nickel challenge.",12915773_2,12915773_D009532_D014581,,
770957813,false,true,5,2015-08-15T00:21:00,,No Relation,0.8077,D009532,nickel,D004342,hypersensitivity,"The results of this study demonstrate that, in some patients with a positive patch test to nickel sulphate, the perpetuation of RAS can be related to a hypersensitivity to ingested nickel salts, independently of local contact to nickel.",12915773_14,12915773_D009532_D004342,,
770957814,false,true,5,2015-08-15T01:15:00,,No Relation,1,C106791,Telithromycin,D003147,community-acquired pneumonia,Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.,12925111_0,12925111_C106791_D003147,,
770957815,false,true,5,2015-08-14T21:18:00,,No Relation,1,C106791,telithromycin/HMR 3647,D003147,CAP/community-acquired pneumonia,"This open, multinational study examined the efficacy and tolerability of telithromycin (HMR 3647), the first ketolide antibacterial agent, at an oral dose of 800 mg once daily for seven to ten days (further validated using pharmacokinetic analysis) as an empiric therapy in adults with mild to moderate community-acquired pneumonia (CAP).",12925111_1,12925111_C106791_D003147,,
770957816,false,true,5,2015-08-14T22:05:00,,No Relation,1,C106791,telithromycin,D003147,CAP,An oral dose of telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated first-line treatment for mild to moderate CAP in adults.,12925111_14,12925111_C106791_D003147,,
770957817,false,true,5,2015-08-15T00:05:00,,No Relation,1,C073007,ibandronate,D048909,skeletal complications,Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.,12954579_0,12954579_C073007_D048909,,
770957818,false,true,5,2015-08-15T01:39:00,,No Relation,1,C073007,ibandronate,D009369,breast cancer,Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.,12954579_0,12954579_C073007_D009369,,
770957819,false,true,5,2015-08-14T21:35:00,,No Relation,1,D004164,bisphosphonate,D009369,breast cancer,"This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.",12954579_1,12954579_D004164_D009369,,
770957820,false,true,5,2015-08-15T00:48:00,,No Relation,1,D004164,bisphosphonate,D001847,bone disease,"This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.",12954579_1,12954579_D004164_D001847,,
770957821,false,true,5,2015-08-14T23:43:00,,No Relation,1,C073007,ibandronate,D009369,breast cancer,"This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.",12954579_1,12954579_C073007_D009369,,
770957822,false,true,5,2015-08-15T01:48:00,,No Relation,1,C073007,ibandronate,D001847,bone disease,"This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.",12954579_1,12954579_C073007_D001847,,
770957823,false,true,5,2015-08-15T01:02:00,,No Relation,0.7933,C073007,ibandronate,D010146,bone pain,Patients on ibandronate 6 mg also experienced decreased bone pain scores and analgesic use.,12954579_7,12954579_C073007_D010146,,
770957824,false,true,5,2015-08-14T22:19:00,,No Relation,1,C073007,ibandronate,D009369,breast cancer,These results indicate that 6 mg i.v. ibandronate is effective and safe in the treatment of bone metastases from breast cancer.,12954579_9,12954579_C073007_D009369,,
770957825,false,true,5,2015-08-15T00:57:00,,No Relation,1,D064704,levofloxacin,D009181,bacterial keratitis,"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.",12967804_0,12967804_D064704_D009181,,
770957826,false,true,5,2015-08-14T21:25:00,,No Relation,1,C104727,moxifloxacin,D009181,bacterial keratitis,"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.",12967804_0,12967804_C104727_D009181,,
770957827,false,true,5,2015-08-14T22:05:00,,No Relation,1,D002939,ciprofloxacin,D009181,bacterial keratitis,"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.",12967804_0,12967804_D002939_D009181,,
770957828,false,true,5,2015-08-14T21:56:00,,No Relation,1,C078049,Gatifloxacin,D009181,bacterial keratitis,"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.",12967804_0,12967804_C078049_D009181,,
770957829,false,true,5,2015-08-15T02:04:00,,No Relation,1,D015242,ofloxacin,D009181,bacterial keratitis,"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.",12967804_0,12967804_D015242_D009181,,
770957830,false,true,5,2015-08-14T21:48:00,,No Relation,1,D002939,ciprofloxacin/CIP,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_D002939_D009181,,
770957831,false,true,5,2015-08-14T21:13:00,,No Relation,1,D015242,OFX/ofloxacin,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_D015242_D009181,,
770957832,false,true,5,2015-08-14T23:26:00,,No Relation,1,D064704,LEV/levofloxacin,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_D064704_D009181,,
770957833,false,true,5,2015-08-14T22:00:00,,No Relation,1,C104727,moxifloxacin/MOX,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_C104727_D009181,,
770957834,false,true,5,2015-08-14T21:16:00,,No Relation,1,D024841,fluoroquinolone/fluoroquinolones,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_D024841_D009181,,
770957835,false,true,5,2015-08-15T00:54:00,,No Relation,1,C078049,gatifloxacin,D009181,bacterial keratitis,We compared the in vitro susceptibility patterns and the minimum inhibitory concentrations (MICs) of gatifloxacin (GAT) and moxifloxacin (MOX) (fourth-generation fluoroquinolones) to ciprofloxacin (CIP) and ofloxacin (OFX) (second-generation fluoroquinolones) and levofloxacin (LEV; third-generation fluoroquinolone) using bacterial keratitis isolates.,12967804_1,12967804_C078049_D009181,,
770957836,false,true,5,2015-08-14T22:07:00,,No Relation,1,D015242,OFX,D009181,bacterial keratitis,"In retrospect, the MICs of 177 bacterial keratitis isolates were determined to CIP, OFX, LEV, GAT, and MOX using E tests.",12967804_5,12967804_D015242_D009181,,
770957837,false,true,5,2015-08-15T01:56:00,,No Relation,1,D024841,fluoroquinolones,D007634,keratitis,"For most keratitis isolates, there were no susceptibility differences among the five fluoroquinolones.",12967804_9,12967804_D024841_D007634,,
770957838,false,true,5,2015-08-14T21:42:00,,No Relation,1,D024841,fluoroquinolones,D009181,bacterial keratitis,"Based on in vitro testing, the fourth-generation fluoroquinolones may offer some advantages over those currently available for the treatment of bacterial keratitis.",12967804_14,12967804_D024841_D009181,,
770957839,false,true,5,2015-08-15T01:12:00,,Direct,1,D017886,hydroxyapatite,D013492,suppurative granuloma,"Five patients with hydroxyapatite implants showed lid swelling, discharge, and suppurative granuloma 14 days to 3 years after surgery.",12967870_2,12967870_D017886_D013492,,
770957840,false,true,5,2015-08-14T21:56:00,,No Relation,0.8094,D017886,hydroxyapatite,D011023,Staphylococcus epidermidis,"The culture of specimens removed with swabs from the conjunctiva of patients and from the hydroxyapatite implants showed growth of Staphylococcus aureus, Staphylococcus epidermidis, alpha-hemolytic streptococcus and peptostreptococcus in 4 patients, whereas Streptococcus pyogenes were cultured from the conjunctiva in the Medpor implant patient.",12967870_5,12967870_D017886_D011023,,
770957841,false,true,5,2015-08-15T00:25:00,,No Relation,1,D013256,steroid,D016553,ITP,"We reviewed the medical records of 288 children and adolescents with chronic ITP between 1980 and 1996: 112 were splenectomized; 59 were steroid resistant and 42 were steroid dependent, and 11 were managed with repeated courses of intravenous immunoglobulin (IVIG).",12975552_2,12975552_D013256_D016553,,
770957842,false,true,5,2015-08-14T23:48:00,Probably used as treatment.,No Relation,1,D016572,cyclosporine,D018459,lichen planopilaris,Short course of oral cyclosporine in lichen planopilaris.,14512914_0,14512914_D016572_D018459,,
770957843,false,true,5,2015-08-14T21:02:00,,No Relation,1,D016572,cyclosporine,D018459,lichen planopilaris,"We present 3 patients with lichen planopilaris who were treated with a short course of oral cyclosporine and report their clinical features and responses, using a standardized method of patient assessment and 3 specific outcome measures.",14512914_4,14512914_D016572_D018459,,
770957844,false,true,5,2015-08-14T22:10:00,,Direct,0.5936,D009609,nitrous oxide,D000699,analgesia,Inhalation sedation with nitrous oxide/oxygen sedation to reach a plane of relative analgesia may be administered easily and safely to children in general dental practice and is a potential alternative to general anaesthesia.,14558199_4,14558199_D009609_D000699,,
770957845,false,true,5,2015-08-14T21:22:00,,No Relation,0.5869,D010100,oxygen,D000699,analgesia,Inhalation sedation with nitrous oxide/oxygen sedation to reach a plane of relative analgesia may be administered easily and safely to children in general dental practice and is a potential alternative to general anaesthesia.,14558199_4,14558199_D010100_D000699,,
770957846,false,true,5,2015-08-14T21:09:00,,No Relation,1,D009761,nystatin,D012514,MCD,"In the cell lines, RA#1 and MC116, sIgM aggregated into patches that were insensitive to the disruption of cholesterol-rich membrane microdomains by nystatin or beta-MCD.",14565868_3,14565868_D009761_D012514,,
770957847,false,true,5,2015-08-14T21:58:00,,No Relation,1,D002784,cholesterol,D012514,MCD,"In the cell lines, RA#1 and MC116, sIgM aggregated into patches that were insensitive to the disruption of cholesterol-rich membrane microdomains by nystatin or beta-MCD.",14565868_3,14565868_D002784_D012514,,
770957848,false,true,5,2015-08-14T21:52:00,,No Relation,1,D009761,nystatin,D012514,MCD,"However, in this case, the lipid raft inhibitors nystatin and beta-MCD disrupted the patching.",14565868_5,14565868_D009761_D012514,,
770957849,false,true,5,2015-08-14T21:05:00,,No Relation,0.8079,D009761,nystatin,D012514,MCD,"In 2G6 cells, BCR-mediated apoptosis was not affected by nystatin treatment, whereas it increased in beta-MCD pretreated cells.",14565868_6,14565868_D009761_D012514,,
770957850,false,true,5,2015-08-14T21:42:00,,No Relation,1,C459628,9-methoxycanthin-6-one,D008175,human lung cancer,"These compounds were screened for in vitro cytotoxic and antimalarial activities, and 9-methoxycanthin-6-one (4) and canthin-6-one (5) demonstrated significant cytotoxicity against human lung cancer (A-549) and human breast cancer (MCF-7) cell lines.",14575431_3,14575431_C459628_D008175,,
770957851,false,true,5,2015-08-14T21:42:00,,No Relation,1,C453379,canthin-6-one,D009369,breast cancer,"These compounds were screened for in vitro cytotoxic and antimalarial activities, and 9-methoxycanthin-6-one (4) and canthin-6-one (5) demonstrated significant cytotoxicity against human lung cancer (A-549) and human breast cancer (MCF-7) cell lines.",14575431_3,14575431_C453379_D009369,,
770957852,false,true,5,2015-08-14T21:42:00,,No Relation,1,C459628,9-methoxycanthin-6-one,D009369,breast cancer,"These compounds were screened for in vitro cytotoxic and antimalarial activities, and 9-methoxycanthin-6-one (4) and canthin-6-one (5) demonstrated significant cytotoxicity against human lung cancer (A-549) and human breast cancer (MCF-7) cell lines.",14575431_3,14575431_C459628_D009369,,
770957853,false,true,5,2015-08-14T22:08:00,,No Relation,1,C453379,canthin-6-one,D008175,human lung cancer,"These compounds were screened for in vitro cytotoxic and antimalarial activities, and 9-methoxycanthin-6-one (4) and canthin-6-one (5) demonstrated significant cytotoxicity against human lung cancer (A-549) and human breast cancer (MCF-7) cell lines.",14575431_3,14575431_C453379_D008175,,
770957854,false,true,5,2015-08-14T21:15:00,,No Relation,1,D005283,fentanyl,D010146,chronic pain,Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.,14583070_0,14583070_D005283_D010146,,
770957855,false,true,5,2015-08-14T22:52:00,,No Relation,1,D005283,fentanyl,D010146,chronic pain,Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused by malignancy and non-malignant conditions when administered according to the manufacturer's recommendations.,14583070_1,14583070_D005283_D010146,,
770957856,false,true,5,2015-08-15T00:21:00,,Direct,0.8116,D005283,fentanyl,D014839,vomiting,"Compared with oral opioids, the advantages of transdermal fentanyl include a lower incidence and impact of adverse effects (constipation, nausea and vomiting, and daytime drowsiness), a higher degree of patient satisfaction, improved quality of life, improved convenience and compliance resulting from administration every 72 hours, and decreased use of rescue medication.",14583070_2,14583070_D005283_D014839,,
770957857,false,true,5,2015-08-14T21:24:00,,No Relation,0.8066,D005283,fentanyl,D003248,constipation,"Compared with oral opioids, the advantages of transdermal fentanyl include a lower incidence and impact of adverse effects (constipation, nausea and vomiting, and daytime drowsiness), a higher degree of patient satisfaction, improved quality of life, improved convenience and compliance resulting from administration every 72 hours, and decreased use of rescue medication.",14583070_2,14583070_D005283_D003248,,
770957858,false,true,5,2015-08-14T21:54:00,,No Relation,1,D005283,fentanyl,D009325,nausea,"Compared with oral opioids, the advantages of transdermal fentanyl include a lower incidence and impact of adverse effects (constipation, nausea and vomiting, and daytime drowsiness), a higher degree of patient satisfaction, improved quality of life, improved convenience and compliance resulting from administration every 72 hours, and decreased use of rescue medication.",14583070_2,14583070_D005283_D009325,,
770957859,false,true,5,2015-08-14T22:07:00,,No Relation,1,D005283,fentanyl,D005767,gastrointestinal problems,Transdermal fentanyl is a useful analgesic for cancer patients who are unable to swallow or have gastrointestinal problems.,14583070_3,14583070_D005283_D005767,,
770957860,false,true,5,2015-08-14T21:02:00,,No Relation,1,D005283,fentanyl,D009369,cancer,Transdermal fentanyl is a useful analgesic for cancer patients who are unable to swallow or have gastrointestinal problems.,14583070_3,14583070_D005283_D009369,,
770957861,false,true,5,2015-08-15T00:03:00,Used as treatment.,No Relation,0.7981,D005283,fentanyl,D010146,chronic pain/pain,Patients with chronic pain should be titrated to adequate relief with short-acting oral or parenteral opioids prior to the initiation of transdermal fentanyl in order to prevent exacerbations of pain or opioid-related adverse effects.,14583070_6,14583070_D005283_D010146,,
770957862,false,true,5,2015-08-14T23:38:00,,No Relation,0.8016,D005283,fentanyl,D000699,analgesia,Transdermal fentanyl can then be initiated based on the 24-hour opioid requirement once adequate analgesia has been achieved.,14583070_7,14583070_D005283_D000699,,
770957863,false,true,5,2015-08-15T01:40:00,,Direct,0.598,D005283,fentanyl,D007040,hypoventilation,"The prolonged elimination of transdermal fentanyl can become problematic if patients develop opioid-related adverse effects, especially hypoventilation.",14583070_8,14583070_D005283_D007040,,
770957864,false,true,5,2015-08-14T22:10:00,,No Relation,1,D009270,naloxone,D064420,toxicity,Patients who experience opioid-related toxicity associated with respiratory depression should be treated immediately with an opioid antagonist such as naloxone and closely monitored for at least 24 hours.,14583070_10,14583070_D009270_D064420,,
770957865,false,true,5,2015-08-15T01:25:00,,No Relation,1,D009270,naloxone,D012131,respiratory depression,Patients who experience opioid-related toxicity associated with respiratory depression should be treated immediately with an opioid antagonist such as naloxone and closely monitored for at least 24 hours.,14583070_10,14583070_D009270_D012131,,
770957866,false,true,5,2015-08-14T22:19:00,,Direct,0.602,D005283,fentanyl,D007040,hypoventilation,Transdermal fentanyl should be administered cautiously to patients with pre-existing conditions such as emphysema that may predispose them to the development of hypoventilation.,14583070_12,14583070_D005283_D007040,,
770957867,false,true,5,2015-08-14T21:45:00,,No Relation,1,D005283,fentanyl,D004646,emphysema,Transdermal fentanyl should be administered cautiously to patients with pre-existing conditions such as emphysema that may predispose them to the development of hypoventilation.,14583070_12,14583070_D005283_D004646,,
770957868,false,true,5,2015-08-15T00:05:00,,No Relation,1,D005283,fentanyl,D010146,chronic pain,Transdermal fentanyl is indicated only for patients who require continuous opioid administration for the treatment of chronic pain that cannot be managed with other medications.,14583070_13,14583070_D005283_D010146,,
770957869,false,true,5,2015-08-14T21:45:00,,No Relation,1,D005283,fentanyl,D010146,pain/postoperative pain,"It is contraindicated in the management of acute and postoperative pain, as pain may decrease more rapidly in these circumstances than fentanyl blood levels can be adjusted, leading to the development of life-threatening hypoventilation.",14583070_14,14583070_D005283_D010146,,
770957870,false,true,5,2015-08-15T00:22:00,,Direct,0.8061,D005283,fentanyl,D007040,hypoventilation,"It is contraindicated in the management of acute and postoperative pain, as pain may decrease more rapidly in these circumstances than fentanyl blood levels can be adjusted, leading to the development of life-threatening hypoventilation.",14583070_14,14583070_D005283_D007040,,
770957871,false,true,5,2015-08-15T01:58:00,,Direct,1,D005283,fentanyl,D059445,physical impairments,Cognitive and physical impairments such as confusion and abnormal co-ordination can occur with transdermal fentanyl.,14583070_15,14583070_D005283_D059445,,
770957872,false,true,5,2015-08-14T23:41:00,,Direct,1,D005283,fentanyl,D003221,confusion,Cognitive and physical impairments such as confusion and abnormal co-ordination can occur with transdermal fentanyl.,14583070_15,14583070_D005283_D003221,,
770957873,false,true,5,2015-08-14T21:22:00,,No Relation,1,C406224,valdecoxib,D004415,dyspepsia,"In comparative trials of celecoxib or valdecoxib with non-specific NSAIDs, COX-2-specific inhibitors were demonstrated to have superior dyspepsia tolerability than non-specific NSAIDs.",14585916_5,14585916_C406224_D004415,,
770957874,false,true,5,2015-08-14T22:34:00,,No Relation,1,C105934,celecoxib,D004415,dyspepsia,"In comparative trials of celecoxib or valdecoxib with non-specific NSAIDs, COX-2-specific inhibitors were demonstrated to have superior dyspepsia tolerability than non-specific NSAIDs.",14585916_5,14585916_C105934_D004415,,
770957875,false,true,5,2015-08-14T23:26:00,Used as treatment.,No Relation,0.7996,D002166,camptothecin,D001254,mixed oligoastrocytoma,"To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.Patients from seven centers with recurrent or progressive disease were treated with topotecan, 1.5 mg/m(2) intravenously (i.v.), 30 min dailyx5 days every 3 weeks.",14586216_1,14586216_D002166_D001254,,
770957876,false,true,5,2015-08-15T02:31:00,,No Relation,0.8128,D002166,camptothecin,D064420,toxicity,"To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.Patients from seven centers with recurrent or progressive disease were treated with topotecan, 1.5 mg/m(2) intravenously (i.v.), 30 min dailyx5 days every 3 weeks.",14586216_1,14586216_D002166_D064420,,
770957877,false,true,5,2015-08-15T00:50:00,,No Relation,0.5983,D011078,PCBs,D009369,cancer,Potential human cancer risks from exposure to PCBs: a tale of two evaluations.,14594106_0,14594106_D011078_D009369,,
770957878,false,true,5,2015-08-14T21:29:00,,No Relation,1,D011078,PCBs,D009369,cancer,"In reviewing the potential human carcinogenicity of PCBs, ATSDR (1999) concluded that ""The weight of evidence does not support a causal association for PCBs and human cancer at this time"".",14594106_2,14594106_D011078_D009369,,
770957879,false,true,5,2015-08-14T23:37:00,,Direct,0.8078,D011078,PCBs,D009369,cancer,"The present review addresses the additional scientific data that became available between the ATSDR 1999 and 2000 evaluations that was of a magnitude to offset the weight of evidence from numerous epidemiological studies that exposure to PCBs was not causally associated with human cancer to a conclusion only 1 year later that there was now ""meaningful evidence"" that PCBs posed a carcinogenic risk to humans.",14594106_5,14594106_D011078_D009369,,
770957880,false,true,5,2015-08-14T22:19:00,,No Relation,1,D004967,estrogen,D009369,tumors,The levels of CRASH mRNA were significantly up-regulated in tumors compared with normal breast tissues and correlate with lack of estrogen receptor expression of the tumors.,14654938_8,14654938_D004967_D009369,,
770957881,false,true,5,2015-08-14T22:13:00,,No Relation,0.8038,D011241,prednisone,D009290,hypocretin-deficiency narcolepsy,Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy.,14655912_0,14655912_D011241_D009290,,
770957882,false,true,5,2015-08-15T02:04:00,,No Relation,1,D011241,prednisone,D009290,narcolepsy,To explore whether acute destruction of hypocretin cells in a patient with narcolepsy could be detected and if the course of the disease could be reversed or altered by the use of prednisone for immunosuppression.,14655912_1,14655912_D011241_D009290,,
770957883,false,true,5,2015-08-14T21:52:00,,No Relation,0.8156,D004298,dopamine,D009369,breast cancer,Are dopamine antagonists a risk factor for breast cancer?,14659314_0,14659314_D004298_D009369,,
770957884,false,true,5,2015-08-14T21:38:00,,No Relation,0.621,D004298,dopamine,D009369,breast cancer/cancer,Women undergoing chemotherapy for breast cancer are often administered dopamine antagonist adjuvant medications that may increase levels of prolactin potentially increasing the risk of cancer.,14659314_2,14659314_D004298_D009369,,
770957885,false,true,5,2015-08-15T00:31:00,,No Relation,0.8282,D004298,dopamine,D010300,Parkinson's disease/PD,"Using nationwide computerized registers of death data for the years 1991 through 1996 we examined 12,430,473 deaths of persons over 40 years of age and extracted 144,364 cases with Parkinson's disease (PD), a dopamine deficient population.",14659314_3,14659314_D004298_D010300,,
770957886,false,true,5,2015-08-15T01:28:00,,No Relation,1,C508672,methylenecyclopropane,D020031,HHV-8/EBV,"These results indicate that members of this series of methylenecyclopropane analogs are highly active against HCMV, HHV-6, and HHV-8 but are less active against HSV, VZV, and EBV.",14714760_9,14714760_C508672_D020031,,
770957887,false,true,5,2015-08-15T00:50:00,,No Relation,1,C508672,methylenecyclopropane,D020804,VZV,"These results indicate that members of this series of methylenecyclopropane analogs are highly active against HCMV, HHV-6, and HHV-8 but are less active against HSV, VZV, and EBV.",14714760_9,14714760_C508672_D020804,,
770957888,false,true,5,2015-08-14T21:35:00,,No Relation,1,D002996,clomiphene citrate,D011085,polycystic ovary syndrome,168 patients with clomiphene citrate resistant polycystic ovary syndrome: 83 were allocated electrocautery and 85 were allocated recombinant follicle stimulating hormone.,14739186_4,14739186_D002996_D011085,,
770957889,false,true,5,2015-08-15T02:31:00,,No Relation,1,D002996,clomiphene citrate,D011254,multiple pregnancy,"The ongoing pregnancy rate from ovulation induction with laparoscopic electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or recombinant follicle stimulating hormone, seems equivalent to ovulation induction with recombinant follicle stimulating hormone, but the former procedure carries a lower risk of multiple pregnancy.",14739186_13,14739186_D002996_D011254,,
770957890,false,true,5,2015-08-14T21:27:00,,No Relation,1,D047310,apigenin,D053448,prostate carcinoma,Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells.,14750216_0,14750216_D047310_D053448,,
770957891,false,true,5,2015-08-14T21:19:00,,No Relation,0.5978,D047310,apigenin,D053448,prostate carcinoma,"We have reported recently that apigenin (4',5,7-trihydroxyflavone), found in many common fruits and vegetables, has shown remarkable effects in inhibiting cell growth and inducing apoptosis in many human prostate carcinoma cells.",14750216_2,14750216_D047310_D053448,,
770957892,false,true,5,2015-08-15T00:00:00,,No Relation,1,D047310,apigenin,D053448,prostate carcinoma,Here we demonstrate the molecular mechanism of inhibitory action of apigenin on androgen-refractory human prostate carcinoma DU145 cells that have mutations in the tumor suppressor gene p53 and pRb.,14750216_3,14750216_D047310_D053448,,
770957893,false,true,5,2015-08-15T02:21:00,,No Relation,0.6011,D000728,androgen,D053448,prostate carcinoma,Here we demonstrate the molecular mechanism of inhibitory action of apigenin on androgen-refractory human prostate carcinoma DU145 cells that have mutations in the tumor suppressor gene p53 and pRb.,14750216_3,14750216_D000728_D053448,,
770957894,false,true,5,2015-08-14T22:20:00,,No Relation,1,D047310,apigenin,D009369,tumor,Here we demonstrate the molecular mechanism of inhibitory action of apigenin on androgen-refractory human prostate carcinoma DU145 cells that have mutations in the tumor suppressor gene p53 and pRb.,14750216_3,14750216_D047310_D009369,,
770957895,false,true,5,2015-08-15T01:37:00,,No Relation,1,D000728,androgen,D009369,tumor,Here we demonstrate the molecular mechanism of inhibitory action of apigenin on androgen-refractory human prostate carcinoma DU145 cells that have mutations in the tumor suppressor gene p53 and pRb.,14750216_3,14750216_D000728_D009369,,
770957896,false,true,5,2015-08-15T01:57:00,,Direct,1,D009532,nickel,D009369,respiratory cancer,Excess risks of respiratory cancer have been demonstrated in some groups of nickel-exposed workers.,14963251_1,14963251_D009532_D009369,,
770957897,false,true,5,2015-08-14T23:45:00,,Direct,1,D009532,nickel,D009369,cancer/nasal cancer,"Aim To determine whether occupational exposures received in the manufacture of nickel alloys lead to increased risks of cancer, in particular nasal cancer and lung cancer.",14963251_3,14963251_D009532_D009369,,
770957898,false,true,5,2015-08-14T22:09:00,,Direct,0.6,D009532,nickel,D008175,lung cancer,"Aim To determine whether occupational exposures received in the manufacture of nickel alloys lead to increased risks of cancer, in particular nasal cancer and lung cancer.",14963251_3,14963251_D009532_D008175,,
770957899,false,true,5,2015-08-15T00:03:00,,No Relation,0.5915,D017313,N- (4-hydroxyphenyl)retinamide,D009369,breast cancer,Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.,14973114_0,14973114_D017313_D009369,,
770957900,false,true,5,2015-08-14T22:21:00,,No Relation,0.6042,D009569,nitric oxide,D009369,breast cancer,We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production.,14973114_1,14973114_D009569_D009369,,
770957901,false,true,5,2015-08-14T23:33:00,,No Relation,0.6045,D017313,N-(4-hydroxyphenyl)retinamide,D009369,breast cancer,We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production.,14973114_1,14973114_D017313_D009369,,
770957902,false,true,5,2015-08-14T22:00:00,,No Relation,1,D015232,prostaglandin E(2),D009369,breast cancer,"Apoptosis induced by the 4-HPR and COX-2 inhibitor combination, although unaffected by an anti-HER2/neu antibody, was reversed by the COX-2 product prostaglandin E(2), indicating that COX-2 is a major mechanism by which HER2/neu suppresses 4-HPR apoptosis in breast cancer cells.",14973114_3,14973114_D015232_D009369,,
770957903,false,true,5,2015-08-15T01:41:00,,No Relation,0.8253,D014443,tyrosine,D000012,ABL,Chromosomal translocations of tyrosine kinase c-ABL gene from chromosome 9 may generate oncogenic kinases exhibiting constitutive tyrosine kinase activity.,14987801_1,14987801_D014443_D000012,,
770957904,false,true,5,2015-08-14T22:09:00,,No Relation,0.7887,D014443,tyrosine,D000012,ABL,"Recently, we have shown that ABL-fusion oncogenic tyrosine kinases, BCR/ABL and TEL/ABL, specific to hematopoietic malignances, induced resistance to DNA-damaging agents.",14987801_2,14987801_D014443_D000012,,
770957905,false,true,5,2015-08-15T01:01:00,,No Relation,1,D014443,tyrosine,D019337,hematopoietic malignances,"Recently, we have shown that ABL-fusion oncogenic tyrosine kinases, BCR/ABL and TEL/ABL, specific to hematopoietic malignances, induced resistance to DNA-damaging agents.",14987801_2,14987801_D014443_D019337,,
770957906,false,true,5,2015-08-14T21:28:00,,No Relation,0.8075,D015255,idarubicin,D000012,ABL,"To elucidate the role of DNA repair in this phenomenon we examined the capacity of murine BaF3 lymphoid cells and their TEL/ABL-transformed counterparts to repair DNA lesions caused by gamma- and UV-radiations and the anti-cancer drug, idarubicin.",14987801_3,14987801_D015255_D000012,,
770957907,false,true,5,2015-08-15T00:02:00,,No Relation,1,D015255,idarubicin,D009369,cancer,"To elucidate the role of DNA repair in this phenomenon we examined the capacity of murine BaF3 lymphoid cells and their TEL/ABL-transformed counterparts to repair DNA lesions caused by gamma- and UV-radiations and the anti-cancer drug, idarubicin.",14987801_3,14987801_D015255_D009369,,
770957908,false,true,5,2015-08-14T23:03:00,,No Relation,0.8008,D015255,idarubicin,D000012,ABL,"We also examined the capability of BCR/ABL-fusion to modulate the repair of oxidative lesions, considered as a major side effect of various anti-cancer drugs including idarubicin and radiation.",14987801_7,14987801_D015255_D000012,,
770957909,false,true,5,2015-08-14T23:54:00,,No Relation,1,D015255,idarubicin,D009369,cancer,"We also examined the capability of BCR/ABL-fusion to modulate the repair of oxidative lesions, considered as a major side effect of various anti-cancer drugs including idarubicin and radiation.",14987801_7,14987801_D015255_D009369,,
770957910,false,true,5,2015-08-15T02:09:00,,No Relation,1,C029217,alpha-phenyl-N-tert-butyl nitrone/PBN,D000012,ABL,"Employing the free radical scavenger alpha-phenyl-N-tert-butyl nitrone (PBN, a spin trap) and DNA repair enzymes: endonuclease III (EndoIII) that nicks DNA at sites of oxidized bases, we found that BCR/ABL-transformed cells repaired oxidative DNA lesions more effectively than control cells.",14987801_8,14987801_C029217_D000012,,
770957911,false,true,5,2015-08-14T22:25:00,,No Relation,0.8025,D010100,oxygen,D006973,hypertension,Reactive oxygen species in vascular biology: role in arterial hypertension.,15030300_0,15030300_D010100_D006973,,
770957912,false,true,5,2015-08-15T01:26:00,,No Relation,1,D010100,oxygen,D057772,vascular injury,This development has evoked considerable interest because of the possibilities that therapies targeted against reactive oxygen intermediates by decreasing the generation of reactive oxygen species and/or by increasing availability of antioxidants may be useful in minimizing vascular injury.,15030300_5,15030300_D010100_D057772,,
770957913,false,true,5,2015-08-15T01:56:00,,No Relation,1,D010100,oxygen,D006973,hypertension,"This review focuses on the vascular actions of reactive oxygen species, the role of oxidative stress in vascular damage in hypertension and the therapeutic potential of modulating oxygen radical bioavailability in hypertension.",15030300_6,15030300_D010100_D006973,,
770957914,false,true,5,2015-08-15T00:31:00,,No Relation,1,D010100,oxygen,D006177,vascular damage,"This review focuses on the vascular actions of reactive oxygen species, the role of oxidative stress in vascular damage in hypertension and the therapeutic potential of modulating oxygen radical bioavailability in hypertension.",15030300_6,15030300_D010100_D006177,,
770957915,false,true,5,2015-08-14T21:54:00,,No Relation,0.7886,D010100,oxygen,D006973,hypertension,"In particular, the following topics will be highlighted: chemistry and sources of reactive oxygen species, antioxidant defense mechanisms, signaling events mediated by reactive oxygen species, role of reactive oxygen species in hypertension and the putative therapeutic role of antioxidants in cardiovascular disease.",15030300_7,15030300_D010100_D006973,,
770957916,false,true,5,2015-08-14T21:46:00,,No Relation,1,D010100,oxygen,D002318,cardiovascular disease,"In particular, the following topics will be highlighted: chemistry and sources of reactive oxygen species, antioxidant defense mechanisms, signaling events mediated by reactive oxygen species, role of reactive oxygen species in hypertension and the putative therapeutic role of antioxidants in cardiovascular disease.",15030300_7,15030300_D010100_D002318,,
770957917,false,true,5,2015-08-15T01:47:00,,No Relation,1,D000431,ethanol,D006528,hepatocellular carcinoma,Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma.,15040025_0,15040025_D000431_D006528,,
770957918,false,true,5,2015-08-15T02:02:00,,No Relation,1,D000431,ethanol,C562451,arterioportal shunt,Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma.,15040025_0,15040025_D000431_C562451,,
770957919,false,true,5,2015-08-15T01:11:00,,No Relation,1,D000431,ethanol,D006528,HCC/hepatocellular carcinoma,"To evaluate long-term effect of ethanol embolization for the treatment of hepatocellular carcinoma (HCC) with severe hepatic arterioportal shunt (APS), compared with Gelfoam embolization.",15040025_1,15040025_D000431_D006528,,
770957920,false,true,5,2015-08-15T00:28:00,,No Relation,1,D000431,ethanol,C562451,APS/arterioportal shunt,"To evaluate long-term effect of ethanol embolization for the treatment of hepatocellular carcinoma (HCC) with severe hepatic arterioportal shunt (APS), compared with Gelfoam embolization.",15040025_1,15040025_D000431_C562451,,
770957921,false,true,5,2015-08-14T21:09:00,,No Relation,1,D000431,ethanol,D006528,HCC,Sixty-four patients (ethanol group) and 33 patients (Gelfoam group) with HCC and APS were respectively treated with ethanol and Gelfoam for APS before the routine interventional treatment for the tumor.,15040025_2,15040025_D000431_D006528,,
770957922,false,true,5,2015-08-15T00:32:00,,No Relation,1,D000431,ethanol,D009369,tumor,Sixty-four patients (ethanol group) and 33 patients (Gelfoam group) with HCC and APS were respectively treated with ethanol and Gelfoam for APS before the routine interventional treatment for the tumor.,15040025_2,15040025_D000431_D009369,,
770957923,false,true,5,2015-08-14T22:26:00,,No Relation,1,D000431,ethanol,C562451,APS,Sixty-four patients (ethanol group) and 33 patients (Gelfoam group) with HCC and APS were respectively treated with ethanol and Gelfoam for APS before the routine interventional treatment for the tumor.,15040025_2,15040025_D000431_C562451,,
770957924,false,true,5,2015-08-15T00:23:00,,No Relation,0.7843,D000431,ethanol,C562451,APS,"The occlusion rate of APS after initial treatment in ethanol group was 70.3%(45/64), and recanalization rate of 1 month after embolization was 17.8%(8/45), and complete occlusion rate was 82.8%(53/64).",15040025_4,15040025_D000431_C562451,,
770957925,false,true,5,2015-08-15T01:25:00,,No Relation,1,D000431,ethanol,D006528,HCC,"In the ethanol group, there was a significant prolongation of survival in patients with monofocal HCC (P<0.05) and Child class A (P<0.05).",15040025_9,15040025_D000431_D006528,,
770957926,false,true,5,2015-08-15T01:32:00,,Direct,0.8014,D000431,ethanol,D015746,abdominal pain,The incidence rate of abdominal pain during procedure in ethanol group was 82.8%.,15040025_11,15040025_D000431_D015746,,
770957927,false,true,5,2015-08-15T02:03:00,,No Relation,1,D000431,ethanol,D017093,hepatic failure,Procedure-related hepatic failure did not occur in ethanol group.,15040025_13,15040025_D000431_D017093,,
770957928,false,true,5,2015-08-15T02:10:00,,No Relation,1,D000431,Ethanol,D006528,HCC,"Ethanol embolization for patients with HCC and severe APS is efficacious and safe, and may contribute to prolongation of the life span versus Gelfoam embolization.",15040025_14,15040025_D000431_D006528,,
770957929,false,true,5,2015-08-14T23:51:00,,No Relation,1,D000431,Ethanol,C562451,APS,"Ethanol embolization for patients with HCC and severe APS is efficacious and safe, and may contribute to prolongation of the life span versus Gelfoam embolization.",15040025_14,15040025_D000431_C562451,,
770957930,false,true,5,2015-08-15T01:16:00,,No Relation,1,D016572,CsA,C564016,chronic allograft nephropathy,This can partly be attributed to the side effects of CsA and partly to the fact that the use of CsA has not led to a reduced incidence of chronic allograft nephropathy.,15041316_4,15041316_D016572_C564016,,
770957931,false,true,5,2015-08-14T21:53:00,,Direct,0.7933,D016572,CsA,D064420,toxicity,"Thus, there has been a continuing search for strategies that minimize CsA toxicity but maintain adequate immunosuppression.",15041316_5,15041316_D016572_D064420,,
770957932,false,true,5,2015-08-15T01:06:00,,No Relation,1,D013792,Thalidomide,D007249,inflammatory skin diseases,"Thalidomide (N-phtalimidoglutarimide), initially used as a tranquilizer, has recently been used in the management of several inflammatory skin diseases.",15057007_3,15057007_D013792_D007249,,
770957933,false,true,5,2015-08-15T00:39:00,,No Relation,1,D013792,thalidomide,D006646,LCH,"In conclusion, thalidomide monotherapy represents an effective, safe and well-tolerated treatment option that should be considered as first-line therapy for mucocutaneous LCH.",15057007_11,15057007_D013792_D006646,,
770957934,false,true,5,2015-08-15T01:27:00,,No Relation,1,D002245,CO(2),D006935,hypercapnia,"From normocapnia to hypercapnia, V(op) did not change significantly (mean +/- SD, 18 +/- 4 cm*sec(-1) to 18 +/- 6 cm*sec(-1)), (end-tidal CO(2), etCO(2), = 43 +/- 5 mmHg to 53 +/- 4 mmHg, respectively).",15064270_8,15064270_D002245_D006935,,
770957935,false,true,5,2015-08-14T22:20:00,,No Relation,0.7948,D002245,CO(2),D016857,hypocapnia,The CO(2)-reactivity slope of V(op) from normocapnia to hypocapnia was 2.57% per mmHg.,15064270_10,15064270_D002245_D016857,,
770957936,false,true,5,2015-08-14T22:05:00,,No Relation,1,C424862,MTH-68/H,D009369,aggressive neuroectodermal neoplasm,"Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year.",15072452_3,15072452_C424862_D009369,,
770957937,false,true,5,2015-08-14T21:41:00,,No Relation,1,C424862,MTH-68/H,D005909,glioblastoma,"Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year.",15072452_3,15072452_C424862_D005909,,
770957938,false,true,5,2015-08-15T01:45:00,,Direct,0.5822,C076029,olanzapine,D003920,diabetes mellitus,Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.,15107197_0,15107197_C076029_D003920,,
770957939,false,true,5,2015-08-15T00:12:00,,Direct,1,D003024,clozapine,D003920,glucose dysregulation or new onset diabetes mellitus,"In spite of conflicting reports, there is emerging evidence that at least two of the atypical antipsychotics, clozapine and olanzapine, are associated with an increased risk of developing glucose dysregulation or new onset diabetes mellitus.",15107197_1,15107197_D003024_D003920,,
770957940,false,true,5,2015-08-14T21:28:00,,Direct,1,C076029,olanzapine,D003920,glucose dysregulation or new onset diabetes mellitus,"In spite of conflicting reports, there is emerging evidence that at least two of the atypical antipsychotics, clozapine and olanzapine, are associated with an increased risk of developing glucose dysregulation or new onset diabetes mellitus.",15107197_1,15107197_C076029_D003920,,
770957941,false,true,5,2015-08-14T21:50:00,,No Relation,1,D005947,glucose,D003920,glucose dysregulation or new onset diabetes mellitus,"In spite of conflicting reports, there is emerging evidence that at least two of the atypical antipsychotics, clozapine and olanzapine, are associated with an increased risk of developing glucose dysregulation or new onset diabetes mellitus.",15107197_1,15107197_D005947_D003920,,
770957942,false,true,5,2015-08-15T01:38:00,,Direct,0.5855,C076029,olanzapine,D003929,diabetes,"We report on the management of six patients who developed diabetes mellitus following treatment with olanzapine, five of whom had independent risk factors for diabetes.",15107197_2,15107197_C076029_D003929,,
770957943,false,true,5,2015-08-15T00:03:00,,Direct,0.7911,C076029,olanzapine,D003920,diabetes mellitus,"We report on the management of six patients who developed diabetes mellitus following treatment with olanzapine, five of whom had independent risk factors for diabetes.",15107197_2,15107197_C076029_D003920,,
770957944,false,true,5,2015-08-14T23:03:00,,No Relation,0.6075,C076029,olanzapine,D003929,diabetes,"In view of the uncertainty of the size and mechanism of the link between olanzapine and diabetes, we discuss issues surrounding routine clinical management and monitoring of patients on antipsychotics and the clinical implications.",15107197_4,15107197_C076029_D003929,,
770957945,false,true,5,2015-08-14T21:29:00,,No Relation,1,D005473,fluoxetine,D003865,major depressive disorder,Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.,15119918_0,15119918_D005473_D003865,,
770957946,false,true,5,2015-08-15T01:46:00,,No Relation,0.8036,D005473,fluoxetine,D003865,major depressive disorder/MDD,In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD).,15119918_1,15119918_D005473_D003865,,
770957947,false,true,5,2015-08-14T23:45:00,Disease is a pre-existing condition,No Relation,0.8072,D005473,fluoxetine,D003865,DSM-III-R MDD,87 outpatients (mean age = 41.4 +/- 10.2 years; 59.8% women) with DSM-III-R MDD who had sustained acute response to fluoxetine completed the Symptom Questionnaire (SQ) at baseline.,15119918_2,15119918_D005473_D003865,,
770957948,false,true,5,2015-08-15T00:42:00,,No Relation,1,D005473,fluoxetine,D003865,MDD,Somatic symptoms of depression were found to be associated with a delayed onset of antidepressant response to fluoxetine in MDD.,15119918_8,15119918_D005473_D003865,,
770957949,false,true,5,2015-08-15T01:43:00,,Direct,0.5978,D005473,fluoxetine,D003866,depression,Somatic symptoms of depression were found to be associated with a delayed onset of antidepressant response to fluoxetine in MDD.,15119918_8,15119918_D005473_D003866,,
770957950,false,true,5,2015-08-14T21:20:00,,No Relation,1,D002784,cholesterol,D050197,atherosclerosis,Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages.,15136056_0,15136056_D002784_D050197,,
770957951,false,true,5,2015-08-15T02:25:00,,No Relation,1,D019787,linoleic acid,D050197,atherosclerosis,Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages.,15136056_0,15136056_D019787_D050197,,
770957952,false,true,5,2015-08-15T00:34:00,,No Relation,0.6185,D002784,cholesterol,D050197,atherosclerosis,Macrophage cholesterol homeostasis is a key process involved in the initiation and progression of atherosclerosis.,15136056_1,15136056_D002784_D050197,,
770957953,false,true,5,2015-08-14T23:56:00,,Direct,0.6219,D002784,cholesterol,D050197,atherosclerosis,Peroxisome proliferator-activated receptors (PPARs) regulate the transcription of the genes involved in cholesterol homeostasis and thus represent an important therapeutic target in terms of reducing atherosclerosis.,15136056_2,15136056_D002784_D050197,,
770957954,false,true,5,2015-08-14T21:03:00,,No Relation,1,D019787,linoleic acid,D050197,atherosclerosis,Conjugated linoleic acid (CLA) is a potent anti-atherogenic dietary fatty acid in animal models of atherosclerosis and is capable of activating PPARs in vitro and in vivo.,15136056_3,15136056_D019787_D050197,,
770957955,false,true,5,2015-08-14T22:30:00,,No Relation,1,D019821,simvastatin,D009103,multiple sclerosis,Oral simvastatin treatment in relapsing-remitting multiple sclerosis.,15145635_0,15145635_D019821_D009103,,
770957956,false,true,5,2015-08-14T21:38:00,,No Relation,1,D019821,simvastatin,D009103,multiple sclerosis,We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis.,15145635_2,15145635_D019821_D009103,,
770957957,false,true,5,2015-08-15T01:02:00,,No Relation,0.6115,D019821,simvastatin,D009069,neurological disability,Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.,15145635_6,15145635_D019821_D009069,,
770957958,false,true,5,2015-08-14T21:16:00,,No Relation,1,D019821,simvastatin,D009103,multiple sclerosis,Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.,15145635_6,15145635_D019821_D009103,,
770957959,false,true,5,2015-08-14T23:59:00,,No Relation,0.8072,D005905,glibenclamide,D018222,undergoing aggressive diabetes management,"In conclusion, severe hypoglycaemia is a serious and not uncommon problem among elderly patients with T2DM; it is more frequent in patients undergoing aggressive diabetes management and in users of a long-acting sulphonylurea (eg, glibenclamide).",15163121_12,15163121_D005905_D018222,,
770957960,false,true,5,2015-08-15T01:59:00,,No Relation,0.6157,D005905,glibenclamide,D003920,T2DM,"In conclusion, severe hypoglycaemia is a serious and not uncommon problem among elderly patients with T2DM; it is more frequent in patients undergoing aggressive diabetes management and in users of a long-acting sulphonylurea (eg, glibenclamide).",15163121_12,15163121_D005905_D003920,,
770957961,false,true,5,2015-08-14T21:52:00,,No Relation,0.7987,D005947,glucose,D003920,diabetes mellitus,"Finally, each patient's risk for hypoglycaemia should be considered and therapy should be individualised accordingly; in our opinion, a great number of episodes of serious hypoglycaemia may be prevented by teaching the principles of blood glucose monitoring and involving general practitioners in outpatient management of diabetes mellitus in the elderly.",15163121_14,15163121_D005947_D003920,,
770957962,false,true,5,2015-08-15T00:35:00,,Direct,0.5997,D012964,Na(+),D006333,heart failure,[Na(+)](i) and NCX expression have been reported to be increased in human heart failure.,15165985_3,15165985_D012964_D006333,,
770957963,false,true,5,2015-08-15T02:04:00,,No Relation,1,D037621,artemisinins,D009369,tumor,Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines.,15183112_0,15183112_D037621_D009369,,
770957964,false,true,5,2015-08-14T21:29:00,,No Relation,1,D018943,anthracyclines,D009369,tumor,Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines.,15183112_0,15183112_D018943_D009369,,
770957965,false,true,5,2015-08-14T23:33:00,,No Relation,1,D037621,artemisinins,D009369,tumor,The antimalarial artemisinins also reveal profound cytotoxic activity against tumor cells.,15183112_1,15183112_D037621_D009369,,
770957966,false,true,5,2015-08-14T23:26:00,,Direct,1,D018943,anthracyclines,D066126,cardiotoxicity,Established cancer drugs such as anthracyclines also form ROS and free radicals that are responsible for the cardiotoxicity of anthracyclines.,15183112_3,15183112_D018943_D066126,,
770957967,false,true,5,2015-08-14T23:42:00,,No Relation,1,D018943,anthracyclines,D009369,cancer,Established cancer drugs such as anthracyclines also form ROS and free radicals that are responsible for the cardiotoxicity of anthracyclines.,15183112_3,15183112_D018943_D009369,,
770957968,false,true,5,2015-08-15T02:10:00,,No Relation,1,D037621,artemisinins,D066126,cardiotoxicity,"In contrast, artemisinins do not reveal cardiotoxicity.",15183112_4,15183112_D037621_D066126,,
770957969,false,true,5,2015-08-14T22:17:00,,No Relation,1,D014805,Vitamin B(12),D000740,anemia,"Frequent strategies included dietary changes, vitamins, modification of routines, rest, exercise, and prescribed medications for anemia, Vitamin B(12) deficiency, or testosterone deficiency.",15186711_5,15186711_D014805_D000740,,
770957970,false,true,5,2015-08-15T02:19:00,,No Relation,1,D014805,Vitamin B(12),D003677,testosterone deficiency,"Frequent strategies included dietary changes, vitamins, modification of routines, rest, exercise, and prescribed medications for anemia, Vitamin B(12) deficiency, or testosterone deficiency.",15186711_5,15186711_D014805_D003677,,
770957971,false,true,5,2015-08-14T23:07:00,,No Relation,1,D013739,testosterone,D000740,anemia,"Frequent strategies included dietary changes, vitamins, modification of routines, rest, exercise, and prescribed medications for anemia, Vitamin B(12) deficiency, or testosterone deficiency.",15186711_5,15186711_D013739_D000740,,
770957972,false,true,5,2015-08-15T01:03:00,,No Relation,1,D013739,testosterone,D003677,testosterone deficiency,"Frequent strategies included dietary changes, vitamins, modification of routines, rest, exercise, and prescribed medications for anemia, Vitamin B(12) deficiency, or testosterone deficiency.",15186711_5,15186711_D013739_D003677,,
770957973,false,true,5,2015-08-15T01:32:00,,No Relation,1,C097613,Imatinib,D015464,chronic myelogenous leukemia,Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.,15215876_0,15215876_C097613_D015464,,
770957974,false,true,5,2015-08-14T23:48:00,Used as treatment.,No Relation,1,C097613,Imatinib,D015464,CML/chronic myelogenous leukemia,"Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia (CML).",15215876_1,15215876_C097613_D015464,,
770957975,false,true,5,2015-08-14T21:18:00,,Direct,0.5939,D014443,tyrosine,D015464,CML/chronic myelogenous leukemia,"Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia (CML).",15215876_1,15215876_D014443_D015464,,
770957976,false,true,5,2015-08-15T01:50:00,,No Relation,1,C097613,imatinib,D015464,CML,"Selective inhibition of BCR-ABL activity by imatinib has demonstrated efficacy in the treatment of CML, particularly in chronic phase.",15215876_2,15215876_C097613_D015464,,
770957977,false,true,5,2015-08-15T01:00:00,,No Relation,1,C097613,imatinib,D020178,advanced disease,"Some patients, however, primarily those with advanced disease, are either refractory to imatinib or eventually relapse.",15215876_3,15215876_C097613_D020178,,
770957978,false,true,5,2015-08-15T00:34:00,,No Relation,1,C097613,imatinib,D015464,CML,"These observations and more recent trials with imatinib, combined with insights provided by an increased understanding of the molecular mechanisms of resistance, have established the rationale for strategies to avoid and overcome imatinib resistance in the management of CML patients.",15215876_6,15215876_C097613_D015464,,
770957979,false,true,5,2015-08-14T22:22:00,,No Relation,1,D013759,Delta(9)-THC,C564052,THC,"Under the clinical point of view, Delta(9)-THC produces some therapeutic benefits which are beyond reasonable doubt.",15302527_3,15302527_D013759_C564052,,
770957980,false,true,5,2015-08-14T22:16:00,,No Relation,0.6053,D013759,Delta(9)-THC,C564052,THC,Delta(9)-THC is not devoid of ill effects.,15302527_5,15302527_D013759_C564052,,
770957981,false,true,5,2015-08-14T22:05:00,,No Relation,1,D013759,THC,C564052,THC,"On the psychic area Delta(9)-THC may induce unpleasant reactions such as disconnected thoughts, panic reactions, disturbing changes in perception, delusions and hallucinatory experiences.",15302527_7,15302527_D013759_C564052,,
770957982,false,true,5,2015-08-15T00:36:00,,No Relation,1,D013759,Delta(9)-THC,C564052,THC,"However, the long term effects on the psyche and cognition are not known as there are no reports of prolonged use of Delta(9)-THC.",15302527_8,15302527_D013759_C564052,,
770957983,false,true,5,2015-08-14T21:47:00,,No Relation,1,D013759,Delta(9)-THC,C564052,THC,"Actually, it has been proposed by WHO that Delta(9)-THC should be rescheduled to schedule IV of the United Nations Convention on Psychotropic Drugs, as it does not constitute a substantial risk to public health and its abuse is rare if at all.",15302527_9,15302527_D013759_C564052,,
770957984,false,true,5,2015-08-15T01:00:00,,Direct,0.8248,D003024,clozapine,D010493,pericarditis,"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine.",15319023_0,15319023_D003024_D010493,,
770957985,false,true,5,2015-08-14T22:09:00,,Direct,0.8047,D003024,clozapine,D009205,myocarditis,"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine.",15319023_0,15319023_D003024_D009205,,
770957986,false,true,5,2015-08-14T22:19:00,,Direct,0.5891,D003024,clozapine,D009202,cardiomyopathy,"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine.",15319023_0,15319023_D003024_D009202,,
770957987,false,true,5,2015-08-14T21:42:00,,Direct,1,D003024,Clozapine,D010493,pericarditis,"Clozapine is known to cause cardiac side effects, including myocarditis, pericarditis, and cardiomyopathy.",15319023_1,15319023_D003024_D010493,,
770957988,false,true,5,2015-08-15T01:31:00,,Direct,1,D003024,Clozapine,D009205,myocarditis,"Clozapine is known to cause cardiac side effects, including myocarditis, pericarditis, and cardiomyopathy.",15319023_1,15319023_D003024_D009205,,
770957989,false,true,5,2015-08-15T02:09:00,,Direct,1,D003024,Clozapine,D009202,cardiomyopathy,"Clozapine is known to cause cardiac side effects, including myocarditis, pericarditis, and cardiomyopathy.",15319023_1,15319023_D003024_D009202,,
770957990,false,true,5,2015-08-15T02:22:00,,Direct,1,D003024,clozapine,D010493,pericarditis,"Prompted by a case of clozapine-related pericarditis in an adolescent, we undertook a retrospective chart review to discover whether any unrecognized cases of myocarditis, pericarditis, or cardiomyopathy were among the children, adolescents, and young adults we had treated with clozapine.",15319023_2,15319023_D003024_D010493,,
770957991,false,true,5,2015-08-14T23:31:00,,Direct,0.5871,D003024,clozapine,D009205,myocarditis,"Prompted by a case of clozapine-related pericarditis in an adolescent, we undertook a retrospective chart review to discover whether any unrecognized cases of myocarditis, pericarditis, or cardiomyopathy were among the children, adolescents, and young adults we had treated with clozapine.",15319023_2,15319023_D003024_D009205,,
770957992,false,true,5,2015-08-14T21:42:00,,Direct,0.7879,D003024,clozapine,D009202,cardiomyopathy,"Prompted by a case of clozapine-related pericarditis in an adolescent, we undertook a retrospective chart review to discover whether any unrecognized cases of myocarditis, pericarditis, or cardiomyopathy were among the children, adolescents, and young adults we had treated with clozapine.",15319023_2,15319023_D003024_D009202,,
770957993,false,true,5,2015-08-15T02:02:00,,No Relation,0.8026,D003024,clozapine,D009358,such disorder,"With the exception of the case which prompted our study, none of the patients were found to have developed any such disorder in the course of further treatment with clozapine.",15319023_8,15319023_D003024_D009358,,
770957994,false,true,5,2015-08-14T23:16:00,,No Relation,1,C065179,atorvastatin,D054058,ACS,Early aggressive lipid-lowering therapy by atorvastatin for 6 months significantly reduced the plaque volume in patients with ACS.,15326073_11,15326073_C065179_D054058,,
770957995,false,true,5,2015-08-15T01:19:00,,No Relation,1,C104727,moxifloxacin,D016470,iatrogenic oral bacteremia,In vitro activity of moxifloxacin compared to other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain.,15327647_0,15327647_C104727_D016470,,
770957996,false,true,5,2015-08-14T22:10:00,,No Relation,1,C104727,moxifloxacin,D005490,focal infections,"All the isolates showed a low MIC of moxifloxacin in vitro, making it a promising antimicrobial alternative for the prevention of streptococcal focal infections associated with certain dental manipulations, when the administration of beta-lactam agents is not indicated.",15327647_15,15327647_C104727_D005490,,
770957997,false,true,5,2015-08-14T22:28:00,,No Relation,1,D047090,beta-lactam,D005490,focal infections,"All the isolates showed a low MIC of moxifloxacin in vitro, making it a promising antimicrobial alternative for the prevention of streptococcal focal infections associated with certain dental manipulations, when the administration of beta-lactam agents is not indicated.",15327647_15,15327647_D047090_D005490,,
770957998,false,true,5,2015-08-14T21:35:00,,Direct,0.6103,D016898,Interferon-alpha,D003866,symptoms of depression,Interferon-alpha (IFN-alpha) treatment is frequently complicated by symptoms of depression.,15331126_1,15331126_D016898_D003866,,
770957999,false,true,5,2015-08-14T21:16:00,,No Relation,0.7928,D009569,NO,D009447,neuroblastoma,We have studied this regulatory function of NO in neuroblastoma cell lines (SK-N-BE) and in primary cerebellar granule cell cultures.,15331636_3,15331636_D009569_D009447,,
770958000,false,true,5,2015-08-14T21:15:00,,No Relation,0.8096,D014212,retinoic acid,D009447,neuroblastoma,"In a neuronal NO synthase (nNOS) overexpressing neuroblastoma cell line exposed to the differentiative action of retinoic acid, NO slowed down proliferation and accelerated differentiation towards a neuronal phenotype.",15331636_4,15331636_D014212_D009447,,
770958001,false,true,5,2015-08-15T02:12:00,,No Relation,1,D009569,NO,D009447,neuroblastoma,"In a neuronal NO synthase (nNOS) overexpressing neuroblastoma cell line exposed to the differentiative action of retinoic acid, NO slowed down proliferation and accelerated differentiation towards a neuronal phenotype.",15331636_4,15331636_D009569_D009447,,
770958002,false,true,5,2015-08-15T01:04:00,,No Relation,1,D009569,NO,D009447,neuroblastoma,"Because a high N-Myc expression level is essential for neuroblastoma progression as well as for proliferation of neuronal precursors, its negative regulation by NO highlights a novel physiopathological function of this important messenger molecule.",15331636_10,15331636_D009569_D009447,,
770958003,false,true,5,2015-08-14T21:07:00,,No Relation,1,D005947,glucose,D009369,tumor,Effect on tumor cells of blocking survival response to glucose deprivation.,15339968_0,15339968_D005947_D009369,,
770958004,false,true,5,2015-08-14T23:39:00,,No Relation,1,D005947,Glucose,D012892,Glucose deprivation,"Glucose deprivation, a feature of poorly vascularized solid tumors, activates the unfolded protein response (UPR), a stress-signaling pathway, in tumor cells.",15339968_1,15339968_D005947_D012892,,
770958005,false,true,5,2015-08-14T21:42:00,,No Relation,0.8299,D005947,Glucose,D009369,tumor/tumors,"Glucose deprivation, a feature of poorly vascularized solid tumors, activates the unfolded protein response (UPR), a stress-signaling pathway, in tumor cells.",15339968_1,15339968_D005947_D009369,,
770958006,false,true,5,2015-08-15T01:14:00,,No Relation,1,D005947,glucose,D009369,tumor,We examined the effect of VST on the UPR induced by glucose deprivation or other stressors and on tumor growth in vivo.,15339968_3,15339968_D005947_D009369,,
770958007,false,true,5,2015-08-15T02:21:00,,No Relation,0.8306,D002118,calcium,D007003,hypoglycemia,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D002118_D007003,,
770958008,false,true,5,2015-08-14T21:50:00,,No Relation,1,D014415,tunicamycin,D007003,hypoglycemia,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D014415_D007003,,
770958009,false,true,5,2015-08-14T21:52:00,,No Relation,1,D005947,glucose,D007003,hypoglycemia,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D005947_D007003,,
770958010,false,true,5,2015-08-14T21:35:00,,No Relation,0.8169,D000001,A23187,D009369,stomach cancer/colon cancer,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D000001_D009369,,
770958011,false,true,5,2015-08-14T22:14:00,,No Relation,1,D000001,A23187,D007003,hypoglycemia,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D000001_D007003,,
770958012,false,true,5,2015-08-14T21:48:00,,No Relation,0.8241,D003847,2-deoxyglucose,D005354,fibrosarcoma,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D003847_D005354,,
770958013,false,true,5,2015-08-15T01:33:00,,No Relation,0.8109,D005947,glucose,D005354,fibrosarcoma,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D005947_D005354,,
770958014,false,true,5,2015-08-15T01:34:00,,No Relation,1,D003847,2-deoxyglucose,D009369,stomach cancer/colon cancer,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D003847_D009369,,
770958015,false,true,5,2015-08-15T02:05:00,,No Relation,0.8047,D014415,tunicamycin,D009369,stomach cancer/colon cancer,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D014415_D009369,,
770958016,false,true,5,2015-08-14T21:36:00,,No Relation,1,D002118,calcium,D009369,stomach cancer/colon cancer,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D002118_D009369,,
770958017,false,true,5,2015-08-15T00:59:00,,No Relation,1,D005947,glucose,D009369,stomach cancer/colon cancer,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D005947_D009369,,
770958018,false,true,5,2015-08-14T21:37:00,,No Relation,0.8122,D003847,2-deoxyglucose,D007003,hypoglycemia,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D003847_D007003,,
770958019,false,true,5,2015-08-15T01:02:00,,No Relation,0.8159,D002118,calcium,D005354,fibrosarcoma,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D002118_D005354,,
770958020,false,true,5,2015-08-14T23:51:00,,No Relation,1,D000001,A23187,D005354,fibrosarcoma,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D000001_D005354,,
770958021,false,true,5,2015-08-14T23:46:00,,No Relation,1,D014415,tunicamycin,D005354,fibrosarcoma,"Human colon cancer HT-29, fibrosarcoma HT1080, and stomach cancer MKN74 cells were cultured in the absence of glucose or in the presence of glucose and a UPR-inducing chemical stressor (the N-glycosylation inhibitor tunicamycin, the calcium ionophore A23187, or the hypoglycemia-mimicking agent 2-deoxyglucose [2DG]).",15339968_4,15339968_D014415_D005354,,
770958022,false,true,5,2015-08-14T22:53:00,,No Relation,1,D002945,cisplatin,D009369,tumor,"VST alone and in combination with cisplatin statistically significantly (P =.004 and P<.001 for comparisons with untreated control, respectively) inhibited tumor growth of MKN74 xenografts.",15339968_11,15339968_D002945_D009369,,
770958023,false,true,5,2015-08-14T21:41:00,,No Relation,1,D005947,glucose,D009369,tumors,Disruption of the UPR may provide a novel therapeutic approach to targeting glucose-deprived solid tumors.,15339968_12,15339968_D005947_D009369,,
770958024,false,true,5,2015-08-15T00:04:00,,No Relation,1,C060076,mangafodipir/manganese-DPDP,D010195,pancreatic lesions,Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.,15343134_0,15343134_C060076_D010195,,
770958025,false,true,5,2015-08-15T00:59:00,,No Relation,1,C060076,Mn-DPDP/Mangafodipir,D010195,pancreatic lesions,To assess the accuracy of magnetic resonance (MR) with Mangafodipir (Mn-DPDP) in the identification of focal solid pancreatic lesions.,15343134_1,15343134_C060076_D010195,,
770958026,false,true,5,2015-08-15T02:10:00,,No Relation,1,C060076,Mn-DPDP,D010195,pancreatitis/pancreatic lesions,"Mn-DPDP MR identified 17/18 malignancies, 2/3 endocrine neoplasms 5/5 focal pancreatitis; the 4 patients with no pancreatic lesions were correctly identified.",15343134_11,15343134_C060076_D010195,,
770958027,false,true,5,2015-08-15T02:12:00,,No Relation,1,C060076,Mn-DPDP,D009369,neoplasms,"Mn-DPDP MR identified 17/18 malignancies, 2/3 endocrine neoplasms 5/5 focal pancreatitis; the 4 patients with no pancreatic lesions were correctly identified.",15343134_11,15343134_C060076_D009369,,
770958028,false,true,5,2015-08-14T22:09:00,,No Relation,1,C060076,Mn-DPDP,D010195,pancreatitis,"Due to the small number of inflammatory lesions included in the study, no significant differences were found in signal intensity and Mn-DPDP uptake between focal pancreatitis and neoplasms.",15343134_14,15343134_C060076_D010195,,
770958029,false,true,5,2015-08-14T22:23:00,,No Relation,1,C060076,Mn-DPDP,D009369,neoplasms,"Due to the small number of inflammatory lesions included in the study, no significant differences were found in signal intensity and Mn-DPDP uptake between focal pancreatitis and neoplasms.",15343134_14,15343134_C060076_D009369,,
770958030,false,true,5,2015-08-15T01:56:00,,No Relation,1,C060076,DPDP,D010195,pancreatic lesions,MR with Mn-DPDP is very accurate in the identification of focal solid pancreatic lesions.,15343134_15,15343134_C060076_D010195,,
770958031,false,true,5,2015-08-15T00:18:00,,No Relation,1,C060076,Mangafodi-pir,D010195,pancreatic lesions,Mangafodi-pir is also very useful for excluding the presence of pancreatic lesions suspected at US or CT.,15343134_16,15343134_C060076_D010195,,
770958032,false,true,5,2015-08-15T00:50:00,,No Relation,1,C060076,mangafodipir,D006505,hepatic lesions,Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.,15390224_0,15390224_C060076_D006505,,
770958033,false,true,5,2015-08-14T21:22:00,,No Relation,0.8089,C000499,iron oxide,D006505,hepatic lesions,Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.,15390224_0,15390224_C000499_D006505,,
770958034,false,true,5,2015-08-15T01:11:00,,No Relation,1,C060076,mangafodipir,D006505,hepatic lesions,To compare the mangafodipir-enhanced magnetic resonance (MR) and superparamagnetic iron oxide (SPIO)-enhanced images for their ability to detect and characterize focal hepatic lesions.,15390224_1,15390224_C060076_D006505,,
770958035,false,true,5,2015-08-14T23:41:00,,No Relation,1,C000499,iron oxide,D006505,hepatic lesions,To compare the mangafodipir-enhanced magnetic resonance (MR) and superparamagnetic iron oxide (SPIO)-enhanced images for their ability to detect and characterize focal hepatic lesions.,15390224_1,15390224_C000499_D006505,,
770958036,false,true,5,2015-08-14T22:13:00,,No Relation,1,C060076,mangafodipir,D006528,HCCs,"SPIO- and mangafodipir-enhanced images were comparable for detection of focal hepatic lesions other than small HCCs, which were better detected on the SPIO-enhanced images.",15390224_11,15390224_C060076_D006528,,
770958037,false,true,5,2015-08-14T23:18:00,,No Relation,1,C060076,mangafodipir,D006505,hepatic lesions,"SPIO- and mangafodipir-enhanced images were comparable for detection of focal hepatic lesions other than small HCCs, which were better detected on the SPIO-enhanced images.",15390224_11,15390224_C060076_D006505,,
770958038,false,true,5,2015-08-14T22:23:00,,No Relation,0.8065,C060076,Mangafodipir,D008107,liver lesions,Mangafodipir-enhanced images are likely better than the SPIO-enhanced images for distinguishing between focal liver lesions with a hepatocellular or nonhepatocellular origin.,15390224_12,15390224_C060076_D008107,,
770958039,false,true,5,2015-08-15T00:12:00,,Direct,1,C065655,FEIBA,D013927,Thrombosis,Thrombosis is a rare but well-recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA) infusion.,15456478_1,15456478_C065655_D013927,,
770958040,false,true,5,2015-08-14T21:35:00,,No Relation,1,C065655,FEIBA,D057049,thrombotic,"Recombinant factor VIIa (rFVIIa) is increasingly used as an alternative to FEIBA; however, the thrombotic safety profile of rFVIIa remains incompletely characterized.",15456478_2,15456478_C065655_D057049,,
770958041,false,true,5,2015-08-14T21:01:00,,No Relation,0.5845,C065655,FEIBA,D057049,thrombotic,"Data from the MedWatch pharmacovigilance program of the US Food and Drug Administration, as supplemented by published case reports, were used in conjunction with estimated numbers of infusions available from manufacturers to assess comparative incidence of thrombotic AEs in patients receiving rFVIIa or FEIBA in the period from April 1999 through June 2002.",15456478_4,15456478_C065655_D057049,,
770958042,false,true,5,2015-08-14T22:12:00,,No Relation,1,C065655,FEIBA,D057049,thrombotic,"Reported thrombotic AEs were rare, with incidence rates of 24.6 per 10(5) infusions (CI, 19.1-31.2 per 10(5) infusions) for rFVIIa and 8.24 per 10(5) infusions (CI, 4.71-13.4 per 10(5) infusions) for FEIBA.",15456478_5,15456478_C065655_D057049,,
770958043,false,true,5,2015-08-15T02:42:00,,No Relation,1,C065655,FEIBA,D057049,Thrombotic,"Thrombotic AEs were significantly more frequent in rFVIIa than FEIBA recipients (incidence rate ratio, 2.98; CI, 1.71-5.52).",15456478_6,15456478_C065655_D057049,,
770958044,false,true,5,2015-08-14T21:05:00,,No Relation,0.6123,C065655,FEIBA,D057049,thrombotic,"The most commonly documented single type of thrombotic AE after rFVIIa infusion was cerebrovascular thrombosis, while myocardial infarction was the most frequent type in patients receiving FEIBA.",15456478_7,15456478_C065655_D057049,,
770958045,false,true,5,2015-08-14T23:41:00,,Direct,1,C065655,FEIBA,D009203,myocardial infarction,"The most commonly documented single type of thrombotic AE after rFVIIa infusion was cerebrovascular thrombosis, while myocardial infarction was the most frequent type in patients receiving FEIBA.",15456478_7,15456478_C065655_D009203,,
770958046,false,true,5,2015-08-15T01:56:00,,No Relation,1,C065655,FEIBA,D013927,thrombosis,"The most commonly documented single type of thrombotic AE after rFVIIa infusion was cerebrovascular thrombosis, while myocardial infarction was the most frequent type in patients receiving FEIBA.",15456478_7,15456478_C065655_D013927,,
770958047,false,true,5,2015-08-15T02:08:00,,No Relation,0.7964,C065655,FEIBA,D057049,thrombotic,Contrasting AE reporting patterns between rFVIIa and FEIBA may have contributed to the observed difference in thrombotic event incidence.,15456478_8,15456478_C065655_D057049,,
770958048,false,true,5,2015-08-14T23:11:00,,No Relation,1,D002045,bupivacaine,D010146,pain,Efficacy of bupivacaine for post-tonsillectomy pain: a study with the intra-individual design.,15488969_0,15488969_D002045_D010146,,
770958049,false,true,5,2015-08-14T21:52:00,,Direct,0.5861,D000431,Alcohol,D011470,prostatic hyperplasia,Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.,15491708_0,15491708_D000431_D011470,,
770958050,false,true,5,2015-08-14T23:03:00,,No Relation,0.798,D000431,Alcohol,D011471,prostate cancer,Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.,15491708_0,15491708_D000431_D011471,,
770958051,false,true,5,2015-08-15T00:50:00,,No Relation,0.6063,D000431,alcohol,D011471,BPH/cancer/benign prostatic hyperplasia,"To examine the association between alcohol and the risk of prostate cancer/benign prostatic hyperplasia (BPH) in a population with a wide range of alcohol consumption, using a hospital-based, case-control study.",15491708_1,15491708_D000431_D011471,,
770958052,false,true,5,2015-08-14T21:13:00,,Direct,0.5936,D000431,alcohol,D011471,prostate cancer,Data from several epidemiologic studies have allowed us to exclude a strong association between alcohol drinking and prostate cancer risk.,15491708_2,15491708_D000431_D011471,,
770958053,false,true,5,2015-08-14T21:48:00,,No Relation,1,D000431,Alcohol,D011471,BPH/prostate cancer,"Alcohol consumption showed no consistent association with prostate cancer risk, but a statistically significant inverse trend in risk for BPH.",15491708_9,15491708_D000431_D011471,,
770958054,false,true,5,2015-08-14T21:44:00,,No Relation,0.5894,D000431,alcohol,D011471,BPH,The inverse relation between elevated alcohol consumption and BPH was apparently stronger in subjects with a lower body mass index.,15491708_12,15491708_D000431_D011471,,
770958055,false,true,5,2015-08-15T00:37:00,,No Relation,0.8158,D000431,Alcohol,D011471,prostate cancer,Alcohol drinking is unrelated to prostate cancer risk.,15491708_13,15491708_D000431_D011471,,
770958056,false,true,5,2015-08-15T02:13:00,,No Relation,0.795,D000728,androgen,D011471,BPH,"The inverse relationship with BPH may be related to the hormonal correlates (ie, lower androgen levels) of heavy alcohol drinkers.",15491708_14,15491708_D000728_D011471,,
770958057,false,true,5,2015-08-15T00:34:00,,No Relation,0.5999,D000431,alcohol,D011471,BPH,"The inverse relationship with BPH may be related to the hormonal correlates (ie, lower androgen levels) of heavy alcohol drinkers.",15491708_14,15491708_D000431_D011471,,
770958058,false,true,5,2015-08-14T21:03:00,,No Relation,1,C116890,SU5416,D009369,tumor,"Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.",15519795_0,15519795_C116890_D009369,,
770958059,false,true,5,2015-08-14T21:35:00,,No Relation,1,C116890,SU5416,C535318,Triple combination,"Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.",15519795_0,15519795_C116890_C535318,,
770958060,false,true,5,2015-08-14T21:58:00,,No Relation,1,C116890,SU5416,D009369,tumor,"The combination of the folate antimetabolite pemetrexed, SU5416, a receptor tyrosine kinase inhibitor of VEGFR2, and irradiation was investigated in human endothelial cells and tumor cell lines.",15519795_2,15519795_C116890_D009369,,
770958061,false,true,5,2015-08-15T00:13:00,,No Relation,1,D005492,folate,D009369,tumor,"The combination of the folate antimetabolite pemetrexed, SU5416, a receptor tyrosine kinase inhibitor of VEGFR2, and irradiation was investigated in human endothelial cells and tumor cell lines.",15519795_2,15519795_D005492_D009369,,
770958062,false,true,5,2015-08-15T01:58:00,,No Relation,1,D014443,tyrosine,D009369,tumor,"The combination of the folate antimetabolite pemetrexed, SU5416, a receptor tyrosine kinase inhibitor of VEGFR2, and irradiation was investigated in human endothelial cells and tumor cell lines.",15519795_2,15519795_D014443_D009369,,
770958063,false,true,5,2015-08-15T00:15:00,,No Relation,1,C116890,SU5416,D011471,prostate cancer,"Primary isolated human umbilical vein endothelial cells (HUVEC), human dermal microvascular endothelial cells (HDMEC), and human glioblastoma (U87) and prostate cancer cells (PC3) were exposed to pemetrexed (2 h) alone and in combination with SU5416 (2 h).",15519795_3,15519795_C116890_D011471,,
770958064,false,true,5,2015-08-15T02:23:00,,No Relation,1,C116890,SU5416,D005909,glioblastoma,"Primary isolated human umbilical vein endothelial cells (HUVEC), human dermal microvascular endothelial cells (HDMEC), and human glioblastoma (U87) and prostate cancer cells (PC3) were exposed to pemetrexed (2 h) alone and in combination with SU5416 (2 h).",15519795_3,15519795_C116890_D005909,,
770958065,false,true,5,2015-08-14T21:24:00,,No Relation,0.8143,C116890,SU5416,D009369,tumor,Triple combination using only a low-toxicity drug exposure of pemetrexed and SU5416 results in greater response than each treatment alone or than each combination of two modalities in all tested endothelial and tumor cell models.,15519795_9,15519795_C116890_D009369,,
770958066,false,true,5,2015-08-15T01:25:00,,No Relation,1,C116890,SU5416,C535318,Triple combination,Triple combination using only a low-toxicity drug exposure of pemetrexed and SU5416 results in greater response than each treatment alone or than each combination of two modalities in all tested endothelial and tumor cell models.,15519795_9,15519795_C116890_C535318,,
770958067,false,true,5,2015-08-14T23:35:00,,No Relation,0.8038,C116890,SU5416,D064420,toxicity,Triple combination using only a low-toxicity drug exposure of pemetrexed and SU5416 results in greater response than each treatment alone or than each combination of two modalities in all tested endothelial and tumor cell models.,15519795_9,15519795_C116890_D064420,,
770958068,false,true,5,2015-08-15T02:01:00,,No Relation,1,D003894,Desmopressin,D053158,nocturia,Desmopressin is a synthetic vasopressin analogue mainly used in treatment of diabetes insipidus and nocturia.,15525445_1,15525445_D003894_D053158,,
770958069,false,true,5,2015-08-14T21:22:00,,No Relation,1,D014667,vasopressin,D003919,diabetes insipidus,Desmopressin is a synthetic vasopressin analogue mainly used in treatment of diabetes insipidus and nocturia.,15525445_1,15525445_D014667_D003919,,
770958070,false,true,5,2015-08-15T00:02:00,,No Relation,1,D003894,Desmopressin,D003919,diabetes insipidus,Desmopressin is a synthetic vasopressin analogue mainly used in treatment of diabetes insipidus and nocturia.,15525445_1,15525445_D003894_D003919,,
770958071,false,true,5,2015-08-14T21:22:00,,No Relation,1,D014667,vasopressin,D053158,nocturia,Desmopressin is a synthetic vasopressin analogue mainly used in treatment of diabetes insipidus and nocturia.,15525445_1,15525445_D014667_D053158,,
770958072,false,true,5,2015-08-14T21:54:00,,No Relation,1,D017336,loratadine,D011695,allergic,"Systemic antihistamines, such as loratadine and cetrizine hydrochloride, have proven efficacious in the control of many allergic conditions; however, patients complain about their drying effects.",15562885_1,15562885_D017336_D011695,,
770958073,false,true,5,2015-08-14T21:31:00,,No Relation,0.8092,D017336,loratadine,C535679,chamber that regulates humidity,"Participants were evaluated in a CAE (a chamber that regulates humidity, temperature, airflow, and visual tasking) at baseline and after taking 10 mg of either loratadine or cetirizine hydrochloride daily for 4 days.",15562885_4,15562885_D017336_C535679,,
770958074,false,true,5,2015-08-14T22:09:00,,No Relation,0.5721,D017336,loratadine,D005128,ocular discomfort,"After 4 days, use of loratadine yielded a mean increase of 0.75 points (107%) in keratitis (P < .001), a mean increase of 1.35 points (133%) in conjunctival staining (P < .001), a mean decrease of 1.38 seconds (33.7%) in TFBUT (P < .001), and a mean increase of 0.32 points (24.8%) in ocular discomfort (P = .05) vs baseline.",15562885_7,15562885_D017336_D005128,,
770958075,false,true,5,2015-08-14T22:17:00,,Direct,0.8012,D017336,loratadine,D007634,keratitis,"After 4 days, use of loratadine yielded a mean increase of 0.75 points (107%) in keratitis (P < .001), a mean increase of 1.35 points (133%) in conjunctival staining (P < .001), a mean decrease of 1.38 seconds (33.7%) in TFBUT (P < .001), and a mean increase of 0.32 points (24.8%) in ocular discomfort (P = .05) vs baseline.",15562885_7,15562885_D017336_D007634,,
770958076,false,true,5,2015-08-15T01:17:00,,Direct,0.7958,D017336,Loratadine,D005128,increased ocular discomfort,"Loratadine and cetirizine hydrochloride induced signs and symptoms associated with ocular dryness, including increased corneal and conjunctival staining, decreased TFBUT, and increased ocular discomfort in healthy individuals.",15562885_10,15562885_D017336_D005128,,
770958077,false,true,5,2015-08-15T00:21:00,,Direct,1,D017336,Loratadine,D014987,ocular dryness,"Loratadine and cetirizine hydrochloride induced signs and symptoms associated with ocular dryness, including increased corneal and conjunctival staining, decreased TFBUT, and increased ocular discomfort in healthy individuals.",15562885_10,15562885_D017336_D014987,,
770958078,false,true,5,2015-08-14T22:53:00,"In many populations, high intakes of saturated fat are associated with elevated serum cholesterol concentrations and increased coronary heart disease (CHD) mortality. While ""cholesterol"" and ""coronary heart disease (CHD) mortality"" should be connected, this sentence does not make connection clear, but refers to ""high intakes of saturated fat""",Direct,0.7844,D002784,cholesterol,D003327,CHD/coronary heart disease,"In many populations, high intakes of saturated fat are associated with elevated serum cholesterol concentrations and increased coronary heart disease (CHD) mortality.",15563444_2,15563444_D002784_D003327,,
770958079,false,true,5,2015-08-15T00:15:00,,Direct,0.5899,D002241,carbohydrates,D003327,CHD,"However, the intakes of animal foods, total protein, dietary cholesterol and less plant derived carbohydrates were predictors of CHD.",15563444_12,15563444_D002241_D003327,,
770958080,false,true,5,2015-08-14T21:48:00,,No Relation,0.5723,D002784,cholesterol,D003327,CHD,"However, the intakes of animal foods, total protein, dietary cholesterol and less plant derived carbohydrates were predictors of CHD.",15563444_12,15563444_D002784_D003327,,
770958081,false,true,5,2015-08-14T23:40:00,,No Relation,1,D006493,heparin,D054556,venous thromboembolism,The prolonged administration of heparin for prevention and treatment of venous thromboembolism has been associated with a risk of heparin-induced osteoporosis.,15584059_1,15584059_D006493_D054556,,
770958082,false,true,5,2015-08-14T22:24:00,,Direct,0.8081,D006493,heparin,D010024,osteoporosis,The prolonged administration of heparin for prevention and treatment of venous thromboembolism has been associated with a risk of heparin-induced osteoporosis.,15584059_1,15584059_D006493_D010024,,
770958083,false,true,5,2015-08-15T00:57:00,,Direct,1,D006493,heparin,D010024,osteoporosis,Fondaparinux did not inhibit osteoblast proliferation in vitro and may reduce the risk of heparin-induced osteoporosis associated with long-term heparin administration.,15584059_9,15584059_D006493_D010024,,
770958084,false,true,5,2015-08-15T00:39:00,,No Relation,0.804,D001663,bilirubin,D006980,hyperthyroidism,The patient's jaundice promptly resolved with therapy for hyperthyroidism and thyroid storm as bilirubin levels decreased from 35 mg/dL (normal: 0.5-1.2 mg/dL) to 0.4 mg/dL.,15599331_5,15599331_D001663_D006980,,
770958085,false,true,5,2015-08-14T21:49:00,,No Relation,1,D001663,bilirubin,D013958,thyroid storm,The patient's jaundice promptly resolved with therapy for hyperthyroidism and thyroid storm as bilirubin levels decreased from 35 mg/dL (normal: 0.5-1.2 mg/dL) to 0.4 mg/dL.,15599331_5,15599331_D001663_D013958,,
770958086,false,true,5,2015-08-14T22:04:00,,No Relation,0.8058,D001663,bilirubin,D007565,jaundice,The patient's jaundice promptly resolved with therapy for hyperthyroidism and thyroid storm as bilirubin levels decreased from 35 mg/dL (normal: 0.5-1.2 mg/dL) to 0.4 mg/dL.,15599331_5,15599331_D001663_D007565,,
770958087,false,true,5,2015-08-15T01:46:00,,No Relation,0.7975,D000431,alcohol,D006528,hepatocellular carcinoma,"Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea.",15601641_0,15601641_D000431_D006528,,
770958088,false,true,5,2015-08-14T23:00:00,,No Relation,1,D000431,alcohol,D006509,hepatitis B,"Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea.",15601641_0,15601641_D000431_D006509,,
770958089,false,true,5,2015-08-15T02:15:00,,No Relation,1,D000348,aflatoxin,D006506,infectious hepatitis,"Liver cancer is one of the most common cancers worldwide, particularly in Asia and Africa, where infectious hepatitis and aflatoxin exposures are common.",15601641_1,15601641_D000348_D006506,,
770958090,false,true,5,2015-08-15T02:13:00,,Direct,0.7989,D000348,aflatoxin,D009369,cancers/Liver cancer,"Liver cancer is one of the most common cancers worldwide, particularly in Asia and Africa, where infectious hepatitis and aflatoxin exposures are common.",15601641_1,15601641_D000348_D009369,,
770958091,false,true,5,2015-08-14T21:16:00,,No Relation,0.4056,D000431,alcohol,D006528,hepatocellular carcinoma,"We conducted a prospective cohort study of liver cancer in Korea to assess the independent effects and interactions of smoking, alcohol consumption, and hepatitis B on risk of mortality from hepatocellular carcinoma.",15601641_2,15601641_D000431_D006528,,
770958092,false,true,5,2015-08-14T21:45:00,,No Relation,1,D000431,alcohol,D006509,hepatitis B,"We conducted a prospective cohort study of liver cancer in Korea to assess the independent effects and interactions of smoking, alcohol consumption, and hepatitis B on risk of mortality from hepatocellular carcinoma.",15601641_2,15601641_D000431_D006509,,
770958093,false,true,5,2015-08-14T22:29:00,,No Relation,0.7946,D000431,alcohol,D009369,liver cancer,"We conducted a prospective cohort study of liver cancer in Korea to assess the independent effects and interactions of smoking, alcohol consumption, and hepatitis B on risk of mortality from hepatocellular carcinoma.",15601641_2,15601641_D000431_D009369,,
770958094,false,true,5,2015-08-14T21:12:00,,No Relation,1,D000431,alcohol,D006509,hepatitis B,"All participants reported their smoking and alcohol consumption, and hepatitis B surface antigen (HBsAg) status was documented for 47.2% of the participants.",15601641_4,15601641_D000431_D006509,,
770958095,false,true,5,2015-08-14T21:13:00,,No Relation,1,D006514,hepatitis B surface antigen,D006509,hepatitis B,"All participants reported their smoking and alcohol consumption, and hepatitis B surface antigen (HBsAg) status was documented for 47.2% of the participants.",15601641_4,15601641_D006514_D006509,,
770958096,false,true,5,2015-08-14T22:23:00,,No Relation,1,D000431,alcohol,D003929,diabetes,"Relative risk and 95% confidence intervals (CIs) of mortality from hepatocellular carcinoma were calculated using proportional hazards models adjusted for age, alcohol drinking, diabetes, and HBsAg status.",15601641_5,15601641_D000431_D003929,,
770958097,false,true,5,2015-08-14T22:00:00,,No Relation,0.5954,D000431,alcohol,D006528,hepatocellular carcinoma,"Relative risk and 95% confidence intervals (CIs) of mortality from hepatocellular carcinoma were calculated using proportional hazards models adjusted for age, alcohol drinking, diabetes, and HBsAg status.",15601641_5,15601641_D000431_D006528,,
770958098,false,true,5,2015-08-14T22:43:00,,Direct,0.8073,D000431,alcohol,D006528,hepatocellular carcinoma,Heavy alcohol drinking was associated with hepatocellular carcinoma mortality risk in the subgroup of men who were tested for HBsAg (RR =1.5; 95% CI = 1.2 to 2.0).,15601641_8,15601641_D000431_D006528,,
770958099,false,true,5,2015-08-14T21:53:00,,No Relation,1,D006514,HBsAg,D006528,hepatocellular carcinoma,Heavy alcohol drinking was associated with hepatocellular carcinoma mortality risk in the subgroup of men who were tested for HBsAg (RR =1.5; 95% CI = 1.2 to 2.0).,15601641_8,15601641_D006514_D006528,,
770958100,false,true,5,2015-08-14T21:58:00,,No Relation,1,D000431,alcohol,D006528,hepatocellular carcinoma,"There was no interaction among smoking, alcohol drinking, and HBsAg in terms of hepatocellular carcinoma mortality.",15601641_9,15601641_D000431_D006528,,
770958101,false,true,5,2015-08-15T02:20:00,,No Relation,1,D006514,HBsAg,D006528,hepatocellular carcinoma,"There was no interaction among smoking, alcohol drinking, and HBsAg in terms of hepatocellular carcinoma mortality.",15601641_9,15601641_D006514_D006528,,
770958102,false,true,5,2015-08-14T21:37:00,,Direct,0.7964,D000431,alcohol,D006528,hepatocellular carcinoma,"Cigarette smoking, heavy alcohol consumption, and HBsAg were independently associated with increased risk of mortality from hepatocellular carcinoma but did not interact synergistically.",15601641_10,15601641_D000431_D006528,,
770958103,false,true,5,2015-08-15T01:20:00,,Direct,1,D006514,HBsAg,D006528,hepatocellular carcinoma,"Cigarette smoking, heavy alcohol consumption, and HBsAg were independently associated with increased risk of mortality from hepatocellular carcinoma but did not interact synergistically.",15601641_10,15601641_D006514_D006528,,
770958104,false,true,5,2015-08-14T21:24:00,,No Relation,1,D002794,choline,D002796,CHT/choline uptake transporter,The capacity of the high-affinity choline uptake transporter (CHT) to import choline from the extracellular space to presynaptic terminals is essential for normal acetylcholine synthesis and therefore cholinergic transmission.,15611726_2,15611726_D002794_D002796,,
770958105,false,true,5,2015-08-15T01:12:00,,No Relation,1,D000109,acetylcholine,D002796,CHT/choline uptake transporter,The capacity of the high-affinity choline uptake transporter (CHT) to import choline from the extracellular space to presynaptic terminals is essential for normal acetylcholine synthesis and therefore cholinergic transmission.,15611726_2,15611726_D000109_D002796,,
770958106,false,true,5,2015-08-14T21:59:00,,No Relation,0.8058,D002045,bupivacaine,D010146,pain,"Median (25th, 75th centile) visual analog scale pain scores associated with drain removal in the bupivacaine, Entonox, and morphine groups were 9.5 mm (3, 18 mm), 37.0 mm (13, 56 mm), and 15.0 mm (7, 27 mm), respectively.",15616079_4,15616079_D002045_D010146,,
770958107,false,true,5,2015-08-15T00:43:00,,No Relation,1,D009020,morphine,D010146,pain,"Median (25th, 75th centile) visual analog scale pain scores associated with drain removal in the bupivacaine, Entonox, and morphine groups were 9.5 mm (3, 18 mm), 37.0 mm (13, 56 mm), and 15.0 mm (7, 27 mm), respectively.",15616079_4,15616079_D009020_D010146,,
770958108,false,true,5,2015-08-14T23:11:00,,No Relation,0.8085,D002045,bupivacaine,D010146,pain,The pain scores were higher in the Entonox group compared with the bupivacaine group (P=0.005) and the morphine group (P=0.047).,15616079_5,15616079_D002045_D010146,,
770958109,false,true,5,2015-08-14T21:15:00,,No Relation,0.8048,D009020,morphine,D010146,pain,The pain scores were higher in the Entonox group compared with the bupivacaine group (P=0.005) and the morphine group (P=0.047).,15616079_5,15616079_D009020_D010146,,
770958110,false,true,5,2015-08-15T00:31:00,,No Relation,0.7944,D002045,Bupivacaine,D010146,pain,"Bupivacaine and morphine, unlike Entonox, produce lower pain scores associated with drain removal.",15616079_8,15616079_D002045_D010146,,
770958111,false,true,5,2015-08-14T21:17:00,,No Relation,0.8033,D009020,morphine,D010146,pain,"Bupivacaine and morphine, unlike Entonox, produce lower pain scores associated with drain removal.",15616079_8,15616079_D009020_D010146,,
770958112,false,true,5,2015-08-15T00:43:00,,No Relation,1,D009638,norepinephrine,D020210,Central hypercapnic chemosensitivity,Central hypercapnic chemosensitivity and plasma norepinephrine were measured in 99 patients with chronic heart failure.,15632879_3,15632879_D009638_D020210,,
770958113,false,true,5,2015-08-14T23:34:00,,No Relation,1,D009638,norepinephrine,D007676,chronic heart failure,Central hypercapnic chemosensitivity and plasma norepinephrine were measured in 99 patients with chronic heart failure.,15632879_3,15632879_D009638_D007676,,
770958114,false,true,5,2015-08-15T01:56:00,,No Relation,1,D019821,statins,D003324,coronary artery disease,"Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.",15642557_0,15642557_D019821_D003324,,
770958115,false,true,5,2015-08-14T23:18:00,,No Relation,1,D019821,statins,D003324,coronary artery disease,"This study assessed the effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand after percutaneous coronary intervention in patients who had stable coronary artery disease.",15642557_1,15642557_D019821_D003324,,
770958116,false,true,5,2015-08-14T21:31:00,,No Relation,1,C081643,candesartan,D006973,hypertension,Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.,15662234_0,15662234_C081643_D006973,,
770958117,false,true,5,2015-08-15T02:09:00,,No Relation,1,D009543,nifedipine,D006973,hypertension,Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.,15662234_0,15662234_D009543_D006973,,
770958118,false,true,5,2015-08-15T00:26:00,,No Relation,1,C081643,candesartan,D006973,hypertension,"Patients with essential hypertension, who did not achieve their target blood pressure with baseline treatment of candesartan 8 mg/day for 8 weeks.",15662234_4,15662234_C081643_D006973,,
770958119,false,true,5,2015-08-15T01:32:00,,No Relation,1,C081643,candesartan,D006973,hypertension,These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension.,15662234_9,15662234_C081643_D006973,,
770958120,false,true,5,2015-08-14T21:03:00,,No Relation,1,D009543,nifedipine,D006973,hypertension,These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension.,15662234_9,15662234_D009543_D006973,,
770958121,false,true,5,2015-08-15T01:45:00,,No Relation,1,D002945,cisplatin,D005909,glioblastoma,Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease.,15662978_0,15662978_D002945_D005909,,
770958122,false,true,5,2015-08-14T22:14:00,,No Relation,1,C047246,temozolomide,D005909,glioblastoma,Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease.,15662978_0,15662978_C047246_D005909,,
770958123,false,true,5,2015-08-14T23:49:00,,No Relation,1,D002945,cisplatin,D005909,glioblastoma,"This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival.",15662978_2,15662978_D002945_D005909,,
770958124,false,true,5,2015-08-14T22:22:00,,No Relation,1,C047246,temozolomide,D005909,glioblastoma,"This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival.",15662978_2,15662978_C047246_D005909,,
770958125,false,true,5,2015-08-14T22:17:00,,No Relation,1,D000305,corticosteroids,D065631,allergic rhinitis,The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome.,15663563_0,15663563_D000305_D065631,,
770958126,false,true,5,2015-08-14T22:19:00,,No Relation,1,D000305,corticosteroids,D001249,asthma syndrome,The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome.,15663563_0,15663563_D000305_D001249,,
770958127,false,true,5,2015-08-14T22:40:00,,No Relation,1,D005680,GABA,D001523,psychiatric,"The GABA system is an active target for drugs to treat a variety of disorders and the availability of an indirect measure of central GABA activity would not only enhance psychiatric research, but also permit assessment of the pharmacodynamic effects of drugs designed to act on this system.",15672555_1,15672555_D005680_D001523,,
770958128,false,true,5,2015-08-15T01:53:00,,No Relation,1,D005680,GABA,D003072,cognitive impairments,The relationships between plasma baseline pre-drug GABA concentrations and cognitive impairments induced by an acute oral dose of lorazepam (0.5 and 1.0 mg) were investigated in 22 healthy elderly individuals.,15672555_2,15672555_D005680_D003072,,
770958129,false,true,5,2015-08-14T21:40:00,,Direct,1,D008140,lorazepam,D003072,cognitive impairments,The relationships between plasma baseline pre-drug GABA concentrations and cognitive impairments induced by an acute oral dose of lorazepam (0.5 and 1.0 mg) were investigated in 22 healthy elderly individuals.,15672555_2,15672555_D008140_D003072,,
770958130,false,true,5,2015-08-14T23:03:00,,Direct,0.6175,D001569,benzodiazepine,D064420,cognitive toxicity,Plasma GABA concentration does not appear to be a useful marker of susceptibility to benzodiazepine-induced cognitive toxicity in the elderly.,15672555_4,15672555_D001569_D064420,,
770958131,false,true,5,2015-08-14T23:04:00,,No Relation,0.8235,D005680,GABA,D064420,cognitive toxicity,Plasma GABA concentration does not appear to be a useful marker of susceptibility to benzodiazepine-induced cognitive toxicity in the elderly.,15672555_4,15672555_D005680_D064420,,
770958132,false,true,5,2015-08-15T00:11:00,,No Relation,0.5813,D008795,metronidazole,D012008,recurrent disease,"Vancomycin and metronidazole have been used for treating Clostridium difficile-associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease.",15673502_1,15673502_D008795_D012008,,
770958133,false,true,5,2015-08-14T21:49:00,,Direct,1,D014640,Vancomycin,D012008,recurrent disease,"Vancomycin and metronidazole have been used for treating Clostridium difficile-associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease.",15673502_1,15673502_D014640_D012008,,
770958134,false,true,5,2015-08-15T01:10:00,,No Relation,1,C465304,argentatin A,D009369,cancer,Synthesis of argentatin A derivatives as growth inhibitors of human cancer cell lines in vitro.,15686901_0,15686901_C465304_D009369,,
770958135,false,true,5,2015-08-14T22:17:00,,Direct,0.8096,D046934,ginkgolides,D006470,bleeding complications,Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts.,15693702_0,15693702_D046934_D006470,,
770958136,false,true,5,2015-08-15T01:22:00,,Indirect,0.4104,D046934,ginkgolides,D006470,bleeding,"Although a clear causality between Ginkgo intake and bleeding could not be established, these observations have generally been explained by the platelet-activating factor (PAF)-antagonistic action of ginkgolides, which represent characteristic constituents of Ginkgo extracts.",15693702_4,15693702_D046934_D006470,,
770958137,false,true,5,2015-08-14T21:03:00,,Direct,0.7996,D046934,ginkgolides,D006470,hemorrhage,"These concentrations are generally more than 100 times higher as the peak plasma values measured after oral intake of EGb 761 at recommended doses between 120 and 240 mg. As PAF is a 'weak' platelet activator, which does not appear to be of importance for primary hemostasis, our results rise serious doubts that the PAF antagonistic effect of ginkgolides could be responsible for hemorrhage in patients taking EGb 761.",15693702_8,15693702_D046934_D006470,,
770958138,false,true,5,2015-08-14T23:49:00,,No Relation,1,D019829,nevirapine/NVP,D015658,HIV-infected,Babies of HIV-infected women were randomised at birth to receive a single dose of nevirapine (NVP) alone or with zidovudine (ZDV) twice daily for a week.,15720887_2,15720887_D019829_D015658,,
770958139,false,true,5,2015-08-14T21:16:00,,No Relation,1,D015215,zidovudine/ZDV,D015658,HIV-infected,Babies of HIV-infected women were randomised at birth to receive a single dose of nevirapine (NVP) alone or with zidovudine (ZDV) twice daily for a week.,15720887_2,15720887_D015215_D015658,,
770958140,false,true,5,2015-08-14T21:07:00,,No Relation,0.7951,D019829,NVP,D000740,anaemia,Age-specific mean haemoglobin levels and prevalence of anaemia (haemoglobin < 10 g/dL) were not significantly different in cases where only the babies received a single dose of NVP and cases where NVP was given to mother/infant pairs or additional ZDV to the baby.,15720887_7,15720887_D019829_D000740,,
770958141,false,true,5,2015-08-14T23:29:00,,No Relation,1,D015215,ZDV,D000740,anaemia,Age-specific mean haemoglobin levels and prevalence of anaemia (haemoglobin < 10 g/dL) were not significantly different in cases where only the babies received a single dose of NVP and cases where NVP was given to mother/infant pairs or additional ZDV to the baby.,15720887_7,15720887_D015215_D000740,,
770958142,false,true,5,2015-08-14T21:52:00,,No Relation,0.803,D002118,Calcium,D015663,postmenopausal bone loss,Calcium supplementation slows postmenopausal bone loss by inhibiting PTH secretion.,15755853_2,15755853_D002118_D015663,,
770958143,false,true,5,2015-08-15T00:46:00,,No Relation,1,D019355,calcium citrate,D016301,bone loss,This study explores whether combined treatment with potassium citrate and calcium citrate is more effective than either agent alone in inhibiting bone loss.,15755853_3,15755853_D019355_D016301,,
770958144,false,true,5,2015-08-14T23:50:00,,No Relation,1,D019357,potassium citrate,D016301,bone loss,This study explores whether combined treatment with potassium citrate and calcium citrate is more effective than either agent alone in inhibiting bone loss.,15755853_3,15755853_D019357_D016301,,
770958145,false,true,5,2015-08-15T00:34:00,,No Relation,1,D009020,morphine,D020250,PONV/postoperative nausea and vomiting,"The secondary outcomes were amplitude of knee flexion, morphine consumption, and occurrence of postoperative nausea and vomiting (PONV).",15765454_7,15765454_D009020_D020250,,
770958146,false,true,5,2015-08-14T21:04:00,,No Relation,0.8122,D009020,morphine,D020250,PONV,The combined femoral and sciatic blocks decreased the morphine consumption by 81% and significantly decreased the occurrence of PONV.,15765454_10,15765454_D009020_D020250,,
770958147,false,true,5,2015-08-15T00:25:00,,No Relation,1,D009020,morphine,D000699,analgesia,"During the 36 hours immediately after total knee replacement, the combination of continuous femoral and sciatic nerve blocks improves analgesia while decreasing morphine consumption and PONV.",15765454_11,15765454_D009020_D000699,,
770958148,false,true,5,2015-08-15T01:39:00,,No Relation,1,D009020,morphine,D020250,PONV,"During the 36 hours immediately after total knee replacement, the combination of continuous femoral and sciatic nerve blocks improves analgesia while decreasing morphine consumption and PONV.",15765454_11,15765454_D009020_D020250,,
770958149,false,true,5,2015-08-14T22:00:00,,No Relation,1,C089995,Glatiramer acetate,D009103,multiple sclerosis,Glatiramer acetate (GLAT) is a well tolerated and safe immunomodulatory drug for the treatment of relapsing-remitting multiple sclerosis.,15794402_1,15794402_C089995_D009103,,
770958150,false,true,5,2015-08-14T21:36:00,Feel like this is not a complete sentence.,No Relation,1,D014810,vitamin E,D001167,neuropathy,Isolated vitamin E deficiency with demyelinating neuropathy.,15803482_0,15803482_D014810_D001167,,
770958151,false,true,5,2015-08-14T21:36:00,,Direct,0.5876,D010634,phenobarbital,D020754,spinocerebellar ataxia,"A 22-year-old man, with a past history of generalized tonic-clonic seizures treated with phenobarbital, presented with spinocerebellar ataxia.",15803482_1,15803482_D010634_D020754,,
770958152,false,true,5,2015-08-14T22:08:00,,No Relation,0.8102,D010634,phenobarbital,D012640,tonic-clonic seizures,"A 22-year-old man, with a past history of generalized tonic-clonic seizures treated with phenobarbital, presented with spinocerebellar ataxia.",15803482_1,15803482_D010634_D012640,,
770958153,false,true,5,2015-08-15T00:43:00,,No Relation,0.8201,D014810,Vitamin E,D014811,Vitamin E deficiency,"Vitamin E deficiency leading to a demyelinating neuropathy, as in the present case, suggests that the full spectrum of the disease entity is not fully defined.",15803482_7,15803482_D014810_D014811,,
770958154,false,true,5,2015-08-14T21:56:00,,No Relation,0.8,D014810,Vitamin E,D001167,neuropathy,"Vitamin E deficiency leading to a demyelinating neuropathy, as in the present case, suggests that the full spectrum of the disease entity is not fully defined.",15803482_7,15803482_D014810_D001167,,
770958155,false,true,5,2015-08-14T21:30:00,,No Relation,0.8094,D005947,glucose,D003929,diabetics,A fuzzy logic based closed-loop control system for blood glucose level regulation in diabetics.,15804854_0,15804854_D005947_D003929,,
770958156,false,true,5,2015-08-14T23:16:00,It's 'plasma glucose level' and not just 'Glucose',No Relation,1,D005947,glucose,D003920,diabetes mellitus type,"In this study, a closed-loop system to control the plasma glucose level in patients with diabetes mellitus type 1 is proposed.",15804854_1,15804854_D005947_D003920,,
770958157,false,true,5,2015-08-14T21:07:00,,No Relation,0.8158,D005947,glucose,D003929,diabetic,"This control scheme is based on fuzzy logic control theory to maintain a normoglycaemic average of 4.5 mmol 1(-1) and the normal conditions for free plasma insulin concentration in severe initial state; in particular, when the diabetic patient is subjected to a glucose meal disturbance or fluctuations in the measured glucose level due to error in the measuring instrument.",15804854_2,15804854_D005947_D003929,,
770958158,false,true,5,2015-08-14T22:00:00,,No Relation,1,D000547,Amantadine,D006689,granulomatous disease,Amantadine in chronic granulomatous disease.,15805000_0,15805000_D000547_D006689,,
770958159,false,true,5,2015-08-15T01:00:00,,No Relation,1,D000547,amantadine,D006105,CGD,"Because a weak base such as amantadine could potentially reverse these pH abnormalities, the authors used this drug to treat 2 CGD patients.",15805000_3,15805000_D000547_D006105,,
770958160,false,true,5,2015-08-14T22:14:00,,No Relation,1,D000547,amantadine,D006105,CGD,"Since the drug has been employed, the patients have not developed new infections, suggesting a role of amantadine as a part of CGD prophylactic regimen.",15805000_5,15805000_D000547_D006105,,
770958161,false,true,5,2015-08-14T23:54:00,,No Relation,1,D000547,amantadine,D007239,infections,"Since the drug has been employed, the patients have not developed new infections, suggesting a role of amantadine as a part of CGD prophylactic regimen.",15805000_5,15805000_D000547_D007239,,
770958162,false,true,5,2015-08-15T01:19:00,,No Relation,1,D008727,methotrexate,D001172,rheumatoid arthritis,Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.,15818697_0,15818697_D008727_D001172,,
770958163,false,true,5,2015-08-15T02:13:00,,No Relation,1,D008727,methotrexate,D009369,tumor,Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.,15818697_0,15818697_D008727_D009369,,
770958164,false,true,5,2015-08-15T00:30:00,,No Relation,1,D008727,methotrexate,D009336,necrosis,Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.,15818697_0,15818697_D008727_D009336,,
770958165,false,true,5,2015-08-14T23:09:00,,No Relation,1,D008727,methotrexate/MTX,D001172,RA,Changes from baseline to week 54 in clinical variables and measures of radiographic progression were compared between patients who received infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX) and those who received MTX plus placebo in the Anti-Tumor Necrosis Factor Trial in RA with Concomitant Therapy trial.,15818697_2,15818697_D008727_D001172,,
770958166,false,true,5,2015-08-14T21:37:00,,No Relation,1,D008727,methotrexate/MTX,D009369,Tumor,Changes from baseline to week 54 in clinical variables and measures of radiographic progression were compared between patients who received infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX) and those who received MTX plus placebo in the Anti-Tumor Necrosis Factor Trial in RA with Concomitant Therapy trial.,15818697_2,15818697_D008727_D009369,,
770958167,false,true,5,2015-08-14T22:11:00,,No Relation,1,C043211,Carvedilol,D006333,heart failure,Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.,15820297_0,15820297_C043211_D006333,,
770958168,false,true,5,2015-08-14T22:59:00,,No Relation,0.8218,C043211,carvedilol,D007676,chronic heart failure/CHF,The aim of this study was to determine the effects of carvedilol on the costs related to the treatment of severe chronic heart failure (CHF).,15820297_1,15820297_C043211_D007676,,
770958169,false,true,5,2015-08-14T23:43:00,,No Relation,1,C043211,Carvedilol,D006333,heart failure,Costs for the treatment for heart failure within the National Health Service (NHS) in the United Kingdom (UK) were applied to resource utilisation data prospectively collected in all patients randomized into the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study.,15820297_2,15820297_C043211_D006333,,
770958170,false,true,5,2015-08-14T22:19:00,,No Relation,1,C043211,carvedilol,D007676,CHF,These findings suggest that not only can carvedilol treatment increase survival and reduce hospital admissions in patients with severe CHF but that it can also cut costs in the process.,15820297_11,15820297_C043211_D007676,,
770958171,false,true,5,2015-08-15T01:29:00,,No Relation,1,D013752,tetracycline,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_D013752_D009877,,
770958172,false,true,5,2015-08-15T00:09:00,,No Relation,1,D014640,vancomycin,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_D014640_D009877,,
770958173,false,true,5,2015-08-15T01:14:00,,No Relation,1,D015242,ofloxacin,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_D015242_D009877,,
770958174,false,true,5,2015-08-15T01:31:00,,No Relation,1,C043265,tazobactam,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_C043265_D009877,,
770958175,false,true,5,2015-08-14T21:53:00,,No Relation,1,D010878,piperacillin,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_D010878_D009877,,
770958176,false,true,5,2015-08-15T01:54:00,,No Relation,1,D019980,amoxicillin+clavulanic acid,D009877,posttraumatic endophthalmitis,"We describe a case of posttraumatic endophthalmitis unresponsive to systemic (amoxicillin+clavulanic acid and piperacillin/tazobactam), intra-ocular (vancomycin) and topical (ofloxacin, tetracycline and sulfametoxazole) antibiotic therapy.",15834610_1,15834610_D019980_D009877,,
770958177,false,true,5,2015-08-15T00:49:00,,No Relation,1,D009569,nitric oxide,D006261,headache,To classify the headache syndromes under treatment with calcineurin inhibitors and to investigate whether the latter influence the nitric oxide production of human brain microvascular cells (HBMEC).,15836594_1,15836594_D009569_D006261,,
770958178,false,true,5,2015-08-15T00:15:00,,Direct,0.7967,D016572,cyclosporine,D006261,headaches,Single cases of cyclosporine-induced headaches have been reported.,15836594_2,15836594_D016572_D006261,,
770958179,false,true,5,2015-08-15T00:28:00,,Direct,0.788,D009569,NO,D018781,tension-type headache,"Since calcineurin inhibitors are known to influence the renal metabolism of NO, a key molecule in tension-type headache and migraine, we were interested whether calcineurin inhibitors might change NO metabolism in HBMEC as well.",15836594_3,15836594_D009569_D018781,,
770958180,false,true,5,2015-08-14T23:03:00,,No Relation,1,D009569,NO,D008881,migraine,"Since calcineurin inhibitors are known to influence the renal metabolism of NO, a key molecule in tension-type headache and migraine, we were interested whether calcineurin inhibitors might change NO metabolism in HBMEC as well.",15836594_3,15836594_D009569_D008881,,
770958181,false,true,5,2015-08-15T00:55:00,,Direct,0.6079,D016559,tacrolimus,D006261,Headache,Headache symptoms of 74 patients receiving cyclosporine and/or tacrolimus for organ transplantation were retrospectively assessed.,15836594_4,15836594_D016559_D006261,,
770958182,false,true,5,2015-08-14T23:43:00,,Direct,1,D016572,cyclosporine,D006261,Headache,Headache symptoms of 74 patients receiving cyclosporine and/or tacrolimus for organ transplantation were retrospectively assessed.,15836594_4,15836594_D016572_D006261,,
770958183,false,true,5,2015-08-14T21:20:00,,Direct,0.6207,D009569,NO,D006261,headaches,The pathophysiological mechanism of these headaches may be connected with an endothelial dysfunction in terms of increased production of NO.,15836594_9,15836594_D009569_D006261,,
770958184,false,true,5,2015-08-15T02:16:00,,Direct,0.6037,D009569,NO,C565156,endothelial dysfunction,The pathophysiological mechanism of these headaches may be connected with an endothelial dysfunction in terms of increased production of NO.,15836594_9,15836594_D009569_C565156,,
770958185,false,true,5,2015-08-14T21:58:00,,Direct,0.7903,D004317,doxorubicin,D064420,toxicity,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D004317_D064420,,
770958186,false,true,5,2015-08-14T23:02:00,,Direct,0.6145,D002945,cisplatin,D064420,toxicity,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D002945_D064420,,
770958187,false,true,5,2015-08-14T23:21:00,Used as treatment.,No Relation,1,D008727,methotrexate,D001749,bladder cancer,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D008727_D001749,,
770958188,false,true,5,2015-08-14T21:12:00,,Direct,0.6045,D014747,vinblastine,D064420,toxicity,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D014747_D064420,,
770958189,false,true,5,2015-08-15T02:20:00,,No Relation,1,D004317,doxorubicin,D001749,bladder cancer,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D004317_D001749,,
770958190,false,true,5,2015-08-15T00:16:00,,Direct,0.8174,D008727,methotrexate,D064420,toxicity,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D008727_D064420,,
770958191,false,true,5,2015-08-15T00:02:00,,No Relation,1,D014747,vinblastine,D001749,bladder cancer,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D014747_D001749,,
770958192,false,true,5,2015-08-14T21:52:00,,No Relation,0.8146,D002945,cisplatin,D001749,bladder cancer,"Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity.",15842461_1,15842461_D002945_D001749,,
770958193,false,true,5,2015-08-15T01:54:00,,No Relation,1,C056507,gemcitabine,D064420,toxicity,The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al.,15842461_2,15842461_C056507_D064420,,
770958194,false,true,5,2015-08-14T23:24:00,,No Relation,0.5919,D002945,cisplatin,D064420,toxicity,The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al.,15842461_2,15842461_D002945_D064420,,
770958195,false,true,5,2015-08-14T22:12:00,,No Relation,0.7968,D009705,nucleoside,D054038,reverse transcriptase,"HIV-1 isolates harboring multiple nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations are more susceptible (""hypersusceptible"") to the nonnucleoside reverse transcriptase inhibitors (NNRTIs) than isolates lacking NRTI resistance mutations, but this has only been reported with a single-cycle replication phenotypic assay.",15851917_1,15851917_D009705_D054038,,
770958196,false,true,5,2015-08-14T22:20:00,,No Relation,1,D019829,Nevirapine,D054038,RT,Nevirapine and efavirenz susceptibilities were tested and compared with a control wild-type virus or RT.,15851917_6,15851917_D019829_D054038,,
770958197,false,true,5,2015-08-15T00:18:00,,No Relation,1,C098320,efavirenz,D054038,RT,Nevirapine and efavirenz susceptibilities were tested and compared with a control wild-type virus or RT.,15851917_6,15851917_C098320_D054038,,
770958198,false,true,5,2015-08-15T00:39:00,,No Relation,1,D009271,Naltrexone,D000437,alcohol dependence,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D009271_D000437,,
770958199,false,true,5,2015-08-15T02:13:00,,No Relation,1,D000431,alcohol,D001523,psychiatric disorders,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D000431_D001523,,
770958200,false,true,5,2015-08-14T21:19:00,,No Relation,0.8055,D009271,Naltrexone,D001523,psychiatric disorders,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D009271_D001523,,
770958201,false,true,5,2015-08-15T01:19:00,,No Relation,0.8117,D004221,disulfiram,D000437,alcohol dependence,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D004221_D000437,,
770958202,false,true,5,2015-08-15T02:21:00,,No Relation,0.8115,D000431,alcohol,D000437,alcohol dependence,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D000431_D000437,,
770958203,false,true,5,2015-08-14T21:54:00,,No Relation,1,D004221,disulfiram,D001523,psychiatric disorders,Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.,15866552_0,15866552_D004221_D001523,,
770958204,false,true,5,2015-08-14T21:23:00,,No Relation,1,D009271,naltrexone,D000437,alcoholism,"Disulfiram and naltrexone are approved by the Food and Drug Administration (FDA) for the treatment of alcoholism, but these agents have not been rigorously evaluated in dually diagnosed individuals.",15866552_1,15866552_D009271_D000437,,
770958205,false,true,5,2015-08-15T02:12:00,,No Relation,1,D004221,Disulfiram,D000437,alcoholism,"Disulfiram and naltrexone are approved by the Food and Drug Administration (FDA) for the treatment of alcoholism, but these agents have not been rigorously evaluated in dually diagnosed individuals.",15866552_1,15866552_D004221_D000437,,
770958206,false,true,5,2015-08-15T00:26:00,,No Relation,0.6076,D000431,alcohol,D001523,psychiatric disorder,Two-hundred and fifty-four patients with an Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at three Veterans Administration outpatient clinics.,15866552_2,15866552_D000431_D001523,,
770958207,false,true,5,2015-08-14T21:35:00,,No Relation,0.7945,D000431,alcohol,D000437,alcohol dependence,Two-hundred and fifty-four patients with an Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at three Veterans Administration outpatient clinics.,15866552_2,15866552_D000431_D000437,,
770958208,false,true,5,2015-08-14T21:56:00,,No Relation,1,D000431,alcohol,D001523,psychiatric symptoms,"Secondary outcomes included psychiatric symptoms, alcohol craving, g-GGT levels and adverse events.",15866552_6,15866552_D000431_D001523,,
770958209,false,true,5,2015-08-14T22:27:00,,No Relation,1,D003404,creatinine,D012595,SSc,"At baseline, subjects had stable, moderately severe, diffuse SSc of disease duration < or = 5 years, modified Rodnan skin score > or = 20, serum creatinine < 2.0 mg/dl, percentage forced vital capacity (% FVC) predicted > or = 50%, and % DLCO predicted > or = 40% and were not receiving concomitant disease modifying therapies.",15868618_3,15868618_D003404_D012595,,
770958210,false,true,5,2015-08-14T21:09:00,,No Relation,1,D014747,vinblastine,D001749,bladder cancer,Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer.,15878100_0,15878100_D014747_D001749,,
770958211,false,true,5,2015-08-14T23:30:00,,No Relation,1,D003000,clonidine,D065446,premenstrual dysphoric disorder,Histories of sexual abuse are associated with differential effects of clonidine on autonomic function in women with premenstrual dysphoric disorder.,15925031_0,15925031_D003000_D065446,,
770958212,false,true,5,2015-08-15T00:09:00,'Histories of sexual abuse' and not just 'sexual abuse',Direct,0.5957,D003000,clonidine,D019966,sexual abuse,Histories of sexual abuse are associated with differential effects of clonidine on autonomic function in women with premenstrual dysphoric disorder.,15925031_0,15925031_D003000_D019966,,
770958213,false,true,5,2015-08-15T01:42:00,,No Relation,1,D003000,clonidine,D065446,PMDD/premenstrual dysphoric disorder,"In women meeting strict criteria for premenstrual dysphoric disorder (PMDD), we examined whether clonidine, an alpha2-adrenergic receptor (AR) agonist, would have different effects on sexually abused versus non-abused PMDD women for measures of autonomic nervous system function.",15925031_1,15925031_D003000_D065446,,
770958214,false,true,5,2015-08-15T01:49:00,,No Relation,1,D003000,clonidine,D065446,PMDD,"Twelve women meeting prospective, DSM-IV criteria for PMDD, five of whom had a history of sexual abuse, participated in a randomized, placebo-controlled, double-blind, cross-over design study, comparing 2 months of on oral clonidine (0.3 mg/day) with 2 months on active placebo.",15925031_2,15925031_D003000_D065446,,
770958215,false,true,5,2015-08-15T02:16:00,,No Relation,0.827,D003000,clonidine,D019966,sexual abuse,"Twelve women meeting prospective, DSM-IV criteria for PMDD, five of whom had a history of sexual abuse, participated in a randomized, placebo-controlled, double-blind, cross-over design study, comparing 2 months of on oral clonidine (0.3 mg/day) with 2 months on active placebo.",15925031_2,15925031_D003000_D019966,,
770958216,false,true,5,2015-08-15T00:18:00,,No Relation,1,D003000,clonidine,D065446,PMDD,"Results revealed that in comparison to placebo, clonidine significantly reduced plasma norepinephrine concentrations, increased both beta1- and beta2-AR responsivity, and reduced resting and stress heart rate (HR) and blood pressure (BP) (p < 0.05) in all PMDD women.",15925031_4,15925031_D003000_D065446,,
770958217,false,true,5,2015-08-15T00:15:00,,No Relation,1,D009638,norepinephrine,D007022,stress heart rate (HR) and blood pressure,"Results revealed that in comparison to placebo, clonidine significantly reduced plasma norepinephrine concentrations, increased both beta1- and beta2-AR responsivity, and reduced resting and stress heart rate (HR) and blood pressure (BP) (p < 0.05) in all PMDD women.",15925031_4,15925031_D009638_D007022,,
770958218,false,true,5,2015-08-15T02:26:00,,No Relation,1,D003000,clonidine,D007022,stress heart rate (HR) and blood pressure,"Results revealed that in comparison to placebo, clonidine significantly reduced plasma norepinephrine concentrations, increased both beta1- and beta2-AR responsivity, and reduced resting and stress heart rate (HR) and blood pressure (BP) (p < 0.05) in all PMDD women.",15925031_4,15925031_D003000_D007022,,
770958219,false,true,5,2015-08-15T01:16:00,,No Relation,1,D009638,norepinephrine,D065446,PMDD,"Results revealed that in comparison to placebo, clonidine significantly reduced plasma norepinephrine concentrations, increased both beta1- and beta2-AR responsivity, and reduced resting and stress heart rate (HR) and blood pressure (BP) (p < 0.05) in all PMDD women.",15925031_4,15925031_D009638_D065446,,
770958220,false,true,5,2015-08-14T22:24:00,,No Relation,1,D003000,clonidine,D065446,PMDD,"With clonidine, sexually abused PMDD women exhibited greater decreases in resting and stress-induced HR (p < 0.01) and stress-induced systolic BP (p < 0.05), while non-abused PMDD women exhibited greater reductions in plasma NE concentration (p = 0.07), and greater increases in beta2-AR responsivity (p < 0.05) than abused PMDD women.",15925031_5,15925031_D003000_D065446,,
770958221,false,true,5,2015-08-15T00:54:00,,No Relation,1,D003000,clonidine,D065446,PMDD,"These results suggest PMDD women with and without a history of sexual abuse respond differently to a clonidine challenge in measures reflecting autonomic nervous system functioning, indicating that abuse may modify presynaptic alpha2-AR function in PMDD.",15925031_6,15925031_D003000_D065446,,
770958222,false,true,5,2015-08-15T02:01:00,,No Relation,1,D003000,clonidine,D019966,sexual abuse,"These results suggest PMDD women with and without a history of sexual abuse respond differently to a clonidine challenge in measures reflecting autonomic nervous system functioning, indicating that abuse may modify presynaptic alpha2-AR function in PMDD.",15925031_6,15925031_D003000_D019966,,
770958223,false,true,5,2015-08-15T01:57:00,,No Relation,0.8288,D005947,glucose,D003929,diabetic,Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin.,15931603_0,15931603_D005947_D003929,,
770958224,false,true,5,2015-08-14T21:49:00,,No Relation,1,D005947,glucose,D009765,obese,Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin.,15931603_0,15931603_D005947_D009765,,
770958225,false,true,5,2015-08-15T01:19:00,,No Relation,1,D005947,glucose,D003929,diabetic,"The mechanism of the blood glucose-lowering effect of a 2-day very low calorie diet (VLCD; 1890 kJ/d) in combination with the cessation of all blood glucose-lowering agents was studied in 12 (7 women, 5 men) obese (body mass index, 36.3 +/- 1.0 kg/m 2 [mean +/- SEM]) type 2 diabetic patients (age, 55 +/- 4 years; HbA 1c , 7.3% +/- 0.4%) undergoing insulin therapy.",15931603_1,15931603_D005947_D003929,,
770958226,false,true,5,2015-08-14T22:01:00,,No Relation,1,D005947,glucose,D009765,obese,"The mechanism of the blood glucose-lowering effect of a 2-day very low calorie diet (VLCD; 1890 kJ/d) in combination with the cessation of all blood glucose-lowering agents was studied in 12 (7 women, 5 men) obese (body mass index, 36.3 +/- 1.0 kg/m 2 [mean +/- SEM]) type 2 diabetic patients (age, 55 +/- 4 years; HbA 1c , 7.3% +/- 0.4%) undergoing insulin therapy.",15931603_1,15931603_D005947_D009765,,
770958227,false,true,5,2015-08-14T21:15:00,,No Relation,1,D005947,glucose,D006946,hyperinsulinemia,"During hyperinsulinemia, EGP (5.5 +/- 0.8 to 5.2 +/- 0.5 mu mol/kg per minute), whole body glucose disposal (12.1 +/- 0.7 to 11.3 +/- 1.0 mu mol/kg per minute), the metabolic clearance rate of glucose, and the rate of lipolysis did not change after the 2-day intervention.",15931603_6,15931603_D005947_D006946,,
770958228,false,true,5,2015-08-14T23:22:00,No relationship found.,No Relation,1,D005947,glucose,D006943,hyperglycemia,Cessation of blood glucose-lowering therapy in combination with a 2-day VLCD does not lead to hyperglycemia and is associated with a reduction in basal EGP.,15931603_7,15931603_D005947_D006943,,
770958229,false,true,5,2015-08-15T02:12:00,,No Relation,1,D004967,estrogen,D007249,inflammatory,Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.,15953991_0,15953991_D004967_D007249,,
770958230,false,true,5,2015-08-14T22:55:00,,No Relation,1,D004958,17beta-estradiol,D007249,inflammatory,"SERMs but not 17beta-estradiol induced a significant, concentration-dependent anti-inflammatory response both in rat primary microglial cells and in mouse N9 microglial cells.",15953991_5,15953991_D004958_D007249,,
770958231,false,true,5,2015-08-14T23:51:00,'anti' being the key term.,No Relation,1,D020849,raloxifene,D007249,inflammatory,"Our results show that tamoxifen, raloxifene and ICI 182.780 induce an anti-inflammatory response in acute models of mouse and rat microglial cells.",15953991_12,15953991_D020849_D007249,,
770958232,false,true,5,2015-08-14T23:24:00,,No Relation,1,D013629,tamoxifen,D007249,inflammatory,"Our results show that tamoxifen, raloxifene and ICI 182.780 induce an anti-inflammatory response in acute models of mouse and rat microglial cells.",15953991_12,15953991_D013629_D007249,,
770958233,false,true,5,2015-08-14T22:19:00,,No Relation,0.6214,C070081,ICI 182.780,D007249,inflammatory,"Our results show that tamoxifen, raloxifene and ICI 182.780 induce an anti-inflammatory response in acute models of mouse and rat microglial cells.",15953991_12,15953991_C070081_D007249,,
770958234,false,true,5,2015-08-15T00:20:00,,No Relation,1,D004967,estrogen,D007249,inflammatory,"It seems that this response is not estrogen receptor-mediated but, probably, is attributable to some SERM-induced modulation of LPS-activated pro-inflammatory signalling cascades.",15953991_13,15953991_D004967_D007249,,
770958235,false,true,5,2015-08-15T00:23:00,,No Relation,1,D009569,Nitric oxide,D000544,Alzheimer's disease,Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease.,15974915_0,15974915_D009569_D000544,,
770958236,false,true,5,2015-08-15T00:05:00,,No Relation,1,D009569,NO,D003704,dementia,"Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimer's disease.",15974915_2,15974915_D009569_D003704,,
770958237,false,true,5,2015-08-14T21:37:00,,No Relation,1,D009569,NO,D000544,Alzheimer's disease,"Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimer's disease.",15974915_2,15974915_D009569_D000544,,
770958238,false,true,5,2015-08-15T00:58:00,,No Relation,1,D009569,NO,D003704,dementia,"Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia.",15974915_4,15974915_D009569_D003704,,
770958239,false,true,5,2015-08-15T00:30:00,,No Relation,1,D011092,polyethylene glycol,C531816,ADA deficiency/adenosine deaminase/ADA,polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.,16002636_0,16002636_D011092_C531816,,
770958240,false,true,5,2015-08-15T01:40:00,,No Relation,1,D000241,adenosine,C531816,ADA deficiency/adenosine deaminase/ADA,polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.,16002636_0,16002636_D000241_C531816,,
770958241,false,true,5,2015-08-15T00:18:00,,No Relation,1,D011092,polyethylene glycol,C531816,ADA deficiency/adenosine deaminase/ADA,"We describe the effects of polyethylene glycol-conjugated adenosine deaminase (ADA) replacement therapy on lymphocyte counts, activation, apoptosis, proliferation, and cytokine secretion in a 14-month-old girl with ""delayed-onset"" ADA deficiency and marked immunodysregulation.",16002636_1,16002636_D011092_C531816,,
770958242,false,true,5,2015-08-15T00:08:00,,No Relation,1,D000241,adenosine,C531816,ADA deficiency/adenosine deaminase/ADA,"We describe the effects of polyethylene glycol-conjugated adenosine deaminase (ADA) replacement therapy on lymphocyte counts, activation, apoptosis, proliferation, and cytokine secretion in a 14-month-old girl with ""delayed-onset"" ADA deficiency and marked immunodysregulation.",16002636_1,16002636_D000241_C531816,,
770958243,false,true,5,2015-08-15T01:06:00,,No Relation,0.5815,C056507,gemcitabine,D006463,Hemolytic-uremic syndrome,Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.,16006690_0,16006690_C056507_D006463,,
770958244,false,true,5,2015-08-14T21:04:00,,Direct,0.8173,D016685,mitomycin,D006463,Hemolytic uremic syndrome,"Hemolytic uremic syndrome may be associated with a variety of etiologies, and chemotherapeutic agents have also been reported to be associated with hemolytic uremic syndrome, including mitomycin, cisplatin, bleomycin, and most recently gemcitabine.",16006690_2,16006690_D016685_D006463,,
770958245,false,true,5,2015-08-14T22:05:00,,Direct,0.8248,D002945,cisplatin,D006463,Hemolytic uremic syndrome,"Hemolytic uremic syndrome may be associated with a variety of etiologies, and chemotherapeutic agents have also been reported to be associated with hemolytic uremic syndrome, including mitomycin, cisplatin, bleomycin, and most recently gemcitabine.",16006690_2,16006690_D002945_D006463,,
770958246,false,true,5,2015-08-14T23:32:00,,Direct,1,D001761,bleomycin,D006463,Hemolytic uremic syndrome,"Hemolytic uremic syndrome may be associated with a variety of etiologies, and chemotherapeutic agents have also been reported to be associated with hemolytic uremic syndrome, including mitomycin, cisplatin, bleomycin, and most recently gemcitabine.",16006690_2,16006690_D001761_D006463,,
770958247,false,true,5,2015-08-14T23:01:00,,Direct,0.8075,C056507,gemcitabine,D006463,Hemolytic uremic syndrome,"Hemolytic uremic syndrome may be associated with a variety of etiologies, and chemotherapeutic agents have also been reported to be associated with hemolytic uremic syndrome, including mitomycin, cisplatin, bleomycin, and most recently gemcitabine.",16006690_2,16006690_C056507_D006463,,
770958248,false,true,5,2015-08-14T23:31:00,,Direct,0.7967,C056507,gemcitabine,D006463,hemolytic uremic syndrome,"A 72-year-old Caucasian male treated with four cycles of gemcitabine at 1,000 mg/m2 developed clinical and laboratory findings compatible with hemolytic uremic syndrome.",16006690_3,16006690_C056507_D006463,,
770958249,false,true,5,2015-08-14T23:43:00,,No Relation,0.5973,C056507,gemcitabine,D006463,hemolytic uremic syndrome,"With multiple reports of hemolytic uremic syndrome complicating gemcitabine therapy, it is imperative that clinicians heighten their awareness of this potentially lethal complication.",16006690_6,16006690_C056507_D006463,,
770958250,false,true,5,2015-08-14T22:29:00,,Direct,0.8125,D000070,Acebutolol,D008178,cutaneous lupus erythematosus,Acebutolol-induced subacute cutaneous lupus erythematosus.,16015021_0,16015021_D000070_D008178,,
770958251,false,true,5,2015-08-15T01:59:00,,Direct,0.8168,D000070,acebutolol,D008178,SCLE,We present herein the first case of SCLE induced by acebutolol.,16015021_2,16015021_D000070_D008178,,
770958252,false,true,5,2015-08-15T00:03:00,,No Relation,1,D000070,acebutolol,D006973,hypertension,"One month ago, the patient had started a treatment with oral acebutolol to cure a hypertension of 1-year evolution.",16015021_4,16015021_D000070_D006973,,
770958253,false,true,5,2015-08-15T01:35:00,,Direct,1,D000070,acebutolol,C536397,lupus syndrome,"Literature data, along with our case, suggest a link between acebutolol therapy and the onset of a lupus syndrome.",16015021_8,16015021_D000070_C536397,,
770958254,false,true,5,2015-08-15T02:05:00,,No Relation,0.8011,D000070,acebutolol,D008180,lupus erythematosus,"Although this is the first report of acebutolol-induced SCLE, we should be aware of this occurrence, and avoidance of acebutolol is recommended in patients with stigmata of lupus erythematosus.",16015021_9,16015021_D000070_D008180,,
770958255,false,true,5,2015-08-14T22:28:00,,Direct,1,D000070,acebutolol,D008178,SCLE,"Although this is the first report of acebutolol-induced SCLE, we should be aware of this occurrence, and avoidance of acebutolol is recommended in patients with stigmata of lupus erythematosus.",16015021_9,16015021_D000070_D008178,,
770958256,false,true,5,2015-08-15T00:02:00,,No Relation,1,D004967,estrogens,D014947,traumatic injuries,"For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system.",16024758_4,16024758_D004967_D014947,,
770958257,false,true,5,2015-08-15T01:47:00,,No Relation,1,D004967,estrogens,D016609,HT,"For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system.",16024758_4,16024758_D004967_D016609,,
770958258,false,true,5,2015-08-14T21:29:00,,No Relation,1,D011374,progesterone,D014947,traumatic injuries,"For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system.",16024758_4,16024758_D011374_D014947,,
770958259,false,true,5,2015-08-14T22:08:00,,No Relation,1,D011374,progesterone,D016609,HT,"For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system.",16024758_4,16024758_D011374_D016609,,
770958260,false,true,5,2015-08-14T21:57:00,,No Relation,0.7978,D011374,progesterone,D016609,HT,"This article reviews some of those properties and discusses the evidence suggesting that, if HT is to be reconsidered, progesterone should be given more attention as a potent neurotrophic agent that may play an important role in reducing or preventing motor, cognitive, and sensory impairments that can accompany senescence in both males and females.",16024758_5,16024758_D011374_D016609,,
770958261,false,true,5,2015-08-14T23:58:00,,No Relation,1,D011374,progesterone,D034381,sensory impairments,"This article reviews some of those properties and discusses the evidence suggesting that, if HT is to be reconsidered, progesterone should be given more attention as a potent neurotrophic agent that may play an important role in reducing or preventing motor, cognitive, and sensory impairments that can accompany senescence in both males and females.",16024758_5,16024758_D011374_D034381,,
770958262,false,true,5,2015-08-15T02:32:00,,No Relation,1,C008047,3-hydroxy-3-methylglutaryl coenzyme A,D009369,rectal cancer,"To assess whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, might enhance the efficacy of neoadjuvant chemoradiation in rectal cancer.",16029794_1,16029794_C008047_D009369,,
770958263,false,true,5,2015-08-15T00:59:00,,No Relation,1,D002045,bupivacaine,D010146,pain,To evaluate the efficacy of intraoperative infusion of bupivacaine solution for the relief of pain after operative gynecologic laparoscopy.,16036193_1,16036193_D002045_D010146,,
770958264,false,true,5,2015-08-15T02:00:00,,No Relation,1,D002045,bupivacaine,D015746,AVP,"Intraperitoneal bupivacaine administration both immediately after placement of trocars and at the end of surgery was found to be effective in reducing the intensity of AVP but not in reducing STP, APP, or postoperative analgesia consumption after nonadvanced gynecologic laparoscopic procedures.",16036193_13,16036193_D002045_D015746,,
770958265,false,true,5,2015-08-14T21:18:00,,No Relation,1,D009020,morphine,D009369,delirious cancer,Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.,16043013_0,16043013_D009020_D009369,,
770958266,false,true,5,2015-08-15T01:45:00,,No Relation,1,D005283,fentanyl,D009369,delirious cancer,Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.,16043013_0,16043013_D005283_D009369,,
770958267,false,true,5,2015-08-14T21:02:00,,No Relation,1,D005283,fentanyl,D009759,opioid rotation,"Although recent studies suggest that opioid rotation could be an effective treatment strategy for morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl.",16043013_1,16043013_D005283_D009759,,
770958268,false,true,5,2015-08-15T01:47:00,,No Relation,1,D005283,fentanyl,D003693,delirium,"Although recent studies suggest that opioid rotation could be an effective treatment strategy for morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl.",16043013_1,16043013_D005283_D003693,,
770958269,false,true,5,2015-08-14T21:29:00,,Direct,0.6005,D009020,morphine,D003693,delirium,"Although recent studies suggest that opioid rotation could be an effective treatment strategy for morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl.",16043013_1,16043013_D009020_D003693,,
770958270,false,true,5,2015-08-15T00:20:00,,No Relation,1,D009020,morphine,D009759,opioid rotation,"Although recent studies suggest that opioid rotation could be an effective treatment strategy for morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl.",16043013_1,16043013_D009020_D009759,,
770958271,false,true,5,2015-08-14T21:19:00,,No Relation,1,D005283,fentanyl,D009759,opioid rotation,The primary aim of this study was to clarify the efficacy of opioid rotation from morphine to fentanyl in symptom palliation of morphine-induced delirium.,16043013_2,16043013_D005283_D009759,,
770958272,false,true,5,2015-08-14T23:21:00,,No Relation,1,D005283,fentanyl,D003693,delirium,The primary aim of this study was to clarify the efficacy of opioid rotation from morphine to fentanyl in symptom palliation of morphine-induced delirium.,16043013_2,16043013_D005283_D003693,,
770958273,false,true,5,2015-08-14T22:30:00,,Direct,1,D009020,morphine,D003693,delirium,The primary aim of this study was to clarify the efficacy of opioid rotation from morphine to fentanyl in symptom palliation of morphine-induced delirium.,16043013_2,16043013_D009020_D003693,,
770958274,false,true,5,2015-08-14T21:01:00,,No Relation,0.795,D009020,morphine,D009759,opioid rotation,The primary aim of this study was to clarify the efficacy of opioid rotation from morphine to fentanyl in symptom palliation of morphine-induced delirium.,16043013_2,16043013_D009020_D009759,,
770958275,false,true,5,2015-08-15T00:15:00,,No Relation,1,D009020,morphine,D009369,cancer,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D009020_D009369,,
770958276,false,true,5,2015-08-15T00:57:00,,No Relation,0.8375,D005283,fentanyl,D003693,delirium,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D005283_D003693,,
770958277,false,true,5,2015-08-14T21:25:00,,No Relation,1,D005283,fentanyl,D009369,cancer,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D005283_D009369,,
770958278,false,true,5,2015-08-14T23:29:00,,No Relation,1,D005283,fentanyl,D009759,opioid rotation,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D005283_D009759,,
770958279,false,true,5,2015-08-15T00:02:00,,Direct,0.8073,D009020,morphine,D003693,delirium,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D009020_D003693,,
770958280,false,true,5,2015-08-15T01:51:00,,Direct,0.7834,D009020,morphine,D009759,opioid rotation,Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl.,16043013_3,16043013_D009020_D009759,,
770958281,false,true,5,2015-08-14T21:37:00,,No Relation,1,D009020,morphine,D009369,cancer,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D009020_D009369,,
770958282,false,true,5,2015-08-15T02:02:00,,No Relation,1,D005283,fentanyl,D003693,delirium,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D005283_D003693,,
770958283,false,true,5,2015-08-14T21:47:00,,No Relation,0.7968,D009020,morphine,D010146,pain,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D009020_D010146,,
770958284,false,true,5,2015-08-14T21:47:00,,No Relation,1,D005283,fentanyl,D009369,cancer,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D005283_D009369,,
770958285,false,true,5,2015-08-15T02:33:00,,No Relation,0.8113,D005283,fentanyl,D010146,pain,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D005283_D010146,,
770958286,false,true,5,2015-08-14T21:14:00,,Direct,0.7928,D009020,morphine,D003693,delirium,Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium.,16043013_12,16043013_D009020_D003693,,
770958287,false,true,5,2015-08-14T21:29:00,,No Relation,0.8024,D014212,Retinoic acid,D009369,cancer,Retinoic acid-induced downmodulation of telomerase activity in human cancer cells.,16054129_0,16054129_D014212_D009369,,
770958288,false,true,5,2015-08-14T22:22:00,,No Relation,1,D014284,triiodothyronine,D003865,major depressive disorder,An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.,16086620_0,16086620_D014284_D003865,,
770958289,false,true,5,2015-08-14T21:12:00,,No Relation,1,D012701,serotonin,D003865,major depressive disorder,An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.,16086620_0,16086620_D012701_D003865,,
770958290,false,true,5,2015-08-14T22:24:00,,No Relation,1,D014284,triiodothyronine,D003865,major depressive disorder/MDD,"In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment.",16086620_1,16086620_D014284_D003865,,
770958291,false,true,5,2015-08-14T21:27:00,,No Relation,1,D017367,SSRI,D003865,major depressive disorder/MDD,"In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment.",16086620_1,16086620_D017367_D003865,,
770958292,false,true,5,2015-08-14T21:18:00,,No Relation,1,D012701,serotonin,D003865,major depressive disorder/MDD,"In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment.",16086620_1,16086620_D012701_D003865,,
770958293,false,true,5,2015-08-14T23:55:00,,No Relation,1,D014284,Triiodothyronine,D003865,MDD,"Triiodothyronine augmentation of SSRIs may be a promising treatment strategy in SSRI-resistant MDD, particularly in subjects with the atypical MDD subtype.",16086620_9,16086620_D014284_D003865,,
770958294,false,true,5,2015-08-15T02:31:00,,No Relation,1,C402769,Tipifarnib/R115777,D009369,breast cancer,"Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.",16101130_0,16101130_C402769_D009369,,
770958295,false,true,5,2015-08-14T21:19:00,,No Relation,1,C402769,R115777,D009369,breast cancer,"Farnesyltransferase inhibitor R115777 (Tipifamib, Zarnestra) is active in breast cancer, but its efficacy in drug combinations has not been extensively investigated.",16101130_1,16101130_C402769_D009369,,
770958296,false,true,5,2015-08-15T00:54:00,,No Relation,1,D017239,paclitaxel,D009369,tumor/breast cancer,"The activity of R115777 and paclitaxel, alone and in combination, was studied in the human breast cancer cell lines, BT-474 (overexpressed HER2/neu) and MDA-MB-231 (low HER2/neu), with cell viability and biomarkers for farnesylation (HDJ-2, Rho B), tumor growth (Raf/MEK/ERK), survival (PI3K/Akt) and angiogenesis (VEGF, FGF-2, MMP-1, MMP-2, MMP-9) as the endpoints.",16101130_2,16101130_D017239_D009369,,
770958297,false,true,5,2015-08-15T02:04:00,,No Relation,1,C402769,R115777,D009369,tumor/breast cancer,"The activity of R115777 and paclitaxel, alone and in combination, was studied in the human breast cancer cell lines, BT-474 (overexpressed HER2/neu) and MDA-MB-231 (low HER2/neu), with cell viability and biomarkers for farnesylation (HDJ-2, Rho B), tumor growth (Raf/MEK/ERK), survival (PI3K/Akt) and angiogenesis (VEGF, FGF-2, MMP-1, MMP-2, MMP-9) as the endpoints.",16101130_2,16101130_C402769_D009369,,
770958298,false,true,5,2015-08-15T00:16:00,,No Relation,1,C045645,cilostazol,D007383,claudication,"Symptomatic treatment of claudication includes smoking cessation, exercise, cilostazol, statins, and revascularization with percutaneous or surgical therapy.",16105478_4,16105478_C045645_D007383,,
770958299,false,true,5,2015-08-14T21:16:00,,No Relation,1,D019821,statins,D007383,claudication,"Symptomatic treatment of claudication includes smoking cessation, exercise, cilostazol, statins, and revascularization with percutaneous or surgical therapy.",16105478_4,16105478_D019821_D007383,,
770958300,false,true,5,2015-08-14T21:03:00,,No Relation,1,D001241,aspirin,D007383,claudication,Antithrombotic therapy with aspirin or clopidogrel is important to reduce cardiovascular events but does not affect symptoms of claudication.,16105478_5,16105478_D001241_D007383,,
770958301,false,true,5,2015-08-14T22:27:00,,No Relation,1,C055162,clopidogrel,D007383,claudication,Antithrombotic therapy with aspirin or clopidogrel is important to reduce cardiovascular events but does not affect symptoms of claudication.,16105478_5,16105478_C055162_D007383,,
770958302,false,true,5,2015-08-15T01:54:00,,No Relation,1,C099154,Ruboxistaurin,D020151,protein kinase C,"Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.",16160002_0,16160002_C099154_D020151,,
770958303,false,true,5,2015-08-14T21:41:00,,No Relation,1,C099154,ruboxistaurin/LY333531,D020151,PKC/protein kinase C,"To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor of protein kinase C (PKC) beta, and its role to potentially reduce the development and/or the progression of diabetic microvascular complications.",16160002_1,16160002_C099154_D020151,,
770958304,false,true,5,2015-08-15T00:18:00,,No Relation,0.798,D008698,mesylate,D020151,PKC/protein kinase C,"To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor of protein kinase C (PKC) beta, and its role to potentially reduce the development and/or the progression of diabetic microvascular complications.",16160002_1,16160002_D008698_D020151,,
770958305,false,true,5,2015-08-14T23:36:00,,No Relation,1,C099154,ruboxistaurin,D020151,PKC,"Literature relevant to PKC physiology, the pharmacokinetics of ruboxistaurin, and data evaluating the use of ruboxistaurin in treating diabetic microvascular complications in human and relevant animal models was reviewed.",16160002_3,16160002_C099154_D020151,,
770958306,false,true,5,2015-08-14T21:08:00,,Direct,0.7849,D024841,fluoroquinolone,D052256,tendinopathy,Achilles tendinopathy after treatment with fluoroquinolone.,16174181_0,16174181_D024841_D052256,,
770958307,false,true,5,2015-08-15T02:13:00,,Direct,0.6069,D024841,Fluoroquinolone,D052256,tendinopathy,Fluoroquinolone antibiotic therapy is a recognized but poorly understood cause for Achilles tendinopathy.,16174181_1,16174181_D024841_D052256,,
770958308,false,true,5,2015-08-15T00:33:00,,No Relation,0.7959,D014443,tyrosine,D002289,nonsmall cell lung cancer,"Inhibitors of the tyrosine kinase activity associated with this receptor have been approved for the treatment of chemotherapy-refractory nonsmall cell lung cancer, and are in clinical trials for additional tumor types.",16177570_2,16177570_D014443_D002289,,
770958309,false,true,5,2015-08-14T23:51:00,It's 'tyrosine kinase' and not just 'Tyrosine',No Relation,0.8029,D014443,tyrosine,D009369,tumor,"Inhibitors of the tyrosine kinase activity associated with this receptor have been approved for the treatment of chemotherapy-refractory nonsmall cell lung cancer, and are in clinical trials for additional tumor types.",16177570_2,16177570_D014443_D009369,,
770958310,false,true,5,2015-08-14T21:36:00,,No Relation,1,C419708,gefitinib,D009369,tumor,"While these inhibitors, gefitinib and erlotinib, display limited response rates when assessed in cohorts that include all patients, there are subgroups, defined by patient and tumor characteristics, that preferentially respond to these agents.",16177570_3,16177570_C419708_D009369,,
770958311,false,true,5,2015-08-14T21:55:00,,No Relation,1,C400278,erlotinib,D009369,tumor,"While these inhibitors, gefitinib and erlotinib, display limited response rates when assessed in cohorts that include all patients, there are subgroups, defined by patient and tumor characteristics, that preferentially respond to these agents.",16177570_3,16177570_C400278_D009369,,
770958312,false,true,5,2015-08-14T21:02:00,,No Relation,1,C400278,erlotinib,D005909,glioblastoma,"We recently performed an analysis of tumors obtained from a Phase I trial of erlotinib in patients with glioblastoma multiforme (GBM), the most common malignant brain tumor in adults.",16177570_4,16177570_C400278_D005909,,
770958313,false,true,5,2015-08-15T00:31:00,,No Relation,1,C400278,erlotinib,D001932,brain tumor,"We recently performed an analysis of tumors obtained from a Phase I trial of erlotinib in patients with glioblastoma multiforme (GBM), the most common malignant brain tumor in adults.",16177570_4,16177570_C400278_D001932,,
770958314,false,true,5,2015-08-15T01:43:00,,No Relation,1,C400278,erlotinib,D009369,tumors,"We recently performed an analysis of tumors obtained from a Phase I trial of erlotinib in patients with glioblastoma multiforme (GBM), the most common malignant brain tumor in adults.",16177570_4,16177570_C400278_D009369,,
770958315,false,true,5,2015-08-15T01:24:00,,No Relation,1,D005947,glucose,D006973,hypertension,"Children and adolescents were classified as having the metabolic syndrome if they met three or more of the following criteria: hypertriglyceridemia, low levels of high-density lipoprotein (HDL), high fasting glucose, obesity, and hypertension.",16189445_3,16189445_D005947_D006973,,
770958316,false,true,5,2015-08-14T22:17:00,,No Relation,0.6049,D005947,glucose,D008659,metabolic syndrome,"Children and adolescents were classified as having the metabolic syndrome if they met three or more of the following criteria: hypertriglyceridemia, low levels of high-density lipoprotein (HDL), high fasting glucose, obesity, and hypertension.",16189445_3,16189445_D005947_D008659,,
770958317,false,true,5,2015-08-14T22:00:00,,No Relation,0.7989,D005947,glucose,D009765,"glucose, obesity","Children and adolescents were classified as having the metabolic syndrome if they met three or more of the following criteria: hypertriglyceridemia, low levels of high-density lipoprotein (HDL), high fasting glucose, obesity, and hypertension.",16189445_3,16189445_D005947_D009765,,
770958318,false,true,5,2015-08-15T00:54:00,,No Relation,1,D005947,glucose,D015228,hypertriglyceridemia,"Children and adolescents were classified as having the metabolic syndrome if they met three or more of the following criteria: hypertriglyceridemia, low levels of high-density lipoprotein (HDL), high fasting glucose, obesity, and hypertension.",16189445_3,16189445_D005947_D015228,,
770958319,false,true,5,2015-08-15T00:43:00,,No Relation,1,D005947,glucose,D008659,metabolic syndrome,"Three criteria for the metabolic syndrome (high triglyceride levels, glucose intolerance, and obesity) were fulfilled by three subjects (5.76%).",16189445_12,16189445_D005947_D008659,,
770958320,false,true,5,2015-08-14T23:43:00,,No Relation,1,D005947,glucose,D009765,obesity,"Three criteria for the metabolic syndrome (high triglyceride levels, glucose intolerance, and obesity) were fulfilled by three subjects (5.76%).",16189445_12,16189445_D005947_D009765,,
770958321,false,true,5,2015-08-14T21:05:00,,No Relation,1,D005947,glucose,D018149,glucose intolerance,"Three criteria for the metabolic syndrome (high triglyceride levels, glucose intolerance, and obesity) were fulfilled by three subjects (5.76%).",16189445_12,16189445_D005947_D018149,,
770958322,false,true,5,2015-08-14T23:03:00,,Direct,0.5968,D047228,sartans,D006973,hypertensive,We report two cases of adverse fetal outcome in hypertensive pregnancies exposed to sartans.,16203601_3,16203601_D047228_D006973,,
770958323,false,true,5,2015-08-15T01:06:00,,No Relation,1,D000255,ATP,D012480,Salmonella,"We showed that the cell-free culture supernatant of L. acidophilus strain LB (LB-CFCS) induced the following effects in S. enterica SL1344: (i) a decrease in intracellular ATP that paralleled bacterial death, (ii) the release of lipopolysaccharide, (iii) permeabilization of the bacterial membrane, and (iv) an increase in the sensitivity of Salmonella to the lytic action of sodium dodecyl sulfate.",16204528_3,16204528_D000255_D012480,,
770958324,false,true,5,2015-08-15T00:11:00,,Direct,0.6013,D012967,sodium dodecyl sulfate,D012480,Salmonella,"We showed that the cell-free culture supernatant of L. acidophilus strain LB (LB-CFCS) induced the following effects in S. enterica SL1344: (i) a decrease in intracellular ATP that paralleled bacterial death, (ii) the release of lipopolysaccharide, (iii) permeabilization of the bacterial membrane, and (iv) an increase in the sensitivity of Salmonella to the lytic action of sodium dodecyl sulfate.",16204528_3,16204528_D012967_D012480,,
770958325,false,true,5,2015-08-14T23:20:00,Used in treatment.,No Relation,1,D000109,acetylcholine,D010300,Parkinson's disease,Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.,16210393_0,16210393_D000109_D010300,,
770958326,false,true,5,2015-08-14T21:47:00,,No Relation,0.8154,D009538,nicotine,D010300,Parkinson's disease,This latter observation coupled with the finding that nicotine protects against nigrostriatal damage suggest that alpha6(*) nAChRs may represent unique targets for neurodegenerative disorders linked to the nigrostriatal system such as Parkinson's disease.,16210393_7,16210393_D009538_D010300,,
770958327,false,true,5,2015-08-14T21:25:00,,No Relation,1,D009538,nicotine,D019636,neurodegenerative disorders,This latter observation coupled with the finding that nicotine protects against nigrostriatal damage suggest that alpha6(*) nAChRs may represent unique targets for neurodegenerative disorders linked to the nigrostriatal system such as Parkinson's disease.,16210393_7,16210393_D009538_D019636,,
770958328,false,true,5,2015-08-15T01:16:00,,No Relation,1,D008687,metformin,D011085,PCOS,"Treatment with insulin sensitizers, metformin, and thiazolidinediones (TZDs) improve both metabolic and hormonal patterns and also improve ovulation in PCOS.",16217983_6,16217983_D008687_D011085,,
770958329,false,true,5,2015-08-15T00:49:00,,No Relation,1,D045162,thiazolidinediones/TZDs,D011085,PCOS,"Treatment with insulin sensitizers, metformin, and thiazolidinediones (TZDs) improve both metabolic and hormonal patterns and also improve ovulation in PCOS.",16217983_6,16217983_D045162_D011085,,
770958330,false,true,5,2015-08-15T00:05:00,,No Relation,1,D009569,nitric oxide/NO,D009336,necrosis,"EP has been shown to decrease the expression of various pro-inflammatory mediators, including nitric oxide (NO*), tumor necrosis factor (TNF), cyclooxygenase-2, and interleukin (IL)-6, in a variety of in vitro and in vivo model systems.",16226725_2,16226725_D009569_D009336,,
770958331,false,true,5,2015-08-14T22:39:00,,No Relation,1,D009569,nitric oxide/NO,D009369,tumor,"EP has been shown to decrease the expression of various pro-inflammatory mediators, including nitric oxide (NO*), tumor necrosis factor (TNF), cyclooxygenase-2, and interleukin (IL)-6, in a variety of in vitro and in vivo model systems.",16226725_2,16226725_D009569_D009369,,
770958332,false,true,5,2015-08-15T02:17:00,,No Relation,1,D014280,triacylglycerol,D018205,ADRP,"When J774 murine macrophages were incubated with either VLDL or oleic acid, their content of both ADRP and triacylglycerol (TG) increased 3- to 4-fold.",16230742_3,16230742_D014280_D018205,,
770958333,false,true,5,2015-08-14T22:07:00,,Direct,0.7935,D019301,oleic acid,D018205,ADRP,"When J774 murine macrophages were incubated with either VLDL or oleic acid, their content of both ADRP and triacylglycerol (TG) increased 3- to 4-fold.",16230742_3,16230742_D019301_D018205,,
770958334,false,true,5,2015-08-14T21:13:00,,Direct,0.6312,D019301,oleic acid,D018205,ADRP,Induction of ADRP during TG accumulation was also observed in oleic acid-treated HuH-7 human liver cells.,16230742_4,16230742_D019301_D018205,,
770958335,false,true,5,2015-08-15T02:05:00,,No Relation,0.7967,C034613,triacsin C,D018205,ADRP,"Addition of triacsin C, a potent inhibitor of acyl-CoA synthase, for 6 h decreased the amount of TG in VLDL-induced foam cells and oleic acid-treated liver cells; it decreased the amount of ADRP protein in parallel, indicating the amount of ADRP reduced during regression of the lipid-storing cells.",16230742_5,16230742_C034613_D018205,,
770958336,false,true,5,2015-08-14T23:45:00,,No Relation,1,D000214,acyl-CoA,D018205,ADRP,"Addition of triacsin C, a potent inhibitor of acyl-CoA synthase, for 6 h decreased the amount of TG in VLDL-induced foam cells and oleic acid-treated liver cells; it decreased the amount of ADRP protein in parallel, indicating the amount of ADRP reduced during regression of the lipid-storing cells.",16230742_5,16230742_D000214_D018205,,
770958337,false,true,5,2015-08-15T00:31:00,,No Relation,1,D019301,oleic acid,D018205,ADRP,"Addition of triacsin C, a potent inhibitor of acyl-CoA synthase, for 6 h decreased the amount of TG in VLDL-induced foam cells and oleic acid-treated liver cells; it decreased the amount of ADRP protein in parallel, indicating the amount of ADRP reduced during regression of the lipid-storing cells.",16230742_5,16230742_D019301_D018205,,
770958338,false,true,5,2015-08-15T01:25:00,,No Relation,0.7962,C034613,triacsin C,D018205,ADRP,Addition of a proteasome inhibitor during triacsin C treatment abolished the ADRP decrease and accumulated polyubiquitinated ADRP.,16230742_6,16230742_C034613_D018205,,
770958339,false,true,5,2015-08-15T00:50:00,,No Relation,0.7874,C034613,triacsin C,D018205,ADRP,"In addition, the proteasome inhibitor reversed not only the degradation of ADRP but also TG reduction by triacsin C. These results suggest that cellular amounts of ADRP and TG regulate each other and that the ubiquitin-proteasome system is involved in degradation of ADRP during regression of lipid-storing cells.",16230742_7,16230742_C034613_D018205,,
770958340,false,true,5,2015-08-14T21:24:00,,No Relation,1,D043823,taxanes,D009369,breast cancer,Trastuzumab has been repeatedly shown to result in significant clinical benefits and was subsequently accepted as the treatment of choice for HER2-positive advanced breast cancer - particularly as first-line treatment in combination with taxanes and as monotherapy in the second-line or third-line setting.,16249641_1,16249641_D043823_D009369,,
770958341,false,true,5,2015-08-14T21:32:00,,No Relation,1,C110904,capecitabine,D009369,breast cancer,"We determined the safety of i.v. trastuzumab (8 mg/kg followed by 6 mg/kg) every 3 weeks in combination with chemotherapeutic agents administered in 3-weekly courses (docetaxel, vinorelbine and capecitabine) in 31 patients with HER2-positive recurrent locoregional and/or metastatic breast cancer.",16249641_3,16249641_C110904_D009369,,
770958342,false,true,5,2015-08-14T22:46:00,,No Relation,1,C030852,vinorelbine,D009369,breast cancer,"We determined the safety of i.v. trastuzumab (8 mg/kg followed by 6 mg/kg) every 3 weeks in combination with chemotherapeutic agents administered in 3-weekly courses (docetaxel, vinorelbine and capecitabine) in 31 patients with HER2-positive recurrent locoregional and/or metastatic breast cancer.",16249641_3,16249641_C030852_D009369,,
770958343,false,true,5,2015-08-14T22:19:00,,No Relation,1,C067311,docetaxel,D009369,breast cancer,"We determined the safety of i.v. trastuzumab (8 mg/kg followed by 6 mg/kg) every 3 weeks in combination with chemotherapeutic agents administered in 3-weekly courses (docetaxel, vinorelbine and capecitabine) in 31 patients with HER2-positive recurrent locoregional and/or metastatic breast cancer.",16249641_3,16249641_C067311_D009369,,
770958344,false,true,5,2015-08-14T22:09:00,,No Relation,1,C056507,Gemcitabine,D006689,refractory Hodgkin's disease,Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.,16249642_0,16249642_C056507_D006689,,
770958345,false,true,5,2015-08-15T01:27:00,,No Relation,1,C056507,gemcitabine,D006689,refractory Hodgkin's disease,We treated 14 patients with relapsed or refractory Hodgkin's disease with gemcitabine.,16249642_3,16249642_C056507_D006689,,
770958346,false,true,5,2015-08-14T22:19:00,,No Relation,1,C056507,Gemcitabine,D006689,Hodgkin's disease,Gemcitabine is an effective treatment for Hodgkin's disease.,16249642_18,16249642_C056507_D006689,,
770958347,false,true,5,2015-08-14T22:12:00,,No Relation,1,D007665,ketotifen,D012167,artificial tear substitute,"Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.",16291412_0,16291412_D007665_D012167,,
770958348,false,true,5,2015-08-14T22:19:00,,No Relation,1,C074921,olopatadine,D003233,SAC,The aims of this study were to compare the clinical efficacy of topical ketotifen and olopatadine eye drops and to determine the effects of these 2 drugs on the expression of cell adhesion molecules (CAMs) and inflammatory markers in conjunctival surface cells in patients with SAC.,16291412_4,16291412_C074921_D003233,,
770958349,false,true,5,2015-08-14T23:51:00,,No Relation,1,D007665,ketotifen,D003233,SAC,The aims of this study were to compare the clinical efficacy of topical ketotifen and olopatadine eye drops and to determine the effects of these 2 drugs on the expression of cell adhesion molecules (CAMs) and inflammatory markers in conjunctival surface cells in patients with SAC.,16291412_4,16291412_D007665_D003233,,
770958350,false,true,5,2015-08-15T00:26:00,,No Relation,1,D007665,ketotifen fumarate,D012167,ATS,"Patients with SAC were included in the study and randomly assigned to 1 of 3 groups: topical ketotifen fumarate 0.025% ophthalmic solution, topical olopatadine HCl 0.1% ophthalmic solution, or ATS (control group).",16291412_6,16291412_D007665_D012167,,
770958351,false,true,5,2015-08-14T22:27:00,,No Relation,1,D007665,ketotifen fumarate,D003233,SAC,"Patients with SAC were included in the study and randomly assigned to 1 of 3 groups: topical ketotifen fumarate 0.025% ophthalmic solution, topical olopatadine HCl 0.1% ophthalmic solution, or ATS (control group).",16291412_6,16291412_D007665_D003233,,
770958352,false,true,5,2015-08-15T00:18:00,,No Relation,1,C074921,olopatadine,D012167,ATS,"Twelve patients received ketotifen; 13, olopatadine; and 14, ATS.",16291412_13,16291412_C074921_D012167,,
770958353,false,true,5,2015-08-14T23:43:00,,No Relation,1,D007665,ketotifen,D012167,ATS,"Twelve patients received ketotifen; 13, olopatadine; and 14, ATS.",16291412_13,16291412_D007665_D012167,,
770958354,false,true,5,2015-08-14T21:19:00,,No Relation,1,C074921,olopatadine,D012167,ATS,"In both active-treatment groups, the improvements of clinical scores (tearing and itching) were more pronounced compared with those in the ATS group, although the day-30 difference in tearing score between the olopatadine and ATS groups was not statistically significant.",16291412_14,16291412_C074921_D012167,,
770958355,false,true,5,2015-08-14T21:03:00,,No Relation,1,C074921,olopatadine,D012167,ATS,The expression rates of CAMs and inflammatory markers in conjunctival surface cells were significantly more reduced with ketotifen and olopatadine compared with ATS.,16291412_16,16291412_C074921_D012167,,
770958356,false,true,5,2015-08-15T01:59:00,,No Relation,1,D007665,ketotifen,D012167,ATS,The expression rates of CAMs and inflammatory markers in conjunctival surface cells were significantly more reduced with ketotifen and olopatadine compared with ATS.,16291412_16,16291412_D007665_D012167,,
770958357,false,true,5,2015-08-14T22:43:00,,No Relation,1,C074921,olopatadine,D003233,SAC,"In this short-term study in a selected, small study population with SAC, ketotifen and olopatadine diminished the expression of CAMs and inflammatory markers on the conjunctival surface cells effectively.",16291412_19,16291412_C074921_D003233,,
770958358,false,true,5,2015-08-14T21:40:00,,No Relation,1,D007665,ketotifen,D003233,SAC,"In this short-term study in a selected, small study population with SAC, ketotifen and olopatadine diminished the expression of CAMs and inflammatory markers on the conjunctival surface cells effectively.",16291412_19,16291412_D007665_D003233,,
770958359,false,true,5,2015-08-14T21:34:00,,No Relation,1,D000111,N-acetyl cysteine,D029424,chronic obstructive pulmonary disease,Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: Prevention by N-acetyl cysteine.,16298736_0,16298736_D000111_D029424,,
770958360,false,true,5,2015-08-15T00:01:00,Oxygen is not a chemical.,No Relation,0.5959,D010100,Oxygen,D029424,chronic obstructive pulmonary disease,Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: Prevention by N-acetyl cysteine.,16298736_0,16298736_D010100_D029424,,
770958361,false,true,5,2015-08-14T22:14:00,,Direct,1,D010100,oxygen,D064420,toxicity,Exposure to high oxygen concentration produces toxicity by free radical release.,16298736_1,16298736_D010100_D064420,,
770958362,false,true,5,2015-08-15T01:20:00,,No Relation,0.8285,D000111,N-acetyl-cysteine/NAC,D029424,chronic obstructive pulmonary disease/COPD,We aimed to study: whether stable chronic obstructive pulmonary disease (COPD) patients present an unbalance in the blood redox status; the effect of oxygen administration on blood redox balance; the efficacy of N-acetyl-cysteine (NAC) treatment against the oxidative stress-induced by oxygen administration and whether it is dose-related.,16298736_2,16298736_D000111_D029424,,
770958363,false,true,5,2015-08-15T00:45:00,,No Relation,1,D010100,oxygen,D029424,chronic obstructive pulmonary disease/COPD,We aimed to study: whether stable chronic obstructive pulmonary disease (COPD) patients present an unbalance in the blood redox status; the effect of oxygen administration on blood redox balance; the efficacy of N-acetyl-cysteine (NAC) treatment against the oxidative stress-induced by oxygen administration and whether it is dose-related.,16298736_2,16298736_D010100_D029424,,
770958364,false,true,5,2015-08-14T21:05:00,,No Relation,1,D019803,GSSG,D029424,COPD,"To this, 45 stable state III COPD patients were recruited and reduced glutathione (GSH) and oxidised glutathione (GSSG) in erythrocytes and thiol proteins (P-SH) and carbonyl proteins (PC) in both erythrocytes and plasma were evaluated.",16298736_3,16298736_D019803_D029424,,
770958365,false,true,5,2015-08-15T00:41:00,,No Relation,1,D005978,GSH/glutathione,D029424,COPD,"To this, 45 stable state III COPD patients were recruited and reduced glutathione (GSH) and oxidised glutathione (GSSG) in erythrocytes and thiol proteins (P-SH) and carbonyl proteins (PC) in both erythrocytes and plasma were evaluated.",16298736_3,16298736_D005978_D029424,,
770958366,false,true,5,2015-08-15T00:05:00,,No Relation,1,D000111,NAC,D029424,COPD,All COPD patients underwent 2 l/m oxygen for 18 h and NAC at 1200 or 1800 mg/day or placebo for 48 h starting with oxygen administration.,16298736_4,16298736_D000111_D029424,,
770958367,false,true,5,2015-08-15T01:16:00,,No Relation,1,D010100,oxygen,D029424,COPD,All COPD patients underwent 2 l/m oxygen for 18 h and NAC at 1200 or 1800 mg/day or placebo for 48 h starting with oxygen administration.,16298736_4,16298736_D010100_D029424,,
770958368,false,true,5,2015-08-14T22:10:00,,No Relation,1,D000111,NAC,D029424,COPD,"In conclusion, stable state III COPD patients present an unstable redox balance; long term low flow oxygen administration induces systemic oxidative stress, which is prevented by NAC treatment.",16298736_9,16298736_D000111_D029424,,
770958369,false,true,5,2015-08-15T02:15:00,,No Relation,1,D010100,oxygen,D029424,COPD,"In conclusion, stable state III COPD patients present an unstable redox balance; long term low flow oxygen administration induces systemic oxidative stress, which is prevented by NAC treatment.",16298736_9,16298736_D010100_D029424,,
770958370,false,true,5,2015-08-15T00:10:00,,No Relation,1,D000431,alcohol,D001523,psychiatric,"In the preceding 12 months, respondents who screened positive on the MDQ had greater use of psychiatric hospitals, emergency departments, and urgent care centers and also had more outpatient visits to primary care physicians, psychiatrists, and alcohol treatment centers than those who screened negative.",16339614_6,16339614_D000431_D001523,,
770958371,false,true,5,2015-08-14T21:42:00,,Direct,1,D005947,glucose,D010995,pleural thickening,The development of pleural thickening was related to the level of pleural fluid glucose (p = 0.04).,16340225_9,16340225_D005947_D010995,,
770958372,false,true,5,2015-08-15T00:57:00,,Direct,1,D013629,tamoxifen,D009369,breast cancer/uterine cancer,There is a greater than 7-fold increased risk of uterine cancer in women with breast cancer exposed to tamoxifen.,16352333_1,16352333_D013629_D009369,,
770958373,false,true,5,2015-08-15T00:45:00,,Direct,0.611,D013629,tamoxifen,D009369,uterine cancer,The objective of this study was to determine the percentage of women who developed uterine cancer more than 12 months after discontinuing tamoxifen (past users) and to compare their clinical and pathologic features with those of women who developed uterine cancer while on tamoxifen therapy or within 12 months of stopping therapy (recent users).,16352333_2,16352333_D013629_D009369,,
770958375,false,true,5,2015-08-14T23:23:00,,No Relation,0.6071,D013629,tamoxifen,D009369,breast cancer/uterine cancer,All women with a diagnosis of uterine cancer at Memorial Sloan-Kettering Cancer Center between 1980 and June 2004 with a past history of breast cancer treated with tamoxifen were identified.,16352333_3,16352333_D013629_D009369,,
770958376,false,true,5,2015-08-14T22:17:00,,No Relation,0.7906,D013629,tamoxifen,D009369,breast cancer/uterine cancer,There were 106 women identified with a history of breast cancer treated with tamoxifen preceding their diagnosis of uterine cancer.,16352333_5,16352333_D013629_D009369,,
770958377,false,true,5,2015-08-14T21:38:00,,No Relation,0.8117,D013629,tamoxifen,D009369,uterine cancer,Thirty-nine (37%) developed uterine cancer more than 12 months after discontinuing tamoxifen.,16352333_6,16352333_D013629_D009369,,
770958378,false,true,5,2015-08-14T21:03:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,"There were no significant differences in age at breast cancer diagnosis, body mass index, parity, stage of breast cancer, modality of breast cancer treatment, or duration of tamoxifen therapy between past and recent users of tamoxifen.",16352333_8,16352333_D013629_D009369,,
770958379,false,true,5,2015-08-14T22:22:00,,Direct,0.7929,D013629,tamoxifen,D009369,uterine cancer,More than one third of women treated with tamoxifen develop uterine cancer more than 12 months after discontinuing therapy.,16352333_10,16352333_D013629_D009369,,
770958380,false,true,5,2015-08-15T01:47:00,,No Relation,0.5888,D013629,tamoxifen,D009369,uterine cancer,"Therefore, women with a past history of tamoxifen therapy should have continued surveillance after completion of tamoxifen to ensure early diagnosis of uterine cancer.",16352333_12,16352333_D013629_D009369,,
770958381,false,true,5,2015-08-14T21:33:00,This has no sense.,No Relation,1,D009173,mycophenolic acid/MPA,C531854,mycophenolic acid/MPA,"Therapeutic drug monitoring of mycophenolic acid (MPA) in combination with cyclosporine 2-h concentration (CsA C2, n = 68) or tacrolimus trough concentration (n = 10) was investigated by repeated measurements of MPA and MPA-glucuronide (MPAG) trough concentrations in renal allograft recipients during the first 3 months post-transplant.",16359376_1,16359376_D009173_C531854,,
770958382,false,true,5,2015-08-14T22:27:00,,No Relation,1,D016572,cyclosporine,C531854,mycophenolic acid/MPA,"Therapeutic drug monitoring of mycophenolic acid (MPA) in combination with cyclosporine 2-h concentration (CsA C2, n = 68) or tacrolimus trough concentration (n = 10) was investigated by repeated measurements of MPA and MPA-glucuronide (MPAG) trough concentrations in renal allograft recipients during the first 3 months post-transplant.",16359376_1,16359376_D016572_C531854,,
770958383,false,true,5,2015-08-15T01:00:00,,No Relation,1,D016559,tacrolimus,C531854,mycophenolic acid/MPA,"Therapeutic drug monitoring of mycophenolic acid (MPA) in combination with cyclosporine 2-h concentration (CsA C2, n = 68) or tacrolimus trough concentration (n = 10) was investigated by repeated measurements of MPA and MPA-glucuronide (MPAG) trough concentrations in renal allograft recipients during the first 3 months post-transplant.",16359376_1,16359376_D016559_C531854,,
770958384,false,true,5,2015-08-14T23:16:00,,No Relation,1,C113145,MPA-glucuronide/MPAG,C531854,mycophenolic acid/MPA,"Therapeutic drug monitoring of mycophenolic acid (MPA) in combination with cyclosporine 2-h concentration (CsA C2, n = 68) or tacrolimus trough concentration (n = 10) was investigated by repeated measurements of MPA and MPA-glucuronide (MPAG) trough concentrations in renal allograft recipients during the first 3 months post-transplant.",16359376_1,16359376_C113145_C531854,,
770958385,false,true,5,2015-08-14T21:41:00,,No Relation,1,D009173,MPA,C531854,MPA,"Median MPA concentration was 0.9 and 1.2 microg/ml in patients within or below C2 range, respectively (P = 0.19).",16359376_3,16359376_D009173_C531854,,
770958386,false,true,5,2015-08-15T00:55:00,,No Relation,1,D009173,MPA,C531854,MPA,"CsA C2 correlated with MPAG-to-MPA ratio (P < 0.01, r = 0.91) and gamma-glutamyl-transpeptidase (GGT, P < 0.01, r = 0.86).",16359376_4,16359376_D009173_C531854,,
770958387,false,true,5,2015-08-15T01:46:00,,No Relation,1,D009173,MPA,C564422,gamma-glutamyl-transpeptidase/GGT,"CsA C2 correlated with MPAG-to-MPA ratio (P < 0.01, r = 0.91) and gamma-glutamyl-transpeptidase (GGT, P < 0.01, r = 0.86).",16359376_4,16359376_D009173_C564422,,
770958388,false,true,5,2015-08-15T00:44:00,,No Relation,1,D009173,MPA,C531854,MPA,"Total MPA concentration increased during the 3 months, but not in patients on tacrolimus.",16359376_5,16359376_D009173_C531854,,
770958389,false,true,5,2015-08-14T21:42:00,,No Relation,1,D016559,tacrolimus,C531854,MPA,"Total MPA concentration increased during the 3 months, but not in patients on tacrolimus.",16359376_5,16359376_D016559_C531854,,
770958390,false,true,5,2015-08-14T21:43:00,,No Relation,1,D009173,MPA,C531854,MPA,High CsA C2 lowered the acute rejection rate and plasma MPA.,16359376_6,16359376_D009173_C531854,,
770958391,false,true,5,2015-08-14T22:16:00,,No Relation,0.7843,D009173,MPA,C531854,MPA,"High CsA C2 is associated with elevated GGT, probably because of cholestatic effects, which explain the increased MPAG-to-MPA ratio.",16359376_7,16359376_D009173_C531854,,
770958392,false,true,5,2015-08-14T22:23:00,,No Relation,1,D009173,MPA,C564422,GGT,"High CsA C2 is associated with elevated GGT, probably because of cholestatic effects, which explain the increased MPAG-to-MPA ratio.",16359376_7,16359376_D009173_C564422,,
770958393,false,true,5,2015-08-14T22:20:00,,No Relation,1,C113145,MPAG,C531854,MPA,"High CsA C2 is associated with elevated GGT, probably because of cholestatic effects, which explain the increased MPAG-to-MPA ratio.",16359376_7,16359376_C113145_C531854,,
770958394,false,true,5,2015-08-15T00:18:00,,No Relation,0.7992,C113145,MPAG,C564422,GGT,"High CsA C2 is associated with elevated GGT, probably because of cholestatic effects, which explain the increased MPAG-to-MPA ratio.",16359376_7,16359376_C113145_C564422,,
770958395,false,true,5,2015-08-15T01:15:00,,No Relation,1,D009173,MPA,C531854,MPA,Increasing MPA concentration is ascribed to per-protocol CsA C2 reductions.,16359376_8,16359376_D009173_C531854,,
770958396,false,true,5,2015-08-14T23:46:00,,No Relation,1,D009173,MPA,C531854,MPA,"In conclusion, CsA may confound the relationship between MPA and the incidence of rejection, and contribute to the difficulty of obtaining a therapeutic range for MPA in clinical practice.",16359376_9,16359376_D009173_C531854,,
770958397,false,true,5,2015-08-14T21:37:00,,No Relation,0.8086,D016572,CsA,C531854,MPA,"In conclusion, CsA may confound the relationship between MPA and the incidence of rejection, and contribute to the difficulty of obtaining a therapeutic range for MPA in clinical practice.",16359376_9,16359376_D016572_C531854,,
770958398,false,true,5,2015-08-14T22:09:00,,No Relation,1,D014859,Warfarin,D003027,cluster headache,Warfarin as a therapeutic option in the control of chronic cluster headache: a report of three cases.,16362716_0,16362716_D014859_D003027,,
770958399,false,true,5,2015-08-14T23:49:00,,No Relation,0.8158,D014859,warfarin,D003027,cluster headache,Two of them remained cluster headache-free while taking warfarin.,16362716_4,16362716_D014859_D003027,,
770958400,false,true,5,2015-08-14T21:56:00,,Direct,1,D014859,warfarin,D003027,cluster headache,"In the third patient, the use of warfarin for three weeks initially increased the frequency and intensity of cluster headache attacks but subsequently induced a prolonged remission.",16362716_5,16362716_D014859_D003027,,
770958401,false,true,5,2015-08-14T23:35:00,Used as treatment.,No Relation,1,D007372,interferon,D006526,HIV/hepatitis C virus-coinfected,"With the introduction of pegylated interferon/ribavirin combination therapy significantly improved treatment options for HIV/hepatitis C virus-coinfected patients have become available, leading to sustained virological response rates of over 40%.",16374211_4,16374211_D007372_D006526,,
770958402,false,true,5,2015-08-15T00:24:00,,No Relation,1,D012254,ribavirin,D006526,HIV/hepatitis C virus-coinfected,"With the introduction of pegylated interferon/ribavirin combination therapy significantly improved treatment options for HIV/hepatitis C virus-coinfected patients have become available, leading to sustained virological response rates of over 40%.",16374211_4,16374211_D012254_D006526,,
770958403,false,true,5,2015-08-14T21:51:00,,No Relation,1,C417083,pegylated interferon,D006526,HIV/hepatitis C virus-coinfected,Treatment with pegylated interferon plus ribavirin is safe and effective in HIV/hepatitis C virus-coinfected patients.,16374211_6,16374211_C417083_D006526,,
770958404,false,true,5,2015-08-14T22:27:00,,No Relation,1,D012254,ribavirin,D006526,HIV/hepatitis C virus-coinfected,Treatment with pegylated interferon plus ribavirin is safe and effective in HIV/hepatitis C virus-coinfected patients.,16374211_6,16374211_D012254_D006526,,
770958405,false,true,5,2015-08-14T23:46:00,,No Relation,0.7876,D008942,mitoxantrone,D066126,cardiotoxicity,Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.,16374818_0,16374818_D008942_D066126,,
770958406,false,true,5,2015-08-14T23:08:00,,No Relation,1,D064730,dexrazoxane,D066126,cardiotoxicity,Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.,16374818_0,16374818_D064730_D066126,,
770958407,false,true,5,2015-08-15T01:15:00,,No Relation,1,D064730,dexrazoxane,D009103,multiple sclerosis,Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.,16374818_0,16374818_D064730_D009103,,
770958408,false,true,5,2015-08-15T00:42:00,,No Relation,0.8073,D008942,mitoxantrone,D009103,multiple sclerosis,Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.,16374818_0,16374818_D008942_D009103,,
770958409,false,true,5,2015-08-15T02:25:00,,Direct,0.6058,D008942,mitoxantrone,D066126,cardiotoxicity,To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.,16374818_1,16374818_D008942_D066126,,
770958410,false,true,5,2015-08-14T23:38:00,,No Relation,1,D064730,dexrazoxane,D066126,cardiotoxicity,To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.,16374818_1,16374818_D064730_D066126,,
770958411,false,true,5,2015-08-14T21:54:00,,No Relation,1,D064730,dexrazoxane,D009103,MS,To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.,16374818_1,16374818_D064730_D009103,,
770958412,false,true,5,2015-08-15T01:00:00,,No Relation,1,D008942,mitoxantrone,D009103,MS,To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.,16374818_1,16374818_D008942_D009103,,
770958413,false,true,5,2015-08-14T21:03:00,,No Relation,0.7872,D008942,mitoxantrone,D066126,cardiotoxicity,"An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.",16374818_2,16374818_D008942_D066126,,
770958414,false,true,5,2015-08-15T00:07:00,,No Relation,1,D064730,dexrazoxane,D066126,cardiotoxicity,"An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.",16374818_2,16374818_D064730_D066126,,
770958415,false,true,5,2015-08-15T02:13:00,,No Relation,1,D064730,dexrazoxane,D009103,multiple sclerosis,"An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.",16374818_2,16374818_D064730_D009103,,
770958416,false,true,5,2015-08-14T22:20:00,,No Relation,0.8119,D008942,mitoxantrone,D009103,multiple sclerosis,"An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.",16374818_2,16374818_D008942_D009103,,
770958417,false,true,5,2015-08-14T23:46:00,,No Relation,1,D008942,mitoxantrone,D009103,multiple sclerosis,These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.,16374818_5,16374818_D008942_D009103,,
770958418,false,true,5,2015-08-15T00:03:00,,No Relation,1,D064730,dexrazoxane,D009103,multiple sclerosis,These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.,16374818_5,16374818_D064730_D009103,,
770958419,false,true,5,2015-08-15T01:32:00,,No Relation,1,D013256,steroid,D020338,vestibular neuritis,"He was diagnosed with vestibular neuritis, and steroid therapy was initiated.",16376278_7,16376278_D013256_D020338,,
770958420,false,true,5,2015-08-15T00:09:00,,No Relation,1,D019793,fluorescein,D004487,Cytotoxicity,"Cytotoxicity remained the same whether cells were treated with anginex at 4 degrees C or at 37 degrees C. At low temperatures, fluorescein-conjugated anginex accumulated on the endothelial surface, but did not reach into the cytoplasm, indicating that the cell membrane is the primary target for the peptide.",16403516_3,16403516_D019793_D004487,,
770958421,false,true,5,2015-08-15T02:15:00,,No Relation,1,D000728,Androgen,D011471,prostate cancer,Androgen ablation remains the cornerstone of management for advanced prostate cancer.,16406864_1,16406864_D000728_D011471,,
770958422,false,true,5,2015-08-15T00:26:00,,No Relation,1,D007987,gonadotropin-releasing hormone,D011471,prostate cancer,"A comprehensive review of the peer reviewed literature was performed on the topic of secondary hormonal therapies, including oral antiandrogens, adrenal androgen inhibitors, corticosteroids, estrogenic compounds, gonadotropin-releasing hormone antagonists and alternative hormonal therapies for advanced prostate cancer.",16406864_5,16406864_D007987_D011471,,
770958423,false,true,5,2015-08-15T01:52:00,,No Relation,1,D000305,corticosteroids,D011471,prostate cancer,"A comprehensive review of the peer reviewed literature was performed on the topic of secondary hormonal therapies, including oral antiandrogens, adrenal androgen inhibitors, corticosteroids, estrogenic compounds, gonadotropin-releasing hormone antagonists and alternative hormonal therapies for advanced prostate cancer.",16406864_5,16406864_D000305_D011471,,
770958424,false,true,5,2015-08-14T23:18:00,,No Relation,1,D000728,androgen,D011471,prostate cancer,"A comprehensive review of the peer reviewed literature was performed on the topic of secondary hormonal therapies, including oral antiandrogens, adrenal androgen inhibitors, corticosteroids, estrogenic compounds, gonadotropin-releasing hormone antagonists and alternative hormonal therapies for advanced prostate cancer.",16406864_5,16406864_D000728_D011471,,
770958425,false,true,5,2015-08-14T21:15:00,,No Relation,1,C076731,Levosimendan,D017682,myocardial stunning,Levosimendan: a promising treatment for myocardial stunning?,16409345_0,16409345_C076731_D017682,,
770958426,false,true,5,2015-08-14T21:14:00,,No Relation,1,D002395,catecholamine,D054549,intra aortic balloon counterpulsation,"Immediate percutaneous transluminal coronary angioplasty, intra aortic balloon counterpulsation, and catecholamine therapy failed to stabilise haemodynamics.",16409345_4,16409345_D002395_D054549,,
770958427,false,true,5,2015-08-14T22:42:00,,No Relation,1,D005419,flavonoids,D015459,human cell line/HL,This study was designed to screen antichlamydial activity of natural flavonoids and other natural and structurally similar synthetic compounds against Chlamydia pneumoniae in human cell line (HL).,16414027_4,16414027_D005419_D015459,,
770958428,false,true,5,2015-08-14T21:37:00,,No Relation,1,D005419,flavonoids,D002690,Chlamydia pneumoniae,This study was designed to screen antichlamydial activity of natural flavonoids and other natural and structurally similar synthetic compounds against Chlamydia pneumoniae in human cell line (HL).,16414027_4,16414027_D005419_D002690,,
770958429,false,true,5,2015-08-14T21:23:00,,No Relation,1,C057823,Salmeterol,D001249,asthma,The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.,16424409_0,16424409_C057823_D001249,,
770958430,false,true,5,2015-08-15T00:57:00,,No Relation,0.829,C057823,Salmeterol,D058545,MDI/metered-dose inhaler,"Salmeterol, 42 mug bid via metered-dose inhaler (MDI), and placebo bid via MDI.",16424409_7,16424409_C057823_D058545,,
770958431,false,true,5,2015-08-14T21:04:00,,No Relation,0.6134,C057823,salmeterol,D003643,deaths,"The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14).",16424409_9,16424409_C057823_D003643,,
770958432,false,true,5,2015-08-15T01:18:00,,Direct,0.6195,C057823,salmeterol,D003643,deaths,"There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo.",16424409_10,16424409_C057823_D003643,,
770958433,false,true,5,2015-08-14T22:13:00,,Direct,0.6223,C057823,salmeterol,D001249,asthma,"There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo.",16424409_10,16424409_C057823_D001249,,
770958434,false,true,5,2015-08-15T01:30:00,,No Relation,0.6008,C057823,salmeterol,D003643,deaths,"The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo.",16424409_11,16424409_C057823_D003643,,
770958435,false,true,5,2015-08-14T21:10:00,,Direct,1,C057823,salmeterol,D001249,asthma,"The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo.",16424409_11,16424409_C057823_D001249,,
770958436,false,true,5,2015-08-15T00:43:00,,Indirect,0.4222,C057823,salmeterol,D003643,deaths,"There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol.",16424409_13,16424409_C057823_D003643,,
770958437,false,true,5,2015-08-14T21:38:00,,Direct,1,C057823,salmeterol,D001249,asthma,"There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol.",16424409_13,16424409_C057823_D001249,,
770958438,false,true,5,2015-08-15T00:12:00,,No Relation,1,D010406,penicillin,D006948,neuropsychiatric symptoms,His neuropsychiatric symptoms recovered gradually after penicillin treatment two months later.,16425549_4,16425549_D010406_D006948,,
770958439,false,true,5,2015-08-15T01:45:00,,No Relation,1,C509125,marinomycin A,D008545,melanoma,"In room light, marinomycin A slowly isomerizes to its geometrical isomers marinomycins B and C. Marinomycins A-D show significant antimicrobial activities against drug resistant bacterial pathogens and demonstrate impressive and selective cancer cell cytotoxicities against six of the eight melanoma cell lines in the National Cancer Institute's 60 cell line panel.",16448135_3,16448135_C509125_D008545,,
770958440,false,true,5,2015-08-15T00:13:00,,No Relation,1,C509125,marinomycin A,D009369,cancer,"In room light, marinomycin A slowly isomerizes to its geometrical isomers marinomycins B and C. Marinomycins A-D show significant antimicrobial activities against drug resistant bacterial pathogens and demonstrate impressive and selective cancer cell cytotoxicities against six of the eight melanoma cell lines in the National Cancer Institute's 60 cell line panel.",16448135_3,16448135_C509125_D009369,,
770958441,false,true,5,2015-08-14T21:38:00,,No Relation,0.8213,D013498,suramin,D014352,trypanosomiasis,The first reported human case of trypanosomiasis caused by Trypanosoma evansi was treated using suramin.,16455122_1,16455122_D013498_D014352,,
770958442,false,true,5,2015-08-14T21:02:00,,No Relation,1,D013498,Suramin,D007239,infection,"Suramin should be considered in the treatment of other cases of human T. evansi infection, if they occur.",16455122_4,16455122_D013498_D007239,,
770958443,false,true,5,2015-08-14T21:11:00,,No Relation,1,D010100,oxygen,D006470,SAH,"Continuous monitoring of arterial blood pressure (ABP), ICP, cerebral perfusion pressure (CPP), brain tissue oxygen (PbO2), middle cerebral artery flow velocity (FV), and microdialysis was performed in 14 poor grade SAH patients.",16463835_5,16463835_D010100_D006470,,
770958444,false,true,5,2015-08-15T00:04:00,,No Relation,1,D006820,sodium hyaluronate,D008173,postoperative small bowel obstruction,This study aimed to evaluate the efficacy of sodium hyaluronate and carboxymethylcellulose membrane (Seprafilm) on early postoperative small bowel obstruction (EPSBO).,16468536_1,16468536_D006820_D008173,,
770958445,false,true,5,2015-08-15T00:32:00,,No Relation,1,C118198,Seprafilm,D009371,surgical site infection,It also examined whether using Seprafilm affected surgical site infection rates in gastrointestinal surgery.,16468536_2,16468536_C118198_D009371,,
770958446,false,true,5,2015-08-14T21:49:00,,No Relation,1,C022616,"3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide",D004487,cytotoxicity,"Our results show that at nanomolar concentrations S100B protects cells against Abeta-mediated cytotoxicity, as assessed by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein isothiocyanate nick end-labeling (TUNEL) experiments, by countering the Abeta-mediated decrease in the expression of the anti-apoptotic factor Bcl-2.",16477616_6,16477616_C022616_D004487,,
770958447,false,true,5,2015-08-14T22:48:00,,No Relation,1,C003223,propionylcarnitine,D007383,intermittent claudication,Effect of propionylcarnitine on changes in endothelial function and plasma levels of adhesion molecules induced by acute exercise in patients with intermittent claudication.,16518521_0,16518521_C003223_D007383,,
770958448,false,true,5,2015-08-14T22:35:00,,No Relation,1,C047638,Alfuzosin,D011470,benign prostatic hyperplasia,Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.,16536764_0,16536764_C047638_D011470,,
770958449,false,true,5,2015-08-14T21:16:00,,No Relation,1,C047638,alfuzosin,D011470,benign prostatic hyperplasia,To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH).,16536764_1,16536764_C047638_D011470,,
770958450,false,true,5,2015-08-14T22:39:00,,No Relation,1,C101426,Sildenafil citrate,D018917,ischemic optic neuropathy,Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.,16620369_0,16620369_C101426_D018917,,
770958451,false,true,5,2015-08-14T23:14:00,,No Relation,0.5822,C101426,sildenafil,D018917,ischemic optic neuropathy,Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely in men after taking sildenafil or other phosphodiesterase 5 inhibitors for erectile dysfunction (ED).,16620369_1,16620369_C101426_D018917,,
770958452,false,true,5,2015-08-15T01:24:00,,No Relation,0.8165,C101426,sildenafil,D007172,ED/erectile dysfunction,Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely in men after taking sildenafil or other phosphodiesterase 5 inhibitors for erectile dysfunction (ED).,16620369_1,16620369_C101426_D007172,,
770958453,false,true,5,2015-08-15T01:46:00,,No Relation,1,C101426,sildenafil,D007172,ED,The incidence of NAION in men receiving sildenafil treatment for ED was estimated using pooled safety data from global clinical trials and European observational studies.,16620369_2,16620369_C101426_D007172,,
770958454,false,true,5,2015-08-14T23:11:00,,No Relation,1,C101426,sildenafil,D007172,ED,The data cited herein do not suggest an increased incidence of NAION in men who took sildenafil for ED.,16620369_5,16620369_C101426_D007172,,
770958455,false,true,5,2015-08-14T22:00:00,,No Relation,0.8069,C111217,vinflunine,D001749,bladder cancer,A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.,16622447_0,16622447_C111217_D001749,,
770958456,false,true,5,2015-08-14T22:43:00,,No Relation,1,D010984,platinum,D001749,bladder cancer,A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.,16622447_0,16622447_D010984_D001749,,
770958457,false,true,5,2015-08-14T21:25:00,,Direct,0.5953,C111217,vinflunine,D064420,toxicity,"A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in patients with advanced transitional cell carcinoma (TCC) of the bladder; secondary objectives were to assess duration of response, progression-free survival (PFS) and overall survival (OS), and to evaluate the toxicity associated with this treatment.",16622447_1,16622447_C111217_D064420,,
770958458,false,true,5,2015-08-15T02:17:00,,No Relation,1,C111217,vinflunine,D002295,transitional cell carcinoma/TCC,"A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in patients with advanced transitional cell carcinoma (TCC) of the bladder; secondary objectives were to assess duration of response, progression-free survival (PFS) and overall survival (OS), and to evaluate the toxicity associated with this treatment.",16622447_1,16622447_C111217_D002295,,
770958459,false,true,5,2015-08-15T02:10:00,,No Relation,0.8067,D010984,platinum,D009369,tumours,"Patients had tumours that failed or progressed after first-line platinum-containing regimens for advanced or metastatic disease, or had progressive disease after platinum-containing chemotherapy given with adjuvant or neoadjuvant intent.",16622447_2,16622447_D010984_D009369,,
770958460,false,true,5,2015-08-14T21:48:00,,No Relation,1,D010984,platinum,D018223,metastatic disease,"Patients had tumours that failed or progressed after first-line platinum-containing regimens for advanced or metastatic disease, or had progressive disease after platinum-containing chemotherapy given with adjuvant or neoadjuvant intent.",16622447_2,16622447_D010984_D018223,,
770958461,false,true,5,2015-08-15T02:17:00,,No Relation,1,D014748,vinca alkaloids,D018223,metastatic disease,"Of note, responses were seen in patients with relatively poor prognostic factors such as a short (<12 months) interval from prior platinum therapy (19%, including an 11% response rate in those progressing <3 months after platinum treatment), prior treatment for metastatic disease (24%), prior treatment with vinca alkaloids (14%) and visceral involvement (20%).",16622447_5,16622447_D014748_D018223,,
770958462,false,true,5,2015-08-14T23:42:00,,No Relation,1,D010984,platinum,D018223,metastatic disease,"Of note, responses were seen in patients with relatively poor prognostic factors such as a short (<12 months) interval from prior platinum therapy (19%, including an 11% response rate in those progressing <3 months after platinum treatment), prior treatment for metastatic disease (24%), prior treatment with vinca alkaloids (14%) and visceral involvement (20%).",16622447_5,16622447_D010984_D018223,,
770958463,false,true,5,2015-08-14T21:42:00,,No Relation,1,C111217,Vinflunine,D002295,TCC,"Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.",16622447_14,16622447_C111217_D002295,,
770958464,false,true,5,2015-08-14T22:16:00,,No Relation,1,C111217,Vinflunine,D001749,bladder cancer,"Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.",16622447_14,16622447_C111217_D001749,,
770958465,false,true,5,2015-08-14T21:49:00,,No Relation,1,D010984,platinum,D001749,bladder cancer,"Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.",16622447_14,16622447_D010984_D001749,,
770958466,false,true,5,2015-08-14T21:57:00,,No Relation,1,D010984,platinum,D002295,TCC,"Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.",16622447_14,16622447_D010984_D002295,,
770958467,false,true,5,2015-08-15T02:21:00,,No Relation,1,D010672,phenytoin,D019966,antiepileptic drugs,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D010672_D019966,,
770958468,false,true,5,2015-08-14T23:42:00,,No Relation,1,D002220,CBZ/carbamazepine,D019966,antiepileptic drugs,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D002220_D019966,,
770958469,false,true,5,2015-08-15T00:44:00,,No Relation,1,D010672,phenytoin,D004827,epileptic,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D010672_D004827,,
770958470,false,true,5,2015-08-15T00:54:00,,No Relation,1,D002220,CBZ/carbamazepine,D004827,epileptic,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D002220_D004827,,
770958471,false,true,5,2015-08-15T00:05:00,,No Relation,1,D010672,phenytoin,D006976,PHT,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D010672_D006976,,
770958472,false,true,5,2015-08-15T00:51:00,,No Relation,1,D002220,CBZ/carbamazepine,D006976,PHT,"Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).",16631625_1,16631625_D002220_D006976,,
770958473,false,true,5,2015-08-15T01:42:00,,No Relation,1,D005680,GABA,D004827,epileptic,Slices from drug-resistant epileptic patients made hypersynchronous/hyperexcitable by elevated potassium or inhibition of GABA-A receptors behaved similarly.,16631625_7,16631625_D005680_D004827,,
770958474,false,true,5,2015-08-14T21:09:00,,No Relation,0.7936,D011188,potassium,D004827,epileptic,Slices from drug-resistant epileptic patients made hypersynchronous/hyperexcitable by elevated potassium or inhibition of GABA-A receptors behaved similarly.,16631625_7,16631625_D011188_D004827,,
770958475,false,true,5,2015-08-15T00:13:00,,No Relation,1,D019821,statins,C535382,renal dysfunction,"The aim of the present study was to assess the effect of statins on renal function in patients at high risk for renal dysfunction, that is, those who underwent suprarenal aortic cross clamping-declamping.",16635616_2,16635616_D019821_C535382,,
770958476,false,true,5,2015-08-15T01:09:00,,No Relation,1,D003404,creatinine,D019106,blood loss,"An analysis-of-variance model for repeated measurements was applied to compare creatinine levels between statin users and nonusers, with adjustment for clamping time and blood loss.",16635616_5,16635616_D003404_D019106,,
770958477,false,true,5,2015-08-14T23:34:00,It's 'Alcohol-impaired driving' and not just 'Alcohol-impaired' :),No Relation,0.6021,D000431,Alcohol,D000437,Alcohol-impaired,Alcohol-impaired driving and its consequences in the United States: the past 25 years.,16647085_0,16647085_D000431_D000437,,
770958478,false,true,5,2015-08-14T21:25:00,,No Relation,0.6051,D000431,Alcohol,D000437,Alcohol-impaired,Alcohol-impaired driving is still a major problem that needs continuing attention.,16647085_11,16647085_D000431_D000437,,
770958479,false,true,5,2015-08-15T00:32:00,,No Relation,0.6032,D002118,calcium,D012516,osteosarcoma,Bone-like tissue formation by three-dimensional culture of MG63 osteosarcoma cells in gelatin hydrogels using calcium-enriched medium.,16674304_0,16674304_D002118_D012516,,
770958480,false,true,5,2015-08-15T00:38:00,,No Relation,1,D002118,calcium,D012516,Human osteosarcoma,Human osteosarcoma MG63 cells were cultured on tissue culture dish under various Ca(2+) concentrations to evaluate the effect of Ca(2+) concentration on calcium deposition.,16674304_2,16674304_D002118_D012516,,
770958481,false,true,5,2015-08-14T21:23:00,,No Relation,1,C064276,Pantoprazole,D006470,ulcer bleeding,Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial.,16677158_0,16677158_C064276_D006470,,
770958482,false,true,5,2015-08-14T23:20:00,'Improve the outcome' being the key term.,No Relation,1,C064276,pantoprazole,D006470,ulcer bleeding,We investigated whether or not administration of pantoprazole infusion would improve the outcome in ulcer bleeding following successful endoscopic therapy.,16677158_3,16677158_C064276_D006470,,
770958483,false,true,5,2015-08-14T21:10:00,,No Relation,1,D004837,epinephrine,D013276,gastric or duodenal ulcers with active bleeding,"In this double-blind, placebo-controlled, prospective trial, patients who had gastric or duodenal ulcers with active bleeding or non-bleeding visible vessel received combined endoscopy therapy with injection of epinephrine and heater probe application.",16677158_4,16677158_D004837_D013276,,
770958484,false,true,5,2015-08-14T23:32:00,,No Relation,1,D004837,epinephrine,D006470,bleeding,"In this double-blind, placebo-controlled, prospective trial, patients who had gastric or duodenal ulcers with active bleeding or non-bleeding visible vessel received combined endoscopy therapy with injection of epinephrine and heater probe application.",16677158_4,16677158_D004837_D006470,,
770958485,false,true,5,2015-08-14T21:31:00,,No Relation,0.5942,C064276,pantoprazole,D006470,bleeding,Three (2.9%) patients in the pantoprazole group and eight (7.9%) in the placebo group required surgery to control their bleeding (P = 0.12).,16677158_9,16677158_C064276_D006470,,
770958486,false,true,5,2015-08-14T22:22:00,,No Relation,1,C064276,pantoprazole,D010438,bleeding peptic ulcers,"In patients with bleeding peptic ulcers, the use of high dose pantoprazole infusion following successful endoscopic therapy is effective in reducing rebleeding, transfusion requirements and hospital stay.",16677158_11,16677158_C064276_D010438,,
770958487,false,true,5,2015-08-15T02:02:00,,No Relation,1,C037663,Ropivacaine,D004409,akinesia,Ropivacaine used for retrobulbar-peribulbar combined anesthesia in vitreoretinal surgery showed excellent clinical efficacy as regards analgesia and muscle akinesia.,16703549_16,16703549_C037663_D004409,,
770958488,false,true,5,2015-08-15T00:18:00,,No Relation,1,D000728,androgen,D011471,prostate cancer,Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.,16763722_0,16763722_D000728_D011471,,
770958489,false,true,5,2015-08-15T02:10:00,,No Relation,1,D000728,androgen,D011471,prostate cancer/PCa,To investigate the involvement of the prostate androgen-regulated (PAR) gene in the androgen receptor (AR) signaling pathway and the malignant phenotype of androgen-independent prostate cancer (PCa) cells.,16763722_1,16763722_D000728_D011471,,
770958490,false,true,5,2015-08-14T21:22:00,,No Relation,0.7879,D000728,androgen,D011471,PCa,"To determine the importance of PAR in the malignant proliferation of androgen-independent PCa cells, we used small interfering RNA (siRNA) transfection to knock down the expression of the gene in PC3 cells.",16763722_4,16763722_D000728_D011471,,
770958491,false,true,5,2015-08-15T02:04:00,,No Relation,1,D000728,androgen,D011471,PCa,"Because of the possibility that PAR is downstream from the AR, and because of its contribution to malignant proliferation in androgen-independent PCa cells, the gene could be a potential therapeutic target for androgen-independent PCa with AR signaling pathway alteration.",16763722_11,16763722_D000728_D011471,,
770958492,false,true,5,2015-08-14T21:19:00,,No Relation,1,C047781,lamotrigine,D001523,Mental Disorders,"We evaluated all patients under age 18 with Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) bipolar disorder in our outpatient clinic treated with lamotrigine, using the Clinical Global Impression (CGI) scale.",16768643_2,16768643_C047781_D001523,,
770958493,false,true,5,2015-08-14T21:07:00,,No Relation,1,C047781,lamotrigine,D001714,bipolar disorder,"We evaluated all patients under age 18 with Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) bipolar disorder in our outpatient clinic treated with lamotrigine, using the Clinical Global Impression (CGI) scale.",16768643_2,16768643_C047781_D001714,,
770958494,false,true,5,2015-08-14T23:43:00,,No Relation,1,C047781,lamotrigine,D001714,bipolar disorder,"This open, retrospective chart review suggests that lamotrigine may be effective and well tolerated as an adjunctive treatment in adolescents with bipolar disorder.",16768643_12,16768643_C047781_D001714,,
770958495,false,true,5,2015-08-15T01:21:00,,Direct,1,D002104,Cd,D006470,hemorrhage,"In animal experiments, high-dose exposure to Cd induced severe testicular interstitial hemorrhage with edema, and increased incidence of fetal death and placental necrosis.",16788562_3,16788562_D002104_D006470,,
770958496,false,true,5,2015-08-15T02:10:00,,Direct,0.7946,D002104,Cd,D009336,necrosis,"In animal experiments, high-dose exposure to Cd induced severe testicular interstitial hemorrhage with edema, and increased incidence of fetal death and placental necrosis.",16788562_3,16788562_D002104_D009336,,
770958497,false,true,5,2015-08-15T01:21:00,,Direct,0.6045,D002104,Cd,D005313,fetal death,"In animal experiments, high-dose exposure to Cd induced severe testicular interstitial hemorrhage with edema, and increased incidence of fetal death and placental necrosis.",16788562_3,16788562_D002104_D005313,,
770958498,false,true,5,2015-08-15T02:12:00,,Direct,0.6051,D002104,Cd,D004487,edema,"In animal experiments, high-dose exposure to Cd induced severe testicular interstitial hemorrhage with edema, and increased incidence of fetal death and placental necrosis.",16788562_3,16788562_D002104_D004487,,
770958499,false,true,5,2015-08-15T02:02:00,,Direct,0.7838,C110904,Capecitabine,D064420,cerebellar toxicity,Capecitabine-induced cerebellar toxicity.,16796795_0,16796795_C110904_D064420,,
770958500,false,true,5,2015-08-15T00:31:00,,No Relation,1,C110904,Capecitabine,D000230,adenocarcinoma of the colon,Capecitabine is an oral prodrug of 5-fluorouracil used in the treatment of adenocarcinoma of the colon.,16796795_1,16796795_C110904_D000230,,
770958501,false,true,5,2015-08-14T21:31:00,,No Relation,1,D005472,5-fluorouracil,D000230,adenocarcinoma of the colon,Capecitabine is an oral prodrug of 5-fluorouracil used in the treatment of adenocarcinoma of the colon.,16796795_1,16796795_D005472_D000230,,
770958502,false,true,5,2015-08-14T23:13:00,,Direct,0.5956,C110904,capecitabine,D020258,Neurotoxicity,Neurotoxicity is an infrequently reported toxicity of capecitabine.,16796795_2,16796795_C110904_D020258,,
770958503,false,true,5,2015-08-15T01:24:00,,Direct,0.7993,C110904,capecitabine,D064420,toxicity,Neurotoxicity is an infrequently reported toxicity of capecitabine.,16796795_2,16796795_C110904_D064420,,
770958504,false,true,5,2015-08-14T22:00:00,,No Relation,1,D014031,tobramycin,D003550,cystic fibrosis,Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.,16801404_0,16801404_D014031_D003550,,
770958505,false,true,5,2015-08-15T00:51:00,,No Relation,1,D014031,tobramycin,D003550,cystic fibrosis,We undertook assessment of hearing in patients with cystic fibrosis who were taking part in a large randomized controlled trial of once- versus three-times-daily tobramycin for pulmonary exacerbations of cystic fibrosis (the TOPIC study).,16801404_1,16801404_D014031_D003550,,
770958506,false,true,5,2015-08-15T01:35:00,,No Relation,1,D014031,tobramycin,D009461,auditory deficit,"We conclude that for a single 14-day course of tobramycin treatment in patients with cystic fibrosis with no preexisiting auditory deficit, no measurable effect on hearing was apparent with either once- or three-times-daily treatment.",16801404_11,16801404_D014031_D009461,,
770958507,false,true,5,2015-08-15T02:30:00,,No Relation,1,D014031,tobramycin,D003550,cystic fibrosis,"We conclude that for a single 14-day course of tobramycin treatment in patients with cystic fibrosis with no preexisiting auditory deficit, no measurable effect on hearing was apparent with either once- or three-times-daily treatment.",16801404_11,16801404_D014031_D003550,,
770958508,false,true,5,2015-08-15T00:27:00,,Direct,0.5888,D000617,aminoglycoside,D034381,hearing loss,"Estimation of the cumulative cochleotoxic risk in cystic fibrosis patients due to repeated aminoglycoside therapy, as evidenced by the patients excluded from this study due to hearing loss, also requires further characterization.",16801404_12,16801404_D000617_D034381,,
770958509,false,true,5,2015-08-14T23:19:00,,Direct,0.5734,D000617,aminoglycoside,D003550,cystic fibrosis,"Estimation of the cumulative cochleotoxic risk in cystic fibrosis patients due to repeated aminoglycoside therapy, as evidenced by the patients excluded from this study due to hearing loss, also requires further characterization.",16801404_12,16801404_D000617_D003550,,
770958510,false,true,5,2015-08-15T01:26:00,,No Relation,1,D014280,triacylglycerol,D064250,hypertriglyceridemic,"Ten healthy elderly men (70-78 y of age, body mass index 21-27 kg/m(2)) and 10 healthy young men (19-45 y of age, body mass index 19-26 kg/m(2)) were studied with a hypertriglyceridemic clamp (primed infusion of a long-chain triacylglycerol emulsion to reach and stabilize at a triacylglycerol concentration of 4 mmol/L for 180 min).",16815487_2,16815487_D014280_D064250,,
770958511,false,true,5,2015-08-15T01:38:00,,No Relation,1,D014280,triacylglycerol,D064250,hypertriglyceridemic,Elderly healthy men have a similar capacity as young healthy men to clear and oxidize a high triacylglycerol load administered as a hypertriglyceridemic clamp.,16815487_11,16815487_D014280_D064250,,
770958512,false,true,5,2015-08-15T02:07:00,,No Relation,1,C068329,clofarabine,D015451,chronic lymphocytic leukemia,Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.,16818700_0,16818700_C068329_D015451,,
770958513,false,true,5,2015-08-14T22:26:00,,No Relation,1,C024352,fludarabine,D007938,leukemias,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_C024352_D007938,,
770958514,false,true,5,2015-08-14T23:16:00,,No Relation,1,D017338,cladribine,D007938,leukemias,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_D017338_D007938,,
770958515,false,true,5,2015-08-14T23:32:00,,No Relation,1,C024352,fludarabine,D015451,CLL/chronic lymphocytic leukemia,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_C024352_D015451,,
770958516,false,true,5,2015-08-14T23:11:00,Used as treatment.,No Relation,1,C068329,clofarabine,D015451,CLL/chronic lymphocytic leukemia,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_C068329_D015451,,
770958517,false,true,5,2015-08-14T21:29:00,,No Relation,1,D017338,cladribine,D015451,CLL/chronic lymphocytic leukemia,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_D017338_D015451,,
770958518,false,true,5,2015-08-15T00:55:00,,No Relation,1,C068329,clofarabine,D007938,leukemias,"Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias.",16818700_1,16818700_C068329_D007938,,
770958519,false,true,5,2015-08-15T02:12:00,,No Relation,1,C068329,clofarabine,D015451,CLL,The present study was conducted to determine the efficacy and cellular pharmacology during clinical trials of single-agent clofarabine in CLL.,16818700_2,16818700_C068329_D015451,,
770958520,false,true,5,2015-08-15T00:20:00,,No Relation,1,C005692,triphosphate,D015451,CLL,"In the majority of cases, >50% of the analogue triphosphate was present 24 hours after infusion, indicating prolonged retention of the triphosphate in CLL cells.",16818700_9,16818700_C005692_D015451,,
770958521,false,true,5,2015-08-14T21:22:00,,No Relation,0.6051,C068329,clofarabine,D015451,CLL,In vitro clofarabine incubation of leukemic lymphocytes from 29 CLL patients showed that clofarabine monophosphate accumulated to a higher concentration compared with the triphosphate.,16818700_11,16818700_C068329_D015451,,
770958522,false,true,5,2015-08-14T22:00:00,,No Relation,1,C005692,triphosphate,D015451,CLL,In vitro clofarabine incubation of leukemic lymphocytes from 29 CLL patients showed that clofarabine monophosphate accumulated to a higher concentration compared with the triphosphate.,16818700_11,16818700_C005692_D015451,,
770958523,false,true,5,2015-08-14T22:19:00,,No Relation,1,C068329,clofarabine,D015451,CLL,Levels of clofarabine triphosphate at higher doses and prolonged maintenance of clofarabine triphosphate in leukemic lymphocytes provide a rationale to treat CLL in a weekly clofarabine schedule.,16818700_13,16818700_C068329_D015451,,
770958524,false,true,5,2015-08-14T21:37:00,,No Relation,1,C024307,bucindolol,D006333,HF,"Potential pathophysiologic correlates were assessed in a placebo-controlled trial of bucindolol in 1,040 HF patients.",16844790_7,16844790_C024307_D006333,,
770958525,false,true,5,2015-08-15T00:47:00,,No Relation,1,D000305,Corticosteroid,D003424,Crohn's disease,Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.,16861053_0,16861053_D000305_D003424,,
770958526,false,true,5,2015-08-14T21:41:00,,No Relation,1,D019829,nevirapine/NVP,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019829_D000163,,
770958527,false,true,5,2015-08-15T01:00:00,,No Relation,1,C098320,EFV/efavirenz,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_C098320_D000163,,
770958528,false,true,5,2015-08-15T00:36:00,,No Relation,1,C106538,abacavir,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_C106538_D000163,,
770958529,false,true,5,2015-08-14T23:43:00,Used as treatment.,No Relation,1,D019829,nevirapine/NVP,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019829_D003643,,
770958530,false,true,5,2015-08-15T01:30:00,,No Relation,1,C098320,EFV/efavirenz,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_C098320_D003643,,
770958531,false,true,5,2015-08-14T21:42:00,,No Relation,1,D019258,saquinavir,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019258_D000163,,
770958532,false,true,5,2015-08-15T01:39:00,,No Relation,1,C106538,abacavir,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_C106538_D003643,,
770958533,false,true,5,2015-08-14T21:49:00,,No Relation,1,D019888,nelfinavir,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019888_D000163,,
770958534,false,true,5,2015-08-14T21:29:00,,No Relation,1,D019258,saquinavir,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019258_D003643,,
770958535,false,true,5,2015-08-14T22:03:00,,No Relation,1,D019888,nelfinavir,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019888_D003643,,
770958536,false,true,5,2015-08-14T22:00:00,,No Relation,1,D019438,ritonavir/RTV,D000163,AIDS,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019438_D000163,,
770958537,false,true,5,2015-08-14T21:15:00,,No Relation,0.8046,D019438,ritonavir/RTV,D003643,death,"We analyzed progression to death from any cause and to AIDS or death (AIDS/death), comparing efavirenz (EFV), nevirapine (NVP), nelfinavir, idinavir, ritonavir (RTV), RTV-boosted protease inhibitors (PIs), saquinavir, and abacavir.",16897660_3,16897660_D019438_D003643,,
770958538,false,true,5,2015-08-15T01:46:00,,No Relation,1,D019829,NVP,D000163,AIDS,"Compared with EFV, the adjusted hazard ratio (HR) for AIDS/death was 1.28 (95% confidence interval [CI], 1.03-1.60) for NVP, 1.31 (95% CI, 1.01-1.71) for RTV, and 1.45 (95% CI, 1.15-1.81) for RTV-boosted PIs.",16897660_6,16897660_D019829_D000163,,
770958539,false,true,5,2015-08-15T00:48:00,,No Relation,1,D019438,RTV,D000163,AIDS,"Compared with EFV, the adjusted hazard ratio (HR) for AIDS/death was 1.28 (95% confidence interval [CI], 1.03-1.60) for NVP, 1.31 (95% CI, 1.01-1.71) for RTV, and 1.45 (95% CI, 1.15-1.81) for RTV-boosted PIs.",16897660_6,16897660_D019438_D000163,,
770958540,false,true,5,2015-08-15T01:46:00,,No Relation,0.7923,D019829,NVP,D003643,death,"Compared with EFV, the adjusted hazard ratio (HR) for AIDS/death was 1.28 (95% confidence interval [CI], 1.03-1.60) for NVP, 1.31 (95% CI, 1.01-1.71) for RTV, and 1.45 (95% CI, 1.15-1.81) for RTV-boosted PIs.",16897660_6,16897660_D019829_D003643,,
770958541,false,true,5,2015-08-15T00:54:00,,No Relation,1,D019438,RTV,D003643,death,"Compared with EFV, the adjusted hazard ratio (HR) for AIDS/death was 1.28 (95% confidence interval [CI], 1.03-1.60) for NVP, 1.31 (95% CI, 1.01-1.71) for RTV, and 1.45 (95% CI, 1.15-1.81) for RTV-boosted PIs.",16897660_6,16897660_D019438_D003643,,
770958542,false,true,5,2015-08-14T22:10:00,,No Relation,1,D019829,NVP,D003643,death,"For death, the adjusted HR for NVP was 1.65 (95% CI, 1.16-2.36).",16897660_7,16897660_D019829_D003643,,
770958543,false,true,5,2015-08-15T01:55:00,,No Relation,1,D019259,3TC,D003643,death,"The adjusted HR for death for D4T/3TC was 1.35 (95% CI, 1.14-1.59), compared with AZT/3TC.",16897660_8,16897660_D019259_D003643,,
770958544,false,true,5,2015-08-14T23:03:00,,No Relation,0.7999,D015215,AZT,D003643,death,"The adjusted HR for death for D4T/3TC was 1.35 (95% CI, 1.14-1.59), compared with AZT/3TC.",16897660_8,16897660_D015215_D003643,,
770958545,false,true,5,2015-08-14T21:36:00,,No Relation,0.5989,C099041,Tolterodine,D053201,overactive bladder/overactive bladder symptoms,Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.,16904446_0,16904446_C099041_D053201,,
770958546,false,true,5,2015-08-15T00:55:00,,No Relation,1,C099041,Tolterodine,D053158,nocturia,Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.,16904446_0,16904446_C099041_D053158,,
770958547,false,true,5,2015-08-14T21:16:00,,No Relation,1,C099041,tolterodine,D053201,overactive bladder/OAB,To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia.,16904446_1,16904446_C099041_D053201,,
770958548,false,true,5,2015-08-15T01:40:00,,No Relation,0.8111,C099041,tolterodine,D053158,nocturia,To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia.,16904446_1,16904446_C099041_D053158,,
770958549,false,true,5,2015-08-14T23:35:00,,No Relation,1,D004280,Dobutamine,D009203,myocardial infarct,Dobutamine response and myocardial infarct transmurality: functional improvement after coronary artery bypass grafting--initial experience.,16926330_0,16926330_D004280_D009203,,
770958550,false,true,5,2015-08-15T02:15:00,,No Relation,1,D004280,dobutamine,D007238,infarction,The purpose of the study was to prospectively test the hypothesis that addition of low-dose dobutamine and quantification of inotropic reserve in segments with 1%-50% infarct transmurality (IT) would improve the predictive value for functional recovery after revascularization in chronic infarction.,16926330_3,16926330_D004280_D007238,,
770958551,false,true,5,2015-08-15T00:05:00,,No Relation,1,C080245,Pregabalin,D010146,neuropathic pain,"Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients.",16939547_0,16939547_C080245_D010146,,
770958552,false,true,5,2015-08-14T21:42:00,,No Relation,1,C080245,pregabalin,D010146,neuropathic pain,"The aim of this study was to evaluate the tolerability, safety and efficacy of pregabalin in Indian patients with peripheral neuropathic pain.",16939547_1,16939547_C080245_D010146,,
770958553,false,true,5,2015-08-14T21:52:00,,No Relation,1,C080245,pregabalin,D010146,neuropathic pain,"In this prospective, multicenter, non-comparative, open-label study, patients with peripheral neuropathic pain (n = 111) received pregabalin in doses ranging from 75 to 300 mg twice daily for 3 weeks.",16939547_2,16939547_C080245_D010146,,
770958554,false,true,5,2015-08-15T00:10:00,,Direct,0.8029,C080245,Pregabalin,D004244,dizziness,"Pregabalin was well tolerated, and the most common adverse events were dizziness and somnolence.",16939547_6,16939547_C080245_D004244,,
770958555,false,true,5,2015-08-15T02:33:00,,Direct,1,C080245,Pregabalin,D006970,somnolence,"Pregabalin was well tolerated, and the most common adverse events were dizziness and somnolence.",16939547_6,16939547_C080245_D006970,,
770958556,false,true,5,2015-08-15T02:00:00,,No Relation,1,C080245,pregabalin,D010146,neuropathic pain,"This study has demonstrated the safety, tolerability and efficacy of pregabalin for peripheral neuropathic pain in Indian patients.",16939547_8,16939547_C080245_D010146,,
770958557,false,true,5,2015-08-15T01:35:00,,No Relation,0.832,D001151,arsenic,D007938,leukemia,Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.,16968895_0,16968895_D001151_D007938,,
770958558,false,true,5,2015-08-14T21:18:00,,No Relation,1,C006632,Arsenic trioxide,D015473,APL/acute promyelocytic leukemia,Arsenic trioxide (As2O3) is highly efficacious in acute promyelocytic leukemia (APL).,16968895_1,16968895_C006632_D015473,,
770958559,false,true,5,2015-08-15T01:53:00,,Direct,0.6074,D001151,arsenic,D004487,cytotoxicity,"The K562(EGFP-AQP9) transfectant accumulated significantly higher levels of intracellular arsenic than control K562(EGFP) when incubated with As2O3, resulting in significantly increased As2O3-induced cytotoxicity.",16968895_6,16968895_D001151_D004487,,
770958560,false,true,5,2015-08-14T21:14:00,,No Relation,0.8057,D014212,ATRA/all-trans retinoic acid,D007951,myeloid leukemia,"Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.",16968895_7,16968895_D014212_D007951,,
770958561,false,true,5,2015-08-15T02:39:00,,No Relation,0.7897,D014212,ATRA/all-trans retinoic acid,D004487,cytotoxicity,"Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.",16968895_7,16968895_D014212_D004487,,
770958562,false,true,5,2015-08-15T02:18:00,,No Relation,1,D001151,arsenic,D007951,myeloid leukemia,"Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.",16968895_7,16968895_D001151_D007951,,
770958563,false,true,5,2015-08-14T23:18:00,,No Relation,0.8011,D001151,arsenic,D004487,cytotoxicity,"Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.",16968895_7,16968895_D001151_D004487,,
770958564,false,true,5,2015-08-14T23:16:00,,No Relation,1,D001663,bilirubin,D006528,hepatocellular carcinoma,"Higher bilirubin level, refractory ascites, and the presence of hepatocellular carcinoma were the predictive parameters for mortality in 77 patients as determined by multivariate analysis.",16984593_11,16984593_D001663_D006528,,
770958565,false,true,5,2015-08-15T00:47:00,,No Relation,1,D000431,alcohol,D009369,breast cancer,"To describe the baseline healthy lifestyle behaviors (dietary, calcium, vitamin D, caffeine and alcohol intake, smoking history, and physical activity) of postmenopausal breast cancer survivors (BCS); and to identify any relationship of healthy lifestyle behaviors with bone mineral density (BMD) at the forearm, total hip and spine, L1-L4.",16999712_1,16999712_D000431_D009369,,
770958566,false,true,5,2015-08-14T21:11:00,,No Relation,1,D014807,vitamin D,D009369,breast cancer,"To describe the baseline healthy lifestyle behaviors (dietary, calcium, vitamin D, caffeine and alcohol intake, smoking history, and physical activity) of postmenopausal breast cancer survivors (BCS); and to identify any relationship of healthy lifestyle behaviors with bone mineral density (BMD) at the forearm, total hip and spine, L1-L4.",16999712_1,16999712_D014807_D009369,,
770958567,false,true,5,2015-08-15T00:26:00,,No Relation,1,D002110,caffeine,D009369,breast cancer,"To describe the baseline healthy lifestyle behaviors (dietary, calcium, vitamin D, caffeine and alcohol intake, smoking history, and physical activity) of postmenopausal breast cancer survivors (BCS); and to identify any relationship of healthy lifestyle behaviors with bone mineral density (BMD) at the forearm, total hip and spine, L1-L4.",16999712_1,16999712_D002110_D009369,,
770958568,false,true,5,2015-08-14T23:44:00,,No Relation,1,D002118,calcium,D009369,breast cancer,"To describe the baseline healthy lifestyle behaviors (dietary, calcium, vitamin D, caffeine and alcohol intake, smoking history, and physical activity) of postmenopausal breast cancer survivors (BCS); and to identify any relationship of healthy lifestyle behaviors with bone mineral density (BMD) at the forearm, total hip and spine, L1-L4.",16999712_1,16999712_D002118_D009369,,
770958569,false,true,5,2015-08-15T00:19:00,,No Relation,1,D002118,calcium,C536430,coaching,"The healthcare provider must incorporate appropriate teaching strategies, intensive counseling, and coaching, along with a support mechanism, to enable BCS to understand the importance of a healthy diet, calcium, and vitamin D supplement, and a regular strength/weight program that will be integrated into their daily lifestyle.",16999712_15,16999712_D002118_C536430,,
770958570,false,true,5,2015-08-15T00:38:00,,No Relation,1,D014807,vitamin D,C536430,coaching,"The healthcare provider must incorporate appropriate teaching strategies, intensive counseling, and coaching, along with a support mechanism, to enable BCS to understand the importance of a healthy diet, calcium, and vitamin D supplement, and a regular strength/weight program that will be integrated into their daily lifestyle.",16999712_15,16999712_D014807_C536430,,
770958571,false,true,5,2015-08-15T00:17:00,,No Relation,1,D013974,levothyroxine,D007037,hypothyroidism,Effect of levothyroxine on total lipid profiles as assessed by analytical capillary isotachophoresis in a patient with hypothyroidism.,17001111_0,17001111_D013974_D007037,,
770958572,false,true,5,2015-08-15T00:25:00,,No Relation,1,C065179,atorvastatin,D006949,hyperlipidemia,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_C065179_D006949,,
770958573,false,true,5,2015-08-15T02:07:00,,No Relation,0.8245,D017035,pravastatin,D006949,hyperlipidemia,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_D017035_D006949,,
770958574,false,true,5,2015-08-14T21:42:00,,No Relation,1,D017035,pravastatin,D007037,hypothyroidism,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_D017035_D007037,,
770958575,false,true,5,2015-08-14T21:52:00,,No Relation,1,D009531,niceritrol,D006949,hyperlipidemia,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_D009531_D006949,,
770958576,false,true,5,2015-08-14T23:34:00,,No Relation,1,D009531,niceritrol,D007037,hypothyroidism,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_D009531_D007037,,
770958577,false,true,5,2015-08-14T21:27:00,,No Relation,1,C065179,atorvastatin,D007037,hypothyroidism,"Since hyperlipidemia was not improved by pravastatin, atorvastatin or niceritrol, and since the levels of thyroid-stimulating hormone (TSH) and free T4 were 730 IU/ml and 0.3 ng/dl, respectively, the patient was diagnosed as secondary hyperlipidemia with hypothyroidism.",17001111_3,17001111_C065179_D007037,,
770958578,false,true,5,2015-08-15T00:59:00,,No Relation,0.5976,D002784,cholesterol,D003327,coronary heart disease,"A method for the charge isolation of lipoproteins using capillary isotachophoresis (cITP) is proposed as a clinical application because it allows us to quantitatively measure electronegative low-density lipoprotein cholesterol (LDL-C), a potent marker of coronary heart disease.",17001111_4,17001111_D002784_D003327,,
770958579,false,true,5,2015-08-14T22:20:00,,No Relation,1,D013974,levothyroxine,D007037,hypothyroidism,The cITP analysis was able to obtain more information about coronary risk factors and may be clinically useful for evaluating the effect of treatment with levothyroxine in patients with hypothyroidism and secondary hyperlipidemia.,17001111_7,17001111_D013974_D007037,,
770958580,false,true,5,2015-08-14T22:21:00,,No Relation,1,D013974,levothyroxine,D006949,hyperlipidemia,The cITP analysis was able to obtain more information about coronary risk factors and may be clinically useful for evaluating the effect of treatment with levothyroxine in patients with hypothyroidism and secondary hyperlipidemia.,17001111_7,17001111_D013974_D006949,,
770958581,false,true,5,2015-08-14T22:22:00,,No Relation,1,D014859,warfarin,D020521,stroke,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,17020434_D014859_D020521,,
770958582,false,true,5,2015-08-14T21:59:00,,No Relation,1,D001241,aspirin,D020521,stroke,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,17020434_D001241_D020521,,
770958583,false,true,5,2015-08-14T22:26:00,,No Relation,1,D014859,warfarin,D020521,strokes,"Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.",17020434_3,17020434_D014859_D020521,,
770958584,false,true,5,2015-08-14T23:35:00,'Preventing' being the key term,No Relation,1,D001241,aspirin,D020521,strokes,"Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.",17020434_3,17020434_D001241_D020521,,
770958585,false,true,5,2015-08-15T00:21:00,,Direct,1,C426686,Ximelagatran,D011681,abnormal liver function,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,17020434_C426686_D011681,,
770958586,false,true,5,2015-08-14T21:46:00,,No Relation,0.819,D014812,vitamin K,D011681,abnormal liver function,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,17020434_D014812_D011681,,
770958587,false,true,5,2015-08-14T22:34:00,,No Relation,1,D014812,vitamin K,D004617,embolic events,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,17020434_D014812_D004617,,
770958588,false,true,5,2015-08-15T02:13:00,,No Relation,1,C426686,Ximelagatran,D004617,embolic events,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,17020434_C426686_D004617,,
770958589,false,true,5,2015-08-14T21:05:00,,No Relation,1,C055162,Clopidogrel,D001281,Atrial Fibrillation,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_C055162_D001281,,
770958590,false,true,5,2015-08-15T00:20:00,,No Relation,1,C081309,Irbesartan,D004617,embolic events,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_C081309_D004617,,
770958591,false,true,5,2015-08-15T02:09:00,,No Relation,1,D014859,warfarin,D004617,embolic events,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_D014859_D004617,,
770958592,false,true,5,2015-08-14T22:19:00,,No Relation,1,C055162,Clopidogrel,D004617,embolic events,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_C055162_D004617,,
770958593,false,true,5,2015-08-14T21:42:00,,No Relation,0.814,D001241,aspirin,D001281,Atrial Fibrillation,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_D001241_D001281,,
770958594,false,true,5,2015-08-14T22:17:00,,No Relation,1,D014859,warfarin,D001281,Atrial Fibrillation,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_D014859_D001281,,
770958595,false,true,5,2015-08-14T22:27:00,,No Relation,1,D001241,aspirin,D004617,embolic events,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_D001241_D004617,,
770958596,false,true,5,2015-08-14T21:11:00,,No Relation,1,C081309,Irbesartan,D001281,Atrial Fibrillation,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,17020434_C081309_D001281,,
770958597,false,true,5,2015-08-15T02:16:00,,No Relation,0.8134,D000809,Angiotensin,D001281,atrial fibrillation,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,17020434_D000809_D001281,,
770958598,false,true,5,2015-08-15T01:54:00,,No Relation,1,D000809,Angiotensin,D020257,cardiac remodelling,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,17020434_D000809_D020257,,
770958599,false,true,5,2015-08-15T01:28:00,,No Relation,1,D001647,bile acid,D001471,Barrett's esophagus,Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.,17054793_0,17054793_D001647_D001471,,
770958600,false,true,5,2015-08-15T01:19:00,,No Relation,1,D001647,bile acid,D001471,Barrett's esophagus,"The aim of this study was to assess the expression of bile acid receptors in the esophagus (normal, esophagitis, Barrett's esophagus and adenocarcinoma) and to investigate their possible function.",17054793_2,17054793_D001647_D001471,,
770958601,false,true,5,2015-08-15T01:25:00,,No Relation,1,D001647,bile acid,D000230,adenocarcinoma,"The aim of this study was to assess the expression of bile acid receptors in the esophagus (normal, esophagitis, Barrett's esophagus and adenocarcinoma) and to investigate their possible function.",17054793_2,17054793_D001647_D000230,,
770958602,false,true,5,2015-08-14T23:45:00,,No Relation,1,D001647,bile acid,D004941,esophagitis,"The aim of this study was to assess the expression of bile acid receptors in the esophagus (normal, esophagitis, Barrett's esophagus and adenocarcinoma) and to investigate their possible function.",17054793_2,17054793_D001647_D004941,,
770958603,false,true,5,2015-08-15T01:03:00,,No Relation,1,D001647,bile acid,D001471,Barrett's esophagus,"The expression of the bile acid receptors FXR and VDR in esophageal biopsies from patients with a normal mucosa, esophagitis, Barrett's esophagus or adenocarcinoma (n = 6 per group) and in cell lines derived from Barrett's esophagus and esophageal adenocarcinoma, was assessed by real time Q-PCR and immunohistochemistry.",17054793_3,17054793_D001647_D001471,,
770958604,false,true,5,2015-08-14T22:10:00,,No Relation,1,D001647,bile acid,D000230,esophageal adenocarcinoma/adenocarcinoma,"The expression of the bile acid receptors FXR and VDR in esophageal biopsies from patients with a normal mucosa, esophagitis, Barrett's esophagus or adenocarcinoma (n = 6 per group) and in cell lines derived from Barrett's esophagus and esophageal adenocarcinoma, was assessed by real time Q-PCR and immunohistochemistry.",17054793_3,17054793_D001647_D000230,,
770958605,false,true,5,2015-08-14T22:12:00,,No Relation,1,D001647,bile acid,D004941,esophagitis,"The expression of the bile acid receptors FXR and VDR in esophageal biopsies from patients with a normal mucosa, esophagitis, Barrett's esophagus or adenocarcinoma (n = 6 per group) and in cell lines derived from Barrett's esophagus and esophageal adenocarcinoma, was assessed by real time Q-PCR and immunohistochemistry.",17054793_3,17054793_D001647_D004941,,
770958606,false,true,5,2015-08-15T00:19:00,,No Relation,1,D001647,bile acid,D001471,Barrett's esophagus,"The effect of guggulsterone, an antagonist of bile acid receptors, on apoptosis of Barrett's esophagus-derived cells was assessed morphologically, by flow cytometry and by measuring caspase 3 activity.",17054793_4,17054793_D001647_D001471,,
770958607,false,true,5,2015-08-14T21:36:00,,No Relation,0.8095,C023617,guggulsterone,D001471,Barrett's esophagus,"The effect of guggulsterone, an antagonist of bile acid receptors, on apoptosis of Barrett's esophagus-derived cells was assessed morphologically, by flow cytometry and by measuring caspase 3 activity.",17054793_4,17054793_C023617_D001471,,
770958608,false,true,5,2015-08-15T02:04:00,,No Relation,1,D001647,bile acid,D001471,Barrett's esophagus,"The bile acid receptor FXR is significantly overexpressed in Barrett's esophagus compared to normal mucosa, esophagitis and esophageal adenocarcinoma.",17054793_10,17054793_D001647_D001471,,
770958609,false,true,5,2015-08-15T00:44:00,,No Relation,1,D001647,bile acid,D000230,esophageal adenocarcinoma,"The bile acid receptor FXR is significantly overexpressed in Barrett's esophagus compared to normal mucosa, esophagitis and esophageal adenocarcinoma.",17054793_10,17054793_D001647_D000230,,
770958610,false,true,5,2015-08-14T22:31:00,,No Relation,1,D001647,bile acid,D004941,esophagitis,"The bile acid receptor FXR is significantly overexpressed in Barrett's esophagus compared to normal mucosa, esophagitis and esophageal adenocarcinoma.",17054793_10,17054793_D001647_D004941,,
770958611,false,true,5,2015-08-14T22:16:00,,No Relation,1,D003487,cyanoacrylate,D005402,bronchopleural fistula,Transthoracic closure of a postpneumonectomy bronchopleural fistula with coils and cyanoacrylate.,17062286_0,17062286_D003487_D005402,,
770958612,false,true,5,2015-08-15T01:48:00,,No Relation,1,C036854|D017338,2-chloro-2'-deoxyadenosine,D015448,B-cell leukemia,Inhibition of the ERK pathway promotes apoptosis induced by 2-chloro-2'-deoxyadenosine in the B-cell leukemia cell line EHEB.,17065055_0,17065055_C036854|D017338_D015448,,
770958613,false,true,5,2015-08-15T01:25:00,,No Relation,0.7973,D009705,nucleoside,D015451,chronic lymphocytic leukemia,2-Chloro-2'-deoxyadenosine (CdA) is a nucleoside analogue active in B-cell chronic lymphocytic leukemia (B-CLL).,17065055_1,17065055_D009705_D015451,,
770958614,false,true,5,2015-08-14T22:26:00,,No Relation,1,C036854|D017338,CdA/2-Chloro-2'-deoxyadenosine,D015451,chronic lymphocytic leukemia,2-Chloro-2'-deoxyadenosine (CdA) is a nucleoside analogue active in B-cell chronic lymphocytic leukemia (B-CLL).,17065055_1,17065055_C036854|D017338_D015451,,
770958615,false,true,5,2015-08-15T00:16:00,,No Relation,1,D002976,clenbuterol,D009202,myocardial atrophy,"Once regression of left ventricular enlargement had been achieved, the beta2-adrenergic-receptor agonist clenbuterol was administered to prevent myocardial atrophy.",17079761_6,17079761_D002976_D009202,,
770958616,false,true,5,2015-08-14T21:28:00,,No Relation,1,D002976,clenbuterol,D006332,ventricular enlargement,"Once regression of left ventricular enlargement had been achieved, the beta2-adrenergic-receptor agonist clenbuterol was administered to prevent myocardial atrophy.",17079761_6,17079761_D002976_D006332,,
770958617,false,true,5,2015-08-15T01:52:00,,No Relation,0.7904,D000420,salbutamol,D054318,Flow-mediated dilation,"Flow-mediated dilation (p < 0.001) and PWA with salbutamol (p = 0.03) responses fell after typhoid vaccination, and PCA (p = 0.7) was unchanged.",17084260_9,17084260_D000420_D054318,,
770958618,false,true,5,2015-08-14T22:19:00,,No Relation,1,D000420,salbutamol,D014652,Vascular dysfunction,Vascular dysfunction during acute inflammation can be measured by FMD and by PWA with salbutamol.,17084260_10,17084260_D000420_D014652,,
770958619,false,true,5,2015-08-15T01:35:00,,No Relation,1,D000420,salbutamol,D054318,FMD,Vascular dysfunction during acute inflammation can be measured by FMD and by PWA with salbutamol.,17084260_10,17084260_D000420_D054318,,
770958620,false,true,5,2015-08-14T23:18:00,Measuring drug.,No Relation,1,D000420,salbutamol,D007249,inflammation,Vascular dysfunction during acute inflammation can be measured by FMD and by PWA with salbutamol.,17084260_10,17084260_D000420_D007249,,
770958621,false,true,5,2015-08-15T02:09:00,,No Relation,1,D011729,pyridostigmine,D001327,Autoimmune gastrointestinal dysmotility,Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine.,17101331_0,17101331_D011729_D001327,,
770958622,false,true,5,2015-08-14T22:14:00,,No Relation,1,D000109,acetylcholine,D001327,AGID,"Of numerous autoantibodies currently recognized as biomarkers of AGID, the ganglionic acetylcholine receptor autoantibody is the only proven pathophysiologic effector.",17101331_15,17101331_D000109_D001327,,
770958623,false,true,5,2015-08-14T21:54:00,,No Relation,1,D006513,HBeAg,D006509,hepatitis B,"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.",17127704_0,17127704_D006513_D006509,,
770958624,false,true,5,2015-08-15T01:52:00,,No Relation,1,D019259,lamivudine,D006509,hepatitis B,"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.",17127704_0,17127704_D019259_D006509,,
770958625,false,true,5,2015-08-14T22:26:00,,No Relation,0.7946,D006513,HBeAg/hepatitis B e antigen,D006509,hepatitis B,"In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone.",17127704_1,17127704_D006513_D006509,,
770958626,false,true,5,2015-08-15T02:18:00,,No Relation,1,D019259,lamivudine,D006509,hepatitis B,"In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone.",17127704_1,17127704_D019259_D006509,,
770958627,false,true,5,2015-08-15T00:41:00,,No Relation,1,D000409,alanine,D006509,hepatitis B,"A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml.",17127704_4,17127704_D000409_D006509,,
770958628,false,true,5,2015-08-15T01:29:00,,No Relation,1,D020913,perindopril,D002318,cardiovascular events,Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.,17135223_0,17135223_D020913_D002318,,
770958629,false,true,5,2015-08-14T21:12:00,,No Relation,1,D020913,perindopril,D003324,coronary artery disease,Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.,17135223_0,17135223_D020913_D003324,,
770958630,false,true,5,2015-08-14T21:08:00,,No Relation,1,D020913,Perindopril,D064420,cardiac events,The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported.,17135223_1,17135223_D020913_D064420,,
770958631,false,true,5,2015-08-14T21:08:00,,No Relation,1,D020913,Perindopril,D003324,coronary Artery disease,The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported.,17135223_1,17135223_D020913_D003324,,
770958632,false,true,5,2015-08-15T00:37:00,,No Relation,1,D020913,perindopril,D003327,coronary heart disease,To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK.,17135223_2,17135223_D020913_D003327,,
770958633,false,true,5,2015-08-14T23:43:00,,No Relation,1,D007052,ibuprofen,D000699,analgesia,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D007052_D000699,,
770958634,false,true,5,2015-08-15T01:59:00,,No Relation,1,D000082,acetaminophen,D010146,postoperative pain,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D000082_D010146,,
770958635,false,true,5,2015-08-14T22:32:00,,No Relation,1,D009020,morphine,D010146,postoperative pain,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D009020_D010146,,
770958636,false,true,5,2015-08-15T01:41:00,,No Relation,1,D007052,ibuprofen,D010146,postoperative pain,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D007052_D010146,,
770958637,false,true,5,2015-08-14T23:20:00,It's 'patient-controlled iv analgesia' and not just 'Analgesia',No Relation,1,D000082,acetaminophen,D000699,analgesia,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D000082_D000699,,
770958638,false,true,5,2015-08-14T22:48:00,,No Relation,0.8246,D009020,morphine,D000699,analgesia,To compare the effects of iv acetaminophen with those of oral ibuprofen with respect to postoperative pain control and morphine requirements in patients receiving morphine patient-controlled iv analgesia (PCIA) after Cesarean delivery.,17142654_1,17142654_D009020_D000699,,
770958639,false,true,5,2015-08-15T00:03:00,,No Relation,0.5949,D007052,ibuprofen,D000699,analgesia,Intravenous acetaminophen is a reasonable alternative to oral ibuprofen as an adjunct to morphine patient-controlled analgesia after Cesarean delivery.,17142654_9,17142654_D007052_D000699,,
770958640,false,true,5,2015-08-15T00:00:00,,No Relation,0.8074,D000082,acetaminophen,D000699,analgesia,Intravenous acetaminophen is a reasonable alternative to oral ibuprofen as an adjunct to morphine patient-controlled analgesia after Cesarean delivery.,17142654_9,17142654_D000082_D000699,,
770958641,false,true,5,2015-08-15T00:20:00,,No Relation,1,D019829,nevirapine/NVP,D000744,immunodeficiency,Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.,17178792_0,17178792_D019829_D000744,,
770958642,false,true,5,2015-08-15T02:11:00,,No Relation,1,D019829,NVP,D000744,immunodeficiency,Genotypic resistance analysis was performed on mothers' plasma samples at week 4 postpartum (PP) and on human immunodeficiency virus (HIV) DNA in peripheral blood mononuclear cells (PBMC) when an NVP resistance mutation was detected.,17178792_4,17178792_D019829_D000744,,
770958643,false,true,5,2015-08-14T23:30:00,,Direct,1,D001556,lindane,D005203,farmer's lung,"The insecticides DDT, lindane, and aldicarb were positively associated with farmer's lung among farmers.",17182642_8,17182642_D001556_D005203,,
770958644,false,true,5,2015-08-14T22:42:00,,Direct,1,D003634,DDT,D005203,farmer's lung,"The insecticides DDT, lindane, and aldicarb were positively associated with farmer's lung among farmers.",17182642_8,17182642_D003634_D005203,,
770958645,false,true,5,2015-08-15T01:47:00,,Direct,1,D000448,aldicarb,D005203,farmer's lung,"The insecticides DDT, lindane, and aldicarb were positively associated with farmer's lung among farmers.",17182642_8,17182642_D000448_D005203,,
770958646,false,true,5,2015-08-14T22:27:00,,No Relation,1,D007987,Gonadotropin-releasing hormone,D009214,myoma,Gonadotropin-releasing hormone agonist (GnRH agonist) therapy has been useful as an adjunct before myomectomy or hysterectomy for uterine myoma.,17197363_1,17197363_D007987_D009214,,
770958647,false,true,5,2015-08-14T22:32:00,'Spontaneous expulsion of submucosal myomas' and not just 'submucosal myomas',Direct,0.6131,D007987,GnRH,D009214,submucosal myomas,"Spontaneous expulsion of submucosal myomas might occur after the administration of GnRH agonist; hence, it may be an acceptable alternative for symptomatic females without sexual exposure.",17197363_10,17197363_D007987_D009214,,
770958648,false,true,5,2015-08-15T00:17:00,,No Relation,0.5975,D016685,mitomycin,D064420,toxicity,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D016685_D064420,,
770958649,false,true,5,2015-08-14T23:32:00,,No Relation,1,D016685,mitomycin,D009369,locally advanced breast cancer,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D016685_D009369,,
770958650,false,true,5,2015-08-14T22:04:00,,No Relation,0.7948,D005472,5-fluorouracil,D064420,toxicity,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D005472_D064420,,
770958651,false,true,5,2015-08-14T22:22:00,,Direct,0.5987,D015251,epirubicin,D064420,toxicity,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D015251_D064420,,
770958652,false,true,5,2015-08-14T22:09:00,,No Relation,1,D005472,5-fluorouracil,D009369,locally advanced breast cancer,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D005472_D009369,,
770958653,false,true,5,2015-08-14T21:54:00,,No Relation,0.8142,D015251,epirubicin,D009369,locally advanced breast cancer,"The feasibility, toxicity and local response rates of intra-arterial chemotherapy with 5-fluorouracil, epirubicin and mitomycin in patients over 75 years with locally advanced breast cancer was evaluated.",17203763_1,17203763_D015251_D009369,,
770958654,false,true,5,2015-08-14T23:37:00,,Direct,1,D004298,dopamine,D001480,extrapyramidal symptoms,"The presence of PDE10A in both striatal output pathways may reduce the incidence and severity of dopamine D2 receptor antagonist-like side effects, including extrapyramidal symptoms.",17263185_6,17263185_D004298_D001480,,
770958655,false,true,5,2015-08-15T00:44:00,,No Relation,1,D002131,calcium pyrophosphate dihydrate,D001177,arthropathy,"To the best of our knowledge, no case of calcium pyrophosphate dihydrate arthropathy after total knee arthroplasty has been reported previously.",17275646_6,17275646_D002131_D001177,,
770958656,false,true,5,2015-08-15T00:45:00,,No Relation,0.7978,D004967,Estrogen,D009369,breast cancer,Estrogen receptor alpha regulates expression of the breast cancer 1 associated ring domain 1 (BARD1) gene through intronic DNA sequence.,17275994_0,17275994_D004967_D009369,,
770958657,false,true,5,2015-08-14T22:32:00,,No Relation,0.808,D004967,estrogen,D009369,breast cancer,We have used a chromatin immunoprecipitation (ChIP)-based cloning strategy to isolate and identify genes associated with estrogen receptor alpha (ERalpha) in MCF-7 human breast cancer cells.,17275994_1,17275994_D004967_D009369,,
770958658,false,true,5,2015-08-14T22:05:00,,No Relation,1,C065179,Atorvastatin,D003929,diabetes,"Atorvastatin exerts beneficial vascular effects in diabetes, but the underlying mechanisms are yet to be elucidated.",17279352_1,17279352_C065179_D003929,,
770958659,false,true,5,2015-08-14T22:09:00,,Direct,0.5774,C065179,atorvastatin,D014652,vascular dysfunction,The aim of the present study was to determine whether Rac-1 is involved in the effect of atorvastatin on oxidative stress and vascular dysfunction.,17279352_2,17279352_C065179_D014652,,
770958660,false,true,5,2015-08-14T21:22:00,,No Relation,0.5924,C065179,Atorvastatin,D014652,vascular abnormalities,Atorvastatin failed to afford protection against vascular abnormalities in the presence of a constitutively active mutant of Rac-1.,17279352_10,17279352_C065179_D014652,,
770958661,false,true,5,2015-08-15T02:02:00,,No Relation,1,C065179,atorvastatin,D003929,diabetes,The results of this study demonstrate that the vascular antioxidant effect of atorvastatin in diabetes is mediated through inhibition of Rac-1 via a reduction in GGPP.,17279352_11,17279352_C065179_D003929,,
770958662,false,true,5,2015-08-15T00:35:00,,No Relation,0.5773,D005283,fentanyl,D007022,hypotension,Episodes of hypotension and transient reduction in splanchnic perfusion were more common in patients treated with remifentanil when compared to those receiving the fentanyl opioid regimen.,17285425_10,17285425_D005283_D007022,,
770958663,false,true,5,2015-08-14T22:22:00,,No Relation,0.8002,D005283,fentanyl,D015431,reduction in splanchnic perfusion,Episodes of hypotension and transient reduction in splanchnic perfusion were more common in patients treated with remifentanil when compared to those receiving the fentanyl opioid regimen.,17285425_10,17285425_D005283_D015431,,
770958664,false,true,5,2015-08-15T00:19:00,,Direct,1,C071741,remifentanil,D007022,hypotension,Episodes of hypotension and transient reduction in splanchnic perfusion were more common in patients treated with remifentanil when compared to those receiving the fentanyl opioid regimen.,17285425_10,17285425_C071741_D007022,,
770958665,false,true,5,2015-08-14T22:27:00,,Direct,1,C071741,remifentanil,D015431,reduction in splanchnic perfusion,Episodes of hypotension and transient reduction in splanchnic perfusion were more common in patients treated with remifentanil when compared to those receiving the fentanyl opioid regimen.,17285425_10,17285425_C071741_D015431,,
770958666,false,true,5,2015-08-15T01:58:00,,No Relation,1,D008094,lithium,D003866,depression,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D008094_D003866,,
770958667,false,true,5,2015-08-15T01:15:00,,No Relation,1,D000928,antidepressants,D001714,mania/bipolar disorder,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D000928_D001714,,
770958668,false,true,5,2015-08-15T01:57:00,,No Relation,0.8278,D000928,antidepressants,D003866,depression,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D000928_D003866,,
770958669,false,true,5,2015-08-14T21:42:00,,No Relation,1,D001569,benzodiazepines,D003866,depression,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D001569_D003866,,
770958670,false,true,5,2015-08-14T22:21:00,,No Relation,1,D008094,lithium,D001714,mania/bipolar disorder,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D008094_D001714,,
770958671,false,true,5,2015-08-14T21:56:00,,No Relation,1,D001569,benzodiazepines,D001714,mania/bipolar disorder,"Available options for the treatment of bipolar disorder (including those for mania, hypomania, depression, or maintenance) in the elderly include lithium, antiepileptics, antipsychotics, benzodiazepines, antidepressants, electroconvulsive therapy (ECT), and psychotherapy.",17296540_21,17296540_D001569_D001714,,
770958672,false,true,5,2015-08-14T23:50:00,,No Relation,1,D002220,carbamazepine,D001714,bipolar disorder,"Lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, and antidepressants have all been found to be beneficial in the treatment of elderly patients with bipolar disorder.",17296540_23,17296540_D002220_D001714,,
770958673,false,true,5,2015-08-14T21:46:00,,No Relation,1,D014635,divalproex sodium,D001714,bipolar disorder,"Lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, and antidepressants have all been found to be beneficial in the treatment of elderly patients with bipolar disorder.",17296540_23,17296540_D014635_D001714,,
770958674,false,true,5,2015-08-15T01:52:00,,No Relation,1,C047781,lamotrigine,D001714,bipolar disorder,"Lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, and antidepressants have all been found to be beneficial in the treatment of elderly patients with bipolar disorder.",17296540_23,17296540_C047781_D001714,,
770958675,false,true,5,2015-08-14T23:14:00,,No Relation,1,D008094,Lithium,D001714,bipolar disorder,"Lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, and antidepressants have all been found to be beneficial in the treatment of elderly patients with bipolar disorder.",17296540_23,17296540_D008094_D001714,,
770958676,false,true,5,2015-08-14T22:27:00,,No Relation,1,D006415,hematoporphyrin,D009369,NMSC,"The objective was to present six patients with multiple, nodular, and/or pigmented NMSC treated successfully with purified hematoporphyrin derivative (PHD) and PDT using prior debulking.",17300605_3,17300605_D006415_D009369,,
770958677,false,true,5,2015-08-15T01:46:00,,No Relation,0.8083,D003520,cyclophosphamide,D009369,breast cancer,Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).,17308269_0,17308269_D003520_D009369,,
770958678,false,true,5,2015-08-15T02:23:00,,No Relation,0.8069,D018943,anthracycline,D009369,breast cancer,Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).,17308269_0,17308269_D018943_D009369,,
770958679,false,true,5,2015-08-14T22:19:00,,No Relation,1,D003520,C/cyclophosphamide,D011475,OS/overall survival,We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration of sequential single agents (A --> C) results in superior disease-free survival (DFS) and overall survival (OS) versus the same total dose given in combination (AC).,17308269_1,17308269_D003520_D011475,,
770958680,false,true,5,2015-08-15T00:08:00,,No Relation,1,D003520,C/cyclophosphamide,D009369,breast cancer,We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration of sequential single agents (A --> C) results in superior disease-free survival (DFS) and overall survival (OS) versus the same total dose given in combination (AC).,17308269_1,17308269_D003520_D009369,,
770958681,false,true,5,2015-08-14T22:20:00,,No Relation,0.7993,D004317,doxorubicin,D009369,breast cancer,We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration of sequential single agents (A --> C) results in superior disease-free survival (DFS) and overall survival (OS) versus the same total dose given in combination (AC).,17308269_1,17308269_D004317_D009369,,
770958682,false,true,5,2015-08-15T00:45:00,,No Relation,0.601,D004317,doxorubicin,D011475,OS/overall survival,We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration of sequential single agents (A --> C) results in superior disease-free survival (DFS) and overall survival (OS) versus the same total dose given in combination (AC).,17308269_1,17308269_D004317_D011475,,
770958683,false,true,5,2015-08-14T21:47:00,,No Relation,1,D003520,cyclophosphamide,D009369,breast cancer,High-risk node-negative or low-risk node-positive breast cancer patients received AC given: (arm I) concurrently (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles; or (arm II) in sequence (A C) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles.,17308269_2,17308269_D003520_D009369,,
770958684,false,true,5,2015-08-14T22:14:00,,No Relation,1,D004317,doxorubicin,D009369,breast cancer,High-risk node-negative or low-risk node-positive breast cancer patients received AC given: (arm I) concurrently (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles; or (arm II) in sequence (A C) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles.,17308269_2,17308269_D004317_D009369,,
770958685,false,true,5,2015-08-15T00:13:00,,No Relation,1,D013629,tamoxifen,D009369,tumors,All but premenopausal women with receptor negative tumors received tamoxifen after chemotherapy.,17308269_4,17308269_D013629_D009369,,
770958686,false,true,5,2015-08-15T00:26:00,,No Relation,1,D003520,C,D011475,OS,"No significant differences in OS or DFS were observed; 5-year estimates of OS (95% CI) were 88% (87% to 90%) on AC and 89% (87% to 91%) on A --> C. Grade 4 hematologic toxicity was greater on A --> C, but nonhematological grade 4 was similar.",17308269_7,17308269_D003520_D011475,,
770958687,false,true,5,2015-08-14T21:08:00,,No Relation,0.79,D003520,C,D064420,toxicity,"No significant differences in OS or DFS were observed; 5-year estimates of OS (95% CI) were 88% (87% to 90%) on AC and 89% (87% to 91%) on A --> C. Grade 4 hematologic toxicity was greater on A --> C, but nonhematological grade 4 was similar.",17308269_7,17308269_D003520_D064420,,
770958688,false,true,5,2015-08-15T02:39:00,,No Relation,1,C071315,ramosetron,D043183,IBS,"Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.",17323187_0,17323187_C071315_D043183,,
770958689,false,true,5,2015-08-14T23:16:00,,No Relation,0.6153,D012701,serotonin/5-HT,D015746,abdominal pain,Ramosetron is a potent and selective serotonin (5-HT)(3) receptor antagonist that has been shown to affect abnormal colonic function and abdominal pain in animals.,17323187_1,17323187_D012701_D015746,,
770958690,false,true,5,2015-08-14T23:38:00,,Direct,0.8043,C071315,Ramosetron,D015746,abdominal pain,Ramosetron is a potent and selective serotonin (5-HT)(3) receptor antagonist that has been shown to affect abnormal colonic function and abdominal pain in animals.,17323187_1,17323187_C071315_D015746,,
770958691,false,true,5,2015-08-15T00:18:00,,No Relation,0.788,C084473,cilansetron,D049913,corticotropin releasing factor/CRF,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C084473_D049913,,
770958692,false,true,5,2015-08-15T02:33:00,,No Relation,1,C090840,alosetron,D002869,abnormal defecation,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C090840_D002869,,
770958693,false,true,5,2015-08-15T01:33:00,,No Relation,0.7948,C090840,alosetron,D049913,corticotropin releasing factor/CRF,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C090840_D049913,,
770958694,false,true,5,2015-08-15T00:20:00,,No Relation,1,C084473,cilansetron,D002869,abnormal defecation,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C084473_D002869,,
770958695,false,true,5,2015-08-15T01:22:00,,No Relation,1,D012701,5-HT,D049913,corticotropin releasing factor/CRF,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_D012701_D049913,,
770958696,false,true,5,2015-08-15T02:18:00,,No Relation,0.7981,D008139,loperamide,D049913,corticotropin releasing factor/CRF,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_D008139_D049913,,
770958697,false,true,5,2015-08-14T21:59:00,,No Relation,0.6029,C071315,Ramosetron,D049913,corticotropin releasing factor/CRF,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C071315_D049913,,
770958698,false,true,5,2015-08-15T00:42:00,,No Relation,1,C071315,Ramosetron,D002869,abnormal defecation,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_C071315_D002869,,
770958699,false,true,5,2015-08-14T22:01:00,,No Relation,1,D008139,loperamide,D002869,abnormal defecation,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_D008139_D002869,,
770958700,false,true,5,2015-08-14T21:15:00,,No Relation,0.599,D012701,5-HT,D002869,abnormal defecation,"Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide.",17323187_2,17323187_D012701_D002869,,
770958701,false,true,5,2015-08-14T22:22:00,,No Relation,1,C071315,Ramosetron,D049913,CRF,"Ramosetron (3 to 100 microg/kg, p. o.) also significantly prevented CFS-induced acceleration of colonic transit and CRF-induced abnormal water transport in rats, respectively.",17323187_4,17323187_C071315_D049913,,
770958702,false,true,5,2015-08-14T22:14:00,,No Relation,1,C071315,ramosetron,D010146,colonic pain,"Moreover, ramosetron (0.3 to 3 microg/kg, p. o.) significantly suppressed restraint stress-induced decrease in colonic pain threshold, an effect not observed with loperamide.",17323187_5,17323187_C071315_D010146,,
770958703,false,true,5,2015-08-14T23:44:00,,No Relation,1,D008139,loperamide,D010146,colonic pain,"Moreover, ramosetron (0.3 to 3 microg/kg, p. o.) significantly suppressed restraint stress-induced decrease in colonic pain threshold, an effect not observed with loperamide.",17323187_5,17323187_D008139_D010146,,
770958704,false,true,5,2015-08-14T21:42:00,,No Relation,1,C071315,ramosetron,D043183,IBS,These results indicate that ramosetron produce beneficial clinical effects on IBS symptoms.,17323187_6,17323187_C071315_D043183,,
770958705,false,true,5,2015-08-15T02:16:00,,No Relation,1,D017239,paclitaxel,D005354,fibrosarcoma,"Experiments using human fibrosarcoma HT1080 respiratory-deficient cells (rho(0)) and uncoupler of the mitochondrial respiratory chain (MRC) showed that betaTAC and N-betaTAC impaired the MRC. rho(0) cells displayed an increased sensitivity toward N-betaTAC as compared with rho(+) cells but, in contrast, were resistant to betaTAC or classic chemotherapeutics, such as paclitaxel.",17332362_4,17332362_D017239_D005354,,
770958706,false,true,5,2015-08-15T00:21:00,,No Relation,1,D004967,estrogen,D009369,breast cancer,Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorata.,17391824_0,17391824_D004967_D009369,,
770958707,false,true,5,2015-08-14T21:47:00,,No Relation,1,D004967,estrogen,D009369,breast cancer,The objective of this study was to investigate the fermented culture broth of Antrodia camphorata (A. camphorata) to induce apoptosis and inhibit cyclooxygenase-2 (COX-2) in estrogen-nonresponsive (MDA-MB-231) human breast cancer cells.,17391824_1,17391824_D004967_D009369,,
770958708,false,true,5,2015-08-15T01:14:00,,No Relation,0.7925,D004967,estrogen,D009369,breast cancer,"Analysis of the study data suggests that A. camphorata exerts growth inhibition on (highly invasive) estrogen-nonresponsive human breast cancer cells through apoptosis induction associated with COX-2 inhibition, and that it may possess anticancer properties potentially valuable for application in drug products.",17391824_6,17391824_D004967_D009369,,
770958709,false,true,5,2015-08-15T00:50:00,,No Relation,1,C047426,venlafaxine,D003866,depressive disorder,"Effects of high dose venlafaxine (mean 346.15 mg;) on the cardiovascular system in 37 patients with major depressive disorder were evaluated: BP, ECG (PR, QT, QRSD and QTc intervals) and heart rate.",17397100_2,17397100_C047426_D003866,,
770958710,false,true,5,2015-08-15T02:14:00,,Direct,1,C047426,venlafaxine,D006973,hypertension,12.5% of patients developed hypertension after starting treatment with venlafaxine.,17397100_3,17397100_C047426_D006973,,
770958711,false,true,5,2015-08-14T21:48:00,,No Relation,0.794,D012701,serotonin,D020230,serotonin reuptake inhibitors/SRIs,There are a growing number of concerns about the utilization of serotonin reuptake inhibitors (SRIs) in late pregnancy and the onset of perinatal complications.,17407365_1,17407365_D012701_D020230,,
770958712,false,true,5,2015-08-15T01:52:00,,Direct,0.7841,D000431,Alcohol,D014947,injury in older adults,Alcohol-drinking history and fatal injury in older adults.,17418699_0,17418699_D000431_D014947,,
770958713,false,true,5,2015-08-15T00:33:00,,No Relation,1,D009538,nicotine,D020961,Lewy body diseases,Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.,17425956_0,17425956_D009538_D020961,,
770958714,false,true,5,2015-08-15T00:23:00,,No Relation,1,D010073,oxamniquine,D000208,acute schistosomiasis,Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens.,17426890_0,17426890_D010073_D000208,,
770958715,false,true,5,2015-08-14T21:33:00,,No Relation,1,D010073,oxamniquine,D000208,acute schistosomiasis,Patients with acute schistosomiasis were studied before and after oxamniquine treatment.,17426890_1,17426890_D010073_D000208,,
770958716,false,true,5,2015-08-14T21:49:00,,No Relation,1,D010073,oxamniquine,D000208,acute schistosomiasis,The oxamniquine treatment of acute schistosomiasis patients is followed by an improvement of a Th1 response in vitro.,17426890_5,17426890_D010073_D000208,,
770958717,false,true,5,2015-08-14T23:56:00,,No Relation,1,D001623,betamethasone,D005076,rash,"However, both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash than the combination of dexchlorpheniramine and betamethasone.",17443568_14,17443568_D001623_D005076,,
770958718,false,true,5,2015-08-14T21:12:00,,No Relation,1,C018904,dexchlorpheniramine,D005076,rash,"However, both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash than the combination of dexchlorpheniramine and betamethasone.",17443568_14,17443568_C018904_D005076,,
770958719,false,true,5,2015-08-14T21:15:00,,No Relation,1,D004917,erythromycin,D005076,rash,"The small good quality trial (40 people) that compared oral erythromycin and placebo found that erythromycin was more effective than placebo in terms of rash improvement, as rated by the trialists, after two weeks (RR 13.00; 95% CI 1.91 to 88.64).",17443568_16,17443568_D004917_D005076,,
770958720,false,true,5,2015-08-15T00:32:00,,Direct,0.8068,D004917,erythromycin,D005767,gastrointestinal upset,Two out of 17 people on oral erythromycin and 1 out of 17 on placebo reported minor gastrointestinal upset.,17443568_19,17443568_D004917_D005767,,
770958721,false,true,5,2015-08-14T21:52:00,,No Relation,1,D004917,erythromycin,D005076,rash,Oral erythromycin may be effective in treating the rash and decreasing the itch.,17443568_21,17443568_D004917_D005076,,
770958722,false,true,5,2015-08-15T00:44:00,,No Relation,1,D005947,glucose,D006402,blood glucose,"In most of the studies examined, the efficacy of BIAsp 30 was evaluated in terms of glycaemic control (glycosylated haemoglobin [HbA(1c)] reduction, proportion of patients achieving HbA(1c) target of <6.5% or <7%, fasting blood glucose, blood glucose profile and/or prandial and postprandial glucose increments).",17451279_9,17451279_D005947_D006402,,
770958723,false,true,5,2015-08-14T22:22:00,,No Relation,1,D019270,fructosamine,D007003,postprandial hyperlipidaemia,"In some studies, efficacy was further evaluated using plasma insulin and glucose infusion rates, plasma C-peptide levels, mean serum fructosamine levels, postprandial hyperlipidaemia, overall well-being, treatment satisfaction and quality of life.",17451279_10,17451279_D019270_D007003,,
770958724,false,true,5,2015-08-14T23:26:00,,No Relation,1,D005947,glucose,D007003,postprandial hyperlipidaemia,"In some studies, efficacy was further evaluated using plasma insulin and glucose infusion rates, plasma C-peptide levels, mean serum fructosamine levels, postprandial hyperlipidaemia, overall well-being, treatment satisfaction and quality of life.",17451279_10,17451279_D005947_D007003,,
770958725,false,true,5,2015-08-15T01:17:00,,No Relation,1,C400278,erlotinib,D009369,pancreatic cancer,ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.,17457047_0,17457047_C400278_D009369,,
770958726,false,true,5,2015-08-15T00:16:00,,No Relation,1,C400278,Erlotinib,D009369,pancreatic cancer,"Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been recently approved for pancreatic cancer treatment, but there are no reliable predictors of patient response.",17457047_2,17457047_C400278_D009369,,
770958727,false,true,5,2015-08-14T22:17:00,,No Relation,1,D014443,tyrosine,D009369,pancreatic cancer,"Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been recently approved for pancreatic cancer treatment, but there are no reliable predictors of patient response.",17457047_2,17457047_D014443_D009369,,
770958728,false,true,5,2015-08-14T23:55:00,,No Relation,1,C400278,erlotinib,D009369,pancreatic cancer,We analyzed the influence of ErbB3 expression on pancreatic cancer cell response to erlotinib treatment.,17457047_4,17457047_C400278_D009369,,
770958729,false,true,5,2015-08-14T22:23:00,,No Relation,1,C400278,erlotinib,D009369,pancreatic cancer,Proliferation assays of five human pancreatic cancer cell lines were performed following treatment with erlotinib.,17457047_5,17457047_C400278_D009369,,
770958730,false,true,5,2015-08-15T02:03:00,,No Relation,1,C400278,erlotinib,D009369,pancreatic cancer,The effects of RNA inhibition of ErbB3 on sensitivity to erlotinib treatment were evaluated in AsPC-1 pancreatic cancer cells.,17457047_8,17457047_C400278_D009369,,
770958731,false,true,5,2015-08-15T00:50:00,,No Relation,1,C400278,erlotinib,D009369,Pancreatic cancer,Pancreatic cancer cells which lack ErbB3 do not display activation of the ErbB3-PI3K-Akt cascade induced by EGFR/ErbB3 heterodimers and become less critically dependent on EGFR signaling and therefore resistant to erlotinib.,17457047_12,17457047_C400278_D009369,,
770958732,false,true,5,2015-08-14T21:19:00,,No Relation,1,D005231,polyunsaturated fatty acids,D003929,diabetic,"Although a supplement of low-dose n-3 long-chain polyunsaturated fatty acids had no effect on the plasma high-sensitivity CRP of the supplemented group, a reduction in CRP levels was found when patients were stratified for tertiles of CRP (for the upper tertile) and diabetic status (for nondiabetic patients).",17462553_13,17462553_D005231_D003929,,
770958733,false,true,5,2015-08-15T01:32:00,,No Relation,1,D008694,methamphetamine,D015658,HIV-1 neurodegeneration,Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration.,17504172_0,17504172_D008694_D015658,,
770958734,false,true,5,2015-08-14T21:24:00,,Direct,1,D008694,methamphetamine,D003704,dementia,HIV-1 infection with concurrent methamphetamine (MA) abuse results in exacerbated neurodegenerative changes and rapid progression of a form of sub-cortical dementia termed HIV-1 associated dementia (HAD).,17504172_1,17504172_D008694_D003704,,
770958735,false,true,5,2015-08-15T02:12:00,,No Relation,1,D008694,methamphetamine,D015658,HIV-1 infection,HIV-1 infection with concurrent methamphetamine (MA) abuse results in exacerbated neurodegenerative changes and rapid progression of a form of sub-cortical dementia termed HIV-1 associated dementia (HAD).,17504172_1,17504172_D008694_D015658,,
770958736,false,true,5,2015-08-14T23:43:00,,No Relation,1,D009705,Nucleoside,D000744,immunodeficiency,Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures.,17505984_0,17505984_D009705_D000744,,
770958737,false,true,5,2015-08-14T22:26:00,,Direct,0.7951,D009705,Nucleoside,D014947,axonal injury,Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures.,17505984_0,17505984_D009705_D014947,,
770958738,false,true,5,2015-08-15T02:33:00,,Direct,0.8359,D009705,nucleoside,D028361,mitochondrial injury,"In conclusion, both HIV proteins and nucleoside reverse transcriptase inhibitors (NRTIs) cause axonal damage by inducing mitochondrial injury and rearrangement of microtubules.",17505984_9,17505984_D009705_D028361,,
770958739,false,true,5,2015-08-15T01:06:00,,Direct,0.802,D009705,nucleoside,D006177,axonal damage,"In conclusion, both HIV proteins and nucleoside reverse transcriptase inhibitors (NRTIs) cause axonal damage by inducing mitochondrial injury and rearrangement of microtubules.",17505984_9,17505984_D009705_D006177,,
770958740,false,true,5,2015-08-14T21:19:00,,No Relation,1,C483604,Cloretazine,D009369,CNS tumor,Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.,17522334_0,17522334_C483604_D009369,,
770958741,false,true,5,2015-08-14T21:20:00,,No Relation,0.8048,D006513,HBeAg,D008107,liver disease,"Our aims were to investigate the relationship between serum leptin concentrations and the severity of liver disease in a cohort of subjects with HBeAg negative chronic hepatitis B (CHB) and C (CHC) and to analyze the effect of body composition, the leptin system and insulin resistance together with viral factors on virologic response to antiviral treatment.",17540037_2,17540037_D006513_D008107,,
770958742,false,true,5,2015-08-14T21:24:00,,No Relation,1,D006513,HBeAg,D019694,HBeAg negative chronic hepatitis B/CHB,"Our aims were to investigate the relationship between serum leptin concentrations and the severity of liver disease in a cohort of subjects with HBeAg negative chronic hepatitis B (CHB) and C (CHC) and to analyze the effect of body composition, the leptin system and insulin resistance together with viral factors on virologic response to antiviral treatment.",17540037_2,17540037_D006513_D019694,,
770958743,false,true,5,2015-08-14T23:26:00,,No Relation,0.8343,D019259,lamivudine,D019694,CHB,An inverse correlation between lower leptin levels and response to lamivudine monotherapy was noted in patients with CHB; those with a virologic response presented lower serum leptin levels (5334 vs 13111.5 pg/ml; p-value = 0.003) than non-responders.,17540037_7,17540037_D019259_D019694,,
770958744,false,true,5,2015-08-14T21:42:00,,No Relation,1,D019259,lamivudine,D019694,CHB,Increased serum leptin levels represent a negative prognostic factor for response to lamivudine monotherapy in patients with CHB.,17540037_10,17540037_D019259_D019694,,
770958745,false,true,5,2015-08-14T23:50:00,,No Relation,1,C012629,formoterol,D029424,COPD,Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.,17544264_0,17544264_C012629_D029424,,
770958746,false,true,5,2015-08-15T00:01:00,,No Relation,1,C012629,formoterol,D029424,COPD,"Nineteen patients with varying degrees of COPD were randomized to inhale single doses of formoterol (Oxis) Turbuhaler 4.5, 9, 18, and 36 microg in a double blind, placebo-controlled, crossover design.",17544264_2,17544264_C012629_D029424,,
770958747,false,true,5,2015-08-15T02:13:00,,No Relation,1,C012629,formoterol,D029424,COPD,This study could not show any difference in lung deposition of formoterol inhaled via Turbuhaler between patients with moderate and severe COPD.,17544264_11,17544264_C012629_D029424,,
770958748,false,true,5,2015-08-15T00:37:00,,Direct,0.5895,D005227,fatty acids,D015212,inflammatory bowel disease,"Numerous clinical trials utilizing various types of lipids, including fish oil and short chain fatty acids, suggest that fats play an important role in the inflammatory response that characterizes inflammatory bowel disease.",17545776_5,17545776_D005227_D015212,,
770958749,false,true,5,2015-08-15T00:34:00,,No Relation,0.804,D009599,nitroprusside,D006461,hemolysis,"Cardiopulmonary bypass, hemolysis, and nitroprusside-induced cyanide production.",17578949_0,17578949_D009599_D006461,,
770958750,false,true,5,2015-08-15T00:18:00,,Direct,1,D009599,sodium nitroprusside,D064420,toxicity,Cyanide toxicity is a complication of sodium nitroprusside administration.,17578949_1,17578949_D009599_D064420,,
770958751,false,true,5,2015-08-14T23:57:00,,No Relation,0.6143,D009599,sodium nitroprusside,D064420,toxicity,"Cardiac surgery may increase the risk of cyanide toxicity, because hemolysis during cardiopulmonary bypass (CPB) may catalyze the release of free cyanide from sodium nitroprusside.",17578949_2,17578949_D009599_D064420,,
770958752,false,true,5,2015-08-14T22:00:00,,No Relation,1,D009599,sodium nitroprusside,D006461,hemolysis,"Cardiac surgery may increase the risk of cyanide toxicity, because hemolysis during cardiopulmonary bypass (CPB) may catalyze the release of free cyanide from sodium nitroprusside.",17578949_2,17578949_D009599_D006461,,
770958753,false,true,5,2015-08-15T01:29:00,,No Relation,1,D009599,sodium nitroprusside,D006461,hemolysis,CPB-associated hemolysis and free hemoglobin release accelerated the immediate release of free cyanide from sodium nitroprusside.,17578949_7,17578949_D009599_D006461,,
770958754,false,true,5,2015-08-15T02:13:00,,Direct,0.8057,D009599,sodium nitroprusside,D064420,toxicity,These in vitro findings suggest that cardiac surgical patients may be at increased risk of cyanide toxicity in response to the perioperative administration of sodium nitroprusside.,17578949_8,17578949_D009599_D064420,,
770958755,false,true,5,2015-08-14T21:30:00,,No Relation,1,D014221,triamcinolone,D004487,macular oedema,Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema.,17608830_0,17608830_D014221_D004487,,
770958756,false,true,5,2015-08-14T22:12:00,,No Relation,1,D014222,triamcinolone acetonide,D004487,macular oedema,To evaluate the effect of intravitreal injections of triamcinolone acetonide (IVTA) combined with panretinal photocoagulation (PRP) on visual acuity (VA) and foveal thickness in patients with concomitant high-risk proliferative diabetic retinopathy (PDR) and clinically significant macular oedema (CSMO).,17608830_1,17608830_D014222_D004487,,
770958757,false,true,5,2015-08-14T21:35:00,,No Relation,0.8032,D014807,vitamin D,D010024,osteoporosis,Experimental osteoporosis induced by ovariectomy and vitamin D deficiency does not markedly affect fracture healing in rats.,17611855_0,17611855_D014807_D010024,,
770958758,false,true,5,2015-08-15T01:35:00,,No Relation,1,D014807,vitamin D,D014082,fracture,Experimental osteoporosis induced by ovariectomy and vitamin D deficiency does not markedly affect fracture healing in rats.,17611855_0,17611855_D014807_D014082,,
770958759,false,true,5,2015-08-14T21:10:00,,Direct,0.5818,D014807,vitamin D,D005265,weakening of the femoral neck,"We therefore studied this issue in vitamin D-depleted ovariectomized (OVX) rats, an OP model previously shown to induce weakening of the femoral neck, and thus thought to be closer to the human condition than the classic OVX rat model.",17611855_2,17611855_D014807_D005265,,
770958760,false,true,5,2015-08-14T21:31:00,,No Relation,1,D014807,vitamin D,D010024,OP,"We therefore studied this issue in vitamin D-depleted ovariectomized (OVX) rats, an OP model previously shown to induce weakening of the femoral neck, and thus thought to be closer to the human condition than the classic OVX rat model.",17611855_2,17611855_D014807_D010024,,
770958761,false,true,5,2015-08-15T00:15:00,,No Relation,0.8011,D004958,estradiol,D016301,Bone loss,Bone loss and callus formation were monitored with DXA; serum levels of estradiol and vitamin D3 were measured and histomorphometric analyses were performed.,17611855_5,17611855_D004958_D016301,,
770958762,false,true,5,2015-08-15T00:50:00,,No Relation,1,D002762,vitamin D3,D016301,Bone loss,Bone loss and callus formation were monitored with DXA; serum levels of estradiol and vitamin D3 were measured and histomorphometric analyses were performed.,17611855_5,17611855_D002762_D016301,,
770958763,false,true,5,2015-08-14T21:48:00,,No Relation,1,D004967,estrogen,D014082,fracture,Our results suggest that the systemic effects of estrogen and vitamin D deficiency are not crucial for fracture healing or mechanical properties of the callus.,17611855_10,17611855_D004967_D014082,,
770958764,false,true,5,2015-08-15T00:47:00,,No Relation,1,D014807,vitamin D,D014082,fracture,Our results suggest that the systemic effects of estrogen and vitamin D deficiency are not crucial for fracture healing or mechanical properties of the callus.,17611855_10,17611855_D014807_D014082,,
770958765,false,true,5,2015-08-14T21:56:00,,No Relation,0.6154,D002945,cisplatin,D003643,death,"A meta-analysis of early trials of adjuvant chemotherapy by the Non-Small Cell Lung Cancer Collaborative Group showed that while chemotherapy with alkylating agents was also detrimental, chemotherapy with cisplatin-based adjuvant chemotherapy was associated with an improved hazard ratio for death (HR = 0.87), equating to a 5 percent survival benefit at 5 years.",17612931_3,17612931_D002945_D003643,,
770958766,false,true,5,2015-08-15T00:57:00,,No Relation,1,D002945,cisplatin,D002289,NSCLC,"Three trials (IALT, JBR 10, and ANITA) that utilized cisplatin-based doublets showed a significantly positive survival benefit of adjuvant chemotherapy in patients with Stage II-IIIA NSCLC.",17612931_6,17612931_D002945_D002289,,
770958767,false,true,5,2015-08-14T21:10:00,,No Relation,1,D002945,cisplatin,D002289,NSCLC,These data indicate that medically fit patients with resected Stage II-IIIA NSCLC should be offered adjuvant chemotherapy with a modern cisplatin-based doublet.,17612931_8,17612931_D002945_D002289,,
770958768,false,true,5,2015-08-14T21:20:00,,No Relation,1,D002945,Cisplatin,D009369,primary tumor,Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.,17639394_0,17639394_D002945_D009369,,
770958769,false,true,5,2015-08-14T23:20:00,,No Relation,0.7895,D002945,cisplatin,D009369,primary tumor,"In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated.",17639394_1,17639394_D002945_D009369,,
770958770,false,true,5,2015-08-14T23:48:00,,No Relation,0.7963,D006151,guanosine,D009369,tumor,Linear relationships and high correlations were observed between the levels of two guanosine- and adenosine-guanosine-adducts in normal and tumor tissue.,17639394_5,17639394_D006151_D009369,,
770958771,false,true,5,2015-08-15T01:13:00,,No Relation,0.5764,D000241,adenosine,D009369,tumor,Linear relationships and high correlations were observed between the levels of two guanosine- and adenosine-guanosine-adducts in normal and tumor tissue.,17639394_5,17639394_D000241_D009369,,
770958772,false,true,5,2015-08-15T01:06:00,,No Relation,0.6022,D002945,cisplatin,D009369,tumors,"In concurrent chemoradiotherapy schedules, cisplatin adduct levels in tumors were significantly higher than in normal tissues (WBC).",17639394_8,17639394_D002945_D009369,,
770958773,false,true,5,2015-08-14T22:06:00,,No Relation,1,D000666,amphotericin B,D004696,valve endocarditis,"We describe a diabetic patient with Lecythophora mutabilis prosthetic valve endocarditis who was treated surgically, as well as with amphotericin B lipid complex and voriconazole, which were subsequently followed by prolonged voriconazole suppressive therapy.",17654274_3,17654274_D000666_D004696,,
770958774,false,true,5,2015-08-14T21:46:00,,No Relation,1,C102790,voriconazole,D004696,valve endocarditis,"We describe a diabetic patient with Lecythophora mutabilis prosthetic valve endocarditis who was treated surgically, as well as with amphotericin B lipid complex and voriconazole, which were subsequently followed by prolonged voriconazole suppressive therapy.",17654274_3,17654274_C102790_D004696,,
770958775,false,true,5,2015-08-15T02:22:00,,No Relation,1,C102790,voriconazole,D003929,diabetic,"We describe a diabetic patient with Lecythophora mutabilis prosthetic valve endocarditis who was treated surgically, as well as with amphotericin B lipid complex and voriconazole, which were subsequently followed by prolonged voriconazole suppressive therapy.",17654274_3,17654274_C102790_D003929,,
770958776,false,true,5,2015-08-15T02:27:00,,No Relation,1,D000666,amphotericin B,D003929,diabetic,"We describe a diabetic patient with Lecythophora mutabilis prosthetic valve endocarditis who was treated surgically, as well as with amphotericin B lipid complex and voriconazole, which were subsequently followed by prolonged voriconazole suppressive therapy.",17654274_3,17654274_D000666_D003929,,
770958777,false,true,5,2015-08-14T22:05:00,,No Relation,1,D003024,Clozapine,D012559,schizophrenia,"Clozapine is uniquely effective in refractory schizophrenia, but treatment attrition is high.",17685738_1,17685738_D003024_D012559,,
770958778,false,true,5,2015-08-14T21:25:00,,Direct,0.6081,D003024,Clozapine,D019217,attrition,"Clozapine is uniquely effective in refractory schizophrenia, but treatment attrition is high.",17685738_1,17685738_D003024_D019217,,
770958779,false,true,5,2015-08-15T00:00:00,,No Relation,0.6094,D003024,clozapine,D003643,Death,Death is a common cause of clozapine cessation.,17685738_12,17685738_D003024_D003643,,
770958780,false,true,5,2015-08-14T22:06:00,,No Relation,0.8042,D002981,clindamycin,D011014,pneumonia,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D002981_D011014,,
770958781,false,true,5,2015-08-15T00:15:00,,No Relation,1,D011319,primaquine,D016720,Pneumocystis,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D011319_D016720,,
770958782,false,true,5,2015-08-14T21:10:00,,No Relation,0.7849,D002981,clindamycin,D016720,Pneumocystis,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D002981_D016720,,
770958783,false,true,5,2015-08-15T00:58:00,,No Relation,1,D011319,primaquine,D011014,pneumonia,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D011319_D011014,,
770958784,false,true,5,2015-08-14T21:38:00,,No Relation,0.8018,D011319,primaquine,D015658,HIV-infected,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D011319_D015658,,
770958785,false,true,5,2015-08-15T02:20:00,,No Relation,1,D002981,clindamycin,D015658,HIV-infected,An HIV-infected man became increasingly breathless and cyanosed while receiving clindamycin and primaquine treatment for Pneumocystis jirovecii pneumonia.,17686226_1,17686226_D002981_D015658,,
770958786,false,true,5,2015-08-14T21:38:00,,No Relation,1,D010710,phosphate,D006177,ileal villous damage,"In the hemorrhagic-shock model, rats pretreated with Bifidobacteria showed decreases in total aerobes in cecum, magnitude of total aerobes to BT, levels of plasma endotoxin, and percentage of ileal villous damage when compared with rats treated with phosphate buffered saline.",17706400_5,17706400_D010710_D006177,,
770958787,false,true,5,2015-08-15T00:36:00,,No Relation,0.5987,D010710,phosphate,D006470,hemorrhagic-shock,"In the hemorrhagic-shock model, rats pretreated with Bifidobacteria showed decreases in total aerobes in cecum, magnitude of total aerobes to BT, levels of plasma endotoxin, and percentage of ileal villous damage when compared with rats treated with phosphate buffered saline.",17706400_5,17706400_D010710_D006470,,
770958788,false,true,5,2015-08-14T21:59:00,,No Relation,1,D014975,lutein,D008545,melanoma,"Regulation of the extracellular matrix remodeling by lutein in dermal fibroblasts, melanoma cells, and ultraviolet radiation exposed fibroblasts.",17710425_0,17710425_D014975_D008545,,
770958789,false,true,5,2015-08-14T21:27:00,,No Relation,1,D014975,lutein,D008545,melanoma,"To this purpose, the effects of lutein on the expression of MMPs and their inhibitors (TIMPs, tissue inhibitors of metalloproteinases) in dermal fibroblasts (intrinsic aging) and melanoma cells were examined.",17710425_5,17710425_D014975_D008545,,
770958790,false,true,5,2015-08-14T21:10:00,,No Relation,1,D014975,Lutein,D008545,melanoma,Lutein did not alter fibroblast or melanoma cell viability or membrane integrity.,17710425_9,17710425_D014975_D008545,,
770958791,false,true,5,2015-08-14T23:58:00,,No Relation,1,D014975,lutein,D008545,melanoma,"In summary, the mechanism to lutein's anti-aging and anti-carcinogenic effects include the inhibition of MMP to TIMP ratio in dermal fibroblasts and melanoma cells, and the inhibition of cell loss, membrane damage and elastin expression in ultraviolet radiation exposed fibroblasts.",17710425_11,17710425_D014975_D008545,,
770958792,false,true,5,2015-08-14T21:37:00,,No Relation,1,D007792,lactulose,D003248,constipation,The presence of methane on lactulose breath testing is associated with constipation-predominant IBS.,17713456_6,17713456_D007792_D003248,,
770958793,false,true,5,2015-08-14T23:11:00,,Direct,1,D008697,methane,D003248,constipation,The presence of methane on lactulose breath testing is associated with constipation-predominant IBS.,17713456_6,17713456_D008697_D003248,,
770958794,false,true,5,2015-08-15T01:46:00,,No Relation,0.8121,D007792,lactulose,D043183,IBS,The presence of methane on lactulose breath testing is associated with constipation-predominant IBS.,17713456_6,17713456_D007792_D043183,,
770958795,false,true,5,2015-08-14T23:03:00,,Direct,0.8121,D008697,methane,D043183,IBS,The presence of methane on lactulose breath testing is associated with constipation-predominant IBS.,17713456_6,17713456_D008697_D043183,,
770958796,false,true,5,2015-08-14T23:44:00,,No Relation,1,D007792,lactulose,D001765,bacterial overgrowth,"Once a good clinical response and normalization of the lactulose breath test are achieved, a prokinetic agent may be used to stimulate phase III of interdigestive motility to delay relapse of bacterial overgrowth.",17713456_9,17713456_D007792_D001765,,
770958797,false,true,5,2015-08-14T21:42:00,,No Relation,1,C009687,wortmannin,D009369,tumor,"In addition, platelets taken from mice treated with wortmannin were blocked from PAR-induced ex vivo activation concomitantly with a decrease in phosphorylation of AKT from excised tumor xenografts.",17766838_6,17766838_C009687_D009369,,
770958798,false,true,5,2015-08-14T23:49:00,,No Relation,1,D003520,cyclophosphamide,D009369,pediatric cancer,BK virus-associated hemorrhagic cystitis in pediatric cancer patients receiving high-dose cyclophosphamide.,17805036_0,17805036_D003520_D009369,,
770958799,false,true,5,2015-08-15T02:02:00,,Direct,1,D003520,cyclophosphamide,D003556,hemorrhagic cystitis,BK virus-associated hemorrhagic cystitis in pediatric cancer patients receiving high-dose cyclophosphamide.,17805036_0,17805036_D003520_D003556,,
770958800,false,true,5,2015-08-14T22:22:00,,Direct,0.589,D003520,cyclophosphamide,D006417,hematuria,"BK virus (BKV) has been commonly found to be associated with hematuria in stem cell transplant patients; however, it has rarely been reported after cyclophosphamide chemotherapy alone.",17805036_2,17805036_D003520_D006417,,
770958801,false,true,5,2015-08-14T21:18:00,,No Relation,1,C059262,cidofovir,D006417,hematuria,One patient was treated with intravenous cidofovir with resolution of BK viruria and hematuria.,17805036_6,17805036_C059262_D006417,,
770958802,false,true,5,2015-08-14T21:48:00,,Direct,0.6006,D003520,cyclophosphamide,D003556,HC,Patients with HC after cyclophosphamide or ifosfamide with negative bacterial cultures should be studied for BKV.,17805036_9,17805036_D003520_D003556,,
770958803,false,true,5,2015-08-15T00:12:00,,No Relation,0.5956,D007069,ifosfamide,D003556,HC,Patients with HC after cyclophosphamide or ifosfamide with negative bacterial cultures should be studied for BKV.,17805036_9,17805036_D007069_D003556,,
770958804,false,true,5,2015-08-15T00:57:00,,No Relation,1,C059262,Cidofovir,D003556,HC,"Cidofovir may be beneficial in certain patients with BK viruria and HC; however, definitive data will require a clinical trial.",17805036_10,17805036_C059262_D003556,,
770958805,false,true,5,2015-08-14T22:43:00,,No Relation,1,D002955,leukovorin,D002833,choroidal melanoma,A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer.,17823640_1,17823640_D002955_D002833,,
770958806,false,true,5,2015-08-14T21:34:00,,No Relation,1,D005472,fluorouracil,D015179,colorectal cancer,A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer.,17823640_1,17823640_D005472_D015179,,
770958807,false,true,5,2015-08-15T00:50:00,,No Relation,1,D002955,leukovorin,D015179,colorectal cancer,A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer.,17823640_1,17823640_D002955_D015179,,
770958808,false,true,5,2015-08-15T00:55:00,,No Relation,1,D005472,fluorouracil,D002833,choroidal melanoma,A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer.,17823640_1,17823640_D005472_D002833,,
770958809,false,true,5,2015-08-15T00:04:00,,No Relation,1,D005947,glucose,D009369,ovarian cancer,Resveratrol inhibits glucose metabolism in human ovarian cancer cells.,17825886_0,17825886_D005947_D009369,,
770958810,false,true,5,2015-08-14T23:45:00,,No Relation,1,C059514,Resveratrol,D009369,ovarian cancer,Resveratrol inhibits glucose metabolism in human ovarian cancer cells.,17825886_0,17825886_C059514_D009369,,
770958811,false,true,5,2015-08-14T23:50:00,,No Relation,0.7806,C059514,Resveratrol,D009369,tumor,Resveratrol is a phytoalexin found in grapes that inhibits the in vitro growth of multiple tumor cell types.,17825886_1,17825886_C059514_D009369,,
770958812,false,true,5,2015-08-15T00:21:00,,No Relation,0.8084,C059514,resveratrol,D003643,death,We showed previously that resveratrol induces autophagic cell death in ovarian cancer cells.,17825886_2,17825886_C059514_D003643,,
770958813,false,true,5,2015-08-15T02:02:00,,No Relation,0.8112,C059514,resveratrol,D009369,ovarian cancer,We showed previously that resveratrol induces autophagic cell death in ovarian cancer cells.,17825886_2,17825886_C059514_D009369,,
770958814,false,true,5,2015-08-15T01:24:00,,No Relation,0.8142,C059514,resveratrol,D009369,ovarian cancer,"Because autophagy is typically an adaptive response to nutrient starvation, we hypothesized that autophagy would also be triggered when ovarian cancer cells are nutrient deprived and that resveratrol could in fact be acting by inducing a starvation-like signaling response.",17825886_3,17825886_C059514_D009369,,
770958815,false,true,5,2015-08-14T21:09:00,,No Relation,1,D000596,amino acids,D009369,Ovarian cancer,"Ovarian cancer cells were incubated with normal media, media containing resveratrol, glucose free media, or media lacking amino acids.",17825886_4,17825886_D000596_D009369,,
770958816,false,true,5,2015-08-14T22:03:00,,No Relation,1,D005947,glucose,D009369,Ovarian cancer,"Ovarian cancer cells were incubated with normal media, media containing resveratrol, glucose free media, or media lacking amino acids.",17825886_4,17825886_D005947_D009369,,
770958817,false,true,5,2015-08-14T22:10:00,,No Relation,0.7995,C059514,resveratrol,D009369,Ovarian cancer,"Ovarian cancer cells were incubated with normal media, media containing resveratrol, glucose free media, or media lacking amino acids.",17825886_4,17825886_C059514_D009369,,
770958818,false,true,5,2015-08-14T23:02:00,,No Relation,1,D005947,glucose,D003643,death,"We show here that epithelial ovarian cancer cells are highly sensitive to glucose-deprivation-induced cell death and like resveratrol, glucose deprivation induces caspase-independent cell death with hallmarks of autophagy.",17825886_8,17825886_D005947_D003643,,
770958819,false,true,5,2015-08-14T22:27:00,,No Relation,0.7981,D005947,glucose,D009369,ovarian cancer,"We show here that epithelial ovarian cancer cells are highly sensitive to glucose-deprivation-induced cell death and like resveratrol, glucose deprivation induces caspase-independent cell death with hallmarks of autophagy.",17825886_8,17825886_D005947_D009369,,
770958820,false,true,5,2015-08-15T01:09:00,,No Relation,1,C059514,resveratrol,D003643,death,"We show here that epithelial ovarian cancer cells are highly sensitive to glucose-deprivation-induced cell death and like resveratrol, glucose deprivation induces caspase-independent cell death with hallmarks of autophagy.",17825886_8,17825886_C059514_D003643,,
770958821,false,true,5,2015-08-14T22:26:00,,No Relation,0.7921,C059514,resveratrol,D009369,ovarian cancer,"We show here that epithelial ovarian cancer cells are highly sensitive to glucose-deprivation-induced cell death and like resveratrol, glucose deprivation induces caspase-independent cell death with hallmarks of autophagy.",17825886_8,17825886_C059514_D009369,,
770958822,false,true,5,2015-08-15T01:25:00,,No Relation,0.8053,D005947,glucose,D009369,ovarian cancer,Our findings are consistent with the hypothesis that resveratrol-induced changes in glucose utilization comprise the mechanism that underlies resveratrol-induced autophagocytosis in ovarian cancer.,17825886_11,17825886_D005947_D009369,,
770958823,false,true,5,2015-08-15T00:46:00,,No Relation,0.7914,C059514,resveratrol,D009369,ovarian cancer,Our findings are consistent with the hypothesis that resveratrol-induced changes in glucose utilization comprise the mechanism that underlies resveratrol-induced autophagocytosis in ovarian cancer.,17825886_11,17825886_C059514_D009369,,
770958824,false,true,5,2015-08-15T02:49:00,,No Relation,1,C059514,resveratrol,D009369,ovarian cancer,Inhibition of glycolysis in ovarian cancer with resveratrol or other compounds may be effective therapy for ovarian cancer.,17825886_12,17825886_C059514_D009369,,
770958825,false,true,5,2015-08-15T00:20:00,,No Relation,1,D000305,corticosteroids,D065631,allergic rhinitis,Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis.,17826020_0,17826020_D000305_D065631,,
770958826,false,true,5,2015-08-15T00:50:00,,No Relation,1,D013256,steroid,D065631,AR,We investigated clinical efficacy of monotherapy with topical steroid and combined therapy in AR patients.,17826020_2,17826020_D013256_D065631,,
770958827,false,true,5,2015-08-14T22:22:00,,No Relation,1,D000305,corticosteroids,D065631,allergic rhinitis,"Although corticosteroids are the mainstay of treatment in allergic rhinitis, montelukast may be considered as an additional agent especially in treatment of patients with impaired quality of life and it may be used to reduce nasal symptom scores.",17826020_11,17826020_D000305_D065631,,
770958828,false,true,5,2015-08-14T21:50:00,,No Relation,1,D000431,ethanol,D019966,drug abuse,"Therefore attenuation of the activity of the EC system would have therapeutic benefit in treating disorders that might have a component of excess appetite drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.",17879500_2,17879500_D000431_D019966,,
770958829,false,true,5,2015-08-15T00:48:00,,No Relation,1,D000431,ethanol,D009765,obesity,"Therefore attenuation of the activity of the EC system would have therapeutic benefit in treating disorders that might have a component of excess appetite drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.",17879500_2,17879500_D000431_D009765,,
770958830,false,true,5,2015-08-14T21:41:00,,No Relation,1,C089032,Rimonabant,D009765,obesity,"Rimonabant is the only compound in this group which along this pathway is now approved as a selective CB (1) (cannabinoid receptor subtype 1) antagonist, or inverse agonist, in the European Union and India and under regulatory review in the United States for the treatment of obesity and associated cardiometabolic risk.",17879500_4,17879500_C089032_D009765,,
770958831,false,true,5,2015-08-14T21:57:00,,No Relation,1,C007734,flunisolide,D001249,asthma,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience.,17883883_0,17883883_C007734_D001249,,
770958832,false,true,5,2015-08-15T00:40:00,,No Relation,1,C007734,FLU,D001249,asthma,Clinical data indicate that nebulized FLU is effective in asthma treatment in infants and children.,17883883_14,17883883_C007734_D001249,,
770958833,false,true,5,2015-08-14T21:51:00,,No Relation,0.8108,D011092,polyethylene glycol,D016638,critically ill,"Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial.",17893628_0,17893628_D011092_D016638,,
770958834,false,true,5,2015-08-14T22:43:00,,No Relation,0.8057,D007792,lactulose,D016638,critically ill,"Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial.",17893628_0,17893628_D007792_D016638,,
770958835,false,true,5,2015-08-14T23:25:00,Disease is a pre-existing condition.,No Relation,1,D011092,polyethylene glycol,D016638,critically ill,"To study whether lactulose or polyethylene glycol is effective to promote defecation in critically ill patients, whether either of the two is superior, and whether the use of enteral laxatives is related to clinical outcome.",17893628_1,17893628_D011092_D016638,,
770958836,false,true,5,2015-08-15T00:28:00,,No Relation,1,D007792,lactulose,D016638,critically ill,"To study whether lactulose or polyethylene glycol is effective to promote defecation in critically ill patients, whether either of the two is superior, and whether the use of enteral laxatives is related to clinical outcome.",17893628_1,17893628_D007792_D016638,,
770958837,false,true,5,2015-08-15T01:41:00,,Direct,0.576,D007792,lactulose,D007418,Intestinal pseudoobstruction,"Intestinal pseudoobstruction or Ogilvie's syndrome occurred in 4.1% of patients in the placebo group, 5.5% of patients in the lactulose group, and 1.0% of patients in the polyethylene glycol group.",17893628_9,17893628_D007792_D007418,,
770958838,false,true,5,2015-08-15T01:57:00,,Direct,0.7976,D007792,lactulose,D003112,Ogilvie's syndrome,"Intestinal pseudoobstruction or Ogilvie's syndrome occurred in 4.1% of patients in the placebo group, 5.5% of patients in the lactulose group, and 1.0% of patients in the polyethylene glycol group.",17893628_9,17893628_D007792_D003112,,
770958839,false,true,5,2015-08-15T00:33:00,,No Relation,0.5924,D011092,polyethylene glycol,D007418,Intestinal pseudoobstruction,"Intestinal pseudoobstruction or Ogilvie's syndrome occurred in 4.1% of patients in the placebo group, 5.5% of patients in the lactulose group, and 1.0% of patients in the polyethylene glycol group.",17893628_9,17893628_D011092_D007418,,
770958840,false,true,5,2015-08-14T21:12:00,,Direct,0.5981,D011092,polyethylene glycol,D003112,Ogilvie's syndrome,"Intestinal pseudoobstruction or Ogilvie's syndrome occurred in 4.1% of patients in the placebo group, 5.5% of patients in the lactulose group, and 1.0% of patients in the polyethylene glycol group.",17893628_9,17893628_D011092_D003112,,
770958841,false,true,5,2015-08-14T21:41:00,,No Relation,1,D007792,lactulose,D007418,intestinal pseudoobstruction,"Patients receiving polyethylene glycol had a slightly lower incidence of acute intestinal pseudoobstruction, whereas length of stay was shorter in lactulose-treated patients.",17893628_14,17893628_D007792_D007418,,
770958842,false,true,5,2015-08-15T00:58:00,,No Relation,0.8003,D011092,polyethylene glycol,D007418,intestinal pseudoobstruction,"Patients receiving polyethylene glycol had a slightly lower incidence of acute intestinal pseudoobstruction, whereas length of stay was shorter in lactulose-treated patients.",17893628_14,17893628_D011092_D007418,,
770958843,false,true,5,2015-08-14T23:08:00,,No Relation,0.6017,C110904,capecitabine,D009369,tumour/breast cancer,"Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.",17904787_0,17904787_C110904_D009369,,
770958844,false,true,5,2015-08-14T21:52:00,,No Relation,0.7942,C030852,vinorelbine,D009369,tumour/breast cancer,"Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.",17904787_0,17904787_C030852_D009369,,
770958845,false,true,5,2015-08-14T22:43:00,'Theraputic' being the key word.,No Relation,1,C110904,capecitabine,D009369,tumour/breast cancer,The present study investigates the therapeutic value of single use capecitabine on solid tumour tissues in vitro using breast cancer cell lines and as reference.,17904787_4,17904787_C110904_D009369,,
770958846,false,true,5,2015-08-14T22:09:00,,No Relation,1,C030852,vinorelbine,D009369,breast cancer,The data is to be compared with the use of vinorelbine which is a conventionally applied drug for advanced breast cancer patients.,17904787_5,17904787_C030852_D009369,,
770958847,false,true,5,2015-08-14T22:26:00,,No Relation,1,C110904,Capecitabine,D009369,tumor/tumour/breast cancer,Capecitabine demonstrated similar inhibitory effects as vinorelbine in breast cancer cell lines and solid tumour tissues at decreasing cell proliferation and metabolism as well as decreasing the expression of metabolic proteins and tumor suppressor genes.,17904787_16,17904787_C110904_D009369,,
770958848,false,true,5,2015-08-15T01:45:00,,No Relation,1,C030852,vinorelbine,D009369,tumor/tumour/breast cancer,Capecitabine demonstrated similar inhibitory effects as vinorelbine in breast cancer cell lines and solid tumour tissues at decreasing cell proliferation and metabolism as well as decreasing the expression of metabolic proteins and tumor suppressor genes.,17904787_16,17904787_C030852_D009369,,
770958849,false,true,5,2015-08-14T22:16:00,,No Relation,0.6022,D014280,triglycerides,D051436,CKD/Chronic kidney disease,"Chronic kidney disease (CKD) is associated with a highly atherogenic lipid profile, characterized by elevated triglycerides, low high-density lipoprotein (HDL) cholesterol and accumulation of small dense low-density lipoprotein (LDL) particles.",17912226_1,17912226_D014280_D051436,,
770958850,false,true,5,2015-08-15T00:43:00,,Direct,0.5995,D002784,cholesterol,D051436,CKD/Chronic kidney disease,"Chronic kidney disease (CKD) is associated with a highly atherogenic lipid profile, characterized by elevated triglycerides, low high-density lipoprotein (HDL) cholesterol and accumulation of small dense low-density lipoprotein (LDL) particles.",17912226_1,17912226_D002784_D051436,,
770958851,false,true,5,2015-08-15T00:55:00,,No Relation,0.5951,D019821,statins,D018805,sepsis,Observational studies found a reduction in the risk of contrast media induced nephropathy and a reduction in the risk of hospitalization for sepsis in patients who had CKD and were treated with statins.,17912226_4,17912226_D019821_D018805,,
770958852,false,true,5,2015-08-15T01:19:00,,No Relation,0.809,D019821,statins,D051436,CKD,Observational studies found a reduction in the risk of contrast media induced nephropathy and a reduction in the risk of hospitalization for sepsis in patients who had CKD and were treated with statins.,17912226_4,17912226_D019821_D051436,,
770958853,false,true,5,2015-08-14T22:22:00,,No Relation,0.822,D019821,statins,C562889,nephropathy,Observational studies found a reduction in the risk of contrast media induced nephropathy and a reduction in the risk of hospitalization for sepsis in patients who had CKD and were treated with statins.,17912226_4,17912226_D019821_C562889,,
770958854,false,true,5,2015-08-14T22:28:00,,No Relation,1,C056493,imiquimod,D002280,basal cell carcinomas,Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod.,17922128_0,17922128_C056493_D002280,,
770958855,false,true,5,2015-08-15T02:23:00,,No Relation,1,C056493,imiquimod,D009369,tumor,"In this way, imiquimod may act as a stimulator of the Notch pathway in sBCC tumor cells by up-regulating protein expression of the Notch ligand, Jagged1.",17922128_8,17922128_C056493_D009369,,
770958856,false,true,5,2015-08-14T23:31:00,,No Relation,1,C079150,Paliperidone,D012559,schizophrenia,Paliperidone extended release (ER) is the most recent atypical antipsychotic to become available for the treatment of schizophrenia.,17927485_1,17927485_C079150_D012559,,
770958857,false,true,5,2015-08-14T21:12:00,,No Relation,1,C079150,paliperidone,D012559,schizophrenia,"Several randomized, double-blinded, placebo-controlled trials have shown paliperidone ER to be efficacious in the management of acute schizophrenia as well as for the prevention of symptom recurrence when compared with placebo.",17927485_3,17927485_C079150_D012559,,
770958858,false,true,5,2015-08-15T01:56:00,,No Relation,1,C079150,Paliperidone,D012559,schizophrenia,"Paliperidone ER has the potential to offer advantages over its parent compound and other second generation agents, and may aid in ensuring compliance among persons with schizophrenia.",17927485_8,17927485_C079150_D012559,,
770958859,false,true,5,2015-08-15T02:18:00,,No Relation,0.6021,D017879,isothiocyanates,D007249,chronic inflammation,"Aberrant patterns of DNA methylation develop as a result of pathological processes such as chronic inflammation, and in response to various dietary factors, including imbalances in the supply of methyl donors, particularly folates, and exposure to DNA methyltransferase inhibitors, which include polyphenols and possibly isothiocyanates from plant foods.",17976883_4,17976883_D017879_D007249,,
770958860,false,true,5,2015-08-15T02:10:00,,No Relation,0.5803,D059808,polyphenols,D007249,chronic inflammation,"Aberrant patterns of DNA methylation develop as a result of pathological processes such as chronic inflammation, and in response to various dietary factors, including imbalances in the supply of methyl donors, particularly folates, and exposure to DNA methyltransferase inhibitors, which include polyphenols and possibly isothiocyanates from plant foods.",17976883_4,17976883_D059808_D007249,,
770958861,false,true,5,2015-08-14T23:42:00,,Direct,1,D007213,indomethacin,D007969,periventricular leukomalacia,"Antenatal indomethacin was associated with an increased risk of periventricular leukomalacia (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.3-3.1).",17980183_10,17980183_D007213_D007969,,
770958862,false,true,5,2015-08-15T00:55:00,,Direct,1,D007213,indomethacin,D009336,necrotizing enterocolitis,"Recent exposure to antenatal indomethacin was associated with necrotizing enterocolitis (OR, 2.2; 95% CI; 1.1-4.2).",17980183_11,17980183_D007213_D009336,,
770958863,false,true,5,2015-08-14T21:29:00,,No Relation,1,D007213,indomethacin,D004374,patent ductus arteriosus,"Antenatal indomethacin was not associated with intraventricular hemorrhage, patent ductus arteriosus, respiratory distress syndrome, bronchopulmonary dysplasia, and mortality.",17980183_12,17980183_D007213_D004374,,
770958864,false,true,5,2015-08-15T00:27:00,,No Relation,1,D007213,indomethacin,D012128,respiratory distress syndrome,"Antenatal indomethacin was not associated with intraventricular hemorrhage, patent ductus arteriosus, respiratory distress syndrome, bronchopulmonary dysplasia, and mortality.",17980183_12,17980183_D007213_D012128,,
770958865,false,true,5,2015-08-14T22:19:00,,No Relation,1,D007213,indomethacin,D006470,intraventricular hemorrhage,"Antenatal indomethacin was not associated with intraventricular hemorrhage, patent ductus arteriosus, respiratory distress syndrome, bronchopulmonary dysplasia, and mortality.",17980183_12,17980183_D007213_D006470,,
770958866,false,true,5,2015-08-15T00:31:00,,No Relation,1,D007213,indomethacin,D001997,bronchopulmonary dysplasia,"Antenatal indomethacin was not associated with intraventricular hemorrhage, patent ductus arteriosus, respiratory distress syndrome, bronchopulmonary dysplasia, and mortality.",17980183_12,17980183_D007213_D001997,,
770958867,false,true,5,2015-08-14T21:54:00,,Direct,1,D007213,indomethacin,D007969,periventricular leukomalacia,Antenatal indomethacin may be associated with an increased risk of periventricular leukomalacia and necrotizing enterocolitis in premature infants and therefore should be used judiciously for tocolysis.,17980183_13,17980183_D007213_D007969,,
770958868,false,true,5,2015-08-14T23:31:00,As long as it's antenatal.,Direct,1,D007213,indomethacin,D009336,necrotizing enterocolitis,Antenatal indomethacin may be associated with an increased risk of periventricular leukomalacia and necrotizing enterocolitis in premature infants and therefore should be used judiciously for tocolysis.,17980183_13,17980183_D007213_D009336,,
770958869,false,true,5,2015-08-14T23:18:00,,No Relation,1,D008774,methylphenidate,D010300,Parkinson's disease,Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state.,17982887_0,17982887_D008774_D010300,,
770958870,false,true,5,2015-08-15T00:21:00,,No Relation,1,D008774,methylphenidate/MPD,D010300,PD/idiopathic Parkinson's disease,Five men with advanced idiopathic Parkinson's disease (PD) were examined to assess the effect of low dose methylphenidate (MPD) on gait.,17982887_1,17982887_D008774_D010300,,
770958871,false,true,5,2015-08-14T21:19:00,,No Relation,0.796,D008774,MPD,D010300,PD,"The study demonstrates that low dose of MPD may improve gait, and especially freezing, in patients with severe PD, without the need for exogenous L-dopa.",17982887_7,17982887_D008774_D010300,,
770958872,false,true,5,2015-08-14T22:53:00,,No Relation,1,D007980,L-dopa,D010300,PD,"The study demonstrates that low dose of MPD may improve gait, and especially freezing, in patients with severe PD, without the need for exogenous L-dopa.",17982887_7,17982887_D007980_D010300,,
770958873,false,true,5,2015-08-15T02:08:00,,No Relation,1,D008774,MPD,D010300,PD,The mechanism of MPD action in patients with advanced PD is further discussed.,17982887_8,17982887_D008774_D010300,,
770958874,false,true,5,2015-08-15T00:35:00,,No Relation,1,D008790,metoprolol,D016891,autosomal dominant polycystic kidney disease,Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.,17984104_0,17984104_D008790_D016891,,
770958875,false,true,5,2015-08-14T23:32:00,,No Relation,1,D017257,ramipril,D016891,autosomal dominant polycystic kidney disease,Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.,17984104_0,17984104_D017257_D016891,,
770958876,false,true,5,2015-08-15T01:59:00,,No Relation,1,D017257,ramipril,D006973,hypertension,This prospective randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the beta-blocker metoprolol as first line therapy in ADPKD patients with hypertension.,17984104_2,17984104_D017257_D006973,,
770958877,false,true,5,2015-08-14T22:32:00,,No Relation,1,D008790,metoprolol,D016891,ADPKD,This prospective randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the beta-blocker metoprolol as first line therapy in ADPKD patients with hypertension.,17984104_2,17984104_D008790_D016891,,
770958878,false,true,5,2015-08-15T01:50:00,,No Relation,1,D017257,ramipril,D016891,ADPKD,This prospective randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the beta-blocker metoprolol as first line therapy in ADPKD patients with hypertension.,17984104_2,17984104_D017257_D016891,,
770958879,false,true,5,2015-08-15T00:47:00,,No Relation,1,D008790,metoprolol,D006973,hypertension,This prospective randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the beta-blocker metoprolol as first line therapy in ADPKD patients with hypertension.,17984104_2,17984104_D008790_D006973,,
770958880,false,true,5,2015-08-14T21:09:00,,No Relation,1,D008790,metoprolol,D016891,ADPKD,Forty-six hypertensive ADPKD patients were randomized to either ramipril (n = 23) or metoprolol (n = 23).,17984104_3,17984104_D008790_D016891,,
770958881,false,true,5,2015-08-15T00:02:00,,No Relation,1,D017257,ramipril,D016891,ADPKD,Forty-six hypertensive ADPKD patients were randomized to either ramipril (n = 23) or metoprolol (n = 23).,17984104_3,17984104_D017257_D016891,,
770958882,false,true,5,2015-08-14T22:04:00,,No Relation,1,D008790,metoprolol,D016891,ADPKD,"In our study population of hypertensive ADPKD patients, no differences in renal function, urinary albumin excretion and LVMI were detected between those treated with ramipril or metoprolol, respectively, during a 3 years follow-up.",17984104_12,17984104_D008790_D016891,,
770958883,false,true,5,2015-08-15T00:55:00,,No Relation,1,D017257,ramipril,D016891,ADPKD,"In our study population of hypertensive ADPKD patients, no differences in renal function, urinary albumin excretion and LVMI were detected between those treated with ramipril or metoprolol, respectively, during a 3 years follow-up.",17984104_12,17984104_D017257_D016891,,
770958884,false,true,5,2015-08-15T01:11:00,,No Relation,0.8117,D009566,nitrate,D002318,cardiovascular disease,"Data on individuals with purchase of antihypertensive or serum lipid-reducing agents, but without a diagnosis of cardiovascular disease, were also linked to purchase of nitrate vasodilators (C01D).",17987590_6,17987590_D009566_D002318,,
770958885,false,true,5,2015-08-15T01:59:00,,Direct,0.8056,D009538,Nicotine,D009759,NIN/nicotine-induced nystagmus,"Nicotine has wellknown, unpleasant side effects, e.g., transient dizziness, nausea, and nicotine-induced nystagmus (NIN).",17990061_1,17990061_D009538_D009759,,
770958886,false,true,5,2015-08-14T22:23:00,,Direct,1,D009538,Nicotine,D009325,nausea,"Nicotine has wellknown, unpleasant side effects, e.g., transient dizziness, nausea, and nicotine-induced nystagmus (NIN).",17990061_1,17990061_D009538_D009325,,
770958887,false,true,5,2015-08-15T01:48:00,,Direct,1,D009538,Nicotine,D004244,dizziness,"Nicotine has wellknown, unpleasant side effects, e.g., transient dizziness, nausea, and nicotine-induced nystagmus (NIN).",17990061_1,17990061_D009538_D004244,,
770958888,false,true,5,2015-08-14T21:41:00,"it is a question whether there is a link. It is not answered here, so ""it doesn't say""",No Relation,1,D009538,nicotine,D009759,NIN,"To investigate factors influencing these effects, we addressed three questions: (1) Is the intensity of dizziness, nausea, NIN, and unsteadiness dependent on nicotine dosage?",17990061_2,17990061_D009538_D009759,,
770958889,false,true,5,2015-08-15T02:13:00,,Direct,0.5957,D009538,nicotine,D020233,unsteadiness,"To investigate factors influencing these effects, we addressed three questions: (1) Is the intensity of dizziness, nausea, NIN, and unsteadiness dependent on nicotine dosage?",17990061_2,17990061_D009538_D020233,,
770958890,false,true,5,2015-08-14T23:00:00,,Direct,0.793,D009538,nicotine,D009325,nausea,"To investigate factors influencing these effects, we addressed three questions: (1) Is the intensity of dizziness, nausea, NIN, and unsteadiness dependent on nicotine dosage?",17990061_2,17990061_D009538_D009325,,
770958891,false,true,5,2015-08-14T22:10:00,,No Relation,0.6094,D009538,nicotine,D004244,dizziness,"To investigate factors influencing these effects, we addressed three questions: (1) Is the intensity of dizziness, nausea, NIN, and unsteadiness dependent on nicotine dosage?",17990061_2,17990061_D009538_D004244,,
770958892,false,true,5,2015-08-14T23:30:00,,Direct,0.8056,D009538,nicotine,D009759,NIN/nystagmus,"Dizziness, nausea, NIN, and unsteadiness also depended on the nicotine dosage (p < 0.01).Nicotine blood concentration was a better predictor for the temporal dependence of nystagmus than nicotine dosage.",17990061_7,17990061_D009538_D009759,,
770958893,false,true,5,2015-08-14T22:03:00,,Direct,1,D009538,nicotine,D020233,unsteadiness,"Dizziness, nausea, NIN, and unsteadiness also depended on the nicotine dosage (p < 0.01).Nicotine blood concentration was a better predictor for the temporal dependence of nystagmus than nicotine dosage.",17990061_7,17990061_D009538_D020233,,
770958894,false,true,5,2015-08-14T21:07:00,,Direct,0.7769,D009538,nicotine,D009325,nausea,"Dizziness, nausea, NIN, and unsteadiness also depended on the nicotine dosage (p < 0.01).Nicotine blood concentration was a better predictor for the temporal dependence of nystagmus than nicotine dosage.",17990061_7,17990061_D009538_D009325,,
770958895,false,true,5,2015-08-14T21:54:00,,Direct,0.5912,D009538,nicotine,D004244,Dizziness,"Dizziness, nausea, NIN, and unsteadiness also depended on the nicotine dosage (p < 0.01).Nicotine blood concentration was a better predictor for the temporal dependence of nystagmus than nicotine dosage.",17990061_7,17990061_D009538_D004244,,
770958896,false,true,5,2015-08-14T21:48:00,,Direct,1,D009538,nicotine,D009325,nausea,The degree of nicotine-induced nausea significantly correlated with postural imbalance.,17990061_9,17990061_D009538_D009325,,
770958897,false,true,5,2015-08-15T02:03:00,,No Relation,1,D009538,nicotine,D009759,NIN,"Motion stimulation increased nicotine-induced dizziness and nausea, but did not significantly influence NIN or postural imbalance.",17990061_11,17990061_D009538_D009759,,
770958898,false,true,5,2015-08-14T21:38:00,,No Relation,0.4134,D009538,nicotine,D009325,nausea,"Motion stimulation increased nicotine-induced dizziness and nausea, but did not significantly influence NIN or postural imbalance.",17990061_11,17990061_D009538_D009325,,
770958899,false,true,5,2015-08-14T23:13:00,,Direct,0.408,D009538,nicotine,D004244,dizziness,"Motion stimulation increased nicotine-induced dizziness and nausea, but did not significantly influence NIN or postural imbalance.",17990061_11,17990061_D009538_D004244,,
770958900,false,true,5,2015-08-14T21:41:00,,Direct,0.6028,D009538,nicotine,D015837,vestibular dysfunction,Our data support the view that all measured adverse effects reflect dose-dependent nicotine-induced vestibular dysfunction.,17990061_12,17990061_D009538_D015837,,
770958901,false,true,5,2015-08-15T00:32:00,,Direct,0.8026,D009538,nicotine,D004244,dizziness,"Additional motion stimulation aggravates dizziness and nausea, i.e., nicotine increases sensitivity to motion sickness.",17990061_13,17990061_D009538_D004244,,
770958902,false,true,5,2015-08-14T21:35:00,,Direct,0.5952,D009538,nicotine,D009325,nausea,"Additional motion stimulation aggravates dizziness and nausea, i.e., nicotine increases sensitivity to motion sickness.",17990061_13,17990061_D009538_D009325,,
770958903,false,true,5,2015-08-14T22:04:00,,Direct,1,D009538,nicotine,D009041,motion sickness,"Additional motion stimulation aggravates dizziness and nausea, i.e., nicotine increases sensitivity to motion sickness.",17990061_13,17990061_D009538_D009041,,
770958904,false,true,5,2015-08-15T02:16:00,,No Relation,1,D000255,ATP,D016403,DLBCL,"Herein, we assess the role of SYK-dependent tonic BCR survival signals in DLBCL cell lines and primary tumors and evaluate the efficacy of an ATP-competitive inhibitor of SYK, R406, in vitro.",18006696_4,18006696_D000255_D016403,,
770958905,false,true,5,2015-08-14T23:11:00,,No Relation,1,D000255,ATP,D009369,primary tumors,"Herein, we assess the role of SYK-dependent tonic BCR survival signals in DLBCL cell lines and primary tumors and evaluate the efficacy of an ATP-competitive inhibitor of SYK, R406, in vitro.",18006696_4,18006696_D000255_D009369,,
770958906,false,true,5,2015-08-14T21:28:00,,Direct,0.5815,D013256,steroids,D007027,hypothalamic networks,These steroids are reported to activate the hypothalamic networks in a sex-differentiated way.,18056697_3,18056697_D013256_D007027,,
770958907,false,true,5,2015-08-15T01:34:00,,No Relation,0.5902,D004967,Estrogens/estrogen,D009369,tumors/breast cancer,"Estrogens are required for the proliferation of hormone dependent breast cancer cells, making estrogen receptor (ER) positive tumors amenable to endocrine therapies such as antiestrogens.",18060053_1,18060053_D004967_D009369,,
770958908,false,true,5,2015-08-15T00:44:00,,No Relation,1,D004967,estrogen,D012175,retinoblastoma,"We previously demonstrated that inactivation of the retinoblastoma protein (pRb) family tumor suppressors causes antiestrogen resistance in MCF-7 cells, a widely studied model of estrogen responsive human breast cancers.",18060053_3,18060053_D004967_D012175,,
770958909,false,true,5,2015-08-14T22:20:00,,No Relation,0.6239,D004967,estrogen,D009369,tumor/breast cancers,"We previously demonstrated that inactivation of the retinoblastoma protein (pRb) family tumor suppressors causes antiestrogen resistance in MCF-7 cells, a widely studied model of estrogen responsive human breast cancers.",18060053_3,18060053_D004967_D009369,,
770958910,false,true,5,2015-08-14T23:43:00,,No Relation,1,D019821,Simvastatin,D002544,ischemic stroke,Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial.,18070096_0,18070096_D019821_D002544,,
770958911,false,true,5,2015-08-14T22:27:00,,No Relation,1,D019821,statins,D002544,ischemic stroke,"Although statins are being used for secondary prevention of ischemic stroke, recent experimental data have shown new pleiotropic effects of these drugs responsible for their role in neuroprotection.",18070096_1,18070096_D019821_D002544,,
770958912,false,true,5,2015-08-15T01:41:00,,No Relation,1,D019821,simvastatin,D002544,ischemic stroke,"We conducted a pilot, double-blind, randomized, multicenter clinical trial to study for the first time safety and efficacy of simvastatin in the acute phase of ischemic stroke.",18070096_2,18070096_D019821_D002544,,
770958913,false,true,5,2015-08-15T01:42:00,,No Relation,0.8179,D019821,Simvastatin,D020521,cortical strokes,Simvastatin/placebo was given at 3-12 h from symptom onset to 60 patients with cortical strokes.,18070096_3,18070096_D019821_D020521,,
770958914,false,true,5,2015-08-15T01:02:00,,Direct,0.8084,D019821,simvastatin,D007239,infections,"Although simvastatin patients improved significantly by the third day (46.4% vs. 17.9%, P = 0.022), a non-significant increase in mortality and greater proportion of infections (odds ratio 2.4, confidence interval 1.06-5.4) in the simvastatin group were the main safety concerns.",18070096_6,18070096_D019821_D007239,,
770958915,false,true,5,2015-08-14T23:18:00,,No Relation,1,C523467,CJ-042794,D009369,tumor,PGE(2) inhibited the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha) in human whole blood (HWB); CJ-042794 reversed the inhibitory effects of PGE(2) on LPS-induced TNFalpha production in a concentration-dependent manner.,18155068_6,18155068_C523467_D009369,,
770958916,false,true,5,2015-08-15T00:55:00,,No Relation,1,D015232,PGE(2),D009369,tumor,PGE(2) inhibited the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha) in human whole blood (HWB); CJ-042794 reversed the inhibitory effects of PGE(2) on LPS-induced TNFalpha production in a concentration-dependent manner.,18155068_6,18155068_D015232_D009369,,
770958917,false,true,5,2015-08-15T01:43:00,,No Relation,1,C523467,CJ-042794,D009336,necrosis,PGE(2) inhibited the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha) in human whole blood (HWB); CJ-042794 reversed the inhibitory effects of PGE(2) on LPS-induced TNFalpha production in a concentration-dependent manner.,18155068_6,18155068_C523467_D009336,,
770958918,false,true,5,2015-08-14T22:04:00,,No Relation,0.7961,D015232,PGE(2),D009336,necrosis,PGE(2) inhibited the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha) in human whole blood (HWB); CJ-042794 reversed the inhibitory effects of PGE(2) on LPS-induced TNFalpha production in a concentration-dependent manner.,18155068_6,18155068_D015232_D009336,,
770958919,false,true,5,2015-08-14T21:23:00,,Direct,1,C006632,arsenic trioxide,D003643,death,Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells.,18158874_0,18158874_C006632_D003643,,
770958920,false,true,5,2015-08-14T23:08:00,,No Relation,0.7947,C006632,arsenic trioxide,D007938,leukemia,Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells.,18158874_0,18158874_C006632_D007938,,
770958921,false,true,5,2015-08-14T21:37:00,,No Relation,0.8203,C025946,3-methyladenine/3-MA,D003643,death,The blockade of autophagy maturation with the autophagy-specific inhibitor 3-methyladenine (3-MA) or the lysosome-neutralizing agent NH4Cl 1 h before As2O3 potentiated the As2O3-induced death of HL60 cells.,18158874_7,18158874_C025946_D003643,,
770958922,false,true,5,2015-08-14T21:04:00,,No Relation,0.612,D000643,NH4Cl,D003643,death,The blockade of autophagy maturation with the autophagy-specific inhibitor 3-methyladenine (3-MA) or the lysosome-neutralizing agent NH4Cl 1 h before As2O3 potentiated the As2O3-induced death of HL60 cells.,18158874_7,18158874_D000643_D003643,,
770958923,false,true,5,2015-08-14T23:34:00,,Direct,0.5958,C025946,3-MA,D003643,death,"In contrast, 3-MA attenuated As2O3-induced death when administered 30 min after As2O3.",18158874_8,18158874_C025946_D003643,,
770958924,false,true,5,2015-08-15T00:43:00,,Direct,0.801,D014212,ATRA/all-trans retinoic acid,C538324,HL,"In the present study, we demonstrated that bufalin enhanced all-trans retinoic acid (ATRA) induced differentiation of HL-60 cells, accompanied by up-regulation of the Cbl family of ubiquitin ligases.",18164258_4,18164258_D014212_C538324,,
770958925,false,true,5,2015-08-14T23:35:00,,No Relation,1,D014212,ATRA,C538324,HL,"These results suggested that up-regulation of c-Cbl and Cbl-b was involved in the regulation of ATRA and bufalin-induced HL-60 cell adhesion rather than cell differentiation, which might be mediated by lipid raft localization, ubiquitin ligase activity and C-terminal structure of Cbl proteins.",18164258_9,18164258_D014212_C538324,,
770958926,false,true,5,2015-08-14T21:58:00,,No Relation,0.6007,D004318,doxycycline,D017823,furcation defects,Regeneration of degree ii furcation defects with a 4% doxycycline hyclate bioabsorbable barrier.,18166095_0,18166095_D004318_D017823,,
770958927,false,true,5,2015-08-14T21:51:00,,No Relation,1,C473478,sunitinib,D002276,Thymic carcinoid,Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.,18166847_0,18166847_C473478_D002276,,
770958928,false,true,5,2015-08-15T00:10:00,,No Relation,1,D015282,octreotide,D002276,Thymic carcinoid,Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.,18166847_0,18166847_D015282_D002276,,
770958929,false,true,5,2015-08-14T22:09:00,,No Relation,0.8032,C473478,sunitinib,D002276,thymic carcinoid,"We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor.",18166847_2,18166847_C473478_D002276,,
770958930,false,true,5,2015-08-14T21:27:00,,No Relation,0.5999,D015282,octreotide,D002276,thymic carcinoid,"We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor.",18166847_2,18166847_D015282_D002276,,
770958931,false,true,5,2015-08-14T22:02:00,,No Relation,1,D015282,octreotide,D018358,management of neuroendocrine tumors,We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.,18166847_4,18166847_D015282_D018358,,
770958932,false,true,5,2015-08-15T01:15:00,,No Relation,1,D015282,octreotide,D009369,tumors,We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.,18166847_4,18166847_D015282_D009369,,
770958933,false,true,5,2015-08-15T02:13:00,,No Relation,1,C473478,sunitinib,D009369,tumors,We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.,18166847_4,18166847_C473478_D009369,,
770958934,false,true,5,2015-08-14T22:10:00,,No Relation,1,C473478,sunitinib,D018358,management of neuroendocrine tumors,We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.,18166847_4,18166847_C473478_D018358,,
770958935,false,true,5,2015-08-14T21:22:00,,No Relation,0.5956,D007455,iodine,D003244,consciousness,Iodoform intoxication; a case report of prolonged consciousness disturbance in a patient with a high plasma iodine level.,18186295_0,18186295_D007455_D003244,,
770958936,false,true,5,2015-08-15T01:49:00,,No Relation,1,D007455,iodine,D014946,infected wounds,This report describes a case in which a consciousness disturbance was associated with a high plasma iodine level and which improved after the removal of iodoform gauze that had been applied to infected wounds.,18186295_1,18186295_D007455_D014946,,
770958937,false,true,5,2015-08-14T21:25:00,,Direct,0.7923,D007455,iodine,D003244,consciousness,This report describes a case in which a consciousness disturbance was associated with a high plasma iodine level and which improved after the removal of iodoform gauze that had been applied to infected wounds.,18186295_1,18186295_D007455_D003244,,
770958938,false,true,5,2015-08-15T01:13:00,,No Relation,0.6114,D007455,iodine,D003244,consciousness,His consciousness recovered gradually with a concomitant decrease in the plasma iodine level.,18186295_6,18186295_D007455_D003244,,
770958939,false,true,5,2015-08-15T02:47:00,,No Relation,1,D000431,ethanol,C531854,oleic acid/OA,"The influence of propylen glycol (PG), ethanol, and oleic acid (OA) on nortriptyline hydrochloride (NTH) penetration through human epidermis was studied in vitro at two different pH values (5.5 and 7.4).",18191555_1,18191555_D000431_C531854,,
770958940,false,true,5,2015-08-15T02:10:00,,No Relation,1,D009661,nortriptyline hydrochloride,C531854,oleic acid/OA,"The influence of propylen glycol (PG), ethanol, and oleic acid (OA) on nortriptyline hydrochloride (NTH) penetration through human epidermis was studied in vitro at two different pH values (5.5 and 7.4).",18191555_1,18191555_D009661_C531854,,
770958941,false,true,5,2015-08-15T00:46:00,,No Relation,1,D019301,oleic acid,C531854,oleic acid/OA,"The influence of propylen glycol (PG), ethanol, and oleic acid (OA) on nortriptyline hydrochloride (NTH) penetration through human epidermis was studied in vitro at two different pH values (5.5 and 7.4).",18191555_1,18191555_D019301_C531854,,
770958942,false,true,5,2015-08-15T00:45:00,,No Relation,1,D011136,polysorbate 80,C531854,OA,The vehicles showed an increasing enhancement effect in the order: polysorbate 80>ethanol/PG/OA>PG>ethanol>ethanol/lactic acid>lactic acid at pH 5.5 while they reduced the permeation of NTH at pH 7.4.,18191555_5,18191555_D011136_C531854,,
770958943,false,true,5,2015-08-14T21:22:00,,No Relation,1,D000431,ethanol,C531854,OA,The vehicles showed an increasing enhancement effect in the order: polysorbate 80>ethanol/PG/OA>PG>ethanol>ethanol/lactic acid>lactic acid at pH 5.5 while they reduced the permeation of NTH at pH 7.4.,18191555_5,18191555_D000431_C531854,,
770958944,false,true,5,2015-08-15T02:18:00,,No Relation,1,D011136,polysorbate 80,C531854,OA,"Considering the results obtained at pH 5.5, the maximum enhancement ratios were found for polysorbate 80 and the combination ethanol/PG/OA (10.72 and 3.90).",18191555_6,18191555_D011136_C531854,,
770958945,false,true,5,2015-08-14T21:08:00,,No Relation,1,D000431,ethanol,C531854,OA,"Considering the results obtained at pH 5.5, the maximum enhancement ratios were found for polysorbate 80 and the combination ethanol/PG/OA (10.72 and 3.90).",18191555_6,18191555_D000431_C531854,,
770958946,false,true,5,2015-08-15T00:47:00,,No Relation,1,D000431,ethanol,C531854,OA,"The NTH-TDS based on the combination of ethanol/PG/OA showed an enhancement ratio with respect to control of 2.09 and the addition of polysorbate 80 to the matrix, of 5.82.",18191555_8,18191555_D000431_C531854,,
770958947,false,true,5,2015-08-14T21:38:00,,No Relation,1,D025762,pristinamycin,D011023,Staphylococcus epidermidis,Analysis of pristinamycin-resistant Staphylococcus epidermidis isolates in the Tunisian Bone Marrow Transplant Center.,18194160_0,18194160_D025762_D011023,,
770958948,false,true,5,2015-08-14T22:05:00,,No Relation,0.8055,D025762,pristinamycin,D011023,Staphylococcus epidermidis,We report the analysis of genetic determinants conferring resistance to pristinamycin in Staphylococcus epidermidis strains and epidemiology typing of these strains by pulsed-field gel electrophoresis.,18194160_1,18194160_D025762_D011023,,
770958949,false,true,5,2015-08-15T01:37:00,,No Relation,1,D025762,pristinamycin,D011023,Staphylococcus epidermidis,Staphylococcus epidermidis (346 isolates) were searched for strains with pristinamycin resistance.,18194160_2,18194160_D025762_D011023,,
770958950,false,true,5,2015-08-14T21:37:00,,No Relation,1,D025762,Pristinamycin,D009369,cancer,Pristinamycin-resistant strains (seven isolates) were isolated in five patients with haematological cancer in the Bone Marrow Transplant Centre of Tunisia in 2002.,18194160_3,18194160_D025762_D009369,,
770958951,false,true,5,2015-08-14T22:10:00,,No Relation,1,D002395,catecholamines,D014947,trauma,"Effect of exogenous catecholamines on tumor necrosis factor alpha, interleukin-6, interleukin-10 and beta-endorphin levels following severe trauma.",18234565_0,18234565_D002395_D014947,,
770958952,false,true,5,2015-08-14T23:43:00,,No Relation,0.7924,D002395,catecholamines,D009336,tumor necrosis factor alpha,"Effect of exogenous catecholamines on tumor necrosis factor alpha, interleukin-6, interleukin-10 and beta-endorphin levels following severe trauma.",18234565_0,18234565_D002395_D009336,,
770958953,false,true,5,2015-08-14T21:36:00,,No Relation,1,D002395,catecholamines,D014947,trauma,"The aim of this study was to determine the effect of exogenous catecholamines on tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), interleukin-10 (IL-10) and beta(beta)-endorphin levels in patients with severe trauma, during the first 24 h after injury.",18234565_2,18234565_D002395_D014947,,
770958954,false,true,5,2015-08-15T00:10:00,,No Relation,1,D002395,catecholamines,D009336,tumor necrosis factor alpha/TNFa,"The aim of this study was to determine the effect of exogenous catecholamines on tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), interleukin-10 (IL-10) and beta(beta)-endorphin levels in patients with severe trauma, during the first 24 h after injury.",18234565_2,18234565_D002395_D009336,,
770958955,false,true,5,2015-08-15T02:17:00,,Direct,0.5924,D002395,catecholamines,D009336,TNFa,"Baseline values were different between the two groups, but an altered pattern of release was observed for TNFa, IL-6, IL-10 and beta-endorphin levels in patients treated with catecholamines.",18234565_6,18234565_D002395_D009336,,
770958956,false,true,5,2015-08-15T01:29:00,,No Relation,1,D002395,catecholamine,D014947,trauma,"Findings support an altered pattern of cytokine release during the early phase after trauma, probably due to catecholamine presence.",18234565_8,18234565_D002395_D014947,,
770958957,false,true,5,2015-08-14T22:00:00,,No Relation,1,D004005,dichlorphenamide/DCP,D010243,paralysis,"In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria.",18254068_8,18254068_D004005_D010243,,
770958958,false,true,5,2015-08-15T02:08:00,,No Relation,1,D004005,dichlorphenamide/DCP,D020514,HypoPP/hypokalemic periodic paralysis,"In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria.",18254068_8,18254068_D004005_D020514,,
770958959,false,true,5,2015-08-14T23:26:00,,No Relation,1,D004005,dichlorphenamide/DCP,D020513,hyperkalemic,"In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria.",18254068_8,18254068_D004005_D020513,,
770958960,false,true,5,2015-08-15T02:34:00,,No Relation,1,D004005,DCP,D010243,paralysis,"Twenty-four of 31 participants with hyperkalemic periodic paralysis completed both treatment phases: for the 16 participants who had attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.006) and in severity-weighted attack rate (P = 0.02) on DCP relative to placebo were significant.",18254068_12,18254068_D004005_D010243,,
770958961,false,true,5,2015-08-14T23:21:00,,No Relation,1,D004005,DCP,D020513,hyperkalemic,"Twenty-four of 31 participants with hyperkalemic periodic paralysis completed both treatment phases: for the 16 participants who had attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.006) and in severity-weighted attack rate (P = 0.02) on DCP relative to placebo were significant.",18254068_12,18254068_D004005_D020513,,
770958962,false,true,5,2015-08-14T21:18:00,,No Relation,1,D020110,pinacidil,D020514,HypoPP,"Acetazolamide proved to improve muscle strength in eight participants with HypoPP in one other study and pinacidil, a potassium channel opener, also improved muscle strength in 2/4 participants with HypoPP in a third study.",18254068_14,18254068_D020110_D020514,,
770958963,false,true,5,2015-08-15T00:03:00,,No Relation,1,D011188,potassium,D020514,HypoPP,"Acetazolamide proved to improve muscle strength in eight participants with HypoPP in one other study and pinacidil, a potassium channel opener, also improved muscle strength in 2/4 participants with HypoPP in a third study.",18254068_14,18254068_D011188_D020514,,
770958964,false,true,5,2015-08-14T22:17:00,,No Relation,1,D000086,Acetazolamide,D020514,HypoPP,"Acetazolamide proved to improve muscle strength in eight participants with HypoPP in one other study and pinacidil, a potassium channel opener, also improved muscle strength in 2/4 participants with HypoPP in a third study.",18254068_14,18254068_D000086_D020514,,
770958965,false,true,5,2015-08-14T23:14:00,,No Relation,1,D004005,DCP,D010243,paralyses,The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness in both hypokalemic and hyperkalemic periodic paralyses.,18254068_15,18254068_D004005_D010243,,
770958966,false,true,5,2015-08-14T21:12:00,,No Relation,1,D004005,DCP,D018908,weakness in both hypokalemic,The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness in both hypokalemic and hyperkalemic periodic paralyses.,18254068_15,18254068_D004005_D018908,,
770958967,false,true,5,2015-08-14T23:00:00,,No Relation,1,D004005,DCP,D020513,hyperkalemic,The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness in both hypokalemic and hyperkalemic periodic paralyses.,18254068_15,18254068_D004005_D020513,,
770958968,false,true,5,2015-08-14T23:22:00,,No Relation,1,C012629,arformoterol,D029424,COPD,Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.,18259972_0,18259972_C012629_D029424,,
770958969,false,true,5,2015-08-15T01:56:00,,No Relation,1,C012629,Arformoterol,D029424,COPD,"Arformoterol, a single isomer long-acting beta(2)-agonist, was developed as an inhalation solution for the maintenance treatment of bronchoconstriction in COPD.",18259972_1,18259972_C012629_D029424,,
770958970,false,true,5,2015-08-15T00:47:00,,No Relation,1,C012629,arformoterol,D029424,COPD,"In these trials, COPD subjects administered nebulized arformoterol demonstrated significant and sustained improvement in lung function over 12 weeks.",18259972_9,18259972_C012629_D029424,,
770958971,false,true,5,2015-08-14T23:22:00,Used as treatment.,No Relation,1,D010431,pentoxifylline,D004715,endometriosis,To compare outcomes after conservative surgery for endometriosis with and without pentoxifylline and to assess the efficacy of pentoxifylline in preventing recurrence of endometriosis after conservative surgery.,18262146_1,18262146_D010431_D004715,,
770958972,false,true,5,2015-08-14T21:52:00,,No Relation,1,D010431,pentoxifylline,D004715,endometriosis,The use of pentoxifylline after conservative surgery for endometriosis resulted in improved VAS scores at 2 and 3 months after the procedure when compared with patients having conservative surgery only.,18262146_24,18262146_D010431_D004715,,
770958973,false,true,5,2015-08-14T21:22:00,,No Relation,1,D010431,pentoxifylline,D004715,endometriosis,The longer-term use of pentoxifylline after conservative surgery may improve long-term outcomes after surgical treatment for endometriosis.,18262146_25,18262146_D010431_D004715,,
770958974,false,true,5,2015-08-14T21:35:00,,No Relation,1,D015122,6-mercaptopurine,D015212,inflammatory bowel disease,Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.,18266236_0,18266236_D015122_D015212,,
770958975,false,true,5,2015-08-15T00:54:00,,No Relation,0.8178,D001379,azathioprine,D015212,inflammatory bowel disease,Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.,18266236_0,18266236_D001379_D015212,,
770958976,false,true,5,2015-08-15T00:19:00,,No Relation,1,D015122,6-MP/6-Mercaptopurine,D015212,IBD/inflammatory bowel disease,6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are effective for the induction and maintenance of remission and reduction of corticosteroid exposure for pediatric inflammatory bowel disease (IBD).,18266236_1,18266236_D015122_D015212,,
770958977,false,true,5,2015-08-15T00:27:00,,No Relation,1,D001379,AZA/azathioprine,D015212,IBD/inflammatory bowel disease,6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are effective for the induction and maintenance of remission and reduction of corticosteroid exposure for pediatric inflammatory bowel disease (IBD).,18266236_1,18266236_D001379_D015212,,
770958978,false,true,5,2015-08-14T23:39:00,,No Relation,1,D015122,6-MP,D015212,IBD,The aim of this study was to determine whether IBD patients 6 years of age and younger require higher than standard doses of 6-MP/AZA to achieve clinical remission.,18266236_3,18266236_D015122_D015212,,
770958979,false,true,5,2015-08-15T02:25:00,,No Relation,1,D001379,AZA,D015212,IBD,The aim of this study was to determine whether IBD patients 6 years of age and younger require higher than standard doses of 6-MP/AZA to achieve clinical remission.,18266236_3,18266236_D001379_D015212,,
770958980,false,true,5,2015-08-14T21:14:00,,No Relation,0.806,D015122,6-MP,D015212,IBD,Clinical data was collected retrospectively for all IBD patients 6 years of age or younger treated with 6-MP/AZA at The Children's Hospital of Philadelphia.,18266236_4,18266236_D015122_D015212,,
770958981,false,true,5,2015-08-14T22:04:00,,No Relation,1,D001379,AZA,D015212,IBD,Clinical data was collected retrospectively for all IBD patients 6 years of age or younger treated with 6-MP/AZA at The Children's Hospital of Philadelphia.,18266236_4,18266236_D001379_D015212,,
770958982,false,true,5,2015-08-14T22:56:00,,No Relation,1,D015122,6-MP,D015212,IBD,IBD was diagnosed at a median age of 3.3 years (25-75th %ile 2.3-4.6 years) and 6-MP/AZA was initiated at a median age of 3.9 years (range 0.8-6.8 years).,18266236_6,18266236_D015122_D015212,,
770958983,false,true,5,2015-08-14T22:18:00,,No Relation,1,D001379,AZA,D015212,IBD,IBD was diagnosed at a median age of 3.3 years (25-75th %ile 2.3-4.6 years) and 6-MP/AZA was initiated at a median age of 3.9 years (range 0.8-6.8 years).,18266236_6,18266236_D001379_D015212,,
770958984,false,true,5,2015-08-14T21:36:00,,No Relation,0.805,D001379,AZA,D007757,laboratory abnormalities,"No patients had to discontinue 6-MP/AZA, and all laboratory abnormalities improved spontaneously or with dose reduction.",18266236_11,18266236_D001379_D007757,,
770958985,false,true,5,2015-08-14T21:13:00,,No Relation,0.5932,D015122,6-MP,D007757,laboratory abnormalities,"No patients had to discontinue 6-MP/AZA, and all laboratory abnormalities improved spontaneously or with dose reduction.",18266236_11,18266236_D015122_D007757,,
770958986,false,true,5,2015-08-15T01:43:00,,No Relation,1,D015122,6-MP,D015212,IBD,The standard dose of 6-MP/AZA may not be adequate for IBD patients 6 years of age and younger.,18266236_12,18266236_D015122_D015212,,
770958987,false,true,5,2015-08-14T22:27:00,,No Relation,1,D001379,AZA,D015212,IBD,The standard dose of 6-MP/AZA may not be adequate for IBD patients 6 years of age and younger.,18266236_12,18266236_D001379_D015212,,
770958988,false,true,5,2015-08-14T21:09:00,,No Relation,0.4244,D008353,mannitol,D065627,arterial hypertension,"Other first-tier options include induced hypocapnea (hyperventilation; paCO2 < 35 mmHg), hyperosmolar therapy (mannitol, hypertonic saline) and induced arterial hypertension (CPP concept).",18286835_14,18286835_D008353_D065627,,
770958989,false,true,5,2015-08-14T21:13:00,,No Relation,1,D008353,mannitol,D006944,hyperosmolar,"Other first-tier options include induced hypocapnea (hyperventilation; paCO2 < 35 mmHg), hyperosmolar therapy (mannitol, hypertonic saline) and induced arterial hypertension (CPP concept).",18286835_14,18286835_D008353_D006944,,
770958990,false,true,5,2015-08-14T21:15:00,,No Relation,1,D007213,indomethacin,D018476,coma,"These include 'forced hyperventilation' (paCO2 < 25 mmHg), barbiturate coma or experimental protocols such as tris buffer, indomethacin or induced hypothermia.",18286835_17,18286835_D007213_D018476,,
770958991,false,true,5,2015-08-14T21:45:00,,No Relation,0.8216,D007213,indomethacin,D007035,hypothermia,"These include 'forced hyperventilation' (paCO2 < 25 mmHg), barbiturate coma or experimental protocols such as tris buffer, indomethacin or induced hypothermia.",18286835_17,18286835_D007213_D007035,,
770958992,false,true,5,2015-08-14T21:09:00,,Direct,0.6201,C032232,barbiturate,D018476,coma,"These include 'forced hyperventilation' (paCO2 < 25 mmHg), barbiturate coma or experimental protocols such as tris buffer, indomethacin or induced hypothermia.",18286835_17,18286835_C032232_D018476,,
770958993,false,true,5,2015-08-15T00:16:00,,No Relation,1,C032232,barbiturate,D007035,hypothermia,"These include 'forced hyperventilation' (paCO2 < 25 mmHg), barbiturate coma or experimental protocols such as tris buffer, indomethacin or induced hypothermia.",18286835_17,18286835_C032232_D007035,,
770958994,false,true,5,2015-08-14T21:23:00,,No Relation,1,D013739,testosterone,D007006,hypogonadism,"Clinically, reports of patients with erectile dysfunction (ED) combined with hypogonadism who receive testosterone therapy have inconsistent results.",18305486_6,18305486_D013739_D007006,,
770958995,false,true,5,2015-08-14T23:46:00,,No Relation,0.7879,D013739,testosterone,D007172,ED/erectile dysfunction,"Clinically, reports of patients with erectile dysfunction (ED) combined with hypogonadism who receive testosterone therapy have inconsistent results.",18305486_6,18305486_D013739_D007172,,
770958996,false,true,5,2015-08-14T21:36:00,,No Relation,0.6242,D013739,testosterone,D011471,prostate cancer,"Because of potential risks in clinical use, testosterone therapy should be individualized, carefully considered and closely monitored, especially, in patients with possible occult prostate cancer, and large benign prostatic hyperplasia.",18305486_8,18305486_D013739_D011471,,
770958997,false,true,5,2015-08-14T22:00:00,,No Relation,1,D013739,testosterone,D011470,prostatic hyperplasia,"Because of potential risks in clinical use, testosterone therapy should be individualized, carefully considered and closely monitored, especially, in patients with possible occult prostate cancer, and large benign prostatic hyperplasia.",18305486_8,18305486_D013739_D011470,,
770958998,false,true,5,2015-08-15T00:50:00,,No Relation,1,D008140,lorazepam,D002389,catatonia,"Although lorazepam is helpful in treating catatonia, it may not suffice, as in the cases presented.",18327024_9,18327024_D008140_D002389,,
770958999,false,true,5,2015-08-15T02:08:00,,No Relation,1,D008140,lorazepam,D004660,encephalitis,"ECT deserves serious consideration early in the course of malignant catatonia and for catatonia nested in encephalopathy secondary to encephalitis, unresolved with lorazepam.",18327024_10,18327024_D008140_D004660,,
770959000,false,true,5,2015-08-15T01:03:00,,No Relation,1,D008140,lorazepam,D001925,encephalopathy,"ECT deserves serious consideration early in the course of malignant catatonia and for catatonia nested in encephalopathy secondary to encephalitis, unresolved with lorazepam.",18327024_10,18327024_D008140_D001925,,
770959001,false,true,5,2015-08-15T00:22:00,,No Relation,1,D008140,lorazepam,D002389,catatonia,"ECT deserves serious consideration early in the course of malignant catatonia and for catatonia nested in encephalopathy secondary to encephalitis, unresolved with lorazepam.",18327024_10,18327024_D008140_D002389,,
770959002,false,true,5,2015-08-15T00:16:00,,No Relation,1,D015283,escitalopram,D003866,depressive disorder,A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.,18331669_0,18331669_D015283_D003866,,
770959003,false,true,5,2015-08-14T21:35:00,,No Relation,1,C058218,duloxetine,D003866,depressive disorder,A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.,18331669_0,18331669_C058218_D003866,,
770959004,false,true,5,2015-08-14T21:19:00,,No Relation,1,D015283,escitalopram,D003866,depression,This analysis suggests that escitalopram was more effective in terms of QALWs and less costly than duloxetine for treatment of depression.,18331669_14,18331669_D015283_D003866,,
770959005,false,true,5,2015-08-14T21:22:00,,No Relation,1,C058218,duloxetine,D003866,depression,This analysis suggests that escitalopram was more effective in terms of QALWs and less costly than duloxetine for treatment of depression.,18331669_14,18331669_C058218_D003866,,
770959006,false,true,5,2015-08-15T02:20:00,,No Relation,1,C117268,Pimecrolimus,D003876,atopic dermatitis,Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression.,18341665_0,18341665_C117268_D003876,,
770959007,false,true,5,2015-08-14T22:17:00,,No Relation,1,C117268,pimecrolimus,D003876,atopic dermatitis/AD,Previous studies suggested that early intervention with pimecrolimus cream 1% at the first signs and/or symptoms of a relapse of atopic dermatitis (AD) following remission may prevent the occurrence of more severe flares and therefore reduce corticosteroid exposure in the long term.,18341665_2,18341665_C117268_D003876,,
770959008,false,true,5,2015-08-15T01:23:00,,No Relation,1,C117268,pimecrolimus,D003876,AD,To evaluate the effectiveness of pimecrolimus cream 1% for the prevention of flare progression in adults with AD.,18341665_4,18341665_C117268_D003876,,
770959009,false,true,5,2015-08-14T21:19:00,,No Relation,0.7894,C117268,pimecrolimus,D003876,AD,"A 26-week randomized controlled study was conducted in 543 patients aged>or=18 years, with a history of mild or moderate AD, who were clear/almost clear of disease before randomization to pimecrolimus cream 1% (n=277) or matching vehicle cream (n=266).",18341665_5,18341665_C117268_D003876,,
770959010,false,true,5,2015-08-14T22:21:00,,No Relation,1,C117268,pimecrolimus,D003876,AD,"In adults with a history of mild or moderate AD but free of active skin lesions, intervention with pimecrolimus cream 1% at the first signs and/or symptoms of a subsequent recurrence reduces the number of flares requiring TCS use and decreases the number of disease-related office visits.",18341665_12,18341665_C117268_D003876,,
770959011,false,true,5,2015-08-15T00:03:00,Used as treatment.,No Relation,1,C117268,pimecrolimus,C537466,skin lesions,"In adults with a history of mild or moderate AD but free of active skin lesions, intervention with pimecrolimus cream 1% at the first signs and/or symptoms of a subsequent recurrence reduces the number of flares requiring TCS use and decreases the number of disease-related office visits.",18341665_12,18341665_C117268_C537466,,
770959012,false,true,5,2015-08-14T21:18:00,,No Relation,1,C056507,gemcitabine,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C056507_D007938,,
770959013,false,true,5,2015-08-15T01:06:00,,No Relation,1,D015255,idarubicin,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_D015255_D008223,,
770959014,false,true,5,2015-08-15T00:37:00,,No Relation,1,C483604,cloretazine,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C483604_D007938,,
770959015,false,true,5,2015-08-14T21:58:00,,No Relation,1,D015255,idarubicin,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_D015255_D007938,,
770959016,false,true,5,2015-08-15T00:24:00,,No Relation,1,C483604,cloretazine,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C483604_D008223,,
770959017,false,true,5,2015-08-15T01:06:00,,No Relation,1,D019772,topotecan,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_D019772_D008223,,
770959018,false,true,5,2015-08-14T22:06:00,,No Relation,1,C051890,irinotecan,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C051890_D008223,,
770959019,false,true,5,2015-08-15T02:25:00,,No Relation,1,D019772,topotecan,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_D019772_D007938,,
770959020,false,true,5,2015-08-15T00:24:00,,No Relation,1,C047645,CP-4055,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C047645_D008223,,
770959021,false,true,5,2015-08-14T22:46:00,,No Relation,1,C051890,irinotecan,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C051890_D007938,,
770959022,false,true,5,2015-08-15T00:52:00,,No Relation,1,C056507,gemcitabine,D008223,lymphoma,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C056507_D008223,,
770959023,false,true,5,2015-08-15T00:23:00,,No Relation,1,C047645,CP-4055,D007938,leukemia,"Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.",18398748_0,18398748_C047645_D007938,,
770959024,false,true,5,2015-08-14T21:54:00,,No Relation,1,C047645,CP-4055,D008223,lymphoma,"In summary, CP-4055 produced additive to synergistic anti proliferative activity when combined simultaneously with drugs from four mechanistic classes in cell culture models of human leukemia and lymphoma.",18398748_7,18398748_C047645_D008223,,
770959025,false,true,5,2015-08-15T01:47:00,,No Relation,1,C047645,CP-4055,D007938,leukemia,"In summary, CP-4055 produced additive to synergistic anti proliferative activity when combined simultaneously with drugs from four mechanistic classes in cell culture models of human leukemia and lymphoma.",18398748_7,18398748_C047645_D007938,,
770959026,false,true,5,2015-08-14T22:05:00,,No Relation,0.7955,D004801,eosin,D009369,cancer,"Uni- and multivariable variable analyses showed that the lowest recurrence rates were reported in studies performed in cancer centres, in studies that described the use of (99m)Tc-sulphur colloid, and also when investigators used the superficial injection technique or evaluated the harvested sentinel nodes with haematoxylin-eosin and immunohistochemistry staining (p<0.01).",18406100_8,18406100_D004801_D009369,,
770959027,false,true,5,2015-08-14T21:19:00,,No Relation,1,D014280,triglycerides,D015228,hypertriglyceridemia,"Moderate hypertriglyceridemia is fairly common, and elevated triglycerides are a risk factor for coronary heart disease.",18422480_1,18422480_D014280_D015228,,
770959028,false,true,5,2015-08-15T02:47:00,,Direct,0.798,D014280,triglycerides,D003327,coronary heart disease,"Moderate hypertriglyceridemia is fairly common, and elevated triglycerides are a risk factor for coronary heart disease.",18422480_1,18422480_D014280_D003327,,
770959029,false,true,5,2015-08-15T02:02:00,,No Relation,1,D014280,triglycerides,D015228,hypertriglyceridemia,This review provides an overview of the use of omega-3 concentrates (both P-OM3 and over-the-counter fish oil) to lower triglycerides in people who have moderate hypertriglyceridemia (triglycerides in the range of 150 - 500 mg/dl).,18422480_5,18422480_D014280_D015228,,
770959030,false,true,5,2015-08-15T01:41:00,,No Relation,1,D014280,triglycerides,D050171,dyslipidemia,"P-OM3 are effective in reducing triglycerides by approximately 30% in this population and are likely to be combined with other drugs (e.g., statins) to treat combined dyslipidemia.",18422480_9,18422480_D014280_D050171,,
770959031,false,true,5,2015-08-15T01:29:00,,Direct,0.6081,C022202,9-anilinoacridine,D004487,cytotoxicity,Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine.,18454048_0,18454048_C022202_D004487,,
770959032,false,true,5,2015-08-14T21:20:00,,No Relation,1,C530271,2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol/CK0402,D009369,multiple cancer,"Two recently developed sulfide derivatives of 9-anilinoacridines, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) and 3-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(3-hydroxypropyl)amino)propan-1-ol (CK0403), displayed potent cytotoxic activity in multiple cancer cell lines.",18454048_2,18454048_C530271_D009369,,
770959033,false,true,5,2015-08-15T00:13:00,,No Relation,0.6165,C530272,3-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(3-hydroxypropyl)amino)propan-1-ol/CK0403,D009369,multiple cancer,"Two recently developed sulfide derivatives of 9-anilinoacridines, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) and 3-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(3-hydroxypropyl)amino)propan-1-ol (CK0403), displayed potent cytotoxic activity in multiple cancer cell lines.",18454048_2,18454048_C530272_D009369,,
770959034,false,true,5,2015-08-14T22:12:00,,No Relation,1,C098350,verteporfin,D020256,choroidal neovascularization,Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.,18463509_0,18463509_C098350_D020256,,
770959035,false,true,5,2015-08-15T00:26:00,,No Relation,1,C098350,verteporfin,D008268,age-related macular degeneration,Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.,18463509_0,18463509_C098350_D008268,,
770959036,false,true,5,2015-08-14T21:43:00,,No Relation,1,C098350,verteporfin,D020256,choroidal neovascularization/CNV,To report the outcome for eyes treated with intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).,18463509_1,18463509_C098350_D020256,,
770959037,false,true,5,2015-08-14T21:27:00,,No Relation,1,C098350,verteporfin,D008268,AMD/age-related macular degeneration,To report the outcome for eyes treated with intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).,18463509_1,18463509_C098350_D008268,,
770959038,false,true,5,2015-08-14T22:09:00,,Direct,1,D019797,MIBG,D006976,pulmonary hypertension,(123)I-MIBG is also used as a potential marker of pulmonary endothelial cell function and may be related to pulmonary hypertension.,18471462_2,18471462_D019797_D006976,,
770959039,false,true,5,2015-08-15T02:05:00,,No Relation,1,D019797,MIBG,D002311,idiopathic dilated cardiomyopathy,"In conclusion, the combined assessment of lung and heart 123I-MIBG uptake may help to predict future clinical outcome for patients with idiopathic dilated cardiomyopathy more accurately than myocardial evaluation alone.",18471462_12,18471462_D019797_D002311,,
770959040,false,true,5,2015-08-14T21:10:00,,No Relation,1,C015542,gaboxadol,D012893,Slow wave sleep/daytime sleepiness/sleep restriction,Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restriction.,18517036_0,18517036_C015542_D012893,,
770959041,false,true,5,2015-08-14T23:20:00,,No Relation,1,C015542,gaboxadol,D012893,SWS/sleep restriction,"A double-blind, parallel group, placebo-controlled design was used to compare gaboxadol (GBX) 15 mg, a SWS-enhancing drug, to placebo during 4 nights of sleep restriction (5 h/night).",18517036_2,18517036_C015542_D012893,,
770959042,false,true,5,2015-08-15T02:12:00,,No Relation,1,C015542,GBX,D012893,sleep restriction,"Each group received either GBX 15 mg or placebo on all sleep restriction nights, and both groups received placebo on baseline and recovery nights.",18517036_7,18517036_C015542_D012893,,
770959043,false,true,5,2015-08-14T22:11:00,,No Relation,1,D012503,Saponins,D009369,tumor,Saponins in tumor therapy.,18537712_0,18537712_D012503_D009369,,
770959044,false,true,5,2015-08-14T22:09:00,,No Relation,1,D012503,Saponins,D002471,tumorigenic,Saponins are plant glycosides with favorable anti-tumorigenic properties.,18537712_1,18537712_D012503_D002471,,
770959045,false,true,5,2015-08-15T00:10:00,,No Relation,0.8008,D012503,saponins,D009369,tumor,Several saponins inhibit tumor cell growth by cell cycle arrest and apoptosis with IC50 values of up to 0.2 microM.,18537712_2,18537712_D012503_D009369,,
770959046,false,true,5,2015-08-15T01:15:00,,No Relation,0.8179,C025759,saikosaponins,D009369,tumor,"We discuss diverse groups of saponins (dioscins, saikosaponins, julibrosides, soy saponins, ginseng saponins and avicins) investigated in relation to tumor therapy and focus on cellular and systemic mechanisms of tumor cell growth inhibition both in vitro and in vivo.",18537712_3,18537712_C025759_D009369,,
770959047,false,true,5,2015-08-14T21:52:00,,No Relation,1,D012503,saponins,D009369,tumor,"We discuss diverse groups of saponins (dioscins, saikosaponins, julibrosides, soy saponins, ginseng saponins and avicins) investigated in relation to tumor therapy and focus on cellular and systemic mechanisms of tumor cell growth inhibition both in vitro and in vivo.",18537712_3,18537712_D012503_D009369,,
770959048,false,true,5,2015-08-14T21:14:00,,No Relation,1,D012503,saponins,D009369,tumor,"The review also describes saponins in combination with conventional tumor treatment strategies, which result in improved therapeutic success.",18537712_4,18537712_D012503_D009369,,
770959049,false,true,5,2015-08-14T22:49:00,,No Relation,1,D012503,saponins,D002471,tumorigenic,Some combinations of saponins and anti-tumorigenic drugs induce synergistic effects with potentiated growth inhibition.,18537712_5,18537712_D012503_D002471,,
770959050,false,true,5,2015-08-14T23:23:00,,No Relation,1,D012643,selenium,D015658,HIV-infected,"Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes.",18541571_0,18541571_D012643_D015658,,
770959051,false,true,5,2015-08-14T22:10:00,,No Relation,1,D012643,selenium,D015658,HIV disease progression,"In observational studies, adequate selenium status has been associated with better pregnancy outcomes and slowed HIV disease progression.",18541571_1,18541571_D012643_D015658,,
770959052,false,true,5,2015-08-15T01:11:00,,No Relation,1,D012643,selenium,D015658,HIV-infected,"We investigated the effects of daily selenium supplements on CD4 cell counts, viral load, pregnancy outcomes, and maternal and infant mortality among 913 HIV-infected pregnant women.",18541571_2,18541571_D012643_D015658,,
770959053,false,true,5,2015-08-15T01:06:00,,Direct,1,D012643,Selenium,D005313,fetal death,"Selenium was marginally associated with a reduced risk of low birth weight [relative risk (RR) = 0.71; 95% CI: 0.49, 1.05; P = 0.09] and increased risk of fetal death (RR = 1.58; 95% CI = 0.95, 2.63; P = 0.08), but had no effect on risk of prematurity or small-for-gestational age birth.",18541571_6,18541571_D012643_D005313,,
770959054,false,true,5,2015-08-14T23:23:00,Used as a lame treatment.,No Relation,1,D012643,selenium,D015658,HIV disease progression/HIV-infected,"Among HIV-infected women from Dar es Salaam, Tanzania, selenium supplements given during and after pregnancy did not improve HIV disease progression or pregnancy outcomes, but may improve child survival.",18541571_9,18541571_D012643_D015658,,
770959055,false,true,5,2015-08-14T22:06:00,,No Relation,1,D011794,Quercetin,D009369,tumor,Quercetin dose-dependently inhibited in vitro lipopolysaccharide-induced tumor necrosis factor-alpha production in the blood of healthy volunteers.,18549926_4,18549926_D011794_D009369,,
770959056,false,true,5,2015-08-14T21:09:00,,No Relation,0.8192,D011794,Quercetin,D009336,necrosis,Quercetin dose-dependently inhibited in vitro lipopolysaccharide-induced tumor necrosis factor-alpha production in the blood of healthy volunteers.,18549926_4,18549926_D011794_D009336,,
770959057,false,true,5,2015-08-15T02:17:00,,No Relation,1,D004967,estrogen,D010146,neuropathic pain,Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.,18559275_0,18559275_D004967_D010146,,
770959058,false,true,5,2015-08-14T21:15:00,,No Relation,1,D004967,estrogens,D010146,pain,The effects of estrogens on pain perception remain controversial.,18559275_1,18559275_D004967_D010146,,
770959059,false,true,5,2015-08-15T01:34:00,,No Relation,1,D004967,estrogen,D010146,pain animal models involving nerve injury or sensitization,ERb-131 a non-steroidal estrogen receptor beta ligand was evaluated in several pain animal models involving nerve injury or sensitization.,18559275_3,18559275_D004967_D010146,,
770959060,false,true,5,2015-08-15T00:59:00,,No Relation,1,D002211,capsaicin,D020436,spinal nerve ligation,"ERb-131 alleviated tactile hyperalgesia induced by capsaicin, and reversed tactile allodynia caused by spinal nerve ligation and various chemical insults.",18559275_6,18559275_D002211_D020436,,
770959061,false,true,5,2015-08-14T21:35:00,,Direct,0.7959,D002211,capsaicin,D006930,tactile hyperalgesia/allodynia,"ERb-131 alleviated tactile hyperalgesia induced by capsaicin, and reversed tactile allodynia caused by spinal nerve ligation and various chemical insults.",18559275_6,18559275_D002211_D006930,,
770959062,false,true,5,2015-08-15T02:10:00,,No Relation,1,D014700,verapamil,D001281,AF,"Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF.",18562808_4,18562808_D014700_D001281,,
770959063,false,true,5,2015-08-15T02:39:00,,No Relation,1,D004110,diltiazem,D001281,AF,"Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF.",18562808_4,18562808_D004110_D001281,,
770959064,false,true,5,2015-08-14T21:17:00,,No Relation,1,D014700,verapamil,D001281,AF,"An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin.",18562808_5,18562808_D014700_D001281,,
770959065,false,true,5,2015-08-14T23:25:00,Used as treatment.,No Relation,1,D004110,diltiazem,D001281,AF,"An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin.",18562808_5,18562808_D004110_D001281,,
770959066,false,true,5,2015-08-15T01:16:00,,No Relation,1,D004077,digoxin,D001281,AF,"An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin.",18562808_5,18562808_D004077_D001281,,
770959067,false,true,5,2015-08-14T22:40:00,,No Relation,1,D000638,Amiodarone,D001281,AF,Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs.,18562808_6,18562808_D000638_D001281,,
770959068,false,true,5,2015-08-14T21:25:00,,No Relation,1,D004077,Digoxin,D001281,AF,Digoxin should not be used to treat patients with paroxysmal AF.,18562808_7,18562808_D004077_D001281,,
770959069,false,true,5,2015-08-15T01:52:00,,Direct,0.6086,D034261,epothilones,D010523,peripheral neuropathy,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D034261_D010523,,
770959070,false,true,5,2015-08-14T21:24:00,,Direct,0.8026,D043823,taxanes,D010523,peripheral neuropathy,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D043823_D010523,,
770959071,false,true,5,2015-08-15T00:18:00,,No Relation,1,D014748,vinca alkaloids,D009369,breast cancer,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D014748_D009369,,
770959072,false,true,5,2015-08-15T01:20:00,,No Relation,1,D043823,taxanes,D009369,breast cancer,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D043823_D009369,,
770959073,false,true,5,2015-08-14T23:10:00,,No Relation,1,D034261,epothilones,D009369,breast cancer,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D034261_D009369,,
770959074,false,true,5,2015-08-14T23:31:00,,Direct,1,D014748,vinca alkaloids,D010523,peripheral neuropathy,"Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy.",18567992_1,18567992_D014748_D010523,,
770959075,false,true,5,2015-08-14T23:34:00,,Direct,1,D014750,vincristine,D015417,sensory/motor neuropathy,"Although some first-generation vinca alkaloids, such as vincristine, were associated with severe mixed sensory/motor neuropathy, the deficits associated with newer agents in this class (eg, vinflunine) are generally milder and limited to distal sensory signs and symptoms.",18567992_3,18567992_D014750_D015417,,
770959076,false,true,5,2015-08-15T01:51:00,,No Relation,0.5916,C111217,vinflunine,D015417,sensory/motor neuropathy,"Although some first-generation vinca alkaloids, such as vincristine, were associated with severe mixed sensory/motor neuropathy, the deficits associated with newer agents in this class (eg, vinflunine) are generally milder and limited to distal sensory signs and symptoms.",18567992_3,18567992_C111217_D015417,,
770959077,false,true,5,2015-08-14T21:54:00,,Direct,1,D034261,Epothilones,D010523,peripheral neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_D034261_D010523,,
770959078,false,true,5,2015-08-14T21:16:00,,Direct,0.5983,C093788,epothilone B,D001167,neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_C093788_D001167,,
770959079,false,true,5,2015-08-15T00:41:00,,Direct,0.8199,C430592,ixabepilone,D010523,peripheral neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_C430592_D010523,,
770959080,false,true,5,2015-08-15T01:52:00,,Direct,0.7976,D034261,Epothilones,D001167,neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_D034261_D001167,,
770959081,false,true,5,2015-08-14T23:48:00,,Direct,1,C430592,ixabepilone,D001167,neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_C430592_D001167,,
770959082,false,true,5,2015-08-14T21:22:00,,No Relation,0.5861,C093788,epothilone B,D010523,peripheral neuropathy,"Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels.",18567992_5,18567992_C093788_D010523,,
770959083,false,true,5,2015-08-14T22:23:00,,No Relation,0.7912,D043823,taxanes,D020258,neurotoxicities,"This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone.",18567992_7,18567992_D043823_D020258,,
770959084,false,true,5,2015-08-14T22:03:00,,Direct,0.6274,C111217,vinflunine,D020258,neurotoxicities,"This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone.",18567992_7,18567992_C111217_D020258,,
770959085,false,true,5,2015-08-15T02:25:00,,No Relation,1,D014748,vinca alkaloids,D020258,neurotoxicities,"This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone.",18567992_7,18567992_D014748_D020258,,
770959086,false,true,5,2015-08-15T00:00:00,,Direct,0.6012,C430592,ixabepilone,D020258,neurotoxicities,"This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone.",18567992_7,18567992_C430592_D020258,,
770959087,false,true,5,2015-08-14T23:54:00,,Direct,0.7974,C535053,AEG40730,D015431,dramatic reduction,"We demonstrate that AEG40730, a compound modeled on BIR-binding tetrapeptides, binds to cIAP1 and cIAP2, facilitates their autoubiquitination and proteosomal degradation, and causes a dramatic reduction in RIP1 ubiquitination.",18570872_3,18570872_C535053_D015431,,
770959088,false,true,5,2015-08-14T21:18:00,,No Relation,1,C055162,clopidogrel,D009203,STEMI,Long-term cost-effectiveness of clopidogrel in STEMI patients.,18586338_0,18586338_C055162_D009203,,
770959089,false,true,5,2015-08-14T23:02:00,,No Relation,1,C055162,clopidogrel,D020521,stroke,"The COMMIT trial demonstrated that clopidogrel produced a 9% relative reduction in death, reinfarction or stroke (9.2% vs. 10.1%, 95% CI: 0.86-0.97) in ST-elevated myocardial infarction (STEMI) patients.",18586338_1,18586338_C055162_D020521,,
770959090,false,true,5,2015-08-15T01:51:00,,No Relation,1,C055162,clopidogrel,D009203,ST-elevated myocardial infarction/STEMI,"The COMMIT trial demonstrated that clopidogrel produced a 9% relative reduction in death, reinfarction or stroke (9.2% vs. 10.1%, 95% CI: 0.86-0.97) in ST-elevated myocardial infarction (STEMI) patients.",18586338_1,18586338_C055162_D009203,,
770959091,false,true,5,2015-08-14T22:27:00,,No Relation,0.8001,C055162,clopidogrel,D003643,death,"The COMMIT trial demonstrated that clopidogrel produced a 9% relative reduction in death, reinfarction or stroke (9.2% vs. 10.1%, 95% CI: 0.86-0.97) in ST-elevated myocardial infarction (STEMI) patients.",18586338_1,18586338_C055162_D003643,,
770959092,false,true,5,2015-08-14T22:29:00,,No Relation,1,C055162,clopidogrel,D009203,STEMI,"Between 08/1999 and 05/2005, 45,852 STEMI patients were randomized to clopidogrel (n=22,961) or matching placebo (n=22,891) in addition to aspirin.",18586338_2,18586338_C055162_D009203,,
770959093,false,true,5,2015-08-15T00:57:00,,No Relation,1,D001241,aspirin,D009203,STEMI,"Between 08/1999 and 05/2005, 45,852 STEMI patients were randomized to clopidogrel (n=22,961) or matching placebo (n=22,891) in addition to aspirin.",18586338_2,18586338_D001241_D009203,,
770959094,false,true,5,2015-08-15T00:15:00,,No Relation,1,C055162,clopidogrel,D009203,STEMI,"Addition of clopidogrel to aspirin, given up to 1 year, in the setting of STEMI is a highly cost-effective strategy.",18586338_12,18586338_C055162_D009203,,
770959095,false,true,5,2015-08-15T00:27:00,,No Relation,1,D001241,aspirin,D009203,STEMI,"Addition of clopidogrel to aspirin, given up to 1 year, in the setting of STEMI is a highly cost-effective strategy.",18586338_12,18586338_D001241_D009203,,
770959096,false,true,5,2015-08-14T21:36:00,,Direct,0.7902,D008774,methylphenidate,D006816,Juvenile Huntington disease,Juvenile Huntington disease exacerbated by methylphenidate: case report.,18658080_0,18658080_D008774_D006816,,
770959097,false,true,5,2015-08-15T01:25:00,,No Relation,1,D008774,methylphenidate,D001289,attention-deficit hyperactivity disorder/ADHD,"The authors describe the case of an 8-year-old boy, otherwise healthy, who presented with symptoms consistent with attention-deficit hyperactivity disorder (ADHD) and was started on a trial of methylphenidate.",18658080_1,18658080_D008774_D001289,,
770959098,false,true,5,2015-08-15T01:53:00,,Direct,0.6181,D004967,estrogen,D009369,breast cancer,"After EPHT recruited in 1999-2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence.",18673555_5,18673555_D004967_D009369,,
770959099,false,true,5,2015-08-14T23:43:00,,No Relation,1,D004967,estrogen,D003327,coronary heart disease,"After EPHT recruited in 1999-2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence.",18673555_5,18673555_D004967_D003327,,
770959100,false,true,5,2015-08-14T21:32:00,,Direct,1,D004967,estrogen,D020521,stroke,"After EPHT recruited in 1999-2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence.",18673555_5,18673555_D004967_D020521,,
770959101,false,true,5,2015-08-15T01:26:00,,No Relation,1,D004967,estrogen,D006620,hip fracture,"After EPHT recruited in 1999-2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence.",18673555_5,18673555_D004967_D006620,,
770959102,false,true,5,2015-08-14T22:20:00,,No Relation,1,D013256,steroids,D029424,COPD,"In addition, high doses of steroids have a minimal effect on the inexorable decline in lung function in COPD patients and only a small effect on reducing exacerbations.",18682458_3,18682458_D013256_D029424,,
770959103,false,true,5,2015-08-15T00:15:00,,No Relation,1,D002725,chloroform,D008223,glycoprotein of mouse lymphoma,"In the present work, extracts of 12 selected herbs were prepared with methanol, chloroform, ethyl acetate and water, and the effects of these on the multidrug resistance (MDR) and P-glycoprotein of mouse lymphoma cells transfected with the human mdr1 gene and on a human lung alveolar epithelial cell line were investigated.",18690658_2,18690658_D002725_D008223,,
770959104,false,true,5,2015-08-14T21:56:00,,No Relation,1,D000432,methanol,D008223,glycoprotein of mouse lymphoma,"In the present work, extracts of 12 selected herbs were prepared with methanol, chloroform, ethyl acetate and water, and the effects of these on the multidrug resistance (MDR) and P-glycoprotein of mouse lymphoma cells transfected with the human mdr1 gene and on a human lung alveolar epithelial cell line were investigated.",18690658_2,18690658_D000432_D008223,,
770959105,false,true,5,2015-08-14T22:19:00,,No Relation,1,C007650,ethyl acetate,D008223,glycoprotein of mouse lymphoma,"In the present work, extracts of 12 selected herbs were prepared with methanol, chloroform, ethyl acetate and water, and the effects of these on the multidrug resistance (MDR) and P-glycoprotein of mouse lymphoma cells transfected with the human mdr1 gene and on a human lung alveolar epithelial cell line were investigated.",18690658_2,18690658_C007650_D008223,,
770959106,false,true,5,2015-08-14T23:44:00,,No Relation,0.7889,D002725,chloroform,D008175,lung cancer,The possible chemopreventive effect of the chloroform extracts was studied on the expression of cytomegalovirus (CMV) immediate-early (IE) antigen in human lung cancer cells (A549).,18690658_4,18690658_D002725_D008175,,
770959107,false,true,5,2015-08-15T00:28:00,,No Relation,1,D002725,chloroform,D008223,MDR mouse lymphoma,Two of the chloroform extracts enhanced the antiproliferative effect of doxorubicin on MDR mouse lymphoma cells.,18690658_7,18690658_D002725_D008223,,
770959108,false,true,5,2015-08-14T21:48:00,,No Relation,1,D004317,doxorubicin,D008223,MDR mouse lymphoma,Two of the chloroform extracts enhanced the antiproliferative effect of doxorubicin on MDR mouse lymphoma cells.,18690658_7,18690658_D004317_D008223,,
770959109,false,true,5,2015-08-14T23:16:00,It's the mutation that causes the hyperthermia,No Relation,0.6206,D012433,ryanodine,D008305,malignant hyperthermia,Novel ryanodine receptor mutation that may cause malignant hyperthermia.,18719443_0,18719443_D012433_D008305,,
770959110,false,true,5,2015-08-14T21:42:00,,Direct,0.7979,D002118,Ca,D008305,Malignant hyperthermia/MH,Malignant hyperthermia (MH) is a hypermetabolic condition caused by a genetic disposition leading to increased Ca release from the sarcoplasmic reticulum after exposure to triggering agents.,18719443_1,18719443_D002118_D008305,,
770959111,false,true,5,2015-08-15T01:24:00,,No Relation,1,D012433,ryanodine,D008305,MH,"In the authors' ongoing evaluation of patients undergoing MH testing in Austria, they detected a family with a new variant of the ryanodine receptor 1.",18719443_2,18719443_D012433_D008305,,
770959112,false,true,5,2015-08-15T02:08:00,,No Relation,0.7965,D011239,prednisolone,D011125,polyposis,Thirty-two patients with nasal polyposis were randomized to unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and nasal budesonide bilaterally for 1 month.,18720067_3,18720067_D011239_D011125,,
770959113,false,true,5,2015-08-15T00:54:00,,No Relation,1,D019819,budesonide,D011125,polyposis,Thirty-two patients with nasal polyposis were randomized to unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and nasal budesonide bilaterally for 1 month.,18720067_3,18720067_D019819_D011125,,
770959114,false,true,5,2015-08-15T00:10:00,,No Relation,1,D019344,lactic acid/lactate,D009336,necrosis,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D009336,,
770959115,false,true,5,2015-08-14T23:42:00,,No Relation,1,D019344,lactic acid/lactate,D007249,inflammatory arthropathy,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D007249,,
770959116,false,true,5,2015-08-15T02:12:00,,No Relation,1,D019344,lactic acid/lactate,D010003,osteoarthritis,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D010003,,
770959117,false,true,5,2015-08-15T02:05:00,,No Relation,1,D019344,lactic acid/lactate,D001172,rheumatoid arthritis,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D001172,,
770959118,false,true,5,2015-08-15T00:16:00,,No Relation,1,D019344,lactic acid/lactate,D001177,arthropathy,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D001177,,
770959119,false,true,5,2015-08-14T22:17:00,,No Relation,1,D019344,lactic acid/lactate,D002805,pseudogout,"Concentrations of tumor necrosis factor alpha, interleukin-6, vascular endothelial growth factor, lactic acid, lactate dehydrogenase, and HMGB-1 were measured in synovial fluid (SF) samples from patients with inflammatory arthropathy (rheumatoid arthritis and pseudogout) and patients with noninflammatory arthropathy (osteoarthritis).",18759291_3,18759291_D019344_D002805,,
770959120,false,true,5,2015-08-14T23:13:00,,No Relation,0.4196,D019344,lactic acid,D007249,inflammatory arthropathy,"In SF samples from patients with HMGB-1-associated inflammatory arthropathy (i.e., samples with HMGB-1 levels >2 SD above the mean level in samples from patients with noninflammatory arthropathy), concentrations of HMGB-1 were significantly correlated with those of lactic acid, a marker of tissue hypoxia.",18759291_6,18759291_D019344_D007249,,
770959121,false,true,5,2015-08-14T22:38:00,,No Relation,0.5947,D019344,lactic acid,D001177,arthropathy,"In SF samples from patients with HMGB-1-associated inflammatory arthropathy (i.e., samples with HMGB-1 levels >2 SD above the mean level in samples from patients with noninflammatory arthropathy), concentrations of HMGB-1 were significantly correlated with those of lactic acid, a marker of tissue hypoxia.",18759291_6,18759291_D019344_D001177,,
770959122,false,true,5,2015-08-15T00:40:00,,No Relation,0.6084,D019344,lactic acid,D000860,hypoxia,"In SF samples from patients with HMGB-1-associated inflammatory arthropathy (i.e., samples with HMGB-1 levels >2 SD above the mean level in samples from patients with noninflammatory arthropathy), concentrations of HMGB-1 were significantly correlated with those of lactic acid, a marker of tissue hypoxia.",18759291_6,18759291_D019344_D000860,,
770959123,false,true,5,2015-08-14T21:23:00,,No Relation,1,D012965,sodium chloride,C562889,nephropathy,Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.,18768415_0,18768415_D012965_C562889,,
770959124,false,true,5,2015-08-14T21:37:00,,No Relation,0.8186,D017693,Sodium bicarbonate,C562889,nephropathy,Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.,18768415_0,18768415_D017693_C562889,,
770959125,false,true,5,2015-08-14T21:12:00,,No Relation,1,D017693,Sodium bicarbonate,D051437,renal failure,"Sodium bicarbonate has been suggested as a possible strategy for prevention of contrast medium-induced nephropathy, a common cause of renal failure associated with prolonged hospitalization, increased health care costs, and substantial morbidity and mortality.",18768415_1,18768415_D017693_D051437,,
770959126,false,true,5,2015-08-14T22:46:00,,No Relation,1,D017693,Sodium bicarbonate,C562889,nephropathy,"Sodium bicarbonate has been suggested as a possible strategy for prevention of contrast medium-induced nephropathy, a common cause of renal failure associated with prolonged hospitalization, increased health care costs, and substantial morbidity and mortality.",18768415_1,18768415_D017693_C562889,,
770959127,false,true,5,2015-08-15T02:31:00,,No Relation,1,D012965,sodium chloride,C562889,nephropathy,To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium-induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography.,18768415_2,18768415_D012965_C562889,,
770959128,false,true,5,2015-08-15T02:17:00,,No Relation,1,D017693,sodium bicarbonate,C562889,nephropathy,To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium-induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography.,18768415_2,18768415_D017693_C562889,,
770959129,false,true,5,2015-08-15T00:01:00,,No Relation,1,D017693,sodium bicarbonate,D007674,kidney dysfunction,To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium-induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography.,18768415_2,18768415_D017693_D007674,,
770959130,false,true,5,2015-08-15T01:13:00,,No Relation,1,D012965,sodium chloride,D007674,kidney dysfunction,To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium-induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography.,18768415_2,18768415_D012965_D007674,,
770959131,false,true,5,2015-08-14T22:27:00,,No Relation,0.8042,D012965,sodium chloride,D003643,death,"In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days (1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months (0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) (P > .10 for all).",18768415_10,18768415_D012965_D003643,,
770959132,false,true,5,2015-08-15T01:03:00,,No Relation,0.7908,D017693,sodium bicarbonate,D009203,myocardial infarction,"In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days (1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months (0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) (P > .10 for all).",18768415_10,18768415_D017693_D009203,,
770959133,false,true,5,2015-08-15T02:02:00,,No Relation,1,D012965,sodium chloride,D009203,myocardial infarction,"In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days (1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months (0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) (P > .10 for all).",18768415_10,18768415_D012965_D009203,,
770959134,false,true,5,2015-08-15T01:54:00,,No Relation,1,D017693,sodium bicarbonate,D003643,death,"In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days (1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months (0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) (P > .10 for all).",18768415_10,18768415_D017693_D003643,,
770959135,false,true,5,2015-08-14T22:19:00,,No Relation,1,D017693,sodium bicarbonate,D051436,chronic kidney disease,The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium-induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography.,18768415_11,18768415_D017693_D051436,,
770959136,false,true,5,2015-08-15T01:34:00,,No Relation,1,D012965,sodium chloride,C562889,nephropathy,The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium-induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography.,18768415_11,18768415_D012965_C562889,,
770959137,false,true,5,2015-08-14T23:35:00,,No Relation,0.798,D017693,sodium bicarbonate,C562889,nephropathy,The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium-induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography.,18768415_11,18768415_D017693_C562889,,
770959138,false,true,5,2015-08-14T21:45:00,,No Relation,1,D012965,sodium chloride,D051436,chronic kidney disease,The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium-induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography.,18768415_11,18768415_D012965_D051436,,
770959139,false,true,5,2015-08-14T21:36:00,,Direct,1,D001241,aspirin,D052016,mucosal defects,Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.,18779739_0,18779739_D001241_D052016,,
770959140,false,true,5,2015-08-14T23:42:00,,No Relation,1,D001241,aspirin,D007511,ischemic heart disease,Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.,18779739_0,18779739_D001241_D007511,,
770959141,false,true,5,2015-08-14T23:26:00,,No Relation,1,D001241,aspirin,D007511,ischemic cerebrovascular disease/ischemic heart disease,Low-dose aspirin is used for secondary prevention of ischemic heart disease and ischemic cerebrovascular disease.,18779739_1,18779739_D001241_D007511,,
770959142,false,true,5,2015-08-15T00:14:00,,No Relation,1,D001241,aspirin,D005767,gastrointestinal disorder,"Currently, the frequency of gastrointestinal disorder among users of low-dose aspirin is unknown.",18779739_2,18779739_D001241_D005767,,
770959143,false,true,5,2015-08-15T02:18:00,,Direct,0.8178,D001241,aspirin,D010437,gastroduodenal disorder,To investigate through endoscopic examination the frequency of gastroduodenal disorder associated with buffered and enteric-coated aspirin (ECA).,18779739_3,18779739_D001241_D010437,,
770959144,false,true,5,2015-08-15T01:22:00,,No Relation,0.5869,D001241,aspirin,D052016,mucosal defects,There were significantly more mucosal defects among users of low-dose aspirin than among those using no aspirin (P<0.0001).,18779739_7,18779739_D001241_D052016,,
770959145,false,true,5,2015-08-14T23:50:00,,Direct,0.5936,D001241,aspirin,D052016,mucosal defects,"Mucosal defects were found in 54 of 98 (60.7%) users of buffered aspirin (BA), whereas 38 of 101 (37.6%) users of ECA had mucosal defects.",18779739_8,18779739_D001241_D052016,,
770959146,false,true,5,2015-08-15T00:40:00,,Direct,0.8001,D001241,aspirin,D010437,gastroduodenal disorder,"As endoscopy frequently reveals gastroduodenal disorder among low-dose aspirin users, both administration of BA and of enteric-coated aspirin warrant concern for gastroduodenal ulcer.",18779739_11,18779739_D001241_D010437,,
770959147,false,true,5,2015-08-14T21:08:00,,Direct,1,D001241,aspirin,D014456,ulcer,"As endoscopy frequently reveals gastroduodenal disorder among low-dose aspirin users, both administration of BA and of enteric-coated aspirin warrant concern for gastroduodenal ulcer.",18779739_11,18779739_D001241_D014456,,
770959148,false,true,5,2015-08-14T21:38:00,,No Relation,1,D000305,Corticosteroids,D003715,dengue illness,Corticosteroids in the treatment of dengue illness.,18789467_0,18789467_D000305_D003715,,
770959149,false,true,5,2015-08-14T21:10:00,,No Relation,0.7975,D000305,corticosteroids,D013921,thrombocytopenia,"Studies so far have only been in patients with shock syndrome, and the possible effects of corticosteroids on thrombocytopenia and bleeding as well as other complications of dengue are unknown.",18789467_5,18789467_D000305_D013921,,
770959150,false,true,5,2015-08-15T00:43:00,,No Relation,1,D000305,corticosteroids,D012769,shock syndrome,"Studies so far have only been in patients with shock syndrome, and the possible effects of corticosteroids on thrombocytopenia and bleeding as well as other complications of dengue are unknown.",18789467_5,18789467_D000305_D012769,,
770959151,false,true,5,2015-08-14T22:22:00,,No Relation,0.5903,D000305,corticosteroids,D006470,bleeding,"Studies so far have only been in patients with shock syndrome, and the possible effects of corticosteroids on thrombocytopenia and bleeding as well as other complications of dengue are unknown.",18789467_5,18789467_D000305_D006470,,
770959152,false,true,5,2015-08-15T00:05:00,,No Relation,1,D000305,corticosteroid,D003715,dengue infection,All previous studies have been in children; the effect of corticosteroid treatment in adults with dengue infection has not been evaluated.,18789467_6,18789467_D000305_D003715,,
770959153,false,true,5,2015-08-15T01:34:00,,No Relation,1,D000305,corticosteroids,D003715,dengue infection,"The possible beneficial effects of corticosteroids on the various manifestations of dengue infection need evaluation by adequately powered, well designed, randomised controlled trials.",18789467_7,18789467_D000305_D003715,,
770959154,false,true,5,2015-08-14T22:24:00,,No Relation,0.804,C037663,ropivacaine,D000699,analgesia,Comparison of three different concentrations of ropivacaine for postoperative patient-controlled thoracic epidural analgesia after upper abdominal surgery.,18809519_0,18809519_C037663_D000699,,
770959155,false,true,5,2015-08-15T02:21:00,,No Relation,1,C037663,ropivacaine,D000699,analgesia,Previous studies have reported the comparable efficacy of ropivacaine/fentanyl for patient-controlled epidural analgesia (PCEA).,18809519_1,18809519_C037663_D000699,,
770959156,false,true,5,2015-08-14T21:30:00,,No Relation,1,D005283,fentanyl,D000699,analgesia,Previous studies have reported the comparable efficacy of ropivacaine/fentanyl for patient-controlled epidural analgesia (PCEA).,18809519_1,18809519_D005283_D000699,,
770959157,false,true,5,2015-08-15T00:14:00,,No Relation,1,D005283,fentanyl,D010146,pain,"In addition to comparing the analgesic effects and the incidence of motor block and opioid-related side effects of these three different ropivacaine/fentanyl solutions, we also evaluated the workload of our pain staff.",18809519_4,18809519_D005283_D010146,,
770959158,false,true,5,2015-08-14T22:00:00,,No Relation,1,C037663,ropivacaine,D010146,pain,"In addition to comparing the analgesic effects and the incidence of motor block and opioid-related side effects of these three different ropivacaine/fentanyl solutions, we also evaluated the workload of our pain staff.",18809519_4,18809519_C037663_D010146,,
770959159,false,true,5,2015-08-15T01:21:00,,No Relation,1,C037663,ropivacaine,D010146,pain,The main purpose of our study was to determine which of these three regimens of ropivacaine was most satisfactory with the least workload for the pain service staff.,18809519_5,18809519_C037663_D010146,,
770959160,false,true,5,2015-08-15T02:09:00,,No Relation,1,D005283,fentanyl,D010146,postoperative pain,Both thoracic epidural 0.15% and 0.2% ropivacaine provide effective postoperative pain control in combination with fentanyl without motor block.,18809519_16,18809519_D005283_D010146,,
770959161,false,true,5,2015-08-15T00:22:00,,No Relation,0.7961,C037663,ropivacaine,D010146,postoperative pain,Both thoracic epidural 0.15% and 0.2% ropivacaine provide effective postoperative pain control in combination with fentanyl without motor block.,18809519_16,18809519_C037663_D010146,,
770959162,false,true,5,2015-08-15T00:27:00,,No Relation,0.8299,D002945,Cisplatin,D002289,non-small-cell lung cancer,Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.,18818921_0,18818921_D002945_D002289,,
770959163,false,true,5,2015-08-14T21:11:00,,No Relation,1,C067311,docetaxel,D002289,non-small-cell lung cancer,Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.,18818921_0,18818921_C067311_D002289,,
770959164,false,true,5,2015-08-14T22:16:00,,No Relation,1,D002945,cisplatin,D002289,non-small-cell lung cancer/NSCLC,Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).,18818921_1,18818921_D002945_D002289,,
770959165,false,true,5,2015-08-15T00:16:00,,No Relation,0.7818,C067311,docetaxel,D064420,toxicity,Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).,18818921_1,18818921_C067311_D064420,,
770959166,false,true,5,2015-08-15T02:19:00,,No Relation,1,D002945,cisplatin,D064420,toxicity,Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).,18818921_1,18818921_D002945_D064420,,
770959167,false,true,5,2015-08-14T23:32:00,,No Relation,1,C067311,docetaxel,D002289,non-small-cell lung cancer/NSCLC,Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).,18818921_1,18818921_C067311_D002289,,
770959168,false,true,5,2015-08-15T00:14:00,,No Relation,1,D002945,Cisplatin,D002289,NSCLC,Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.,18818921_8,18818921_D002945_D002289,,
770959169,false,true,5,2015-08-15T00:19:00,,No Relation,1,C067311,docetaxel,D002289,NSCLC,Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.,18818921_8,18818921_C067311_D002289,,
770959170,false,true,5,2015-08-15T00:25:00,,No Relation,0.4148,D006861,H2O2,D064420,toxicity,H2O2-dependent hyperoxidation of peroxiredoxin 6 (Prdx6) plays a role in cellular toxicity via up-regulation of iPLA2 activity.,18826942_0,18826942_D006861_D064420,,
770959171,false,true,5,2015-08-15T02:57:00,,Direct,1,D006861,H2O2,D064420,toxicity,"Here, we report that H2O2-induced cellular toxicity acts through Prdx6 hyperoxidation.",18826942_2,18826942_D006861_D064420,,
770959172,false,true,5,2015-08-14T21:14:00,,No Relation,1,D005947,glucose,D003922,type 1 diabetes,JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods.,18828243_0,18828243_D005947_D003922,,
770959173,false,true,5,2015-08-15T00:36:00,,No Relation,1,D005947,glucose,D000377,real-time,JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods.,18828243_0,18828243_D005947_D000377,,
770959174,false,true,5,2015-08-14T21:56:00,,No Relation,1,D005947,glucose,D003922,T1D/type 1 diabetes,"While real-time (RT) continuous glucose monitoring (CGM) systems may revolutionize treatment of type 1 diabetes (T1D), there is insufficient evidence currently available to support widespread utilization of these devices.",18828243_1,18828243_D005947_D003922,,
770959175,false,true,5,2015-08-15T00:44:00,,No Relation,1,D005947,glucose,D000377,RT/real-time,"While real-time (RT) continuous glucose monitoring (CGM) systems may revolutionize treatment of type 1 diabetes (T1D), there is insufficient evidence currently available to support widespread utilization of these devices.",18828243_1,18828243_D005947_D000377,,
770959176,false,true,5,2015-08-14T21:09:00,,No Relation,1,D005947,glucose,D000377,RT,Subjects with T1DM who meet eligibility criteria are randomized to either standard self-monitoring of blood glucose (SMBG) alone or use of any of the three current RT-CGM systems as a supplement to SMBG.,18828243_5,18828243_D005947_D000377,,
770959177,false,true,5,2015-08-15T00:50:00,,No Relation,1,D005947,glucose,D003922,T1D,"Other outcomes include the percentage of sensor glucose values within the 70-180 mg/dL range, scores on questionnaires that assess the impact of RT-CGM on living with T1D, and the cost-effectiveness of RT-CGM.",18828243_9,18828243_D005947_D003922,,
770959178,false,true,5,2015-08-14T23:49:00,,No Relation,1,D005947,glucose,D000377,RT,"Other outcomes include the percentage of sensor glucose values within the 70-180 mg/dL range, scores on questionnaires that assess the impact of RT-CGM on living with T1D, and the cost-effectiveness of RT-CGM.",18828243_9,18828243_D005947_D000377,,
770959179,false,true,5,2015-08-14T22:05:00,,No Relation,1,D013739,testosterone,D009765,Obesity,"Obesity, low testosterone levels and erectile dysfunction.",18843273_0,18843273_D013739_D009765,,
770959180,false,true,5,2015-08-14T21:09:00,,No Relation,1,D013739,testosterone,D007172,erectile dysfunction,"Obesity, low testosterone levels and erectile dysfunction.",18843273_0,18843273_D013739_D007172,,
770959181,false,true,5,2015-08-14T21:28:00,,No Relation,1,D013739,testosterone,D009765,obesity,"The relationships among obesity, metabolic syndrome, ED, sex hormone-binding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician.",18843273_4,18843273_D013739_D009765,,
770959182,false,true,5,2015-08-14T21:47:00,,No Relation,1,D013739,testosterone,D007172,ED,"The relationships among obesity, metabolic syndrome, ED, sex hormone-binding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician.",18843273_4,18843273_D013739_D007172,,
770959183,false,true,5,2015-08-15T02:12:00,,No Relation,0.8324,D013739,testosterone,D008659,metabolic syndrome,"The relationships among obesity, metabolic syndrome, ED, sex hormone-binding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician.",18843273_4,18843273_D013739_D008659,,
770959184,false,true,5,2015-08-14T22:22:00,,No Relation,1,D013739,testosterone,D009765,obesity,It is known that BMI is inversely proportional to serum total testosterone concentrations; low serum SHBG levels in obesity contribute to the low serum total testosterone.,18843273_5,18843273_D013739_D009765,,
770959185,false,true,5,2015-08-15T02:07:00,,No Relation,1,D013739,testosterone,D009765,obese,The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus.,18843273_7,18843273_D013739_D009765,,
770959186,false,true,5,2015-08-14T23:19:00,,No Relation,0.8068,D013739,testosterone,D003920,type 2 diabetes mellitus,The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus.,18843273_7,18843273_D013739_D003920,,
770959187,false,true,5,2015-08-15T01:02:00,,No Relation,1,D013739,testosterone,D008659,metabolic syndrome,The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus.,18843273_7,18843273_D013739_D008659,,
770959188,false,true,5,2015-08-14T21:13:00,,No Relation,0.8241,D013739,testosterone,C537389,type,ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels.,18843273_9,18843273_D013739_C537389,,
770959189,false,true,5,2015-08-15T01:41:00,,Direct,0.6078,D013739,testosterone,D007172,ED,ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels.,18843273_9,18843273_D013739_D007172,,
770959190,false,true,5,2015-08-15T02:13:00,,No Relation,0.8119,D013739,testosterone,D003929,diabetes,ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels.,18843273_9,18843273_D013739_D003929,,
770959191,false,true,5,2015-08-14T23:39:00,,No Relation,1,D013739,testosterone,D003920,type 2 diabetes mellitus,This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.,18843273_10,18843273_D013739_D003920,,
770959192,false,true,5,2015-08-14T21:10:00,,No Relation,1,D013739,testosterone,D009765,obese,This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.,18843273_10,18843273_D013739_D009765,,
770959193,false,true,5,2015-08-15T01:13:00,,No Relation,1,D013739,testosterone,D007172,ED,This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.,18843273_10,18843273_D013739_D007172,,
770959194,false,true,5,2015-08-15T00:16:00,,No Relation,0.8148,D013739,testosterone,D008659,metabolic syndrome,This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.,18843273_10,18843273_D013739_D008659,,
770959195,false,true,5,2015-08-14T21:07:00,,No Relation,1,C043265,tazobactam,D008554,melioidosis,The role of piperacillin/ tazobactam for melioidosis remains undefined.,18854938_10,18854938_C043265_D008554,,
770959196,false,true,5,2015-08-14T23:47:00,,No Relation,1,D010878,piperacillin,D008554,melioidosis,The role of piperacillin/ tazobactam for melioidosis remains undefined.,18854938_10,18854938_D010878_D008554,,
770959197,false,true,5,2015-08-14T23:54:00,,No Relation,0.6029,C097613,imatinib,D009369,GIST/gastrointestinal stromal tumours,"Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours (GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of treatment.",18941456_1,18941456_C097613_D009369,,
770959198,false,true,5,2015-08-15T02:18:00,,No Relation,1,D014443,tyrosine,D009369,GIST/gastrointestinal stromal tumours,"Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours (GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of treatment.",18941456_1,18941456_D014443_D009369,,
770959199,false,true,5,2015-08-15T02:05:00,,No Relation,0.8096,D004958,17beta-estradiol,D009369,breast cancer,STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland.,18958632_0,18958632_D004958_D009369,,
770959200,false,true,5,2015-08-14T21:35:00,,No Relation,1,D004967,estrogen,D009369,tumor/breast cancer,"It is also demonstrated that STEAP1 transcription correlates negatively with estrogen receptor (ER) immunoreactivity, and positively with tumor grading in breast cancer cases.",18958632_4,18958632_D004967_D009369,,
770959201,false,true,5,2015-08-15T01:30:00,,Direct,0.804,D004967,estrogens,D009369,breast cancer,"As estrogens are involved in breast cancer onset and progression, the response of STEAP1 to 17beta-estradiol (E2) was investigated in the mammary gland of rats, and in the human breast cancer cell line, MCF-7.",18958632_5,18958632_D004967_D009369,,
770959202,false,true,5,2015-08-14T23:13:00,,No Relation,0.796,D004958,17beta-estradiol,D009369,breast cancer,"As estrogens are involved in breast cancer onset and progression, the response of STEAP1 to 17beta-estradiol (E2) was investigated in the mammary gland of rats, and in the human breast cancer cell line, MCF-7.",18958632_5,18958632_D004958_D009369,,
770959203,false,true,5,2015-08-14T21:10:00,,No Relation,1,D000803,angiotensin I,D051436,chronic kidney disease,The combination of angiotensin I-converting enzyme inhibitors and angiotensin receptor blockers has been shown to be more effective than the individual drugs alone in the treatment of chronic kidney disease and chronic heart failure.,18971536_1,18971536_D000803_D051436,,
770959204,false,true,5,2015-08-14T22:29:00,,No Relation,1,D000803,angiotensin I,D007676,chronic heart failure,The combination of angiotensin I-converting enzyme inhibitors and angiotensin receptor blockers has been shown to be more effective than the individual drugs alone in the treatment of chronic kidney disease and chronic heart failure.,18971536_1,18971536_D000803_D007676,,
770959205,false,true,5,2015-08-14T21:24:00,,No Relation,1,D017311,amlodipine,D006973,hypertension,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D017311_D006973,,
770959206,false,true,5,2015-08-14T21:48:00,,No Relation,1,D002118,calcium,D006973,hypertension,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D002118_D006973,,
770959207,false,true,5,2015-08-14T23:35:00,,No Relation,1,D017311,amlodipine,D001161,arteriosclerosis,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D017311_D001161,,
770959208,false,true,5,2015-08-15T01:46:00,,No Relation,1,D020913,perindopril,D006973,hypertension,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D020913_D006973,,
770959209,false,true,5,2015-08-15T01:35:00,,No Relation,1,D020913,perindopril,D001161,arteriosclerosis,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D020913_D001161,,
770959210,false,true,5,2015-08-14T22:52:00,,No Relation,1,D000809,angiotensin,D006973,hypertension,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D000809_D006973,,
770959211,false,true,5,2015-08-15T00:28:00,,No Relation,1,D002118,calcium,D001161,arteriosclerosis,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D002118_D001161,,
770959212,false,true,5,2015-08-14T22:16:00,,No Relation,0.8127,D000809,angiotensin,D001161,arteriosclerosis,"In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy.",18971536_2,18971536_D000809_D001161,,
770959213,false,true,5,2015-08-14T21:09:00,,No Relation,0.8212,D017311,amlodipine,D006973,hypertension,Thirty-two patients with essential hypertension treated with angiotensin receptor blocker monotherapy were randomized to receive 5 mg of amlodipine (n=16) or 4 mg of perindopril (n=16) once daily in the morning for 24 weeks.,18971536_3,18971536_D017311_D006973,,
770959214,false,true,5,2015-08-14T22:17:00,,No Relation,1,D020913,perindopril,D006973,hypertension,Thirty-two patients with essential hypertension treated with angiotensin receptor blocker monotherapy were randomized to receive 5 mg of amlodipine (n=16) or 4 mg of perindopril (n=16) once daily in the morning for 24 weeks.,18971536_3,18971536_D020913_D006973,,
770959215,false,true,5,2015-08-15T00:00:00,,No Relation,1,D000809,angiotensin,D006973,hypertension,Thirty-two patients with essential hypertension treated with angiotensin receptor blocker monotherapy were randomized to receive 5 mg of amlodipine (n=16) or 4 mg of perindopril (n=16) once daily in the morning for 24 weeks.,18971536_3,18971536_D000809_D006973,,
770959216,false,true,5,2015-08-14T22:22:00,,No Relation,1,D017311,amlodipine,D006973,hypertension,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D017311_D006973,,
770959217,false,true,5,2015-08-15T00:15:00,,No Relation,1,D020913,perindopril,D014652,vascular endothelial dysfunction,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D020913_D014652,,
770959218,false,true,5,2015-08-14T21:38:00,,No Relation,1,D002118,calcium,D006973,hypertension,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D002118_D006973,,
770959219,false,true,5,2015-08-14T23:36:00,,No Relation,1,D002118,calcium,D014652,vascular endothelial dysfunction,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D002118_D014652,,
770959220,false,true,5,2015-08-14T22:00:00,,No Relation,1,D020913,perindopril,D006973,hypertension,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D020913_D006973,,
770959221,false,true,5,2015-08-15T01:09:00,,No Relation,1,D017311,amlodipine,D014652,vascular endothelial dysfunction,"In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension.",18971536_8,18971536_D017311_D014652,,
770959222,false,true,5,2015-08-14T21:18:00,,No Relation,0.8078,C438273,aviptadil,D065627,PAH/idiopathic pulmonary arterial hypertension,In idiopathic pulmonary arterial hypertension (PAH) the vasodilating vasoactive intestinal peptide (aviptadil) is deficient.,18978135_2,18978135_C438273_D065627,,
770959223,false,true,5,2015-08-14T22:17:00,,No Relation,0.8049,C438273,aviptadil,D013923,thromboembolic,"A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in three) inhaled a single 100-microg dose of aviptadil during right-heart catheterisation.",18978135_4,18978135_C438273_D013923,,
770959224,false,true,5,2015-08-15T01:11:00,,No Relation,0.8101,C438273,aviptadil,D008171,lung disease,"A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in three) inhaled a single 100-microg dose of aviptadil during right-heart catheterisation.",18978135_4,18978135_C438273_D008171,,
770959225,false,true,5,2015-08-14T22:00:00,,No Relation,1,C438273,aviptadil,D065627,PAH,"A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in three) inhaled a single 100-microg dose of aviptadil during right-heart catheterisation.",18978135_4,18978135_C438273_D065627,,
770959226,false,true,5,2015-08-14T21:12:00,,Direct,0.5903,C438273,Aviptadil,D020521,stroke,"Aviptadil aerosol caused a small and temporary but significant selective pulmonary vasodilation, an improved stroke volume and mixed venous oxygen saturation.",18978135_6,18978135_C438273_D020521,,
770959227,false,true,5,2015-08-15T00:27:00,,No Relation,1,D010100,oxygen,D020521,stroke,"Aviptadil aerosol caused a small and temporary but significant selective pulmonary vasodilation, an improved stroke volume and mixed venous oxygen saturation.",18978135_6,18978135_D010100_D020521,,
770959228,false,true,5,2015-08-15T00:16:00,,No Relation,1,C438273,aviptadil,D008171,lung disease,"In patients with significant lung disease, aviptadil tended to improve oxygenation.",18978135_8,18978135_C438273_D008171,,
770959229,false,true,5,2015-08-15T02:15:00,,No Relation,1,C438273,Aviptadil,D008171,lung disease,Aviptadil inhalation tended to improve oxygenation in patients with significant lung disease.,18978135_10,18978135_C438273_D008171,,
770959230,false,true,5,2015-08-14T22:11:00,,No Relation,1,D000409,alanine,D064420,adverse drug reactions,"Among 2,930 eligible patients, adverse drug reactions were observed in 3.6%, with the most common being abdominal distension, flatulence, diarrhea, and increased alanine aminotransferase levels.",18987459_5,18987459_D000409_D064420,,
770959231,false,true,5,2015-08-14T21:59:00,,No Relation,1,D000409,alanine,D005414,flatulence,"Among 2,930 eligible patients, adverse drug reactions were observed in 3.6%, with the most common being abdominal distension, flatulence, diarrhea, and increased alanine aminotransferase levels.",18987459_5,18987459_D000409_D005414,,
770959232,false,true,5,2015-08-14T22:17:00,,No Relation,0.8082,D000409,alanine,D003967,diarrhea,"Among 2,930 eligible patients, adverse drug reactions were observed in 3.6%, with the most common being abdominal distension, flatulence, diarrhea, and increased alanine aminotransferase levels.",18987459_5,18987459_D000409_D003967,,
770959233,false,true,5,2015-08-14T23:31:00,,No Relation,0.8066,C088155,R(+)-methanandamide,D002277,carcinoma,R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.,19015962_0,19015962_C088155_D002277,,
770959234,false,true,5,2015-08-15T00:10:00,,No Relation,0.7937,C088155,R(+)-methanandamide,D002277,carcinoma,"Using human cervical carcinoma cells (HeLa), this study investigates the role of cyclooxygenase-2 (COX-2) in apoptosis elicited by the endocannabinoid analog R(+)-methanandamide (MA).",19015962_2,19015962_C088155_D002277,,
770959235,false,true,5,2015-08-15T00:16:00,,No Relation,1,C005581,"3,4-dihydroxybenzaldehyde",D009369,cancer,"Concentration of 300 microM 3,4-dihydroxybenzaldehyde caused 50% growth inhibition of human cancer cell U937.",19023807_6,19023807_C005581_D009369,,
770959236,false,true,5,2015-08-15T02:25:00,,No Relation,0.8267,C005581,"3,4-dihydroxybenzaldehyde",D063646,oncogenesis,"Since CKII is involved in cell proliferation and oncogenesis, these results suggest that 3,4-dihydroxybenzaldehyde may function by inhibiting oncogenic disease, at least in part, through the inhibition of CKII activity.",19023807_10,19023807_C005581_D063646,,
770959237,false,true,5,2015-08-14T21:42:00,,No Relation,1,C022616,"3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide",D004487,cytotoxicity,"For cytotoxicity testing, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed.",19027573_3,19027573_C022616_D004487,,
770959238,false,true,5,2015-08-14T21:07:00,,Direct,0.5986,D002444,cefuroxime,D064420,toxicity,These data suggest a dose-dependent toxicity of cefuroxime and vancomycin on HCECs in vitro with a narrow range of safety.,19027573_12,19027573_D002444_D064420,,
770959239,false,true,5,2015-08-15T00:13:00,,Direct,0.6045,D014640,vancomycin,D064420,toxicity,These data suggest a dose-dependent toxicity of cefuroxime and vancomycin on HCECs in vitro with a narrow range of safety.,19027573_12,19027573_D014640_D064420,,
770959240,false,true,5,2015-08-14T23:40:00,,No Relation,1,C037663,ropivacaine,D009461,TNS,Six lidocaine patients reported TNS (40%) as compared with no patient receiving ropivacaine (0%) (P=0.005).,19032560_7,19032560_C037663_D009461,,
770959241,false,true,5,2015-08-14T22:14:00,,Direct,0.7891,D008012,lidocaine,D009461,TNS,"Recovery of unassisted ambulation and spontaneous voiding occurred earlier with lidocaine, but this was associated with a markedly higher incidence of TNS.",19032560_9,19032560_D008012_D009461,,
770959242,false,true,5,2015-08-14T21:16:00,,Direct,0.6269,D002248,Carbon monoxide,D064420,toxicity,Carbon monoxide toxicity.,19060737_0,19060737_D002248_D064420,,
770959243,false,true,5,2015-08-14T21:36:00,,No Relation,1,C097933,olmesartan medoxomil,D006973,hypertension,"Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.",19067471_0,19067471_C097933_D006973,,
770959244,false,true,5,2015-08-15T02:00:00,,No Relation,0.5772,D017311,amlodipine,D006973,hypertension,"Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.",19067471_0,19067471_D017311_D006973,,
770959245,false,true,5,2015-08-14T21:29:00,,No Relation,1,C097933,olmesartan medoxomil,D006973,hypertension,"The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine.",19067471_2,19067471_C097933_D006973,,
770959246,false,true,5,2015-08-14T22:22:00,,No Relation,1,D017311,amlodipine,D006973,hypertension,"The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine.",19067471_2,19067471_D017311_D006973,,
770959247,false,true,5,2015-08-15T01:57:00,,No Relation,1,C097933,olmesartan medoxomil,D006973,hypertension,These results suggest that olmesartan medoxomil combined with amlodipine is effective and well tolerated in reducing BP in patients with moderate to severe hypertension.,19067471_14,19067471_C097933_D006973,,
770959248,false,true,5,2015-08-14T21:42:00,,No Relation,1,D017311,amlodipine,D006973,hypertension,These results suggest that olmesartan medoxomil combined with amlodipine is effective and well tolerated in reducing BP in patients with moderate to severe hypertension.,19067471_14,19067471_D017311_D006973,,
770959249,false,true,5,2015-08-15T02:10:00,,No Relation,0.8282,D005947,glucose,C537389,Type,Type 2 diabetes occurs when the endocrine pancreas can no longer secrete enough insulin to maintain glucose and lipid homeostasis.,19106615_1,19106615_D005947_C537389,,
770959250,false,true,5,2015-08-15T00:18:00,,No Relation,1,D005947,glucose,D003929,diabetes,Type 2 diabetes occurs when the endocrine pancreas can no longer secrete enough insulin to maintain glucose and lipid homeostasis.,19106615_1,19106615_D005947_D003929,,
770959251,false,true,5,2015-08-15T02:03:00,,Direct,0.6216,D005227,fatty acids,D003643,death,"It is clear from these studies and others, that there are multiple pathways by which fatty acids such as palmitate can lead to beta-cell dysfunction and death.",19106615_4,19106615_D005227_D003643,,
770959252,false,true,5,2015-08-15T00:10:00,,No Relation,1,D013936,thymidine,D006258,head and neck cancer,The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.,19117293_0,19117293_D013936_D006258,,
770959253,false,true,5,2015-08-15T00:54:00,,No Relation,1,C110904,capecitabine,D006258,head and neck cancer,The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.,19117293_0,19117293_C110904_D006258,,
770959254,false,true,5,2015-08-15T00:40:00,,No Relation,1,C025034,5'-DFUR,C535575,head and neck squamous cell carcinoma/HNSCC,"To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5'-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC).",19117293_1,19117293_C025034_C535575,,
770959255,false,true,5,2015-08-14T22:21:00,,No Relation,1,C110904,capecitabine,C535575,head and neck squamous cell carcinoma/HNSCC,"To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5'-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC).",19117293_1,19117293_C110904_C535575,,
770959256,false,true,5,2015-08-15T01:18:00,,No Relation,1,D013936,thymidine,C535575,head and neck squamous cell carcinoma/HNSCC,"To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5'-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC).",19117293_1,19117293_D013936_C535575,,
770959257,false,true,5,2015-08-14T22:03:00,,No Relation,1,C110904,capecitabine,C535575,HNSCC,The effect of TP transgene expression to alter the TP to DPD ratio and hence optimize the therapeutic outcome of capecitabine treatment was further evaluated in a murine model of human HNSCC using immunohistochemistry to detect TP and DPD expression in vivo.,19117293_4,19117293_C110904_C535575,,
770959258,false,true,5,2015-08-15T00:15:00,,No Relation,1,C025034,5'-DFUR,C535575,HNSCC,No correlation was detected between sensitivity to 5'-DFUR and the relative expression levels of TP or DPD in the multiple HNSCC cell lines tested.,19117293_5,19117293_C025034_C535575,,
770959259,false,true,5,2015-08-15T01:45:00,,No Relation,0.802,C110904,capecitabine,C535575,HNSCC tumors,"In addition, we demonstrate that transgene expression of TP significantly enhanced the tumoricidal effect of capecitabine in HNSCC tumors with otherwise low endogenous TP to DPD ratios.",19117293_7,19117293_C110904_C535575,,
770959260,false,true,5,2015-08-14T21:10:00,,No Relation,1,C110904,capecitabine,D009369,tumors,The results of this study suggest that HNSCC patients who would most benefit from capecitabine-based chemotherapy could be identified by examining the TP to DPD ratio of their tumors.,19117293_9,19117293_C110904_D009369,,
770959261,false,true,5,2015-08-15T02:22:00,,No Relation,1,C110904,capecitabine,C535575,HNSCC,The results of this study suggest that HNSCC patients who would most benefit from capecitabine-based chemotherapy could be identified by examining the TP to DPD ratio of their tumors.,19117293_9,19117293_C110904_C535575,,
770959262,false,true,5,2015-08-15T01:30:00,,No Relation,1,C014347,5-aza-2'-deoxycytidine,D009369,tumor,"We find that clinically achievable levels of 5-aza-2'-deoxycytidine (5-AZA-dC), a potent inhibitor of DNA methylation, can modify chromatin and restore the ability of tumor necrosis factor alpha (TNFalpha) to induce monocytic differentiation of the acute myeloid leukemia cells NB4 and U937.",19117987_2,19117987_C014347_D009369,,
770959263,false,true,5,2015-08-14T22:24:00,,Direct,0.6021,C014347,5-aza-2'-deoxycytidine,D009336,necrosis,"We find that clinically achievable levels of 5-aza-2'-deoxycytidine (5-AZA-dC), a potent inhibitor of DNA methylation, can modify chromatin and restore the ability of tumor necrosis factor alpha (TNFalpha) to induce monocytic differentiation of the acute myeloid leukemia cells NB4 and U937.",19117987_2,19117987_C014347_D009336,,
770959264,false,true,5,2015-08-15T00:27:00,,No Relation,0.8283,C014347,5-aza-2'-deoxycytidine,D015470,acute myeloid leukemia,"We find that clinically achievable levels of 5-aza-2'-deoxycytidine (5-AZA-dC), a potent inhibitor of DNA methylation, can modify chromatin and restore the ability of tumor necrosis factor alpha (TNFalpha) to induce monocytic differentiation of the acute myeloid leukemia cells NB4 and U937.",19117987_2,19117987_C014347_D015470,,
770959265,false,true,5,2015-08-14T21:29:00,,No Relation,1,D008712,methicillin,D011023,Staphylococcus aureus carriage,Clustering and risk factors of methicillin-resistant Staphylococcus aureus carriage in two Italian long-term care facilities.,19148574_0,19148574_D008712_D011023,,
770959266,false,true,5,2015-08-15T00:46:00,,No Relation,1,D008712,Methicillin,D011023,MRSA/Methicillin-resistant Staphylococcus aureus,"Methicillin-resistant Staphylococcus aureus (MRSA) is a well-recognized agent of health care-associated infections in long-term care facilities, but few data about the circulation of MRSA in this setting in Italy are available.",19148574_1,19148574_D008712_D011023,,
770959267,false,true,5,2015-08-15T00:14:00,,No Relation,0.789,D008712,Methicillin,D007239,infections,"Methicillin-resistant Staphylococcus aureus (MRSA) is a well-recognized agent of health care-associated infections in long-term care facilities, but few data about the circulation of MRSA in this setting in Italy are available.",19148574_1,19148574_D008712_D007239,,
770959268,false,true,5,2015-08-14T21:29:00,,No Relation,1,D009532,nickel,D006949,hyperlipidemia,"According to multivariate analysis, the most significant predictor for CR-ISR was reference vessel diameter (P=.0010) followed by nickel-positive (P=.0033) and hyperlipidemia (P=.0305).",19159850_7,19159850_D009532_D006949,,
770959269,false,true,5,2015-08-15T02:19:00,,No Relation,0.5768,D016572,cyclosporine,D001171,Still's disease,Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab.,19184270_0,19184270_D016572_D001171,,
770959270,false,true,5,2015-08-14T21:35:00,,No Relation,0.7982,D013256,steroid,D006013,Her disease,"Her disease was refractory to high-dose glucocorticoids, two courses of steroid pulse therapy, and addition of cyclosporine (3.5 mg/kg/day).",19184270_2,19184270_D013256_D006013,,
770959271,false,true,5,2015-08-15T00:50:00,,No Relation,0.6062,D016572,cyclosporine,D006013,Her disease,"Her disease was refractory to high-dose glucocorticoids, two courses of steroid pulse therapy, and addition of cyclosporine (3.5 mg/kg/day).",19184270_2,19184270_D016572_D006013,,
770959272,false,true,5,2015-08-14T21:35:00,,No Relation,1,D016572,Cyclosporine,D017093,hepatic failure,"Cyclosporine is one of the first-line immunosuppressants for AOSD, especially when associated with DIC, hepatic failure, or hemophagocytic syndrome.",19184270_7,19184270_D016572_D017093,,
770959273,false,true,5,2015-08-14T21:04:00,,No Relation,0.8089,D016572,Cyclosporine,D051359,hemophagocytic syndrome,"Cyclosporine is one of the first-line immunosuppressants for AOSD, especially when associated with DIC, hepatic failure, or hemophagocytic syndrome.",19184270_7,19184270_D016572_D051359,,
770959274,false,true,5,2015-08-15T00:21:00,,No Relation,1,D005472,5-fluorouracil,D009369,rectal cancer,"Patients with histological proven rectal cancer staged T2N+ or T3 are randomized to receive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days or RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later.",19200365_6,19200365_D005472_D009369,,
770959275,false,true,5,2015-08-14T21:43:00,,No Relation,1,D005472,5-fluorouracil,C535338,TME,"Patients with histological proven rectal cancer staged T2N+ or T3 are randomized to receive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days or RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later.",19200365_6,19200365_D005472_C535338,,
770959276,false,true,5,2015-08-14T21:10:00,,No Relation,0.8009,C089995,glatiramer acetate,D003866,depressive symptoms,There is some evidence that interferon-beta treatment may exacerbate depressive symptoms and a switch to glatiramer acetate can be envisaged in patients treated with an interferon-beta in whom depressive symptoms become an issue.,19200865_5,19200865_C089995_D003866,,
770959277,false,true,5,2015-08-14T21:52:00,,No Relation,0.6074,C089995,glatiramer acetate,D005221,fatigue,"There is growing evidence that immunomodulatory treatments, in particular glatiramer acetate, improve fatigue symptoms in patients with multiple sclerosis.",19200865_8,19200865_C089995_D005221,,
770959278,false,true,5,2015-08-14T23:29:00,,No Relation,1,C089995,glatiramer acetate,D009103,multiple sclerosis,"There is growing evidence that immunomodulatory treatments, in particular glatiramer acetate, improve fatigue symptoms in patients with multiple sclerosis.",19200865_8,19200865_C089995_D009103,,
770959279,false,true,5,2015-08-15T02:08:00,,No Relation,1,D015032,zinc,D006527,Wilson disease,Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease.,19210288_0,19210288_D015032_D006527,,
770959280,false,true,5,2015-08-14T21:35:00,,No Relation,1,D010396,D-penicillamine,D006527,Wilson disease,"Original studies on clinical efficacy of D-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included.",19210288_4,19210288_D010396_D006527,,
770959281,false,true,5,2015-08-14T21:20:00,,No Relation,1,D015032,zinc,D006527,Wilson disease,"Original studies on clinical efficacy of D-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included.",19210288_4,19210288_D015032_D006527,,
770959282,false,true,5,2015-08-14T21:49:00,,No Relation,1,D014266,trientine,D006527,Wilson disease,"Original studies on clinical efficacy of D-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included.",19210288_4,19210288_D014266_D006527,,
770959283,false,true,5,2015-08-15T02:15:00,,No Relation,1,C020809,tetrathiomolybdate,D006527,Wilson disease,"Original studies on clinical efficacy of D-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included.",19210288_4,19210288_C020809_D006527,,
770959284,false,true,5,2015-08-14T23:23:00,,No Relation,1,D010396,D-penicillamine,D006527,Wilson disease,"Nevertheless, according to currently available data, patients with hepatic presentation of Wilson disease are probably most effectively treated by D-penicillamine.",19210288_8,19210288_D010396_D006527,,
770959285,false,true,5,2015-08-15T01:43:00,,No Relation,1,D012428,ruthenium,D009369,tumors,"Among these drugs, ruthenium compounds have been showing promising results to treat tumors and represent an important development of new antitumor therapy.",19214395_2,19214395_D012428_D009369,,
770959286,false,true,5,2015-08-14T23:26:00,,No Relation,1,C543901,cis-[RuCl(2)(NH(3))(4)]Cl,C536987,MI,"MI in human peripheral blood lymphocyte cultures treated with 1, 10, 100, and 1,000 microg mL(-1) cis-[RuCl(2)(NH(3))(4)]Cl were 5.9%, 4.6%, 3.9%, and 0%, respectively.",19214395_5,19214395_C543901_C536987,,
770959287,false,true,5,2015-08-15T01:19:00,,No Relation,1,D000305,corticosteroid,D015472,acute eosinophilic pneumonia,"With the exception of acute eosinophilic pneumonia, which responds well to corticosteroid therapy, the role of corticosteroid and other immune-suppressive treatments in the management of smoking-related interstitial lung diseases is not entirely clear and is probably of limited utility, particularly in the absence of smoking cessation.",19221962_6,19221962_D000305_D015472,,
770959288,false,true,5,2015-08-15T00:23:00,,No Relation,1,D000305,corticosteroid,D017563,interstitial lung diseases,"With the exception of acute eosinophilic pneumonia, which responds well to corticosteroid therapy, the role of corticosteroid and other immune-suppressive treatments in the management of smoking-related interstitial lung diseases is not entirely clear and is probably of limited utility, particularly in the absence of smoking cessation.",19221962_6,19221962_D000305_D017563,,
770959289,false,true,5,2015-08-14T21:15:00,,No Relation,0.8048,D002784,cholesterol,D052439,lipid disorders,"In this cross-sectional study in dyslipidaemic patients receiving lipid-lowering therapy, lipid disorders were defined as triglyceride greater than 1.5 g/L, HDL-C lesser than 0.4 g/L and low-density lipoprotein cholesterol (LDL-C) above the recommended concentration according to French guidelines.",19233108_2,19233108_D002784_D052439,,
770959290,false,true,5,2015-08-15T02:13:00,,No Relation,1,D015761,4-aminopyridine,D009103,multiple sclerosis,Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis.,19249634_1,19249634_D015761_D009103,,
770959291,false,true,5,2015-08-14T21:43:00,,No Relation,1,D008012,lidocaine,D005356,fibromyalgia,Intravenous lidocaine for fibromyalgia syndrome: an open trial.,19263182_0,19263182_D008012_D005356,,
770959292,false,true,5,2015-08-14T21:59:00,,No Relation,1,D008012,lidocaine,D005356,fibromyalgia,"In this study, we investigated the effect of intravenous infusions of lidocaine in pain and quality of life of patients with fibromyalgia.",19263182_2,19263182_D008012_D005356,,
770959293,false,true,5,2015-08-15T00:30:00,,No Relation,0.7951,D008012,lidocaine,D010146,pain,"In this study, we investigated the effect of intravenous infusions of lidocaine in pain and quality of life of patients with fibromyalgia.",19263182_2,19263182_D008012_D010146,,
770959294,false,true,5,2015-08-15T01:54:00,,No Relation,1,D008012,lidocaine,D005356,Fibromyalgia,"Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire, and a visual analog scale (VAS) for pain were applied before the first lidocaine infusion, immediately after the fifth infusion and 30 days after the fifth infusion.",19263182_4,19263182_D008012_D005356,,
770959295,false,true,5,2015-08-15T00:27:00,,No Relation,0.6101,D008012,lidocaine,D010146,pain,"Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire, and a visual analog scale (VAS) for pain were applied before the first lidocaine infusion, immediately after the fifth infusion and 30 days after the fifth infusion.",19263182_4,19263182_D008012_D010146,,
770959296,false,true,5,2015-08-14T21:07:00,,No Relation,1,D008012,lidocaine,D005356,fibromyalgia,Intravenous lidocaine infusions are safe and effective in the management of fibromyalgia.,19263182_7,19263182_D008012_D005356,,
770959297,false,true,5,2015-08-15T02:34:00,,No Relation,1,C060836,Pioglitazone,D044882,impaired glucose tolerance,Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).,19277602_0,19277602_C060836_D044882,,
770959298,false,true,5,2015-08-15T02:07:00,,No Relation,1,C060836,Pioglitazone,D003929,diabetes,Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).,19277602_0,19277602_C060836_D003929,,
770959299,false,true,5,2015-08-14T22:26:00,,No Relation,1,D005947,glucose,D044882,impaired glucose tolerance,Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).,19277602_0,19277602_D005947_D044882,,
770959300,false,true,5,2015-08-14T21:18:00,,No Relation,1,D005947,glucose,D003929,diabetes,Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).,19277602_0,19277602_D005947_D003929,,
770959301,false,true,5,2015-08-15T01:16:00,,No Relation,0.801,D005947,glucose,D003929,diabetes,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_D005947_D003929,,
770959302,false,true,5,2015-08-14T21:40:00,,No Relation,1,D005947,glucose,D044882,impaired glucose tolerance,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_D005947_D044882,,
770959303,false,true,5,2015-08-14T22:22:00,,No Relation,1,D005947,glucose,C537389,type,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_D005947_C537389,,
770959304,false,true,5,2015-08-15T00:16:00,,No Relation,1,C060836,pioglitazone,D044882,impaired glucose tolerance,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_C060836_D044882,,
770959305,false,true,5,2015-08-15T00:18:00,,No Relation,1,C060836,pioglitazone,D003929,diabetes,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_C060836_D003929,,
770959306,false,true,5,2015-08-15T02:22:00,,No Relation,1,C060836,pioglitazone,C537389,type,The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.,19277602_1,19277602_C060836_C537389,,
770959307,false,true,5,2015-08-15T01:38:00,,No Relation,1,C060836,pioglitazone,D044882,impaired glucose tolerance,"In a community-based, placebo-controlled 3 year prospective study, 407 participants with impaired glucose tolerance (mean age 45.3 +/- 6.2 years, mean BMI 25.9 +/- 3.3 kg/m(2)) were sequentially grouped to receive either: lifestyle modification plus pioglitazone, 30 mg (n = 204) or lifestyle modification plus placebo (n = 203).",19277602_2,19277602_C060836_D044882,,
770959308,false,true,5,2015-08-14T22:50:00,'impaired glucose tolerance' is the whole term and should not be evaluated as the juxtaposition of its parts. :),No Relation,1,D005947,glucose,D044882,impaired glucose tolerance,"In a community-based, placebo-controlled 3 year prospective study, 407 participants with impaired glucose tolerance (mean age 45.3 +/- 6.2 years, mean BMI 25.9 +/- 3.3 kg/m(2)) were sequentially grouped to receive either: lifestyle modification plus pioglitazone, 30 mg (n = 204) or lifestyle modification plus placebo (n = 203).",19277602_2,19277602_D005947_D044882,,
770959309,false,true,5,2015-08-14T21:42:00,,Direct,0.8045,C060836,pioglitazone,D003929,diabetes,"The cumulative incidence of diabetes was 29.8% with pioglitazone and 31.6% with placebo (unadjusted HR 1.084 [95% CI 0.753-1.560], p = 0.665).",19277602_7,19277602_C060836_D003929,,
770959310,false,true,5,2015-08-14T21:04:00,,No Relation,0.6036,C060836,pioglitazone,D006331,cardiac disease,"In pioglitazone group, two deaths and two non-fatal hospitalisations occurred due to cardiac problems; in the placebo group there were two occurrences of cardiac disease.",19277602_9,19277602_C060836_D006331,,
770959311,false,true,5,2015-08-14T23:46:00,,No Relation,0.7818,C060836,pioglitazone,D003643,deaths,"In pioglitazone group, two deaths and two non-fatal hospitalisations occurred due to cardiac problems; in the placebo group there were two occurrences of cardiac disease.",19277602_9,19277602_C060836_D003643,,
770959312,false,true,5,2015-08-14T22:17:00,,No Relation,1,C060836,pioglitazone,D003929,diabetes,The results are at variance with studies that showed significant relative risk reduction in conversion to diabetes with pioglitazone in Americans with IGT.,19277602_12,19277602_C060836_D003929,,
770959313,false,true,5,2015-08-14T21:12:00,,No Relation,1,C060836,pioglitazone,D003929,diabetic,An ethnicity-related difference in the action of pioglitazone in non-diabetic participants may be one explanation.,19277602_13,19277602_C060836_D003929,,
770959314,false,true,5,2015-08-15T00:17:00,,No Relation,1,D016190,carboplatin,D009369,tumor,Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.,19299243_0,19299243_D016190_D009369,,
770959315,false,true,5,2015-08-14T21:53:00,,No Relation,1,D016190,carboplatin,D002277,metaplastic carcinoma,Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.,19299243_0,19299243_D016190_D002277,,
770959316,false,true,5,2015-08-15T02:18:00,,No Relation,1,D017239,paclitaxel,D009369,tumor,Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.,19299243_0,19299243_D017239_D009369,,
770959317,false,true,5,2015-08-15T00:58:00,,No Relation,1,D017239,paclitaxel,D002277,metaplastic carcinoma,Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.,19299243_0,19299243_D017239_D002277,,
770959318,false,true,5,2015-08-15T00:43:00,,No Relation,0.824,D002945,cisplatin,D000860,hypoxia,"NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.",19339107_0,19339107_D002945_D000860,,
770959319,false,true,5,2015-08-14T21:34:00,,No Relation,1,C514334,NSC606985,D000860,hypoxia,"NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.",19339107_0,19339107_C514334_D000860,,
770959320,false,true,5,2015-08-14T22:22:00,,No Relation,1,D002945,cisplatin,D009369,ovarian cancer,"NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.",19339107_0,19339107_D002945_D009369,,
770959321,false,true,5,2015-08-15T01:56:00,,No Relation,0.8126,C514334,NSC606985,D009369,ovarian cancer,"NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.",19339107_0,19339107_C514334_D009369,,
770959322,false,true,5,2015-08-15T00:03:00,Possible treatment.,No Relation,0.6058,C514334,NSC606985,D009369,ovarian cancer,"In the present study, we investigated the potential anti-human ovarian cancer effects of NSC606985, a novel and rarely studied camptothecin analog, and its combination with cisplatin (CDDP).",19339107_2,19339107_C514334_D009369,,
770959323,false,true,5,2015-08-14T22:55:00,,No Relation,1,D002945,cisplatin/CDDP,D009369,ovarian cancer,"In the present study, we investigated the potential anti-human ovarian cancer effects of NSC606985, a novel and rarely studied camptothecin analog, and its combination with cisplatin (CDDP).",19339107_2,19339107_D002945_D009369,,
770959324,false,true,5,2015-08-15T00:15:00,,No Relation,1,D002166,camptothecin,D009369,ovarian cancer,"In the present study, we investigated the potential anti-human ovarian cancer effects of NSC606985, a novel and rarely studied camptothecin analog, and its combination with cisplatin (CDDP).",19339107_2,19339107_D002166_D009369,,
770959325,false,true,5,2015-08-14T21:49:00,,No Relation,1,D002945,CDDP,D009369,ovarian cancer,"Human ovarian cancer cell line COC1 cells were treated with different nanomolar of NSC606985 with or without CDDP, and cell growth and apoptosis were evaluated, respectively, by MTT assay and annexin-V assay on flow cytometry.",19339107_3,19339107_D002945_D009369,,
770959326,false,true,5,2015-08-14T22:08:00,,No Relation,1,C514334,NSC606985,D009369,ovarian cancer,"Human ovarian cancer cell line COC1 cells were treated with different nanomolar of NSC606985 with or without CDDP, and cell growth and apoptosis were evaluated, respectively, by MTT assay and annexin-V assay on flow cytometry.",19339107_3,19339107_C514334_D009369,,
770959327,false,true,5,2015-08-15T01:41:00,,No Relation,0.7878,C514334,NSC606985,D000860,hypoxia,"In addition, NSC606985 significantly antagonized the accumulation of HIF-1alpha stabilized by hypoxia or hypoxia-mimetic agent.",19339107_8,19339107_C514334_D000860,,
770959328,false,true,5,2015-08-14T23:11:00,,No Relation,1,D002945,CDDP,D009369,ovarian cancer,"These results suggest that NSC606985 and its combination with CDDP present the therapeutic potential on ovarian cancer, and deserve further preclinical and clinical studies.",19339107_9,19339107_D002945_D009369,,
770959329,false,true,5,2015-08-15T00:51:00,,No Relation,1,C514334,NSC606985,D009369,ovarian cancer,"These results suggest that NSC606985 and its combination with CDDP present the therapeutic potential on ovarian cancer, and deserve further preclinical and clinical studies.",19339107_9,19339107_C514334_D009369,,
770959330,false,true,5,2015-08-14T21:49:00,,No Relation,0.7906,D008985,monensin,D000230,adenocarcinoma,"The monolayers of Human ileocecal adenocarcinoma cells (HCT-8) were infected by sporozoites excysted directly on the cells and were incubated with monensin, halofuginone bromide and hexadecylphosphocholine until 45h post infection (p.i.).",19342176_3,19342176_D008985_D000230,,
770959331,false,true,5,2015-08-14T21:11:00,,No Relation,0.8018,D008985,monensin,D007239,infection,"The monolayers of Human ileocecal adenocarcinoma cells (HCT-8) were infected by sporozoites excysted directly on the cells and were incubated with monensin, halofuginone bromide and hexadecylphosphocholine until 45h post infection (p.i.).",19342176_3,19342176_D008985_D007239,,
770959332,false,true,5,2015-08-15T01:28:00,,No Relation,1,C039128,hexadecylphosphocholine,D000230,adenocarcinoma,"The monolayers of Human ileocecal adenocarcinoma cells (HCT-8) were infected by sporozoites excysted directly on the cells and were incubated with monensin, halofuginone bromide and hexadecylphosphocholine until 45h post infection (p.i.).",19342176_3,19342176_C039128_D000230,,
770959333,false,true,5,2015-08-14T22:31:00,,No Relation,1,C039128,hexadecylphosphocholine,D007239,infection,"The monolayers of Human ileocecal adenocarcinoma cells (HCT-8) were infected by sporozoites excysted directly on the cells and were incubated with monensin, halofuginone bromide and hexadecylphosphocholine until 45h post infection (p.i.).",19342176_3,19342176_C039128_D007239,,
770959334,false,true,5,2015-08-15T00:10:00,,No Relation,1,D014443,tyrosine,D002289,non-small cell lung cancer,Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.,19343300_0,19343300_D014443_D002289,,
770959335,false,true,5,2015-08-14T21:24:00,,No Relation,1,D014443,Tyrosine,D002289,NSCLC,"Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC.",19343300_3,19343300_D014443_D002289,,
770959336,false,true,5,2015-08-15T01:49:00,,No Relation,1,C400278,erlotinib,D002289,NSCLC,"Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC.",19343300_3,19343300_C400278_D002289,,
770959337,false,true,5,2015-08-14T21:10:00,,No Relation,1,C419708,gefitinib,D002289,NSCLC,"Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC.",19343300_3,19343300_C419708_D002289,,
770959338,false,true,5,2015-08-14T21:56:00,,No Relation,1,C400278,erlotinib,D002289,NSCLC,This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC.,19343300_5,19343300_C400278_D002289,,
770959339,false,true,5,2015-08-15T01:29:00,,No Relation,0.8032,C419708,gefitinib,D002289,NSCLC,This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC.,19343300_5,19343300_C419708_D002289,,
770959340,false,true,5,2015-08-14T22:05:00,,No Relation,1,D009241,ipratropium bromide,D002559,rhinorrhea,This review assesses two widely used intranasal treatments for nasal congestion and rhinorrhea in the common cold: xylometazoline hydrochloride and ipratropium bromide.,19351236_2,19351236_D009241_D002559,,
770959341,false,true,5,2015-08-14T21:33:00,,No Relation,1,C009695,xylometazoline hydrochloride,D002559,rhinorrhea,This review assesses two widely used intranasal treatments for nasal congestion and rhinorrhea in the common cold: xylometazoline hydrochloride and ipratropium bromide.,19351236_2,19351236_C009695_D002559,,
770959342,false,true,5,2015-08-15T02:02:00,,No Relation,1,D009241,ipratropium,D002559,rhinorrhea,"Xylometazoline quickly and effectively relieves nasal congestion, while ipratropium is effective at reducing rhinorrhea.",19351236_3,19351236_D009241_D002559,,
770959343,false,true,5,2015-08-15T01:16:00,,No Relation,1,C009695,Xylometazoline,D002559,rhinorrhea,"Xylometazoline quickly and effectively relieves nasal congestion, while ipratropium is effective at reducing rhinorrhea.",19351236_3,19351236_C009695_D002559,,
770959344,false,true,5,2015-08-14T22:24:00,,No Relation,1,C471405,sorafenib,C536915,papillary thyroid carcinoma,The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.,19355831_0,19355831_C471405_C536915,,
770959345,false,true,5,2015-08-14T21:42:00,,No Relation,1,C471405,Sorafenib,D013964,thyroid cancer,"Sorafenib is an orally administered multi-kinase inhibitor that has shown promise in the treatment of adults with advanced thyroid cancer, but it has not yet been studied in children with this disease.",19355831_3,19355831_C471405_D013964,,
770959346,false,true,5,2015-08-14T22:48:00,,No Relation,1,C471405,sorafenib,C536915,PTC,Our objective is to present an adolescent with a progressive RAI-resistant PTC who was successfully treated with sorafenib.,19355831_4,19355831_C471405_C536915,,
770959347,false,true,5,2015-08-14T22:23:00,,No Relation,1,C471405,Sorafenib,C536915,PTC,A 14-year-old girl had progressive lung metastases from PTC despite previous therapies with almost 400 mCi (131)I. Sorafenib was initiated at a starting dose of 200 mg twice daily and decreased to a maintenance dose of 200 mg daily due to side effects that developed within 3 weeks of treatment.,19355831_5,19355831_C471405_C536915,,
770959348,false,true,5,2015-08-15T00:26:00,,No Relation,1,C471405,sorafenib,C536915,PTC,"In the very rare case of the pediatric patient with progressive RAI-refractory PTC, for which no good systemic therapy exists, sorafenib may play an important role in the management of this disease.",19355831_10,19355831_C471405_C536915,,
770959349,false,true,5,2015-08-14T21:22:00,,No Relation,0.8144,D008727,methotrexate,D006660,histoplasmosis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D008727_D006660,,
770959350,false,true,5,2015-08-14T22:22:00,,Direct,0.5882,D011241,prednisone,D006660,histoplasmosis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D011241_D006660,,
770959351,false,true,5,2015-08-14T21:20:00,,No Relation,0.4211,D008727,methotrexate,D006689,granulomatous hepatitis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D008727_D006689,,
770959352,false,true,5,2015-08-15T00:15:00,,No Relation,0.8011,D011241,prednisone,D003882,dermatomyositis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D011241_D003882,,
770959353,false,true,5,2015-08-14T21:35:00,,No Relation,1,D011241,prednisone,D006689,granulomatous hepatitis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D011241_D006689,,
770959354,false,true,5,2015-08-15T02:10:00,,No Relation,1,D008727,methotrexate,D003882,dermatomyositis,We present a rare case of isolated granulomatous hepatitis due to histoplasmosis in a 35-year-old female with dermatomyositis receiving low-dose prednisone and methotrexate.,19434026_4,19434026_D008727_D003882,,
770959355,false,true,5,2015-08-15T01:42:00,,No Relation,1,D004967,estrogen,D009369,breast cancer,Targeting the vascular endothelial growth factor (VEGF) and estrogen receptor (ER) signaling pathways concomitantly may provide enhanced therapeutic benefit in ER-positive breast cancer.,19435899_2,19435899_D004967_D009369,,
770959356,false,true,5,2015-08-15T02:49:00,,No Relation,1,C404768,ZK222584,D009369,breast cancer,"Therefore, the effects of the VEGF receptor (VEGFR) tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK) were investigated using human breast cancer cell lines engineered to express aromatase.",19435899_3,19435899_C404768_D009369,,
770959357,false,true,5,2015-08-15T00:38:00,,No Relation,1,D000212,aciclovir,D018792,viral encephalitis,The management of infants and children treated with aciclovir for suspected viral encephalitis.,19457882_0,19457882_D000212_D018792,,
770959358,false,true,5,2015-08-14T22:51:00,,No Relation,0.8074,D000212,aciclovir,D004660,encephalitis,Case notes of all infants and children who received intravenous aciclovir for suspected encephalitis over a 6-month period were reviewed.,19457882_2,19457882_D000212_D004660,,
770959359,false,true,5,2015-08-15T01:13:00,,No Relation,1,D012701,serotonin,D003866,depression,We aimed to determine the potential correlations of 5-HTT/NET gene polymorphisms with the susceptibility to depression and the antidepressant response to selective serotonin reuptake inhibitors (SSRIs) or dual selective serotonin/norepinephrine reuptake inhibitors (SNRIs).,19468717_2,19468717_D012701_D003866,,
770959360,false,true,5,2015-08-14T23:14:00,,No Relation,0.6023,D009638,norepinephrine,D003866,depression,We aimed to determine the potential correlations of 5-HTT/NET gene polymorphisms with the susceptibility to depression and the antidepressant response to selective serotonin reuptake inhibitors (SSRIs) or dual selective serotonin/norepinephrine reuptake inhibitors (SNRIs).,19468717_2,19468717_D009638_D003866,,
770959361,false,true,5,2015-08-15T00:55:00,,No Relation,1,D000666,AMB/amphotericin B,D009091,mucormycosis,Standard therapy for invasive mucormycosis includes parenteral amphotericin B (AMB) in combination with radical debridement of infected tissues.,19485785_3,19485785_D000666_D009091,,
770959362,false,true,5,2015-08-14T22:30:00,,No Relation,1,C101425,Posaconazole,D009091,mucormycosis,"Posaconazole is a novel, extended-spectrum triazole oral antifungal agent with documented success in the treatment of patients with invasive mucormycosis.",19485785_6,19485785_C101425_D009091,,
770959363,false,true,5,2015-08-14T21:38:00,,No Relation,1,D000666,AMB,D007239,infection,The infection did not respond to AMB but was treated successfully with a combination of posaconazole and liposomal AMB (LAMB) without surgical debridement.,19485785_9,19485785_D000666_D007239,,
770959364,false,true,5,2015-08-14T21:51:00,,No Relation,1,C101425,posaconazole,D007239,infection,The infection did not respond to AMB but was treated successfully with a combination of posaconazole and liposomal AMB (LAMB) without surgical debridement.,19485785_9,19485785_C101425_D007239,,
770959365,false,true,5,2015-08-15T02:16:00,,Direct,0.609,C101425,posaconazole,D013272,gastric and intrahepatic mucormycosis,"To our knowledge, this is the first reported case of extensive gastric and intrahepatic mucormycosis that responded to combination posaconazole and LAMB without surgical debridement.",19485785_10,19485785_C101425_D013272,,
770959366,false,true,5,2015-08-14T21:31:00,,No Relation,1,D004837,epinephrine,D008309,Mallory-Weiss syndrome,Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine.,19485979_0,19485979_D004837_D008309,,
770959367,false,true,5,2015-08-15T01:15:00,,No Relation,1,D004837,epinephrine,D006470,bleeding,Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine.,19485979_0,19485979_D004837_D006470,,
770959368,false,true,5,2015-08-14T21:16:00,,No Relation,1,D004837,adrenaline/epinephrine,D008309,MWS,To compare the efficacy of endoscopic band ligation vs. hemoclip plus epinephrine (adrenaline) in bleeding MWS.,19485979_2,19485979_D004837_D008309,,
770959369,false,true,5,2015-08-15T00:30:00,,No Relation,1,D004837,adrenaline/epinephrine,D006470,bleeding,To compare the efficacy of endoscopic band ligation vs. hemoclip plus epinephrine (adrenaline) in bleeding MWS.,19485979_2,19485979_D004837_D006470,,
770959370,false,true,5,2015-08-14T22:31:00,,Direct,0.5969,D004837,epinephrine,D006470,bleeding,The use of hemoclips plus epinephrine (OR = 3; 95% CI = 1.15-15.8) and active bleeding at endoscopy (OR = 1.9; 95% CI = 1.04-5.2) were independent predictive factors of early recurrent bleeding.,19485979_9,19485979_D004837_D006470,,
770959371,false,true,5,2015-08-15T00:54:00,,No Relation,1,D017239,paclitaxel,D009369,breast cancer,"The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.",19509275_0,19509275_D017239_D009369,,
770959372,false,true,5,2015-08-14T21:11:00,,No Relation,1,D017239,paclitaxel,D009369,breast cancer,"Importantly, the cellular response to GRN163L significantly augmented the effects of the microtubule stabilizer paclitaxel in MDA-MB-231 breast cancer cell growth in vitro and in vivo compared with paclitaxel alone or a mismatch control oligonucleotide plus paclitaxel.",19509275_7,19509275_D017239_D009369,,
770959373,false,true,5,2015-08-15T01:52:00,,No Relation,1,D017239,paclitaxel,D009369,breast cancer,These data support a rationale for potentially combining GRN163L with paclitaxel for the treatment of breast cancer in the clinical setting.,19509275_9,19509275_D017239_D009369,,
770959374,false,true,5,2015-08-15T01:39:00,,No Relation,0.8211,C055162,clopidogrel,D009203,ST-elevation myocardial infarction/STEMI,"The present single-center, longitudinal, cohort study will include 1,750 consecutive patients with ST-elevation myocardial infarction (STEMI), undergoing pPCI after pretreatment with 300 mg aspirin and 600 mg clopidogrel.",19515084_3,19515084_C055162_D009203,,
770959375,false,true,5,2015-08-14T21:42:00,,No Relation,0.6126,D001241,aspirin,D009203,ST-elevation myocardial infarction/STEMI,"The present single-center, longitudinal, cohort study will include 1,750 consecutive patients with ST-elevation myocardial infarction (STEMI), undergoing pPCI after pretreatment with 300 mg aspirin and 600 mg clopidogrel.",19515084_3,19515084_D001241_D009203,,
770959376,false,true,5,2015-08-14T23:46:00,,No Relation,1,D005947,glucose,C537389,type,Rosiglitazone significantly increased glucose uptake in wild-type podocytes and this was associated with translocation of GLUT1 to the plasma membrane.,19533082_8,19533082_D005947_C537389,,
770959377,false,true,5,2015-08-14T22:43:00,,No Relation,1,C089730,Rosiglitazone,C537389,type,Rosiglitazone significantly increased glucose uptake in wild-type podocytes and this was associated with translocation of GLUT1 to the plasma membrane.,19533082_8,19533082_C089730_C537389,,
770959378,false,true,5,2015-08-15T00:33:00,,No Relation,1,D005947,glucose,C537389,type,"In conclusion, rosiglitazone has a direct and protective effect on glucose uptake in wild-type human podocytes.",19533082_12,19533082_D005947_C537389,,
770959379,false,true,5,2015-08-14T23:46:00,,No Relation,1,C089730,rosiglitazone,C537389,type,"In conclusion, rosiglitazone has a direct and protective effect on glucose uptake in wild-type human podocytes.",19533082_12,19533082_C089730_C537389,,
770959380,false,true,5,2015-08-14T23:38:00,,No Relation,1,D012254,ribavirin,D006505,hepatitis,The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.,19578243_0,19578243_D012254_D006505,,
770959381,false,true,5,2015-08-14T21:48:00,,No Relation,1,C417083,pegylated interferon-alpha2b,D006505,hepatitis,The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.,19578243_0,19578243_C417083_D006505,,
770959382,false,true,5,2015-08-14T21:18:00,,No Relation,1,D012254,ribavirin,D005355,cirrhosis,"Treatment failure to pegylated interferon (PEG-IFN)-alpha2b and ribavirin (RBV) largely depends upon virus genotype, but the interaction between genotype, cirrhosis and pattern of treatment failure is unclear.",19578243_2,19578243_D012254_D005355,,
770959383,false,true,5,2015-08-14T21:35:00,,No Relation,1,C417083,pegylated interferon (PEG-IFN)-alpha2b,D005355,cirrhosis,"Treatment failure to pegylated interferon (PEG-IFN)-alpha2b and ribavirin (RBV) largely depends upon virus genotype, but the interaction between genotype, cirrhosis and pattern of treatment failure is unclear.",19578243_2,19578243_C417083_D005355,,
770959384,false,true,5,2015-08-14T21:52:00,,Direct,0.6132,D003622,dapsone,D054537,atrioventricular block,Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome.,19583683_0,19583683_D003622_D054537,,
770959385,false,true,5,2015-08-14T22:21:00,,Direct,0.6247,D003622,dapsone,D063926,dapsone-induced hypersensitivity syndrome,Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome.,19583683_0,19583683_D003622_D063926,,
770959386,false,true,5,2015-08-14T23:01:00,,No Relation,1,D003622,Dapsone,D007249,infectious and inflammatory diseases,Dapsone is still widely used for a range of infectious and inflammatory diseases.,19583683_1,19583683_D003622_D007249,,
770959387,false,true,5,2015-08-15T00:12:00,,Direct,0.4077,D003622,dapsone,D063926,DHS/dapsone-induced hypersensitivity syndrome,"A potential severe side-effect, known as dapsone-induced hypersensitivity syndrome (DHS), may occur.",19583683_2,19583683_D003622_D063926,,
770959388,false,true,5,2015-08-15T01:46:00,,Direct,0.7922,D003622,dapsone,D063926,DHS,We describe here a 45-year-old Chinese woman who developed DHS after 5 weeks of dapsone therapy for pustular palmoplantar psoriasis.,19583683_5,19583683_D003622_D063926,,
770959389,false,true,5,2015-08-14T21:36:00,,No Relation,0.8219,D003622,dapsone,D011565,psoriasis,We describe here a 45-year-old Chinese woman who developed DHS after 5 weeks of dapsone therapy for pustular palmoplantar psoriasis.,19583683_5,19583683_D003622_D011565,,
770959390,false,true,5,2015-08-14T21:43:00,,No Relation,1,D007501,iron,C563738,RT,Two studies used supplemental iron in the RT plus EPO group and not in the RT alone group.,19588382_15,19588382_D007501_C563738,,
770959391,false,true,5,2015-08-15T02:39:00,,No Relation,1,C011049,Oil Red O,D012175,Rb/retinoblastoma,"The effects of lactoferrin on adipogenesis were studied through the expression of different lipogenic markers, AMP-activated protein kinase (AMPK) activation, retinoblastoma (Rb) activity and Oil Red O staining in 3T3-L1 cells.",19652659_5,19652659_C011049_D012175,,
770959392,false,true,5,2015-08-14T23:01:00,,No Relation,0.8037,D000667,AMP,D012175,Rb/retinoblastoma,"The effects of lactoferrin on adipogenesis were studied through the expression of different lipogenic markers, AMP-activated protein kinase (AMPK) activation, retinoblastoma (Rb) activity and Oil Red O staining in 3T3-L1 cells.",19652659_5,19652659_D000667_D012175,,
770959393,false,true,5,2015-08-15T01:18:00,,Direct,0.5839,D005227,saturated fatty acids/SFAs,D007249,inflammation,"It has been proposed that dietary saturated fatty acids (SFAs) may also serve as endogenous ligands of TLR2 or TLR4, thereby promoting diseases associated with inflammation and dyslipidemia, including atherosclerosis and insulin resistance.",19661481_2,19661481_D005227_D007249,,
770959394,false,true,5,2015-08-14T22:17:00,,Direct,1,D005227,saturated fatty acids/SFAs,D050171,dyslipidemia,"It has been proposed that dietary saturated fatty acids (SFAs) may also serve as endogenous ligands of TLR2 or TLR4, thereby promoting diseases associated with inflammation and dyslipidemia, including atherosclerosis and insulin resistance.",19661481_2,19661481_D005227_D050171,,
770959395,false,true,5,2015-08-14T23:19:00,,Direct,0.7936,D005227,saturated fatty acids/SFAs,D050197,atherosclerosis,"It has been proposed that dietary saturated fatty acids (SFAs) may also serve as endogenous ligands of TLR2 or TLR4, thereby promoting diseases associated with inflammation and dyslipidemia, including atherosclerosis and insulin resistance.",19661481_2,19661481_D005227_D050197,,
770959396,false,true,5,2015-08-14T22:28:00,,No Relation,0.5775,D005227,SFAs,C536528,LPS,Further analysis showed that the effect seen with the complexed SFAs was attributable to LPS and lipopeptide contamination of fatty-acid-free BSA.,19661481_6,19661481_D005227_C536528,,
770959397,false,true,5,2015-08-14T23:23:00,,No Relation,0.7874,D005227,SFAs,C536528,LPS,LPS and lipopeptide contamination of the widely used reagent fatty-acid-free BSA explains the previously reported stimulation of TLR2 and TLR4 by SFAs.,19661481_9,19661481_D005227_C536528,,
770959398,false,true,5,2015-08-15T02:10:00,,No Relation,1,D009569,nitric oxide,D003550,cystic fibrosis,Extended nitric oxide measurements in exhaled air of cystic fibrosis and healthy adults.,19669109_0,19669109_D009569_D003550,,
770959399,false,true,5,2015-08-15T00:57:00,,No Relation,1,D009569,nitric oxide,D003550,cystic fibrosis/CF,"In cystic fibrosis (CF) lung disease, exhaled nitric oxide (FeNO) is not raised, but rather is normal or even decreased when measured at a single expiratory flow.",19669109_1,19669109_D009569_D003550,,
770959400,false,true,5,2015-08-14T21:19:00,,No Relation,0.8077,D009569,nitric oxide,D008171,lung disease,"In cystic fibrosis (CF) lung disease, exhaled nitric oxide (FeNO) is not raised, but rather is normal or even decreased when measured at a single expiratory flow.",19669109_1,19669109_D009569_D008171,,
770959401,false,true,5,2015-08-14T22:23:00,,No Relation,1,D009569,NO,D003550,CF,"The median J(NO,Br) was significantly lower in CF adults than in healthy controls [0.31 nl/s (range = 0.11-0.63) vs. 0.70 nl/s (0.27-3.52); P < 0.001], while the median C(Alv) was similar in both groups [1.7 ppb (0.3-3.9) vs. 1.2 (0.1-5.2)].",19669109_8,19669109_D009569_D003550,,
770959402,false,true,5,2015-08-15T01:39:00,,No Relation,1,D009569,NO,D003550,CF,Pulmonary NO exchange did not differ significantly between subgroups of CF patients with and without chronic Pseudomonas aeruginosa infection.,19669109_9,19669109_D009569_D003550,,
770959403,false,true,5,2015-08-14T21:36:00,,No Relation,1,D009569,NO,D011552,Pseudomonas aeruginosa infection,Pulmonary NO exchange did not differ significantly between subgroups of CF patients with and without chronic Pseudomonas aeruginosa infection.,19669109_9,19669109_D009569_D011552,,
770959404,false,true,5,2015-08-14T22:13:00,,No Relation,0.8043,D009569,NO,D003550,CF,Extended FeNO measurements can separate alveolar and bronchial NO outputs in CF adults.,19669109_11,19669109_D009569_D003550,,
770959405,false,true,5,2015-08-14T21:24:00,,No Relation,1,D019808,losartan,D007674,kidney diseases,CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.,19669737_0,19669737_D019808_D007674,,
770959406,false,true,5,2015-08-14T22:13:00,,No Relation,1,D019808,Losartan,D051436,CKD/chronic kidney disease,Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD).,19669737_1,19669737_D019808_D051436,,
770959407,false,true,5,2015-08-14T23:50:00,,No Relation,0.7928,D019808,losartan,D051436,CKD,These preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan.,19669737_8,19669737_D019808_D051436,,
770959408,false,true,5,2015-08-15T01:50:00,,No Relation,0.5917,D019808,losartan,D011507,proteinuria,These preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan.,19669737_8,19669737_D019808_D011507,,
770959409,false,true,5,2015-08-14T23:46:00,,No Relation,1,D008687,metformin,D003920,type 2 diabetes mellitus,A question often asked by health-care providers is whether metformin has added benefits if continued after patients with type 2 diabetes mellitus switch to insulin.,19690559_1,19690559_D008687_D003920,,
770959410,false,true,5,2015-08-14T21:08:00,,No Relation,1,C422923,Rosuvastatin,D007003,impaired fasting glucose,Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.,19691613_0,19691613_C422923_D007003,,
770959411,false,true,5,2015-08-15T01:21:00,,No Relation,1,D005947,glucose,D007003,impaired fasting glucose,Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.,19691613_0,19691613_D005947_D007003,,
770959412,false,true,5,2015-08-15T01:34:00,,No Relation,1,D005947,glucose,D003929,diabetes,The increase in physician-reported diabetes following rosuvastatin treatment in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study has raised concerns whether this statin exerts a detrimental effect on glucose metabolism.,19691613_1,19691613_D005947_D003929,,
770959413,false,true,5,2015-08-15T02:02:00,,Direct,0.6285,C422923,rosuvastatin,D003929,diabetes,The increase in physician-reported diabetes following rosuvastatin treatment in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study has raised concerns whether this statin exerts a detrimental effect on glucose metabolism.,19691613_1,19691613_C422923_D003929,,
770959414,false,true,5,2015-08-15T02:31:00,,No Relation,1,C422923,rosuvastatin,D007003,IFG/impaired fasting glucose,"We assessed the effect of rosuvastatin treatment across dose range on glucose homeostasis in hyperlipidaemic patients with impaired fasting glucose (IFG), who are at high risk to develop diabetes mellitus.",19691613_2,19691613_C422923_D007003,,
770959415,false,true,5,2015-08-14T22:08:00,,No Relation,0.5969,C422923,rosuvastatin,D003920,diabetes mellitus,"We assessed the effect of rosuvastatin treatment across dose range on glucose homeostasis in hyperlipidaemic patients with impaired fasting glucose (IFG), who are at high risk to develop diabetes mellitus.",19691613_2,19691613_C422923_D003920,,
770959416,false,true,5,2015-08-14T21:11:00,,No Relation,0.7998,D005947,glucose,D007003,IFG/impaired fasting glucose,"We assessed the effect of rosuvastatin treatment across dose range on glucose homeostasis in hyperlipidaemic patients with impaired fasting glucose (IFG), who are at high risk to develop diabetes mellitus.",19691613_2,19691613_D005947_D007003,,
770959417,false,true,5,2015-08-14T23:57:00,,No Relation,0.807,D005947,glucose,D003920,diabetes mellitus,"We assessed the effect of rosuvastatin treatment across dose range on glucose homeostasis in hyperlipidaemic patients with impaired fasting glucose (IFG), who are at high risk to develop diabetes mellitus.",19691613_2,19691613_D005947_D003920,,
770959418,false,true,5,2015-08-14T23:16:00,,No Relation,0.7986,C422923,rosuvastatin,D007003,IFG,"The medical records of 72 hypelipidaemic patients with IFG on rosuvastatin 10 (RSV10 group), 20 (RSV20 group) and 40 mg/day (RSV40 group) were reviewed.",19691613_3,19691613_C422923_D007003,,
770959419,false,true,5,2015-08-15T01:27:00,,No Relation,0.8032,C422923,rosuvastatin,D007003,IFG,"In patients with IFG and hyperlipidaemia, rosuvastatin treatment was associated with a dose-dependent increase in insulin resistance.",19691613_8,19691613_C422923_D007003,,
770959420,false,true,5,2015-08-14T23:37:00,,No Relation,1,D016572,cyclosporin,D064420,toxicity,The relationship between drug transporter function and endogenous melanogenic toxicity was assessed by treating cells with the cyclosporin analog PSC-833 and by assessing vacuole formation and cell growth inhibition.,19704071_6,19704071_D016572_D064420,,
770959421,false,true,5,2015-08-15T01:54:00,,No Relation,0.8055,C070272,PSC-833,D064420,toxicity,The relationship between drug transporter function and endogenous melanogenic toxicity was assessed by treating cells with the cyclosporin analog PSC-833 and by assessing vacuole formation and cell growth inhibition.,19704071_6,19704071_C070272_D064420,,
770959422,false,true,5,2015-08-14T21:19:00,,No Relation,1,C042382,fludarabine phosphate,D013577,HPS,"We aimed to identify the contribution of HPS to engraftment failure after CBT, following preparative regimens containing fludarabine phosphate, in 119 patients (median age, 55 years; range; 17-69 years) with haematological diseases.",19709082_2,19709082_C042382_D013577,,
770959423,false,true,5,2015-08-15T00:16:00,,No Relation,0.8042,C042382,fludarabine phosphate,D004194,haematological diseases,"We aimed to identify the contribution of HPS to engraftment failure after CBT, following preparative regimens containing fludarabine phosphate, in 119 patients (median age, 55 years; range; 17-69 years) with haematological diseases.",19709082_2,19709082_C042382_D004194,,
770959424,false,true,5,2015-08-15T01:06:00,,No Relation,1,C063008,mycophenolate mofetil,D006086,Graft-versus-host disease,Graft-versus-host disease prophylaxis comprised continuous infusion of a calcineurin inhibitor with or without mycophenolate mofetil.,19709082_3,19709082_C063008_D006086,,
770959425,false,true,5,2015-08-15T01:06:00,,No Relation,1,D014212,retinoic acid,D009447,neuroblastoma,"We studied miR-128, a brain-enriched microRNA, in retinoic acid-differentiated neuroblastoma cells, and we found that this microRNA is up-regulated in treated cells, where it down-modulates the expression of two proteins involved in the migratory potential of neural cells: Reelin and DCX.",19713529_3,19713529_D014212_D009447,,
770959426,false,true,5,2015-08-15T02:17:00,,No Relation,0.811,D006632,histamine,D003072,sleep or cognitive disorders,Antagonism of the histamine-H(3) receptor is one tactic being explored to increase wakefulness for the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive disorders.,19722526_1,19722526_D006632_D003072,,
770959427,false,true,5,2015-08-14T21:41:00,,No Relation,0.8129,D006859,H,D012893,daytime sleepiness,Antagonism of the histamine-H(3) receptor is one tactic being explored to increase wakefulness for the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive disorders.,19722526_1,19722526_D006859_D012893,,
770959428,false,true,5,2015-08-15T01:23:00,,No Relation,0.8111,D006632,histamine,D012893,daytime sleepiness,Antagonism of the histamine-H(3) receptor is one tactic being explored to increase wakefulness for the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive disorders.,19722526_1,19722526_D006632_D012893,,
770959429,false,true,5,2015-08-15T00:20:00,,No Relation,0.8086,D006859,H,D003072,sleep or cognitive disorders,Antagonism of the histamine-H(3) receptor is one tactic being explored to increase wakefulness for the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive disorders.,19722526_1,19722526_D006859_D003072,,
770959430,false,true,5,2015-08-14T21:12:00,,No Relation,1,C426063,Vardenafil,D007172,ED/erectile dysfunction,Vardenafil is reported to improve success rates in the maintenance of an erection sufficient for completion of intercourse (SEP-3) compared with placebo in erectile dysfunction (ED) patients who attempted intercourse from as early as 15 minutes after dosing.,19732311_1,19732311_C426063_D007172,,
770959431,false,true,5,2015-08-14T23:29:00,,No Relation,1,C426063,vardenafil,D003920,DM,To determine whether early onset of activity with vardenafil is also achievable in ED patients with DM.,19732311_4,19732311_C426063_D003920,,
770959432,false,true,5,2015-08-15T01:46:00,,No Relation,1,C426063,vardenafil,D007172,ED,To determine whether early onset of activity with vardenafil is also achievable in ED patients with DM.,19732311_4,19732311_C426063_D007172,,
770959433,false,true,5,2015-08-15T00:48:00,,No Relation,1,C426063,Vardenafil,D003920,DM,Vardenafil improved successful intercourse rates compared with placebo in Japanese DM patients who inserted from as early as 15 minutes to >120 minutes after dosing.,19732311_13,19732311_C426063_D003920,,
770959434,false,true,5,2015-08-15T00:25:00,,No Relation,1,D016190,carboplatin,D009369,ovarian cancer,"Between January 1998 and April 2004, we reviewed the records of 95 patients with high-risk, early stage epithelial ovarian cancer who had elevated CA125 levels at the time of diagnosis and were complete responders after 6 cycles of adjuvant paclitaxel/carboplatin chemotherapy.",19818996_2,19818996_D016190_D009369,,
770959435,false,true,5,2015-08-15T00:58:00,,No Relation,1,D017239,paclitaxel,D009369,ovarian cancer,"Between January 1998 and April 2004, we reviewed the records of 95 patients with high-risk, early stage epithelial ovarian cancer who had elevated CA125 levels at the time of diagnosis and were complete responders after 6 cycles of adjuvant paclitaxel/carboplatin chemotherapy.",19818996_2,19818996_D017239_D009369,,
770959436,false,true,5,2015-08-14T23:48:00,,Direct,0.5984,D001548,benzalkonium chloride,D007249,inflammation,Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.,19857103_0,19857103_D001548_D007249,,
770959437,false,true,5,2015-08-14T23:02:00,,No Relation,0.7997,D006861,H(2)O(2),D007249,inflammation,"To evaluate the inflammation BAK causes to the ocular surface, enzyme linked immunosorbant assays (ELISAs) were utilized to quantify the levels of inflammatory biomarkers in response to BAK and/or H(2)O(2).",19857103_5,19857103_D006861_D007249,,
770959438,false,true,5,2015-08-14T21:22:00,,No Relation,1,D006861,H(2)O(2),D009336,necrosis,"Additional experimentation was performed in which testing solutions were replaced with media after 1 h and the resulting supernatants quantified after 24 h. BAK induced significant amounts of interleukin (IL-) 1 and tumor necrosis factor (TNF), but only moderate amounts of C-reactive protein (CRP), IL- 10 and 12, and H(2)O(2).",19857103_7,19857103_D006861_D009336,,
770959439,false,true,5,2015-08-14T21:54:00,,No Relation,1,D012293,rifampicin,D014376,tuberculosis,Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Morocco.,19861020_0,19861020_D012293_D014376,,
770959440,false,true,5,2015-08-14T23:50:00,,No Relation,1,D012293,rifampicin/RMP,D014376,tuberculosis,Mutations in the rpoB gene associated with rifampicin (RMP) resistance were studied in 47 RMP-resistant and 147 RMP-susceptible clinical strains of Mycobacterium tuberculosis from Morocco using probe-based assay and DNA sequencing.,19861020_1,19861020_D012293_D014376,,
770959441,false,true,5,2015-08-15T00:50:00,,No Relation,1,C045463,leflunomide,D001172,rheumatoid arthritis,Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature.,19862529_0,19862529_C045463_D001172,,
770959442,false,true,5,2015-08-14T23:00:00,,Direct,1,D008727,methotrexate,D012218,rheumatoid nodule,"Antirheumatic drugs, methotrexate, leflunomide (LEF), infliximab and etanercept, were known as risk factors for developing rheumatoid nodule.",19862529_4,19862529_D008727_D012218,,
770959443,false,true,5,2015-08-15T01:19:00,,Direct,1,C045463,leflunomide,D012218,rheumatoid nodule,"Antirheumatic drugs, methotrexate, leflunomide (LEF), infliximab and etanercept, were known as risk factors for developing rheumatoid nodule.",19862529_4,19862529_C045463_D012218,,
770959444,false,true,5,2015-08-14T22:09:00,,No Relation,1,D005996,nitroglycerin,D054058,acute coronary syndromes,"Current guidelines call for nitroglycerin to be prescribed in patients with coronary heart disease, including those with stable angina and those recovering from acute coronary syndromes and myocardial infarction.",19887953_1,19887953_D005996_D054058,,
770959445,false,true,5,2015-08-15T01:48:00,,No Relation,1,D005996,nitroglycerin,D009203,myocardial infarction,"Current guidelines call for nitroglycerin to be prescribed in patients with coronary heart disease, including those with stable angina and those recovering from acute coronary syndromes and myocardial infarction.",19887953_1,19887953_D005996_D009203,,
770959446,false,true,5,2015-08-15T00:37:00,,No Relation,1,D005996,nitroglycerin,D060050,stable angina,"Current guidelines call for nitroglycerin to be prescribed in patients with coronary heart disease, including those with stable angina and those recovering from acute coronary syndromes and myocardial infarction.",19887953_1,19887953_D005996_D060050,,
770959447,false,true,5,2015-08-15T01:09:00,,No Relation,1,D005996,nitroglycerin,D003327,coronary heart disease,"Current guidelines call for nitroglycerin to be prescribed in patients with coronary heart disease, including those with stable angina and those recovering from acute coronary syndromes and myocardial infarction.",19887953_1,19887953_D005996_D003327,,
770959448,false,true,5,2015-08-14T21:29:00,,No Relation,1,D005996,nitroglycerin,D017202,myocardial ischemia,"These patients are at risk for coronary events, and nitroglycerin may be required to treat acute symptoms of myocardial ischemia.",19887953_2,19887953_D005996_D017202,,
770959449,false,true,5,2015-08-15T00:16:00,,No Relation,1,D005996,nitroglycerin,D003327,coronary heart disease,The prescription of nitroglycerin is frequently omitted in patients with coronary heart disease.,19887953_11,19887953_D005996_D003327,,
770959450,false,true,5,2015-08-14T21:12:00,,No Relation,0.799,D005947,glucose,D009062,oral glucose tolerance,"Fasting glucose, insulin, lipid, and lipoprotein profiles; oral glucose tolerance; insulin secretion and insulin-mediated glucose disposal by hyperglycemic clamp; and body composition by dual energy X-ray absorptiometry were determined before and after lopinavir/ritonavir administration.",19890203_5,19890203_D005947_D009062,,
770959451,false,true,5,2015-08-15T00:47:00,,No Relation,1,C558899,lopinavir/ritonavir,D007003,Fasting glucose,"Fasting glucose, insulin, lipid, and lipoprotein profiles; oral glucose tolerance; insulin secretion and insulin-mediated glucose disposal by hyperglycemic clamp; and body composition by dual energy X-ray absorptiometry were determined before and after lopinavir/ritonavir administration.",19890203_5,19890203_C558899_D007003,,
770959452,false,true,5,2015-08-14T23:32:00,,No Relation,0.794,D005947,glucose,D007003,Fasting glucose,"Fasting glucose, insulin, lipid, and lipoprotein profiles; oral glucose tolerance; insulin secretion and insulin-mediated glucose disposal by hyperglycemic clamp; and body composition by dual energy X-ray absorptiometry were determined before and after lopinavir/ritonavir administration.",19890203_5,19890203_D005947_D007003,,
770959453,false,true,5,2015-08-15T02:33:00,,No Relation,0.7892,C558899,lopinavir/ritonavir,D009062,oral glucose tolerance,"Fasting glucose, insulin, lipid, and lipoprotein profiles; oral glucose tolerance; insulin secretion and insulin-mediated glucose disposal by hyperglycemic clamp; and body composition by dual energy X-ray absorptiometry were determined before and after lopinavir/ritonavir administration.",19890203_5,19890203_C558899_D009062,,
770959454,false,true,5,2015-08-14T22:35:00,,No Relation,1,D005947,glucose,D009062,oral glucose tolerance,"There was no change in first-phase insulin secretion (2.82 +/- 0.30 versus 2.71 +/- 0.31 nmol/l; P = 0.60), as well as fasting insulin and glucose levels, oral glucose tolerance, or insulin-mediated glucose disposal after 4 weeks administration of lopinavir/ritonavir.",19890203_6,19890203_D005947_D009062,,
770959455,false,true,5,2015-08-14T21:08:00,,No Relation,0.7928,D019438,ritonavir,D009062,oral glucose tolerance,"There was no change in first-phase insulin secretion (2.82 +/- 0.30 versus 2.71 +/- 0.31 nmol/l; P = 0.60), as well as fasting insulin and glucose levels, oral glucose tolerance, or insulin-mediated glucose disposal after 4 weeks administration of lopinavir/ritonavir.",19890203_6,19890203_D019438_D009062,,
770959456,false,true,5,2015-08-14T22:00:00,,No Relation,1,D061466,lopinavir,D009062,oral glucose tolerance,"There was no change in first-phase insulin secretion (2.82 +/- 0.30 versus 2.71 +/- 0.31 nmol/l; P = 0.60), as well as fasting insulin and glucose levels, oral glucose tolerance, or insulin-mediated glucose disposal after 4 weeks administration of lopinavir/ritonavir.",19890203_6,19890203_D061466_D009062,,
770959457,false,true,5,2015-08-14T21:18:00,,No Relation,0.808,D008712,methicillin,D018461,tissue infections,The role of antimicrobial therapy for treatment of uncomplicated skin and soft tissue infections from community-acquired methicillin-resistant Staphylococcus aureus in children.,19949756_0,19949756_D008712_D018461,,
770959458,false,true,5,2015-08-14T21:37:00,,No Relation,0.6208,D008712,methicillin,D007239,infections,Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections in skin and soft tissues are increasing in children in Taiwan.,19949756_1,19949756_D008712_D007239,,
770959459,false,true,5,2015-08-15T02:30:00,,No Relation,1,C078284,Panton-Valentine leukocidin,D018461,tissue infections,"This study investigated the outcomes of therapy with or without appropriate antibiotics among children with CA-MRSA skin and soft tissue infections (SSTIs), and analyzed the outcomes of management among children with Panton-Valentine leukocidin (PVL)-positive strains and PVL-negative strains.",19949756_2,19949756_C078284_D018461,,
770959460,false,true,5,2015-08-15T01:20:00,,No Relation,1,D016210,methacholine,D001249,asthma,"Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma.",20004781_0,20004781_D016210_D001249,,
770959461,false,true,5,2015-08-14T22:27:00,,No Relation,1,D016210,methacholine,D001249,asthma,To examine the bronchoprotective effects of single doses of BI 1744 against methacholine provocation in subjects with mild asthma.,20004781_3,20004781_D016210_D001249,,
770959462,false,true,5,2015-08-14T22:11:00,,No Relation,0.7976,D005472,5-FU,D013274,gastric cancer,HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.,20020496_0,20020496_D005472_D013274,,
770959463,false,true,5,2015-08-14T21:42:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D013274,gastric cancer,"Among several chemotherapeutic agents, 5-fluorouracil (5-FU) has been widely used as a key drug in adjuvant chemotherapy for gastric cancer.",20020496_1,20020496_D005472_D013274,,
770959464,false,true,5,2015-08-14T21:42:00,,No Relation,1,D005472,5-FU,D013274,gastric cancer,We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU.,20020496_5,20020496_D005472_D013274,,
770959465,false,true,5,2015-08-14T21:53:00,,No Relation,0.7887,D005472,5-FU,D013274,gastric cancer,"In conclusion, the current study confirmed, for the first time that HIF-1alpha expression is an independent risk factor for relapse in high-risk gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.",20020496_10,20020496_D005472_D013274,,
770959466,false,true,5,2015-08-15T00:27:00,,No Relation,1,D002945,Cisplatin,D009369,tumours,Cisplatin remains a principal chemotherapy agent in the treatment of many solid tumours.,20084783_1,20084783_D002945_D009369,,
770959467,false,true,5,2015-08-14T21:47:00,,No Relation,0.8045,C110904,capecitabine,D009369,rectal cancer,Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.,20106720_0,20106720_C110904_D009369,,
770959468,false,true,5,2015-08-15T00:04:00,,No Relation,1,C030110,oxaliplatin,D009369,rectal cancer,Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.,20106720_0,20106720_C030110_D009369,,
770959469,false,true,5,2015-08-14T21:43:00,,No Relation,1,D003676,Deferoxamine,D012497,beta-thalassemic,"Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.",20113293_0,20113293_D003676_D012497,,
770959470,false,true,5,2015-08-15T02:00:00,,No Relation,1,D003676,DFO/deferoxamine,D012497,beta-thalassemic,"We examined 21 beta-thalassemic patients undergoing deferoxamine (DFO) (9/21) or combined therapy [DFO and deferiprone (L1), 12/21] with two abdominal MRI studies using T1-w/Pd-w/T2*-wGRE and T1-wTSE sequences.",20113293_2,20113293_D003676_D012497,,
770959471,false,true,5,2015-08-14T21:09:00,,No Relation,0.801,C044919,deferiprone,D012497,beta-thalassemic,"We examined 21 beta-thalassemic patients undergoing deferoxamine (DFO) (9/21) or combined therapy [DFO and deferiprone (L1), 12/21] with two abdominal MRI studies using T1-w/Pd-w/T2*-wGRE and T1-wTSE sequences.",20113293_2,20113293_C044919_D012497,,
770959472,false,true,5,2015-08-14T22:00:00,,No Relation,1,D003676,DFO,D012497,beta-thalassemic,"Combined therapy is more effective than DFO for removing and preventing liver, spleen and bone marrow iron accumulation in beta-thalassemic patients.",20113293_7,20113293_D003676_D012497,,
770959473,false,true,5,2015-08-15T01:47:00,,No Relation,0.8135,D007501,iron,D012497,beta-thalassemic,"Combined therapy is more effective than DFO for removing and preventing liver, spleen and bone marrow iron accumulation in beta-thalassemic patients.",20113293_7,20113293_D007501_D012497,,
770959474,false,true,5,2015-08-15T02:17:00,,No Relation,1,D003374,coumarins,D006470,alveolar hemorrhage,"We hypothesized that in patients treated with coumarins, alveolar hemorrhage is associated with vitamin K epoxide reductase (VKORC1) and cytochrome P450 (CYP) 2C9 (CYP2C9) variant alleles.",20121287_2,20121287_D003374_D006470,,
770959475,false,true,5,2015-08-14T23:49:00,,Direct,0.8047,C016186,vitamin K epoxide,D006470,alveolar hemorrhage,"We hypothesized that in patients treated with coumarins, alveolar hemorrhage is associated with vitamin K epoxide reductase (VKORC1) and cytochrome P450 (CYP) 2C9 (CYP2C9) variant alleles.",20121287_2,20121287_C016186_D006470,,
770959476,false,true,5,2015-08-15T01:20:00,,No Relation,1,D004298,Dopamine,D012893,sleep disturbances,Dopamine receptor agonists and sleep disturbances in Parkinson's disease.,20123546_0,20123546_D004298_D012893,,
770959477,false,true,5,2015-08-14T22:29:00,,No Relation,1,D004298,Dopamine,D010300,Parkinson's disease,Dopamine receptor agonists and sleep disturbances in Parkinson's disease.,20123546_0,20123546_D004298_D010300,,
770959478,false,true,5,2015-08-14T21:54:00,,No Relation,1,C046649,ropinirole,D010300,Parkinson's disease/PD,"Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.",20123546_1,20123546_C046649_D010300,,
770959479,false,true,5,2015-08-15T01:34:00,,No Relation,0.8088,C061333,pramipexole,D010300,Parkinson's disease/PD,"Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.",20123546_1,20123546_C061333_D010300,,
770959480,false,true,5,2015-08-15T02:13:00,,No Relation,1,C047508,rotigotine,D010300,Parkinson's disease/PD,"Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.",20123546_1,20123546_C047508_D010300,,
770959481,false,true,5,2015-08-15T00:31:00,,No Relation,1,D004298,dopamine,D010300,Parkinson's disease/PD,"Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.",20123546_1,20123546_D004298_D010300,,
770959482,false,true,5,2015-08-15T00:34:00,,No Relation,0.8095,D001058,apomorphine,D010300,Parkinson's disease/PD,"Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.",20123546_1,20123546_D001058_D010300,,
770959483,false,true,5,2015-08-14T21:10:00,,No Relation,0.5912,D004298,dopamine,D010300,PD,"In this review, we discuss how dopamine receptor agonists can both ameliorate and aggravate the sleep problems in PD, a key non-motor symptom of this disease.",20123546_2,20123546_D004298_D010300,,
770959484,false,true,5,2015-08-15T00:21:00,,No Relation,1,D004999,amifostine,D013964,thyroid cancer,Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.,20130857_0,20130857_D004999_D013964,,
770959485,false,true,5,2015-08-15T01:58:00,,No Relation,1,D007455,iodine,D013964,thyroid cancer,Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.,20130857_0,20130857_D007455_D013964,,
770959486,false,true,5,2015-08-14T21:32:00,,No Relation,0.8072,D004999,amifostine,D013964,thyroid cancer,To assess the effects of amifostine on salivary glands in radioactive iodine-treated differentiated thyroid cancer.,20130857_1,20130857_D004999_D013964,,
770959487,false,true,5,2015-08-14T21:22:00,,No Relation,1,D007455,iodine,D013964,thyroid cancer,To assess the effects of amifostine on salivary glands in radioactive iodine-treated differentiated thyroid cancer.,20130857_1,20130857_D007455_D013964,,
770959488,false,true,5,2015-08-15T02:33:00,,No Relation,1,D004999,amifostine,D014987,xerostomia,"There were no statistically significant differences between the effects of amifostine and acid-stimulating agents on the incidence of xerostomia (RR 0.24, 95% CI 0.01 to 9.52), the decrease of scintigraphically measured uptake of (99m)Tc by the parotid (RR 0.30, 95% CI -2.28 to 2.88) or submandibular glands (RR 1.90, 95% CI -1.46 to 5.26) at 12 months, or the reduction in blood pressure (RR 5.00, 95% CI 0.25 to 99.16).",20130857_5,20130857_D004999_D014987,,
770959489,false,true,5,2015-08-15T01:33:00,,No Relation,1,D004999,amifostine,D013964,thyroid cancer,The results of two randomized controlled clinical trials suggest that amifostine has no significant radioprotective effects on salivary glands in radioactive iodine treatment of differentiated thyroid cancer.,20130857_7,20130857_D004999_D013964,,
770959490,false,true,5,2015-08-15T02:21:00,,No Relation,1,D007455,iodine,D013964,thyroid cancer,The results of two randomized controlled clinical trials suggest that amifostine has no significant radioprotective effects on salivary glands in radioactive iodine treatment of differentiated thyroid cancer.,20130857_7,20130857_D007455_D013964,,
770959491,false,true,5,2015-08-14T22:04:00,,No Relation,1,C495058,pegaptanib,D008269,diabetic macular edema,"For diabetic macular edema, phase II trials of intravitreal pegaptanib and intravitreal ranibizumab have shown short-term benefit in visual acuity.",20174816_4,20174816_C495058_D008269,,
770959492,false,true,5,2015-08-14T21:22:00,,No Relation,1,D005947,glucose,D007249,inflammation,"The aim was to investigate the effects of daily coffee consumption on biomarkers of coffee intake, subclinical inflammation, oxidative stress, glucose, and lipid metabolism.",20181814_3,20181814_D005947_D007249,,
770959493,false,true,5,2015-08-15T01:52:00,,No Relation,1,D002784,cholesterol,D007249,inflammation,"Coffee consumption appears to have beneficial effects on subclinical inflammation and HDL cholesterol, whereas no changes in glucose metabolism were found in our study.",20181814_10,20181814_D002784_D007249,,
770959494,false,true,5,2015-08-15T02:12:00,,No Relation,1,D005947,glucose,D007249,inflammation,"Coffee consumption appears to have beneficial effects on subclinical inflammation and HDL cholesterol, whereas no changes in glucose metabolism were found in our study.",20181814_10,20181814_D005947_D007249,,
770959495,false,true,5,2015-08-14T21:12:00,,No Relation,1,D010984,platinum,D006258,head and neck cancer,"Survival gains were achieved in head and neck cancer patients treated with a multidisciplinary approach, including platinum-based concurrent chemoradiation, with a substantial increase in toxicity.",20186057_1,20186057_D010984_D006258,,
770959496,false,true,5,2015-08-15T01:30:00,,No Relation,0.5857,D010984,platinum,D064420,toxicity,"Survival gains were achieved in head and neck cancer patients treated with a multidisciplinary approach, including platinum-based concurrent chemoradiation, with a substantial increase in toxicity.",20186057_1,20186057_D010984_D064420,,
770959497,false,true,5,2015-08-15T00:58:00,,No Relation,1,D004999,Amifostine,D014987,xerostomia,"Amifostine, as an acute and late xerostomia-preventive agent, may be considered in patients undergoing fractionated radiation therapy alone.",20186057_4,20186057_D004999_D014987,,
770959498,false,true,5,2015-08-15T02:02:00,,No Relation,1,D013110,sphingosine,D006323,growth arrest,"These inhibitors display K(I) values in the submicromolar range for both sphingosine kinases and, in cultured vascular smooth muscle cells, decrease S1P levels and initiate growth arrest.",20205392_4,20205392_D013110_D006323,,
770959499,false,true,5,2015-08-15T00:17:00,,No Relation,1,D002857,chromium,D007938,leukemia,Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays.,20230219_0,20230219_D002857_D007938,,
770959500,false,true,5,2015-08-15T02:12:00,,No Relation,1,D002857,chromium,D004487,cytotoxicity,Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays.,20230219_0,20230219_D002857_D004487,,
770959501,false,true,5,2015-08-15T01:39:00,,No Relation,1,D002857,chromium,D004487,cytotoxicity,"While the chromium-release assay is the most common method for assessing cytotoxicity of immune effectors, and flow cytometry is increasingly used, the relationship of either assay to clonogenic readouts remains unknown.",20230219_3,20230219_D002857_D004487,,
770959502,false,true,5,2015-08-15T01:47:00,,No Relation,0.5894,D003561,cytarabine,D004487,Cytotoxicity,"Cytotoxicity of NK-92, daunorubicin and cytarabine against KG1 was measured using the chromium-release assay, flow cytometry and clonogenic assays.",20230219_6,20230219_D003561_D004487,,
770959503,false,true,5,2015-08-14T21:57:00,,Direct,0.6205,D003630,daunorubicin,D004487,Cytotoxicity,"Cytotoxicity of NK-92, daunorubicin and cytarabine against KG1 was measured using the chromium-release assay, flow cytometry and clonogenic assays.",20230219_6,20230219_D003630_D004487,,
770959504,false,true,5,2015-08-15T00:50:00,,No Relation,1,D002857,chromium,D004487,Cytotoxicity,"Cytotoxicity of NK-92, daunorubicin and cytarabine against KG1 was measured using the chromium-release assay, flow cytometry and clonogenic assays.",20230219_6,20230219_D002857_D004487,,
770959505,false,true,5,2015-08-15T02:02:00,,No Relation,1,D002857,chromium,D004487,cytotoxicity,The cumulative flow cytotoxicity assay was more sensitive than the chromium-release assay in detecting target cell killing.,20230219_9,20230219_D002857_D004487,,
770959506,false,true,5,2015-08-14T23:33:00,,No Relation,1,D018943,anthracycline,D015473,acute promyelocytic leukaemia,Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.,20230404_0,20230404_D018943_D015473,,
770959507,false,true,5,2015-08-14T21:19:00,,Direct,1,D018943,anthracyclines,D066126,cardiotoxicity,"Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity.",20230404_1,20230404_D018943_D066126,,
770959508,false,true,5,2015-08-15T01:06:00,,No Relation,1,D018943,anthracyclines,D015473,Acute promyelocytic leukaemia/APL,"Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity.",20230404_1,20230404_D018943_D015473,,
770959509,false,true,5,2015-08-14T21:13:00,,No Relation,1,D018943,anthracycline,D015473,APL,"Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).",20230404_2,20230404_D018943_D015473,,
770959510,false,true,5,2015-08-15T02:13:00,,No Relation,1,D003561,cytarabine,D015473,APL,"Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).",20230404_2,20230404_D003561_D015473,,
770959511,false,true,5,2015-08-14T21:36:00,,No Relation,1,D003561,cytarabine,C580075,acute myeloid leukaemia,"Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).",20230404_2,20230404_D003561_C580075,,
770959512,false,true,5,2015-08-14T23:18:00,,No Relation,1,D018943,anthracycline,C580075,acute myeloid leukaemia,"Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).",20230404_2,20230404_D018943_C580075,,
770959513,false,true,5,2015-08-14T23:36:00,,No Relation,1,C006632,arsenic trioxide,D015473,APL,"Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long-term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients).",20230404_10,20230404_C006632_D015473,,
770959514,false,true,5,2015-08-15T02:17:00,,No Relation,1,D018943,anthracycline,D066126,cardiotoxicity,"Our results demonstrate that - combined with ATRA - a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long-term sequelae, such as cardiotoxicity in APL patients.",20230404_11,20230404_D018943_D066126,,
770959515,false,true,5,2015-08-14T21:51:00,,No Relation,1,D018943,anthracycline,D015473,APL,"Our results demonstrate that - combined with ATRA - a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long-term sequelae, such as cardiotoxicity in APL patients.",20230404_11,20230404_D018943_D015473,,
770959516,false,true,5,2015-08-14T22:48:00,,No Relation,1,C048159,monostearin,C531854,oleic acid/OA,Anionic lipid nanoparticles consisting of monostearin (MS) and different content of oleic acid (OA) were prepared.,20230883_2,20230883_C048159_C531854,,
770959517,false,true,5,2015-08-14T21:22:00,,No Relation,1,D019301,oleic acid,C531854,oleic acid/OA,Anionic lipid nanoparticles consisting of monostearin (MS) and different content of oleic acid (OA) were prepared.,20230883_2,20230883_D019301_C531854,,
770959518,false,true,5,2015-08-14T22:44:00,,No Relation,1,D000638,amiodarone,D001281,atrial fibrillation,"A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.",20384650_0,20384650_D000638_D001281,,
770959519,false,true,5,2015-08-14T22:26:00,,No Relation,1,C118667,dronedarone,D001281,atrial fibrillation,"A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.",20384650_0,20384650_C118667_D001281,,
770959520,false,true,5,2015-08-14T21:10:00,,No Relation,1,D000638,amiodarone,D001281,atrial fibrillation/AF,We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF).,20384650_1,20384650_D000638_D001281,,
770959521,false,true,5,2015-08-14T22:11:00,,No Relation,1,C118667,dronedarone,D001281,atrial fibrillation/AF,We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF).,20384650_1,20384650_C118667_D001281,,
770959522,false,true,5,2015-08-15T01:52:00,,No Relation,1,D000638,amiodarone,D001281,AF,"The primary composite endpoint was 75.1 and 58.8% with dronedarone and amiodarone, respectively, at 12 months (hazard ratio [HR] 1.59; 95% confidence interval [CI] 1.28-1.98; P < 0.0001), mainly driven by AF recurrence with dronedarone compared with amiodarone (63.5 vs 42.0%).",20384650_6,20384650_D000638_D001281,,
770959523,false,true,5,2015-08-15T00:18:00,,No Relation,0.6238,C118667,dronedarone,D001281,AF,"The primary composite endpoint was 75.1 and 58.8% with dronedarone and amiodarone, respectively, at 12 months (hazard ratio [HR] 1.59; 95% confidence interval [CI] 1.28-1.98; P < 0.0001), mainly driven by AF recurrence with dronedarone compared with amiodarone (63.5 vs 42.0%).",20384650_6,20384650_C118667_D001281,,
770959524,false,true,5,2015-08-15T00:38:00,,No Relation,1,D000638,amiodarone,D001281,AF,"AF recurrence after successful cardioversion was 36.5 and 24.3% with dronedarone and amiodarone, respectively.",20384650_7,20384650_D000638_D001281,,
770959525,false,true,5,2015-08-15T00:50:00,,No Relation,1,C118667,dronedarone,D001281,AF,"AF recurrence after successful cardioversion was 36.5 and 24.3% with dronedarone and amiodarone, respectively.",20384650_7,20384650_C118667_D001281,,
770959526,false,true,5,2015-08-14T23:42:00,,No Relation,1,D000638,amiodarone,D001281,AF,"In this short-term study, dronedarone was less effective than amiodarone in decreasing AF recurrence, but had a better safety profile, specifically with regard to thyroid and neurologic events and a lack of interaction with oral anticoagulants.",20384650_10,20384650_D000638_D001281,,
770959527,false,true,5,2015-08-14T23:34:00,,No Relation,1,C118667,dronedarone,D001281,AF,"In this short-term study, dronedarone was less effective than amiodarone in decreasing AF recurrence, but had a better safety profile, specifically with regard to thyroid and neurologic events and a lack of interaction with oral anticoagulants.",20384650_10,20384650_C118667_D001281,,
770959528,false,true,5,2015-08-15T02:34:00,,No Relation,0.8156,D006493,heparin,D013923,thromboembolic,We retrospectively evaluated the effects of heparin use on thromboembolic and bleeding complications after implantation of the HeartMate II left ventricular assist device (LVAD).,20400335_2,20400335_D006493_D013923,,
770959529,false,true,5,2015-08-14T22:20:00,,No Relation,0.8164,D006493,heparin,D006470,bleeding,We retrospectively evaluated the effects of heparin use on thromboembolic and bleeding complications after implantation of the HeartMate II left ventricular assist device (LVAD).,20400335_2,20400335_D006493_D006470,,
770959530,false,true,5,2015-08-14T22:09:00,,No Relation,1,D001241,aspirin,D057049,thrombotic,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D001241_D057049,,
770959531,false,true,5,2015-08-15T02:18:00,,No Relation,0.8121,D014859,warfarin,D006470,bleeding,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D014859_D006470,,
770959532,false,true,5,2015-08-15T01:16:00,,No Relation,0.7971,D001241,aspirin,D006470,bleeding,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D001241_D006470,,
770959533,false,true,5,2015-08-14T21:33:00,,No Relation,1,D001241,aspirin,D013923,thromboembolic,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D001241_D013923,,
770959534,false,true,5,2015-08-15T00:12:00,,No Relation,1,D014859,warfarin,D057049,thrombotic,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D014859_D057049,,
770959535,false,true,5,2015-08-14T21:40:00,,No Relation,0.7956,D014859,warfarin,D013923,thromboembolic,"In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced.",20400335_9,20400335_D014859_D013923,,
770959536,false,true,5,2015-08-14T22:17:00,,No Relation,1,D010100,oxygen,D014474,loss of consciousness,On tracking the course of cerebral oxygen saturation and pilot performance during gravity-induced loss of consciousness.,20415154_0,20415154_D010100_D014474,,
770959537,false,true,5,2015-08-14T23:12:00,,No Relation,1,D010100,oxygen,D014474,loss of consciousness,The aim of this study was to track the course of cerebral tissue oxygen saturation (rSO2) and pilot performance during an episode of gravity-induced loss of consciousness (GLOC).,20415154_1,20415154_D010100_D014474,,
770959538,false,true,5,2015-08-15T01:18:00,,No Relation,1,D003276,oral contraceptives,D010146,endogenous pain,Influence of oral contraceptives on endogenous pain control in healthy women.,20419369_0,20419369_D003276_D010146,,
770959539,false,true,5,2015-08-14T22:10:00,,No Relation,1,D010100,oxygen,D003929,diabetes,Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes.,20427683_0,20427683_D010100_D003929,,
770959540,false,true,5,2015-08-14T22:12:00,,No Relation,1,D010100,oxygen,D017719,diabetic foot ulcers,The aim of this study was to evaluate the effect of hyperbaric oxygen therapy (HBOT) in the management of chronic diabetic foot ulcers.,20427683_2,20427683_D010100_D017719,,
770959541,false,true,5,2015-08-15T01:49:00,,No Relation,0.8341,D004298,dopamine,D013981,tic disorders,"While alpha-2 agonists and dopamine antagonists constitute the mainstay of pharmacological agents for tic disorders, advances in neurobiology and psychopharmacology have discovered newer avenues for treatment of tic disorders.",20459362_4,20459362_D004298_D013981,,
770959542,false,true,5,2015-08-14T23:43:00,,No Relation,1,D018698,glutamate,D013981,tic disorders,"Apart from reviewing evidence based literature and recent updates on alpha-2 agonists and dopamine antagonists in treating tic disorders, the review also includes novel treatment approaches such as glutamate modulators, nicotinic agents, antiandrogens and botulinum injection.",20459362_5,20459362_D018698_D013981,,
770959543,false,true,5,2015-08-15T01:38:00,,No Relation,1,D004298,dopamine,D013981,tic disorders,"Apart from reviewing evidence based literature and recent updates on alpha-2 agonists and dopamine antagonists in treating tic disorders, the review also includes novel treatment approaches such as glutamate modulators, nicotinic agents, antiandrogens and botulinum injection.",20459362_5,20459362_D004298_D013981,,
770959544,false,true,5,2015-08-15T02:10:00,,No Relation,1,D004298,dopamine,D013981,tic disorders,"In addition to psychosocial interventions, alpha-2 agonists and dopamine antagonists constitute the mainstay of treatment approaches for treating tic disorders.",20459362_8,20459362_D004298_D013981,,
770959545,false,true,5,2015-08-15T00:09:00,,No Relation,1,D015363,quinolones,D004927,Escherichia,Escherichia coli resistance to quinolones at a comprehensive cancer center.,20471765_0,20471765_D015363_D004927,,
770959546,false,true,5,2015-08-14T21:35:00,,No Relation,1,D015363,quinolones,D009369,cancer,Escherichia coli resistance to quinolones at a comprehensive cancer center.,20471765_0,20471765_D015363_D009369,,
770959547,false,true,5,2015-08-15T01:52:00,,No Relation,1,C059500,Meropenem,D004927,Escherichia,"As part of Meropenem Yearly Susceptibility Test Information Collection/USA Surveillance Programme, we monitored the occurrence of quinolone resistance in Escherichia coli over a 10-year period.",20471765_1,20471765_C059500_D004927,,
770959548,false,true,5,2015-08-14T22:17:00,,No Relation,0.815,C400082,Bortezomib,C562729,esophageal squamous cell carcinoma,Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.,20515944_0,20515944_C400082_C562729,,
770959549,false,true,5,2015-08-15T02:12:00,,No Relation,0.8367,C400082,bortezomib/Velcade,C562729,ESCC,We investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with the proteasome inhibitor bortezomib (Velcade) on human ESCC cell lines.,20515944_2,20515944_C400082_C562729,,
770959550,false,true,5,2015-08-15T00:00:00,,No Relation,1,C400082,bortezomib/Velcade,D009369,tumor,We investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with the proteasome inhibitor bortezomib (Velcade) on human ESCC cell lines.,20515944_2,20515944_C400082_D009369,,
770959551,false,true,5,2015-08-14T23:24:00,,No Relation,1,C400082,bortezomib/Velcade,D009336,necrosis,We investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with the proteasome inhibitor bortezomib (Velcade) on human ESCC cell lines.,20515944_2,20515944_C400082_D009336,,
770959552,false,true,5,2015-08-14T21:48:00,,No Relation,1,C400082,Bortezomib,C562729,ESCC,"Bortezomib enhanced the susceptibility to TRAIL in 12 of the 15 ESCC cell lines tested, although most showed low sensitivity to TRAIL as a single agent.",20515944_3,20515944_C400082_C562729,,
770959553,false,true,5,2015-08-14T23:26:00,,No Relation,0.8098,C400082,bortezomib,D003643,death,"However, the increased cell surface expression of death receptors observed on bortezomib treatment did not seem to be crucial for this effect.",20515944_6,20515944_C400082_D003643,,
770959554,false,true,5,2015-08-14T22:26:00,,No Relation,1,C400082,bortezomib,C562729,ESCC,"For some ESCC, bortezomib treatment resulted in a more efficient recruitment of caspase-8 and the Fas-associated death domain to the death-inducing signaling complex.",20515944_7,20515944_C400082_C562729,,
770959555,false,true,5,2015-08-15T00:36:00,,No Relation,1,C400082,bortezomib,D003643,death,"For some ESCC, bortezomib treatment resulted in a more efficient recruitment of caspase-8 and the Fas-associated death domain to the death-inducing signaling complex.",20515944_7,20515944_C400082_D003643,,
770959556,false,true,5,2015-08-14T22:21:00,,No Relation,1,C400082,bortezomib,C562729,ESCC,"For other ESCC, the crucial effect of bortezomib treatment seemed to be increased signaling via the intrinsic apoptotic pathway on subsequent exposure to TRAIL.",20515944_9,20515944_C400082_C562729,,
770959557,false,true,5,2015-08-15T00:05:00,,No Relation,0.8213,C400082,bortezomib,C562729,ESCC,"Thus, bortezomib could sensitize ESCC to TRAIL apoptosis by multiple molecular mechanisms of action.",20515944_10,20515944_C400082_C562729,,
770959558,false,true,5,2015-08-15T01:25:00,,No Relation,1,C400082,bortezomib,C562729,ESCC,"Therefore, the combination of bortezomib and TRAIL might be a novel therapeutic strategy for ESCC patients who fail to respond to standard chemoradiotherapy that predominantly targets the mitochondrial apoptotic pathway.",20515944_11,20515944_C400082_C562729,,
770959559,false,true,5,2015-08-15T02:26:00,,No Relation,0.5998,D012964,sodium,D001145,cardiac arrhythmias,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D001145,,
770959560,false,true,5,2015-08-14T21:51:00,,No Relation,0.5977,D012964,sodium,D014839,vomiting,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D014839,,
770959561,false,true,5,2015-08-14T21:49:00,,No Relation,0.8097,D002118,calcium,D012128,respiratory distress,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D012128,,
770959562,false,true,5,2015-08-14T23:30:00,,No Relation,0.8194,D002118,calcium,D011041,poisoning,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D011041,,
770959563,false,true,5,2015-08-15T01:54:00,,No Relation,0.6094,D012964,sodium,D018476,coma,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D018476,,
770959564,false,true,5,2015-08-15T02:12:00,,No Relation,0.6281,D012964,sodium,D011041,poisoning,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D011041,,
770959565,false,true,5,2015-08-15T00:21:00,,No Relation,0.6036,D002118,calcium,D015746,abdominal pain,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D015746,,
770959566,false,true,5,2015-08-15T02:30:00,,Direct,1,D012964,sodium,D015746,abdominal pain,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D015746,,
770959567,false,true,5,2015-08-15T00:30:00,,No Relation,0.8067,D002118,calcium,D001145,cardiac arrhythmias,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D001145,,
770959568,false,true,5,2015-08-15T02:11:00,,No Relation,0.809,D012964,sodium,D012640,seizures,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D012640,,
770959569,false,true,5,2015-08-14T22:44:00,,No Relation,0.7964,D002118,calcium,D003643,death,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D003643,,
770959570,false,true,5,2015-08-14T21:52:00,,No Relation,1,D002118,calcium,D014839,vomiting,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D014839,,
770959571,false,true,5,2015-08-14T21:41:00,,No Relation,0.599,D002118,calcium,D018476,coma,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D018476,,
770959572,false,true,5,2015-08-15T02:11:00,,No Relation,0.8121,D012964,sodium,D009325,nausea,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D009325,,
770959573,false,true,5,2015-08-15T01:15:00,,No Relation,1,D012964,sodium,D012128,respiratory distress,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D012128,,
770959574,false,true,5,2015-08-14T22:24:00,,No Relation,0.6111,D002118,calcium,D012640,seizures,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D012640,,
770959575,false,true,5,2015-08-15T01:03:00,,No Relation,1,D012964,sodium,D003643,death,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D012964_D003643,,
770959576,false,true,5,2015-08-14T21:43:00,,No Relation,0.4051,D002118,calcium,D009325,nausea,"Taxine A and taxine B, the toxic alkaloids of Taxus, block cardiac sodium and calcium channels causing nausea, vomiting, abdominal pain, cardiac arrhythmias, respiratory distress, coma, seizures, and death in yew poisoning.",20528617_2,20528617_D002118_D009325,,
770959577,false,true,5,2015-08-14T22:38:00,,No Relation,1,D017311,amlodipine,D020521,stroke,Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk.,20532438_0,20532438_D017311_D020521,,
770959578,false,true,5,2015-08-15T00:08:00,,No Relation,1,D020913,perindopril,D020521,stroke,Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk.,20532438_0,20532438_D020913_D020521,,
770959579,false,true,5,2015-08-14T21:48:00,,No Relation,0.5989,D017311,amlodipine,D020521,effective stroke reduction,"Lower within-individual visit-to-visit variability in blood pressure readings in the amlodipine/perindopril combination treatment arm of the ASCOT study has been shown to account for the more effective stroke reduction rate with this combination compared to atenolol and diuretic-based therapies, despite overall similar blood pressure lowering.",20532438_1,20532438_D017311_D020521,,
770959580,false,true,5,2015-08-14T23:43:00,,No Relation,0.7809,D001262,atenolol,D020521,effective stroke reduction,"Lower within-individual visit-to-visit variability in blood pressure readings in the amlodipine/perindopril combination treatment arm of the ASCOT study has been shown to account for the more effective stroke reduction rate with this combination compared to atenolol and diuretic-based therapies, despite overall similar blood pressure lowering.",20532438_1,20532438_D001262_D020521,,
770959581,false,true,5,2015-08-14T22:27:00,,Direct,0.8232,D020913,perindopril,D020521,effective stroke reduction,"Lower within-individual visit-to-visit variability in blood pressure readings in the amlodipine/perindopril combination treatment arm of the ASCOT study has been shown to account for the more effective stroke reduction rate with this combination compared to atenolol and diuretic-based therapies, despite overall similar blood pressure lowering.",20532438_1,20532438_D020913_D020521,,
770959582,false,true,5,2015-08-15T00:36:00,,No Relation,1,C026455,Thymalfasin,D006509,hepatitis B,Thymalfasin in the treatment of hepatitis B and C. Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action.,20536462_0,20536462_C026455_D006509,,
770959583,false,true,5,2015-08-15T01:33:00,,No Relation,1,C026455,thymalfasin,D019694,chronic hepatitis B,"It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate.",20536462_2,20536462_C026455_D019694,,
770959584,false,true,5,2015-08-14T22:25:00,,No Relation,1,D009705,nucleoside,D019694,chronic hepatitis B,"It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate.",20536462_2,20536462_D009705_D019694,,
770959585,false,true,5,2015-08-14T21:50:00,,No Relation,1,D012254,ribavirin,D019698,chronic hepatitis C,"Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) nave and nonresponder patients.",20536462_3,20536462_D012254_D019698,,
770959586,false,true,5,2015-08-15T02:15:00,,No Relation,1,C026455,thymalfasin,D019698,chronic hepatitis C,"Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) nave and nonresponder patients.",20536462_3,20536462_C026455_D019698,,
770959587,false,true,5,2015-08-14T21:48:00,,No Relation,0.7912,D012254,ribavirin,D006526,hepatitis C virus/HCV,"Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) nave and nonresponder patients.",20536462_3,20536462_D012254_D006526,,
770959588,false,true,5,2015-08-14T22:50:00,,No Relation,1,C026455,thymalfasin,D006526,hepatitis C virus/HCV,"Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) nave and nonresponder patients.",20536462_3,20536462_C026455_D006526,,
770959589,false,true,5,2015-08-14T23:52:00,,No Relation,1,C026455,thymalfasin,D006526,HCV,"However, a large phase-III randomized study conducted in Europe in HCV patients nonresponder to Peg-interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate.",20536462_4,20536462_C026455_D006526,,
770959590,false,true,5,2015-08-15T00:32:00,"HCV stands for Hepatitis C virus, therefore it's not a disease, but a virus",No Relation,1,D012254,ribavirin,D006526,HCV,"However, a large phase-III randomized study conducted in Europe in HCV patients nonresponder to Peg-interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate.",20536462_4,20536462_D012254_D006526,,
770959591,false,true,5,2015-08-14T23:28:00,,No Relation,1,C026455,thymalfasin,D019694,chronic hepatitis B,"In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C.",20536462_5,20536462_C026455_D019694,,
770959592,false,true,5,2015-08-14T21:34:00,,Direct,1,D002945,Cisplatin,D020258,neurotoxicity,"Cisplatin is one of the commonly-used chemotherapeutic drugs to efficiently treat malignant tumors in clinic, however, the adverse effects of cisplatin such as nephrotoxicity, neurotoxicity, and hemolytic uremic syndrome are often observed at its clinical doses (approximately 60 mg/m(2)), which limit its broader application.",20540689_1,20540689_D002945_D020258,,
770959593,false,true,5,2015-08-14T21:49:00,,Direct,1,D002945,Cisplatin,D006463,hemolytic uremic syndrome,"Cisplatin is one of the commonly-used chemotherapeutic drugs to efficiently treat malignant tumors in clinic, however, the adverse effects of cisplatin such as nephrotoxicity, neurotoxicity, and hemolytic uremic syndrome are often observed at its clinical doses (approximately 60 mg/m(2)), which limit its broader application.",20540689_1,20540689_D002945_D006463,,
770959594,false,true,5,2015-08-14T21:44:00,,No Relation,1,D002945,Cisplatin,D009369,malignant tumors,"Cisplatin is one of the commonly-used chemotherapeutic drugs to efficiently treat malignant tumors in clinic, however, the adverse effects of cisplatin such as nephrotoxicity, neurotoxicity, and hemolytic uremic syndrome are often observed at its clinical doses (approximately 60 mg/m(2)), which limit its broader application.",20540689_1,20540689_D002945_D009369,,
770959595,false,true,5,2015-08-15T02:02:00,,No Relation,0.6116,D002945,cisplatin,D006528,hepatoma,"This paper reviews current understanding of cisplatin-induced erythrocyte injury, and presents our latest finding that a low dose of cisplatin (3.6 mg/m(2)/day, 14 days) could induce specific hemosiderin deposition in spleen of both normal and hepatoma-22 (H22) inoculated Balb/C mice.",20540689_3,20540689_D002945_D006528,,
770959596,false,true,5,2015-08-14T22:20:00,,No Relation,0.6024,D002945,cisplatin,D001201,ascites,This dose of cisplatin significantly inhibited H22-induced acute ascites development.,20540689_4,20540689_D002945_D001201,,
770959597,false,true,5,2015-08-15T00:59:00,,No Relation,1,D002945,cisplatin,D009369,tumor,No significant toxicity was induced by this dose of cisplatin to tissues except for hemosiderin accumulation in the spleen of both normal and H22 tumor-bearing mice.,20540689_5,20540689_D002945_D009369,,
770959598,false,true,5,2015-08-15T00:01:00,,No Relation,1,D002945,cisplatin,D064420,toxicity,No significant toxicity was induced by this dose of cisplatin to tissues except for hemosiderin accumulation in the spleen of both normal and H22 tumor-bearing mice.,20540689_5,20540689_D002945_D064420,,
770959599,false,true,5,2015-08-14T22:10:00,,Direct,0.5929,D002945,cisplatin,D013158,splenic,Increased splenic iron content and erythrocyte injury were observed after treatment with the low dose of cisplatin.,20540689_6,20540689_D002945_D013158,,
770959600,false,true,5,2015-08-14T21:56:00,,No Relation,0.7999,D007501,iron,D013158,splenic,Increased splenic iron content and erythrocyte injury were observed after treatment with the low dose of cisplatin.,20540689_6,20540689_D007501_D013158,,
770959601,false,true,5,2015-08-14T22:22:00,,No Relation,0.5988,C428463,Hepcidin,D013158,splenic,"Hepcidin inhibits the function of FPN1 as iron-exporter leading to iron overloaded inside ferritins of splenic cells, which are stained with abnormal hemosiderin accumulation.",20540689_11,20540689_C428463_D013158,,
770959602,false,true,5,2015-08-15T00:27:00,,No Relation,0.8283,D007501,iron,D013158,splenic,"Hepcidin inhibits the function of FPN1 as iron-exporter leading to iron overloaded inside ferritins of splenic cells, which are stained with abnormal hemosiderin accumulation.",20540689_11,20540689_D007501_D013158,,
770959603,false,true,5,2015-08-14T21:48:00,,No Relation,1,D007501,iron,D064420,toxicity,These results demonstrate that cisplatin-caused hemosiderin deposition in spleen provides a valuable clue for understanding the molecular basis of toxicity of cisplatin and hemosiderin accumulation and iron metabolism in vivo.,20540689_12,20540689_D007501_D064420,,
770959604,false,true,5,2015-08-15T00:24:00,,Direct,0.6214,D002945,cisplatin,D064420,toxicity,These results demonstrate that cisplatin-caused hemosiderin deposition in spleen provides a valuable clue for understanding the molecular basis of toxicity of cisplatin and hemosiderin accumulation and iron metabolism in vivo.,20540689_12,20540689_D002945_D064420,,
770959605,false,true,5,2015-08-14T22:26:00,,Direct,0.801,D003300,copper,D004487,cytotoxicity,Real-time monitoring of copper ions-induced cytotoxicity by EIS cell chips.,20547054_0,20547054_D003300_D004487,,
770959606,false,true,5,2015-08-14T23:22:00,,No Relation,1,D019289,pyruvate,D008105,primary biliary cirrhosis/PBC,"Our understanding of primary biliary cirrhosis (PBC) has been significantly enhanced by the rigorous dissection of the multilineage T and B cell response against the immunodominant mitochondrial autoantigen, the E2 component of the pyruvate dehydrogenase complex (PDC-E2).",20568301_1,20568301_D019289_D008105,,
770959607,false,true,5,2015-08-15T01:52:00,,No Relation,1,D014580,ursodiol,D008105,PBC,"These results provide a mechanism for the biliary specificity of PBC, the recurrence of disease after liver transplantation, and the success of ursodiol in treatment.",20568301_9,20568301_D014580_D008105,,
770959608,false,true,5,2015-08-14T22:24:00,,No Relation,1,D002244,carbon,D010003,OA,"Analysis of f(SC)K(SA)delta(OCT)/F(OM)K(OA) ratios revealed a significant role of adsorption and absorption in unusually high elemental carbon fractions (ie low OC/EC ratio) in fine particles collected at waste incinerators and the abnormally high organic carbon fractions (ie high OC/EC ratio) observed in those fine particles of an urban residential zone, respectively.",20578474_4,20578474_D002244_D010003,,
770959609,false,true,5,2015-08-14T21:33:00,,No Relation,1,C043211,Carvedilol,D000544,Alzheimer's disease,Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.,20579773_0,20579773_C043211_D000544,,
770959610,false,true,5,2015-08-15T01:18:00,,No Relation,1,C043211,carvedilol,D000544,AD mouse,"Here we present evidence that chronic oral administration of carvedilol, a nonselective _-adrenergic receptor blocker, significantly attenuates brain oligomeric _-amyloid content and cognitive deterioration in 2 independent AD mouse models.",20579773_2,20579773_C043211_D000544,,
770959611,false,true,5,2015-08-14T21:54:00,,No Relation,0.8073,C043211,carvedilol,D003072,cognitive deterioration,"Here we present evidence that chronic oral administration of carvedilol, a nonselective _-adrenergic receptor blocker, significantly attenuates brain oligomeric _-amyloid content and cognitive deterioration in 2 independent AD mouse models.",20579773_2,20579773_C043211_D003072,,
770959612,false,true,5,2015-08-15T00:23:00,,No Relation,1,C043211,carvedilol,D000544,AD,"We found that carvedilol treatment significantly improved neuronal transmission, and that this improvement was associated with the maintenance of number of the less stable ""learning"" thin spines in the brains of AD mice.",20579773_3,20579773_C043211_D000544,,
770959613,false,true,5,2015-08-14T23:43:00,,No Relation,1,C043211,carvedilol,D000544,AD,"Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD.",20579773_4,20579773_C043211_D000544,,
770959614,false,true,5,2015-08-14T23:56:00,Used as treatment,No Relation,0.7854,C043211,carvedilol,D003072,cognitive deterioration,"Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD.",20579773_4,20579773_C043211_D003072,,
770959615,false,true,5,2015-08-14T22:13:00,,No Relation,0.8212,D024841,fluoroquinolone,D009175,Mycoplasma,Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance.,20580532_0,20580532_D024841_D009175,,
770959616,false,true,5,2015-08-15T00:03:00,,No Relation,1,D024841,fluoroquinolone,D009175,Mycoplasma,"The alterations of Ser-83-->Asn, Asp-87-->Tyr and Asp-87-->Val in ParC found in 3 (10.7%) of 28 specimens were analogous to those commonly observed in fluoroquinolone-resistant mutants of other Mycoplasma and Ureaplasma spp.",20580532_7,20580532_D024841_D009175,,
770959617,false,true,5,2015-08-14T21:33:00,,No Relation,1,D013256,steroid,D011778,acute Q fever granulomatous hepatitis,Circulating cytokines and procalcitonin in acute Q fever granulomatous hepatitis with poor response to antibiotic and short-course steroid therapy: a case report.,20594295_0,20594295_D013256_D011778,,
770959618,false,true,5,2015-08-15T01:33:00,,No Relation,0.7795,D011239,prednisolone,D011778,acute Q fever granulomatous hepatitis,We report a rare case of acute Q fever granulomatous hepatitis remained pyrexia despite several antibiotic therapy and 6-day course of oral prednisolone.,20594295_3,20594295_D011239_D011778,,
770959619,false,true,5,2015-08-15T01:35:00,,No Relation,1,D011239,prednisolone,D005334,pyrexia,We report a rare case of acute Q fever granulomatous hepatitis remained pyrexia despite several antibiotic therapy and 6-day course of oral prednisolone.,20594295_3,20594295_D011239_D005334,,
770959620,false,true,5,2015-08-15T02:09:00,,No Relation,1,D009609,nitrous oxide,D010146,pain,The aims of this project were to longitudinally follow plasma levels of beta-endorphin during pregnancy in women with a healthy pregnancy and to investigate whether plasma levels of beta-endorphin in late pregnancy are associated with need for additional pain medication beyond nitrous oxide during labor.,20595705_2,20595705_D009609_D010146,,
770959621,false,true,5,2015-08-14T21:29:00,,No Relation,1,D009609,nitrous oxide,D010146,pain,"Low levels of beta-endorphin at the end of pregnancy were associated with need for additional pain medication beyond nitrous oxide during labor, although the causal relationship is unclear.",20595705_6,20595705_D009609_D010146,,
770959622,false,true,5,2015-08-15T02:21:00,,No Relation,1,D001241,aspirin,D001249,asthma,Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population.,20597903_0,20597903_D001241_D001249,,
770959623,false,true,5,2015-08-14T21:43:00,,Direct,0.6072,D001241,Aspirin,D001249,asthma,Aspirin-intolerant asthma (AIA) occurs from asthma exacerbation after exposure to aspirin.,20597903_1,20597903_D001241_D001249,,
770959624,false,true,5,2015-08-15T01:45:00,,No Relation,0.7982,D005680,GABA,D001249,asthma,"The critical role of the solute carrier family 6 (neurotransmitter transporter, betaine/GABA) member 12 (SLC6A12) gene in GABAergic transmission, which is associated with mucus production in asthma, makes it a candidate gene for AIA association study.",20597903_3,20597903_D005680_D001249,,
770959625,false,true,5,2015-08-15T01:25:00,,No Relation,1,D001241,aspirin,D001249,asthma,Eight single nucleotide polymorphisms (SNPs) in SLC6A12 were genotyped in 163 aspirin-intolerant asthma (AIA) and 429 aspirin-tolerant asthma (ATA) patients of Korean ethnicity.,20597903_4,20597903_D001241_D001249,,
770959626,false,true,5,2015-08-14T21:54:00,,No Relation,1,D001241,aspirin,D055963,aspirin-tolerant asthma/ATA,Eight single nucleotide polymorphisms (SNPs) in SLC6A12 were genotyped in 163 aspirin-intolerant asthma (AIA) and 429 aspirin-tolerant asthma (ATA) patients of Korean ethnicity.,20597903_4,20597903_D001241_D055963,,
770959627,false,true,5,2015-08-15T01:58:00,,No Relation,1,D017963,azithromycin,D008173,obstructive pulmonary diseases,"In addition to its antibiotic properties, azithromycin has immune-modulating effects and is used for this reason in the management of cystic fibrosis and chronic obstructive pulmonary diseases.",20604763_3,20604763_D017963_D008173,,
770959628,false,true,5,2015-08-14T21:42:00,,No Relation,1,D017963,azithromycin,D005355,fibrosis,"In addition to its antibiotic properties, azithromycin has immune-modulating effects and is used for this reason in the management of cystic fibrosis and chronic obstructive pulmonary diseases.",20604763_3,20604763_D017963_D005355,,
770959629,false,true,5,2015-08-15T01:45:00,,No Relation,0.8098,D002118,calcium,D055113,chronic periodontitis,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D002118_D055113,,
770959630,false,true,5,2015-08-15T00:55:00,,No Relation,0.8245,D017963,Azithromycin,D019214,gingival overgrowth,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D017963_D019214,,
770959631,false,true,5,2015-08-14T21:34:00,,No Relation,1,D017963,Azithromycin,D003929,diabetic,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D017963_D003929,,
770959632,false,true,5,2015-08-14T22:08:00,,No Relation,1,D002118,calcium,D003929,diabetic,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D002118_D003929,,
770959633,false,true,5,2015-08-14T22:07:00,,No Relation,0.6098,D002118,calcium,D019214,gingival overgrowth,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D002118_D019214,,
770959634,false,true,5,2015-08-14T21:29:00,,No Relation,1,D017963,Azithromycin,D055113,chronic periodontitis,"Azithromycin, together with monthly subgingival debridement, was the treatment in Case 3 (severe chronic periodontitis in a poorly controlled diabetic complicated by gingival overgrowth related to medication with a calcium channel blocker).",20604763_7,20604763_D017963_D055113,,
770959635,false,true,5,2015-08-14T22:04:00,,No Relation,0.8045,D002392,(-)-epicatechin,D008175,lung cancer,New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin.,20606042_0,20606042_D002392_D008175,,
770959636,false,true,5,2015-08-15T00:14:00,,No Relation,0.6145,D003474,curcumin,D008175,lung cancer,New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin.,20606042_0,20606042_D003474_D008175,,
770959637,false,true,5,2015-08-14T21:44:00,,Direct,1,D003474,Curcumin,D009369,cancer-preventive activity,"Curcumin, a phenolic compound isolated from the plant Curcuma longa (Linn), is ingested every day in the Indian subcontinent and is well reported to possess cancer-preventive activity.",20606042_1,20606042_D003474_D009369,,
770959638,false,true,5,2015-08-14T21:48:00,,No Relation,1,D003474,curcumin,D009369,cancer,"To achieve effective cancer prevention with curcumin, we need to find a new method to enhance the effects of curcumin in the diet.",20606042_2,20606042_D003474_D009369,,
770959639,false,true,5,2015-08-15T00:48:00,,No Relation,0.581,D002392,catechin/(-)-epicatechin,D009369,cancer-preventive activity,"Based on our evidence that (-)-epicatechin (EC), an inert catechin, enhances the cancer-preventive activity of green tea catechins, we studied the enhancing effects of EC on inductions of growth inhibition and apoptosis in human lung cancer cell lines PC-9 and A549 with curcumin.",20606042_3,20606042_D002392_D009369,,
770959640,false,true,5,2015-08-14T21:39:00,,No Relation,1,D002392,catechin/(-)-epicatechin,D008175,lung cancer,"Based on our evidence that (-)-epicatechin (EC), an inert catechin, enhances the cancer-preventive activity of green tea catechins, we studied the enhancing effects of EC on inductions of growth inhibition and apoptosis in human lung cancer cell lines PC-9 and A549 with curcumin.",20606042_3,20606042_D002392_D008175,,
770959641,false,true,5,2015-08-14T21:58:00,"""cancer-preventive activity""  is not a disease",No Relation,1,D003474,curcumin,D009369,cancer-preventive activity,"Based on our evidence that (-)-epicatechin (EC), an inert catechin, enhances the cancer-preventive activity of green tea catechins, we studied the enhancing effects of EC on inductions of growth inhibition and apoptosis in human lung cancer cell lines PC-9 and A549 with curcumin.",20606042_3,20606042_D003474_D009369,,
770959642,false,true,5,2015-08-14T23:39:00,,No Relation,0.8091,D003474,curcumin,D008175,lung cancer,"Based on our evidence that (-)-epicatechin (EC), an inert catechin, enhances the cancer-preventive activity of green tea catechins, we studied the enhancing effects of EC on inductions of growth inhibition and apoptosis in human lung cancer cell lines PC-9 and A549 with curcumin.",20606042_3,20606042_D003474_D008175,,
770959643,false,true,5,2015-08-15T00:35:00,,Direct,0.5913,D003474,curcumin,D009369,cancer-preventive activity,"This report is the first report on the enhancing effects of EC on curcumin, and the data suggest that EC plays a significant role in the enhancement of the cancer-preventive activity of curcumin in the diet.",20606042_9,20606042_D003474_D009369,,
770959644,false,true,5,2015-08-15T00:16:00,,Direct,1,D014640,vancomycin,D016470,Corynebacterium falsenii bacteremia,Corynebacterium falsenii bacteremia occurring in an infant on vancomycin therapy.,20610679_0,20610679_D014640_D016470,,
770959645,false,true,5,2015-08-14T21:33:00,,Direct,1,D014640,vancomycin,D016470,Corynebacterium falsenii bacteremia,We give the first detailed description of a clinically significant Corynebacterium falsenii bacteremia occurring in an infant while on vancomycin therapy.,20610679_2,20610679_D014640_D016470,,
770959646,false,true,5,2015-08-15T00:16:00,,No Relation,0.8101,D017311,amlodipine,D006973,hypertension,Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.,20626210_0,20626210_D017311_D006973,,
770959647,false,true,5,2015-08-15T01:46:00,,No Relation,1,C081489,valsartan,D006973,hypertension,Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.,20626210_0,20626210_C081489_D006973,,
770959648,false,true,5,2015-08-14T21:36:00,,No Relation,1,D000450,aldosterone,D002318,renal and cardiovascular morbidity,Combination therapy with a calcium channel antagonist (calcium channel blocker [CCB]) and an inhibitor of the renin-angiotensin-aldosterone system (RAAS) is a rational approach to achieve BP goals and provide protection against renal and cardiovascular morbidity and mortality.,20626210_3,20626210_D000450_D002318,,
770959649,false,true,5,2015-08-14T23:30:00,,No Relation,1,D002118,calcium,D002318,renal and cardiovascular morbidity,Combination therapy with a calcium channel antagonist (calcium channel blocker [CCB]) and an inhibitor of the renin-angiotensin-aldosterone system (RAAS) is a rational approach to achieve BP goals and provide protection against renal and cardiovascular morbidity and mortality.,20626210_3,20626210_D002118_D002318,,
770959650,false,true,5,2015-08-14T22:21:00,,No Relation,1,D017311,amlodipine,D006973,hypertensive,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_D017311_D006973,,
770959651,false,true,5,2015-08-15T00:31:00,,No Relation,1,D017311,amlodipine,D020521,stroke,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_D017311_D020521,,
770959652,false,true,5,2015-08-15T01:47:00,,No Relation,1,C081489,valsartan,D002318,cardiovascular events,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_C081489_D002318,,
770959653,false,true,5,2015-08-15T02:22:00,,No Relation,1,C081489,valsartan,D020521,stroke,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_C081489_D020521,,
770959654,false,true,5,2015-08-14T22:28:00,,No Relation,1,D017311,amlodipine,D002318,cardiovascular events,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_D017311_D002318,,
770959655,false,true,5,2015-08-15T00:24:00,,No Relation,1,C081489,valsartan,D006973,hypertensive,The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years.,20626210_7,20626210_C081489_D006973,,
770959656,false,true,5,2015-08-14T22:44:00,,No Relation,1,D017311,amlodipine,D006973,hypertension,"Once-daily amlodipine/valsartan is a rational and convenient treatment option for the effective management of patients with hypertension, improving adherence to antihypertensive medication and protecting against cardiovascular and renal morbidity and mortality.",20626210_9,20626210_D017311_D006973,,
770959657,false,true,5,2015-08-15T00:09:00,Used as treatment,No Relation,1,C081489,valsartan,D006973,hypertension,"Once-daily amlodipine/valsartan is a rational and convenient treatment option for the effective management of patients with hypertension, improving adherence to antihypertensive medication and protecting against cardiovascular and renal morbidity and mortality.",20626210_9,20626210_C081489_D006973,,
770959658,false,true,5,2015-08-14T22:00:00,,Direct,0.593,D004958,estradiol,D007249,inflammation,"C-reactive protein (CRP), a marker of generalized inflammation, is raised by oral estradiol therapy (ET).",20632462_2,20632462_D004958_D007249,,
770959659,false,true,5,2015-08-14T21:37:00,,No Relation,1,D004967,Estrogen,D050197,Atherosclerosis,This observational study includes postmenopausal women participating in the Estrogen in the Prevention of Atherosclerosis Trial.,20632462_4,20632462_D004967_D050197,,
770959660,false,true,5,2015-08-14T22:16:00,,No Relation,1,D011166,porphyrins,D016609,PDT/photodynamic therapy,"Light-based treatments and photodynamic therapy (PDT) using topical precursors of porphyrins are off-label alternative treatments for acne vulgaris, with their own advantages and disadvantages.",20633796_3,20633796_D011166_D016609,,
770959661,false,true,5,2015-08-14T22:23:00,,No Relation,1,D011166,porphyrins,D000152,acne vulgaris,"Light-based treatments and photodynamic therapy (PDT) using topical precursors of porphyrins are off-label alternative treatments for acne vulgaris, with their own advantages and disadvantages.",20633796_3,20633796_D011166_D000152,,
770959662,false,true,5,2015-08-14T23:57:00,,No Relation,1,D007501,iron,D018798,iron deficiency anemia,We investigated the efficacy of co-administration of DFAIII with water-insoluble iron in the treatment of iron deficiency anemia in Vietnamese women.,20651460_2,20651460_D007501_D018798,,
770959663,false,true,5,2015-08-14T21:54:00,,No Relation,1,D026023,permethrin,D013984,Dermanyssus gallinae infestation,Dermanyssus gallinae infestation: an unusual cause of scalp pruritus treated with permethrin shampoo.,20687864_0,20687864_D026023_D013984,,
770959664,false,true,5,2015-08-14T22:10:00,,No Relation,1,D002230,carbidopa,D010300,Parkinson's disease,A combination of levodopa (L-DOPA) and carbidopa is the most commonly-used treatment for symptom management in Parkinson's disease.,20700524_1,20700524_D002230_D010300,,
770959665,false,true,5,2015-08-15T02:00:00,,No Relation,1,D007980,levodopa/L-DOPA,D010300,Parkinson's disease,A combination of levodopa (L-DOPA) and carbidopa is the most commonly-used treatment for symptom management in Parkinson's disease.,20700524_1,20700524_D007980_D010300,,
770959666,false,true,5,2015-08-15T00:43:00,,No Relation,1,D002230,carbidopa,D010300,Parkinson's,These observations suggest that oral administration of EGCG may have significant beneficial effects in Parkinson's patients treated with L-DOPA and carbidopa by exerting a modest inhibition of L-DOPA methylation plus a strong neuroprotection against oxidative damage and degeneration.,20700524_9,20700524_D002230_D010300,,
770959667,false,true,5,2015-08-15T01:26:00,,No Relation,1,C045651,EGCG,D010300,Parkinson's,These observations suggest that oral administration of EGCG may have significant beneficial effects in Parkinson's patients treated with L-DOPA and carbidopa by exerting a modest inhibition of L-DOPA methylation plus a strong neuroprotection against oxidative damage and degeneration.,20700524_9,20700524_C045651_D010300,,
770959668,false,true,5,2015-08-14T21:28:00,,No Relation,1,D007980,L-DOPA,D010300,Parkinson's,These observations suggest that oral administration of EGCG may have significant beneficial effects in Parkinson's patients treated with L-DOPA and carbidopa by exerting a modest inhibition of L-DOPA methylation plus a strong neuroprotection against oxidative damage and degeneration.,20700524_9,20700524_D007980_D010300,,
770959669,false,true,5,2015-08-14T22:00:00,,No Relation,1,D009705,nucleoside,D015658,HIV-infected,"HAART-related long-term toxicities, many of them ascribed to mitochondrial (mt) toxicity of the nucleoside analogues, are being increasingly reported in HIV-infected children.",20707732_1,20707732_D009705_D015658,,
770959670,false,true,5,2015-08-14T21:47:00,,No Relation,0.5844,D009705,nucleoside,D064420,toxicity/toxicities,"HAART-related long-term toxicities, many of them ascribed to mitochondrial (mt) toxicity of the nucleoside analogues, are being increasingly reported in HIV-infected children.",20707732_1,20707732_D009705_D064420,,
770959671,false,true,5,2015-08-15T01:41:00,,No Relation,1,D008687,metformin,D003929,diabetic,"In a 24-week, open-label, parallel-group trial, type 2 diabetic patients who were not maintaining glycemic control on basal insulin (glargine or neutral protamine Hagedorn) + oral antidiabetic drugs were randomly assigned to twice-daily BIAsp 30 + metformin or once-daily glargine + metformin + secretagogues (secretagogues were discontinued in the BIAsp 30 arm).",20713345_2,20713345_D008687_D003929,,
770959672,false,true,5,2015-08-15T00:15:00,,Direct,0.79,C005846,tremolite,D008654,mesothelioma,"A case of occupational peritoneal mesothelioma from exposure to tremolite-free chrysotile in Quebec, Canada: A black swan case.",20721899_0,20721899_C005846_D008654,,
770959673,false,true,5,2015-08-15T01:06:00,,Direct,1,C005846,Tremolite,D008654,mesothelioma,Tremolite contamination has been proposed as the cause of mesothelioma in workers exposed to commercial chrysotile.,20721899_1,20721899_C005846_D008654,,
770959674,false,true,5,2015-08-14T21:56:00,,No Relation,0.6306,C005846,tremolite,D008654,mesothelioma,Chrysotile without tremolite can cause peritoneal mesothelioma.,20721899_5,20721899_C005846_D008654,,
770959675,false,true,5,2015-08-14T22:42:00,,Direct,0.8095,D000244,ADP,C566800,platelet aggregation,"In a cross-sectional protocol, platelet aggregation in response to ADP and epinephrine, von Willebrand antigen (vWF:AG), and collagen-binding capacity (vWF:CB) were obtained.",20739614_5,20739614_D000244_C566800,,
770959676,false,true,5,2015-08-15T02:01:00,,No Relation,0.7867,D004837,epinephrine,C566800,platelet aggregation,"In a cross-sectional protocol, platelet aggregation in response to ADP and epinephrine, von Willebrand antigen (vWF:AG), and collagen-binding capacity (vWF:CB) were obtained.",20739614_5,20739614_D004837_C566800,,
770959677,false,true,5,2015-08-15T02:30:00,,No Relation,0.8094,D013654,taurine,D008545,melanoma,Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.,20804622_0,20804622_D013654_D008545,,
770959678,false,true,5,2015-08-14T21:30:00,,No Relation,1,C010038,azelaic acid,D008545,melanoma,Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.,20804622_0,20804622_C010038_D008545,,
770959679,false,true,5,2015-08-14T21:36:00,,No Relation,1,D013654,taurine/Tau,D008545,melanoma,"In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells.",20804622_6,20804622_D013654_D008545,,
770959680,false,true,5,2015-08-15T01:45:00,,No Relation,1,D013654,Tau,D008545,melanoma,AZ combined with Tau inhibited the melanin production and tyrosinase activity of B16F10 melanoma cells without significant cytotoxicity.,20804622_11,20804622_D013654_D008545,,
770959681,false,true,5,2015-08-14T21:38:00,,No Relation,1,D013654,Tau,D004487,cytotoxicity,AZ combined with Tau inhibited the melanin production and tyrosinase activity of B16F10 melanoma cells without significant cytotoxicity.,20804622_11,20804622_D013654_D004487,,
770959682,false,true,5,2015-08-14T23:36:00,,No Relation,1,D005419,flavonoids,D003920,diabetes mellitus,Artificial neural network-based drug design for diabetes mellitus using flavonoids.,20806262_0,20806262_D005419_D003920,,
770959683,false,true,5,2015-08-15T01:57:00,,No Relation,1,D005947,glucose,D003920,Diabetes mellitus,Diabetes mellitus is a chronic metabolic disease involving the failure to regulate glucose blood levels in the body and has been linked with numerous detrimental complications.,20806262_1,20806262_D005947_D003920,,
770959684,false,true,5,2015-08-14T21:37:00,,No Relation,1,D004967,estrogen,D009369,BCa,Mono-layer cell culture models of p53-wild type estrogen receptor (ER)-dependent MCF-7 BCa cells and p53-mutant ER-/progesterone receptor (PR)- and Her2-regular (triple-negative) MDA-MB-231 BCa were exposed to PGG for a comprehensive investigation of cellular consequences and molecular targets/mediators.,20809980_5,20809980_D004967_D009369,,
770959685,false,true,5,2015-08-14T22:21:00,,No Relation,1,D011374,progesterone,D009369,BCa,Mono-layer cell culture models of p53-wild type estrogen receptor (ER)-dependent MCF-7 BCa cells and p53-mutant ER-/progesterone receptor (PR)- and Her2-regular (triple-negative) MDA-MB-231 BCa were exposed to PGG for a comprehensive investigation of cellular consequences and molecular targets/mediators.,20809980_5,20809980_D011374_D009369,,
770959686,false,true,5,2015-08-14T23:14:00,,No Relation,1,D009020,morphine,D000699,analgesia,Adequate intra-operative morphine use can minimize post-operative pain and subsequent need for rescue analgesia.,20827460_10,20827460_D009020_D000699,,
770959687,false,true,5,2015-08-15T00:05:00,,No Relation,1,D009020,morphine,D010146,pain,Adequate intra-operative morphine use can minimize post-operative pain and subsequent need for rescue analgesia.,20827460_10,20827460_D009020_D010146,,
770959688,false,true,5,2015-08-14T21:48:00,,No Relation,1,C437965,olmesartan,D007022,MBPS,"In amlodipine-olmesartan combination therapy, the bedtime administration reduced better MBPS with correcting nocturnal BP fall and improved urinary albumin excretion.",20828223_11,20828223_C437965_D007022,,
770959689,false,true,5,2015-08-15T01:32:00,,No Relation,1,C437965,olmesartan,D048968,MBPS,"In amlodipine-olmesartan combination therapy, the bedtime administration reduced better MBPS with correcting nocturnal BP fall and improved urinary albumin excretion.",20828223_11,20828223_C437965_D048968,,
770959690,false,true,5,2015-08-14T22:20:00,,No Relation,1,D017311,amlodipine,D048968,MBPS,"In amlodipine-olmesartan combination therapy, the bedtime administration reduced better MBPS with correcting nocturnal BP fall and improved urinary albumin excretion.",20828223_11,20828223_D017311_D048968,,
770959691,false,true,5,2015-08-15T02:20:00,,No Relation,1,D017311,amlodipine,D007022,MBPS,"In amlodipine-olmesartan combination therapy, the bedtime administration reduced better MBPS with correcting nocturnal BP fall and improved urinary albumin excretion.",20828223_11,20828223_D017311_D007022,,
770959692,false,true,5,2015-08-14T23:45:00,,No Relation,0.7904,D000450,Aldosterone,D006929,primary aldosteronism,Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.,20837883_0,20837883_D000450_D006929,,
770959693,false,true,5,2015-08-14T23:30:00,,No Relation,0.7964,D000450,aldosterone,D006929,primary aldosteronism,"We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary aldosteronism.",20837883_1,20837883_D000450_D006929,,
770959694,false,true,5,2015-08-14T22:19:00,,No Relation,0.8041,D000450,aldosterone,D006929,primary aldosteronism,"In conclusion, the administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.",20837883_11,20837883_D000450_D006929,,
770959695,false,true,5,2015-08-15T02:00:00,,No Relation,1,D012701,Serotonin,D017180,ventricular tachycardia,Serotonin and catecholaminergic polymorphic ventricular tachycardia: a possible therapeutic role for SSRIs?,20838725_0,20838725_D012701_D017180,,
770959696,false,true,5,2015-08-15T01:03:00,,No Relation,1,D012701,serotonin,D017180,ventricular tachycardia,"However, after a selective serotonin re-uptake inhibitor (SSRI) was added to the therapeutic regimen, no further episodes of ventricular tachycardia occurred during the following two years.",20838725_4,20838725_D012701_D017180,,
770959697,false,true,5,2015-08-14T21:56:00,,Direct,1,D020106,acrylamide,D064420,Toxicity,Toxicity of acrylamide and evaluation of its exposure in baby foods.,20843409_0,20843409_D020106_D064420,,
770959698,false,true,5,2015-08-15T00:19:00,,Direct,1,D020106,acrylamide,D064420,toxicity,"The present review focuses on the several adverse health effects of acrylamide including mutagenicity, genotoxicity, carcinogenicity, neurotoxicity and reproductive toxicity, and the possible outcomes of childhood exposure from baby foods and infant formulas.",20843409_5,20843409_D020106_D064420,,
770959699,false,true,5,2015-08-15T02:22:00,,Direct,1,D020106,acrylamide,D020258,neurotoxicity,"The present review focuses on the several adverse health effects of acrylamide including mutagenicity, genotoxicity, carcinogenicity, neurotoxicity and reproductive toxicity, and the possible outcomes of childhood exposure from baby foods and infant formulas.",20843409_5,20843409_D020106_D020258,,
770959700,false,true,5,2015-08-14T21:40:00,,No Relation,0.812,D005459,fluoride,D010520,generalized aggressive periodontitis/G-AgP,To compare the clinical and microbiological effects of ultrasonic mechanical instrumentation (UMI) associated to home-care use of amine fluoride/stannous fluoride (AmF/SnF(2) )-containing mouthrinse and toothpaste in smoker and non-smoker patients affected by generalized aggressive periodontitis (G-AgP) during a recall session of supportive periodontal therapy (SPT).,20849433_1,20849433_D005459_D010520,,
770959701,false,true,5,2015-08-14T22:18:00,,No Relation,0.809,D002738,chloroquine,D003550,cystic fibrosis,Treatment of cystic fibrosis associated cutaneous vasculitis with chloroquine.,20863769_0,20863769_D002738_D003550,,
770959702,false,true,5,2015-08-14T21:37:00,,No Relation,0.805,D002738,chloroquine,D014657,cutaneous vasculitis,Treatment of cystic fibrosis associated cutaneous vasculitis with chloroquine.,20863769_0,20863769_D002738_D014657,,
770959703,false,true,5,2015-08-14T21:59:00,,No Relation,1,D002738,chloroquine,D014657,cutaneous vasculitis,We describe a case of steroid resistant cutaneous vasculitis which was successfully treated with chloroquine in addition to corticosteroids and a subsequent relapse with chloroquine alone.,20863769_3,20863769_D002738_D014657,,
770959704,false,true,5,2015-08-14T22:14:00,,No Relation,1,D000305,corticosteroids,D014657,cutaneous vasculitis,We describe a case of steroid resistant cutaneous vasculitis which was successfully treated with chloroquine in addition to corticosteroids and a subsequent relapse with chloroquine alone.,20863769_3,20863769_D000305_D014657,,
770959705,false,true,5,2015-08-15T01:53:00,,No Relation,0.8098,D013256,steroid,D014657,cutaneous vasculitis,We describe a case of steroid resistant cutaneous vasculitis which was successfully treated with chloroquine in addition to corticosteroids and a subsequent relapse with chloroquine alone.,20863769_3,20863769_D013256_D014657,,
770959706,false,true,5,2015-08-15T01:49:00,,No Relation,1,D003907,dexamethasone,D009336,necrosis,"Stimulation of primary human corneal epithelial cells, keratocytes, and retinal endothelial cells with 1 to 10 ng/mL interleukin 1_ (IL-1_) resulted in a significant increase in numerous inflammatory cytokines, including IL-6, IL-8, and tumor necrosis factor  (TNF-); and dexamethasone was able to significantly inhibit these effects.",20884859_3,20884859_D003907_D009336,,
770959707,false,true,5,2015-08-15T00:19:00,,No Relation,1,D003907,dexamethasone,D009369,tumor,"Stimulation of primary human corneal epithelial cells, keratocytes, and retinal endothelial cells with 1 to 10 ng/mL interleukin 1_ (IL-1_) resulted in a significant increase in numerous inflammatory cytokines, including IL-6, IL-8, and tumor necrosis factor  (TNF-); and dexamethasone was able to significantly inhibit these effects.",20884859_3,20884859_D003907_D009369,,
770959708,false,true,5,2015-08-14T22:17:00,,No Relation,1,C119467,Lanthanum carbonate,D051436,CKD/chronic kidney disease,Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD).,20921291_1,20921291_C119467_D051436,,
770959709,false,true,5,2015-08-14T21:36:00,,No Relation,1,D002118,calcium,D051436,CKD/chronic kidney disease,Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD).,20921291_1,20921291_D002118_D051436,,
770959710,false,true,5,2015-08-14T23:11:00,It's 'phosphate binders' and not just 'Phosphate',No Relation,1,D010710,phosphate,D051436,CKD/chronic kidney disease,Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD).,20921291_1,20921291_D010710_D051436,,
770959711,false,true,5,2015-08-14T21:29:00,,No Relation,1,D002117,calcitriol,D051436,CKD,Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol.,20921291_2,20921291_D002117_D051436,,
770959712,false,true,5,2015-08-14T21:43:00,,No Relation,1,C405346,sevelamer carbonate,D051436,CKD,Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol.,20921291_2,20921291_C405346_D051436,,
770959713,false,true,5,2015-08-14T21:34:00,,No Relation,1,D014807,vitamin D,D051436,CKD,Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol.,20921291_2,20921291_D014807_D051436,,
770959714,false,true,5,2015-08-14T22:27:00,,No Relation,1,C119467,lanthanum carbonate,D051436,CKD,Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol.,20921291_2,20921291_C119467_D051436,,
770959715,false,true,5,2015-08-15T00:22:00,,No Relation,1,D010710,phosphate,D051436,CKD,This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.,20921291_11,20921291_D010710_D051436,,
770959716,false,true,5,2015-08-15T00:57:00,,No Relation,1,D014807,vitamin D,D051436,CKD,This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.,20921291_11,20921291_D014807_D051436,,
770959717,false,true,5,2015-08-15T02:00:00,,No Relation,0.8116,C517975,AZD6244/selumetinib,D015179,colorectal cancer,Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.,20923857_0,20923857_C517975_D015179,,
770959718,false,true,5,2015-08-14T22:17:00,,No Relation,1,C517975,AZD6244,D015179,CRC,The aim of this study was to develop and characterize predictive biomarkers of response to the MEK1/2 inhibitor AZD6244 in CRC in order to maximize the clinical utility of this agent.,20923857_3,20923857_C517975_D015179,,
770959719,false,true,5,2015-08-14T22:48:00,,No Relation,1,C517975,AZD6244,D015179,CRC,Twenty-seven human CRC cell lines were exposed to AZD6244 and classified according to the IC(50) value as sensitive (_ 0.1 _mol/L) or resistant (>1 _mol/L).,20923857_4,20923857_C517975_D015179,,
770959720,false,true,5,2015-08-14T21:53:00,,No Relation,1,C517975,AZD6244,D015179,CRC,Further testing was done in cell line xenografts and K-ras mutant CRC human explants models to develop a predictive genomic classifier for AZD6244.,20923857_6,20923857_C517975_D015179,,
770959721,false,true,5,2015-08-15T02:01:00,,No Relation,1,C517975,AZD6244,D015179,CRC,"Baseline gene array data from CRC cell lines and xenografts were used to develop a k-top scoring pair (k-TSP) classifier, which predicted with 71% accuracy which of a test set of patient-derived K-ras mutant CRC explants would respond to AZD6244, providing the basis for a patient-selective clinical trial.",20923857_9,20923857_C517975_D015179,,
770959722,false,true,5,2015-08-14T21:37:00,,No Relation,0.7914,C517975,AZD6244,D015179,CRC,"These results also indicate that resistance to AZD6244 may be mediated, in part, by the upregulation of the Wnt pathway, suggesting potential rational combination partners for AZD6244 in CRC.",20923857_10,20923857_C517975_D015179,,
770959723,false,true,5,2015-08-14T23:43:00,,No Relation,1,D001379,AZA/Azathioprine,D009358,rheumatologic disorders,Azathioprine (AZA) is a commonly used drug for the management of various rheumatologic disorders.,20953224_1,20953224_D001379_D009358,,
770959724,false,true,5,2015-08-15T00:59:00,,Direct,0.7807,D001379,AZA,D064420,toxicity,"To determine the current local practice of AZA dosing, identify AZA-related toxicity and to compare the local practice with the British Society of Rheumatology (BSR) recommendations.",20953224_4,20953224_D001379_D064420,,
770959725,false,true,5,2015-08-14T23:38:00,,No Relation,0.801,D001379,AZA,D064420,toxicities,"Data were collected on patient's demographics, treatment history including AZA dosing regimen, TPMT testing, drug-related toxicities and their management.",20953224_6,20953224_D001379_D064420,,
770959726,false,true,5,2015-08-14T23:29:00,,Direct,1,D001379,AZA,D064420,toxicity,Average initial dose of AZA prescribed was 10037 mg. 45% developed AZA related toxicity.,20953224_10,20953224_D001379_D064420,,
770959727,false,true,5,2015-08-14T22:17:00,,Direct,0.7972,D001379,AZA,D064420,toxicity,A significant proportion of the studied cohort of rheumatologic patients on AZA had drug-related toxicity resulting in discontinuation of AZA.,20953224_14,20953224_D001379_D064420,,
770959728,false,true,5,2015-08-14T21:28:00,,No Relation,0.8092,D014750,vincristine,D008228,diffuse large B-cell non-Hodgkin lymphoma,"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.",20960528_0,20960528_D014750_D008228,,
770959729,false,true,5,2015-08-14T22:20:00,,No Relation,1,D011241,prednisone,D008228,diffuse large B-cell non-Hodgkin lymphoma,"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.",20960528_0,20960528_D011241_D008228,,
770959730,false,true,5,2015-08-14T21:56:00,,No Relation,1,D004317,doxorubicin,D008228,diffuse large B-cell non-Hodgkin lymphoma,"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.",20960528_0,20960528_D004317_D008228,,
770959731,false,true,5,2015-08-14T22:20:00,,No Relation,1,D003520,cyclophosphamide,D008228,diffuse large B-cell non-Hodgkin lymphoma,"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.",20960528_0,20960528_D003520_D008228,,
770959732,false,true,5,2015-08-14T22:07:00,,No Relation,1,D014750,vincristine,D008228,diffuse large B-cell non-Hodgkin lymphoma/DLBCL,"This study was designed to assess the activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA-POCH-R) in elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (DLBCL).",20960528_1,20960528_D014750_D008228,,
770959733,false,true,5,2015-08-14T21:42:00,,No Relation,1,D011241,prednisone,D008228,diffuse large B-cell non-Hodgkin lymphoma/DLBCL,"This study was designed to assess the activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA-POCH-R) in elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (DLBCL).",20960528_1,20960528_D011241_D008228,,
770959734,false,true,5,2015-08-14T22:18:00,,No Relation,1,D004317,doxorubicin,D008228,diffuse large B-cell non-Hodgkin lymphoma/DLBCL,"This study was designed to assess the activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA-POCH-R) in elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (DLBCL).",20960528_1,20960528_D004317_D008228,,
770959735,false,true,5,2015-08-15T02:15:00,,No Relation,1,D003520,cyclophosphamide,D008228,diffuse large B-cell non-Hodgkin lymphoma/DLBCL,"This study was designed to assess the activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA-POCH-R) in elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (DLBCL).",20960528_1,20960528_D003520_D008228,,
770959736,false,true,5,2015-08-14T21:52:00,,No Relation,1,C010119,latrepirdine,D006967,allergy,Dimebon (latrepirdine) was developed and used in Russia as an over-the-counter oral antihistamine for allergy treatment.,21031168_1,21031168_C010119_D006967,,
770959737,false,true,5,2015-08-15T01:45:00,,No Relation,1,C006632,arsenic trioxide,D018197,hepatoblastoma,"In this study the effect of chemotherapeutics (cisplatin, doxorubicin, cytosin arabinoside); differentiating agent (13 cis-retinoic acid) and apoptotic agents (5-aza-2'-deoxycytidine, arsenic trioxide) on notch expression in hepatoblastoma were evaluated.",21033247_2,21033247_C006632_D018197,,
770959738,false,true,5,2015-08-15T01:42:00,,No Relation,1,D002945,cisplatin,D018197,hepatoblastoma,"In this study the effect of chemotherapeutics (cisplatin, doxorubicin, cytosin arabinoside); differentiating agent (13 cis-retinoic acid) and apoptotic agents (5-aza-2'-deoxycytidine, arsenic trioxide) on notch expression in hepatoblastoma were evaluated.",21033247_2,21033247_D002945_D018197,,
770959739,false,true,5,2015-08-14T21:43:00,,No Relation,1,D004317,doxorubicin,D018197,hepatoblastoma,"In this study the effect of chemotherapeutics (cisplatin, doxorubicin, cytosin arabinoside); differentiating agent (13 cis-retinoic acid) and apoptotic agents (5-aza-2'-deoxycytidine, arsenic trioxide) on notch expression in hepatoblastoma were evaluated.",21033247_2,21033247_D004317_D018197,,
770959740,false,true,5,2015-08-14T21:52:00,,No Relation,1,D015474,13 cis-retinoic acid,D018197,hepatoblastoma,"In this study the effect of chemotherapeutics (cisplatin, doxorubicin, cytosin arabinoside); differentiating agent (13 cis-retinoic acid) and apoptotic agents (5-aza-2'-deoxycytidine, arsenic trioxide) on notch expression in hepatoblastoma were evaluated.",21033247_2,21033247_D015474_D018197,,
770959741,false,true,5,2015-08-15T00:54:00,,No Relation,1,C014347,5-aza-2'-deoxycytidine,D018197,hepatoblastoma,"In this study the effect of chemotherapeutics (cisplatin, doxorubicin, cytosin arabinoside); differentiating agent (13 cis-retinoic acid) and apoptotic agents (5-aza-2'-deoxycytidine, arsenic trioxide) on notch expression in hepatoblastoma were evaluated.",21033247_2,21033247_C014347_D018197,,
770959742,false,true,5,2015-08-15T01:46:00,,No Relation,0.8111,D014212,retinoic acid,D018197,hepatoblastoma,The use of retinoic acid in the control of minimal residual disease of hepatoblastoma should be discussed.,21033247_11,21033247_D014212_D018197,,
770959743,false,true,5,2015-08-14T21:28:00,,No Relation,0.8117,D002945,Cisplatin,D018197,hepatoblastoma,Cisplatin as main chemotherapeutic agent treatment is shown to change gene expression levels in notch signalling pathway in hepatoblastoma.,21033247_13,21033247_D002945_D018197,,
770959744,false,true,5,2015-08-15T01:00:00,,No Relation,0.8011,D006854,cortisol,D000309,adrenal insufficiency,Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency.,21036888_0,21036888_D006854_D000309,,
770959745,false,true,5,2015-08-14T23:54:00,,No Relation,1,D006854,cortisol,D000309,adrenal insufficiency,To compare the cortisol response of the 1__g and the 250__g ACTH test in a large study of patients with suspected adrenal insufficiency.,21036888_1,21036888_D006854_D000309,,
770959746,false,true,5,2015-08-14T21:40:00,,No Relation,0.8011,D006854,cortisol,D000309,adrenal insufficiency,This study shows that the 1_g and the 250__g ACTH tests have comparable cortisol responses in patients with suspected adrenal insufficiency.,21036888_8,21036888_D006854_D000309,,
770959747,false,true,5,2015-08-14T21:33:00,,No Relation,1,D016190,carboplatin,D009447,neuroblastoma,High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.,21049517_0,21049517_D016190_D009447,,
770959748,false,true,5,2015-08-15T02:42:00,,No Relation,1,C051890,irinotecan,D009447,neuroblastoma,High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.,21049517_0,21049517_C051890_D009447,,
770959749,false,true,5,2015-08-15T01:25:00,,No Relation,1,C047246,temozolomide,D009447,neuroblastoma,High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.,21049517_0,21049517_C047246_D009447,,
770959750,false,true,5,2015-08-15T01:54:00,,No Relation,0.824,D000305,corticosteroids,D065631,allergic rhinitis,The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma.,21050027_0,21050027_D000305_D065631,,
770959751,false,true,5,2015-08-15T00:09:00,,No Relation,1,D000305,corticosteroids,D001249,mild asthma/asthma,The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma.,21050027_0,21050027_D000305_D001249,,
770959752,false,true,5,2015-08-14T23:38:00,,No Relation,0.8178,D019819,budesonide,D001249,mild asthma,"Allergic rhinitics with mild asthma were randomized to a 14-day treatment period with either nasal budesonide 100 _g, 1 puff per nostril twice a day, or placebo.",21050027_3,21050027_D019819_D001249,,
770959753,false,true,5,2015-08-14T21:49:00,,No Relation,1,D004110,diltiazem,D002318,cardiovascular disease,"As diuretics and _-blockers inhibit renal sodium reabsorption and renin release, respectively, we hypothesized that the _-blocker or diuretic-induced blood pressure reduction and prevention of cardiovascular disease would be greater in patients with the highest ENaC expression (rs4149601 G-allele), whereas there would be no such genetically mediated differences in treatment efficacy among patients treated with the vasodilator diltiazem.",21052022_2,21052022_D004110_D002318,,
770959754,false,true,5,2015-08-14T22:20:00,,No Relation,1,D012964,sodium,D002318,cardiovascular disease,"As diuretics and _-blockers inhibit renal sodium reabsorption and renin release, respectively, we hypothesized that the _-blocker or diuretic-induced blood pressure reduction and prevention of cardiovascular disease would be greater in patients with the highest ENaC expression (rs4149601 G-allele), whereas there would be no such genetically mediated differences in treatment efficacy among patients treated with the vasodilator diltiazem.",21052022_2,21052022_D012964_D002318,,
770959755,false,true,5,2015-08-14T21:38:00,,No Relation,1,D004110,diltiazem,D006973,hypertensive,We related rs4149601 status to 6-month blood pressure reduction and risk of cardiovascular events in 5152 hypertensive patients (DBP  100 mmHg) from the Nordic Diltiazem Study (NORDIL) randomized to either _-blocker and/or diuretic-based treatment or diltiazem-based treatment.,21052022_3,21052022_D004110_D006973,,
770959756,false,true,5,2015-08-15T00:19:00,,No Relation,1,D004110,diltiazem,D002318,cardiovascular disease,"The functional NEDD4L rs4149601 polymorphism influences the efficacy of _-blocker and/or diuretic-based antihypertensive treatment both in terms of blood pressure reduction and cardiovascular disease protection, whereas diltiazem-based antihypertensive treatment efficacy is not influenced by this NEDD4L polymorphism.",21052022_7,21052022_D004110_D002318,,
770959757,false,true,5,2015-08-14T22:43:00,,No Relation,1,C440975,silibinin,D015470,AML,"Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).",21084834_0,21084834_C440975_D015470,,
770959758,false,true,5,2015-08-14T21:33:00,,No Relation,1,D002117,"1,25-dihydroxyvitamin D(3)",D015470,AML,"Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).",21084834_0,21084834_D002117_D015470,,
770959759,false,true,5,2015-08-14T22:13:00,,No Relation,0.8182,D002117,"1,25-dihydroxyvitamin D3",D007938,leukemia,"We have investigated in preclinical studies the potential anti-leukemia use of the plant-derived polyphenol Silibinin (SIL) in combination with 1,25-dihydroxyvitamin D3 (1,25D).",21084834_3,21084834_D002117_D007938,,
770959760,false,true,5,2015-08-14T21:37:00,,No Relation,1,D013256,steroid,D001416,chronic function-limiting mid back or upper back pain,To determine the clinical effectiveness of therapeutic local anesthetic medial branch blocks with or without steroid in managing chronic function-limiting mid back or upper back pain of facet joint origin.,21102966_5,21102966_D013256_D001416,,
770959761,false,true,5,2015-08-15T02:08:00,,No Relation,1,D013256,steroid,D001416,chronic function-limiting mid back or upper back pain,"Therapeutic thoracic medial branch blocks, with or without steroid, may provide a management option for chronic function-limiting mid back or upper back pain of facet joint origin.",21102966_15,21102966_D013256_D001416,,
770959762,false,true,5,2015-08-14T23:26:00,,No Relation,1,C092292,ziprasidone,C564058,multiple neurocognitive domains,"The more robust findings, that is those significant across multiple neurocognitive domains and having adjacent SNPs showing evidence for association, were rs286913 at the EHF gene (p-value 6.99  10(-8), q-value 0.034, mediating the effects of ziprasidone on vigilance), rs11240594 at SLC26A9 (p-value 1.4  10(-7), q-value 0.068, mediating the effects of olanzapine on processing speed), and rs11677416 at IL1A (p-value 6.67  10(-7), q-value 0.081, mediating the effects of olanzapine on working memory).",21107309_7,21107309_C092292_C564058,,
770959763,false,true,5,2015-08-15T01:12:00,,No Relation,0.7902,C076029,olanzapine,C564058,multiple neurocognitive domains,"The more robust findings, that is those significant across multiple neurocognitive domains and having adjacent SNPs showing evidence for association, were rs286913 at the EHF gene (p-value 6.99  10(-8), q-value 0.034, mediating the effects of ziprasidone on vigilance), rs11240594 at SLC26A9 (p-value 1.4  10(-7), q-value 0.068, mediating the effects of olanzapine on processing speed), and rs11677416 at IL1A (p-value 6.67  10(-7), q-value 0.081, mediating the effects of olanzapine on working memory).",21107309_7,21107309_C076029_C564058,,
770959764,false,true,5,2015-08-15T01:24:00,,No Relation,1,C084178,telmisartan,D006973,hypertension,Recent meta-analysis demonstrated the possibility that telmisartan was the strongest ARB for the reduction of BP in patients with essential hypertension.,21130741_3,21130741_C084178_D006973,,
770959765,false,true,5,2015-08-14T21:55:00,,No Relation,1,C084178,telmisartan,D002318,cardiovascular disease,"Our present study suggests that due to its ""delta lock"" structure, telmisartan may be superior to other ARBs in halting cardiovascular disease in patients with hypertension.",21130741_9,21130741_C084178_D002318,,
770959766,false,true,5,2015-08-14T23:32:00,,No Relation,0.8173,C084178,telmisartan,D006973,hypertension,"Our present study suggests that due to its ""delta lock"" structure, telmisartan may be superior to other ARBs in halting cardiovascular disease in patients with hypertension.",21130741_9,21130741_C084178_D006973,,
770959767,false,true,5,2015-08-15T01:56:00,,Direct,0.8074,D001241,aspirin,D014947,small bowel injury,Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury.,21133822_0,21133822_D001241_D014947,,
770959768,false,true,5,2015-08-14T23:38:00,,Direct,1,C446540,thienopyridine,D014947,small bowel injury,Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury.,21133822_0,21133822_C446540_D014947,,
770959769,false,true,5,2015-08-14T21:34:00,,Direct,1,D001241,aspirin,D014947,small bowel injury,"In more recent studies, small bowel injury and enteropathy associated with low-dose aspirin are increasingly being recognized.",21133822_2,21133822_D001241_D014947,,
770959770,false,true,5,2015-08-14T21:39:00,,Direct,0.8071,D001241,aspirin,C538273,enteropathy,"In more recent studies, small bowel injury and enteropathy associated with low-dose aspirin are increasingly being recognized.",21133822_2,21133822_D001241_C538273,,
770959771,false,true,5,2015-08-15T00:20:00,,No Relation,0.5892,D001241,aspirin,D014947,small bowel injury,Aim of this study was to evaluate small bowel injury using video capsule endoscopy (VCE) in obscure gastrointestinal bleeding (OGIB) patients taking low-dose aspirin including other antithrombotics.,21133822_3,21133822_D001241_D014947,,
770959772,false,true,5,2015-08-15T01:13:00,,No Relation,0.4121,D001241,aspirin,D006470,OGIB/obscure gastrointestinal bleeding,Aim of this study was to evaluate small bowel injury using video capsule endoscopy (VCE) in obscure gastrointestinal bleeding (OGIB) patients taking low-dose aspirin including other antithrombotics.,21133822_3,21133822_D001241_D006470,,
770959773,false,true,5,2015-08-14T22:35:00,,No Relation,1,D014859,warfarin,D001768,redness lesions,The median number of redness lesions in the combined group was the highest among the four groups and was significantly higher than that in the warfarin group.,21133822_9,21133822_D014859_D001768,,
770959774,false,true,5,2015-08-14T21:53:00,,Direct,0.6056,D001241,aspirin,D014077,redness or small erosions,The lesions of redness or small erosions in the aspirin and the combined groups tended to exist in the proximal part of small bowel.,21133822_10,21133822_D001241_D014077,,
770959775,false,true,5,2015-08-15T01:21:00,,Direct,0.8113,D001241,aspirin,D014947,small bowel injury,"Combination of low-dose aspirin therapy and thienopyridine may exacerbate small bowel injury, and the preventive strategies should be established.",21133822_11,21133822_D001241_D014947,,
770959776,false,true,5,2015-08-14T21:33:00,,Direct,1,C446540,thienopyridine,D014947,small bowel injury,"Combination of low-dose aspirin therapy and thienopyridine may exacerbate small bowel injury, and the preventive strategies should be established.",21133822_11,21133822_C446540_D014947,,
770959777,false,true,5,2015-08-14T22:26:00,,Direct,0.5966,D012436,S-adenosylmethionine,D005354,fibrosarcoma,Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase.,21134486_0,21134486_D012436_D005354,,
770959778,false,true,5,2015-08-14T23:44:00,,No Relation,1,C103100,silver acetate,D004487,cytotoxicity,"Novel benzyl-substituted N-heterocyclic carbene-silver acetate complexes: synthesis, cytotoxicity and antibacterial studies.",21135954_0,21135954_C103100_D004487,,
770959779,false,true,5,2015-08-14T23:58:00,,No Relation,1,D012834,silver,D004927,Escherichia,"Preliminary in vitro antibacterial activity of the NHC-precursors and NHC-silver complexes was investigated against Gram-positive bacteria Staphylococcus aureus, and Gram-negative bacteria Escherichia coli using the qualitative Kirby-Bauer disk-diffusion method.",21135954_4,21135954_D012834_D004927,,
770959780,false,true,5,2015-08-14T21:52:00,,No Relation,0.7914,D012834,silver,D009369,renal-cancer,All six NHC-silver complexes were tested for their cytotoxicity through MTT based in vitro tests on the human renal-cancer cell line Caki-1 in order to determine their IC values.,21135954_6,21135954_D012834_D009369,,
770959781,false,true,5,2015-08-14T21:28:00,,No Relation,1,D012834,silver,D004487,cytotoxicity,All six NHC-silver complexes were tested for their cytotoxicity through MTT based in vitro tests on the human renal-cancer cell line Caki-1 in order to determine their IC values.,21135954_6,21135954_D012834_D004487,,
770959782,false,true,5,2015-08-15T01:22:00,,No Relation,0.593,D002945,cisplatin,D004487,cytotoxicity,"These values represent improved cytotoxicity against Caki-1, most notably for 4c, which is a three times more cytotoxic than cisplatin (IC value = 3.3 _M) itself.",21135954_8,21135954_D002945_D004487,,
770959783,false,true,5,2015-08-14T21:35:00,,No Relation,1,D014801,vitamin A,D014802,A deficiencies,Iron and vitamin A deficiencies impact anemia and the immune system.,21147712_1,21147712_D014801_D014802,,
770959784,false,true,5,2015-08-14T21:33:00,,No Relation,0.5869,D007501,Iron,D000740,anemia,Iron and vitamin A deficiencies impact anemia and the immune system.,21147712_1,21147712_D007501_D000740,,
770959785,false,true,5,2015-08-15T01:48:00,,No Relation,0.5982,D014801,vitamin A,D000740,anemia,Iron and vitamin A deficiencies impact anemia and the immune system.,21147712_1,21147712_D014801_D000740,,
770959786,false,true,5,2015-08-14T21:47:00,,No Relation,1,D007501,Iron,D014802,A deficiencies,Iron and vitamin A deficiencies impact anemia and the immune system.,21147712_1,21147712_D007501_D014802,,
770959787,false,true,5,2015-08-14T21:52:00,,No Relation,0.7977,C012589,Trichostatin A/TSA,D007249,inflammation,"To examine the effects of a histone deacetylase inhibitor, Trichostatin A (TSA), on the behavior of macrophages and subconjunctival fibroblasts in vitro and on ocular surface inflammation and scarring in vivo using an alkali burn wound healing model.",21203344_1,21203344_C012589_D007249,,
770959788,false,true,5,2015-08-14T21:52:00,,No Relation,0.8024,C012589,TSA,D007249,inflammation,Effects of TSA on expression of inflammation-related growth factors or collagen I were examined by real-time RT-PCR or immunoassay in mouse macrophages or human subconjunctival fibroblasts.,21203344_2,21203344_C012589_D007249,,
770959789,false,true,5,2015-08-15T01:35:00,,No Relation,1,C012589,TSA,D065306,cornea,Histology and real-time RT-PCR investigations evaluated the effects of TSA on the healing process of the cornea.,21203344_6,21203344_C012589_D065306,,
770959790,false,true,5,2015-08-14T21:46:00,,No Relation,1,C012589,TSA,D065306,cornea,Real-time PCR and immunocytochemistry studies showed that systemic administration of TSA suppressed the inflammation and fibrotic response in the stroma and accelerated epithelial healing in the alkali-burned mouse cornea.,21203344_9,21203344_C012589_D065306,,
770959791,false,true,5,2015-08-14T21:39:00,,No Relation,1,C012589,TSA,D007249,inflammation,Real-time PCR and immunocytochemistry studies showed that systemic administration of TSA suppressed the inflammation and fibrotic response in the stroma and accelerated epithelial healing in the alkali-burned mouse cornea.,21203344_9,21203344_C012589_D007249,,
770959792,false,true,5,2015-08-14T21:58:00,,No Relation,0.6312,D014443,tyrosine,D009369,cancer,"Studying S->A nonphosphorylatable point mutants suggests that these sites coordinately upregulate FAK Y397 tyrosine phosphorylation, which conventionally initiates FAK activation, and mediate pressure-induced cancer cell adhesion.",21209368_6,21209368_D014443_D009369,,
770959793,false,true,5,2015-08-14T22:16:00,,No Relation,0.8044,D000638,amiodarone,D001281,atrial fibrillation,"Vernakalant has been demonstrated more effective than both placebo and amiodarone for the rapid conversion of atrial fibrillation, without significant adverse events.",21235460_5,21235460_D000638_D001281,,
770959794,false,true,5,2015-08-14T21:36:00,,No Relation,1,D015125,8-quinolinol,D004487,cytotoxicity,The lanthanide complexes 1-3 exhibited significantly enhanced cytotoxicity vs. free substituted 8-quinolinol.,21258737_6,21258737_D015125_D004487,,
770959795,false,true,5,2015-08-15T01:08:00,,No Relation,1,C098010,linezolid,D003550,cystic fibrosis,"Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.",21263048_0,21263048_C098010_D003550,,
770959796,false,true,5,2015-08-14T22:48:00,,No Relation,1,C098010,LZD,D003550,CF,Analysis of clinical data showed that the 8 CF patients with LRSA received more LZD courses (18.8 versus 5.9; P = 0.001) for a longer duration (546.5 versus 211.9 days; P < 0.001) and had extended periods of exposure to LZD (83.1 versus 30.1 days/year; P < 0.001) than the 69 with LZD-susceptible isolates.,21263048_4,21263048_C098010_D003550,,
770959797,false,true,5,2015-08-15T02:13:00,,No Relation,0.5878,C098010,LZD,D003550,CF,Emergence of LRSA is a serious concern for CF patients who undergo prolonged courses of LZD therapy.,21263048_12,21263048_C098010_D003550,,
770959798,false,true,5,2015-08-15T00:17:00,,Direct,1,D000305,corticosteroids,D017449,Allergic contact dermatitis,Allergic contact dermatitis following ocular use of corticosteroids.,21265627_0,21265627_D000305_D017449,,
770959799,false,true,5,2015-08-15T00:41:00,,No Relation,0.622,D014443,tyrosine,D034721,systemic mastocytosis,"Activating mutations in codon D816 of the tyrosine kinase receptor, KIT, are found in the majority of patients with systemic mastocytosis.",21273305_1,21273305_D014443_D034721,,
770959800,false,true,5,2015-08-15T00:04:00,,No Relation,1,C523074,allylpyrocatechol,D001172,Rheumatoid Arthritis,Attenuation of oxidative stress by allylpyrocatechol in synovial cellular infiltrate of patients with Rheumatoid Arthritis.,21284489_0,21284489_C523074_D001172,,
770959801,false,true,5,2015-08-15T00:56:00,,No Relation,1,C523074,Allylpyrocatechol,D001172,Rheumatoid arthritis,"Allylpyrocatechol, a phytoconstituent of Piper betle leaves, has potent anti-inflammatory activity and this study evaluated its anti-oxidant effect on the synovial infiltrate of patients with Rheumatoid arthritis.",21284489_2,21284489_C523074_D001172,,
770959802,false,true,5,2015-08-14T21:38:00,,No Relation,1,C523074,allylpyrocatechol,D001172,Rheumatoid Arthritis,"Taken together, this ex vivo study has established that allylpyrocatechol has potent scavenging activity and could be considered as an add-on therapy in the treatment of inflammation-associated disorders like Rheumatoid Arthritis.",21284489_7,21284489_C523074_D001172,,
770959803,false,true,5,2015-08-14T22:20:00,,No Relation,0.7987,C523074,allylpyrocatechol,D007249,inflammation-associated disorders,"Taken together, this ex vivo study has established that allylpyrocatechol has potent scavenging activity and could be considered as an add-on therapy in the treatment of inflammation-associated disorders like Rheumatoid Arthritis.",21284489_7,21284489_C523074_D007249,,
770959804,false,true,5,2015-08-15T01:37:00,,No Relation,1,C074679,reboxetine,D001289,attention-deficit/hyperactivity disorder,"Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.",21312292_0,21312292_C074679_D001289,,
770959805,false,true,5,2015-08-15T00:38:00,,No Relation,1,C074679,reboxetine,D001289,attention-deficit/hyperactivity disorder/ADHD,"The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD).",21312292_1,21312292_C074679_D001289,,
770959806,false,true,5,2015-08-15T02:20:00,,No Relation,1,C074679,reboxetine,D001289,ADHD,"In a double blind placebo-controlled clinical trial, the efficacy of 8mg/day of reboxetine (twice daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks.",21312292_2,21312292_C074679_D001289,,
770959807,false,true,5,2015-08-15T01:34:00,,Direct,1,C074679,reboxetine,D001008,anxiety,"Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.",21312292_7,21312292_C074679_D001008,,
770959808,false,true,5,2015-08-14T21:58:00,,Direct,1,C074679,reboxetine,D012893,sleep disturbance,"Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.",21312292_7,21312292_C074679_D012893,,
770959809,false,true,5,2015-08-14T21:46:00,,Direct,1,C074679,reboxetine,D014987,dry mouth,"Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.",21312292_7,21312292_C074679_D014987,,
770959810,false,true,5,2015-08-14T21:47:00,,No Relation,1,C074679,Reboxetine,D001289,ADHD,Reboxetine could be used and tolerated as an effective treatment for adults with ADHD.,21312292_8,21312292_C074679_D001289,,
770959811,false,true,5,2015-08-14T21:28:00,,No Relation,1,C024352,fludarabine,D015451,CLL/chronic lymphocytic leukemia,"Over the past few years, more effective therapies have emerged in the treatment of chronic lymphocytic leukemia (CLL); these are mainly combinations of immunotherapy with fludarabine-based regimens.",21322776_1,21322776_C024352_D015451,,
770959812,false,true,5,2015-08-15T01:20:00,,No Relation,1,C522667,Asenapine,D001714,bipolar I disorder/mania,Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.,21323396_0,21323396_C522667_D001714,,
770959813,false,true,5,2015-08-15T02:13:00,,No Relation,1,C522667,Asenapine,D001714,manic/bipolar I disorder,"Asenapine is an atypical antipsychotic agent available in sublingual formulations (5 or 10 mg) and indicated in the US (Saphris) for the acute treatment, as monotherapy or adjunctive therapy, of manic and mixed episodes and in the EU (Sycrest) for the treatment of moderate to severe manic episodes, in adult patients with bipolar I disorder.",21323396_1,21323396_C522667_D001714,,
770959814,false,true,5,2015-08-14T23:18:00,,No Relation,1,C522667,asenapine,D001714,bipolar I disorder/mania,"In two large (both n = 480), well designed, 3-week trials in adult patients with bipolar I disorder, asenapine monotherapy was significantly more effective than placebo at improving mania symptoms, as assessed using the Young Mania Rating Scale total score (YMRS; primary endpoint), with significant differences between the asenapine and placebo groups occurring after 2 days of treatment.",21323396_2,21323396_C522667_D001714,,
770959815,false,true,5,2015-08-15T01:06:00,,No Relation,1,C076029,olanzapine,D001714,mania,"In a 9-week extension study that recruited completers from the monotherapy trials, there were no significant differences between asenapine and olanzapine groups in terms in Montgomery-sberg Depression Rating Scale (MADRS) scores, CGI-BP mania severity scores, YMRS response rates or YMRS remission rates during the extension phase.",21323396_5,21323396_C076029_D001714,,
770959816,false,true,5,2015-08-15T01:25:00,,No Relation,1,C522667,asenapine,D001714,mania,"In a 9-week extension study that recruited completers from the monotherapy trials, there were no significant differences between asenapine and olanzapine groups in terms in Montgomery-sberg Depression Rating Scale (MADRS) scores, CGI-BP mania severity scores, YMRS response rates or YMRS remission rates during the extension phase.",21323396_5,21323396_C522667_D001714,,
770959817,false,true,5,2015-08-15T01:28:00,,No Relation,1,D014635,valproate,D001714,manic symptoms,"In a 12-week trial of asenapine as adjunctive therapy to lithium or valproate, asenapine was more effective than placebo in improving manic symptoms, based on the difference between groups in the YMRS total score at week 3 (primary endpoint).",21323396_7,21323396_D014635_D001714,,
770959818,false,true,5,2015-08-14T21:31:00,,No Relation,1,C522667,asenapine,D001714,manic symptoms,"In a 12-week trial of asenapine as adjunctive therapy to lithium or valproate, asenapine was more effective than placebo in improving manic symptoms, based on the difference between groups in the YMRS total score at week 3 (primary endpoint).",21323396_7,21323396_C522667_D001714,,
770959819,false,true,5,2015-08-14T22:31:00,,No Relation,1,D008094,lithium,D001714,manic symptoms,"In a 12-week trial of asenapine as adjunctive therapy to lithium or valproate, asenapine was more effective than placebo in improving manic symptoms, based on the difference between groups in the YMRS total score at week 3 (primary endpoint).",21323396_7,21323396_D008094_D001714,,
770959820,false,true,5,2015-08-15T01:41:00,,Direct,0.797,C522667,asenapine,D004244,dizziness,"In a pooled analysis of the monotherapy trials, the most common adverse events (occurring in  5% of patients and at twice the incidence of placebo) reported during acute phase asenapine monotherapy for bipolar mania were somnolence, dizziness, extrapyramidal symptoms (EPS, other than akathisia) and increased bodyweight, which were similar in nature to those occurring during longer-term monotherapy with asenapine.",21323396_9,21323396_C522667_D004244,,
770959821,false,true,5,2015-08-15T01:15:00,,Direct,1,C522667,asenapine,D001480,extrapyramidal symptoms/EPS,"In a pooled analysis of the monotherapy trials, the most common adverse events (occurring in  5% of patients and at twice the incidence of placebo) reported during acute phase asenapine monotherapy for bipolar mania were somnolence, dizziness, extrapyramidal symptoms (EPS, other than akathisia) and increased bodyweight, which were similar in nature to those occurring during longer-term monotherapy with asenapine.",21323396_9,21323396_C522667_D001480,,
770959822,false,true,5,2015-08-15T00:26:00,,Direct,0.8132,C522667,asenapine,D006970,somnolence,"In a pooled analysis of the monotherapy trials, the most common adverse events (occurring in  5% of patients and at twice the incidence of placebo) reported during acute phase asenapine monotherapy for bipolar mania were somnolence, dizziness, extrapyramidal symptoms (EPS, other than akathisia) and increased bodyweight, which were similar in nature to those occurring during longer-term monotherapy with asenapine.",21323396_9,21323396_C522667_D006970,,
770959823,false,true,5,2015-08-14T21:48:00,,No Relation,0.7972,C522667,asenapine,D011595,akathisia,"In a pooled analysis of the monotherapy trials, the most common adverse events (occurring in  5% of patients and at twice the incidence of placebo) reported during acute phase asenapine monotherapy for bipolar mania were somnolence, dizziness, extrapyramidal symptoms (EPS, other than akathisia) and increased bodyweight, which were similar in nature to those occurring during longer-term monotherapy with asenapine.",21323396_9,21323396_C522667_D011595,,
770959824,false,true,5,2015-08-14T21:40:00,,No Relation,0.6192,C522667,asenapine,D001714,bipolar mania,"In a pooled analysis of the monotherapy trials, the most common adverse events (occurring in  5% of patients and at twice the incidence of placebo) reported during acute phase asenapine monotherapy for bipolar mania were somnolence, dizziness, extrapyramidal symptoms (EPS, other than akathisia) and increased bodyweight, which were similar in nature to those occurring during longer-term monotherapy with asenapine.",21323396_9,21323396_C522667_D001714,,
770959825,false,true,5,2015-08-14T21:28:00,,No Relation,1,C522667,asenapine,D001480,EPS,EPS did not worsen in severity during longer-term asenapine monotherapy.,21323396_10,21323396_C522667_D001480,,
770959826,false,true,5,2015-08-15T00:15:00,,No Relation,1,C522667,asenapine,D001714,manic/bipolar I disorder,"In the meantime, asenapine is a further option for the management of manic and/or mixed symptoms in patients with bipolar I disorder and may be of particular value for patients who are at high risk for metabolic abnormalities.",21323396_13,21323396_C522667_D001714,,
770959827,false,true,5,2015-08-14T23:33:00,,No Relation,1,C522667,asenapine,C566454,metabolic abnormalities,"In the meantime, asenapine is a further option for the management of manic and/or mixed symptoms in patients with bipolar I disorder and may be of particular value for patients who are at high risk for metabolic abnormalities.",21323396_13,21323396_C522667_C566454,,
770959828,false,true,5,2015-08-14T22:04:00,,No Relation,0.6048,D013256,steroids,D000230,PDAC,"Of the 518 patients resected for PDAC, 13.3% were being treated preoperatively with insulin, 14.8% were on a statin, 1.7% were on steroids, and 7.6% were on thyroxin.",21327533_5,21327533_D013256_D000230,,
770959829,false,true,5,2015-08-14T22:13:00,,Direct,0.6057,D019888,nelfinavir,D008228,endoplasmic reticulum stress,Analysis of nelfinavir-induced endoplasmic reticulum stress.,21329798_0,21329798_D019888_D008228,,
770959830,false,true,5,2015-08-14T22:22:00,,No Relation,1,D019888,Nelfinavir,D009369,cancer,Nelfinavir (Viracept) is an HIV protease inhibitor that has been shown to induce the endoplasmic reticulum (ER) stress reaction in human cancer cells.,21329798_1,21329798_D019888_D009369,,
770959831,false,true,5,2015-08-14T23:35:00,,No Relation,1,D019888,nelfinavir,D009369,cancer,"Although the presumed drug doses needed for an efficient ER stress reaction and ensuing apoptosis in cancer cells is somewhat higher than those prescribed for HIV-infected persons, nelfinavir represents one of the few clinically applicable ER stress-inducing agents, and is currently being tested in clinical studies on cancer patients.",21329798_2,21329798_D019888_D009369,,
770959832,false,true,5,2015-08-15T00:27:00,,No Relation,1,D019888,nelfinavir,D015658,HIV-infected,"Although the presumed drug doses needed for an efficient ER stress reaction and ensuing apoptosis in cancer cells is somewhat higher than those prescribed for HIV-infected persons, nelfinavir represents one of the few clinically applicable ER stress-inducing agents, and is currently being tested in clinical studies on cancer patients.",21329798_2,21329798_D019888_D015658,,
770959833,false,true,5,2015-08-14T22:27:00,,No Relation,0.602,D019888,nelfinavir,D009369,cancer,"In addition, methods are described that might facilitate the analysis and monitoring of the nelfinavir-induced ER stress response either in cancer cells in cell culture or in cancer tissue biopsies.",21329798_4,21329798_D019888_D009369,,
770959834,false,true,5,2015-08-15T02:14:00,,No Relation,1,D016559,Tacrolimus,D003093,ulcerative colitis,Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.,21336140_0,21336140_D016559_D003093,,
770959835,false,true,5,2015-08-14T21:34:00,,No Relation,0.818,D016559,tacrolimus,D003093,ulcerative colitis/UC,"Although the efficacy of tacrolimus for inducing remission of refractory ulcerative colitis (UC) is established, its efficacy for maintaining remission of UC has not been evaluated.",21336140_1,21336140_D016559_D003093,,
770959836,false,true,5,2015-08-14T21:46:00,,No Relation,1,D016559,tacrolimus,D003093,UC,The aim of this study was to evaluate the efficacy of tacrolimus compared with thiopurines for maintaining remission in patients with refractory UC.,21336140_2,21336140_D016559_D003093,,
770959837,false,true,5,2015-08-14T21:47:00,,No Relation,1,D016559,tacrolimus,D003093,UC,"Twenty-four UC patients treated with tacrolimus and 34 treated with thiopurines to maintain remission were enrolled as the tacrolimus group and the thiopurine group, respectively.",21336140_3,21336140_D016559_D003093,,
770959838,false,true,5,2015-08-14T22:19:00,,No Relation,1,D016559,tacrolimus,D003093,UC,Maintenance therapy with tacrolimus for patients with UC could be considered an alternative to thiopurine therapy.,21336140_10,21336140_D016559_D003093,,
770959839,false,true,5,2015-08-14T21:40:00,,No Relation,0.8051,D019829,nevirapine,D015658,HIV-infected,We examined antiretroviral resistance among a cohort of 323 South African HIV-infected children <2 years old exposed to nevirapine for prevention of mother-to-child transmission.,21345162_2,21345162_D019829_D015658,,
770959840,false,true,5,2015-08-14T23:37:00,,No Relation,1,D004997,ethinyl estradiol,D007246,infertility,The multiple uses of ethinyl estradiol for treating infertility.,21355449_0,21355449_D004997_D007246,,
770959841,false,true,5,2015-08-15T01:13:00,,No Relation,0.8094,D004997,ethinyl estradiol,D000568,hypergonadotropic amenorrhea,Twenty to 40 micrograms of ethinyl estradiol can be started on day 2 or 3 of the cycle and combined with exogenous gonadotropin can be useful in improving hostile cervical mucus or inducing ovulation in women with hypergonadotropic amenorrhea.,21355449_2,21355449_D004997_D000568,,
770959842,false,true,5,2015-08-15T01:57:00,,No Relation,1,D002738,chloroquine,D008180,systemic lupus erythematosus,"In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time.",21398612_2,21398612_D002738_D008180,,
770959843,false,true,5,2015-08-14T22:26:00,,No Relation,1,D011796,quinacrine,D008180,systemic lupus erythematosus,"In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time.",21398612_2,21398612_D011796_D008180,,
770959844,false,true,5,2015-08-14T21:48:00,,No Relation,1,D006886,hydroxychloroquine,D008180,systemic lupus erythematosus,"In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time.",21398612_2,21398612_D006886_D008180,,
770959845,false,true,5,2015-08-15T00:36:00,,No Relation,1,D003078,colchicine,D009336,necrosis,Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.,21431291_0,21431291_D003078_D009336,,
770959846,false,true,5,2015-08-14T23:00:00,,No Relation,1,D003078,colchicine,D009369,tumor,Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.,21431291_0,21431291_D003078_D009369,,
770959847,false,true,5,2015-08-15T00:48:00,,No Relation,1,D003078,colchicine,C536657,TNF,Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.,21431291_0,21431291_D003078_C536657,,
770959848,false,true,5,2015-08-14T23:11:00,,No Relation,1,D003078,colchicine,D011507,proteinuria,Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.,21431291_0,21431291_D003078_D011507,,
770959849,false,true,5,2015-08-15T00:47:00,,No Relation,1,D003078,colchicine,D010505,FMF/familial mediterranean fever,Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.,21431291_0,21431291_D003078_D010505,,
770959850,false,true,5,2015-08-15T00:59:00,,No Relation,1,D003078,colchicine,D000686,amyloidosis,The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine.,21431291_2,21431291_D003078_D000686,,
770959851,false,true,5,2015-08-14T23:43:00,,No Relation,1,D003078,colchicine,D010505,FMF,The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine.,21431291_2,21431291_D003078_D010505,,
770959852,false,true,5,2015-08-14T21:54:00,,No Relation,1,D003078,colchicine,D010505,familial mediterranean fever,About 5-10% of cases with familial mediterranean fever may be resistant to colchicine.,21431291_3,21431291_D003078_D010505,,
770959853,false,true,5,2015-08-14T22:00:00,,No Relation,1,D003078,colchicine,D010505,FMF,"In literature, there is a controversy about the treatment of FMF patients resistant to colchicine.",21431291_4,21431291_D003078_D010505,,
770959854,false,true,5,2015-08-14T21:43:00,,No Relation,0.7949,C467566,pomalidomide,D000740,anemia,"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.",21442636_0,21442636_C467566_D000740,,
770959855,false,true,5,2015-08-14T22:10:00,,No Relation,1,C467566,pomalidomide,D055728,myelofibrosis,"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.",21442636_0,21442636_C467566_D055728,,
770959856,false,true,5,2015-08-14T21:33:00,,No Relation,1,C467566,Pomalidomide,D000740,anemia,Pomalidomide therapy is effective for alleviating anemia in myelofibrosis; we examined the relationship between plasma cytokine/chemokine levels and response to treatment with pomalidomide.,21442636_2,21442636_C467566_D000740,,
770959857,false,true,5,2015-08-14T21:36:00,,No Relation,1,C467566,Pomalidomide,D055728,myelofibrosis,Pomalidomide therapy is effective for alleviating anemia in myelofibrosis; we examined the relationship between plasma cytokine/chemokine levels and response to treatment with pomalidomide.,21442636_2,21442636_C467566_D055728,,
770959858,false,true,5,2015-08-14T23:53:00,,No Relation,1,C467566,pomalidomide,D055728,myelofibrosis,The study population included 32 Mayo Clinic patients (median age 66 years) who participated in two consecutive clinical trials of pomalidomide therapy for myelofibrosis-associated anemia.,21442636_3,21442636_C467566_D055728,,
770959859,false,true,5,2015-08-14T23:09:00,,No Relation,0.8011,C467566,pomalidomide,D000740,anemia,The study population included 32 Mayo Clinic patients (median age 66 years) who participated in two consecutive clinical trials of pomalidomide therapy for myelofibrosis-associated anemia.,21442636_3,21442636_C467566_D000740,,
770959860,false,true,5,2015-08-14T22:46:00,,No Relation,1,C467566,pomalidomide,D013163,splenomegaly,"Current data suggest that, in the context of pomalidomide treatment, response is more likely in the presence of JAK2V617F and further predicted by the absence of marked splenomegaly or increased levels of proinflammatory cytokines.",21442636_8,21442636_C467566_D013163,,
770959861,false,true,5,2015-08-14T21:36:00,,Direct,1,D013792,thalidomide,D054556,VTE,"Since the introduction of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide in the therapeutic armamentarium of MM, VTE has emerged as one of the leading complications, in particular in patients with newly diagnosed MM.",21455855_5,21455855_D013792_D054556,,
770959862,false,true,5,2015-08-15T00:02:00,,Direct,0.794,C467567,lenalidomide,D054556,VTE,"Since the introduction of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide in the therapeutic armamentarium of MM, VTE has emerged as one of the leading complications, in particular in patients with newly diagnosed MM.",21455855_5,21455855_C467567_D054556,,
770959863,false,true,5,2015-08-15T02:33:00,,No Relation,0.8087,C467567,lenalidomide,D009101,MM,"Since the introduction of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide in the therapeutic armamentarium of MM, VTE has emerged as one of the leading complications, in particular in patients with newly diagnosed MM.",21455855_5,21455855_C467567_D009101,,
770959864,false,true,5,2015-08-15T01:34:00,,No Relation,1,D013792,thalidomide,D009101,MM,"Since the introduction of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide in the therapeutic armamentarium of MM, VTE has emerged as one of the leading complications, in particular in patients with newly diagnosed MM.",21455855_5,21455855_D013792_D009101,,
770959865,false,true,5,2015-08-14T21:42:00,,Direct,0.6057,D003907,dexamethasone,D054556,VTE,"In this setting, IMiDs-based treatments are associated with rates of VTE reaching values up to 14 to 26%, particularly when dexamethasone or chemotherapy are added.",21455855_6,21455855_D003907_D054556,,
770959866,false,true,5,2015-08-14T23:15:00,,No Relation,0.7911,D005947,glucose,D015430,weight gain,"The AHRQ systematic review indicated that premixed insulin analogues are more effective than long-acting insulin analogues in lowering postprandial glucose and hemoglobin A1c; however, in this comparison the premixed analogues were associated with higher rates of hypoglycemia and more weight gain.",21476781_8,21476781_D005947_D015430,,
770959867,false,true,5,2015-08-15T00:19:00,,No Relation,0.8172,D005947,glucose,D007003,hypoglycemia,"The AHRQ systematic review indicated that premixed insulin analogues are more effective than long-acting insulin analogues in lowering postprandial glucose and hemoglobin A1c; however, in this comparison the premixed analogues were associated with higher rates of hypoglycemia and more weight gain.",21476781_8,21476781_D005947_D007003,,
770959868,false,true,5,2015-08-15T00:44:00,,No Relation,1,C515425,Ki23057,D013274,gastric cancer,"A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.",21482024_0,21482024_C515425_D013274,,
770959869,false,true,5,2015-08-14T21:39:00,,No Relation,1,D005047,etoposide/VP16,D013274,gastric cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_D005047_D013274,,
770959870,false,true,5,2015-08-15T00:00:00,,No Relation,1,D005047,etoposide/VP16,D009369,cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_D005047_D009369,,
770959871,false,true,5,2015-08-14T22:00:00,,No Relation,1,D017239,paclitaxel/PTX,D009369,cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_D017239_D009369,,
770959872,false,true,5,2015-08-14T22:46:00,,No Relation,1,D017239,paclitaxel/PTX,D013274,gastric cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_D017239_D013274,,
770959873,false,true,5,2015-08-15T00:46:00,,No Relation,1,C051890,irinotecan/SN38,D009369,cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C051890_D009369,,
770959874,false,true,5,2015-08-14T21:33:00,,No Relation,0.8176,C030110,OXA/oxaliplatin,D013274,gastric cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C030110_D013274,,
770959876,false,true,5,2015-08-15T00:27:00,,No Relation,1,C051890,irinotecan/SN38,D013274,gastric cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C051890_D013274,,
770959877,false,true,5,2015-08-14T22:23:00,,No Relation,1,C030110,OXA/oxaliplatin,D009369,cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C030110_D009369,,
770959878,false,true,5,2015-08-14T22:16:00,,No Relation,1,C056507,GEM/gemcitabine,D009369,cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C056507_D009369,,
770959879,false,true,5,2015-08-15T02:17:00,,No Relation,1,C056507,GEM/gemcitabine,D013274,gastric cancer,"Five cancer cell lines resistant to irinotecan (SN38), paclitaxel (PTX), etoposide (VP16), oxaliplatin (OXA), and gemcitabine (GEM) were respectively established from a parent gastric cancer cell line, OCUM-2M, and were named OCUM-2M/SN38, OCUM-2M/PTX, OCUM-2M/VP16, OCUM-2M/OXA, and OCUM-2M/GEM.",21482024_2,21482024_C056507_D013274,,
770959880,false,true,5,2015-08-14T21:33:00,,No Relation,0.7956,D005047,VP16,D013274,gastric cancer,"The FGFR2 inhibitor Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16.",21482024_8,21482024_D005047_D013274,,
770959881,false,true,5,2015-08-15T01:35:00,,No Relation,1,C515425,Ki23057,D013274,gastric cancer,"The FGFR2 inhibitor Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16.",21482024_8,21482024_C515425_D013274,,
770959882,false,true,5,2015-08-15T00:18:00,,No Relation,1,D017239,PTX,D013274,gastric cancer,"The FGFR2 inhibitor Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16.",21482024_8,21482024_D017239_D013274,,
770959883,false,true,5,2015-08-14T22:00:00,,No Relation,1,D016190,Carboplatin,D009369,breast cancer,Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.,21482494_0,21482494_D016190_D009369,,
770959884,false,true,5,2015-08-15T01:16:00,,No Relation,1,C056507,gemcitabine,D009369,breast cancer,Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.,21482494_0,21482494_C056507_D009369,,
770959885,false,true,5,2015-08-14T22:50:00,Used as treatment.,No Relation,1,D002945,cisplatin,D009369,tumors,"Preclinical data indicate cisplatin sensitivity, suggesting that these tumors may have defects in the BRCA1 pathway.",21482494_2,21482494_D002945_D009369,,
770959886,false,true,5,2015-08-15T00:26:00,,No Relation,1,C080625,taxane,D064726,TNBC,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_C080625_D064726,,
770959887,false,true,5,2015-08-14T23:30:00,,No Relation,1,D016190,carboplatin,D064726,TNBC,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_D016190_D064726,,
770959888,false,true,5,2015-08-14T22:10:00,,No Relation,0.8044,D018943,anthracycline,D064726,TNBC,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_D018943_D064726,,
770959889,false,true,5,2015-08-14T21:28:00,,No Relation,1,C080625,taxane,D009369,breast cancer,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_C080625_D009369,,
770959890,false,true,5,2015-08-15T00:58:00,,No Relation,1,D018943,anthracycline,D009369,breast cancer,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_D018943_D009369,,
770959891,false,true,5,2015-08-15T01:35:00,,No Relation,1,C056507,gemcitabine,D064726,TNBC,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_C056507_D064726,,
770959892,false,true,5,2015-08-14T22:20:00,,No Relation,0.7948,D016190,carboplatin,D009369,breast cancer,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_D016190_D009369,,
770959893,false,true,5,2015-08-14T23:26:00,,No Relation,0.8036,C056507,gemcitabine,D009369,breast cancer,"The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.",21482494_3,21482494_C056507_D009369,,
770959894,false,true,5,2015-08-14T22:23:00,,No Relation,1,D000431,alcohol,D019966,drug dependency,"Current injecting drug use (odds ratio [OR], 0.26; 95% CI, 0.08-0.77), past and current treatment for drug dependency (OR, 0.34; 95% CI, 0.18-0.67, and OR, 0.42; 95% CI, 0.22-0.81, respectively) and alcohol use above 20 g/day (OR, 0.20; 95% CI, 0.08-0.46) were independent predictors of deferral of treatment.",21495939_7,21495939_D000431_D019966,,
770959895,false,true,5,2015-08-14T21:36:00,,No Relation,0.8044,D000431,alcohol,D006526,HCV,"Factors related to drug and alcohol use, rather than clinical factors, influenced uptake of treatment for HCV.",21495939_10,21495939_D000431_D006526,,
770959896,false,true,5,2015-08-14T23:20:00,,No Relation,0.8233,D000431,alcohol,D000437,alcohol dependency,Further support for patients with drug and alcohol dependency is required to optimise treatment uptake.,21495939_11,21495939_D000431_D000437,,
770959897,false,true,5,2015-08-14T21:46:00,,No Relation,1,C400082,Bortezomib,D012008,relapsed disease,"Bortezomib, thalidomide and lenalidomide have improved the therapeutic armentarium for patients with refractory or relapsed disease and are often used in combination with dexamethasone or chemotherapeutic agents.",21509688_3,21509688_C400082_D012008,,
770959898,false,true,5,2015-08-14T23:16:00,,No Relation,1,C467567,lenalidomide,D012008,relapsed disease,"Bortezomib, thalidomide and lenalidomide have improved the therapeutic armentarium for patients with refractory or relapsed disease and are often used in combination with dexamethasone or chemotherapeutic agents.",21509688_3,21509688_C467567_D012008,,
770959899,false,true,5,2015-08-15T00:41:00,,No Relation,0.8306,D013792,thalidomide,D012008,relapsed disease,"Bortezomib, thalidomide and lenalidomide have improved the therapeutic armentarium for patients with refractory or relapsed disease and are often used in combination with dexamethasone or chemotherapeutic agents.",21509688_3,21509688_D013792_D012008,,
770959900,false,true,5,2015-08-15T01:56:00,,No Relation,1,D003907,dexamethasone,D012008,relapsed disease,"Bortezomib, thalidomide and lenalidomide have improved the therapeutic armentarium for patients with refractory or relapsed disease and are often used in combination with dexamethasone or chemotherapeutic agents.",21509688_3,21509688_D003907_D012008,,
770959901,false,true,5,2015-08-15T02:05:00,,No Relation,0.5866,D002045,bupivacaine,D000699,analgesia,"Doppler velocimetry indices, systolic/diastolic ratios, pulsatility index, and resistance index, of the fetal umbilical artery and uterine artery were recorded in 15 women receiving continuous epidural analgesia with 0.075% bupivacaine and 0.0002% fentanyl during labor; the same indices were recorded of the fetal umbilical and middle cerebral arteries in 10 women receiving the same analgesia.",21519310_3,21519310_D002045_D000699,,
770959902,false,true,5,2015-08-15T00:22:00,,No Relation,0.5875,D005283,fentanyl,D000699,analgesia,"Doppler velocimetry indices, systolic/diastolic ratios, pulsatility index, and resistance index, of the fetal umbilical artery and uterine artery were recorded in 15 women receiving continuous epidural analgesia with 0.075% bupivacaine and 0.0002% fentanyl during labor; the same indices were recorded of the fetal umbilical and middle cerebral arteries in 10 women receiving the same analgesia.",21519310_3,21519310_D005283_D000699,,
770959903,false,true,5,2015-08-14T23:46:00,,Direct,0.6157,D003024,clozapine,D012798,sialorrhea,Current treatment strategies for clozapine-induced sialorrhea.,21540404_0,21540404_D003024_D012798,,
770959904,false,true,5,2015-08-14T23:43:00,,Direct,0.8101,D003024,clozapine,D012798,sialorrhea,To provide an understanding of the underlying pathophysiology and current treatment options for clozapine-induced sialorrhea.,21540404_1,21540404_D003024_D012798,,
770959905,false,true,5,2015-08-14T21:28:00,,No Relation,1,D003024,clozapine,D012798,hypersalivation/sialorrhea,"Literature was retrieved through MEDLINE (1977-February 2011) using the key search terms clozapine, sialorrhea, hypersalivation, drooling, and treatment.",21540404_2,21540404_D003024_D012798,,
770959906,false,true,5,2015-08-15T00:27:00,,Direct,0.8067,D003024,clozapine,D012798,Sialorrhea,Sialorrhea is a common and disabling adverse effect of clozapine use.,21540404_5,21540404_D003024_D012798,,
770959907,false,true,5,2015-08-14T22:03:00,,No Relation,0.5688,D006024,Glycopyrrolate,D012798,reduction of hypersalivation,"Glycopyrrolate, however, demonstrated significant reduction of hypersalivation in a randomized controlled trial.",21540404_10,21540404_D006024_D012798,,
770959908,false,true,5,2015-08-14T21:37:00,,No Relation,0.6001,D003024,clozapine,D012798,hypersalivation/sialorrhea,"Botulinum toxin also significantly improved sialorrhea in both a case report and double-blind study, although the trial included hypersalivation from other etiologies in addition to clozapine.",21540404_12,21540404_D003024_D012798,,
770959909,false,true,5,2015-08-15T02:07:00,,Direct,0.6075,D003024,clozapine,D012798,sialorrhea,Current pharmacologic treatment options for clozapine-induced sialorrhea are limited in number and efficacy.,21540404_15,21540404_D003024_D012798,,
770959910,false,true,5,2015-08-14T23:32:00,,No Relation,1,D013256,steroid,D016889,endometrial cancer,We investigated whether variants in sex steroid hormone metabolism genes modify the effect of hormone therapy (HT) on endometrial cancer risk in postmenopausal non-Hispanic white women.,21544810_1,21544810_D013256_D016889,,
770959911,false,true,5,2015-08-14T23:38:00,,No Relation,0.8009,D009828,oleanolic acid,C531854,oleanolic acid/OA,"In this study, the main active compound, oleanolic acid (OA) was isolated from an ethanol extract and its chemical structure was identified according to the results of high performance liquid chromatography (HPLC), high performance thin layer chromatography (HPTLC) and liquid chromatography-mass spectrography (LC-MS).",21545203_2,21545203_D009828_C531854,,
770959912,false,true,5,2015-08-15T02:11:00,,No Relation,1,D000431,ethanol,C531854,oleanolic acid/OA,"In this study, the main active compound, oleanolic acid (OA) was isolated from an ethanol extract and its chemical structure was identified according to the results of high performance liquid chromatography (HPLC), high performance thin layer chromatography (HPTLC) and liquid chromatography-mass spectrography (LC-MS).",21545203_2,21545203_D000431_C531854,,
770959913,false,true,5,2015-08-14T21:46:00,,No Relation,1,D000431,ethanol,C531854,OA,Results for cell viability indictated no notable differences between OA and ethanol extract of PV in lung adenocarcinoma SPC-A-1 cells measured by MTT assay.,21545203_3,21545203_D000431_C531854,,
770959914,false,true,5,2015-08-14T21:57:00,,No Relation,1,D000431,ethanol,C538231,PV in lung adenocarcinoma,Results for cell viability indictated no notable differences between OA and ethanol extract of PV in lung adenocarcinoma SPC-A-1 cells measured by MTT assay.,21545203_3,21545203_D000431_C538231,,
770959915,false,true,5,2015-08-14T22:48:00,,No Relation,1,D004121,DMSO,C531854,OA,OA at 16 and 8 microM group increased significantly the apoptosis rate compared with normal and 1% DMSO groups (p<0.05).,21545203_6,21545203_D004121_C531854,,
770959916,false,true,5,2015-08-15T00:02:00,,No Relation,1,C110904,capecitabine,D009369,tumors,"Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.",21547572_0,21547572_C110904_D009369,,
770959917,false,true,5,2015-08-14T21:28:00,,No Relation,1,C479543,Tesetaxel,D009369,tumors,"Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.",21547572_0,21547572_C479543_D009369,,
770959918,false,true,5,2015-08-14T23:45:00,,No Relation,1,C080625,taxane,D009369,tumors,"Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.",21547572_0,21547572_C080625_D009369,,
770959919,false,true,5,2015-08-14T22:05:00,,No Relation,1,C110904,capecitabine,D009369,tumors,"This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors.",21547572_1,21547572_C110904_D009369,,
770959920,false,true,5,2015-08-15T00:13:00,,No Relation,1,C479543,tesetaxel,D009369,tumors,"This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors.",21547572_1,21547572_C479543_D009369,,
770959921,false,true,5,2015-08-14T23:21:00,,No Relation,1,C080625,taxane,D009369,tumors,"This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors.",21547572_1,21547572_C080625_D009369,,
770959922,false,true,5,2015-08-14T21:33:00,,No Relation,1,C479543,tesetaxel,D009369,cancer,These data further support the continued clinical development of tesetaxel both as a single agent and in combination with other active cancer therapeutics.,21547572_14,21547572_C479543_D009369,,
770959923,false,true,5,2015-08-14T23:53:00,,No Relation,1,C552042,BAL30072,D013180,pseudomallei strains,"In this study, the anti-B. pseudomallei efficacy of a new monosulfactam, BAL30072, was tested against laboratory strains 1026b and 1710b and several isogenic mutant derivatives as well as a collection of clinical and environmental B. pseudomallei strains from Thailand.",21596528_4,21596528_C552042_D013180,,
770959924,false,true,5,2015-08-14T22:27:00,'blood manganese' is not a disease. :-),No Relation,1,D008345,manganese,D006402,blood manganese,Relationship between blood manganese and blood pressure in the Korean general population according to KNHANES 2008.,21601843_0,21601843_D008345_D006402,,
770959925,false,true,5,2015-08-14T23:10:00,,Direct,0.5999,D008345,Mn/manganese,D006973,hypertension,We present data on the association of manganese (Mn) level with hypertension in a representative sample of the adult Korean population who participated in the Korean National Health and Nutrition Examination Survey (KNHANES) 2008.,21601843_1,21601843_D008345_D006973,,
770959926,false,true,5,2015-08-15T00:46:00,,Direct,1,D008345,Mn,D006973,hypertension,"In addition, doubling the blood Mn increased the risk of hypertension 1.828, 1.573, and 1.567 fold in women, men, and all participants, respectively, after adjustment for covariates.",21601843_5,21601843_D008345_D006973,,
770959927,false,true,5,2015-08-14T21:57:00,,No Relation,0.7997,D008345,Mn,D006973,hypertension,"The addition of blood lead, mercury, and cadmium as covariates did not affect the association between blood Mn and the prevalence of hypertension.",21601843_6,21601843_D008345_D006973,,
770959928,false,true,5,2015-08-14T22:59:00,,No Relation,1,D008628,mercury,D006973,hypertension,"The addition of blood lead, mercury, and cadmium as covariates did not affect the association between blood Mn and the prevalence of hypertension.",21601843_6,21601843_D008628_D006973,,
770959929,false,true,5,2015-08-15T00:59:00,,No Relation,1,D002104,cadmium,D006973,hypertension,"The addition of blood lead, mercury, and cadmium as covariates did not affect the association between blood Mn and the prevalence of hypertension.",21601843_6,21601843_D002104_D006973,,
770959930,false,true,5,2015-08-15T00:42:00,,Direct,1,D008345,Mn,D006973,hypertension,Blood Mn level was associated with an increased risk of hypertension in a representative sample of the Korean adult population.,21601843_7,21601843_D008345_D006973,,
770959931,false,true,5,2015-08-14T23:38:00,,No Relation,0.804,D004298,dopamine,D007174,impulse control disorders,The risky business of dopamine agonists in Parkinson disease and impulse control disorders.,21604834_0,21604834_D004298_D007174,,
770959932,false,true,5,2015-08-14T22:15:00,,No Relation,0.8069,D004298,dopamine,D010300,Parkinson disease,The risky business of dopamine agonists in Parkinson disease and impulse control disorders.,21604834_0,21604834_D004298_D010300,,
770959933,false,true,5,2015-08-15T02:13:00,,Direct,0.8078,D004298,dopamine,D007174,impulse control disorder/ICD,"In patients with Parkinson's disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA).",21604834_3,21604834_D004298_D007174,,
770959934,false,true,5,2015-08-15T02:21:00,,No Relation,1,D004298,dopamine,D010300,Parkinson's disease/PD,"In patients with Parkinson's disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA).",21604834_3,21604834_D004298_D010300,,
770959935,false,true,5,2015-08-15T02:10:00,,No Relation,1,D010713,phosphatidylcholine,D009362,metastasis,Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo.,21628892_0,21628892_D010713_D009362,,
770959936,false,true,5,2015-08-15T01:23:00,,No Relation,0.7924,D010713,phosphatidylcholine,D003108,colon carcinoma,Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo.,21628892_0,21628892_D010713_D003108,,
770959937,false,true,5,2015-08-14T22:09:00,,No Relation,1,D002945,cisplatin,C562729,ESCC,"In ESCC cells treated with cisplatin, a common chemotherapeutic drug, Smac and cytochrome c were released from mitochondria, and caspase-3 and caspase-9 were activated.",21676925_9,21676925_D002945_C562729,,
770959938,false,true,5,2015-08-14T21:29:00,,Direct,0.5986,D002945,cisplatin,C565304,mitochondrial dysfunction,"Knockdown of Smac abrogated cisplatin-induced apoptosis, mitochondrial dysfunction, cytochrome c release, and caspase activation.",21676925_10,21676925_D002945_C565304,,
770959939,false,true,5,2015-08-15T02:12:00,,No Relation,1,D002945,cisplatin,D009369,tumors,"Smac deficiency also reduced the effect of cisplatin on long-term cell viability, and led to cisplatin resistance in xenograft tumors in vivo.",21676925_11,21676925_D002945_D009369,,
770959940,false,true,5,2015-08-14T22:22:00,,No Relation,0.7894,C476513,Levobupivacaine,D002318,cardiovascular and central nervous system toxicity,"Levobupivacaine is a new long-acting local anesthetic, which is the isolated S-enantiomer of racemic bupivacaine with less cardiovascular and central nervous system toxicity than bupivacaine.",21696081_1,21696081_C476513_D002318,,
770959941,false,true,5,2015-08-15T01:32:00,,No Relation,0.7942,D002045,bupivacaine,D002318,cardiovascular and central nervous system toxicity,"Levobupivacaine is a new long-acting local anesthetic, which is the isolated S-enantiomer of racemic bupivacaine with less cardiovascular and central nervous system toxicity than bupivacaine.",21696081_1,21696081_D002045_D002318,,
770959942,false,true,5,2015-08-15T01:11:00,,No Relation,1,D014807,vitamin D,D014808,vitamin D deficiency,"Diet, environmental factors, and lifestyle underlie the high prevalence of vitamin D deficiency in healthy adults in Scotland, and supplementation reduces the proportion that are severely deficient.",21697298_0,21697298_D014807_D014808,,
770959943,false,true,5,2015-08-14T23:17:00,,No Relation,0.5976,D014807,Vitamin D,D004194,numerous diseases,"Vitamin D deficiency has recently been implicated as a possible risk factor in the etiology of numerous diseases, including nonskeletal conditions.",21697298_1,21697298_D014807_D004194,,
770959944,false,true,5,2015-08-15T01:00:00,,No Relation,1,D014807,Vitamin D,D014808,Vitamin D deficiency,"Vitamin D deficiency has recently been implicated as a possible risk factor in the etiology of numerous diseases, including nonskeletal conditions.",21697298_1,21697298_D014807_D014808,,
770959945,false,true,5,2015-08-15T00:25:00,,No Relation,1,D014807,vitamin D,D014808,vitamin D deficiency,"In humans, skin synthesis following exposure to UVB is a potent source of vitamin D, but in regions with low UVB, individuals are at risk of vitamin D deficiency.",21697298_2,21697298_D014807_D014808,,
770959946,false,true,5,2015-08-15T01:35:00,,No Relation,1,C104450,25-hydroxyvitamin D,D014808,vitamin D deficiency,Our objectives were to describe the prevalence of vitamin D deficiency and to investigate determinants of plasma 25-hydroxyvitamin D (25-OHD) concentrations in a high northern latitude country.,21697298_3,21697298_C104450_D014808,,
770959947,false,true,5,2015-08-15T00:07:00,,No Relation,1,D014807,vitamin D,D014808,vitamin D deficiency,Our objectives were to describe the prevalence of vitamin D deficiency and to investigate determinants of plasma 25-hydroxyvitamin D (25-OHD) concentrations in a high northern latitude country.,21697298_3,21697298_D014807_D014808,,
770959948,false,true,5,2015-08-15T01:35:00,,No Relation,1,D014807,vitamin D,D014808,vitamin D deficiency,Only 36.6% of participants were at low risk of vitamin D deficiency or had adequate levels (>40 nmol/L).,21697298_7,21697298_D014807_D014808,,
770959949,false,true,5,2015-08-14T22:15:00,,No Relation,1,D014807,Vitamin D,D014808,Vitamin D deficiency,Vitamin D deficiency in Scotland is highly prevalent due to a combination of insufficient exposure to UVB and insufficient dietary intake.,21697298_10,21697298_D014807_D014808,,
770959950,false,true,5,2015-08-15T01:10:00,,No Relation,1,C037199,poly-N-acetyllactosamine,D007938,leukemia,"The expressions of _1,3-N-acetylglucosamonyltransferase-2 and -8 (_3GnT-2, _3GnT-8),-the two main glycosyltransferases responsible for the synthesis of poly-N-acetyllactosamine (polyLacNAc) in glycans, and _3GnT-5 participating in the syntheses of sphingoglycolipids were studied in leukemia cell lines during differentiation using RT-PCR method.",21720768_1,21720768_C037199_D007938,,
770959951,false,true,5,2015-08-15T02:21:00,,No Relation,1,D014212,ATRA/all-trans retinoic acid,D015470,acute myeloid leukemia,"ATRA (all-trans retinoic acid) and dimethylsulfoxide (DMSO), which induce the differentiation of HL-60 and NB4 (two human acute myeloid leukemia cell lines) to myelocytic lineage, up-regulated these two enzymes with various degrees at 2 and 72 h of treatment.",21720768_3,21720768_D014212_D015470,,
770959952,false,true,5,2015-08-14T22:03:00,,No Relation,0.8046,D004121,DMSO/dimethylsulfoxide,D015470,acute myeloid leukemia,"ATRA (all-trans retinoic acid) and dimethylsulfoxide (DMSO), which induce the differentiation of HL-60 and NB4 (two human acute myeloid leukemia cell lines) to myelocytic lineage, up-regulated these two enzymes with various degrees at 2 and 72 h of treatment.",21720768_3,21720768_D004121_D015470,,
770959953,false,true,5,2015-08-14T21:37:00,,Direct,0.7858,D002118,calcium,D003643,death,"Cardiomyocyte calcium (Ca(2+)) loading is recognized to be a major factor in acute ischaemia-reperfusion pathology, promoting cell death, contractile dysfunction and arrhythmogenic activity.",21722161_6,21722161_D002118_D003643,,
770959954,false,true,5,2015-08-14T21:29:00,,No Relation,1,D002118,Ca,D005517,CRF/Ca-rich-food,The study aimed to (i) segment parents of early adolescents into subgroups according to their Ca-rich-food (CRF) practices and perceptions regarding early adolescent CRF intake and (ii) determine whether Ca intake of parents and early adolescents differed by subgroup.,21729479_1,21729479_D002118_D005517,,
770959955,false,true,5,2015-08-15T02:23:00,,No Relation,1,D002118,Ca,D005517,CRF,Parent education programmes should address CRF practices/perceptions tailored to parent group to improve Ca intake of early adolescent children.,21729479_10,21729479_D002118_D005517,,
770959956,false,true,5,2015-08-15T00:45:00,,No Relation,0.6099,D011736,pyridoxine,D012640,seizures,Long-term follow-up in two siblings with pyridoxine-dependent seizures associated with a novel ALDH7A1 mutation.,21733724_0,21733724_D011736_D012640,,
770959957,false,true,5,2015-08-15T01:08:00,,No Relation,0.7914,D011736,Pyridoxine,C536254,Pyridoxine-dependent seizures/PDS,Pyridoxine-dependent seizures (PDS) is a rare disorder characterized by seizures resistant to anticonvulsants but controlled by daily pharmacologic doses of pyridoxine.,21733724_1,21733724_D011736_C536254,,
770959958,false,true,5,2015-08-14T21:49:00,,No Relation,0.6009,D011736,Pyridoxine,D012640,seizures,Pyridoxine-dependent seizures (PDS) is a rare disorder characterized by seizures resistant to anticonvulsants but controlled by daily pharmacologic doses of pyridoxine.,21733724_1,21733724_D011736_D012640,,
770959959,false,true,5,2015-08-14T21:56:00,,No Relation,1,C110904,capecitabine,D009369,breast cancer,Continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabine (X) alone in women with HER2-positive breast cancer progressing during trastuzumab treatment.,21741829_1,21741829_C110904_D009369,,
770959960,false,true,5,2015-08-14T23:51:00,,No Relation,1,D003907,DEX/dexamethasone,C565529,HGF/hepatocyte growth factor,"We compared the effect of hepatocyte growth factor (HGF), oncostatin M (OSM), dexamethasone (DEX), or a combination on the expression of a liver-specific marker, albumin (ALB).",21751216_3,21751216_D003907_C565529,,
770959961,false,true,5,2015-08-15T00:26:00,,No Relation,1,D014508,urea,C565529,HGF,"Moreover, cells exposed to the combination of OSM, DEX, and HGF gradually featured highly differentiated hepatic functions, including ALB secretion, glycogen storage, urea production, and cytochrome P450 (CYP) activity.",21751216_6,21751216_D014508_C565529,,
770959962,false,true,5,2015-08-15T02:05:00,,No Relation,1,C058728,combretastatin-A4-phosphate,C535575,squamous cell carcinoma of the head and neck,"Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.",21765046_0,21765046_C058728_C535575,,
770959963,false,true,5,2015-08-15T01:46:00,,No Relation,1,C058728,combretastatin-A4-phosphate,D011471,prostate adenocarcinoma,"Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.",21765046_0,21765046_C058728_D011471,,
770959964,false,true,5,2015-08-15T00:45:00,,No Relation,1,C058728,combretastatin-A4-phosphate,D002289,non-small-cell lung cancer,"Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.",21765046_0,21765046_C058728_D002289,,
770959965,false,true,5,2015-08-14T23:00:00,,Direct,1,C058728,CA4P,D015840,oculomotor nerve palsy,Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2.,21765046_7,21765046_C058728_D015840,,
770959966,false,true,5,2015-08-14T21:48:00,,No Relation,1,C058728,CA4P,D011471,prostate cancer,Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2.,21765046_7,21765046_C058728_D011471,,
770959967,false,true,5,2015-08-14T21:33:00,,No Relation,1,C058728,CA4P,D001259,ataxia,Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2.,21765046_7,21765046_C058728_D001259,,
770959968,false,true,5,2015-08-14T23:26:00,,No Relation,1,D011718,Pyrazinamide,D014376,tuberculosis,Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.,21768515_0,21768515_D011718_D014376,,
770959969,false,true,5,2015-08-14T21:40:00,,No Relation,0.7875,D011718,pyrazinamide,D014376,tuberculosis,Standard culture-based testing of the susceptibility of Mycobacterium tuberculosis to pyrazinamide is difficult to perform.,21768515_1,21768515_D011718_D014376,,
770959970,false,true,5,2015-08-14T21:33:00,,No Relation,1,D011718,pyrazinamide,D014376,tuberculosis,The median prevalence (range) of pyrazinamide resistance was 51% (31% to 89%) in multidrug-resistant M. tuberculosis isolates and 5% (0% to 9%) in non-multidrug-resistant isolates.,21768515_7,21768515_D011718_D014376,,
770959971,false,true,5,2015-08-14T22:59:00,,No Relation,1,D011718,pyrazinamide,D014376,tuberculosis,"Considering the prevalence of pyrazinamide resistance in different clinical settings, PCR-DNA sequencing, and possibly other molecular assays targeting pncA, can detect pyrazinamide resistance in multidrug-resistant M. tuberculosis isolates, with predictive values largely exceeding 90%, and rule out pyrazinamide resistance in non-multidrug-resistant isolates, with predictive values exceeding 99%.",21768515_10,21768515_D011718_D014376,,
770959972,false,true,5,2015-08-15T02:14:00,,No Relation,0.802,C516667,pazopanib,D018250,aggressive pediatric solid tumor,Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.,21788355_0,21788355_C516667_D018250,,
770959973,false,true,5,2015-08-15T00:50:00,,No Relation,1,C516667,pazopanib,D009369,tumor,"We have tested the efficacies of daily oral LDM topotecan alone and in combination with pazopanib, a VEGF receptor inhibitor, in three pediatric extracranial solid tumor mouse models.",21788355_2,21788355_C516667_D009369,,
770959974,false,true,5,2015-08-15T01:16:00,,No Relation,0.8026,C516667,pazopanib,D009447,neuroblastoma,"In vitro dose-response study of topotecan and pazopanib was conducted on several neuroblastoma, osteosarcoma, and rhabdomyosarcoma cell lines.",21788355_3,21788355_C516667_D009447,,
770959975,false,true,5,2015-08-14T21:48:00,,No Relation,0.8226,C516667,pazopanib,D012208,rhabdomyosarcoma,"In vitro dose-response study of topotecan and pazopanib was conducted on several neuroblastoma, osteosarcoma, and rhabdomyosarcoma cell lines.",21788355_3,21788355_C516667_D012208,,
770959976,false,true,5,2015-08-15T01:57:00,,No Relation,0.8114,C516667,pazopanib,D012516,osteosarcoma,"In vitro dose-response study of topotecan and pazopanib was conducted on several neuroblastoma, osteosarcoma, and rhabdomyosarcoma cell lines.",21788355_3,21788355_C516667_D012516,,
770959977,false,true,5,2015-08-15T00:09:00,Used as treatment.,No Relation,1,C516667,pazopanib,D009447,neuroblastoma,In vivo antitumor efficacies of the LDM topotecan and pazopanib as single agents and in combination were tested on 4 subcutaneous xenograft models and on 2 neuroblastoma metastatic models.,21788355_4,21788355_C516667_D009447,,
770959978,false,true,5,2015-08-14T21:58:00,,No Relation,0.8242,D016559,TAC,D006086,graft-versus-host disease/GVHD,An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).,21802143_4,21802143_D016559_D006086,,
770959979,false,true,5,2015-08-14T22:02:00,,No Relation,1,D016559,TAC,D017728,anaplastic large cell lymphoma,An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).,21802143_4,21802143_D016559_D017728,,
770959980,false,true,5,2015-08-15T02:12:00,,Direct,0.5962,C058687,LAN,D006086,GVHD,"The LAN dose was reduced to 15 mg/d PO on day 26, and the blood TAC concentration subsequently decreased to 6.6 ng/mL, with GVHD-related symptoms emerging on day 28.",21802143_8,21802143_C058687_D006086,,
770959981,false,true,5,2015-08-15T02:02:00,,No Relation,0.6004,D015777,eicosanoids,D007249,inflammation,"The aim of the study was to determine the quantity of produced mediators of inflammation (cytokines and eicosanoids), during carotid endarterectomy (CEA), which are factors of ischemic damage of the brain.",21804481_1,21804481_D015777_D007249,,
770959982,false,true,5,2015-08-15T02:10:00,,Direct,0.4237,D015777,eicosanoids,D007511,ischemic damage,"The aim of the study was to determine the quantity of produced mediators of inflammation (cytokines and eicosanoids), during carotid endarterectomy (CEA), which are factors of ischemic damage of the brain.",21804481_1,21804481_D015777_D007511,,
770959983,false,true,5,2015-08-15T02:01:00,,No Relation,1,D013929,Thromboxane B2/TXB2,D009336,tumor necrosis factor-a/TNFa,"Plasma concentrations of Interleukin-1b (IL-1b), Thromboxane B2 (TXB2), Prostaglandin E2 (PGE2) and tumor necrosis factor-a (TNFa) were measured by enzyme-linked immunosorbent assay (ELISA) technique.",21804481_4,21804481_D013929_D009336,,
770959984,false,true,5,2015-08-14T21:28:00,,No Relation,1,D015232,PGE2/Prostaglandin E2,D009336,tumor necrosis factor-a/TNFa,"Plasma concentrations of Interleukin-1b (IL-1b), Thromboxane B2 (TXB2), Prostaglandin E2 (PGE2) and tumor necrosis factor-a (TNFa) were measured by enzyme-linked immunosorbent assay (ELISA) technique.",21804481_4,21804481_D015232_D009336,,
770959985,false,true,5,2015-08-15T02:07:00,,No Relation,0.8248,D013929,TXB2,D009336,TNFa,"The concentration of IL-1b and TNFa remained almost stable in group B, whereas the concentration of TXB2 reduced but not significantly (P>0.05).",21804481_7,21804481_D013929_D009336,,
770959986,false,true,5,2015-08-14T21:40:00,,No Relation,1,D012701,serotonin,D006470,oral bleeding complications,Selective serotonin reuptake inhibitors and oral bleeding complications after invasive dental treatment.,21821439_0,21821439_D012701_D006470,,
770959987,false,true,5,2015-08-14T21:46:00,,No Relation,0.62,D012701,serotonin,D006470,oral bleeding complications,The purpose of this study was to examine the frequency of oral bleeding complications after invasive dental procedures in patients taking selective serotonin reuptake inhibitor (SSRI) medications.,21821439_1,21821439_D012701_D006470,,
770959988,false,true,5,2015-08-15T01:28:00,,No Relation,0.8086,D000583,Amikacin,D014947,increased in burn injury,"Amikacin clearance can be increased in burn injury, which is often complicated by renal insufficiency.",21825289_1,21825289_D000583_D014947,,
770959989,false,true,5,2015-08-14T21:58:00,,No Relation,0.6149,D000583,Amikacin,D051437,renal insufficiency,"Amikacin clearance can be increased in burn injury, which is often complicated by renal insufficiency.",21825289_1,21825289_D000583_D051437,,
770959990,false,true,5,2015-08-15T01:03:00,,No Relation,0.7986,D020123,rapamycin,D002292,RCC,Inhibitors of the mammalian target of rapamycin (mTOR) have entered the landscape of treatment for advanced RCC.,21827395_1,21827395_D020123_D002292,,
770959991,false,true,5,2015-08-14T22:13:00,,No Relation,1,C401859,Temsirolimus,D009369,tumor,Although Temsirolimus is capable of improving overall survival it does so only in a minority of selected mRCC patients and its effects on tumor burden reduction and PFS are minimal.,21827395_4,21827395_C401859_D009369,,
770959992,false,true,5,2015-08-14T22:28:00,,No Relation,1,C107135,Everolimus,D009369,cancer,"First, because it is unknown if mTOR becomes the major driver or cancer growth after developing progressive disease on a VEGF inhibitor and secondly because existing sequential VEGF data in same setting appears to be the same if not a bit more robust to that reported with Everolimus.",21827395_6,21827395_C107135_D009369,,
770959993,false,true,5,2015-08-15T01:06:00,,No Relation,1,D003078,colchicine,D010490,pericardial effusion,Recurrent pericardial effusion after cardiac surgery: the use of colchicine after recalcitrant conventional therapy.,21831274_0,21831274_D003078_D010490,,
770959994,false,true,5,2015-08-14T23:38:00,,No Relation,1,D003078,colchicine,D010490,pericardial effusion,Recent literature shows that colchicine therapy should be useful in the treatment of recurrent post surgical pericardial effusion.,21831274_3,21831274_D003078_D010490,,
770959995,false,true,5,2015-08-14T22:00:00,,No Relation,0.6032,D001241,Aspirin,D003643,death,Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.,21835634_0,21835634_D001241_D003643,,
770959996,false,true,5,2015-08-15T02:10:00,,No Relation,1,D001241,Aspirin,D002544,ischemic stroke,Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.,21835634_0,21835634_D001241_D002544,,
770959997,false,true,5,2015-08-14T22:55:00,,No Relation,0.6124,D001241,Aspirin,D020521,stroke,Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.,21835634_0,21835634_D001241_D020521,,
770959998,false,true,5,2015-08-14T23:50:00,,No Relation,1,D001241,aspirin,D002544,ischemic stroke,The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known.,21835634_1,21835634_D001241_D002544,,
770959999,false,true,5,2015-08-15T00:22:00,,No Relation,1,D001241,aspirin,D003643,death,Our objective was to determine if aspirin treatment failure predicts recurrent ischemic stroke and/or death.,21835634_2,21835634_D001241_D003643,,
770960000,false,true,5,2015-08-15T02:33:00,,No Relation,1,D001241,aspirin,D002544,ischemic stroke,Our objective was to determine if aspirin treatment failure predicts recurrent ischemic stroke and/or death.,21835634_2,21835634_D001241_D002544,,
770960001,false,true,5,2015-08-14T23:08:00,,Direct,0.5902,D001241,aspirin,D003643,death,Multivariate analysis was used to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 months for NINDS rt-PA trial patients).,21835634_4,21835634_D001241_D003643,,
770960002,false,true,5,2015-08-14T21:38:00,,Direct,0.7989,D001241,aspirin,D020521,stroke,Multivariate analysis was used to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 months for NINDS rt-PA trial patients).,21835634_4,21835634_D001241_D020521,,
770960003,false,true,5,2015-08-14T22:03:00,,No Relation,1,D001241,aspirin,D003643,death,"The risk of stroke and death at 3 months and 1 year was not higher among patients classified as aspirin treatment failures among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8-1.6; P = .7) or NINDS rt-PA trial patients (OR 0.8; 95% CI 0.6-1.3; P = .4), respectively.",21835634_6,21835634_D001241_D003643,,
770960004,false,true,5,2015-08-15T02:26:00,,No Relation,0.8105,D001241,aspirin,D020521,stroke,"The risk of stroke and death at 3 months and 1 year was not higher among patients classified as aspirin treatment failures among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8-1.6; P = .7) or NINDS rt-PA trial patients (OR 0.8; 95% CI 0.6-1.3; P = .4), respectively.",21835634_6,21835634_D001241_D020521,,
770960005,false,true,5,2015-08-14T23:16:00,,No Relation,1,D001241,aspirin,D003643,death,"In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis.",21835634_7,21835634_D001241_D003643,,
770960006,false,true,5,2015-08-14T22:59:00,,No Relation,1,D001241,aspirin,D020521,stroke,"In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis.",21835634_7,21835634_D001241_D020521,,
770960007,false,true,5,2015-08-15T01:03:00,,No Relation,1,D001241,aspirin,D050197,atherosclerosis,"In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis.",21835634_7,21835634_D001241_D050197,,
770960008,false,true,5,2015-08-15T01:06:00,,No Relation,1,D001241,aspirin,D003643,death,"In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.",21835634_8,21835634_D001241_D003643,,
770960009,false,true,5,2015-08-14T22:28:00,,No Relation,1,D001241,aspirin,D002544,ischemic stroke,"In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.",21835634_8,21835634_D001241_D002544,,
770960010,false,true,5,2015-08-15T01:35:00,,No Relation,1,D001241,aspirin,D020521,stroke,"In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.",21835634_8,21835634_D001241_D020521,,
770960011,false,true,5,2015-08-14T22:19:00,,No Relation,1,D008691,methadone,D006526,hepatitis C,Low risk for hepatitis C seroconversion in methadone maintenance treatment.,21844836_0,21844836_D008691_D006526,,
770960012,false,true,5,2015-08-14T22:29:00,,No Relation,1,D008691,methadone,D006526,hepatitis C virus (HCV) infection,To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group.,21844836_1,21844836_D008691_D006526,,
770960013,false,true,5,2015-08-14T22:09:00,,No Relation,1,D006632,histamine,D006967,allergic reaction,"This chemical intoxication, due to high histamine concentration in fish, is often mistaken for an allergic reaction.",21875451_2,21875451_D006632_D006967,,
770960014,false,true,5,2015-08-14T21:39:00,,No Relation,1,D008687,metformin,D003920,diabetes mellitus,Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction.,21884027_0,21884027_D008687_D003920,,
770960015,false,true,5,2015-08-15T00:57:00,,No Relation,1,D008687,metformin,D009203,acute myocardial infarction,Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction.,21884027_0,21884027_D008687_D009203,,
770960016,false,true,5,2015-08-15T01:35:00,,No Relation,1,D008687,Metformin,C537389,type,Metformin is one of the most commonly prescribed antihyperglycemic agents for the treatment of type 2 diabetes.,21884027_1,21884027_D008687_C537389,,
770960017,false,true,5,2015-08-14T21:34:00,,No Relation,1,D008687,Metformin,D003929,diabetes,Metformin is one of the most commonly prescribed antihyperglycemic agents for the treatment of type 2 diabetes.,21884027_1,21884027_D008687_D003929,,
770960018,false,true,5,2015-08-15T02:19:00,,No Relation,1,D008687,metformin,D003929,diabetic,"However, little is known about the effect of metformin on no-reflow in diabetic patients.",21884027_2,21884027_D008687_D003929,,
770960019,false,true,5,2015-08-15T00:43:00,,No Relation,1,D008687,metformin,D003929,diabetic,"In this study, we investigated retrospectively whether chronic pretreatment with metformin was associated with no-reflow in diabetic patients who underwent primary coronary intervention for acute myocardial infarction (AMI).",21884027_3,21884027_D008687_D003929,,
770960020,false,true,5,2015-08-14T21:43:00,,No Relation,0.8205,D008687,metformin,D009203,AMI/acute myocardial infarction,"In this study, we investigated retrospectively whether chronic pretreatment with metformin was associated with no-reflow in diabetic patients who underwent primary coronary intervention for acute myocardial infarction (AMI).",21884027_3,21884027_D008687_D009203,,
770960021,false,true,5,2015-08-14T21:33:00,,No Relation,0.8068,D008687,metformin,D009203,AMI,"Multivariable logistic regression analysis revealed that absence of metformin pretreatment was a significant predictor of the no-reflow along with high-burden thrombus, ejection fraction on admission and anterior AMI.",21884027_9,21884027_D008687_D009203,,
770960022,false,true,5,2015-08-14T21:49:00,,No Relation,1,D008687,metformin,D003920,diabetes mellitus,These results suggested that chronic pretreatment with metformin may be associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for AMI.,21884027_10,21884027_D008687_D003920,,
770960023,false,true,5,2015-08-15T00:54:00,,No Relation,1,D008687,metformin,D009203,AMI,These results suggested that chronic pretreatment with metformin may be associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for AMI.,21884027_10,21884027_D008687_D009203,,
770960024,false,true,5,2015-08-14T21:33:00,,No Relation,1,D020123,rapamycin,D010195,pancreatic NET,"In this review, we consider the data supporting exploitation of different targets in pancreatic NET, including peptide receptors, receptor tyrosine kinases (involved in tumor angiogenesis and more directly supporting tumor growth), and intracellular targets, such as the mammalian target of rapamycin (mTOR), which has a central role in regulating cell growth, metabolism, and apoptosis.",21893937_4,21893937_D020123_D010195,,
770960025,false,true,5,2015-08-14T21:35:00,,No Relation,0.8066,D020123,rapamycin,D009369,tumor,"In this review, we consider the data supporting exploitation of different targets in pancreatic NET, including peptide receptors, receptor tyrosine kinases (involved in tumor angiogenesis and more directly supporting tumor growth), and intracellular targets, such as the mammalian target of rapamycin (mTOR), which has a central role in regulating cell growth, metabolism, and apoptosis.",21893937_4,21893937_D020123_D009369,,
770960026,false,true,5,2015-08-15T02:07:00,,No Relation,1,D014443,tyrosine,D010195,pancreatic NET,"In this review, we consider the data supporting exploitation of different targets in pancreatic NET, including peptide receptors, receptor tyrosine kinases (involved in tumor angiogenesis and more directly supporting tumor growth), and intracellular targets, such as the mammalian target of rapamycin (mTOR), which has a central role in regulating cell growth, metabolism, and apoptosis.",21893937_4,21893937_D014443_D010195,,
770960027,false,true,5,2015-08-15T01:50:00,,No Relation,0.6057,D014443,tyrosine,D009369,tumor,"In this review, we consider the data supporting exploitation of different targets in pancreatic NET, including peptide receptors, receptor tyrosine kinases (involved in tumor angiogenesis and more directly supporting tumor growth), and intracellular targets, such as the mammalian target of rapamycin (mTOR), which has a central role in regulating cell growth, metabolism, and apoptosis.",21893937_4,21893937_D014443_D009369,,
770960028,false,true,5,2015-08-14T22:18:00,,No Relation,1,D009638,norepinephrine,D001289,attention deficit-hyperactive disorder/ADHD,"Methylphenidate (MPH)-Ritalin(R) , a compound that blocks reuptake of synaptically released norepinephrine (NE) and dopamine (DA) in the brain, has been used for more than 30 years in low dose, long-term regimens to treat attention deficit-hyperactive disorder (ADHD) in juveniles, adolescents, and adults.",21901844_2,21901844_D009638_D001289,,
770960029,false,true,5,2015-08-15T01:09:00,,No Relation,1,D008774,Methylphenidate/MPH,D001289,attention deficit-hyperactive disorder/ADHD,"Methylphenidate (MPH)-Ritalin(R) , a compound that blocks reuptake of synaptically released norepinephrine (NE) and dopamine (DA) in the brain, has been used for more than 30 years in low dose, long-term regimens to treat attention deficit-hyperactive disorder (ADHD) in juveniles, adolescents, and adults.",21901844_2,21901844_D008774_D001289,,
770960030,false,true,5,2015-08-14T22:57:00,,No Relation,1,D004298,dopamine,D001289,attention deficit-hyperactive disorder/ADHD,"Methylphenidate (MPH)-Ritalin(R) , a compound that blocks reuptake of synaptically released norepinephrine (NE) and dopamine (DA) in the brain, has been used for more than 30 years in low dose, long-term regimens to treat attention deficit-hyperactive disorder (ADHD) in juveniles, adolescents, and adults.",21901844_2,21901844_D004298_D001289,,
770960031,false,true,5,2015-08-14T22:37:00,,No Relation,1,D008774,MPH,D001289,ADHD,"Although there is agreement regarding the primary biochemical action of MPH, the physiological basis for its efficacy in normal individuals and ADHD patients is lacking.",21901844_4,21901844_D008774_D001289,,
770960032,false,true,5,2015-08-14T23:11:00,,No Relation,1,D008774,MPH,D001289,ADHD,Study of the behavioral and physiological actions of clinically and behaviorally relevant doses of MPH in normal animals provides an opportunity to explore the role of catecholamine transmitters in prefrontal cortical function and attentional processes as they relate to normal operation of brain circuits and ADHD pathology.,21901844_5,21901844_D008774_D001289,,
770960033,false,true,5,2015-08-15T00:31:00,,No Relation,0.6026,D002395,catecholamine,D001289,ADHD,Study of the behavioral and physiological actions of clinically and behaviorally relevant doses of MPH in normal animals provides an opportunity to explore the role of catecholamine transmitters in prefrontal cortical function and attentional processes as they relate to normal operation of brain circuits and ADHD pathology.,21901844_5,21901844_D002395_D001289,,
770960034,false,true,5,2015-08-15T00:41:00,,No Relation,1,D020123,sirolimus,D006526,hepatitis C,Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.,21967703_0,21967703_D020123_D006526,,
770960035,false,true,5,2015-08-14T23:13:00,"'Hepatitis C virus' is not so much a disease as it is a virus, but also sirolimus is used as treatment, so regardless l choose the third answer",No Relation,1,D020123,sirolimus,D006526,HCV,We reviewed 1274 liver recipients from 2002 to 2010 and identified a cohort of HCV recipients exposed to sirolimus as primary immunosuppression (SRL Cohort) and an HCV Control Group of recipients who had never received sirolimus.,21967703_3,21967703_D020123_D006526,,
770960036,false,true,5,2015-08-15T01:56:00,,No Relation,1,D020123,SRL,D005355,fibrosis,"In an intent-to-treat analysis, the SRL Cohort had significantly less advanced fibrosis (stage 2) compared to the HCV Control Group at year one (15.3% vs. 36.2%, p < 0.0001) and year two (30.1% vs. 50.5%, p = 0.001).",21967703_5,21967703_D020123_D005355,,
770960037,false,true,5,2015-08-15T02:21:00,,No Relation,0.8339,D020123,SRL,D006526,HCV,"In an intent-to-treat analysis, the SRL Cohort had significantly less advanced fibrosis (stage 2) compared to the HCV Control Group at year one (15.3% vs. 36.2%, p < 0.0001) and year two (30.1% vs. 50.5%, p = 0.001).",21967703_5,21967703_D020123_D006526,,
770960038,false,true,5,2015-08-15T01:54:00,,No Relation,0.7971,D020123,sirolimus/SRL,D005355,fibrosis,"Because sirolimus is sometimes discontinued for side effects, the SRL Cohort was subgroup stratified for sirolimus duration, showing progressively less fibrosis with longer sirolimus duration.",21967703_6,21967703_D020123_D005355,,
770960039,false,true,5,2015-08-15T00:29:00,,No Relation,0.8059,D020123,sirolimus,D005355,fibrosis,"Multivariate analysis demonstrated sirolimus as an independent predictor of minimal fibrosis at year one, and year two.",21967703_7,21967703_D020123_D005355,,
770960040,false,true,5,2015-08-14T23:43:00,,No Relation,1,D020123,sirolimus,D005355,fibrosis,This is the first study among liver transplant recipients with recurrent HCV to describe the positive impact of sirolimus in respect of reduced fibrosis extent and rate of progression.,21967703_8,21967703_D020123_D005355,,
770960041,false,true,5,2015-08-14T23:05:00,,No Relation,1,D020123,sirolimus,D006526,HCV,This is the first study among liver transplant recipients with recurrent HCV to describe the positive impact of sirolimus in respect of reduced fibrosis extent and rate of progression.,21967703_8,21967703_D020123_D006526,,
770960042,false,true,5,2015-08-14T22:31:00,Probably used as tratment.,No Relation,1,C031967,Rasagiline,D010300,Parkinson's disease,Rasagiline in Parkinson's disease.,21971007_0,21971007_C031967_D010300,,
770960043,false,true,5,2015-08-15T02:11:00,,No Relation,1,C031967,Rasagiline,D010300,PD,Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy.,21971007_3,21971007_C031967_D010300,,
770960044,false,true,5,2015-08-14T23:51:00,,No Relation,1,C031967,rasagiline,D010300,PD,"Clinical trials have also shown putative disease-modifying effects, though rasagiline's potential to alter the long-term course of PD remains controversial.",21971007_4,21971007_C031967_D010300,,
770960045,false,true,5,2015-08-14T22:30:00,,No Relation,1,C031967,rasagiline,D010300,PD,"Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy.",21971007_5,21971007_C031967_D010300,,
770960046,false,true,5,2015-08-14T23:37:00,,No Relation,1,D003276,oral contraceptives,D013966,thyroid dysfunction,"Its precise etio-pathogenesis is evasive, genetic influences, exposure to sunlight, pregnancy, oral contraceptives, estrogen-progesterone therapies, thyroid dysfunction, cosmetics, and drugs have been proposed.",21981383_2,21981383_D003276_D013966,,
770960047,false,true,5,2015-08-14T22:55:00,,No Relation,1,C031927,hydroquinone,D008548,melasma,"The use of broad-spectrum sunscreen is important, lightening agents like retinoic acid (tretinoin), azelaic acid, and combination therapies containing hydroquinone, tretinoin, and corticosteroids, have been used in the treatment of melasma, and are thought to have increased efficacy as compared with monotherapy.",21981383_8,21981383_C031927_D008548,,
770960048,false,true,5,2015-08-15T00:45:00,,No Relation,1,D014212,retinoic acid/tretinoin,D008548,melasma,"The use of broad-spectrum sunscreen is important, lightening agents like retinoic acid (tretinoin), azelaic acid, and combination therapies containing hydroquinone, tretinoin, and corticosteroids, have been used in the treatment of melasma, and are thought to have increased efficacy as compared with monotherapy.",21981383_8,21981383_D014212_D008548,,
770960049,false,true,5,2015-08-15T01:43:00,,No Relation,1,C010038,azelaic acid,D008548,melasma,"The use of broad-spectrum sunscreen is important, lightening agents like retinoic acid (tretinoin), azelaic acid, and combination therapies containing hydroquinone, tretinoin, and corticosteroids, have been used in the treatment of melasma, and are thought to have increased efficacy as compared with monotherapy.",21981383_8,21981383_C010038_D008548,,
770960050,false,true,5,2015-08-14T22:32:00,,No Relation,1,D000305,corticosteroids,D008548,melasma,"The use of broad-spectrum sunscreen is important, lightening agents like retinoic acid (tretinoin), azelaic acid, and combination therapies containing hydroquinone, tretinoin, and corticosteroids, have been used in the treatment of melasma, and are thought to have increased efficacy as compared with monotherapy.",21981383_8,21981383_D000305_D008548,,
770960051,false,true,5,2015-08-14T23:43:00,,No Relation,1,D010126,ozone,D003920,T2DM/type 2 diabetes mellitus,"We examined whether short-term exposures to air pollution (fine particles, ozone) and heat resulted in perturbation of arterial blood pressure (BP) in persons with type 2 diabetes mellitus (T2DM).",22020729_2,22020729_D010126_D003920,,
770960052,false,true,5,2015-08-14T22:41:00,,No Relation,1,D010126,ozone,D003920,T2DM,"In subjects with T2DM, PM was associated with increased BP, and ozone was associated with decreased BP.",22020729_9,22020729_D010126_D003920,,
770960053,false,true,5,2015-08-15T00:23:00,,Direct,0.6094,D001920,Bradykinin,D014412,Sindbis virus infection,Bradykinin enhances Sindbis virus infection in human brain microvascular endothelial cells.,22047990_0,22047990_D001920_D014412,,
770960054,false,true,5,2015-08-14T22:42:00,,Direct,0.819,D001920,bradykinin,D004487,inflammatory edema,"We investigated whether endothelial cells infected by SINV are differentially responsive to bradykinin (BK), a potent inducer of inflammatory edema in a broad range of infectious diseases.",22047990_3,22047990_D001920_D004487,,
770960055,false,true,5,2015-08-15T00:15:00,,Direct,0.5811,D001920,bradykinin,D003141,infectious diseases,"We investigated whether endothelial cells infected by SINV are differentially responsive to bradykinin (BK), a potent inducer of inflammatory edema in a broad range of infectious diseases.",22047990_3,22047990_D001920_D003141,,
770960056,false,true,5,2015-08-15T01:58:00,,No Relation,1,D004087,dihydroergotamine,D006261,headaches,Intravenous dihydroergotamine for inpatient management of refractory primary headaches.,22049203_0,22049203_D004087_D006261,,
770960057,false,true,5,2015-08-14T22:44:00,,Direct,0.6039,D004087,dihydroergotamine,D051270,primary headache disorders,To determine dosing and side effects of dihydroergotamine as they affect outcomes in primary headache disorders.,22049203_1,22049203_D004087_D051270,,
770960058,false,true,5,2015-08-15T02:10:00,,No Relation,1,D004087,dihydroergotamine,D006261,headache,"We audited our use of dihydroergotamine for inpatient management of disabling primary headache, focusing on the commonly treated problems.",22049203_2,22049203_D004087_D006261,,
770960059,false,true,5,2015-08-14T23:36:00,,No Relation,0.7941,D004087,dihydroergotamine,D006261,headache,The data suggest that IV dihydroergotamine given over 5 days produces improvement in headache and disability in patients with migraine more than shorter courses.,22049203_5,22049203_D004087_D006261,,
770960060,false,true,5,2015-08-14T22:43:00,,No Relation,1,D004087,dihydroergotamine,D008881,migraine,The data suggest that IV dihydroergotamine given over 5 days produces improvement in headache and disability in patients with migraine more than shorter courses.,22049203_5,22049203_D004087_D008881,,
770960061,false,true,5,2015-08-15T00:35:00,,No Relation,1,D004087,dihydroergotamine,D010146,pain,Giving more dihydroergotamine predicts a greater pain-free rate.,22049203_7,22049203_D004087_D010146,,
770960062,false,true,5,2015-08-14T22:51:00,,No Relation,0.6097,D004087,dihydroergotamine,D003027,cluster headache,Patients with cluster headache benefit from IV dihydroergotamine.,22049203_8,22049203_D004087_D003027,,
770960063,false,true,5,2015-08-15T00:21:00,,No Relation,1,D019319,okadaic acid,D009369,breast cancer,"Here we treated human breast cancer cells with the structurally distinct toxins calyculin A, okadaic acid, and cantharidin, which are known to inhibit Ser/Thr phosphatases of the PPP family.",22069692_4,22069692_D019319_D009369,,
770960064,false,true,5,2015-08-14T23:01:00,,No Relation,1,D002193,cantharidin,D009369,breast cancer,"Here we treated human breast cancer cells with the structurally distinct toxins calyculin A, okadaic acid, and cantharidin, which are known to inhibit Ser/Thr phosphatases of the PPP family.",22069692_4,22069692_D002193_D009369,,
770960065,false,true,5,2015-08-15T01:17:00,,No Relation,0.7875,C059041,Calyculin A,D009369,breast cancer,"A reverse phase phosphoprotein array analysis revealed increased phosphorylation of only 6 out of 33 Ser/Thr phosphosites, indicating selective inhibition of phosphatases by calyculin A. Calyculin A treatment induced cell cycle arrest in MDA-MB-468 and MCF-7 breast cancer cells.",22069692_8,22069692_C059041_D009369,,
770960066,false,true,5,2015-08-15T01:58:00,,No Relation,0.8067,D005472,5-fluorouracil,D009369,cancer,We evaluated whether an experimental systems biology strategy which analyses the susceptibility of cancer cells to undergo caspase activation can be exploited to predict patient responses to 5-fluorouracil-based chemotherapy and to case-specifically identify potential alternative targeted treatments to reactivate apoptosis.,22082587_2,22082587_D005472_D009369,,
770960067,false,true,5,2015-08-14T22:37:00,Used as treatment.,No Relation,0.7973,D005472,5-fluorouracil,D015179,colorectal cancer,Systems-level analysis correctly predicted positive or negative outcome in 85% (p=0.004) of colorectal cancer patients receiving 5-fluorouracil based chemotherapy and significantly outperformed common uni- and multi-variate statistical approaches.,22082587_6,22082587_D005472_D015179,,
770960068,false,true,5,2015-08-15T02:05:00,,No Relation,1,D015742,propofol,D007511,ischemic,Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial.,22103808_0,22103808_D015742_D007511,,
770960069,false,true,5,2015-08-14T22:31:00,,No Relation,1,D007530,isoflurane,D007511,ischemic,Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial.,22103808_0,22103808_D007530_D007511,,
770960070,false,true,5,2015-08-15T01:03:00,,No Relation,1,D015742,propofol,D007511,RIPC,"Specifically, we hypothesized that RIPC during isoflurane anesthesia attenuates myocardial injury in patients undergoing coronary artery bypass graft (CABG) surgery, and that effects may be different during propofol anesthesia.",22103808_3,22103808_D015742_D007511,,
770960071,false,true,5,2015-08-14T23:42:00,,No Relation,0.5867,D007530,isoflurane,D009202,myocardial injury,"Specifically, we hypothesized that RIPC during isoflurane anesthesia attenuates myocardial injury in patients undergoing coronary artery bypass graft (CABG) surgery, and that effects may be different during propofol anesthesia.",22103808_3,22103808_D007530_D009202,,
770960072,false,true,5,2015-08-15T00:16:00,,No Relation,1,D015742,propofol,D009202,myocardial injury,"Specifically, we hypothesized that RIPC during isoflurane anesthesia attenuates myocardial injury in patients undergoing coronary artery bypass graft (CABG) surgery, and that effects may be different during propofol anesthesia.",22103808_3,22103808_D015742_D009202,,
770960073,false,true,5,2015-08-15T02:12:00,,No Relation,1,D007530,isoflurane,D007511,RIPC,"Specifically, we hypothesized that RIPC during isoflurane anesthesia attenuates myocardial injury in patients undergoing coronary artery bypass graft (CABG) surgery, and that effects may be different during propofol anesthesia.",22103808_3,22103808_D007530_D007511,,
770960074,false,true,5,2015-08-15T02:32:00,,No Relation,1,D007530,isoflurane,D003929,diabetic,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D007530_D003929,,
770960075,false,true,5,2015-08-15T00:12:00,,No Relation,1,D015742,propofol,D007511,RIPC/ischemia,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D015742_D007511,,
770960076,false,true,5,2015-08-15T02:30:00,,No Relation,1,D017409,sufentanil,D003324,coronary artery disease,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D017409_D003324,,
770960077,false,true,5,2015-08-15T01:18:00,,No Relation,1,D017409,sufentanil,D003929,diabetic,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D017409_D003929,,
770960078,false,true,5,2015-08-14T22:58:00,The disease is a pre-existing condition.,No Relation,1,D007530,isoflurane,D003324,coronary artery disease,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D007530_D003324,,
770960079,false,true,5,2015-08-15T00:26:00,,No Relation,1,D007530,isoflurane,D007511,RIPC/ischemia,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D007530_D007511,,
770960080,false,true,5,2015-08-14T23:43:00,,No Relation,1,D015742,propofol,D003324,coronary artery disease,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D015742_D003324,,
770960081,false,true,5,2015-08-14T23:46:00,,No Relation,1,D017409,sufentanil,D007511,RIPC/ischemia,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D017409_D007511,,
770960082,false,true,5,2015-08-15T01:24:00,,No Relation,1,D015742,propofol,D003929,diabetic,"In a randomized, single-blinded, placebo-controlled prospective study, serum troponin I concentration (cTnI) (baseline, and 1, 6, 12, 24, 48, and 72 h postoperatively) were measured during isoflurane/sufentanil or propofol/sufentanil anesthesia with or without RIPC (three 5-min periods of intermittent left upper arm ischemia with 5 min reperfusion each) in non-diabetic patients (n = 72) with three-vessel coronary artery disease (ClinicalTrials.gov NCT01406678).",22103808_4,22103808_D015742_D003929,,
770960083,false,true,5,2015-08-14T23:03:00,,No Relation,0.7865,D007530,isoflurane,D007511,RIPC,"RIPC during isoflurane anesthesia (n = 20) decreased the area under the cTnI time curve (cTnI AUC) (-50%, 190  105 ng/ml  72 h vs. 383  262 ng/ml  72 h, P = 0.004), and the peak (7.3  3.6 ng/ml vs. 11.8  5.5, P = 0.004) and serial (P < 0.041) postoperative cTnI when compared to isoflurane alone (n = 19).",22103808_5,22103808_D007530_D007511,,
770960084,false,true,5,2015-08-14T22:46:00,,No Relation,0.802,D015742,propofol,D007511,RIPC,"In contrast, RIPC during propofol anesthesia (n = 14) did not alter the cTnI AUC [263  157 ng/ml  72 h vs. 372  376 ng/ml  72 h (n = 19), P = 0.318] or peak postoperative cTnI (10.1  4.5 ng/ml vs. 12  8.2, P = 0.444).",22103808_6,22103808_D015742_D007511,,
770960085,false,true,5,2015-08-14T23:16:00,"I am a fifth year medical student in Hungary, I really enjoyed working on these tasks and if you happen to have some work for me online, I'd be more than willing. My email: daloloparizs@gmail.comThanks in advance!",No Relation,1,D015742,propofol,D007511,RIPC,"Thus, RIPC during isoflurane but not during propofol anesthesia decreased myocardial damage in patients undergoing CABG surgery.",22103808_8,22103808_D015742_D007511,,
770960086,false,true,5,2015-08-15T02:39:00,,No Relation,1,D007530,isoflurane,D009202,myocardial damage,"Thus, RIPC during isoflurane but not during propofol anesthesia decreased myocardial damage in patients undergoing CABG surgery.",22103808_8,22103808_D007530_D009202,,
770960087,false,true,5,2015-08-15T00:47:00,,No Relation,1,D015742,propofol,D009202,myocardial damage,"Thus, RIPC during isoflurane but not during propofol anesthesia decreased myocardial damage in patients undergoing CABG surgery.",22103808_8,22103808_D015742_D009202,,
770960088,false,true,5,2015-08-15T00:15:00,,No Relation,0.805,D007530,isoflurane,D007511,RIPC,"Thus, RIPC during isoflurane but not during propofol anesthesia decreased myocardial damage in patients undergoing CABG surgery.",22103808_8,22103808_D007530_D007511,,
770960089,false,true,5,2015-08-14T22:41:00,,No Relation,1,D007530,isoflurane,D007511,RIPC/ischemia,"Accordingly, effects of RIPC evoked by upper limb ischemia/reperfusion depend on background anesthesia, with combined RIPC/isoflurane exerting greater beneficial effects under conditions studied.",22103808_9,22103808_D007530_D007511,,
770960090,false,true,5,2015-08-15T02:21:00,,No Relation,1,D004492,EDTA,D051436,Renal Disease,"The aim was to evaluate the accuracy of Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae as a substitute for the gold standard measure of glomerular filtration rate (GFR) using chromium 51 EDTA.",22104575_1,22104575_D004492_D051436,,
770960091,false,true,5,2015-08-14T23:06:00,,No Relation,1,D005947,glucose,D007018,hypopituitarism,"Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.",22108915_0,22108915_D005947_D007018,,
770960092,false,true,5,2015-08-14T23:37:00,,No Relation,0.8026,D004967,estrogen,D007018,hypopituitarism,"Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.",22108915_0,22108915_D004967_D007018,,
770960093,false,true,5,2015-08-15T00:03:00,,No Relation,1,D004958,estradiol,D007018,hypopituitarism,To evaluate the effects of oral estradiol and transdermal 17_-estradiol on serum concentrations of IGF1 and its binding proteins in women with hypopituitarism.,22108915_1,22108915_D004958_D007018,,
770960094,false,true,5,2015-08-14T22:38:00,,No Relation,1,D004958,estradiol,D007018,hypopituitarism,Eleven patients with hypopituitarism were randomly allocated to receive 2_mg oral estradiol (n=6) or 50__g/day of transdermal 17_-estradiol (n=5) for 3 months.,22108915_3,22108915_D004958_D007018,,
770960095,false,true,5,2015-08-14T23:41:00,,No Relation,0.7987,D004967,estrogen,D007018,hypopituitarism,"These findings in patients with hypopituitarism have an impact on their response to treatment with GH, since patients receiving oral estrogen require increased GH dosage.",22108915_10,22108915_D004967_D007018,,
770960096,false,true,5,2015-08-14T23:55:00,,No Relation,1,C104450,25-hydroxyvitamin D,D014808,vitamin D deficiency,Several studies in pregnant women and early childhood suggest that vitamin D deficiency (serum 25-hydroxyvitamin D levels <50 nmol/l) is common in both population groups.,22123632_1,22123632_C104450_D014808,,
770960097,false,true,5,2015-08-14T23:32:00,,No Relation,0.7988,D014807,vitamin D,D014808,vitamin D deficiency,Several studies in pregnant women and early childhood suggest that vitamin D deficiency (serum 25-hydroxyvitamin D levels <50 nmol/l) is common in both population groups.,22123632_1,22123632_D014807_D014808,,
770960098,false,true,5,2015-08-14T23:42:00,"This one is ambiguous. Logically, lack of Vitamin D directly contributes to or causes vitamin D deficiency - in one sense, therefore,  it is true that ""Vitamin D directly contributes to or causes vitamin D deficiency."" However that is not what most people think, is it?",No Relation,0.7974,D014807,Vitamin D,D014808,vitamin D deficiency,"In 2011, the US Endocrine Task Force on Vitamin D commented that 600 IU per day may not be sufficient to correct vitamin D deficiency in pregnant and lactating women.",22123632_4,22123632_D014807_D014808,,
770960099,false,true,5,2015-08-14T22:48:00,,No Relation,0.7975,D014807,vitamin D,D014808,vitamin D deficiency,"Their recommendation was 1,500-2,000 IU vitamin D per day in pregnant and lactating women with vitamin D deficiency.",22123632_5,22123632_D014807_D014808,,
770960100,false,true,5,2015-08-14T22:34:00,,No Relation,1,C473478,sunitinib,D002292,renal cell carcinoma,Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.,22126730_0,22126730_C473478_D002292,,
770960101,false,true,5,2015-08-14T22:42:00,,No Relation,1,C473478,Sunitinib,C536851,renal carcinoma,"INTRODUCTION Sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, delays disease progression, with a median overall survival (OS) of more than 2 years, improves quality of life and is becoming the first-line standard of care for metastatic renal carcinoma (mRCC).",22126730_1,22126730_C473478_C536851,,
770960102,false,true,5,2015-08-15T01:41:00,,No Relation,1,D014443,tyrosine,C536851,renal carcinoma,"INTRODUCTION Sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, delays disease progression, with a median overall survival (OS) of more than 2 years, improves quality of life and is becoming the first-line standard of care for metastatic renal carcinoma (mRCC).",22126730_1,22126730_D014443_C536851,,
770960103,false,true,5,2015-08-15T01:54:00,,No Relation,1,D014221,triamcinolone,D003251,stricture,The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection.,22136782_0,22136782_D014221_D003251,,
770960104,false,true,5,2015-08-14T22:54:00,,No Relation,1,D014221,triamcinolone,D003251,stricture,The goal of this study was to determine the efficacy of endoscopic triamcinolone injection (ETI) for the prevention of stricture formation after ESD.,22136782_2,22136782_D014221_D003251,,
770960105,false,true,5,2015-08-14T22:44:00,,No Relation,1,D005227,fatty acids,D015179,colorectal cancer,"Vitamins, minerals, essential fatty acids and colorectal cancer risk in the United Kingdom Dietary Cohort Consortium.",22139959_0,22139959_D005227_D015179,,
770960106,false,true,5,2015-08-14T22:34:00,,Direct,0.8045,D005227,fatty acids,D015179,colorectal cancer,"The risk for colorectal cancer may be influenced by the dietary intake of various vitamins, minerals and essential fatty acids.",22139959_1,22139959_D005227_D015179,,
770960107,false,true,5,2015-08-14T23:46:00,Used as prevention.,No Relation,0.5824,D015525,n - 3 fatty acids,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D015525_D015179,,
770960108,false,true,5,2015-08-14T23:08:00,,No Relation,0.8117,D025101,vitamin B6,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D025101_D015179,,
770960109,false,true,5,2015-08-15T00:58:00,,No Relation,0.8125,D002118,calcium,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D002118_D015179,,
770960110,false,true,5,2015-08-14T22:33:00,,No Relation,0.7939,D014807,vitamin D,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D014807_D015179,,
770960111,false,true,5,2015-08-15T02:27:00,,No Relation,0.8024,D000431,alcohol,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D000431_D015179,,
770960112,false,true,5,2015-08-15T02:12:00,,No Relation,0.808,D011188,potassium,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D011188_D015179,,
770960113,false,true,5,2015-08-14T23:25:00,,No Relation,0.7921,D007501,iron,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D007501_D015179,,
770960114,false,true,5,2015-08-14T22:51:00,,No Relation,0.6044,D005492,folate,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D005492_D015179,,
770960115,false,true,5,2015-08-15T00:58:00,,No Relation,1,D014801,retinol/vitamin A,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D014801_D015179,,
770960116,false,true,5,2015-08-14T22:52:00,,No Relation,0.8126,D014805,vitamin B12,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D014805_D015179,,
770960117,false,true,5,2015-08-14T22:37:00,,No Relation,1,D012256,riboflavin,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D012256_D015179,,
770960118,false,true,5,2015-08-14T22:38:00,,No Relation,1,D043371,n - 6 fatty acids,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D043371_D015179,,
770960119,false,true,5,2015-08-14T22:55:00,,No Relation,1,D008274,magnesium,D015179,colorectal cancer,"Dietary intakes of retinol, vitamin A, thiamin, riboflavin, vitamin B6, folate, vitamin B12, vitamin D, calcium, iron, magnesium, potassium, n - 6 fatty acids, n - 3 fatty acids and the ratio of n - 6 to n - 3 fatty acids were estimated and their associations with colorectal cancer examined using conditional logistic regression models, adjusting for exact age, height, weight, energy intake, alcohol intake, fiber intake, smoking, education, social class and physical activity.",22139959_4,22139959_D008274_D015179,,
770960120,false,true,5,2015-08-14T23:05:00,,No Relation,1,D005227,fatty acids,D015179,colorectal cancer,"There were no statistically significant associations between colorectal cancer risk and dietary intake of any of the vitamins, minerals or essential fatty acids examined.",22139959_5,22139959_D005227_D015179,,
770960121,false,true,5,2015-08-14T23:10:00,,No Relation,1,D002701,chloramphenicol,D002386,cataract,Endophthalmitis following cataract surgery: the role of prophylactic postoperative chloramphenicol eye drops.,22151787_0,22151787_D002701_D002386,,
770960122,false,true,5,2015-08-15T00:42:00,,No Relation,1,D002701,chloramphenicol,D009877,Endophthalmitis,Endophthalmitis following cataract surgery: the role of prophylactic postoperative chloramphenicol eye drops.,22151787_0,22151787_D002701_D009877,,
770960123,false,true,5,2015-08-14T22:29:00,,No Relation,0.7923,D002701,chloramphenicol,D002386,cataract,The main aim of the study was to assess whether omitting prophylactic postoperative topical antibiotics (chloramphenicol) influenced the risk of developing endophthalmitis after cataract surgery.,22151787_1,22151787_D002701_D002386,,
770960124,false,true,5,2015-08-15T01:41:00,,No Relation,0.8089,D002701,chloramphenicol,D009877,endophthalmitis,The main aim of the study was to assess whether omitting prophylactic postoperative topical antibiotics (chloramphenicol) influenced the risk of developing endophthalmitis after cataract surgery.,22151787_1,22151787_D002701_D009877,,
770960125,false,true,5,2015-08-15T01:28:00,,No Relation,1,D000305,corticosteroids,D009877,PE,We found no difference in the frequency of PE following cataract surgery when changing the postoperative topical medication from a mixture of corticosteroids and antibiotics to only corticosteroids.,22151787_10,22151787_D000305_D009877,,
770960126,false,true,5,2015-08-14T22:35:00,,No Relation,1,D000305,corticosteroids,D002386,cataract,We found no difference in the frequency of PE following cataract surgery when changing the postoperative topical medication from a mixture of corticosteroids and antibiotics to only corticosteroids.,22151787_10,22151787_D000305_D002386,,
770960127,false,true,5,2015-08-14T22:32:00,,No Relation,1,D007501,Iron,D006528,hepatocellular carcinoma,Iron facilitator LS081 reduces hypoxia-inducible factor-1 protein and functions as anticancer agent in hepatocellular carcinoma.,22181812_0,22181812_D007501_D006528,,
770960128,false,true,5,2015-08-14T22:43:00,,No Relation,1,D007501,Iron,D000860,hypoxia,Iron facilitator LS081 reduces hypoxia-inducible factor-1 protein and functions as anticancer agent in hepatocellular carcinoma.,22181812_0,22181812_D007501_D000860,,
770960129,false,true,5,2015-08-15T00:31:00,,No Relation,1,D010100,oxygen,D009369,tumor/cancer,"Hypoxia inducible factor-1 (HIF-1) has a central role in cellular oxygen-sensing, and its overexpression in many types of cancer is considered important in tumor progression.",22181812_1,22181812_D010100_D009369,,
770960130,false,true,5,2015-08-14T23:44:00,,No Relation,1,D010100,oxygen,D000860,Hypoxia,"Hypoxia inducible factor-1 (HIF-1) has a central role in cellular oxygen-sensing, and its overexpression in many types of cancer is considered important in tumor progression.",22181812_1,22181812_D010100_D000860,,
770960131,false,true,5,2015-08-14T22:34:00,,No Relation,0.8118,D007501,iron,D006528,hepatocellular carcinoma,"In the present study, we aimed to inhibit the expression of HIF-1 protein and growth of hepatocellular carcinoma by using the iron-facilitating activity of LS081.",22181812_7,22181812_D007501_D006528,,
770960132,false,true,5,2015-08-15T00:55:00,,No Relation,1,C481046,ammonium citrate,D006528,hepatocellular carcinoma,"In the human hepatocellular carcinoma cell lines Hep3B and HepG2, a combination of LS081 and ferric ammonium citrate (LS081/FeAC) inhibited HIF-1 protein expression but did not inhibit HIF-1 mRNA expression.",22181812_8,22181812_C481046_D006528,,
770960133,false,true,5,2015-08-14T23:54:00,,No Relation,1,C559818,LS081,D006528,hepatocellular carcinoma,"In the human hepatocellular carcinoma cell lines Hep3B and HepG2, a combination of LS081 and ferric ammonium citrate (LS081/FeAC) inhibited HIF-1 protein expression but did not inhibit HIF-1 mRNA expression.",22181812_8,22181812_C559818_D006528,,
770960134,false,true,5,2015-08-14T22:36:00,,No Relation,1,D007501,iron,D006528,hepatocellular carcinoma,These results indicate that the iron-facilitating activity of LS081 inhibits HIF-1 expression through prolyl-hydroxylation of HIF-1 and might have a therapeutic effect in the treatment of hepatocellular carcinoma.,22181812_11,22181812_D007501_D006528,,
770960135,false,true,5,2015-08-15T01:47:00,,No Relation,1,D005947,glucose,D003920,diabetes mellitus,"The influence of glucose, adjusted for body mass index, age, gender and diabetes mellitus on VTE was assessed by logistic regression analyses.",22187097_8,22187097_D005947_D003920,,
770960136,false,true,5,2015-08-14T22:53:00,,No Relation,1,D005947,glucose,D054556,VTE,"The influence of glucose, adjusted for body mass index, age, gender and diabetes mellitus on VTE was assessed by logistic regression analyses.",22187097_8,22187097_D005947_D054556,,
770960137,false,true,5,2015-08-14T22:59:00,,No Relation,0.7876,D005947,glucose,D054556,VTE,Increased glucose levels after total hip replacement were associated with total VTE; adjusted odds ratio (OR) highest versus lowest quartile 1.9 (95% confidence interval [CI] 1.3 to 3.0).,22187097_10,22187097_D005947_D054556,,
770960138,false,true,5,2015-08-15T01:58:00,,Direct,0.5982,D005947,glucose,D054556,VTE,"Furthermore, increase in glucose levels during total hip replacement was associated with total VTE (OR highest versus lowest quartile 1.8 (95%CI 1.2 to 2.8).",22187097_11,22187097_D005947_D054556,,
770960139,false,true,5,2015-08-15T01:15:00,,No Relation,0.7992,D008550,Melatonin,D006528,hepatoma,Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis.,22225575_0,22225575_D008550_D006528,,
770960140,false,true,5,2015-08-14T23:03:00,,Direct,0.8036,D008550,Melatonin,D006528,HCC/apoptosis in hepatocellular carcinoma,"Melatonin induces apoptosis in hepatocellular carcinoma (HCC) in experimental studies, but the effects of melatonin on endoplasmic reticulum (ER) stress-induced apoptosis in HCC have not been tested.",22225575_2,22225575_D008550_D006528,,
770960141,false,true,5,2015-08-14T23:26:00,,Direct,0.587,D014415,tunicamycin,D006528,hepatoma,Differences in ER stress-induced apoptosis in human hepatoma cells and normal human hepatocyte were investigated by exposure to tunicamycin (ER stress inducer).,22225575_3,22225575_D014415_D006528,,
770960142,false,true,5,2015-08-14T22:38:00,,No Relation,1,C105934,celecoxib,D006528,hepatoma,"Furthermore, down-regulation of COX-2 expression using the COX-2 inhibitor, celecoxib, increased tunicamycin-induced apoptosis concomitant with the up-regulation of pro-apoptotic transcription factor CHOP (GADD153) and down-regulation of B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, suggesting that inhibition of COX-2 sensitized human hepatoma cells to ER stress-induced apoptosis.",22225575_6,22225575_C105934_D006528,,
770960143,false,true,5,2015-08-15T00:48:00,,No Relation,1,C105934,celecoxib,D016393,B-cell lymphoma,"Furthermore, down-regulation of COX-2 expression using the COX-2 inhibitor, celecoxib, increased tunicamycin-induced apoptosis concomitant with the up-regulation of pro-apoptotic transcription factor CHOP (GADD153) and down-regulation of B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, suggesting that inhibition of COX-2 sensitized human hepatoma cells to ER stress-induced apoptosis.",22225575_6,22225575_C105934_D016393,,
770960144,false,true,5,2015-08-14T23:51:00,,No Relation,1,D014415,tunicamycin,D016393,B-cell lymphoma,"Furthermore, down-regulation of COX-2 expression using the COX-2 inhibitor, celecoxib, increased tunicamycin-induced apoptosis concomitant with the up-regulation of pro-apoptotic transcription factor CHOP (GADD153) and down-regulation of B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, suggesting that inhibition of COX-2 sensitized human hepatoma cells to ER stress-induced apoptosis.",22225575_6,22225575_D014415_D016393,,
770960145,false,true,5,2015-08-14T23:02:00,Used as treatment.,No Relation,0.8115,D014415,tunicamycin,D006528,hepatoma,"Furthermore, down-regulation of COX-2 expression using the COX-2 inhibitor, celecoxib, increased tunicamycin-induced apoptosis concomitant with the up-regulation of pro-apoptotic transcription factor CHOP (GADD153) and down-regulation of B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, suggesting that inhibition of COX-2 sensitized human hepatoma cells to ER stress-induced apoptosis.",22225575_6,22225575_D014415_D006528,,
770960146,false,true,5,2015-08-15T00:10:00,,No Relation,1,D008550,melatonin,D006528,hepatoma,"These results demonstrate that melatonin sensitizes human hepatoma cells to ER stress-induced apoptosis by down-regulating COX-2 expression, increasing the levels of CHOP and decreasing the Bcl-2/Bax ratio.",22225575_8,22225575_D008550_D006528,,
770960147,false,true,5,2015-08-14T22:42:00,,No Relation,1,D000728,androgen,D011471,prostate cancer,"""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.",22280402_0,22280402_D000728_D011471,,
770960148,false,true,5,2015-08-15T01:40:00,,No Relation,1,D013739,testosterone,D011471,Prostate cancer/PCa,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D013739_D011471,,
770960149,false,true,5,2015-08-15T01:18:00,,No Relation,1,D000728,androgen,D011471,Prostate cancer/PCa,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D000728_D011471,,
770960150,false,true,5,2015-08-14T23:11:00,,No Relation,1,D013196,dihydrotestosterone/DHT,D006938,ligand-binding domain/LBD,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D013196_D006938,,
770960151,false,true,5,2015-08-14T22:33:00,,No Relation,0.8034,D013196,dihydrotestosterone/DHT,D011471,Prostate cancer/PCa,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D013196_D011471,,
770960152,false,true,5,2015-08-14T23:05:00,,No Relation,1,D013739,testosterone,D006938,ligand-binding domain/LBD,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D013739_D006938,,
770960153,false,true,5,2015-08-15T01:18:00,,No Relation,1,D000728,androgen,D006938,ligand-binding domain/LBD,"Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR.",22280402_1,22280402_D000728_D006938,,
770960154,false,true,5,2015-08-15T00:51:00,,No Relation,1,D012828,silicone,D015658,HIV-1 infection,Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature.,22288970_0,22288970_D012828_D015658,,
770960155,false,true,5,2015-08-15T01:06:00,,Direct,0.8097,D012828,silicone,D011014,granulomatous pneumonitis,Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature.,22288970_0,22288970_D012828_D011014,,
770960156,false,true,5,2015-08-15T01:39:00,,Direct,1,D012828,Silicone,D011014,pneumonitis,"Silicone, commonly used in cosmetic procedures owing to its presumed inertness, can yield serious sequelae including acute embolization and pneumonitis.",22288970_1,22288970_D012828_D011014,,
770960157,false,true,5,2015-08-14T22:33:00,,No Relation,1,D012828,silicone,D015658,human immunodeficiency virus,We report a case of chronic progressive granulomatous pneumonitis in response to subcutaneous silicone injections in a transgender male-to-female patient infected with human immunodeficiency virus 1 (HIV-1).,22288970_3,22288970_D012828_D015658,,
770960158,false,true,5,2015-08-14T22:35:00,,Direct,1,D012828,silicone,D011014,granulomatous pneumonitis,We report a case of chronic progressive granulomatous pneumonitis in response to subcutaneous silicone injections in a transgender male-to-female patient infected with human immunodeficiency virus 1 (HIV-1).,22288970_3,22288970_D012828_D011014,,
770960159,false,true,5,2015-08-14T22:55:00,,Direct,1,D012828,silicone,D004417,dyspnea,"After receiving silicone injections to the buttock, the patient developed rapid onset dyspnea, pleuritic chest pain, fever, and chills.",22288970_4,22288970_D012828_D004417,,
770960160,false,true,5,2015-08-14T22:49:00,,Direct,1,D012828,silicone,D002637,chest pain,"After receiving silicone injections to the buttock, the patient developed rapid onset dyspnea, pleuritic chest pain, fever, and chills.",22288970_4,22288970_D012828_D002637,,
770960161,false,true,5,2015-08-14T23:24:00,,Direct,1,D012828,silicone,D005334,fever,"After receiving silicone injections to the buttock, the patient developed rapid onset dyspnea, pleuritic chest pain, fever, and chills.",22288970_4,22288970_D012828_D005334,,
770960162,false,true,5,2015-08-15T00:33:00,,No Relation,0.7964,D012828,silicone,D007249,granulomatous inflammation,"Lung biopsies demonstrated numerous spheroid silicone particles within the lung interstitium and small pulmonary vessels, surrounded by foreign body giant cells and nonnecrotizing granulomatous inflammation.",22288970_9,22288970_D012828_D007249,,
770960163,false,true,5,2015-08-14T23:26:00,,No Relation,0.8343,D012828,silicone,D015658,HIV-1-infected,"We speculate that HIV-1-infected patients may be at risk for chronic, progressive granulomatous pneumonitis due to silicone injection years after their procedure owing to shifting levels of cell-mediated immunity.",22288970_10,22288970_D012828_D015658,,
770960164,false,true,5,2015-08-14T22:53:00,,Direct,1,D012828,silicone,D011014,granulomatous pneumonitis,"We speculate that HIV-1-infected patients may be at risk for chronic, progressive granulomatous pneumonitis due to silicone injection years after their procedure owing to shifting levels of cell-mediated immunity.",22288970_10,22288970_D012828_D011014,,
770960165,false,true,5,2015-08-15T01:15:00,,No Relation,0.8095,D015525,Omega-3 fatty acids,D006331,cardiac disease,Omega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease.,22296885_1,22296885_D015525_D006331,,
770960166,false,true,5,2015-08-15T00:27:00,,No Relation,1,D015525,Omega-3 fatty acids,D007249,inflammation,Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.,22296885_11,22296885_D015525_D007249,,
770960167,false,true,5,2015-08-15T01:10:00,,No Relation,1,D015525,Omega-3 fatty acids,D002539,arterial disease,Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.,22296885_11,22296885_D015525_D002539,,
770960168,false,true,5,2015-08-15T02:00:00,,No Relation,1,D019829,nevirapine,D015658,HIV,"Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of nave HIV patients in Thailand: a 3-year follow-up.",22299411_0,22299411_D019829_D015658,,
770960169,false,true,5,2015-08-15T00:06:00,,No Relation,1,D018119,stavudine,D015658,HIV,"Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of nave HIV patients in Thailand: a 3-year follow-up.",22299411_0,22299411_D018119_D015658,,
770960170,false,true,5,2015-08-15T02:20:00,,No Relation,1,D019259,lamivudine,D015658,HIV,"Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of nave HIV patients in Thailand: a 3-year follow-up.",22299411_0,22299411_D019259_D015658,,
770960171,false,true,5,2015-08-14T23:35:00,,No Relation,1,D019829,nevirapine/NVP,D015658,HIV,"Generic fixed dose combination stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), named GPO-VIR is recommended in the HIV treatment guidelines for Thailand.",22299411_1,22299411_D019829_D015658,,
770960172,false,true,5,2015-08-15T01:13:00,,No Relation,1,D018119,stavudine/d4T,D015658,HIV,"Generic fixed dose combination stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), named GPO-VIR is recommended in the HIV treatment guidelines for Thailand.",22299411_1,22299411_D018119_D015658,,
770960173,false,true,5,2015-08-14T23:26:00,,No Relation,1,D019259,lamivudine/3TC,D015658,HIV,"Generic fixed dose combination stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), named GPO-VIR is recommended in the HIV treatment guidelines for Thailand.",22299411_1,22299411_D019259_D015658,,
770960174,false,true,5,2015-08-14T22:49:00,,No Relation,1,C052342,topiramate,D019964,mood disorders,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_C052342_D019964,,
770960175,false,true,5,2015-08-14T22:49:00,,No Relation,1,D012701,serotonin,D019964,mood disorders,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_D012701_D019964,,
770960177,false,true,5,2015-08-14T22:56:00,,No Relation,0.8023,D012701,serotonin,D056912,binge eating disorder,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_D012701_D056912,,
770960178,false,true,5,2015-08-15T02:01:00,,No Relation,0.6065,C022189,zonisamide,D056912,binge eating disorder,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_C022189_D056912,,
770960179,false,true,5,2015-08-15T00:40:00,,No Relation,1,C022189,zonisamide,D019964,mood disorders,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_C022189_D019964,,
770960180,false,true,5,2015-08-15T00:00:00,,No Relation,0.7991,C052342,topiramate,D056912,binge eating disorder,"For binge eating disorder, the best evidence in mood disorders was for cognitive-behavioral therapy as well as topiramate, zonisamide, and in select cases selective serotonin reuptake inhibitors.",22303523_7,22303523_C052342_D056912,,
770960181,false,true,5,2015-08-14T23:35:00,,No Relation,1,C554292|D013755,12-O-tetradecanoylphorbol-13-acetate/TPA,D009369,tumor,"Compounds 1-17 were examined for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced with 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, a known primary screening test for inhibitors of tumor promotion.",22344919_3,22344919_C554292|D013755_D009369,,
770960182,false,true,5,2015-08-14T22:50:00,,No Relation,0.8119,C554292|D013755,TPA,D063646,skin carcinogenesis,"In addition, compounds 1 and 11 exhibited inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as a promoter.",22344919_5,22344919_C554292|D013755_D063646,,
770960183,false,true,5,2015-08-14T22:59:00,,Direct,0.6069,C554292|D013755,TPA,D009369,skin-tumor promotion,"In addition, compounds 1 and 11 exhibited inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as a promoter.",22344919_5,22344919_C554292|D013755_D009369,,
770960184,false,true,5,2015-08-14T22:46:00,,No Relation,1,D011803,quinine,D016778,falciparum malaria,Efficacy and safety of quinine loading dose in patients with severe falciparum malaria at a tertiary care hospital in Pakistan.,22368898_0,22368898_D011803_D016778,,
770960185,false,true,5,2015-08-15T02:01:00,,No Relation,1,D011803,quinine,D016778,falciparum malaria,To compare the clinical outcomes of a loading dose regimen of quinine with a uniform dose regimen in patients with severe falciparum malaria.,22368898_1,22368898_D011803_D016778,,
770960186,false,true,5,2015-08-14T23:06:00,,No Relation,1,D011803,quinine,D016778,falciparum malaria,"A retrospective chart review of 315 patients admitted with severe falciparum malaria and treated with quinine at a tertiary care teaching hospital of Karachi, Pakistan during 1999-2006 was conducted.",22368898_2,22368898_D011803_D016778,,
770960187,false,true,5,2015-08-14T22:38:00,,Direct,1,D011803,quinine,D064420,toxicity,Although quinine loading dose may be more effective than uniform dose in rapid fever clearance; it also appears to be associated with higher toxicity.,22368898_11,22368898_D011803_D064420,,
770960188,false,true,5,2015-08-14T22:38:00,,No Relation,1,D011803,quinine,D016778,falciparum malaria,Uniform dose of quinine may be prescribed in severe falciparum malaria in view of its better safety profile.,22368898_12,22368898_D011803_D016778,,
770960189,false,true,5,2015-08-15T00:12:00,,No Relation,1,D014443,tyrosine,D015464,chronic myeloid leukemia,Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.,22369329_0,22369329_D014443_D015464,,
770960190,false,true,5,2015-08-15T02:25:00,,No Relation,1,D014443,Tyrosine,D015464,chronic myeloid leukemia,Tyrosine kinase inhibitors (TKIs) were introduced in the late 1990s and have revolutionized the management of chronic myeloid leukemia in chronic phase.,22369329_2,22369329_D014443_D015464,,
770960191,false,true,5,2015-08-14T22:29:00,,No Relation,1,D008687,Metformin,C537389,type,Metformin use among individuals at risk for type 2 diabetes.,22399368_0,22399368_D008687_C537389,,
770960192,false,true,5,2015-08-14T22:33:00,,No Relation,1,D008687,Metformin,D003929,diabetes,Metformin use among individuals at risk for type 2 diabetes.,22399368_0,22399368_D008687_D003929,,
770960193,false,true,5,2015-08-15T02:04:00,,No Relation,0.7882,D005947,glucose,D003929,diabetes,Clinical trials to lower blood glucose have been disappointing probably because the participants were too late in the natural history of diabetes and already had extensive vascular disease.,22399368_2,22399368_D005947_D003929,,
770960194,false,true,5,2015-08-15T01:47:00,,No Relation,1,D005947,glucose,D006402,blood glucose,Clinical trials to lower blood glucose have been disappointing probably because the participants were too late in the natural history of diabetes and already had extensive vascular disease.,22399368_2,22399368_D005947_D006402,,
770960195,false,true,5,2015-08-15T00:03:00,,No Relation,1,D005947,glucose,D014652,vascular disease,Clinical trials to lower blood glucose have been disappointing probably because the participants were too late in the natural history of diabetes and already had extensive vascular disease.,22399368_2,22399368_D005947_D014652,,
770960196,false,true,5,2015-08-14T23:17:00,,No Relation,0.823,D005947,glucose,D003929,diabetes,Metformin will prevent development of diabetes among patients with impaired fasting glucose but only for the short term.,22399368_4,22399368_D005947_D003929,,
770960197,false,true,5,2015-08-14T23:14:00,,No Relation,1,D008687,Metformin,D007003,impaired fasting glucose,Metformin will prevent development of diabetes among patients with impaired fasting glucose but only for the short term.,22399368_4,22399368_D008687_D007003,,
770960198,false,true,5,2015-08-14T23:08:00,,No Relation,1,D008687,Metformin,D003929,diabetes,Metformin will prevent development of diabetes among patients with impaired fasting glucose but only for the short term.,22399368_4,22399368_D008687_D003929,,
770960199,false,true,5,2015-08-14T23:08:00,,No Relation,0.5946,D005947,glucose,D007003,impaired fasting glucose,Metformin will prevent development of diabetes among patients with impaired fasting glucose but only for the short term.,22399368_4,22399368_D005947_D007003,,
770960200,false,true,5,2015-08-15T00:16:00,,No Relation,1,D008687,Metformin,D003327,coronary heart disease,Metformin reduces risk of coronary heart disease.,22399368_5,22399368_D008687_D003327,,
770960201,false,true,5,2015-08-15T01:44:00,,No Relation,1,D008687,metformin,D050197,atherosclerosis,"The combination of diet and exercise followed by metformin in the early phase of ""insulin resistance"" may reduce or delay both atherosclerosis and arteriosclerosis complications associated with diabetes.",22399368_7,22399368_D008687_D050197,,
770960202,false,true,5,2015-08-14T22:44:00,,No Relation,0.7926,D008687,metformin,D003929,diabetes,"The combination of diet and exercise followed by metformin in the early phase of ""insulin resistance"" may reduce or delay both atherosclerosis and arteriosclerosis complications associated with diabetes.",22399368_7,22399368_D008687_D003929,,
770960203,false,true,5,2015-08-14T23:36:00,,No Relation,1,D008687,metformin,D001161,arteriosclerosis,"The combination of diet and exercise followed by metformin in the early phase of ""insulin resistance"" may reduce or delay both atherosclerosis and arteriosclerosis complications associated with diabetes.",22399368_7,22399368_D008687_D001161,,
770960204,false,true,5,2015-08-14T22:37:00,,No Relation,0.8093,D000667,AMP,D015179,colorectal cancer,"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.",22406476_0,22406476_D000667_D015179,,
770960205,false,true,5,2015-08-14T23:39:00,,No Relation,0.6029,D001241,Aspirin,D015179,colorectal cancer,"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.",22406476_0,22406476_D001241_D015179,,
770960206,false,true,5,2015-08-15T01:49:00,,No Relation,1,D001241,Aspirin,D015179,CRC/colorectal cancer,Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms.,22406476_1,22406476_D001241_D015179,,
770960207,false,true,5,2015-08-15T00:31:00,,No Relation,1,D020123,rapamycin,D009369,Cancer,"Cancer cells have defects in signaling via the mechanistic target of rapamycin (mTOR), which regulates proliferation.",22406476_2,22406476_D020123_D009369,,
770960208,false,true,5,2015-08-15T00:22:00,,No Relation,1,D001241,aspirin,D015179,CRC,We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (AMPK) and mTOR signaling in CRC cells.,22406476_3,22406476_D001241_D015179,,
770960209,false,true,5,2015-08-15T01:20:00,,No Relation,1,D000249,adenosine monophosphate,D015179,CRC,We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (AMPK) and mTOR signaling in CRC cells.,22406476_3,22406476_D000249_D015179,,
770960210,false,true,5,2015-08-14T23:00:00,,No Relation,1,D001241,aspirin,D015179,CRC,"The effects of aspirin on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.",22406476_4,22406476_D001241_D015179,,
770960211,false,true,5,2015-08-14T22:38:00,,No Relation,1,D001241,aspirin,D015179,CRC,Phosphorylation of AMPK was measured; the effects of loss of AMPK on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(1/2-/-) mouse embryonic fibroblasts.,22406476_5,22406476_D001241_D015179,,
770960212,false,true,5,2015-08-15T00:12:00,,No Relation,1,D001241,Aspirin,D015179,CRC,Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.,22406476_8,22406476_D001241_D015179,,
770960213,false,true,5,2015-08-14T23:02:00,,No Relation,0.7948,D001241,Aspirin,D015179,CRC,"Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPK, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.",22406476_9,22406476_D001241_D015179,,
770960214,false,true,5,2015-08-15T01:18:00,,No Relation,1,D009711,nucleotide,D015179,CRC,"Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPK, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.",22406476_9,22406476_D009711_D015179,,
770960215,false,true,5,2015-08-15T00:17:00,,No Relation,1,D008687,metformin,D015179,CRC,"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",22406476_11,22406476_D008687_D015179,,
770960216,false,true,5,2015-08-15T00:41:00,,No Relation,0.7907,D001241,Aspirin,D015179,CRC,"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",22406476_11,22406476_D001241_D015179,,
770960217,false,true,5,2015-08-14T23:03:00,,No Relation,0.794,D000082,paracetamol,D016638,critically ill,Mechanism of paracetamol-induced hypotension in critically ill patients: a prospective observational cross-over study.,22424816_0,22424816_D000082_D016638,,
770960218,false,true,5,2015-08-14T23:06:00,,Direct,1,D000082,paracetamol,D007022,hypotension,Mechanism of paracetamol-induced hypotension in critically ill patients: a prospective observational cross-over study.,22424816_0,22424816_D000082_D007022,,
770960219,false,true,5,2015-08-15T02:30:00,,No Relation,0.5955,D000082,paracetamol/acetaminophen,D007022,hypotension,To elucidate the mechanism of hypotension following intravenous administration of paracetamol (acetaminophen) to patients on the Intensive Care Unit.,22424816_1,22424816_D000082_D007022,,
770960220,false,true,5,2015-08-15T02:20:00,,No Relation,1,D000082,paracetamol,D016638,critically ill,Ventilated critically ill patients monitored by PiCCO and administered intravenous paracetamol at the same time were eligible for the study.,22424816_4,22424816_D000082_D016638,,
770960221,false,true,5,2015-08-14T22:43:00,,Direct,1,D000082,paracetamol,D007022,hypotension,Analysis of these cycles suggests that hypotension with paracetamol can be caused by reduction of both cardiac index and systemic vascular resistance.,22424816_11,22424816_D000082_D007022,,
770960222,false,true,5,2015-08-14T23:23:00,The disease was a pre-existing condition.,No Relation,1,D000082,paracetamol,D016638,critically ill,Hypotension with intravenous paracetamol in critically ill patients is caused by a reduction of both cardiac output and systemic vascular resistance.,22424816_14,22424816_D000082_D016638,,
770960223,false,true,5,2015-08-14T22:59:00,,Direct,0.5985,D000082,paracetamol,D007022,Hypotension,Hypotension with intravenous paracetamol in critically ill patients is caused by a reduction of both cardiac output and systemic vascular resistance.,22424816_14,22424816_D000082_D007022,,
770960224,false,true,5,2015-08-14T22:54:00,,Direct,1,C066196,CS5931,D004487,cytotoxicity,CS5931 exhibited significant cytotoxicity for several cancer cell types and induced apoptotic death in HCT-8 cells in a dose- and time-dependent manner.,22440403_7,22440403_C066196_D004487,,
770960225,false,true,5,2015-08-14T23:13:00,,No Relation,1,C066196,CS5931,D009369,cancer,CS5931 exhibited significant cytotoxicity for several cancer cell types and induced apoptotic death in HCT-8 cells in a dose- and time-dependent manner.,22440403_7,22440403_C066196_D009369,,
770960226,false,true,5,2015-08-15T01:11:00,,No Relation,1,D003404,creatinine,D003920,type 2 diabetes mellitus,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D003404_D003920,,
770960227,false,true,5,2015-08-14T23:37:00,,No Relation,1,D045162,TZD,D003920,type 2 diabetes mellitus,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D045162_D003920,,
770960228,false,true,5,2015-08-14T23:31:00,It's 'type 2 diabetes' and not just 'Type',No Relation,1,D045162,TZD,C537389,type,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D045162_C537389,,
770960229,false,true,5,2015-08-14T22:50:00,,No Relation,1,D003404,creatinine,C537389,type,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D003404_C537389,,
770960230,false,true,5,2015-08-14T22:36:00,,No Relation,1,D003404,creatinine,D003929,diabetes,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D003404_D003929,,
770960231,false,true,5,2015-08-14T23:11:00,,No Relation,1,D045162,TZD,D003929,diabetes,"We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified.",22441720_2,22441720_D045162_D003929,,
770960232,false,true,5,2015-08-14T22:33:00,,No Relation,1,D003404,creatinine,D000740,anemia,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D003404_D000740,,
770960233,false,true,5,2015-08-14T23:00:00,,No Relation,0.7798,D057911,ARB,D000740,anemia,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D057911_D000740,,
770960234,false,true,5,2015-08-15T00:34:00,,No Relation,1,D003404,creatinine,D003929,diabetic,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D003404_D003929,,
770960235,false,true,5,2015-08-15T00:48:00,,No Relation,1,D045162,TZD,D003929,diabetic,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D045162_D003929,,
770960236,false,true,5,2015-08-15T02:16:00,,No Relation,1,D057911,ARB,D003929,diabetic,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D057911_D003929,,
770960237,false,true,5,2015-08-15T01:33:00,,No Relation,1,D057911,ARB,C537389,type,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D057911_C537389,,
770960238,false,true,5,2015-08-14T23:26:00,,No Relation,0.5922,D045162,TZD,D000740,anemia,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D045162_D000740,,
770960239,false,true,5,2015-08-14T22:30:00,,No Relation,1,D045162,TZD,C537389,type,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D045162_C537389,,
770960240,false,true,5,2015-08-14T22:29:00,,No Relation,1,D003404,creatinine,C537389,type,"Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-_ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine.",22441720_7,22441720_D003404_C537389,,
770960241,false,true,5,2015-08-14T22:33:00,,No Relation,1,C055162,clopidogrel,D002318,cardiovascular diseases,Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases.,22450429_1,22450429_C055162_D002318,,
770960242,false,true,5,2015-08-14T23:03:00,,No Relation,0.6067,C055162,clopidogrel,D006470,bleeding,The rates of ischaemic and bleeding events were compared between carriers and non-carriers of loss-of-function and gain-of-function alleles in patients randomized to clopidogrel vs. placebo.,22450429_6,22450429_C055162_D006470,,
770960243,false,true,5,2015-08-14T23:35:00,,No Relation,1,C055162,clopidogrel,D006470,bleeding,"However, clopidogrel-treated patients did have a significantly lower rate of any bleeding in carriers: 36.1% (240/665) vs. 42.5% (681/1601) in non-carriers, HR: 0.80, 95% CI: 0.69-0.93, P = 0.003 (genotype/treatment interaction, P-value = 0.023).",22450429_9,22450429_C055162_D006470,,
770960244,false,true,5,2015-08-15T01:49:00,,No Relation,0.7898,C055162,clopidogrel,D006470,less bleeding,"There was, however, significantly less bleeding with clopidogrel in carriers of the loss-of-function allele, suggesting less anti-platelet response.",22450429_12,22450429_C055162_D006470,,
770960245,false,true,5,2015-08-15T00:50:00,,No Relation,0.6191,C055162,clopidogrel,D006470,bleeding,"Although several prior studies, including mainly stented patients, have emphasized the relationship between CYP2C19 loss-of-function alleles and efficacy of clopidogrel, this study of stable patients establishes a potential link with reduced bleeding complications.",22450429_13,22450429_C055162_D006470,,
770960246,false,true,5,2015-08-14T22:43:00,,Direct,0.6018,D012701,serotonin/5-HT/5-hydroxytryptamine,D019966,drug dependence,The present review provides an overview on serotonin (5-hydroxytryptamine; 5-HT)(2C) receptors and their relationship to drug dependence.,22494568_1,22494568_D012701_D019966,,
770960247,false,true,5,2015-08-14T22:46:00,,No Relation,1,D012701,5-HT,D019966,drug dependence,"Accordingly, available nonclinical data and some clinical observations targeting 5-HT(2C) receptors may offer innovative translational strategies for combating drug dependence.This article is part of a Special Issue entitled: Brain Integration.",22494568_5,22494568_D012701_D019966,,
770960248,false,true,5,2015-08-15T02:23:00,,No Relation,1,D004999,amifostine,D014987,xerostomia,Nine patients (20.9%) developed grade 2 acute xerostomia; 2 had grade 0-1 xerostomia (4.7%) but started on amifostine/pilocarpine.,22541957_9,22541957_D004999_D014987,,
770960249,false,true,5,2015-08-14T22:43:00,,No Relation,1,D010862,pilocarpine,D014987,xerostomia,Nine patients (20.9%) developed grade 2 acute xerostomia; 2 had grade 0-1 xerostomia (4.7%) but started on amifostine/pilocarpine.,22541957_9,22541957_D010862_D014987,,
770960250,false,true,5,2015-08-14T23:16:00,,Direct,0.3952,D001241,aspirin,D005767,Gastrointestinal lesions,Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract.,22542152_0,22542152_D001241_D005767,,
770960251,false,true,5,2015-08-14T23:37:00,,Direct,1,D001241,aspirin,D006470,GI bleeding,"Low dose aspirin (ASA) use has been associated with a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms without mucosal lesions to more serious toxicity, including ulcers, GI bleeding, perforation and even death.",22542152_1,22542152_D001241_D006470,,
770960252,false,true,5,2015-08-15T00:48:00,,Direct,1,D001241,aspirin,D064420,toxicity,"Low dose aspirin (ASA) use has been associated with a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms without mucosal lesions to more serious toxicity, including ulcers, GI bleeding, perforation and even death.",22542152_1,22542152_D001241_D064420,,
770960253,false,true,5,2015-08-14T23:16:00,'Without' being the key term.,No Relation,0.5768,D001241,aspirin,D052016,mucosal lesions,"Low dose aspirin (ASA) use has been associated with a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms without mucosal lesions to more serious toxicity, including ulcers, GI bleeding, perforation and even death.",22542152_1,22542152_D001241_D052016,,
770960254,false,true,5,2015-08-14T23:49:00,,Direct,0.8013,D001241,aspirin,D014456,ulcers,"Low dose aspirin (ASA) use has been associated with a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms without mucosal lesions to more serious toxicity, including ulcers, GI bleeding, perforation and even death.",22542152_1,22542152_D001241_D014456,,
770960255,false,true,5,2015-08-15T01:28:00,,Direct,0.7907,D001241,aspirin,D003643,death,"Low dose aspirin (ASA) use has been associated with a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms without mucosal lesions to more serious toxicity, including ulcers, GI bleeding, perforation and even death.",22542152_1,22542152_D001241_D003643,,
770960256,false,true,5,2015-08-14T22:34:00,,No Relation,0.7911,D001241,ASA,D014947,mucosal injury,Upper GI symptoms in low dose ASA users are common but often careless or misinterpreted and they are not always related to the presence of mucosal injury.,22542152_2,22542152_D001241_D014947,,
770960257,false,true,5,2015-08-15T00:16:00,,Direct,1,D001241,ASA,D014456,ulcers,"Usually, low dose ASA related ulcers are reasonably small and asymptomatic, and probably heal over a period of weeks to a few months.",22542152_3,22542152_D001241_D014456,,
770960258,false,true,5,2015-08-15T02:33:00,,Indirect,0.4025,D001241,ASA,D003643,Death,"Death is the worst outcome of GI complications in low dose ASA users, but data about this aspect are scarce.",22542152_6,22542152_D001241_D003643,,
770960259,false,true,5,2015-08-14T22:35:00,,Direct,0.608,D001241,ASA,D005767,GI complications,"Death is the worst outcome of GI complications in low dose ASA users, but data about this aspect are scarce.",22542152_6,22542152_D001241_D005767,,
770960260,false,true,5,2015-08-15T01:20:00,,No Relation,1,D007213,indomethacin,D004374,PDA,"Cyclo-oxygenase inhibitors such as indomethacin and ibuprofen remain the mainstay of medical therapy for PDA, and can be used both for prophylaxis as well as for rescue therapy to achieve PDA closure.",22564132_4,22564132_D007213_D004374,,
770960261,false,true,5,2015-08-15T00:19:00,,No Relation,1,D007052,ibuprofen,D004374,PDA,"Cyclo-oxygenase inhibitors such as indomethacin and ibuprofen remain the mainstay of medical therapy for PDA, and can be used both for prophylaxis as well as for rescue therapy to achieve PDA closure.",22564132_4,22564132_D007052_D004374,,
770960262,false,true,5,2015-08-14T23:36:00,,No Relation,1,C110904,capecitabine,D009369,rectal cancer,Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.,22610353_0,22610353_C110904_D009369,,
770960263,false,true,5,2015-08-14T23:30:00,,No Relation,1,C051890,irinotecan,D009369,rectal cancer,Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.,22610353_0,22610353_C051890_D009369,,
770960264,false,true,5,2015-08-15T00:24:00,,No Relation,1,C110904,capecitabine,D009369,rectal cancer,"We designed this study in locally advanced rectal cancer to determine the pathological response, toxicity, and disease-free survival (DFS) with induction capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy (CRT) and analyze the gene expression of enzymes involved in the metabolism of capecitabine and irinotecan for associations with response and toxicity.",22610353_1,22610353_C110904_D009369,,
770960265,false,true,5,2015-08-14T23:23:00,,No Relation,1,C051890,irinotecan,D009369,rectal cancer,"We designed this study in locally advanced rectal cancer to determine the pathological response, toxicity, and disease-free survival (DFS) with induction capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy (CRT) and analyze the gene expression of enzymes involved in the metabolism of capecitabine and irinotecan for associations with response and toxicity.",22610353_1,22610353_C051890_D009369,,
770960266,false,true,5,2015-08-14T22:54:00,,No Relation,0.6054,C051890,irinotecan,D064420,toxicity,"We designed this study in locally advanced rectal cancer to determine the pathological response, toxicity, and disease-free survival (DFS) with induction capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy (CRT) and analyze the gene expression of enzymes involved in the metabolism of capecitabine and irinotecan for associations with response and toxicity.",22610353_1,22610353_C051890_D064420,,
770960267,false,true,5,2015-08-14T22:57:00,,No Relation,1,C110904,capecitabine,D064420,toxicity,"We designed this study in locally advanced rectal cancer to determine the pathological response, toxicity, and disease-free survival (DFS) with induction capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy (CRT) and analyze the gene expression of enzymes involved in the metabolism of capecitabine and irinotecan for associations with response and toxicity.",22610353_1,22610353_C110904_D064420,,
770960268,false,true,5,2015-08-15T01:31:00,,No Relation,1,C110904,capecitabine,D009369,rectal cancer,"Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50.4 Gy in 28 fractions.",22610353_2,22610353_C110904_D009369,,
770960269,false,true,5,2015-08-15T01:39:00,,No Relation,1,C051890,irinotecan,D009369,rectal cancer,"Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50.4 Gy in 28 fractions.",22610353_2,22610353_C051890_D009369,,
770960270,false,true,5,2015-08-14T23:21:00,,No Relation,1,D014530,uridine-diphosphate/UDP,D009369,tumor,"Gene expression levels or sequencing were used to analyze carboxylesterase-converting enzymes (CES1, CES2), thymidylate synthase (TS), thymidine phosphorylase (TP), dehydropyrimidine dehydrogenase (DPD), topoisomerase I (TOPO I), and uridine-diphosphate (UDP) glucuronosyl transferase 1A1 in pre- and post-treatment tumor and normal tissue samples.",22610353_4,22610353_D014530_D009369,,
770960271,false,true,5,2015-08-14T23:10:00,,No Relation,1,D013936,thymidine,D009369,tumor,"Gene expression levels or sequencing were used to analyze carboxylesterase-converting enzymes (CES1, CES2), thymidylate synthase (TS), thymidine phosphorylase (TP), dehydropyrimidine dehydrogenase (DPD), topoisomerase I (TOPO I), and uridine-diphosphate (UDP) glucuronosyl transferase 1A1 in pre- and post-treatment tumor and normal tissue samples.",22610353_4,22610353_D013936_D009369,,
770960272,false,true,5,2015-08-14T23:15:00,,No Relation,0.6087,C471405,sorafenib,D010146,pain,"The management strategy was based on preventive measures for reducing the development of cutaneous AEs, including pain, risk of infection and patient discomfort, while avoiding the discontinuation or the reduction of the sorafenib dosage.",22646774_2,22646774_C471405_D010146,,
770960273,false,true,5,2015-08-14T23:01:00,,No Relation,0.7924,C471405,sorafenib,D007239,infection,"The management strategy was based on preventive measures for reducing the development of cutaneous AEs, including pain, risk of infection and patient discomfort, while avoiding the discontinuation or the reduction of the sorafenib dosage.",22646774_2,22646774_C471405_D007239,,
770960274,false,true,5,2015-08-14T23:23:00,,No Relation,0.5943,C058120,Cordycepin,D009447,neuroblastoma,Cordycepin induces apoptosis in human neuroblastoma SK-N-BE(2)-C and melanoma SK-MEL-2 cells.,22650004_0,22650004_C058120_D009447,,
770960275,false,true,5,2015-08-15T00:09:00,,Direct,0.5994,C058120,Cordycepin,D008545,melanoma,Cordycepin induces apoptosis in human neuroblastoma SK-N-BE(2)-C and melanoma SK-MEL-2 cells.,22650004_0,22650004_C058120_D008545,,
770960276,false,true,5,2015-08-15T01:04:00,,No Relation,1,D003839,deoxyadenosine,D009447,neuroblastoma,"In this study, the effect of cordycepin (3'-deoxyadenosine), a major component of Cordyceps militaris, an ingredient of traditional Chinese medicine was investigated for the first time on apoptotsis in human neuroblastoma SK-N-BE(2)-C and melanoma SK-MEL-2 cells.",22650004_1,22650004_D003839_D009447,,
770960277,false,true,5,2015-08-15T00:43:00,,No Relation,1,D003839,deoxyadenosine,D008545,melanoma,"In this study, the effect of cordycepin (3'-deoxyadenosine), a major component of Cordyceps militaris, an ingredient of traditional Chinese medicine was investigated for the first time on apoptotsis in human neuroblastoma SK-N-BE(2)-C and melanoma SK-MEL-2 cells.",22650004_1,22650004_D003839_D008545,,
770960278,false,true,5,2015-08-15T00:15:00,,No Relation,0.8136,C058120,Cordycepin,D009447,neuroblastoma,"Cordycepin significantly inhibited the proliferation of human neuroblastoma SK-N-BE(2)-C and human melanoma SK-MEL-2 cells with IC50 values of 120 microM and 80 microM, respectively.",22650004_2,22650004_C058120_D009447,,
770960279,false,true,5,2015-08-14T23:59:00,,No Relation,1,C058120,Cordycepin,D008545,melanoma,"Cordycepin significantly inhibited the proliferation of human neuroblastoma SK-N-BE(2)-C and human melanoma SK-MEL-2 cells with IC50 values of 120 microM and 80 microM, respectively.",22650004_2,22650004_C058120_D008545,,
770960280,false,true,5,2015-08-15T02:18:00,,No Relation,1,D006497,heparan sulphate,C536656,HARP,"In this work, HARP was tested for its capacity to modulate the anticoagulant activity of heparin and heparan sulphate mimetics (OTR4120).",22672269_2,22672269_D006497_C536656,,
770960281,false,true,5,2015-08-15T02:18:00,,No Relation,1,C533322,OTR4120,C536656,HARP,"In this work, HARP was tested for its capacity to modulate the anticoagulant activity of heparin and heparan sulphate mimetics (OTR4120).",22672269_2,22672269_C533322_C536656,,
770960282,false,true,5,2015-08-15T01:32:00,,No Relation,1,D006497,heparan sulphate,C536656,HARP,HARP was found to be differently effective for neutralization of the anticoagulant activity of the mimetic heparan sulphate (OTR4120) and heparin in purified system and human plasma.,22672269_4,22672269_D006497_C536656,,
770960283,false,true,5,2015-08-14T23:09:00,,No Relation,1,C533322,OTR4120,C536656,HARP,HARP was found to be differently effective for neutralization of the anticoagulant activity of the mimetic heparan sulphate (OTR4120) and heparin in purified system and human plasma.,22672269_4,22672269_C533322_C536656,,
770960284,false,true,5,2015-08-14T23:36:00,,No Relation,1,D006493,heparin,C536656,HARP,HARP was found to be differently effective for neutralization of the anticoagulant activity of the mimetic heparan sulphate (OTR4120) and heparin in purified system and human plasma.,22672269_4,22672269_D006493_C536656,,
770960285,false,true,5,2015-08-14T22:38:00,,No Relation,1,C533322,OTR4120,C536656,HARP,"HARP was shown to compete with both antithrombin and thrombin for binding to heparin and to OTR4120, respectively.",22672269_5,22672269_C533322_C536656,,
770960286,false,true,5,2015-08-15T00:30:00,,No Relation,1,C533322,OTR4120,C536656,HARP,"In the presence of OTR4120, the V(max) was constant and the calculated maximum velocity was 1.56U/min; the thrombin Km value (0.011nM) was affected by HARP concentrations.",22672269_6,22672269_C533322_C536656,,
770960287,false,true,5,2015-08-15T01:24:00,,No Relation,1,C533322,OTR4120,C536656,HARP,"The Km (HARP) value was 0.085nM, which is consistent with high affinity of HARP to OTR4120.",22672269_7,22672269_C533322_C536656,,
770960288,false,true,5,2015-08-15T00:05:00,,No Relation,1,C533322,OTR4120,C536656,HARP,"Interestingly, intraperitoneally administered HARP decreased the anticoagulant activity of heparin and of OTR4120 in mice.",22672269_11,22672269_C533322_C536656,,
770960289,false,true,5,2015-08-14T22:54:00,,No Relation,1,D000804,angiotensin II,D005355,cardiac fibrosis,"In cardiac fibroblasts and rats treated with angiotensin II, berberine was found to suppress fibroblast activation, collagen synthesis, and extent of cardiac fibrosis through up-regulating relaxin.",22673230_10,22673230_D000804_D005355,,
770960290,false,true,5,2015-08-14T23:21:00,'Supress' being the key term.,No Relation,0.7922,D001599,berberine,D005355,cardiac fibrosis,"In cardiac fibroblasts and rats treated with angiotensin II, berberine was found to suppress fibroblast activation, collagen synthesis, and extent of cardiac fibrosis through up-regulating relaxin.",22673230_10,22673230_D001599_D005355,,
770960291,false,true,5,2015-08-15T00:55:00,,No Relation,1,C008911,pimaric acid/PiMA,D009369,tumor,"In this study, we revealed that pimaric acid (PiMA) purified from Aralia cordata had an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells (HASMCs) induced by tumor necrosis factor (TNF)-. Down-regulated MMP-9 mRNA transcription was detected in PiMA-treated cells using RT-PCR and the luciferase-tagged MMP-9 promoter assay.",22705379_2,22705379_C008911_D009369,,
770960292,false,true,5,2015-08-15T01:34:00,,No Relation,1,C008911,pimaric acid/PiMA,D009336,necrosis,"In this study, we revealed that pimaric acid (PiMA) purified from Aralia cordata had an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells (HASMCs) induced by tumor necrosis factor (TNF)-. Down-regulated MMP-9 mRNA transcription was detected in PiMA-treated cells using RT-PCR and the luciferase-tagged MMP-9 promoter assay.",22705379_2,22705379_C008911_D009336,,
770960293,false,true,5,2015-08-15T01:22:00,,No Relation,1,C008911,PiMA,D050197,atherosclerotic,These results suggest that PiMA has potent anti-atherosclerotic activity with inhibitory action on MMP-9 production and cell migration in TNF--induced HASMCs.,22705379_8,22705379_C008911_D050197,,
770960294,false,true,5,2015-08-15T00:42:00,,No Relation,1,D012545,Schiff base,D009369,cancer,Anti-cancer activity and mutagenic potential of novel copper(II) quinolinone Schiff base complexes in hepatocarcinoma cells.,22705894_0,22705894_D012545_D009369,,
770960295,false,true,5,2015-08-14T22:35:00,,No Relation,1,D012545,Schiff base,D006505,hepatic carcinoma,"This study determined the cytotoxic, cyto-selective and mutagenic potential of novel quinolinone Schiff base ligands and their corresponding copper(II) complexes in human-derived hepatic carcinoma cells (Hep-G2) and non-malignant human-derived hepatic cells (Chang).",22705894_1,22705894_D012545_D006505,,
770960296,false,true,5,2015-08-14T23:42:00,,No Relation,0.6059,D012545,Schiff bases,D004487,cytotoxicity,Results indicated that complexation of quinolinone Schiff bases with copper served to significantly enhance cytotoxicity.,22705894_2,22705894_D012545_D004487,,
770960297,false,true,5,2015-08-14T22:49:00,,Direct,0.6073,D003300,copper,D004487,cytotoxicity,Results indicated that complexation of quinolinone Schiff bases with copper served to significantly enhance cytotoxicity.,22705894_2,22705894_D003300_D004487,,
770960298,false,true,5,2015-08-14T22:46:00,,No Relation,0.8032,D002738,Chloroquine,D009369,colon cancer,Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration.,22716215_0,22716215_D002738_D009369,,
770960299,false,true,5,2015-08-15T02:12:00,,No Relation,0.8091,D005472,5-fluorouracil,D009369,colon cancer,Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration.,22716215_0,22716215_D005472_D009369,,
770960300,false,true,5,2015-08-15T00:16:00,,No Relation,1,D002738,chloroquine,D009369,cancer,"A number of cancer cell lines have been exposed to chloroquine, an anti-malarial drug, with the aim of inhibiting cell growth and inducing cell death.",22716215_3,22716215_D002738_D009369,,
770960301,false,true,5,2015-08-15T00:49:00,,No Relation,1,D002738,chloroquine,D009369,cancer/colon cancer,"This study was conducted to investigate the anti-cancer effect of autophagy inhibition, using chloroquine together with 5-fluorouracil (5-FU) in a colon cancer cell line.",22716215_5,22716215_D002738_D009369,,
770960302,false,true,5,2015-08-14T22:48:00,,No Relation,1,D005472,5-FU/5-fluorouracil,D009369,cancer/colon cancer,"This study was conducted to investigate the anti-cancer effect of autophagy inhibition, using chloroquine together with 5-fluorouracil (5-FU) in a colon cancer cell line.",22716215_5,22716215_D005472_D009369,,
770960303,false,true,5,2015-08-15T00:19:00,,No Relation,1,D005472,5-FU,D009369,colon cancer,"Human colon cancer DLD-1 cells were treated with 5-FU (10 _) or chloroquine (100 _), or a combination of both.",22716215_6,22716215_D005472_D009369,,
770960304,false,true,5,2015-08-15T02:09:00,,No Relation,1,D002738,chloroquine,D009369,colon cancer,"Human colon cancer DLD-1 cells were treated with 5-FU (10 _) or chloroquine (100 _), or a combination of both.",22716215_6,22716215_D002738_D009369,,
770960305,false,true,5,2015-08-14T22:45:00,,No Relation,0.5831,D005472,5-FU,D004487,cytotoxicity,"LC3-II protein increased after treatment with 5-FU, and chloroquine potentiated the cytotoxicity of 5-FU.",22716215_9,22716215_D005472_D004487,,
770960306,false,true,5,2015-08-14T23:18:00,,Direct,0.8174,D002738,chloroquine,D004487,cytotoxicity,"LC3-II protein increased after treatment with 5-FU, and chloroquine potentiated the cytotoxicity of 5-FU.",22716215_9,22716215_D002738_D004487,,
770960307,false,true,5,2015-08-15T01:43:00,,No Relation,1,D002738,chloroquine,D009369,cancer,These results suggest that chloroquine may potentiate the anti-cancer effect of 5-FU via cell cycle inhibition.,22716215_12,22716215_D002738_D009369,,
770960308,false,true,5,2015-08-15T01:24:00,,No Relation,1,D005472,5-FU,D009369,cancer,These results suggest that chloroquine may potentiate the anti-cancer effect of 5-FU via cell cycle inhibition.,22716215_12,22716215_D005472_D009369,,
770960309,false,true,5,2015-08-15T02:18:00,,No Relation,1,D002738,Chloroquine,D009369,cancer/colon cancer,Chloroquine potentiates the anti-cancer effect of 5-FU in colon cancer cells.,22716215_13,22716215_D002738_D009369,,
770960310,false,true,5,2015-08-15T00:00:00,,No Relation,1,D005472,5-FU,D009369,cancer/colon cancer,Chloroquine potentiates the anti-cancer effect of 5-FU in colon cancer cells.,22716215_13,22716215_D005472_D009369,,
770960311,false,true,5,2015-08-15T00:14:00,,No Relation,1,D002738,chloroquine,D009369,cancer,Supplementation of conventional chemotherapy with chloroquine may provide a new cancer therapy modality.,22716215_14,22716215_D002738_D009369,,
770960312,false,true,5,2015-08-14T23:23:00,,No Relation,0.81,C012566,taurolidine,D018805,sepsis,We further evaluated the immunomodulatory role of the amino-acid derivative taurolidine in our in vitro sepsis model.,22727544_5,22727544_C012566_D018805,,
770960313,false,true,5,2015-08-14T22:34:00,,No Relation,1,D000596,amino-acid,D018805,sepsis,We further evaluated the immunomodulatory role of the amino-acid derivative taurolidine in our in vitro sepsis model.,22727544_5,22727544_D000596_D018805,,
770960314,false,true,5,2015-08-15T01:35:00,,No Relation,1,C012566,Taurolidine,D009336,necrosis,"Taurolidine inhibited immunoglobulin (IL)-6, IL-8 and tumor necrosis factor-alpha expression in a dose dependent-fashion in both, pediatric oncology patients and healthy controls.",22727544_8,22727544_C012566_D009336,,
770960315,false,true,5,2015-08-14T22:53:00,,No Relation,1,D011433,propranolol,D006391,hemangiomas,Outpatient treatment of infantile hemangiomas with propranolol: a prospective study.,22727954_0,22727954_D011433_D006391,,
770960316,false,true,5,2015-08-14T23:02:00,,No Relation,1,D011433,propranolol,D006391,hemangiomas,To assess thesafety and effectiveness of oral propranolol(OP) in the treatment of infantile hemangiomas.,22727954_1,22727954_D011433_D006391,,
770960317,false,true,5,2015-08-15T02:00:00,,No Relation,1,D011433,propranolol,D006391,hemangiomas,We conducted a prospective study of infantile hemangiomas(IHs) treated with oral propranolol between October 2008 and March 2011.,22727954_2,22727954_D011433_D006391,,
770960318,false,true,5,2015-08-14T23:11:00,,No Relation,1,D011433,propranolol,D006391,hemangiomas,"Oral propranolol was clinically effective in reducing the volume and color of infantile hemangiomas, although the reduction was not complete and telangiectasia and scarring persisted after treatment.",22727954_16,22727954_D011433_D006391,,
770960319,false,true,5,2015-08-15T00:38:00,,No Relation,1,D011433,propranolol,D013684,telangiectasia,"Oral propranolol was clinically effective in reducing the volume and color of infantile hemangiomas, although the reduction was not complete and telangiectasia and scarring persisted after treatment.",22727954_16,22727954_D011433_D013684,,
770960320,false,true,5,2015-08-14T23:21:00,,No Relation,0.7984,D014212,ATRA,D015473,APL,Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.,22729365_6,22729365_D014212_D015473,,
770960321,false,true,5,2015-08-14T22:39:00,,No Relation,0.792,D017294,ondansetron,D020250,prophylaxis of postoperative vomiting,"Dexamethasone versus ondansetron in combination with dexamethasone for the prophylaxis of postoperative vomiting in pediatric outpatients: a double-blind, randomized, placebo-controlled clinical trial.",22731240_0,22731240_D017294_D020250,,
770960322,false,true,5,2015-08-14T23:20:00,,No Relation,1,D003907,Dexamethasone,D020250,prophylaxis of postoperative vomiting,"Dexamethasone versus ondansetron in combination with dexamethasone for the prophylaxis of postoperative vomiting in pediatric outpatients: a double-blind, randomized, placebo-controlled clinical trial.",22731240_0,22731240_D003907_D020250,,
770960323,false,true,5,2015-08-14T23:32:00,Used as a not-so-useful prevention.,No Relation,0.6112,D017294,ondansetron,D020250,Postoperative vomiting,"Postoperative vomiting occurred in 12.4% of the children, with no statistically significant difference between the groups: 6.8% in the group receiving ondansetron combined with dexamethasone, 14.3% in the placebo group, and 14% in the group that received dexamethasone alone (P = 0.47).",22731240_8,22731240_D017294_D020250,,
770960324,false,true,5,2015-08-15T01:54:00,,Direct,0.5731,D003907,dexamethasone,D020250,Postoperative vomiting,"Postoperative vomiting occurred in 12.4% of the children, with no statistically significant difference between the groups: 6.8% in the group receiving ondansetron combined with dexamethasone, 14.3% in the placebo group, and 14% in the group that received dexamethasone alone (P = 0.47).",22731240_8,22731240_D003907_D020250,,
770960325,false,true,5,2015-08-14T22:48:00,,No Relation,0.7954,D013256,steroid,D029461,SD,"Before steroid treatment, 60 recurrences occurred, corresponding to a mean of 4.03  4.22 (SD) relapses per year.",22731702_7,22731702_D013256_D029461,,
770960326,false,true,5,2015-08-14T22:49:00,,Direct,0.5907,D011241,prednisone,D029461,SD,"After the first treatment with prednisone, patients experienced 47 relapses, representing a mean of 1.11  1.27 (SD) relapses per year (p = 0.0371).",22731702_8,22731702_D011241_D029461,,
770960327,false,true,5,2015-08-14T22:42:00,,No Relation,0.6139,D000255,ATP,D019636,neurodegenerative diseases,"In addition to ATP synthesis mitochondria are key regulators of calcium homeostasis, free radical production, steroid synthesis and apoptosis, each of these factors could also be associated with essential mechanisms involved in neurodegenerative diseases.",22743330_2,22743330_D000255_D019636,,
770960328,false,true,5,2015-08-14T23:09:00,,No Relation,0.4084,D002118,calcium,D019636,neurodegenerative diseases,"In addition to ATP synthesis mitochondria are key regulators of calcium homeostasis, free radical production, steroid synthesis and apoptosis, each of these factors could also be associated with essential mechanisms involved in neurodegenerative diseases.",22743330_2,22743330_D002118_D019636,,
770960329,false,true,5,2015-08-15T00:47:00,,No Relation,0.7908,D013256,steroid,D019636,neurodegenerative diseases,"In addition to ATP synthesis mitochondria are key regulators of calcium homeostasis, free radical production, steroid synthesis and apoptosis, each of these factors could also be associated with essential mechanisms involved in neurodegenerative diseases.",22743330_2,22743330_D013256_D019636,,
770960330,false,true,5,2015-08-14T23:45:00,'improved dramatically' being the key term.,No Relation,1,D000305,corticosteroids,D009069,ipsilateral ear vesicles,"We report a case of Ramsay Hunt syndrome in an immune compromised patient, with classic facial nerve palsy and ipsilateral ear vesicles, which rapidly evolved to involve multiple cranial neuropathies, and improved dramatically with antiviral therapy and corticosteroids.",22772935_2,22772935_D000305_D009069,,
770960331,false,true,5,2015-08-15T01:22:00,,No Relation,0.8075,D000305,corticosteroids,D016697,Ramsay Hunt syndrome,"We report a case of Ramsay Hunt syndrome in an immune compromised patient, with classic facial nerve palsy and ipsilateral ear vesicles, which rapidly evolved to involve multiple cranial neuropathies, and improved dramatically with antiviral therapy and corticosteroids.",22772935_2,22772935_D000305_D016697,,
770960332,false,true,5,2015-08-14T22:35:00,,No Relation,1,D000305,corticosteroids,D003389,multiple cranial neuropathies,"We report a case of Ramsay Hunt syndrome in an immune compromised patient, with classic facial nerve palsy and ipsilateral ear vesicles, which rapidly evolved to involve multiple cranial neuropathies, and improved dramatically with antiviral therapy and corticosteroids.",22772935_2,22772935_D000305_D003389,,
770960333,false,true,5,2015-08-14T22:52:00,,No Relation,0.8005,D000305,corticosteroids,D005155,facial nerve palsy,"We report a case of Ramsay Hunt syndrome in an immune compromised patient, with classic facial nerve palsy and ipsilateral ear vesicles, which rapidly evolved to involve multiple cranial neuropathies, and improved dramatically with antiviral therapy and corticosteroids.",22772935_2,22772935_D000305_D005155,,
770960334,false,true,5,2015-08-15T01:53:00,,No Relation,1,D000212,acyclovir,D003389,multiple cranial neuropathies,"Varicella zoster virus should be considered as a cause of multiple cranial neuropathies in an immune compromised patient, and abrupt treatment with acyclovir should be initiated once this diagnosis is suspected.",22772935_3,22772935_D000212_D003389,,
770960335,false,true,5,2015-08-14T22:37:00,,No Relation,1,D014443,tyrosine,D000230,adenocarcinomas,We aimed to determine whether a receptor tyrosine kinase (RTK) array could be used to select the most effective therapeutic strategies in molecularly heterogeneous oesophago-gastric adenocarcinomas.,22773546_2,22773546_D014443_D000230,,
770960336,false,true,5,2015-08-15T01:25:00,,Direct,1,D015575,Roxithromycin,D064420,toxic epidermal necrolysis,Roxithromycin-induced toxic epidermal necrolysis.,22777150_0,22777150_D015575_D064420,,
770960337,false,true,5,2015-08-15T01:57:00,,Direct,0.7946,D015575,roxithromycin,D064420,adverse drug reaction/TEN/toxic epidermal necrolysis,This case report highlights a very rare adverse drug reaction of oral roxithromycin causing toxic epidermal necrolysis (TEN).,22777150_1,22777150_D015575_D064420,,
770960338,false,true,5,2015-08-14T22:41:00,,No Relation,1,D015575,roxithromycin,D012141,upper respiratory tract infection,A 54-year-old male patient diagnosed with upper respiratory tract infection was prescribed oral roxithromycin 150 mg twice daily for 7 days.,22777150_2,22777150_D015575_D012141,,
770960339,false,true,5,2015-08-15T00:49:00,,Direct,1,D015575,roxithromycin,D064420,TEN,This episode of TEN was probably drug (roxithromycin) induced.,22777150_8,22777150_D015575_D064420,,
770960340,false,true,5,2015-08-14T23:26:00,,Direct,1,D015575,roxithromycin,D064420,adverse drug reaction/TEN,Naranjo adverse drug reaction probability scale suggested the likelihood that oral administration of roxithromycin was responsible for the TEN was 'probable.,22777150_10,22777150_D015575_D064420,,
770960341,false,true,5,2015-08-15T00:20:00,,No Relation,0.8185,D009173,mycophenolic acid/MPA,D005767,gastrointestinal (GI) complications,"To evaluate the incidence of gastrointestinal (GI) complications in solid organ transplant (SOT) recipients, impact of the complications on transplant outcomes, and the potential interactions between mycophenolic acid (MPA) derivatives and proton pump inhibitors (PPIs).",22811345_1,22811345_D009173_D005767,,
770960342,false,true,5,2015-08-14T23:03:00,,No Relation,0.7945,D009173,mycophenolic acid,D005767,GI complications,"An unrestricted literature search (1980-January 2012) was performed with MEDLINE and EMBASE using the following key words: drug-drug interaction, enteric-coated mycophenolic acid, GI complications, mycophenolate mofetil, solid organ transplant, and proton pump inhibitor, including individual agents within the class.",22811345_2,22811345_D009173_D005767,,
770960343,false,true,5,2015-08-15T00:25:00,,No Relation,1,C063008,mycophenolate mofetil,D005767,GI complications,"An unrestricted literature search (1980-January 2012) was performed with MEDLINE and EMBASE using the following key words: drug-drug interaction, enteric-coated mycophenolic acid, GI complications, mycophenolate mofetil, solid organ transplant, and proton pump inhibitor, including individual agents within the class.",22811345_2,22811345_C063008_D005767,,
770960344,false,true,5,2015-08-15T00:55:00,,No Relation,1,D016559,tacrolimus,D006086,ocular graft versus host disease,Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis.,22870021_0,22870021_D016559_D006086,,
770960345,false,true,5,2015-08-14T23:40:00,,No Relation,1,D016559,tacrolimus,D003233,vernal keratoconjunctivitis,Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis.,22870021_0,22870021_D016559_D003233,,
770960346,false,true,5,2015-08-14T23:02:00,,No Relation,1,D016559,tacrolimus,D006086,ocular graft versus host disease/GVHD,"To determine whether topical tacrolimus might prove effective in the treatment of refractory anterior segment inflammatory diseases, and to evaluate its efficacy in eyes with ocular graft versus host disease (GVHD), and vernal keratoconjunctivitis (VKC).",22870021_1,22870021_D016559_D006086,,
770960347,false,true,5,2015-08-15T01:52:00,,No Relation,1,D016559,tacrolimus,D007249,inflammatory diseases,"To determine whether topical tacrolimus might prove effective in the treatment of refractory anterior segment inflammatory diseases, and to evaluate its efficacy in eyes with ocular graft versus host disease (GVHD), and vernal keratoconjunctivitis (VKC).",22870021_1,22870021_D016559_D007249,,
770960348,false,true,5,2015-08-14T23:50:00,,No Relation,1,D016559,tacrolimus,D003233,vernal keratoconjunctivitis/VKC,"To determine whether topical tacrolimus might prove effective in the treatment of refractory anterior segment inflammatory diseases, and to evaluate its efficacy in eyes with ocular graft versus host disease (GVHD), and vernal keratoconjunctivitis (VKC).",22870021_1,22870021_D016559_D003233,,
770960349,false,true,5,2015-08-14T23:20:00,,No Relation,1,D016559,tacrolimus,D007249,inflammation,"Twenty-eight eyes of 14 patients with anterior segment inflammation refractory to steroid treatment were treated with 0.03% tacrolimus ointment at the Samsung Medical Center, Seoul, Korea from March 2008 through August 2009.",22870021_2,22870021_D016559_D007249,,
770960350,false,true,5,2015-08-15T01:15:00,,No Relation,1,D013256,steroid,D007249,inflammation,"Twenty-eight eyes of 14 patients with anterior segment inflammation refractory to steroid treatment were treated with 0.03% tacrolimus ointment at the Samsung Medical Center, Seoul, Korea from March 2008 through August 2009.",22870021_2,22870021_D013256_D007249,,
770960351,false,true,5,2015-08-14T23:25:00,Used as treatment.,No Relation,1,D016559,tacrolimus,D007249,inflammatory disease,0.03% tacrolimus ointment was safe and effective for use in anterior segment inflammatory disease refractory to steroid.,22870021_13,22870021_D016559_D007249,,
770960352,false,true,5,2015-08-14T23:02:00,,No Relation,0.8164,D013256,steroid,D007249,inflammatory disease,0.03% tacrolimus ointment was safe and effective for use in anterior segment inflammatory disease refractory to steroid.,22870021_13,22870021_D013256_D007249,,
770960353,false,true,5,2015-08-14T22:51:00,,Direct,0.7787,D007980,levodopa,D014082,fractures,"Recurrent bilateral metatarsal ""stress-and-insufficiency"" fractures in a levodopa-treated young woman with Parkinson's disease.",22875460_0,22875460_D007980_D014082,,
770960354,false,true,5,2015-08-14T23:24:00,,No Relation,1,D007980,levodopa,D010300,Parkinson's disease,"Recurrent bilateral metatarsal ""stress-and-insufficiency"" fractures in a levodopa-treated young woman with Parkinson's disease.",22875460_0,22875460_D007980_D010300,,
770960355,false,true,5,2015-08-14T22:42:00,,No Relation,0.5946,D007980,Levodopa,C536141,disease course,"Levodopa treatment of Parkinson's disease is very effective, but many types of adverse events can complicate the disease course, especially dyskinesias.",22875460_1,22875460_D007980_C536141,,
770960356,false,true,5,2015-08-14T23:06:00,,Direct,0.7977,D007980,Levodopa,D004409,dyskinesias,"Levodopa treatment of Parkinson's disease is very effective, but many types of adverse events can complicate the disease course, especially dyskinesias.",22875460_1,22875460_D007980_D004409,,
770960357,false,true,5,2015-08-14T22:33:00,,No Relation,1,D007980,Levodopa,D010300,Parkinson's disease,"Levodopa treatment of Parkinson's disease is very effective, but many types of adverse events can complicate the disease course, especially dyskinesias.",22875460_1,22875460_D007980_D010300,,
770960358,false,true,5,2015-08-15T01:15:00,,Indirect,1,D007980,levodopa,D058866,osteoporotic fractures,"(Calcif Tissue Int 86:132-41, 2010), levodopa intake is associated with increased homocysteinemia that is known to be linked to poorer bone quality and, consequently, osteoporotic fractures.",22875460_3,22875460_D007980_D058866,,
770960359,false,true,5,2015-08-14T23:11:00,,Direct,1,D007980,levodopa,C566403,homocysteinemia,"(Calcif Tissue Int 86:132-41, 2010), levodopa intake is associated with increased homocysteinemia that is known to be linked to poorer bone quality and, consequently, osteoporotic fractures.",22875460_3,22875460_D007980_C566403,,
770960360,false,true,5,2015-08-14T23:55:00,,Direct,0.816,D007980,levodopa,D014082,fractures,"Herein, we report the case of a young woman who suffered recurrent metatarsal fractures in the context of levodopa-treated early-onset Parkinson's disease.",22875460_4,22875460_D007980_D014082,,
770960361,false,true,5,2015-08-14T22:32:00,,No Relation,1,D007980,levodopa,D010300,Parkinson's disease,"Herein, we report the case of a young woman who suffered recurrent metatarsal fractures in the context of levodopa-treated early-onset Parkinson's disease.",22875460_4,22875460_D007980_D010300,,
770960362,false,true,5,2015-08-15T01:23:00,,Direct,0.6093,D006220,haloperidol,D002375,catalepsy,"Further, THPP-1 displays significantly fewer preclinical adverse events in assays measuring prolactin secretion, catalepsy, and weight gain, in contrast to the typical and atypical antipsychotics haloperidol and olanzapine.",22892116_5,22892116_D006220_D002375,,
770960363,false,true,5,2015-08-15T02:34:00,,Direct,0.589,C076029,olanzapine,D015430,weight gain,"Further, THPP-1 displays significantly fewer preclinical adverse events in assays measuring prolactin secretion, catalepsy, and weight gain, in contrast to the typical and atypical antipsychotics haloperidol and olanzapine.",22892116_5,22892116_C076029_D015430,,
770960364,false,true,5,2015-08-14T22:47:00,,No Relation,0.7982,D006220,haloperidol,D015430,weight gain,"Further, THPP-1 displays significantly fewer preclinical adverse events in assays measuring prolactin secretion, catalepsy, and weight gain, in contrast to the typical and atypical antipsychotics haloperidol and olanzapine.",22892116_5,22892116_D006220_D015430,,
770960365,false,true,5,2015-08-15T01:56:00,,No Relation,0.8039,C076029,olanzapine,D002375,catalepsy,"Further, THPP-1 displays significantly fewer preclinical adverse events in assays measuring prolactin secretion, catalepsy, and weight gain, in contrast to the typical and atypical antipsychotics haloperidol and olanzapine.",22892116_5,22892116_C076029_D002375,,
770960366,false,true,5,2015-08-15T01:12:00,,No Relation,0.7908,D002945,cisplatin,D009447,neuroblastoma,MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.,22892391_0,22892391_D002945_D009447,,
770960367,false,true,5,2015-08-14T23:43:00,,No Relation,1,D002945,cisplatin,D009447,neuroblastoma,"MiR-204 is a novel predictor of outcome in neuroblastoma, functioning, at least in part, through increasing sensitivity to cisplatin by direct targeting and downregulation of anti-apoptotic BCL2. miR-204 also targets full-length NTRK2, a potent oncogene involved with chemotherapy drug resistance in neuroblastoma.",22892391_8,22892391_D002945_D009447,,
770960368,false,true,5,2015-08-15T01:21:00,,Direct,0.7942,C098720,fingolimod,D009103,multiple sclerosis,Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.,22907938_0,22907938_C098720_D009103,,
770960369,false,true,5,2015-08-14T22:43:00,,Direct,0.5771,C098720,fingolimod,D009103,multiple sclerosis,We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation.,22907938_1,22907938_C098720_D009103,,
770960370,false,true,5,2015-08-15T01:50:00,,Direct,1,C098720,fingolimod,D019636,neurological condition,We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation.,22907938_1,22907938_C098720_D019636,,
770960371,false,true,5,2015-08-14T22:41:00,,No Relation,1,D001564,benzo[a]pyrene,C535575,HNSCC,"Treatment of these cell lines with the AhR antagonists 6, 2', 4'-trimethoxyflavone, or the more potent GNF351, decreased migration and invasion of HNSCC cells and prevented benzo[a]pyrene-mediated induction of the chemotherapy efflux protein ABCG2.",22912337_9,22912337_D001564_C535575,,
770960372,false,true,5,2015-08-15T02:49:00,,No Relation,1,D053243,zanamivir,D007251,influenza-like illness,"An uncontrolled open-label, multicenter study to monitor the antiviral activity and safety of inhaled zanamivir (as Rotadisk via Diskhaler device) among Chinese adolescents and adults with influenza-like illness.",22932170_0,22932170_D053243_D007251,,
770960373,false,true,5,2015-08-14T22:33:00,,No Relation,1,D053243,zanamivir,D007251,influenza-like illness/ILI,"It is the first multicenter clinical study in China to investigate zanamivir use among Chinese adolescents and adults with influenza-like illness (ILI) since 2009, when inhaled zanamivir (RELENZA()) was marketed in China.",22932170_1,22932170_D053243_D007251,,
770960374,false,true,5,2015-08-14T22:43:00,,No Relation,1,D053243,zanamivir,D007251,ILI,"An uncontrolled open-label, multicentre study to evaluate the antiviral activity, and safety of inhaled zanamivir (as Rotadisk via Diskhaler device); 10 mg administered twice daily for 5 days in subjects  12 years old with ILI.",22932170_2,22932170_D053243_D007251,,
770960375,false,true,5,2015-08-14T23:34:00,,Direct,0.8028,D053243,zanamivir,D001986,Bronchospasm,Bronchospasm was found in a 38 years old woman whose symptoms disappeared after stopping zanamivir and without additional treatment.,22932170_13,22932170_D053243_D001986,,
770960376,false,true,5,2015-08-14T23:11:00,,No Relation,0.5773,D014443,tyrosine,D007037,Hypothyroidism,Hypothyroidism during treatment with tyrosine kinase inhibitors.,22933166_0,22933166_D014443_D007037,,
770960378,false,true,5,2015-08-14T22:38:00,,No Relation,1,D014443,Tyrosine,D009369,pancreatic neuroendocrine tumours/gastrointestinal stromal tumours,"Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastrointestinal stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease.",22933166_1,22933166_D014443_D009369,,
770960379,false,true,5,2015-08-15T00:20:00,,No Relation,1,D014443,Tyrosine,D007674,clear cell kidney carcinoma,"Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastrointestinal stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease.",22933166_1,22933166_D014443_D007674,,
770960380,false,true,5,2015-08-14T23:15:00,,No Relation,1,D014443,Tyrosine,D013964,thyroid carcinoma,"Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastrointestinal stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease.",22933166_1,22933166_D014443_D013964,,
770960381,false,true,5,2015-08-14T23:53:00,,No Relation,0.6104,D014443,tyrosine,D007037,hypothyroidism,This is the most described tyrosine kinase inhibitor which causes hypothyroidism.,22933166_6,22933166_D014443_D007037,,
770960382,false,true,5,2015-08-14T23:01:00,,No Relation,0.805,C471405,sorafenib,D002292,renal cell carcinoma,Symptoms of hypothyroidism occur in 18% of patients treated with sorafenib due to metastatic renal cell carcinoma.,22933166_9,22933166_C471405_D002292,,
770960383,false,true,5,2015-08-15T00:12:00,,Direct,1,C471405,sorafenib,D007037,hypothyroidism,Symptoms of hypothyroidism occur in 18% of patients treated with sorafenib due to metastatic renal cell carcinoma.,22933166_9,22933166_C471405_D007037,,
770960384,false,true,5,2015-08-15T02:17:00,,No Relation,1,D004967,oestrogen,D006470,bleeding,Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation.,22972055_0,22972055_D004967_D006470,,
770960385,false,true,5,2015-08-14T23:10:00,,No Relation,0.8068,D004967,oestrogen,D000858,anovulation,Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation.,22972055_0,22972055_D004967_D000858,,
770960386,false,true,5,2015-08-15T01:03:00,,Direct,1,D013256,steroids,D006470,menstrual bleeding,"Irregular menstrual bleeding may arise due to exogenous sex steroids, lesions of the genital tract or be associated with anovulation.",22972055_1,22972055_D013256_D006470,,
770960387,false,true,5,2015-08-14T22:56:00,,No Relation,0.8075,D013256,steroids,D000858,anovulation,"Irregular menstrual bleeding may arise due to exogenous sex steroids, lesions of the genital tract or be associated with anovulation.",22972055_1,22972055_D013256_D000858,,
770960388,false,true,5,2015-08-15T01:11:00,,Indirect,0.4167,D004967,oestrogen,D006470,bleeding,In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy.,22972055_3,22972055_D004967_D006470,,
770960389,false,true,5,2015-08-14T22:29:00,,No Relation,0.5934,D011374,progesterone,D006470,bleeding,In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy.,22972055_3,22972055_D011374_D006470,,
770960390,false,true,5,2015-08-14T23:36:00,,No Relation,0.7908,D004967,oestrogen,D056806,anovulatory cycles,In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy.,22972055_3,22972055_D004967_D056806,,
770960391,false,true,5,2015-08-15T01:06:00,,No Relation,0.8155,D011374,progesterone,D056806,anovulatory cycles,In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy.,22972055_3,22972055_D011374_D056806,,
770960392,false,true,5,2015-08-15T01:16:00,,No Relation,1,D004967,oestrogen,D014591,endometrial atrophy,Continuous progestogen is intended to induce endometrial atrophy and hence to prevent oestrogen-stimulated endometrial proliferation.,22972055_5,22972055_D004967_D014591,,
770960393,false,true,5,2015-08-15T02:13:00,,No Relation,1,D004967,oestrogens,D006470,menstrual bleeding,"Progestogens, and oestrogens and progestogens in combination, are widely used in the management of irregular menstrual bleeding, but the regime, dose and type of progestogen used vary widely, with little consensus about the optimum treatment approach.",22972055_6,22972055_D004967_D006470,,
770960394,false,true,5,2015-08-14T23:00:00,,No Relation,1,D011374,progestogens,D006470,menstrual bleeding,To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.,22972055_7,22972055_D011374_D006470,,
770960395,false,true,5,2015-08-14T23:06:00,,No Relation,1,D011374,progestogens,D000858,anovulation,To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.,22972055_7,22972055_D011374_D000858,,
770960396,false,true,5,2015-08-15T02:18:00,,No Relation,1,D004967,oestrogens,D006470,menstrual bleeding,To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.,22972055_7,22972055_D004967_D006470,,
770960397,false,true,5,2015-08-14T23:36:00,,No Relation,1,D004967,oestrogens,D000858,anovulation,To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.,22972055_7,22972055_D004967_D000858,,
770960398,false,true,5,2015-08-15T02:17:00,,No Relation,1,D004967,oestrogens,D006470,menstrual bleeding,All randomised controlled trials of progestogens (via any route) alone or in combination with oestrogens in the treatment of irregular menstrual bleeding associated with oligo/anovulation.,22972055_9,22972055_D004967_D006470,,
770960399,false,true,5,2015-08-14T22:39:00,,No Relation,1,D004967,oestrogens,D000858,anovulation,All randomised controlled trials of progestogens (via any route) alone or in combination with oestrogens in the treatment of irregular menstrual bleeding associated with oligo/anovulation.,22972055_9,22972055_D004967_D000858,,
770960400,false,true,5,2015-08-14T22:46:00,,No Relation,1,D004967,oestrogens,D006470,bleeding,No randomised trials were identified that compared progestogens with oestrogens and progestogens or with placebo in the management of irregular bleeding associated with oligo/anovulation.,22972055_12,22972055_D004967_D006470,,
770960401,false,true,5,2015-08-14T23:06:00,,No Relation,1,D004967,oestrogens,D000858,anovulation,No randomised trials were identified that compared progestogens with oestrogens and progestogens or with placebo in the management of irregular bleeding associated with oligo/anovulation.,22972055_12,22972055_D004967_D000858,,
770960402,false,true,5,2015-08-14T22:49:00,,No Relation,1,D004967,oestrogens,D006470,menstrual bleeding,There is a paucity of randomised studies relating to the use of progestogens and of oestrogens and progestogens in combination in the treatment of irregular menstrual bleeding associated with anovulation.,22972055_13,22972055_D004967_D006470,,
770960403,false,true,5,2015-08-15T00:13:00,,No Relation,0.8115,D004967,oestrogens,D000858,anovulation,There is a paucity of randomised studies relating to the use of progestogens and of oestrogens and progestogens in combination in the treatment of irregular menstrual bleeding associated with anovulation.,22972055_13,22972055_D004967_D000858,,
770960404,false,true,5,2015-08-15T01:42:00,,No Relation,1,C408153,prasugrel,D009203,Myocardial Infarction,The data from 422 patients undergoing isolated coronary artery bypass grafting from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 were analyzed retrospectively.,22995726_3,22995726_C408153_D009203,,
770960405,false,true,5,2015-08-14T23:05:00,,No Relation,0.8026,C060836,pioglitazone,D009765,obese,Free carnitine and acylcarnitines inobese patients with polycystic ovary syndrome and effects ofpioglitazone treatment.,22999793_0,22999793_C060836_D009765,,
770960406,false,true,5,2015-08-14T22:51:00,,No Relation,1,D002331,carnitine,D009765,obese,Free carnitine and acylcarnitines inobese patients with polycystic ovary syndrome and effects ofpioglitazone treatment.,22999793_0,22999793_D002331_D009765,,
770960407,false,true,5,2015-08-14T23:17:00,,No Relation,1,C060836,pioglitazone,D011085,polycystic ovary syndrome,Free carnitine and acylcarnitines inobese patients with polycystic ovary syndrome and effects ofpioglitazone treatment.,22999793_0,22999793_C060836_D011085,,
770960408,false,true,5,2015-08-14T22:55:00,,No Relation,1,D002331,carnitine,D011085,polycystic ovary syndrome,Free carnitine and acylcarnitines inobese patients with polycystic ovary syndrome and effects ofpioglitazone treatment.,22999793_0,22999793_D002331_D011085,,
770960409,false,true,5,2015-08-15T02:09:00,,No Relation,1,D002331,carnitine,D011085,polycystic ovary syndrome/PCOS,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_D002331_D011085,,
770960410,false,true,5,2015-08-14T22:38:00,,No Relation,1,C060836,pioglitazone,D009765,obese,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_C060836_D009765,,
770960411,false,true,5,2015-08-14T22:57:00,,No Relation,1,C060836,pioglitazone,D015673,total and free carnitine,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_C060836_D015673,,
770960412,false,true,5,2015-08-15T00:47:00,,No Relation,0.7954,D002331,carnitine,D015673,total and free carnitine,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_D002331_D015673,,
770960413,false,true,5,2015-08-14T22:58:00,,No Relation,0.8005,D002331,carnitine,D009765,obese,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_D002331_D009765,,
770960414,false,true,5,2015-08-14T22:53:00,,No Relation,1,C060836,pioglitazone,D011085,polycystic ovary syndrome/PCOS,"To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS).",22999793_1,22999793_C060836_D011085,,
770960415,false,true,5,2015-08-15T00:59:00,,No Relation,1,D002331,carnitine,D015673,total and free carnitine,"Contrary to controls, patients with PCOS were characterized with slightly lower levels of fasting total and free carnitine, its precursors, and derivatives.",22999793_7,22999793_D002331_D015673,,
770960416,false,true,5,2015-08-14T22:53:00,,No Relation,1,D002331,carnitine,D011085,PCOS,"Contrary to controls, patients with PCOS were characterized with slightly lower levels of fasting total and free carnitine, its precursors, and derivatives.",22999793_7,22999793_D002331_D011085,,
770960417,false,true,5,2015-08-15T02:13:00,,No Relation,1,D002331,carnitine,D011085,PCOS,"Total and free carnitine correlated inversely to sex hormone-binding globulin (SHBG) in patients with PCOS, whereas no associations were found between acylcarnitines and androgenes.",22999793_8,22999793_D002331_D011085,,
770960418,false,true,5,2015-08-14T22:43:00,,No Relation,1,D002331,carnitine,D015673,total and free carnitine,"Insulin stimulation-induced changes in the levels of total and free carnitine, carnitine precursors, and acylcarnitines in the PCOS group followed the same trends as in the control group.",22999793_9,22999793_D002331_D015673,,
770960419,false,true,5,2015-08-15T01:46:00,,No Relation,1,D002331,carnitine,D011085,PCOS,"Insulin stimulation-induced changes in the levels of total and free carnitine, carnitine precursors, and acylcarnitines in the PCOS group followed the same trends as in the control group.",22999793_9,22999793_D002331_D011085,,
770960420,false,true,5,2015-08-15T02:33:00,,No Relation,1,D008687,metformin,D011085,polycystic ovary syndrome,On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis.,23006146_0,23006146_D008687_D011085,,
770960421,false,true,5,2015-08-15T01:49:00,,No Relation,1,D008687,metformin,D047928,preterm delivery,On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis.,23006146_0,23006146_D008687_D047928,,
770960422,false,true,5,2015-08-15T00:11:00,,No Relation,1,D008687,metformin,D011085,polycystic ovary syndrome/PCOS,"Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS).",23006146_1,23006146_D008687_D011085,,
770960423,false,true,5,2015-08-14T22:57:00,,No Relation,1,D008687,metformin,D047928,preterm delivery,"Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS).",23006146_1,23006146_D008687_D047928,,
770960424,false,true,5,2015-08-15T01:57:00,,No Relation,0.8028,D008687,metformin,D016640,gestational diabetes,"Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS).",23006146_1,23006146_D008687_D016640,,
770960425,false,true,5,2015-08-15T00:40:00,,No Relation,1,D008687,metformin,D011225,pre-eclampsia,"Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS).",23006146_1,23006146_D008687_D011225,,
770960426,false,true,5,2015-08-15T01:37:00,,No Relation,1,D008687,metformin,D047928,preterm delivery,The metformin-treated patients had less late miscarriage/preterm delivery; five (3%) vs. 18 (11%) in the placebo group (p < 0.01).,23006146_6,23006146_D008687_D047928,,
770960427,false,true,5,2015-08-14T23:26:00,,No Relation,1,D008687,metformin,D016640,gestational diabetes,There was no difference in the prevalence of gestational diabetes and pre-eclampsia between the metformin and the placebo group.,23006146_7,23006146_D008687_D016640,,
770960428,false,true,5,2015-08-15T01:49:00,,No Relation,1,D008687,metformin,D011225,pre-eclampsia,There was no difference in the prevalence of gestational diabetes and pre-eclampsia between the metformin and the placebo group.,23006146_7,23006146_D008687_D011225,,
770960429,false,true,5,2015-08-15T00:33:00,,No Relation,1,D008687,metformin,D011085,PCOS,"In this epi-analysis, metformin treatment during pregnancy seems to reduce early delivery in women with PCOS.",23006146_8,23006146_D008687_D011085,,
770960430,false,true,5,2015-08-15T00:58:00,,Direct,1,D000638,amiodarone,D011014,pneumonia,In vivo probe-based confocal laser endomicroscopy in amiodarone-related pneumonia.,23018901_0,23018901_D000638_D011014,,
770960431,false,true,5,2015-08-15T02:15:00,,Direct,0.8029,D000638,amiodarone,D011014,pneumonia,The objective of the study was to assess the diagnostic accuracy of pCLE for amiodarone-related pneumonia (AMR-IP).,23018901_2,23018901_D000638_D011014,,
770960432,false,true,5,2015-08-15T01:49:00,,No Relation,0.8026,D000638,amiodarone,D017563,interstitial lung disease/ILD,"Alveolar pCLE was performed in 36 nonsmoking patients, including 33 consecutive patients with acute or subacute interstitial lung disease (ILD), of which 17 were undergoing treatment with amiodarone, and three were amiodarone-treated patients without ILD.",23018901_3,23018901_D000638_D017563,,
770960433,false,true,5,2015-08-15T01:18:00,,No Relation,1,D000638,amiodarone,D007184,HP-AMR-IP,"In contrast, these cells were observed in only two out of 39 areas from LP-AMR-IP patients, in one out of 59 areas from ILD patients not receiving amiodarone and in none of the 10 areas from amiodarone-treated patients without ILD (p<0.001; HP-AMR-IP versus other groups).",23018901_7,23018901_D000638_D007184,,
770960434,false,true,5,2015-08-14T23:08:00,,No Relation,1,D000638,amiodarone,D017563,ILD,"In contrast, these cells were observed in only two out of 39 areas from LP-AMR-IP patients, in one out of 59 areas from ILD patients not receiving amiodarone and in none of the 10 areas from amiodarone-treated patients without ILD (p<0.001; HP-AMR-IP versus other groups).",23018901_7,23018901_D000638_D017563,,
770960435,false,true,5,2015-08-15T01:25:00,,No Relation,1,D010406,penicillin,D013587,syphilis,"It was not until 1943, amid world war, that penicillin was found to be an effective treatment for syphilis.",23054260_1,23054260_D010406_D013587,,
770960436,false,true,5,2015-08-14T23:49:00,,No Relation,0.7883,D010406,penicillin,D013587,syphilis,This study investigated the hypothesis that a decrease in the cost of syphilis due to penicillin spurred an increase in risky non-traditional sex.,23054260_2,23054260_D010406_D013587,,
770960437,false,true,5,2015-08-15T00:39:00,,No Relation,1,D010406,penicillin,D013587,syphilis,"Together, the findings supported the notion that the discovery of penicillin decreased the cost of syphilis and thereby played an important role in shaping modern sexuality.",23054260_8,23054260_D010406_D013587,,
770960438,false,true,5,2015-08-14T23:13:00,,No Relation,1,D010100,oxygen,D054549,OS,"Our aim was to study the response of lymphomonocyte OS status and reactive oxygen species by-products after an oral unsaturated fat load test (OFLT) in those with FH and to compare this response with that obtained in normolipidemic, normoglycemic subjects.",23072926_4,23072926_D010100_D054549,,
770960439,false,true,5,2015-08-15T01:58:00,,No Relation,1,C022616,"3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide",D015179,CRC,"ST13-overexpressed and ST13-knockdown CRC cells were constructed respectively by lentiviral transduction, followed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, plate colony formation, cell-cycle analysis, and migration assays to evaluate the influence of ST13 on proliferation and migration in vitro.",23125081_5,23125081_C022616_D015179,,
770960440,false,true,5,2015-08-14T22:37:00,,No Relation,0.802,D005947,glucose,D003929,diabetes,"Notably, high-glucose treatment or diabetes reduced miR-126 levels of CD34(+) PBMCs, associated with impaired proangiogenic properties that could be rescued by miR-mimic-126 treatment.",23144172_9,23144172_D005947_D003929,,
770960441,false,true,5,2015-08-14T23:50:00,,No Relation,1,D015780,Carbapenems,D007239,infections,Carbapenems are important antimicrobial agents for treating infections due to multidrug resistant Acinetobacter spp.,23154047_2,23154047_D015780_D007239,,
770960442,false,true,5,2015-08-14T22:41:00,,No Relation,1,D001599,berberine,D009369,cancer,"Most strikingly, nonetheless, of the six compounds prepared, sample 8, a farnesyl 9-O-substituted berberine, showed either comparable or better cytotoxic activity against human cancer HepG2 cell line than that of berberine.",23182088_3,23182088_D001599_D009369,,
770960443,false,true,5,2015-08-14T22:46:00,,No Relation,1,D001599,berberine,D006528,hepatoma,Compound 8 had also shown a 104-fold antiproliferation activity in compare with berberine against human hepatoma HepG2 cell lines after 48 incubation hours.,23182088_4,23182088_D001599_D006528,,
770960444,false,true,5,2015-08-15T00:31:00,,No Relation,0.5986,D009388,Neostigmine,D000699,analgesia,"Neostigmine, an anticholinesterase, presents a novel approach to providing analgesia.",23185923_3,23185923_D009388_D000699,,
770960445,false,true,5,2015-08-15T00:33:00,,Direct,0.8045,D009388,Neostigmine,D000699,analgesia,"Neostigmine, when given intrathecally, inhibits breakdown of an endogenous spinal neurotransmitter, acetylcholine, thereby inducing analgesia.",23185923_4,23185923_D009388_D000699,,
770960446,false,true,5,2015-08-15T02:21:00,,No Relation,0.8122,D000109,acetylcholine,D000699,analgesia,"Neostigmine, when given intrathecally, inhibits breakdown of an endogenous spinal neurotransmitter, acetylcholine, thereby inducing analgesia.",23185923_4,23185923_D000109_D000699,,
770960447,false,true,5,2015-08-14T22:31:00,"Though technically, analgesia is not a disease.",No Relation,0.5841,D009388,neostigmine,D000699,analgesia,"The mean duration of effective analgesia was 485.6 +/- 37.6 minutes in neostigmine group compared with saline group, 316.0 +/- 49.15 minutes, p < 0.001.",23185923_8,23185923_D009388_D000699,,
770960448,false,true,5,2015-08-14T23:32:00,,Direct,0.8041,D009388,neostigmine,D000699,analgesia,This study showed that spinal neostigmine 25 microg added to hyperbaric bupivacaine and fentanyl provided a significantly longer surgical analgesia and insignificant adverse effects in male adults who had lower abdominal surgery under spinal anaesthesia.,23185923_11,23185923_D009388_D000699,,
770960449,false,true,5,2015-08-14T23:25:00,,Direct,0.8095,D002045,bupivacaine,D000699,analgesia,This study showed that spinal neostigmine 25 microg added to hyperbaric bupivacaine and fentanyl provided a significantly longer surgical analgesia and insignificant adverse effects in male adults who had lower abdominal surgery under spinal anaesthesia.,23185923_11,23185923_D002045_D000699,,
770960450,false,true,5,2015-08-14T22:59:00,,Direct,0.6175,D005283,fentanyl,D000699,analgesia,This study showed that spinal neostigmine 25 microg added to hyperbaric bupivacaine and fentanyl provided a significantly longer surgical analgesia and insignificant adverse effects in male adults who had lower abdominal surgery under spinal anaesthesia.,23185923_11,23185923_D005283_D000699,,
770960451,false,true,5,2015-08-15T02:13:00,,No Relation,1,C503983,Axitinib,D002292,renal cell carcinoma,"Axitinib: in advanced, treatment-experienced renal cell carcinoma.",23190347_0,23190347_C503983_D002292,,
770960452,false,true,5,2015-08-14T23:35:00,,No Relation,1,C471405,sorafenib,D002292,renal cell carcinoma,"In a pivotal phase III trial in patients with advanced renal cell carcinoma that had progressed despite first-line therapy, axitinib 5mg twice daily significantly prolonged median progression-free survival (primary endpoint) compared with sorafenib 400mg twice daily.",23190347_2,23190347_C471405_D002292,,
770960453,false,true,5,2015-08-14T23:01:00,,No Relation,1,C503983,axitinib,D002292,renal cell carcinoma,"In a pivotal phase III trial in patients with advanced renal cell carcinoma that had progressed despite first-line therapy, axitinib 5mg twice daily significantly prolonged median progression-free survival (primary endpoint) compared with sorafenib 400mg twice daily.",23190347_2,23190347_C503983_D002292,,
770960454,false,true,5,2015-08-15T01:21:00,,No Relation,1,C503983,axitinib,D003643,death,"Significantly more axitinib than sorafenib recipients achieved an objective response, and axitinib therapy significantly prolonged time to deterioration (a composite endpoint of death, disease progression and symptom worsening) relative to sorafenib therapy.",23190347_5,23190347_C503983_D003643,,
770960455,false,true,5,2015-08-14T22:53:00,,No Relation,0.5774,C471405,sorafenib,D003643,death,"Significantly more axitinib than sorafenib recipients achieved an objective response, and axitinib therapy significantly prolonged time to deterioration (a composite endpoint of death, disease progression and symptom worsening) relative to sorafenib therapy.",23190347_5,23190347_C471405_D003643,,
770960456,false,true,5,2015-08-15T00:28:00,,Direct,0.6007,C503983,axitinib,D017499,palmar-plantar erythrodysaesthesia,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C503983_D017499,,
770960457,false,true,5,2015-08-14T23:30:00,,No Relation,0.7951,C471405,sorafenib,D017499,palmar-plantar erythrodysaesthesia,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C471405_D017499,,
770960458,false,true,5,2015-08-14T22:31:00,It's 'cutaneous toxicity' and not just toxicity,Direct,0.8022,C503983,axitinib,D064420,toxicity,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C503983_D064420,,
770960459,false,true,5,2015-08-14T23:35:00,,Direct,0.6113,C503983,axitinib,D000740,anaemia,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C503983_D000740,,
770960460,false,true,5,2015-08-14T22:38:00,,No Relation,1,C471405,sorafenib,D000740,anaemia,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C471405_D000740,,
770960461,false,true,5,2015-08-14T22:35:00,,No Relation,1,C471405,sorafenib,D064420,toxicity,"While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.",23190347_6,23190347_C471405_D064420,,
770960462,false,true,5,2015-08-15T01:52:00,,No Relation,1,C016063,pinocembrin,D050197,atherosclerosis,Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice.,23216643_0,23216643_C016063_D050197,,
770960463,false,true,5,2015-08-14T23:13:00,,No Relation,1,D019821,simvastatin,D050197,atherosclerosis,Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice.,23216643_0,23216643_D019821_D050197,,
770960464,false,true,5,2015-08-14T23:01:00,,No Relation,1,D019821,simvastatin,D006949,hyperlipidemia,"The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium.",23216643_10,23216643_D019821_D006949,,
770960465,false,true,5,2015-08-14T23:42:00,Used as treatment.,No Relation,1,C016063,pinocembrin,D006949,hyperlipidemia,"The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium.",23216643_10,23216643_C016063_D006949,,
770960466,false,true,5,2015-08-15T01:59:00,,No Relation,0.8356,C448659,alvespimycin,D006528,HCC,"Using SVM, several known HCC inhibitors, such as geldanamycin, alvespimycin (HSP90 inhibitors), and doxorubicin (chemotherapy drug), were predicted.",23220021_9,23220021_C448659_D006528,,
770960467,false,true,5,2015-08-14T23:30:00,,No Relation,1,C001277,geldanamycin,D006528,HCC,"Using SVM, several known HCC inhibitors, such as geldanamycin, alvespimycin (HSP90 inhibitors), and doxorubicin (chemotherapy drug), were predicted.",23220021_9,23220021_C001277_D006528,,
770960468,false,true,5,2015-08-14T23:51:00,,No Relation,1,D004317,doxorubicin,D006528,HCC,"Using SVM, several known HCC inhibitors, such as geldanamycin, alvespimycin (HSP90 inhibitors), and doxorubicin (chemotherapy drug), were predicted.",23220021_9,23220021_D004317_D006528,,
770960469,false,true,5,2015-08-15T00:27:00,,No Relation,1,D008727,methotrexate/MTX,D054198,acute lymphoblastic leukemia,Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.,23222202_0,23222202_D008727_D054198,,
770960470,false,true,5,2015-08-14T23:25:00,,No Relation,1,D008727,Methotrexate/MTX,D054198,acute lymphoblastic leukemia/ALL,Methotrexate (MTX) is an important component of therapy for pediatric acute lymphoblastic leukemia (ALL).,23222202_1,23222202_D008727_D054198,,
770960471,false,true,5,2015-08-15T00:28:00,,Direct,1,D008727,MTX,D064420,toxicity,"Treatment with MTX often causes toxicity, which can necessitate dose reduction or treatment cessation.",23222202_2,23222202_D008727_D064420,,
770960472,false,true,5,2015-08-14T23:37:00,polymorphisms in genes from this pathway causes toxicity,Direct,0.8039,D008727,MTX,D064420,toxicity,"As SLCO1B1 is a transporter involved in MTX elimination, other polymorphisms in genes from this pathway could also have a role in MTX toxicity.",23222202_5,23222202_D008727_D064420,,
770960473,false,true,5,2015-08-14T23:08:00,,No Relation,1,D008727,MTX,D054198,ALL,The aim of the present study was to analyze in depth the role of polymorphisms in the genes of the MTX transport pathway as putative toxicity predictors in pediatric ALL.,23222202_6,23222202_D008727_D054198,,
770960474,false,true,5,2015-08-15T01:06:00,,No Relation,0.806,D008727,MTX,D064420,toxicity,The aim of the present study was to analyze in depth the role of polymorphisms in the genes of the MTX transport pathway as putative toxicity predictors in pediatric ALL.,23222202_6,23222202_D008727_D064420,,
770960475,false,true,5,2015-08-14T22:36:00,,No Relation,0.788,D008727,MTX,D054198,ALL,Our results suggest that polymorphisms in ABCC4 and ABCC2 could be novel markers for MTX toxicity in pediatric ALL.,23222202_10,23222202_D008727_D054198,,
770960476,false,true,5,2015-08-14T22:37:00,The polymorphisms in ABCC4 and ABCC2 causes the toxicity.,Direct,0.6027,D008727,MTX,D064420,toxicity,Our results suggest that polymorphisms in ABCC4 and ABCC2 could be novel markers for MTX toxicity in pediatric ALL.,23222202_10,23222202_D008727_D064420,,
770960477,false,true,5,2015-08-14T23:19:00,,No Relation,0.8155,C005466,Ursolic acid,D011471,prostate cancer,Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.,23247106_0,23247106_C005466_D011471,,
770960478,false,true,5,2015-08-15T01:45:00,,No Relation,0.8097,C005466,ursolic acid,D011471,prostate cancer,"Here, we investigated the sensitizing effects of ursolic acid (UA), a pentacyclic triterpenoid found in many plants, on TRAIL-induced prostate cancer cell apoptosis.",23247106_4,23247106_C005466_D011471,,
770960479,false,true,5,2015-08-14T22:34:00,,No Relation,0.5911,D009705,nucleoside,D018088,TDRM,"The prevalence of HIV TDRM was 5.6% for nucleoside reverse transcriptase inhibitors, 2.0% for nonnucleoside reverse transcriptase inhibitors, and 3.0% for protease inhibitors.",23259924_8,23259924_D009705_D018088,,
770960480,false,true,5,2015-08-15T00:01:00,,No Relation,1,C467567,lenalidomide,D009101,MM,"Immunomodulatory agents (IMiDs), such as thalidomide and lenalidomide, have changed the landscape in the treatment of patients with MM while newer IMiDs such as pomalidomide are showing promise in early clinical trials.",23265189_2,23265189_C467567_D009101,,
770960481,false,true,5,2015-08-15T00:18:00,,No Relation,1,C467566,pomalidomide,D009101,MM,"Immunomodulatory agents (IMiDs), such as thalidomide and lenalidomide, have changed the landscape in the treatment of patients with MM while newer IMiDs such as pomalidomide are showing promise in early clinical trials.",23265189_2,23265189_C467566_D009101,,
770960482,false,true,5,2015-08-15T02:01:00,,No Relation,1,D013792,thalidomide,D009101,MM,"Immunomodulatory agents (IMiDs), such as thalidomide and lenalidomide, have changed the landscape in the treatment of patients with MM while newer IMiDs such as pomalidomide are showing promise in early clinical trials.",23265189_2,23265189_D013792_D009101,,
770960483,false,true,5,2015-08-15T01:33:00,,No Relation,0.5933,C467567,Lenalidomide,D064420,better toxicity,Lenalidomide has a better toxicity profile than thalidomide.,23265189_8,23265189_C467567_D064420,,
770960484,false,true,5,2015-08-14T22:35:00,,No Relation,1,D013792,thalidomide,D064420,better toxicity,Lenalidomide has a better toxicity profile than thalidomide.,23265189_8,23265189_D013792_D064420,,
770960485,false,true,5,2015-08-15T00:37:00,,Direct,1,D010269,Paraquat,D011041,poisoning,"Paraquat (1,1'-dimethyl-4,4'-bipyridinium chloride, PQ) is a non-selective herbicide, and PQ poisoning by accidental or intentional ingestion is a cause of numerous fatalities around the world every year.",23291665_1,23291665_D010269_D011041,,
770960486,false,true,5,2015-08-14T22:39:00,,No Relation,1,D000596,amino acids,D002872,deletion,"Furthermore, deletion or substitution of the N-terminal 12 amino acids in DJ-1 resulted in re-localization of E18A, M26I and L166P DJ-1 from mitochondria into the cytoplasm.",23326576_9,23326576_D000596_D002872,,
770960487,false,true,5,2015-08-14T22:59:00,,Direct,0.603,D019284,thapsigargin,D008228,endoplasmic reticulum,XBP1 mRNA splicing and expression of endoplasmic reticulum stress response genes were determined in cells exposed to thapsigargin in the presence or absence of quinotrierixin.,23335849_4,23335849_D019284_D008228,,
770960488,false,true,5,2015-08-15T00:10:00,,No Relation,1,C532275,quinotrierixin,D008228,endoplasmic reticulum,XBP1 mRNA splicing and expression of endoplasmic reticulum stress response genes were determined in cells exposed to thapsigargin in the presence or absence of quinotrierixin.,23335849_4,23335849_C532275_D008228,,
770960489,false,true,5,2015-08-15T02:39:00,,No Relation,1,D019284,thapsigargin,D008228,endoplasmic reticulum,"In cells exposed to thapsigargin, quinotrierixin inhibited XBP1 mRNA splicing and PKR-like endoplasmic reticulum kinase activation, and reduced cellular and nuclear levels of spliced XBP1 and C/EBP homologous protein.",23335849_7,23335849_D019284_D008228,,
770960490,false,true,5,2015-08-14T23:35:00,,No Relation,1,C532275,quinotrierixin,D008228,endoplasmic reticulum,"In cells exposed to thapsigargin, quinotrierixin inhibited XBP1 mRNA splicing and PKR-like endoplasmic reticulum kinase activation, and reduced cellular and nuclear levels of spliced XBP1 and C/EBP homologous protein.",23335849_7,23335849_C532275_D008228,,
770960491,false,true,5,2015-08-15T01:00:00,,Direct,0.6057,C532275,quinotrierixin,D008228,endoplasmic reticulum,"Paradoxically, quinotrierixin exacerbated endoplasmic reticulum stress-induced phosphorylation of eIF2, which in turn led to decreased protein translation.",23335849_8,23335849_C532275_D008228,,
770960492,false,true,5,2015-08-14T23:29:00,,No Relation,1,C532275,quinotrierixin,D019320,Paradoxically,"Paradoxically, quinotrierixin exacerbated endoplasmic reticulum stress-induced phosphorylation of eIF2, which in turn led to decreased protein translation.",23335849_8,23335849_C532275_D019320,,
770960493,false,true,5,2015-08-15T02:05:00,,No Relation,1,C532275,quinotrierixin,D018630,proliferative vitreoretinopathy,Future studies are needed to investigate the in vivo effect of quinotrierixin on RPE proliferation in animal models of proliferative vitreoretinopathy.,23335849_12,23335849_C532275_D018630,,
770960494,false,true,5,2015-08-14T22:41:00,,No Relation,1,D013004,somatostatin,D018358,neuroendocrine tumors,"For treatment of patients with inoperable or metastasized neuroendocrine tumors, somatostatin analogues labeled with the radioisotopes (111)In, (90)Y and (177)Lu have been used so far.",23339764_6,23339764_D013004_D018358,,
770960495,false,true,5,2015-08-15T02:13:00,,No Relation,1,D013004,somatostatin,D009369,tumor,"Labeling with (111)In, mainly an Auger electron emitter, resulted in no reduction of tumor size while somatostatin analogues labeled with (90)Y and (177)Lu gave overall positive response and improved the patients' quality of life.",23339764_7,23339764_D013004_D009369,,
770960496,false,true,5,2015-08-14T22:39:00,,No Relation,0.7872,D005419,Flavonoids,D009369,breast cancer,"Flavonoids, flavonoid subclasses and breast cancer risk: a meta-analysis of epidemiologic studies.",23349849_0,23349849_D005419_D009369,,
770960497,false,true,5,2015-08-14T23:51:00,'chemopreventive'  being the key term.,No Relation,1,D005419,flavonoids,D063646,carcinogenesis,Studies have suggested the chemopreventive effects of flavonoids on carcinogenesis.,23349849_1,23349849_D005419_D063646,,
770960498,false,true,5,2015-08-14T23:26:00,Used as possible prevention.,No Relation,1,D005419,flavonoids,D009369,breast cancer,Yet numbers of epidemiologic studies assessing dietary flavonoids and breast cancer risk have yielded inconsistent results.,23349849_2,23349849_D005419_D009369,,
770960499,false,true,5,2015-08-15T02:00:00,,No Relation,1,D005419,flavonoids,D009369,breast cancer,"The association between flavonoids, flavonoid subclasses (flavonols, flavan-3-ols, etc.) and the risk of breast cancer lacks systematic analysis.",23349849_3,23349849_D005419_D009369,,
770960500,false,true,5,2015-08-14T23:01:00,,No Relation,0.8154,D005419,flavonoids,D009369,breast cancer,"We aimed to examine the association between flavonoids, each flavonoid subclass (except isoflavones) and the risk of breast cancer by conducting a meta-analysis.",23349849_4,23349849_D005419_D009369,,
770960501,false,true,5,2015-08-14T22:34:00,,No Relation,1,D007529,isoflavones,D009369,breast cancer,"We aimed to examine the association between flavonoids, each flavonoid subclass (except isoflavones) and the risk of breast cancer by conducting a meta-analysis.",23349849_4,23349849_D007529_D009369,,
770960502,false,true,5,2015-08-14T22:59:00,,No Relation,1,D047309,flavones,D009369,breast cancer,"The risk of breast cancer significantly decreased in women with high intake of flavonols (RR=0.88, 95% CI 0.80-0.98) and flavones (RR=0.83, 95% CI: 0.76-0.91) compared with that in those with low intake of flavonols and flavones.",23349849_10,23349849_D047309_D009369,,
770960503,false,true,5,2015-08-14T23:17:00,,No Relation,0.8223,D005419,flavonoids,D009369,breast cancer,"However, no significant association of flavan-3-ols (RR=0.93, 95% CI: 0.84-1.02), flavanones (summary RR=0.95, 95% CI: 0.88-1.03), anthocyanins (summary RR=0.97, 95% CI: 0.87-1.08) or total flavonoids (summary RR=0.98, 95% CI: 0.86-1.12) intake with breast cancer risk was observed.",23349849_11,23349849_D005419_D009369,,
770960504,false,true,5,2015-08-15T01:47:00,,No Relation,1,D044950,flavanones,D009369,breast cancer,"However, no significant association of flavan-3-ols (RR=0.93, 95% CI: 0.84-1.02), flavanones (summary RR=0.95, 95% CI: 0.88-1.03), anthocyanins (summary RR=0.97, 95% CI: 0.87-1.08) or total flavonoids (summary RR=0.98, 95% CI: 0.86-1.12) intake with breast cancer risk was observed.",23349849_11,23349849_D044950_D009369,,
770960505,false,true,5,2015-08-15T01:58:00,,No Relation,1,D000872,anthocyanins,D009369,breast cancer,"However, no significant association of flavan-3-ols (RR=0.93, 95% CI: 0.84-1.02), flavanones (summary RR=0.95, 95% CI: 0.88-1.03), anthocyanins (summary RR=0.97, 95% CI: 0.87-1.08) or total flavonoids (summary RR=0.98, 95% CI: 0.86-1.12) intake with breast cancer risk was observed.",23349849_11,23349849_D000872_D009369,,
770960506,false,true,5,2015-08-15T02:09:00,,No Relation,1,D047309,flavones,D009369,breast cancer,"Furthermore, summary RRs of 3 case-control studies stratified by menopausal status suggested flavonols, flavones or flavan-3-ols intake is associated with a significant reduced risk of breast cancer in post-menopausal while not in pre-menopausal women.",23349849_12,23349849_D047309_D009369,,
770960507,false,true,5,2015-08-14T22:36:00,,No Relation,0.8104,D005419,flavonoids,D009369,breast cancer,"The present study suggests the intake of flavonols and flavones, but not other flavonoid subclasses or total flavonoids, is associated with a decreased risk of breast cancer, especially among post-menopausal women.",23349849_13,23349849_D005419_D009369,,
770960508,false,true,5,2015-08-14T23:43:00,,No Relation,0.7968,D047309,flavones,D009369,breast cancer,"The present study suggests the intake of flavonols and flavones, but not other flavonoid subclasses or total flavonoids, is associated with a decreased risk of breast cancer, especially among post-menopausal women.",23349849_13,23349849_D047309_D009369,,
770960509,false,true,5,2015-08-14T22:31:00,,No Relation,1,D008715,methionine,D009369,colon cancer,"Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A.",23363077_0,23363077_D008715_D009369,,
770960510,false,true,5,2015-08-14T22:46:00,,No Relation,1,D019787,linoleic acid,D009369,breast cancer,"The anti-proliferative and pro-apoptotic effects of the trans9, trans11 conjugated linoleic acid isomer on MCF-7 breast cancer cells are associated with LXR activation.",23375583_0,23375583_D019787_D009369,,
770960511,false,true,5,2015-08-14T22:54:00,,No Relation,1,D008041,linoleic acids,D009369,breast cancer,"Conjugated linoleic acids (CLA), naturally found in dairy products and ruminant meat, are positional and geometric isomers (trans: t or cis: c) of linoleic acid, and have been widely reported to possess anti-tumoral activity against breast cancer both in vitro and in vivo.",23375583_1,23375583_D008041_D009369,,
770960512,false,true,5,2015-08-14T23:02:00,,No Relation,1,D019787,linoleic acid,D009369,breast cancer,"Conjugated linoleic acids (CLA), naturally found in dairy products and ruminant meat, are positional and geometric isomers (trans: t or cis: c) of linoleic acid, and have been widely reported to possess anti-tumoral activity against breast cancer both in vitro and in vivo.",23375583_1,23375583_D019787_D009369,,
770960513,false,true,5,2015-08-14T22:30:00,,Direct,0.7914,D005472,5-FU,D064420,toxicities,Drug resistance and severe toxicities are limitations when handling 5-FU.,23386105_1,23386105_D005472_D064420,,
770960514,false,true,5,2015-08-15T00:01:00,,No Relation,1,D002955,folinic acid,D064420,toxicity,We have developed a triple liposomal formulation of 5-FU combined to 2'-deoxyinosine and folinic acid to improve its efficacy-toxicity balance.,23386105_2,23386105_D002955_D064420,,
770960515,false,true,5,2015-08-15T02:00:00,,No Relation,1,C012271,2'-deoxyinosine,D064420,toxicity,We have developed a triple liposomal formulation of 5-FU combined to 2'-deoxyinosine and folinic acid to improve its efficacy-toxicity balance.,23386105_2,23386105_C012271_D064420,,
770960516,false,true,5,2015-08-14T22:40:00,,No Relation,1,D005472,5-FU,D064420,toxicity,We have developed a triple liposomal formulation of 5-FU combined to 2'-deoxyinosine and folinic acid to improve its efficacy-toxicity balance.,23386105_2,23386105_D005472_D064420,,
770960517,false,true,5,2015-08-15T02:11:00,,No Relation,1,D005472,5-FU,D054067,DPD-deficiency,"Beside, milder neutropenia was observed when giving LipoFufol to animals with transient partial DPD-deficiency, as compared with standard 5-FU.",23386105_11,23386105_D005472_D054067,,
770960518,false,true,5,2015-08-14T22:48:00,,No Relation,1,D005472,5-FU,D009503,neutropenia,"Beside, milder neutropenia was observed when giving LipoFufol to animals with transient partial DPD-deficiency, as compared with standard 5-FU.",23386105_11,23386105_D005472_D009503,,
770960519,false,true,5,2015-08-14T23:15:00,,No Relation,0.794,D005472,5-FU,D064420,toxicity,The issues of drug-resistance and drug-related toxicity can be both addressed using a stealth liposomal formulation of modulated 5-FU.,23386105_13,23386105_D005472_D064420,,
770960520,false,true,5,2015-08-14T23:03:00,,No Relation,1,C047246,temozolomide,D009369,tumor,We propose a mathematical model that takes into account a classical maximum tolerated dose (MTD) chemotherapy regimen (whose primary targets are the tumor cells) as well as a metronomic chemotherapy regimen (whose primary targets are the tumor endothelial cells) for the administration of temozolomide (Temodal()) in order to compare the effectiveness of these two types of protocols.,23389760_1,23389760_C047246_D009369,,
770960521,false,true,5,2015-08-14T23:05:00,,No Relation,1,C047246,temozolomide,D009369,tumor/cancer,"The model is built from 4 natural hypotheses: (H1) without treatment the tumor growth follows a Gompertz model, (H2) endothelial cells are more sensitive to temozolomide than cancer cells, (H3) the anti-angiogenic effect blocks tumor growth, and (H4) endothelial cells are more genetically stable than cancer cells and thus less likely to develop resistance to temozolomide.",23389760_2,23389760_C047246_D009369,,
770960522,false,true,5,2015-08-15T01:12:00,,No Relation,0.5769,C047246,temozolomide,D006327,blocks tumor,"The model is built from 4 natural hypotheses: (H1) without treatment the tumor growth follows a Gompertz model, (H2) endothelial cells are more sensitive to temozolomide than cancer cells, (H3) the anti-angiogenic effect blocks tumor growth, and (H4) endothelial cells are more genetically stable than cancer cells and thus less likely to develop resistance to temozolomide.",23389760_2,23389760_C047246_D006327,,
770960523,false,true,5,2015-08-15T00:06:00,,No Relation,1,C047246,temozolomide,D009369,tumor/cancer,"Our mathematical model shows that the metronomic regimen induces tumor regression through anti-angiogenic effects while the MTD regimen fails to do so, due to the emergence of temozolomide resistance in cancer cells.",23389760_4,23389760_C047246_D009369,,
770960524,false,true,5,2015-08-15T01:35:00,,No Relation,1,C101426,Sildenafil,D009203,myocardial infarction,Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.,23406672_0,23406672_C101426_D009203,,
770960525,false,true,5,2015-08-15T00:03:00,,No Relation,1,C101426,Sildenafil,D054144,diastolic dysfunction,Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.,23406672_0,23406672_C101426_D054144,,
770960526,false,true,5,2015-08-15T01:59:00,,No Relation,1,C101426,sildenafil,D009203,myocardial infarction,We hypothesized that sildenafil would reduce filling pressure during exercise in patients with diastolic dysfunction after myocardial infarction.,23406672_2,23406672_C101426_D009203,,
770960527,false,true,5,2015-08-15T01:11:00,,No Relation,1,C101426,sildenafil,D054144,diastolic dysfunction,We hypothesized that sildenafil would reduce filling pressure during exercise in patients with diastolic dysfunction after myocardial infarction.,23406672_2,23406672_C101426_D054144,,
770960528,false,true,5,2015-08-14T23:08:00,,No Relation,1,C101426,sildenafil,D054144,diastolic dysfunction,Seventy patients with diastolic dysfunction and near normal left ventricular ejection fraction on echocardiography were randomly assigned sildenafil 40 mg thrice daily or matching placebo for 9 weeks.,23406672_3,23406672_C101426_D054144,,
770960529,false,true,5,2015-08-14T23:01:00,,No Relation,0.8154,C101426,Sildenafil,D009203,myocardial infarction,Sildenafil did not decrease filling pressure at rest or during exercise in post-myocardial infarction patients with diastolic dysfunction.,23406672_9,23406672_C101426_D009203,,
770960530,false,true,5,2015-08-14T22:37:00,,No Relation,1,C101426,Sildenafil,D054144,diastolic dysfunction,Sildenafil did not decrease filling pressure at rest or during exercise in post-myocardial infarction patients with diastolic dysfunction.,23406672_9,23406672_C101426_D054144,,
770960531,false,true,5,2015-08-15T00:27:00,,No Relation,1,D013974,l-thyroxine,D007037,hypothyroidism,"At re-evaluation, 34.5% of patients showed permanent hypothyroidism and needed l-thyroxine reintroduction, 27.4% had persistent hyperthyrotropinemia (TSH 5-10 mU/L), and 38.1% had transient hypothyroidism.",23426615_6,23426615_D013974_D007037,,
770960532,false,true,5,2015-08-14T22:51:00,,No Relation,1,D013974,l-thyroxine,C562568,hypoplasia,"Major risk factors for permanent CH were prematurity, first-degree familial history of goiter/nodules, thyroid hypoplasia at diagnosis, and high l-thyroxine requirements at follow-up.",23426615_7,23426615_D013974_C562568,,
770960533,false,true,5,2015-08-14T23:25:00,,No Relation,0.5918,D013974,l-thyroxine,D003409,CH,"Major risk factors for permanent CH were prematurity, first-degree familial history of goiter/nodules, thyroid hypoplasia at diagnosis, and high l-thyroxine requirements at follow-up.",23426615_7,23426615_D013974_D003409,,
770960534,false,true,5,2015-08-14T22:38:00,,No Relation,1,D013974,l-thyroxine,D003409,CH,Only one-third of patients with CH and eutopic thyroid gland needed to continue l-thyroxine therapy after re-evaluation.,23426615_10,23426615_D013974_D003409,,
770960535,false,true,5,2015-08-14T23:42:00,,No Relation,1,D004967,estrogen,D009336,necrosis,"We report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.",23455801_2,23455801_D004967_D009336,,
770960536,false,true,5,2015-08-14T22:33:00,,No Relation,1,D011374,progesterone,D009336,necrosis,"We report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.",23455801_2,23455801_D011374_D009336,,
770960537,false,true,5,2015-08-15T01:59:00,,No Relation,1,D011374,progesterone,D002291,papillary carcinoma of the breast,"We report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.",23455801_2,23455801_D011374_D002291,,
770960538,false,true,5,2015-08-14T22:46:00,,No Relation,1,D004967,estrogen,D002291,papillary carcinoma of the breast,"We report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.",23455801_2,23455801_D004967_D002291,,
770960539,false,true,5,2015-08-14T22:33:00,,No Relation,1,C072042,latanoprost,D002386,cataract,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C072042_D002386,,
770960540,false,true,5,2015-08-15T01:23:00,,No Relation,0.7979,D000086,acetazolamide,D010146,pain,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_D000086_D010146,,
770960541,false,true,5,2015-08-15T00:02:00,,No Relation,1,C111827,brinzolamide,D010146,pain,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C111827_D010146,,
770960542,false,true,5,2015-08-14T23:23:00,,No Relation,1,C072042,latanoprost,D010146,pain,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C072042_D010146,,
770960543,false,true,5,2015-08-14T22:49:00,,No Relation,1,D000086,acetazolamide,D002386,cataract,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_D000086_D002386,,
770960544,false,true,5,2015-08-14T22:50:00,,No Relation,1,C111827,brinzolamide,D002386,cataract,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C111827_D002386,,
770960545,false,true,5,2015-08-15T02:21:00,,No Relation,1,C015620,brimonidine,D010146,pain,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C015620_D010146,,
770960546,false,true,5,2015-08-14T22:37:00,,No Relation,1,D013999,timolol,D002386,cataract,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_D013999_D002386,,
770960547,false,true,5,2015-08-14T22:58:00,Suspenseful abstract is suspenseful,No Relation,1,C015620,brimonidine,D002386,cataract,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_C015620_D002386,,
770960548,false,true,5,2015-08-15T00:43:00,,No Relation,1,D013999,timolol,D010146,pain,"This study evaluated the effects of acetazolamide, latanoprost, travoprost, bimatoprost, brimonidine, brinzolamide, and timolol on pain during phacoemulsification cataract surgery.",23461283_1,23461283_D013999_D010146,,
770960549,false,true,5,2015-08-14T23:10:00,,No Relation,0.8106,D011453,prostanoids,D010146,pain,"The brimonidine group exhibited the lowest visual analog pain-scale scores, and the prostanoids, especially the bimatoprost group, demonstrated the highest visual analog pain-scale scores (medianstandard deviation were 0.01.50 and 2.01.91, respectively).",23461283_7,23461283_D011453_D010146,,
770960550,false,true,5,2015-08-14T23:18:00,,No Relation,1,C015620,brimonidine,D010146,pain,"The brimonidine group exhibited the lowest visual analog pain-scale scores, and the prostanoids, especially the bimatoprost group, demonstrated the highest visual analog pain-scale scores (medianstandard deviation were 0.01.50 and 2.01.91, respectively).",23461283_7,23461283_C015620_D010146,,
770960551,false,true,5,2015-08-15T01:41:00,,No Relation,0.8073,C111827,brinzolamide,D010146,pain,"The median visual analog pain-scale scores of the acetazolamide, latanoprost, travoprost, brinzolamide, and timolol groups were 0.01.62, 2.01.67, 2.01.73, 0.01.66, and 1.01.54, respectively.",23461283_8,23461283_C111827_D010146,,
770960552,false,true,5,2015-08-14T23:11:00,,Direct,0.6045,D000086,acetazolamide,D010146,pain,"The median visual analog pain-scale scores of the acetazolamide, latanoprost, travoprost, brinzolamide, and timolol groups were 0.01.62, 2.01.67, 2.01.73, 0.01.66, and 1.01.54, respectively.",23461283_8,23461283_D000086_D010146,,
770960553,false,true,5,2015-08-14T22:53:00,,Direct,0.6214,C072042,latanoprost,D010146,pain,"The median visual analog pain-scale scores of the acetazolamide, latanoprost, travoprost, brinzolamide, and timolol groups were 0.01.62, 2.01.67, 2.01.73, 0.01.66, and 1.01.54, respectively.",23461283_8,23461283_C072042_D010146,,
770960554,false,true,5,2015-08-15T01:43:00,,No Relation,1,D013999,timolol,D010146,pain,"The median visual analog pain-scale scores of the acetazolamide, latanoprost, travoprost, brinzolamide, and timolol groups were 0.01.62, 2.01.67, 2.01.73, 0.01.66, and 1.01.54, respectively.",23461283_8,23461283_D013999_D010146,,
770960555,false,true,5,2015-08-15T00:23:00,,No Relation,1,D013792,thalidomide,D009101,multiple myeloma,Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.,23469567_0,23469567_D013792_D009101,,
770960556,false,true,5,2015-08-14T22:52:00,,No Relation,0.8265,D013792,thalidomide,D009101,multiple myeloma,"Recently, thalidomide has demonstrated significant activity in the treatment of multiple myeloma in various western studies.",23469567_2,23469567_D013792_D009101,,
770960557,false,true,5,2015-08-14T22:43:00,,No Relation,1,D013792,thalidomide,D009101,multiple myeloma,To study the clinical profile of multiple myeloma and the effect of thalidomide based treatment on its outcome in the Indian scenario are the aims and objective of the study.,23469567_4,23469567_D013792_D009101,,
770960558,false,true,5,2015-08-15T00:59:00,,No Relation,0.8002,D013792,thalidomide,D009101,multiple myeloma,"Although multiple myeloma has remained an incurable disease to date, presently available thalidomide based combination chemotherapy represents an active inductive regimen to improve the outcome and achieve eventual cure.",23469567_14,23469567_D013792_D009101,,
770960559,false,true,5,2015-08-15T00:55:00,,No Relation,0.5894,C011421,Methylchloroisothiazolinone,D017449,allergic contact dermatitis,Methylchloroisothiazolinone and methylisothiazolinone allergic contact dermatitis and the effect of patch test concentration.,23474447_0,23474447_C011421_D017449,,
770960560,false,true,5,2015-08-14T22:43:00,,No Relation,0.5933,C011506,methylisothiazolinone,D017449,allergic contact dermatitis,Methylchloroisothiazolinone and methylisothiazolinone allergic contact dermatitis and the effect of patch test concentration.,23474447_0,23474447_C011506_D017449,,
770960561,false,true,5,2015-08-14T22:37:00,,Direct,0.5969,D003042,cocaine,D019970,cocaine dependence,Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence.,23497788_0,23497788_D003042_D019970,,
770960562,false,true,5,2015-08-14T22:41:00,,No Relation,0.58,D003042,cocaine,D019970,cocaine dependence,"To better understand the impact of DCS-facilitated extinction on neural reactivity to drug cues, the present study reports fMRI findings from a randomized, double-blind, placebo-controlled trial of DCS-facilitated cue exposure for cocaine dependence.",23497788_3,23497788_D003042_D019970,,
770960563,false,true,5,2015-08-15T00:06:00,,No Relation,0.7894,D003042,cocaine,D019970,cocaine dependence,Three trials of DCS-facilitated cue exposure therapy for cocaine dependence have found that DCS either increases or does not significantly impact response to cocaine cues.,23497788_9,23497788_D003042_D019970,,
770960564,false,true,5,2015-08-14T23:05:00,,No Relation,1,D012254,ribavirin,D000208,acute hepatitis C infection,Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin.,23514835_0,23514835_D012254_D000208,,
770960565,false,true,5,2015-08-14T23:17:00,,No Relation,1,D016898,interferon-alpha,D000208,acute hepatitis C infection,Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin.,23514835_0,23514835_D016898_D000208,,
770960566,false,true,5,2015-08-15T00:31:00,,No Relation,1,D000596,amino-acid,D006526,HCV infection,"Lipid pathway impairment, decrease in the antioxidant pool and downregulation in amino-acid metabolism are just some of the metabolic variations attributed to chronic HCV infection.",23529134_1,23529134_D000596_D006526,,
770960567,false,true,5,2015-08-15T00:10:00,,No Relation,1,D012254,ribavirin,D003920,diabetes mellitus,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_D012254_D003920,,
770960568,false,true,5,2015-08-14T22:37:00,,No Relation,1,D012254,ribavirin,D006526,hepatitis C,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_D012254_D006526,,
770960569,false,true,5,2015-08-14T23:47:00,,No Relation,1,C417083,pegylated interferon alpha 2b,D006526,hepatitis C,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_C417083_D006526,,
770960570,false,true,5,2015-08-15T01:16:00,,No Relation,1,D012254,ribavirin,D000437,alcoholism,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_D012254_D000437,,
770960571,false,true,5,2015-08-14T23:03:00,,No Relation,1,C417083,pegylated interferon alpha 2b,D000437,alcoholism,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_C417083_D000437,,
770960572,false,true,5,2015-08-14T22:37:00,,No Relation,1,C417083,pegylated interferon alpha 2b,D003920,diabetes mellitus,"We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin.",23529134_4,23529134_C417083_D003920,,
770960573,false,true,5,2015-08-15T00:30:00,,No Relation,1,D000596,amino acid,D000437,alcohol abuse,"The proteomic analysis showed that after therapy, a downregulation of enzymes involved in amino acid metabolism, glycolysis/gluconeogenesis and alcohol catabolism takes place, the latter probably due to cessation of alcohol abuse.",23529134_8,23529134_D000596_D000437,,
770960574,false,true,5,2015-08-14T23:30:00,This one is very obvious but probably not what you meant.,No Relation,0.7881,D000431,alcohol,D000437,alcohol abuse,"The proteomic analysis showed that after therapy, a downregulation of enzymes involved in amino acid metabolism, glycolysis/gluconeogenesis and alcohol catabolism takes place, the latter probably due to cessation of alcohol abuse.",23529134_8,23529134_D000431_D000437,,
770960575,false,true,5,2015-08-14T22:51:00,,No Relation,0.7917,D005227,fatty acids,D006526,HCV infection,"These ""real time"" data confirm in vivo, in humans, that during HCV infection, the pathways related to fatty acids, glucose metabolism and free radical scavenging are inhibited.",23529134_11,23529134_D005227_D006526,,
770960576,false,true,5,2015-08-14T23:03:00,,No Relation,1,D005947,glucose,D006526,HCV infection,"These ""real time"" data confirm in vivo, in humans, that during HCV infection, the pathways related to fatty acids, glucose metabolism and free radical scavenging are inhibited.",23529134_11,23529134_D005947_D006526,,
770960577,false,true,5,2015-08-15T00:50:00,,No Relation,1,D003474,curcumin,D008659,metabolic syndrome,200 mg/kg curcumin was gavaged to adult male Sprague-Dawley rats with high-fat-diet-induced metabolic syndrome for 2 months.,23533564_5,23533564_D003474_D008659,,
770960578,false,true,5,2015-08-14T23:06:00,,No Relation,1,D003474,Curcumin,D009765,obese,"Curcumin reduced serum glucose, cholesterol, triglyceride, low density lipoprotein levels in high-fat-diet-induced obese rats.",23533564_8,23533564_D003474_D009765,,
770960579,false,true,5,2015-08-14T23:05:00,,No Relation,1,D005947,glucose,D009765,obese,"Curcumin reduced serum glucose, cholesterol, triglyceride, low density lipoprotein levels in high-fat-diet-induced obese rats.",23533564_8,23533564_D005947_D009765,,
770960580,false,true,5,2015-08-15T00:31:00,,No Relation,1,D002784,cholesterol,D009765,obese,"Curcumin reduced serum glucose, cholesterol, triglyceride, low density lipoprotein levels in high-fat-diet-induced obese rats.",23533564_8,23533564_D002784_D009765,,
770960581,false,true,5,2015-08-14T22:47:00,,No Relation,1,D003474,curcumin,D008659,metabolic syndrome,"In conclusion, curcumin is effective for the treatment of metabolic syndrome and four novel curcumin derivatives had high potencies for inhibition of human 11_-HSD1 with selectivity against 11_-HSD2.",23533564_12,23533564_D003474_D008659,,
770960582,false,true,5,2015-08-14T22:34:00,,No Relation,0.5783,D059808,polyphenols,D002318,cardiovascular health,Oxidative stress and cardiovascular health: therapeutic potential of polyphenols.,23537433_0,23537433_D059808_D002318,,
770960583,false,true,5,2015-08-14T23:02:00,,No Relation,1,D059808,polyphenols,D002318,cardiovascular health,"In addition, this review summarizes the health benefits of polyphenols, and the recent progress on understanding the cellular and physiological actions by which polyphenols may impart their beneficial properties on cardiovascular health.",23537433_4,23537433_D059808_D002318,,
770960584,false,true,5,2015-08-15T02:33:00,,No Relation,1,D008712,methicillin,D011023,vancomycin-intermediate S. aureus/VISA,We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA).,23539745_1,23539745_D008712_D011023,,
770960585,false,true,5,2015-08-15T00:18:00,,No Relation,1,D014640,vancomycin,D011023,vancomycin-intermediate S. aureus/VISA,We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA).,23539745_1,23539745_D014640_D011023,,
770960586,false,true,5,2015-08-14T22:34:00,,No Relation,1,D014640,vancomycin,D018458,SEVs/simulated endocardial vegetations,Mutants of JH1 were selected in vitro by means of a pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs) and by exposure to vancomycin in laboratory growth medium.,23539745_3,23539745_D014640_D018458,,
770960587,false,true,5,2015-08-15T01:31:00,,No Relation,1,D017576,daptomycin,D011023,VISA,"Both mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg, thicker cell walls and abnormal autolysis) that are typical of in vivo VISA mutants.",23539745_6,23539745_D017576_D011023,,
770960588,false,true,5,2015-08-15T00:41:00,,No Relation,1,D014640,vancomycin,D011023,VISA,"Both mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg, thicker cell walls and abnormal autolysis) that are typical of in vivo VISA mutants.",23539745_6,23539745_D014640_D011023,,
770960589,false,true,5,2015-08-14T22:57:00,,Direct,1,C022172,Zotepine,D012640,seizures,Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia.,23543675_0,23543675_C022172_D012640,,
770960590,false,true,5,2015-08-15T00:50:00,,No Relation,0.8195,C022172,Zotepine,D012559,schizophrenia,Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia.,23543675_0,23543675_C022172_D012559,,
770960591,false,true,5,2015-08-15T01:13:00,,Direct,1,C022172,zotepine,D012640,seizure,The adverse event of zotepine induced seizure is published in few case reports.,23543675_4,23543675_C022172_D012640,,
770960592,false,true,5,2015-08-15T00:36:00,,Direct,0.618,C022172,zotepine,D012640,tonic-clonic seizures,We report the occurrence of myoclonic seizure progressing to generalized tonic-clonic seizures with zotepine along with clear temporal association of dose dependent modulation evident in this case.,23543675_5,23543675_C022172_D012640,,
770960593,false,true,5,2015-08-15T01:29:00,,Direct,0.807,C022172,zotepine,D004831,myoclonic seizure,We report the occurrence of myoclonic seizure progressing to generalized tonic-clonic seizures with zotepine along with clear temporal association of dose dependent modulation evident in this case.,23543675_5,23543675_C022172_D004831,,
770960594,false,true,5,2015-08-14T22:37:00,,No Relation,1,C551177,vemurafenib,D008545,melanoma,"To discuss the clinical efficacy and safety of ipilimumab, vemurafenib, and investigational agents for the treatment of unresectable stage III and stage IV melanoma and define current strategies of first-line treatment selection.",23548648_1,23548648_C551177_D008545,,
770960595,false,true,5,2015-08-14T23:03:00,,No Relation,1,C560077,trametinib,D008545,melanoma,"Literature was accessed through MEDLINE and International Pharmaceutical Abstracts (1970-November 2012) using the terms melanoma, metastatic melanoma, ipilimumab, vemurafenib, dabrafenib, and trametinib.",23548648_2,23548648_C560077_D008545,,
770960596,false,true,5,2015-08-15T02:10:00,,No Relation,1,C551177,vemurafenib,D008545,melanoma,"Literature was accessed through MEDLINE and International Pharmaceutical Abstracts (1970-November 2012) using the terms melanoma, metastatic melanoma, ipilimumab, vemurafenib, dabrafenib, and trametinib.",23548648_2,23548648_C551177_D008545,,
770960597,false,true,5,2015-08-14T22:48:00,,No Relation,1,C561627,dabrafenib,D008545,melanoma,"Literature was accessed through MEDLINE and International Pharmaceutical Abstracts (1970-November 2012) using the terms melanoma, metastatic melanoma, ipilimumab, vemurafenib, dabrafenib, and trametinib.",23548648_2,23548648_C561627_D008545,,
770960598,false,true,5,2015-08-15T00:03:00,,No Relation,1,D003606,dacarbazine,D008545,melanoma,"Two randomized Phase 3 clinical trials have demonstrated a significant survival benefit with the use of ipilimumab compared to a melanoma vaccine (10.1 vs 6.4 months; p = 0.003) and compared to dacarbazine (11.2 months, 95% CI 9.4-13.6 vs 9.1 months, 95% CI 7.8-10.5).",23548648_7,23548648_D003606_D008545,,
770960599,false,true,5,2015-08-15T01:51:00,,Direct,0.59,C551177,vemurafenib,D064420,toxicity,Both new agents possess unique toxicity profiles including immune-related adverse events with ipilimumab and secondary cutaneous cancers reported with vemurafenib use.,23548648_10,23548648_C551177_D064420,,
770960600,false,true,5,2015-08-15T01:45:00,,Direct,1,C551177,vemurafenib,D009369,cancers,Both new agents possess unique toxicity profiles including immune-related adverse events with ipilimumab and secondary cutaneous cancers reported with vemurafenib use.,23548648_10,23548648_C551177_D009369,,
770960601,false,true,5,2015-08-14T23:42:00,,No Relation,1,C551177,vemurafenib,D008545,melanoma,Treatment strategies have changed for patients with advanced melanoma with the use of ipilimumab and vemurafenib as first-line agents.,23548648_11,23548648_C551177_D008545,,
770960602,false,true,5,2015-08-14T22:43:00,,No Relation,0.7913,D005839,gentamicin,D016470,bacteremia,"In chronic bacteremia, gentamicin and doxycycline significantly increased the resolution rate.",23602630_8,23602630_D005839_D016470,,
770960603,false,true,5,2015-08-15T01:25:00,,No Relation,1,D004318,doxycycline,D016470,bacteremia,"In chronic bacteremia, gentamicin and doxycycline significantly increased the resolution rate.",23602630_8,23602630_D004318_D016470,,
770960604,false,true,5,2015-08-14T23:09:00,,Direct,0.6122,D005665,furosemide,D013921,thrombocytopenia,A 7-year case of furosemide-induced immune thrombocytopenia.,23625769_0,23625769_D005665_D013921,,
770960605,false,true,5,2015-08-15T02:32:00,,Direct,0.8106,D005665,furosemide,D013921,thrombocytopenia,"In this report, we describe a case in which furosemide was identified as the probable cause of drug-induced thrombocytopenia in an 84-year-old man with chronic symptomatic idiopathic thrombocytopenia for seven years before discovery.",23625769_4,23625769_D005665_D013921,,
770960606,false,true,5,2015-08-14T22:33:00,,Direct,1,D005665,furosemide,D013921,thrombocytopenia,"Based on the observations of this case report, clinicians should more readily consider furosemide as a potential cause of thrombocytopenia.",23625769_9,23625769_D005665_D013921,,
770960607,false,true,5,2015-08-15T01:53:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.,23635729_0,23635729_D013629_D009369,,
770960608,false,true,5,2015-08-14T22:33:00,,No Relation,1,D016912,levonorgestrel,D009369,breast cancer,Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.,23635729_0,23635729_D016912_D009369,,
770960609,false,true,5,2015-08-14T23:23:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen.,23635729_1,23635729_D013629_D009369,,
770960610,false,true,5,2015-08-14T22:43:00,,No Relation,1,D016912,levonorgestrel,D009369,breast cancer,To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen.,23635729_1,23635729_D016912_D009369,,
770960611,false,true,5,2015-08-14T22:51:00,,No Relation,1,D013629,tamoxifen,D009369,breast cancer,This was a randomized contro-lled trial of 129 Chinese women who attended a university hospital in Hong Kong and required adjuvant tamoxifen for breast cancer after the completion of postoperative radiotherapy and chemotherapy.,23635729_2,23635729_D013629_D009369,,
770960612,false,true,5,2015-08-14T22:57:00,,No Relation,1,D016912,Levonorgestrel,D014591,endometrial polyps,"Levonorgestrel-releasing intrauterine system significantly reduced de novo endometrial polyps (hazard ratio 0.19, 95% confidence interval 0.07-0.48) over the course of 5 years on an intention-to-treat basis.",23635729_8,23635729_D016912_D014591,,
770960613,false,true,5,2015-08-14T23:57:00,'levonorgestrel-releasing intrauterine system' and not just 'levonorgestrel' ... Also it prevents it.,No Relation,1,D016912,levonorgestrel,D014591,endometrial polyps,Prophylactic levonorgestrel-releasing intrauterine system prevents de novo endometrial polyps in women using tamoxifen.,23635729_10,23635729_D016912_D014591,,
770960614,false,true,5,2015-08-15T00:51:00,,No Relation,0.8009,D013629,tamoxifen,D014591,endometrial polyps,Prophylactic levonorgestrel-releasing intrauterine system prevents de novo endometrial polyps in women using tamoxifen.,23635729_10,23635729_D013629_D014591,,
770960615,false,true,5,2015-08-14T23:16:00,,No Relation,0.8015,D006513,HBeAg/hepatitis B e antigen,D006509,HBV infection/hepatitis B,"HBV markers, including hepatitis B surface antigen (HBsAg) and antibody (anti-HBs), anti-HBc, hepatitis B e antigen (HBeAg) and antibody (anti-HBe) were determined in both donors and recipients before LT and in recipients after LT. HBV DNA titer was measured if the recipients were strongly suspected of de novo HBV infection.",23638710_3,23638710_D006513_D006509,,
770960616,false,true,5,2015-08-14T22:51:00,No proper highlighting for the chemical(s).,No Relation,0.7965,D006514,hepatitis B surface antigen,D006509,HBV infection/hepatitis B,"HBV markers, including hepatitis B surface antigen (HBsAg) and antibody (anti-HBs), anti-HBc, hepatitis B e antigen (HBeAg) and antibody (anti-HBe) were determined in both donors and recipients before LT and in recipients after LT. HBV DNA titer was measured if the recipients were strongly suspected of de novo HBV infection.",23638710_3,23638710_D006514_D006509,,
770960617,false,true,5,2015-08-15T00:15:00,,No Relation,1,D019259,lamivudine,D006509,HBV-infected,"Two de novo HBV-infected patients who had YMDD mutation were given adefovir combined with lamivudine, and their liver function gradually improved during the follow-up period.",23638710_7,23638710_D019259_D006509,,
770960618,false,true,5,2015-08-14T23:03:00,,No Relation,1,C053001,adefovir,D006509,HBV-infected,"Two de novo HBV-infected patients who had YMDD mutation were given adefovir combined with lamivudine, and their liver function gradually improved during the follow-up period.",23638710_7,23638710_C053001_D006509,,
770960619,false,true,5,2015-08-14T23:13:00,,No Relation,1,D019259,lamivudine,D006509,HBV infection,Administration with adefovir in patients who are resistant to lamivudine seems to be an effective and safe way for de novo HBV infection.,23638710_9,23638710_D019259_D006509,,
770960620,false,true,5,2015-08-14T22:36:00,,No Relation,0.8061,C053001,adefovir,D006509,HBV infection,Administration with adefovir in patients who are resistant to lamivudine seems to be an effective and safe way for de novo HBV infection.,23638710_9,23638710_C053001_D006509,,
770960621,false,true,5,2015-08-14T23:15:00,,Direct,0.8064,D008094,lithium,D064420,toxicity,"In this research, we used standardized leaching tests, life-cycle impact assessment (LCIA), and hazard assessment models to evaluate hazardous waste classification, resource depletion potential, and toxicity potentials of lithium batteries used in cellphones.",23638841_3,23638841_D008094_D064420,,
770960622,false,true,5,2015-08-15T02:29:00,,No Relation,1,D009532,nickel,D004670,California regulations,"However, according to California regulations, all lithium batteries tested are classified hazardous due to excessive levels of cobalt (average 163,544 mg/kg;  = 62,897; limit 8000), copper (average 98,694 mg/kg;  = 28,734; limit 2500), and nickel (average 9525 mg/kg;  = 11,438; limit 2000).",23638841_5,23638841_D009532_D004670,,
770960623,false,true,5,2015-08-15T00:20:00,,No Relation,1,D003300,copper,D004670,California regulations,"However, according to California regulations, all lithium batteries tested are classified hazardous due to excessive levels of cobalt (average 163,544 mg/kg;  = 62,897; limit 8000), copper (average 98,694 mg/kg;  = 28,734; limit 2500), and nickel (average 9525 mg/kg;  = 11,438; limit 2000).",23638841_5,23638841_D003300_D004670,,
770960624,false,true,5,2015-08-15T01:01:00,,No Relation,0.8301,D003035,cobalt,D004670,California regulations,"However, according to California regulations, all lithium batteries tested are classified hazardous due to excessive levels of cobalt (average 163,544 mg/kg;  = 62,897; limit 8000), copper (average 98,694 mg/kg;  = 28,734; limit 2500), and nickel (average 9525 mg/kg;  = 11,438; limit 2000).",23638841_5,23638841_D003035_D004670,,
770960625,false,true,5,2015-08-15T00:22:00,,No Relation,1,D008094,lithium,D004670,California regulations,"However, according to California regulations, all lithium batteries tested are classified hazardous due to excessive levels of cobalt (average 163,544 mg/kg;  = 62,897; limit 8000), copper (average 98,694 mg/kg;  = 28,734; limit 2500), and nickel (average 9525 mg/kg;  = 11,438; limit 2000).",23638841_5,23638841_D008094_D004670,,
770960626,false,true,5,2015-08-14T23:06:00,,Direct,1,D003035,cobalt,D064420,toxicity,"The environmental impact associated with resource depletion and human toxicity is mainly associated with cobalt, copper, nickel, thallium, and silver, whereas the ecotoxicity potential is primarily associated with cobalt, copper, nickel, thallium, and silver.",23638841_7,23638841_D003035_D064420,,
770960627,false,true,5,2015-08-15T00:46:00,,Direct,0.806,D012834,silver,D064420,toxicity,"The environmental impact associated with resource depletion and human toxicity is mainly associated with cobalt, copper, nickel, thallium, and silver, whereas the ecotoxicity potential is primarily associated with cobalt, copper, nickel, thallium, and silver.",23638841_7,23638841_D012834_D064420,,
770960628,false,true,5,2015-08-15T00:08:00,Nickel is not a chemical.,Direct,0.8045,D009532,nickel,D064420,toxicity,"The environmental impact associated with resource depletion and human toxicity is mainly associated with cobalt, copper, nickel, thallium, and silver, whereas the ecotoxicity potential is primarily associated with cobalt, copper, nickel, thallium, and silver.",23638841_7,23638841_D009532_D064420,,
770960629,false,true,5,2015-08-14T22:36:00,,Direct,0.788,D003300,copper,D064420,toxicity,"The environmental impact associated with resource depletion and human toxicity is mainly associated with cobalt, copper, nickel, thallium, and silver, whereas the ecotoxicity potential is primarily associated with cobalt, copper, nickel, thallium, and silver.",23638841_7,23638841_D003300_D064420,,
770960630,false,true,5,2015-08-15T00:48:00,,Direct,0.8019,D013793,thallium,D064420,toxicity,"The environmental impact associated with resource depletion and human toxicity is mainly associated with cobalt, copper, nickel, thallium, and silver, whereas the ecotoxicity potential is primarily associated with cobalt, copper, nickel, thallium, and silver.",23638841_7,23638841_D013793_D064420,,
770960631,false,true,5,2015-08-14T22:43:00,,No Relation,0.6184,D000535,aluminum,D064420,toxicity,"However, the relative contribution of aluminum and lithium to human toxicity and ecotoxicity could not be estimated due to insufficient toxicity data in the models.",23638841_8,23638841_D000535_D064420,,
770960632,false,true,5,2015-08-14T22:43:00,,Direct,0.6213,D008094,lithium,D064420,toxicity,"However, the relative contribution of aluminum and lithium to human toxicity and ecotoxicity could not be estimated due to insufficient toxicity data in the models.",23638841_8,23638841_D008094_D064420,,
770960633,false,true,5,2015-08-14T22:51:00,,No Relation,1,D002248,Co,D008545,melanoma,Co-injection of melanoma cells with 12(S)-HETE increased the lung homing activity of B16F10 melanoma cells.,23664097_5,23664097_D002248_D008545,,
770960634,false,true,5,2015-08-14T23:37:00,,Direct,0.5868,D019377,12(S)-HETE,D008545,melanoma,Co-injection of melanoma cells with 12(S)-HETE increased the lung homing activity of B16F10 melanoma cells.,23664097_5,23664097_D019377_D008545,,
770960635,false,true,5,2015-08-15T00:36:00,,Direct,0.5809,D019377,12(S)-HETE,D000267,adhesion,In vitro studies showed that 12(S)-HETE and 15(S)-HETE treatment resulted in a concentration-dependent increase of adhesion of B16F10 cells on collagen or fibronectin.,23664097_6,23664097_D019377_D000267,,
770960636,false,true,5,2015-08-14T22:41:00,,No Relation,0.3976,D019377,12(S)-HETE,D008545,melanoma,Treatment of 12(S)-HETE increased the pFAK in melanoma cells adhering on collagen-coated slide.,23664097_9,23664097_D019377_D008545,,
770960637,false,true,5,2015-08-14T22:31:00,There's literally no disease in this sentence. :-),No Relation,0.8007,D019377,12(S)-HETE,D000267,adhesion,The enhancement of adherence elicited by 12(S)-HETE in B16F10 cells could be antagonised by focal adhesion kinase (FAK) inhibitor 14 (FAK inhibitor) or PD98059 (extracellular signal-regulated kinase (ERK) inhibitor).,23664097_10,23664097_D019377_D000267,,
770960638,false,true,5,2015-08-14T23:02:00,,No Relation,0.7958,C093973,PD98059,D000267,adhesion,The enhancement of adherence elicited by 12(S)-HETE in B16F10 cells could be antagonised by focal adhesion kinase (FAK) inhibitor 14 (FAK inhibitor) or PD98059 (extracellular signal-regulated kinase (ERK) inhibitor).,23664097_10,23664097_C093973_D000267,,
770960639,false,true,5,2015-08-14T22:42:00,,No Relation,0.5848,D019377,12(S)-HETE,D008545,melanoma,12(S)-HETE increased the phosphorylation of FAK and ERK in adhering melanoma cells.,23664097_11,23664097_D019377_D008545,,
770960640,false,true,5,2015-08-15T01:03:00,,Direct,0.6133,D019377,12(S)-HETE,D008545,melanoma,The adhesion and lung metastasis of human melanoma cells of C32 in NOD/SCID mice were also potentiated by co-treatment with 12(S)-HETE.,23664097_13,23664097_D019377_D008545,,
770960641,false,true,5,2015-08-15T00:45:00,,No Relation,0.588,D019377,12(S)-HETE,D000267,adhesion,The adhesion and lung metastasis of human melanoma cells of C32 in NOD/SCID mice were also potentiated by co-treatment with 12(S)-HETE.,23664097_13,23664097_D019377_D000267,,
770960642,false,true,5,2015-08-14T22:43:00,,Direct,0.6074,D019377,12(S)-HETE,D053632,SCID,The adhesion and lung metastasis of human melanoma cells of C32 in NOD/SCID mice were also potentiated by co-treatment with 12(S)-HETE.,23664097_13,23664097_D019377_D053632,,
770960643,false,true,5,2015-08-14T22:47:00,,Direct,0.6206,D019377,12(S)-HETE,D009362,metastasis,The adhesion and lung metastasis of human melanoma cells of C32 in NOD/SCID mice were also potentiated by co-treatment with 12(S)-HETE.,23664097_13,23664097_D019377_D009362,,
770960644,false,true,5,2015-08-14T23:26:00,,Direct,0.6452,D019377,12(S)-HETE,D008545,melanoma,"These results demonstrate that 12(S)-HETE/15(S)-HETE activates ERK and FAK signalling pathways, thereby upregulates the adhesion and metastatic potential of melanoma cells.",23664097_14,23664097_D019377_D008545,,
770960645,false,true,5,2015-08-15T02:13:00,,Direct,0.4048,D019377,12(S)-HETE,D000267,adhesion,"These results demonstrate that 12(S)-HETE/15(S)-HETE activates ERK and FAK signalling pathways, thereby upregulates the adhesion and metastatic potential of melanoma cells.",23664097_14,23664097_D019377_D000267,,
770960646,false,true,5,2015-08-15T00:58:00,,Direct,0.6079,D019377,12(S)-HETE,D008545,melanoma,The endogenous release of 12(S)-HETE/15(S)-HETE in the host organ may affect the metastatic potential of melanoma.,23664097_15,23664097_D019377_D008545,,
770960647,false,true,5,2015-08-15T01:16:00,,No Relation,0.8064,D000622,aminolevulinic acid/ALA,D009456,von Recklinghausen disease,We present the case of a 54-year-old male patient with von Recklinghausen disease who had a diffuse contrast-enhancing cerebellar mass that was resected guided by aminolevulinic acid (ALA)-fluorescence.,23670807_5,23670807_D000622_D009456,,
770960648,false,true,5,2015-08-14T22:57:00,,No Relation,1,C047246,temozolomide,D009369,tumor,"Due to the proximity of the tumor to the brainstem, adjuvant temozolomide chemotherapy was administered rather than first-line radiotherapy.",23670807_7,23670807_C047246_D009369,,
770960649,false,true,5,2015-08-14T22:55:00,,No Relation,1,C047246,temozolomide,D009369,Tumor,"Tumor control after resection was achieved in both patients; however, the patient in the mentioned report received radiation instead of temozolomide.",23670807_12,23670807_C047246_D009369,,
770960650,false,true,5,2015-08-15T02:10:00,,No Relation,0.7974,D008140,Lorazepam,D002389,catatonia,Lorazepam achieved full resolution of catatonia in 50% of patients.,23684045_9,23684045_D008140_D002389,,
770960651,false,true,5,2015-08-15T00:26:00,,No Relation,1,D017374,paroxetine,D011537,pruritus,"Therefore, identifying the underlying cause of pruritus is of prime importance in order to develop tailored treatment plans, even if in palliative care the treatment is focused towards the symptom and not necessarily the underlying disease.Results show that in palliative care patients with pruritus of different natures, treatment with the drug paroxetine, a selective serotonin reuptake inhibitor, may be beneficial.",23749733_20,23749733_D017374_D011537,,
770960652,false,true,5,2015-08-15T00:26:00,,No Relation,1,D012701,serotonin,D011537,pruritus,"Therefore, identifying the underlying cause of pruritus is of prime importance in order to develop tailored treatment plans, even if in palliative care the treatment is focused towards the symptom and not necessarily the underlying disease.Results show that in palliative care patients with pruritus of different natures, treatment with the drug paroxetine, a selective serotonin reuptake inhibitor, may be beneficial.",23749733_20,23749733_D012701_D011537,,
770960653,false,true,5,2015-08-15T01:49:00,,No Relation,1,D007213,indomethacin,D011537,pruritus,"For patients suffering from pruritus associated with HIV infection, indomethacin was described as the most effective drug, although the evidence was weak.",23749733_21,23749733_D007213_D011537,,
770960654,false,true,5,2015-08-14T22:36:00,,No Relation,1,D007213,indomethacin,D015658,HIV infection,"For patients suffering from pruritus associated with HIV infection, indomethacin was described as the most effective drug, although the evidence was weak.",23749733_21,23749733_D007213_D015658,,
770960655,false,true,5,2015-08-14T23:43:00,,No Relation,1,C040029,gabapentin,D011537,pruritus,"For patients suffering from chronic kidney disease-associated pruritus, gabapentin may be an option.",23749733_22,23749733_C040029_D011537,,
770960656,false,true,5,2015-08-15T01:49:00,,No Relation,1,C040029,gabapentin,D051436,chronic kidney disease,"For patients suffering from chronic kidney disease-associated pruritus, gabapentin may be an option.",23749733_22,23749733_C040029_D051436,,
770960657,false,true,5,2015-08-14T22:43:00,,No Relation,1,D012293,rifampicin,D011537,pruritus,"As they have exhibited a low incidence of adverse effects, rifampicin and flumecinolmay be recommended for patients with cholestatic pruritus.",23749733_24,23749733_D012293_D011537,,
770960658,false,true,5,2015-08-14T23:50:00,,No Relation,1,C016914,flumecinol,D011537,pruritus,"As they have exhibited a low incidence of adverse effects, rifampicin and flumecinolmay be recommended for patients with cholestatic pruritus.",23749733_24,23749733_C016914_D011537,,
770960659,false,true,5,2015-08-14T22:35:00,,No Relation,1,D009271,naltrexone,D011537,pruritus,The opioid antagonist naltrexone has been shown to offer a therapeutic alternative for patients suffering from uraemic or cholestatic pruritus.,23749733_25,23749733_D009271_D011537,,
770960660,false,true,5,2015-08-14T22:29:00,,Direct,0.8109,D002244,carbon,D064420,toxicity,Understanding the toxicity of carbon nanotubes in the environment is crucial to the control of nanomaterials in producing and processing and the assessment of health risk for human: a review.,23770455_0,23770455_D002244_D064420,,
770960661,false,true,5,2015-08-15T01:03:00,,No Relation,1,D005045,etomidate,D003866,depressed,A retrospective comparison of the effects of propofol and etomidate on stimulus variables and efficacy of electroconvulsive therapy in depressed inpatients.,23774194_0,23774194_D005045_D003866,,
770960662,false,true,5,2015-08-15T01:16:00,,No Relation,1,D015742,propofol,D003866,depressed,A retrospective comparison of the effects of propofol and etomidate on stimulus variables and efficacy of electroconvulsive therapy in depressed inpatients.,23774194_0,23774194_D015742_D003866,,
770960663,false,true,5,2015-08-14T22:43:00,,No Relation,1,D005045,etomidate,D003866,depressed,To compare the effects of propofol and etomidate on the stimulus variables and efficacy of electroconvulsive therapy (ECT) in depressed inpatients.,23774194_1,23774194_D005045_D003866,,
770960664,false,true,5,2015-08-14T22:42:00,Used as treatment.,No Relation,1,D015742,propofol,D003866,depressed,To compare the effects of propofol and etomidate on the stimulus variables and efficacy of electroconvulsive therapy (ECT) in depressed inpatients.,23774194_1,23774194_D015742_D003866,,
770960665,false,true,5,2015-08-14T22:42:00,,No Relation,0.7989,D005045,etomidate,D012640,seizures/seizure,"The propofol group had shorter mean electroencephalogram (etomidate = 69.41  22.50, propofol = 42.95  22.26, p<0.001) seizure duration and motor (etomidate = 46.11  14.38, propofol = 22.89  7.13, p<0.001) seizure duration and a higher mean number of inadequate seizures (etomidate = 0.12  0.15, propofol = 0.47  0.26, p<0.001).",23774194_6,23774194_D005045_D012640,,
770960666,false,true,5,2015-08-15T01:12:00,,No Relation,0.7867,D015742,propofol,D012640,seizures/seizure,"The propofol group had shorter mean electroencephalogram (etomidate = 69.41  22.50, propofol = 42.95  22.26, p<0.001) seizure duration and motor (etomidate = 46.11  14.38, propofol = 22.89  7.13, p<0.001) seizure duration and a higher mean number of inadequate seizures (etomidate = 0.12  0.15, propofol = 0.47  0.26, p<0.001).",23774194_6,23774194_D015742_D012640,,
770960667,false,true,5,2015-08-15T00:31:00,,No Relation,1,D015742,propofol,D012640,seizures/seizure,"Anesthesia with propofol has a significant reducing effect on seizure duration during the course of ECT which results in more inadequate seizures, despite the use of a higher mean stimulus charge.",23774194_9,23774194_D015742_D012640,,
770960668,false,true,5,2015-08-14T22:54:00,,No Relation,1,D010100,oxygen,D014652,vascular diseases,Accumulating evidence has demonstrated that EPCs have therapeutic potential in reactive oxygen species (ROS)-mediated vascular diseases.,23778534_2,23778534_D010100_D014652,,
770960669,false,true,5,2015-08-15T01:14:00,,No Relation,0.8023,D006861,H2O2,D014085,migration,"In this study, to investigate the effects of oxidative stress on EPCs, EPCs were treated with H2O2 at different final concentrations for 3 h. MTT assay, scratch-wound assay and Matrigel invasion assay revealed that cell proliferation, migration and tubule formation and function, respectively, were impaired under H2O2 stress in a concentration-dependent manner.",23778534_3,23778534_D006861_D014085,,
770960670,false,true,5,2015-08-15T00:20:00,,No Relation,1,D002945,cisplatin,D008175,lung cancer,Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.,23783141_0,23783141_D002945_D008175,,
770960671,false,true,5,2015-08-15T01:45:00,,No Relation,1,D002945,Cisplatin,D055752,small cell lung cancers,"Cisplatin is widely used for the treatment of solid tumours including small cell lung cancers, but its success is often compromised by relapse and resistance to further treatment.",23783141_1,23783141_D002945_D055752,,
770960672,false,true,5,2015-08-15T00:19:00,,No Relation,1,D002945,cisplatin,D008175,lung cancer,"Although individually targeting the ERK1/2 or Akt pathway has been reported to sensitize cancer cells to therapy, the effect of concurrently blocking these two pathways on the sensitivity of lung cancer cells to cisplatin has not been investigated.",23783141_4,23783141_D002945_D008175,,
770960673,false,true,5,2015-08-14T22:37:00,,No Relation,1,D002945,cisplatin,D009369,cancer,"Although individually targeting the ERK1/2 or Akt pathway has been reported to sensitize cancer cells to therapy, the effect of concurrently blocking these two pathways on the sensitivity of lung cancer cells to cisplatin has not been investigated.",23783141_4,23783141_D002945_D009369,,
770960674,false,true,5,2015-08-15T00:16:00,,No Relation,1,D002945,cisplatin,D055752,small cell lung cancer,"In the present study, we aimed to determine whether the ERK1/2 and Akt pathways contribute to cisplatin resistance in human small cell lung cancer A549 cells.",23783141_5,23783141_D002945_D055752,,
770960675,false,true,5,2015-08-15T00:48:00,,No Relation,0.61,D002945,cisplatin,D004487,cytotoxicity,"Strikingly, concurrent inhibition of p-ERK1/2 and p-Akt significantly potentiated cisplatin cytotoxicity in vitro and in vivo.",23783141_8,23783141_D002945_D004487,,
770960676,false,true,5,2015-08-15T00:05:00,,Direct,0.606,D002945,cisplatin,D004487,cytotoxicity,"The sensitization of A549 cells to cisplatin cytotoxicity induced by p-Akt inhibition was mediated by the upregulation of PUMA, whereas that induced by p-ERK1/2 inhibition occurred by Bcl-2 downregulation.",23783141_9,23783141_D002945_D004487,,
770960677,false,true,5,2015-08-15T02:03:00,,No Relation,0.5686,D002945,cisplatin,D004487,cytotoxicity,"These data indicate that the cooperative effects of p-ERK1/2 and p-Akt on attenuating cisplatin cytotoxicity are mediated by PUMA and Bcl-2 regulation, and concurrently blocking these pathways may be an effective strategy for improving the efficacy of cisplatin as anticancer treatment.",23783141_10,23783141_D002945_D004487,,
770960678,false,true,5,2015-08-14T23:11:00,,No Relation,1,C067311,docetaxel,D009369,breast cancer,Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.,23809513_0,23809513_C067311_D009369,,
770960679,false,true,5,2015-08-15T00:57:00,,No Relation,1,D019788,fluorine-18 fluorodeoxyglucose,D009369,breast cancer,To prospectively study the value of PET-CT with fluorine-18 fluorodeoxyglucose (FDG) to predict neoadjuvant chemotherapy (NAC) response of locoregional disease of stages II and III breast cancer patients.,23809513_1,23809513_D019788_D009369,,
770960680,false,true,5,2015-08-14T23:51:00,,No Relation,1,C453980,sugammadex,D006261,headache,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C453980_D006261,,
770960681,false,true,5,2015-08-15T01:00:00,,No Relation,1,C453980,sugammadex,D063806,myalgia,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C453980_D063806,,
770960682,false,true,5,2015-08-14T22:31:00,,No Relation,1,C061870,rocuronium,D063806,myalgia,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C061870_D063806,,
770960683,false,true,5,2015-08-14T22:38:00,,No Relation,1,C061870,rocuronium,D006261,headache,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C061870_D006261,,
770960684,false,true,5,2015-08-15T00:18:00,,No Relation,1,C061870,rocuronium,D003865,major depression,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C061870_D003865,,
770960685,false,true,5,2015-08-15T00:03:00,,No Relation,1,C453980,sugammadex,D003865,major depression,Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?,23812022_0,23812022_C453980_D003865,,
770960686,false,true,5,2015-08-14T23:02:00,,No Relation,0.6147,C453980,sugammadex,D006261,headache,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_C453980_D006261,,
770960687,false,true,5,2015-08-15T01:39:00,,No Relation,0.595,C453980,sugammadex,D063806,myalgia,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_C453980_D063806,,
770960688,false,true,5,2015-08-14T22:56:00,,No Relation,1,C061870,rocuronium,D063806,myalgia,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_C061870_D063806,,
770960689,false,true,5,2015-08-15T01:20:00,,No Relation,0.8117,C061870,rocuronium,D006261,headache,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_C061870_D006261,,
770960690,false,true,5,2015-08-15T00:58:00,,No Relation,0.8017,D013390,succinylcholine,D006261,headache,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_D013390_D006261,,
770960691,false,true,5,2015-08-15T01:14:00,,No Relation,1,D013390,succinylcholine,D063806,myalgia,We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).,23812022_1,23812022_D013390_D063806,,
770960692,false,true,5,2015-08-15T01:15:00,,No Relation,1,C453980,Sugammadex,D012640,seizure,Sugammadex 4 mg/kg IV was administered to group R after the motor seizure.,23812022_4,23812022_C453980_D012640,,
770960693,false,true,5,2015-08-15T01:16:00,,No Relation,1,C471405,sorafenib,D009369,breast cancer,A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.,23812905_0,23812905_C471405_D009369,,
770960694,false,true,5,2015-08-15T01:31:00,,No Relation,1,C471405,sorafenib,D009369,breast cancer,We evaluated the efficacy and safety of dual angiogenesis blockade with bevacizumab and sorafenib in patients with metastatic breast cancer.,23812905_2,23812905_C471405_D009369,,
770960695,false,true,5,2015-08-15T00:43:00,,No Relation,0.8062,C471405,sorafenib,D009369,breast cancer,The combination of sorafenib and bevacizumab has substantial toxicity and minimal efficacy in patients with previously treated metastatic breast cancer.,23812905_13,23812905_C471405_D009369,,
770960696,false,true,5,2015-08-14T22:49:00,,Direct,0.6274,C471405,sorafenib,D064420,toxicity,The combination of sorafenib and bevacizumab has substantial toxicity and minimal efficacy in patients with previously treated metastatic breast cancer.,23812905_13,23812905_C471405_D064420,,
770960697,false,true,5,2015-08-15T00:11:00,,No Relation,1,C080625,Taxane,D006258,head and neck cancers/head and neck cancer,Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.,23835714_0,23835714_C080625_D006258,,
770960698,false,true,5,2015-08-14T23:37:00,Used as treatment.,No Relation,1,C067311,docetaxel,D006258,head and neck cancers,"PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregionally advanced head and neck cancers (LAHNCs).",23835714_1,23835714_C067311_D006258,,
770960699,false,true,5,2015-08-14T23:20:00,,No Relation,1,D002945,Cisplatin,D006258,head and neck cancers,"PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregionally advanced head and neck cancers (LAHNCs).",23835714_1,23835714_D002945_D006258,,
770960700,false,true,5,2015-08-14T23:31:00,,No Relation,1,D005472,fluorouracil,D006258,head and neck cancers,"PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregionally advanced head and neck cancers (LAHNCs).",23835714_1,23835714_D005472_D006258,,
770960701,false,true,5,2015-08-14T22:53:00,,No Relation,1,C080625,taxane,D006258,head and neck cancers,"PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregionally advanced head and neck cancers (LAHNCs).",23835714_1,23835714_C080625_D006258,,
770960702,false,true,5,2015-08-15T00:25:00,,No Relation,1,D017239,paclitaxel,D006258,head and neck cancers,"PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregionally advanced head and neck cancers (LAHNCs).",23835714_1,23835714_D017239_D006258,,
770960703,false,true,5,2015-08-15T00:50:00,,No Relation,1,D014443,tyrosine,D018365,MRD,Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.,23836561_0,23836561_D014443_D018365,,
770960704,false,true,5,2015-08-15T01:56:00,,No Relation,1,D014443,tyrosine,D010677,Philadelphia,Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.,23836561_0,23836561_D014443_D010677,,
770960705,false,true,5,2015-08-15T01:34:00,,No Relation,1,D014443,tyrosine,D054198,ALL,Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.,23836561_0,23836561_D014443_D054198,,
770960706,false,true,5,2015-08-15T01:47:00,,No Relation,0.8237,C097613,imatinib,D010677,Philadelphia,"From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68).",23836561_1,23836561_C097613_D010677,,
770960707,false,true,5,2015-08-15T01:52:00,,No Relation,1,C488369,dasatinib,D054198,acute lymphoblastic leukemia,"From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68).",23836561_1,23836561_C488369_D054198,,
770960708,false,true,5,2015-08-14T23:17:00,,No Relation,1,C097613,imatinib,D054198,acute lymphoblastic leukemia,"From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68).",23836561_1,23836561_C097613_D054198,,
770960709,false,true,5,2015-08-15T01:18:00,,No Relation,0.791,C488369,dasatinib,D010677,Philadelphia,"From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68).",23836561_1,23836561_C488369_D010677,,
770960710,false,true,5,2015-08-15T00:13:00,,No Relation,1,D001599,Berberine,D009369,Cancer Cell Growth,"Berberine Targets AP-2/hTERT, NF-B/COX-2, HIF-1/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.",23869238_0,23869238_D001599_D009369,,
770960711,false,true,5,2015-08-15T00:02:00,,No Relation,1,D001599,Berberine,D009369,cancers,"Berberine (BBR), an isoquinoline derivative alkaloid isolated from Chinese herbs, has a long history of uses for the treatment of multiple diseases, including cancers.",23869238_1,23869238_D001599_D009369,,
770960712,false,true,5,2015-08-14T22:51:00,,No Relation,1,C039109,isoquinoline,D000015,multiple diseases,"Berberine (BBR), an isoquinoline derivative alkaloid isolated from Chinese herbs, has a long history of uses for the treatment of multiple diseases, including cancers.",23869238_1,23869238_C039109_D000015,,
770960713,false,true,5,2015-08-15T02:30:00,,No Relation,0.8255,D001599,Berberine,D000015,multiple diseases,"Berberine (BBR), an isoquinoline derivative alkaloid isolated from Chinese herbs, has a long history of uses for the treatment of multiple diseases, including cancers.",23869238_1,23869238_D001599_D000015,,
770960714,false,true,5,2015-08-15T00:47:00,,No Relation,1,C039109,isoquinoline,D009369,cancers,"Berberine (BBR), an isoquinoline derivative alkaloid isolated from Chinese herbs, has a long history of uses for the treatment of multiple diseases, including cancers.",23869238_1,23869238_C039109_D009369,,
770960715,false,true,5,2015-08-15T00:30:00,,No Relation,1,C000499,iron oxide,D009369,cancer,"In particular, the advancements of polymeric nanomaterials in the past decades have paved the way for the development of cancer nanotheranostics that are primarily comprised of polymers or conjugates of polymer and other types of nanomaterials such as gold nanoparticles, quantum dots, carbon nanotubes, and magnetic iron oxide nanoparticles.",23869810_4,23869810_C000499_D009369,,
770960716,false,true,5,2015-08-14T22:34:00,,No Relation,0.7934,D002244,carbon,D009369,cancer,"In particular, the advancements of polymeric nanomaterials in the past decades have paved the way for the development of cancer nanotheranostics that are primarily comprised of polymers or conjugates of polymer and other types of nanomaterials such as gold nanoparticles, quantum dots, carbon nanotubes, and magnetic iron oxide nanoparticles.",23869810_4,23869810_D002244_D009369,,
770960717,false,true,5,2015-08-14T22:36:00,,No Relation,1,D005947,dextrose,D036981,plantar fasciitis,Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis.,23876935_0,23876935_D005947_D036981,,
770960718,false,true,5,2015-08-14T23:03:00,,No Relation,1,D005947,dextrose,D036981,PF/plantar fasciitis,"To determine the efficacy of autologous platelet-rich plasma (PRP) compared with dextrose prolotherapy (DP) in patients with chronic recalcitrant plantar fasciitis (PF) DESIGN: A single-blinded, randomized, controlled study.",23876935_1,23876935_D005947_D036981,,
770960719,false,true,5,2015-08-14T23:30:00,,No Relation,0.7935,D001241,aspirin,D010195,pancreatic disorders,Antiplatelet therapy with aspirin is prevalent among patients presenting for operative treatment of pancreatic disorders.,23890963_1,23890963_D001241_D010195,,
770960720,false,true,5,2015-08-14T22:49:00,,Direct,0.5943,D001241,aspirin,D006470,bleeding,Operative practice has called for the cessation of aspirin 7-10 days before elective procedures because of the perceived increased risk of procedure-related bleeding.,23890963_2,23890963_D001241_D006470,,
770960721,false,true,5,2015-08-15T02:05:00,,No Relation,0.8252,D001241,aspirin,D019106,blood loss,"The estimated intraoperative blood loss was similar between the two groups, aspirin versus no aspirin (median 400 mL vs 400 mL, P = .661), as was the rate of blood transfusion anytime during the index admission (29% vs 26%, P = 0.37) and the postoperative duration of hospital stay (median 7 days vs 6 days, P = .103).",23890963_8,23890963_D001241_D019106,,
770960722,false,true,5,2015-08-15T01:45:00,,Direct,0.8025,D001241,aspirin,D002318,cardiovascular complications,"The aspirin group had a slightly increased rate of cardiovascular complications (10.1% vs 7.0%, P=.107), likely reflecting their increased cardiovascular comorbidities that led to their physicians recommending aspirin therapy.",23890963_9,23890963_D001241_D002318,,
770960723,false,true,5,2015-08-14T22:36:00,,No Relation,1,D001241,aspirin,D006470,bleeding,"This is the first study to report that aspirin therapy is not associated with increased rates of perioperative bleeding, transfusion requirement, or major procedure related complications after elective pancreatic surgery.",23890963_11,23890963_D001241_D006470,,
770960724,false,true,5,2015-08-15T01:15:00,,No Relation,1,D012254,ribavirin,D019698,chronic hepatitis C,Liver histology of chronic hepatitis C patients who relapsed or not responded to conventional interferon and ribavirin therapy.,23894901_0,23894901_D012254_D019698,,
770960725,false,true,5,2015-08-15T01:53:00,,No Relation,1,D012254,ribavirin,D006526,hepatitis C,The study had 109 hepatitis C patients who had relapsed or not responded to the conventional interferon and ribavirin for at least 24 weeks.,23894901_3,23894901_D012254_D006526,,
770960726,false,true,5,2015-08-14T23:23:00,,No Relation,1,D012254,ribavirin,D005355,fibrosis,"Results suggested that even if it failed to eradicate hepatitis C virus, the conventional interferon and ribavirin therapy was able to halt the progress of necroinflammation and fibrosis.",23894901_13,23894901_D012254_D005355,,
770960727,false,true,5,2015-08-14T22:39:00,,No Relation,1,D012254,ribavirin,D006526,hepatitis C virus,"Results suggested that even if it failed to eradicate hepatitis C virus, the conventional interferon and ribavirin therapy was able to halt the progress of necroinflammation and fibrosis.",23894901_13,23894901_D012254_D006526,,
770960728,false,true,5,2015-08-15T01:02:00,,No Relation,0.6045,D011084,polycyclic aromatic hydrocarbons,D064420,toxicity,Bioaccessibility of polycyclic aromatic hydrocarbons: relevance to toxicity and carcinogenesis.,23898780_0,23898780_D011084_D064420,,
770960729,false,true,5,2015-08-14T23:22:00,,No Relation,0.593,D011084,polycyclic aromatic hydrocarbons,D063646,carcinogenesis,Bioaccessibility of polycyclic aromatic hydrocarbons: relevance to toxicity and carcinogenesis.,23898780_0,23898780_D011084_D063646,,
770960730,false,true,5,2015-08-14T23:21:00,,Direct,0.7912,D011084,PAHs,D009369,cancer,"As polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants, they are the toxicants of focus to establish cancer risks in humans.",23898780_2,23898780_D011084_D009369,,
770960731,false,true,5,2015-08-14T22:49:00,,Direct,1,D011084,PAHs,D064420,toxicity,Orally ingested PAHs also cause toxicity and even affect the pharmacokinetic behavior of some therapeutic agents.,23898780_3,23898780_D011084_D064420,,
770960732,false,true,5,2015-08-15T00:47:00,,No Relation,1,D010130,PAH,D010661,PAH,This review also considers the factors that influence bioaccessibility and debates the merits and limitations of using a bioaccessibility concept for estimating risk from ingestion of PAH-contaminated soil and food.,23898780_6,23898780_D010130_D010661,,
770960733,false,true,5,2015-08-15T00:31:00,,Direct,0.8125,D010130,PAH,D064420,toxicity,"Finally, the authors discuss the implications of bioaccessibility for PAH-induced toxicity and cancers in the context of risk assessment.",23898780_7,23898780_D010130_D064420,,
770960734,false,true,5,2015-08-14T23:50:00,,Direct,0.5988,D010130,PAH,D009369,cancers,"Finally, the authors discuss the implications of bioaccessibility for PAH-induced toxicity and cancers in the context of risk assessment.",23898780_7,23898780_D010130_D009369,,
770960735,false,true,5,2015-08-14T23:46:00,,No Relation,1,D010130,PAH,D010661,PAH,"Finally, the authors discuss the implications of bioaccessibility for PAH-induced toxicity and cancers in the context of risk assessment.",23898780_7,23898780_D010130_D010661,,
770960736,false,true,5,2015-08-14T23:05:00,No proper highlighting for the chemical.,No Relation,1,D010130,PAH,D010661,PAH,"So far, much of the focus on PAH bioaccessibility is centered on soil as a preferential matrix.",23898780_8,23898780_D010130_D010661,,
770960737,false,true,5,2015-08-14T23:35:00,,No Relation,1,D013748,tetracaine,D004427,ear infection,The use of extemporaneously compounded 1% tetracaine to improve adherence with clotrimazole 1% topical solution in the treatment of ear infection: a case report.,23932769_0,23932769_D013748_D004427,,
770960738,false,true,5,2015-08-14T22:38:00,,No Relation,1,D003022,clotrimazole,D004427,ear infection,The use of extemporaneously compounded 1% tetracaine to improve adherence with clotrimazole 1% topical solution in the treatment of ear infection: a case report.,23932769_0,23932769_D003022_D004427,,
770960739,false,true,5,2015-08-15T00:51:00,,Direct,1,D003022,clotrimazole,D010146,pain,We report a case of non-adherence due to severe pain associated with the topical use of clotrimazole 1% solution in the ear.,23932769_3,23932769_D003022_D010146,,
770960740,false,true,5,2015-08-15T01:34:00,,No Relation,1,D013748,tetracaine,D010146,pain,Instillation of tetracaine 1% solution prior to the administration of the clotrimazole blocked the pain sensation allowing the patient to successfully complete the antifungal therapy.,23932769_4,23932769_D013748_D010146,,
770960741,false,true,5,2015-08-15T02:21:00,,No Relation,1,D003022,clotrimazole,D010146,pain,Instillation of tetracaine 1% solution prior to the administration of the clotrimazole blocked the pain sensation allowing the patient to successfully complete the antifungal therapy.,23932769_4,23932769_D003022_D010146,,
770960742,false,true,5,2015-08-15T00:20:00,,No Relation,1,D014025,titanium,D006547,hernia,Repair of symptomatic perineal hernia with a titanium mesh.,23934356_0,23934356_D014025_D006547,,
770960743,false,true,5,2015-08-14T23:45:00,,No Relation,1,D014025,titanium,D009437,perineal hernia repair,"Here, we describe the application of a titanium mesh for perineal hernia repair.",23934356_3,23934356_D014025_D009437,,
770960744,false,true,5,2015-08-14T22:54:00,,No Relation,1,D014025,titanium,D006547,hernia,We performed hernia repair with a thin titanium mesh via a perineal approach in three patients who developed secondary perineal hernia following abdominoperineal resection.,23934356_4,23934356_D014025_D006547,,
770960745,false,true,5,2015-08-14T22:30:00,,No Relation,1,D014025,titanium,D006547,hernia sac,"After the hernia sac was isolated and dissected, the titanium mesh was molded and placed over the ischium and coccyx to support the pelvic floor.",23934356_5,23934356_D014025_D006547,,
770960746,false,true,5,2015-08-14T22:44:00,,No Relation,1,D014025,titanium,D009437,perineal hernia repair,"Our successful preliminary results indicate that a titanium mesh is useful for perineal hernia repair by the perineal approach, as it can provide rigid support for the pelvic floor by its entire surface while ensuring stability without any fixation.",23934356_8,23934356_D014025_D009437,,
770960747,false,true,5,2015-08-14T22:33:00,,No Relation,0.5736,D000450,aldosterone,D006333,heart failure,"The heart is one important target tissue for damage due to excess aldosterone, and the role of natriuretic peptides is well recognized in diagnosing heart failure.",23943252_2,23943252_D000450_D006333,,
770960748,false,true,5,2015-08-14T23:03:00,,No Relation,1,D000450,aldosterone,D006929,PA,"We hypothesized that measuring the NT-proBNP could improve the diagnostic evaluation of PA. We enrolled 132 hypertensive patients, who underwent aldosterone to renin ratio (ARR) screening, and 81 underwent an intravenous saline loading test (ivSLT) because of a high ARR.",23943252_3,23943252_D000450_D006929,,
770960749,false,true,5,2015-08-15T01:34:00,,No Relation,1,D000450,aldosterone,D006973,hypertensive,"We hypothesized that measuring the NT-proBNP could improve the diagnostic evaluation of PA. We enrolled 132 hypertensive patients, who underwent aldosterone to renin ratio (ARR) screening, and 81 underwent an intravenous saline loading test (ivSLT) because of a high ARR.",23943252_3,23943252_D000450_D006973,,
770960750,false,true,5,2015-08-14T22:46:00,,No Relation,1,D003000,clonidine,D012852,sinusitis,A group of 44 patients undergoing FESS for chronic sinusitis and polyp removal were enrolled and randomly assigned to receive either oral clonidine or midazolam as preoperative premedication.,23943734_5,23943734_D003000_D012852,,
770960751,false,true,5,2015-08-14T22:50:00,,No Relation,1,D008874,midazolam,D012852,sinusitis,A group of 44 patients undergoing FESS for chronic sinusitis and polyp removal were enrolled and randomly assigned to receive either oral clonidine or midazolam as preoperative premedication.,23943734_5,23943734_D008874_D012852,,
770960752,false,true,5,2015-08-14T23:23:00,,No Relation,1,D002118,calcium,D015875,MDD,"All admixtures were within the specifications set by the USP with respect to the MDD at 0, 24, and 48 hours, but only those batches lacking calcium met the benchmarks set by the pharmacopoeia, with respect to PFAT5, on the day of preparation.",23976766_7,23976766_D002118_D015875,,
770960753,false,true,5,2015-08-15T00:13:00,,No Relation,1,C031327,artemisinin,D008288,malaria,"The malaria treatment recommended by the World Health Organization involves medicines derived from artemisinin, an active compound extracted from the plant Artemisia annua, and some of its derivatives, such as artesunate.",23979886_1,23979886_C031327_D008288,,
770960754,false,true,5,2015-08-15T02:23:00,,No Relation,1,C039726,artesunate,D008288,malaria,"The malaria treatment recommended by the World Health Organization involves medicines derived from artemisinin, an active compound extracted from the plant Artemisia annua, and some of its derivatives, such as artesunate.",23979886_1,23979886_C039726_D008288,,
770960755,false,true,5,2015-08-14T22:36:00,,No Relation,1,C031327,artemisinin,D004487,cytotoxicity,"Considering the lack of data regarding the genotoxic effects of these compounds in human cells, the objective of this study was to evaluate the cytotoxicity and genotoxicity, and expressions of the CASP3 and SOD1 genes in a cultured human hepatocellular liver carcinoma cell line (HepG2 cells) treated with artemisinin and artesunate.",23979886_2,23979886_C031327_D004487,,
770960756,false,true,5,2015-08-15T00:48:00,,No Relation,1,C039726,artesunate,D004487,cytotoxicity,"Considering the lack of data regarding the genotoxic effects of these compounds in human cells, the objective of this study was to evaluate the cytotoxicity and genotoxicity, and expressions of the CASP3 and SOD1 genes in a cultured human hepatocellular liver carcinoma cell line (HepG2 cells) treated with artemisinin and artesunate.",23979886_2,23979886_C039726_D004487,,
770960757,false,true,5,2015-08-15T01:15:00,,No Relation,1,C031327,artemisinin,D002277,carcinoma,"Considering the lack of data regarding the genotoxic effects of these compounds in human cells, the objective of this study was to evaluate the cytotoxicity and genotoxicity, and expressions of the CASP3 and SOD1 genes in a cultured human hepatocellular liver carcinoma cell line (HepG2 cells) treated with artemisinin and artesunate.",23979886_2,23979886_C031327_D002277,,
770960758,false,true,5,2015-08-14T22:49:00,,No Relation,1,C039726,artesunate,D002277,carcinoma,"Considering the lack of data regarding the genotoxic effects of these compounds in human cells, the objective of this study was to evaluate the cytotoxicity and genotoxicity, and expressions of the CASP3 and SOD1 genes in a cultured human hepatocellular liver carcinoma cell line (HepG2 cells) treated with artemisinin and artesunate.",23979886_2,23979886_C039726_D002277,,
770960759,false,true,5,2015-08-14T23:08:00,,No Relation,0.608,C005843,resazurin,D004487,cytotoxicity,"We tested concentrations of 2.5, 5, 7.5, 10, and 20 _g/mL of both substances with a resazurin cytotoxicity assay, and the concentrations used in the genotoxicity experiments (2.5, 5, and 10 _g/mL) and gene expression analysis (5 _g/mL) were determined.",23979886_3,23979886_C005843_D004487,,
770960760,false,true,5,2015-08-15T00:05:00,"Ambiguous, sir. Is B19 the same as curcumin? If so then curcumin causes ovarian cancer. Since it is only ""analogue"" I guess the answer is ""no"" or ""don't know.""",No Relation,0.6131,D003474,curcumin,D009369,ovarian cancer,"B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway.",23983610_0,23983610_D003474_D009369,,
770960761,false,true,5,2015-08-15T01:33:00,,No Relation,1,D003474,Curcumin,D009369,ovarian cancer/cancers,"Curcumin has been used to treat several different cancers, including ovarian cancer, in clinical trials and research; however, the role of ER stress and autophagy in the therapeutic effects of curcumin and new curcumin analogues remains unclear.",23983610_2,23983610_D003474_D009369,,
770960762,false,true,5,2015-08-15T00:58:00,,No Relation,0.817,C025946,3-methyladenine/3-MA,D009369,ovarian cancer,"The inhibition of autophagy using 3-methyladenine (3-MA) increased levels of intracellular misfolded proteins, which enhanced ovarian cancer apoptosis.",23983610_10,23983610_C025946_D009369,,
770960763,false,true,5,2015-08-15T00:32:00,,No Relation,0.7939,D003474,curcumin,D009369,ovarian cancer,Our data indicate that ER stress and autophagy may play a role in the apoptosis that is induced by the curcumin analogue B19 in an epithelial ovarian cancer cell line and that autophagy inhibition can increase curcumin analogue-induced apoptosis by inducing severe ER stress.,23983610_11,23983610_D003474_D009369,,
770960764,false,true,5,2015-08-14T22:31:00,,No Relation,1,C522181,apixaban,D006470,bleeding,"In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death.",24016507_1,24016507_C522181_D006470,,
770960765,false,true,5,2015-08-14T23:11:00,,No Relation,1,C522181,apixaban,D003643,death,"In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death.",24016507_1,24016507_C522181_D003643,,
770960766,false,true,5,2015-08-14T22:52:00,,No Relation,1,C522181,apixaban,D020521,stroke,"In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death.",24016507_1,24016507_C522181_D020521,,
770960767,false,true,5,2015-08-14T23:45:00,,No Relation,1,C486464,telaprevir,D006526,hepatitis C genotype 1 infected,The advent of first-generation direct antiviral agents such as boceprevir and telaprevir has changed the concept of treatment of adult chronic hepatitis C genotype 1 infected patients.,24038567_3,24038567_C486464_D006526,,
770960768,false,true,5,2015-08-15T00:34:00,,No Relation,1,D003520,cyclophosphamide,D014657,vasculitis,Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis.,24080801_1,24080801_D003520_D014657,,
770960769,false,true,5,2015-08-15T01:31:00,,No Relation,1,D001379,azathioprine,D014657,vasculitis,Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis.,24080801_1,24080801_D001379_D014657,,
770960770,false,true,5,2015-08-14T22:33:00,,Direct,0.5903,C400082,Bortezomib,D015470,AML,"Bortezomib exerted a dose-dependent increase in miR-29b expression in AML blasts ex vivo, followed by decreased Dnmts, reduced proliferation, and increased apoptosis.",24085765_4,24085765_C400082_D015470,,
770960771,false,true,5,2015-08-15T01:35:00,,No Relation,1,C400082,bortezomib,D015470,AML,"In vivo, bortezomib was not active against dKI AML, yet liposomal-encapsulated bortezomib, as a single agent, reversed downregulation of miR-29b in vivo and induced a long-term (90-day) disease-free remission in 80% of dKI AML mice that exhibited high leukemic burden at the start of therapy, yet showed no signs of relapse at autopsy.",24085765_5,24085765_C400082_D015470,,
770960772,false,true,5,2015-08-14T23:50:00,,No Relation,1,C400082,bortezomib,D009886,ITD,"Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(PTD/wt):Flt3(ITD/wt) AML in mouse and may represent a powerful and potentially curative approach to high-risk human disease.",24085765_6,24085765_C400082_D009886,,
770960773,false,true,5,2015-08-15T01:59:00,,No Relation,1,C400082,bortezomib,D015470,AML,"Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(PTD/wt):Flt3(ITD/wt) AML in mouse and may represent a powerful and potentially curative approach to high-risk human disease.",24085765_6,24085765_C400082_D015470,,
770960774,false,true,5,2015-08-14T22:42:00,WHAT!? I have to read about that. *Googles it* XD,Direct,1,D001241,aspirin,D014947,Unusual burn injury,Unusual burn injury due to application of white vinegar and aspirin mixture.,24102713_0,24102713_D001241_D014947,,
770960775,false,true,5,2015-08-14T22:57:00,,No Relation,1,D001241,aspirin,D010146,pain,"Here, we describe a patient who suffered from a split-thickness leg burn after applying a self-inflicted mixture consisting of white vinegar and aspirin prepared for knee pain.",24102713_2,24102713_D001241_D010146,,
770960776,false,true,5,2015-08-14T22:34:00,,No Relation,1,D000728,androgen,D003922,T1D,"At the beginning of puberty, the T1D group had higher levels of SHBG (p=0.003) and similar androgen levels than the Control group.",24118936_6,24118936_D000728_D003922,,
770960777,false,true,5,2015-08-14T22:52:00,,No Relation,1,D013739,testosterone,D003922,T1D,Higher HbA1c had a negative effect on total testosterone and cFT and a positive effect on SHBG levels in T1D boys.,24118936_11,24118936_D013739_D003922,,
770960778,false,true,5,2015-08-15T00:13:00,,No Relation,1,D013739,testosterone,D007006,hypogonadism,"Adolescents with T1D do not exhibit hypogonadism, as shown by normal gonadotropin, testosterone, inhibin B, and AMH levels.",24118936_12,24118936_D013739_D007006,,
770960779,false,true,5,2015-08-15T00:05:00,,No Relation,1,D013739,testosterone,D003922,T1D,"Adolescents with T1D do not exhibit hypogonadism, as shown by normal gonadotropin, testosterone, inhibin B, and AMH levels.",24118936_12,24118936_D013739_D003922,,
770960780,false,true,5,2015-08-15T00:20:00,,No Relation,0.8168,D013739,testosterone,D003922,T1D,"However, in T1D boys, HbA1c and BMI-SDS had a negative association with testosterone levels.",24118936_13,24118936_D013739_D003922,,
770960781,false,true,5,2015-08-14T23:54:00,,Direct,0.5727,C005692,triphosphate,D054537,atrioventricular block,Syncope associated with documented paroxysmal atrioventricular block reproduced by adenosine 5' triphosphate injection.,24128810_0,24128810_C005692_D054537,,
770960782,false,true,5,2015-08-14T23:02:00,,Direct,0.5861,C005692,triphosphate,D013575,Syncope,Syncope associated with documented paroxysmal atrioventricular block reproduced by adenosine 5' triphosphate injection.,24128810_0,24128810_C005692_D013575,,
770960783,false,true,5,2015-08-14T22:36:00,,Direct,0.5843,D000241,adenosine,D054537,atrioventricular block,Syncope associated with documented paroxysmal atrioventricular block reproduced by adenosine 5' triphosphate injection.,24128810_0,24128810_D000241_D054537,,
770960784,false,true,5,2015-08-14T22:34:00,,Indirect,0.6025,D000241,adenosine,D013575,Syncope,Syncope associated with documented paroxysmal atrioventricular block reproduced by adenosine 5' triphosphate injection.,24128810_0,24128810_D000241_D013575,,
770960785,false,true,5,2015-08-14T23:13:00,,No Relation,0.7839,D000255,ATP/adenosine triphosphate,D013575,syncope,We sought to investigate in patients with syncope the relationship between documented paroxysmal atrioventricular block (AVB) of unknown mechanism and AVB induced by adenosine triphosphate (ATP) injection.,24128810_1,24128810_D000255_D013575,,
770960786,false,true,5,2015-08-15T01:59:00,,Direct,0.8093,D000255,ATP/adenosine triphosphate,D054537,atrioventricular block/AVB,We sought to investigate in patients with syncope the relationship between documented paroxysmal atrioventricular block (AVB) of unknown mechanism and AVB induced by adenosine triphosphate (ATP) injection.,24128810_1,24128810_D000255_D054537,,
770960787,false,true,5,2015-08-14T22:56:00,,Direct,0.6014,D000255,ATP,D054537,AVB,"In all patients, ATP induced a long ventricular pause related to AVB (mean duration 13.2 s; range from 7 to 56 s).",24128810_6,24128810_D000255_D054537,,
770960788,false,true,5,2015-08-14T23:22:00,It's 'ATP test' and not just 'ATP',Direct,0.4044,D000255,ATP,D013575,syncope,"Some patients, predominantly older females, with 'normal' heart and ECG, have syncope associated with spontaneous AVB of unknown origin reproduced during the ATP test.",24128810_8,24128810_D000255_D013575,,
770960789,false,true,5,2015-08-14T22:37:00,,Direct,0.5903,D000255,ATP,D054537,AVB,"Some patients, predominantly older females, with 'normal' heart and ECG, have syncope associated with spontaneous AVB of unknown origin reproduced during the ATP test.",24128810_8,24128810_D000255_D054537,,
770960790,false,true,5,2015-08-14T23:14:00,,Direct,0.6298,D000255,ATP,D054537,AVB,This unusual behaviour could be interpreted as an abnormal susceptibility to ATP and these patients could be considered to have 'ATP-sensitive AVB'.,24128810_10,24128810_D000255_D054537,,
770960791,false,true,5,2015-08-14T23:30:00,,No Relation,1,C424423,Roflumilast,D029424,COPD,"Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.",24135893_0,24135893_C424423_D029424,,
770960792,false,true,5,2015-08-14T23:32:00,Used as treatment.,No Relation,1,C424423,Roflumilast,D029424,COPD,Roflumilast is the only oral phosphodiesterase 4 inhibitor indicated for use in the treatment of COPD.,24135893_1,24135893_C424423_D029424,,
770960793,false,true,5,2015-08-14T23:09:00,,No Relation,0.8174,C424423,roflumilast,D029424,COPD,"In a placebo-controlled, double-blind, parallel-group, multicenter, phase 3 study, patients of Chinese, Malay, and Indian ethnicity (N = 626) with severe to very severe COPD were randomized 1:1 to receive either roflumilast 500 _g once daily or placebo for 24 weeks.",24135893_4,24135893_C424423_D029424,,
770960794,false,true,5,2015-08-14T22:32:00,,Direct,1,C424423,roflumilast,D003967,diarrhea,"The most frequently reported treatment-related adverse event was diarrhea (6.0% and 1.0% of patients in the roflumilast and placebo groups, respectively).",24135893_10,24135893_C424423_D003967,,
770960795,false,true,5,2015-08-15T01:18:00,,No Relation,1,D005492,folate,C562799,folate deficiency,"The prevalence of biochemical folate deficiency, defined as plasma folate <6.8 nmol/L or erythrocyte folate <305 nmol/L, was 2%.",24174623_8,24174623_D005492_C562799,,
770960796,false,true,5,2015-08-14T22:35:00,,No Relation,1,D005492,folate,C562799,folate deficiency,The prevalence of biochemical folate deficiency in New Zealand adults is low.,24174623_10,24174623_D005492_C562799,,
770960797,false,true,5,2015-08-14T22:37:00,,Direct,1,D020058,styrene,C564013,ototoxic,"The ototoxic effect of the exposure to styrene is evaluated, also in the presence of simultaneous exposure to noise, using otoacoustic emissions as biomarkers of mild cochlear damage.",24180784_1,24180784_D020058_C564013,,
770960798,false,true,5,2015-08-15T02:18:00,,No Relation,0.8074,D020058,styrene,D006177,cochlear damage,"The ototoxic effect of the exposure to styrene is evaluated, also in the presence of simultaneous exposure to noise, using otoacoustic emissions as biomarkers of mild cochlear damage.",24180784_1,24180784_D020058_D006177,,
770960799,false,true,5,2015-08-15T01:58:00,,No Relation,1,C417083,pegylated-interferon,D006526,hepatitis C,"Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin.",24212839_2,24212839_C417083_D006526,,
770960800,false,true,5,2015-08-14T23:01:00,,No Relation,1,D012254,ribavirin,D006526,hepatitis C,"Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin.",24212839_2,24212839_D012254_D006526,,
770960801,false,true,5,2015-08-15T00:35:00,,Direct,0.5735,D044242,Trans fatty acids,D007249,inflammation,Trans fatty acids in diets act as a precipitating factor for gut inflammation?,24251700_0,24251700_D044242_D007249,,
770960802,false,true,5,2015-08-14T23:01:00,,No Relation,0.5893,D044242,TFAs,D003920,diabetes mellitus,"Although an increased report in the effects of the diet containing TFAs on a risk factor of metabolic syndrome, diabetes mellitus, and coronary heart disease has been observed in the recent years, influence on intestinal inflammation remains unknown.",24251700_4,24251700_D044242_D003920,,
770960803,false,true,5,2015-08-14T23:14:00,,Direct,1,D044242,TFAs,D003327,coronary heart disease,"Although an increased report in the effects of the diet containing TFAs on a risk factor of metabolic syndrome, diabetes mellitus, and coronary heart disease has been observed in the recent years, influence on intestinal inflammation remains unknown.",24251700_4,24251700_D044242_D003327,,
770960804,false,true,5,2015-08-14T23:35:00,,Direct,0.8031,D044242,TFAs,D008659,metabolic syndrome,"Although an increased report in the effects of the diet containing TFAs on a risk factor of metabolic syndrome, diabetes mellitus, and coronary heart disease has been observed in the recent years, influence on intestinal inflammation remains unknown.",24251700_4,24251700_D044242_D008659,,
770960805,false,true,5,2015-08-15T00:21:00,,No Relation,1,D044242,TFAs,D007249,inflammation,"Although an increased report in the effects of the diet containing TFAs on a risk factor of metabolic syndrome, diabetes mellitus, and coronary heart disease has been observed in the recent years, influence on intestinal inflammation remains unknown.",24251700_4,24251700_D044242_D007249,,
770960806,false,true,5,2015-08-14T22:59:00,,No Relation,0.5865,D044242,TFAs,D009422,systemic disorders,This review describes pro-inflammatory effects of TFAs in our diary diet on various systemic disorders and also discusses a possible role of TFAs on gut inflammation.,24251700_5,24251700_D044242_D009422,,
770960807,false,true,5,2015-08-15T02:49:00,,Direct,0.8043,D044242,TFAs,D007249,inflammation,This review describes pro-inflammatory effects of TFAs in our diary diet on various systemic disorders and also discusses a possible role of TFAs on gut inflammation.,24251700_5,24251700_D044242_D007249,,
770960808,false,true,5,2015-08-14T22:38:00,,No Relation,1,C551994,crizotinib,D002289,non-small cell lung cancer,Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.,24258622_0,24258622_C551994_D002289,,
770960809,false,true,5,2015-08-14T22:34:00,,No Relation,0.8055,C551994,crizotinib,D008223,anaplastic lymphoma,A total of 38 patients with stage IV anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who were treated with crizotinib were identified.,24258622_3,24258622_C551994_D008223,,
770960810,false,true,5,2015-08-14T22:40:00,,No Relation,1,C551994,crizotinib,D002289,non-small cell lung cancer,A total of 38 patients with stage IV anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who were treated with crizotinib were identified.,24258622_3,24258622_C551994_D002289,,
770960811,false,true,5,2015-08-14T22:59:00,,No Relation,1,C107135,everolimus,D009362,spinal cord metastasis,Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.,24276039_0,24276039_C107135_D009362,,
770960812,false,true,5,2015-08-15T00:15:00,,No Relation,0.5955,C107135,everolimus,D001254,Response of subependymal giant cell astrocytoma,Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.,24276039_0,24276039_C107135_D001254,,
770960813,false,true,5,2015-08-15T01:15:00,,No Relation,1,C107135,everolimus,D014402,tuberous sclerosis,Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus.,24276039_1,24276039_C107135_D014402,,
770960814,false,true,5,2015-08-14T23:19:00,Used as possible treatment.,No Relation,0.8008,C081309,irbesartan,D008382,Marfan syndrome,"A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.",24289736_0,24289736_C081309_D008382,,
770960815,false,true,5,2015-08-15T02:13:00,,No Relation,1,C081309,irbesartan,D001018,aortic dilatation,"A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.",24289736_0,24289736_C081309_D001018,,
770960816,false,true,5,2015-08-15T00:01:00,,No Relation,0.7962,C081309,irbesartan,D008382,Marfan syndrome,This trial will investigate the effects of irbesartan on aortic dilatation in Marfan syndrome.,24289736_5,24289736_C081309_D008382,,
770960817,false,true,5,2015-08-14T23:24:00,,No Relation,0.8187,C081309,irbesartan,D001018,aortic dilatation,This trial will investigate the effects of irbesartan on aortic dilatation in Marfan syndrome.,24289736_5,24289736_C081309_D001018,,
770960818,false,true,5,2015-08-15T00:08:00,,No Relation,1,C081309,irbesartan,D008382,MFS,This is the first clinical trial to evaluate the ARB irbesartan versus placebo in reducing the rate of aortic root dilatation in MFS.,24289736_12,24289736_C081309_D008382,,
770960819,false,true,5,2015-08-15T02:21:00,,No Relation,1,C081309,irbesartan,D001018,aortic root dilatation,This is the first clinical trial to evaluate the ARB irbesartan versus placebo in reducing the rate of aortic root dilatation in MFS.,24289736_12,24289736_C081309_D001018,,
770960820,false,true,5,2015-08-14T22:52:00,,No Relation,1,D019808,losartan,D020521,hypertensive stroke,"Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.",24296324_0,24296324_D019808_D020521,,
770960821,false,true,5,2015-08-14T22:37:00,,No Relation,0.8207,D017311,amlodipine,D020521,hypertensive stroke,"Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.",24296324_0,24296324_D017311_D020521,,
770960822,false,true,5,2015-08-15T01:54:00,,No Relation,0.6058,D019808,losartan,D020521,acute stroke,This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients.,24296324_2,24296324_D019808_D020521,,
770960823,false,true,5,2015-08-14T23:34:00,,No Relation,0.8121,D017311,amlodipine,D020521,acute stroke,This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients.,24296324_2,24296324_D017311_D020521,,
770960824,false,true,5,2015-08-14T23:14:00,,No Relation,1,D000305,corticosteroids,D004828,local or systemic corticosteroids,"Patients received no treatment, short-term (_1 year) treatment including local or systemic corticosteroids, or long-term (>1 year) treatment including systemic corticosteroids and second-line immunosuppressive agents.",24336967_5,24336967_D000305_D004828,,
770960825,false,true,5,2015-08-14T22:37:00,,No Relation,1,D019793,fluorescein,D002386,cataract,"Some clinical indices correlated with transient worse best-corrected visual acuity, including presence of cataract (P=.05), foveal leakage on fluorescein angiography (P=.04), and increased central retinal thickness (P=.02).",24336967_9,24336967_D019793_D002386,,
770960826,false,true,5,2015-08-14T23:43:00,,No Relation,1,D004317,doxorubicin,D000860,hypoxic,Here we characterize the spatial distribution and ability of TH-302 to selectively target hypoxic regions and complement the effect of doxorubicin and docetaxel by modifying biomarker distribution.,24338277_3,24338277_D004317_D000860,,
770960827,false,true,5,2015-08-14T23:42:00,,No Relation,1,C067311,docetaxel,D000860,hypoxic,Here we characterize the spatial distribution and ability of TH-302 to selectively target hypoxic regions and complement the effect of doxorubicin and docetaxel by modifying biomarker distribution.,24338277_3,24338277_C067311_D000860,,
770960828,false,true,5,2015-08-15T00:43:00,,No Relation,1,D004317,doxorubicin,D009369,tumors,Athymic nude mice bearing human breast MCF-7 or prostate PC-3 tumors were treated with doxorubicin or docetaxel respectively and TH-302 alone or in combination.,24338277_4,24338277_D004317_D009369,,
770960829,false,true,5,2015-08-15T00:58:00,,No Relation,1,C067311,docetaxel,D009369,tumors,Athymic nude mice bearing human breast MCF-7 or prostate PC-3 tumors were treated with doxorubicin or docetaxel respectively and TH-302 alone or in combination.,24338277_4,24338277_C067311_D009369,,
770960830,false,true,5,2015-08-14T23:03:00,,No Relation,1,C029652,DiOC7,D009369,tumor,"Biomarkers of drug effect including _H2aX (a marker of DNA damage), cleaved caspase-3 or -6 (markers of apoptosis) and reduction in Ki-67 (a marker of cell proliferation) were quantified in tumor sections in relation to functional blood vessels (recognized by DiOC7) and hypoxia (recognized by EF5) using immunohistochemistry.",24338277_5,24338277_C029652_D009369,,
770960831,false,true,5,2015-08-14T22:42:00,,No Relation,1,C029652,DiOC7,D000860,hypoxia,"Biomarkers of drug effect including _H2aX (a marker of DNA damage), cleaved caspase-3 or -6 (markers of apoptosis) and reduction in Ki-67 (a marker of cell proliferation) were quantified in tumor sections in relation to functional blood vessels (recognized by DiOC7) and hypoxia (recognized by EF5) using immunohistochemistry.",24338277_5,24338277_C029652_D000860,,
770960832,false,true,5,2015-08-15T02:06:00,,No Relation,1,D004317,doxorubicin,D000860,hypoxic,"_H2aX expression at 10 min and cleaved caspase-3 or -6 at 24 hr after doxorubicin or docetaxel decreased with increasing distance from tumor blood vessels, with minimal expression in hypoxic regions; maximum reduction in Ki67 levels was observed in regions closest to vasculature at 24 hr.",24338277_6,24338277_D004317_D000860,,
770960833,false,true,5,2015-08-15T01:41:00,,No Relation,1,C067311,docetaxel,D000860,hypoxic,"_H2aX expression at 10 min and cleaved caspase-3 or -6 at 24 hr after doxorubicin or docetaxel decreased with increasing distance from tumor blood vessels, with minimal expression in hypoxic regions; maximum reduction in Ki67 levels was observed in regions closest to vasculature at 24 hr.",24338277_6,24338277_C067311_D000860,,
770960834,false,true,5,2015-08-15T01:10:00,,No Relation,1,D004317,doxorubicin,D009369,tumor,"_H2aX expression at 10 min and cleaved caspase-3 or -6 at 24 hr after doxorubicin or docetaxel decreased with increasing distance from tumor blood vessels, with minimal expression in hypoxic regions; maximum reduction in Ki67 levels was observed in regions closest to vasculature at 24 hr.",24338277_6,24338277_D004317_D009369,,
770960835,false,true,5,2015-08-14T22:54:00,,No Relation,1,C067311,docetaxel,D009369,tumor,"_H2aX expression at 10 min and cleaved caspase-3 or -6 at 24 hr after doxorubicin or docetaxel decreased with increasing distance from tumor blood vessels, with minimal expression in hypoxic regions; maximum reduction in Ki67 levels was observed in regions closest to vasculature at 24 hr.",24338277_6,24338277_C067311_D009369,,
770960836,false,true,5,2015-08-14T22:33:00,,No Relation,1,D004317,doxorubicin,D009369,tumor,TH-302 given 4 hr before doxorubicin or docetaxel increased DNA damage and apoptosis throughout the tumor compared to chemotherapy alone.,24338277_8,24338277_D004317_D009369,,
770960837,false,true,5,2015-08-14T23:43:00,,No Relation,0.8017,C067311,docetaxel,D009369,tumor,TH-302 given 4 hr before doxorubicin or docetaxel increased DNA damage and apoptosis throughout the tumor compared to chemotherapy alone.,24338277_8,24338277_C067311_D009369,,
770960838,false,true,5,2015-08-14T23:57:00,,No Relation,1,D004317,doxorubicin,D000860,hypoxic,"When given with doxorubicin or docetaxel, TH-302 complements and enhances anticancer effects in both perivascular and hypoxic regions but also increases toxicity.",24338277_9,24338277_D004317_D000860,,
770960839,false,true,5,2015-08-15T00:04:00,,Direct,1,C067311,docetaxel,D064420,toxicity,"When given with doxorubicin or docetaxel, TH-302 complements and enhances anticancer effects in both perivascular and hypoxic regions but also increases toxicity.",24338277_9,24338277_C067311_D064420,,
770960840,false,true,5,2015-08-14T22:42:00,"Only when given with TH-302, making the third answer the best and the first answer the second-best.",Direct,0.8028,D004317,doxorubicin,D064420,toxicity,"When given with doxorubicin or docetaxel, TH-302 complements and enhances anticancer effects in both perivascular and hypoxic regions but also increases toxicity.",24338277_9,24338277_D004317_D064420,,
770960841,false,true,5,2015-08-14T22:57:00,,No Relation,1,C067311,docetaxel,D000860,hypoxic,"When given with doxorubicin or docetaxel, TH-302 complements and enhances anticancer effects in both perivascular and hypoxic regions but also increases toxicity.",24338277_9,24338277_C067311_D000860,,
770960842,false,true,5,2015-08-14T23:05:00,,No Relation,1,D004837,epinephrine,D011471,prostate cancer,Recent reports show that stress inhibits apoptosis in prostate cancer cells via epinephrine/beta2 adrenergic receptor/PKA/BAD pathway.,24339759_2,24339759_D004837_D011471,,
770960843,false,true,5,2015-08-15T02:30:00,,No Relation,1,C018511,paradichlorobenzene,D009103,Multiple sclerosis,Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner.,24343157_0,24343157_C018511_D009103,,
770960844,false,true,5,2015-08-15T01:00:00,,No Relation,1,D004317,adriamycin,D013274,gastric cancer,Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells.,24377601_0,24377601_D004317_D013274,,
770960845,false,true,5,2015-08-14T22:49:00,,No Relation,1,D000255,ATP,D013274,gastric cancer,Multiple drug resistance 1/P-glycoprotein (MDR1/p-gp) contributes to drug resistance via ATP-dependent drug efflux pumps and is overexpressed in many solid tumors including gastric cancer.,24377601_3,24377601_D000255_D013274,,
770960846,false,true,5,2015-08-15T01:25:00,,No Relation,1,D004317,ADR/adriamycin,D013274,gastric cancer,"To investigate the role of MDR1 knockdown on drug resistance reversal, we knocked down MDR1 expression using shRNA in drug resistant gastric cancer cells and examined the consequences with regard to adriamycin (ADR) accumulation and drug- sensitivity.",24377601_4,24377601_D004317_D013274,,
770960847,false,true,5,2015-08-15T00:59:00,,No Relation,1,D012293,Rifampicin,D014376,tuberculosis,Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.,24410906_0,24410906_D012293_D014376,,
770960848,false,true,5,2015-08-14T23:11:00,,No Relation,0.8181,D012293,Rifampicin,D014376,tuberculosis,Rifampicin resistance is a risk factor for poor outcome in tuberculosis.,24410906_1,24410906_D012293_D014376,,
770960849,false,true,5,2015-08-14T22:33:00,,No Relation,1,D012293,Rifampicin,D014376,TB/tuberculosis,"Therefore, we sought to describe the characteristics and management of Rifampicin monoresistant (RMR) tuberculosis (TB) in France.",24410906_2,24410906_D012293_D014376,,
770960850,false,true,5,2015-08-15T00:09:00,,No Relation,1,D000431,alcohol,D060085,HIV-coinfection,"A standardized questionnaire was used to collect basic demographic data, region of birth, history of TB, HIV-coinfection, alcohol use, and antituberculosis treatment.",24410906_4,24410906_D000431_D060085,,
770960851,false,true,5,2015-08-15T00:02:00,,No Relation,1,D000431,alcohol,D014376,TB,"A standardized questionnaire was used to collect basic demographic data, region of birth, history of TB, HIV-coinfection, alcohol use, and antituberculosis treatment.",24410906_4,24410906_D000431_D014376,,
770960852,false,true,5,2015-08-14T23:09:00,,No Relation,1,D000431,alcohol,D060085,HIV-coinfection,Patient with secondary RMR were more likely to have alcohol abuse (P = 0.04) and HIV-coinfection (p = 0.04).,24410906_8,24410906_D000431_D060085,,
770960853,false,true,5,2015-08-15T01:49:00,,No Relation,1,D000431,alcohol,D000437,alcohol abuse,Patient with secondary RMR were more likely to have alcohol abuse (P = 0.04) and HIV-coinfection (p = 0.04).,24410906_8,24410906_D000431_D000437,,
770960854,false,true,5,2015-08-15T02:33:00,,No Relation,1,D014975,lutein,D064420,toxicity,"A new dye for vitreoretinal surgery comprised of soluble lutein/zeaxanthin 1 % and brilliant blue 0.025 % is advantageous compared with other dyes currently used for chromovitrectomy, and showed no signs of toxicity at 1 month of follow-up.",24441951_1,24441951_D014975_D064420,,
770960855,false,true,5,2015-08-14T23:03:00,,No Relation,1,D014975,lutein,D019773,epiretinal membranes/ERM,"To evaluate the feasibility and safety of a dye [soluble lutein/zeaxanthin (LZ) 1 % and brilliant blue (BB) 0.025 %] for improving removal of vitreous, epiretinal membranes (ERM), and internal limiting membranes (ILM) in humans.",24441951_2,24441951_D014975_D019773,,
770960856,false,true,5,2015-08-14T22:48:00,,No Relation,1,C006796,brilliant blue,D019773,epiretinal membranes/ERM,"To evaluate the feasibility and safety of a dye [soluble lutein/zeaxanthin (LZ) 1 % and brilliant blue (BB) 0.025 %] for improving removal of vitreous, epiretinal membranes (ERM), and internal limiting membranes (ILM) in humans.",24441951_2,24441951_C006796_D019773,,
770960857,false,true,5,2015-08-14T22:52:00,,No Relation,1,C005881,zeaxanthin,D019773,epiretinal membranes/ERM,"To evaluate the feasibility and safety of a dye [soluble lutein/zeaxanthin (LZ) 1 % and brilliant blue (BB) 0.025 %] for improving removal of vitreous, epiretinal membranes (ERM), and internal limiting membranes (ILM) in humans.",24441951_2,24441951_C005881_D019773,,
770960858,false,true,5,2015-08-15T01:08:00,,Direct,0.5965,D019438,ritonavir,D014082,fracture,"Tenofovir, particularly when given with a ritonavir-boosted protease inhibitor (rPI), reduces bone mineral density (BMD) and increases bone turnover markers (BTMs), both of which are associated with increased fracture risk.",24460797_1,24460797_D019438_D014082,,
770960859,false,true,5,2015-08-15T01:16:00,,Direct,0.4136,C096918,Tenofovir,D014082,fracture,"Tenofovir, particularly when given with a ritonavir-boosted protease inhibitor (rPI), reduces bone mineral density (BMD) and increases bone turnover markers (BTMs), both of which are associated with increased fracture risk.",24460797_1,24460797_C096918_D014082,,
770960860,false,true,5,2015-08-14T22:41:00,,No Relation,1,C096918,tenofovir,D015658,HIV-infected,Switching virologically suppressed HIV-infected adults with low BMD taking an rPI from tenofovir to raltegravir was safe and significantly improved hip and spine BMD and reduced markers of bone turnover over 48 weeks.,24460797_13,24460797_C096918_D015658,,
770960861,false,true,5,2015-08-15T00:08:00,,No Relation,0.6004,D005680,GABA,D003643,neuronal death,GABA(A) receptor dephosphorylation followed by internalization is coupled to neuronal death in in vitro ischemia.,24513087_0,24513087_D005680_D003643,,
770960862,false,true,5,2015-08-14T22:49:00,,No Relation,0.8175,D005680,GABA,D007511,ischemia,GABA(A) receptor dephosphorylation followed by internalization is coupled to neuronal death in in vitro ischemia.,24513087_0,24513087_D005680_D007511,,
770960863,false,true,5,2015-08-14T22:30:00,,No Relation,1,D010100,oxygen,D000860,oxygen-glucose deprivation/OGD,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D010100_D000860,,
770960864,false,true,5,2015-08-15T00:18:00,,No Relation,1,D005680,GABA,D007511,ischemia,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D005680_D007511,,
770960865,false,true,5,2015-08-14T23:12:00,,No Relation,1,D005680,GABA,D000860,oxygen-glucose deprivation/OGD,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D005680_D000860,,
770960866,false,true,5,2015-08-15T02:01:00,,No Relation,1,D005947,glucose,D000860,oxygen-glucose deprivation/OGD,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D005947_D000860,,
770960867,false,true,5,2015-08-14T23:25:00,It's 'oxygen-glucose deprivation' and not just 'Glucose',No Relation,0.8006,D005947,glucose,D007511,ischemia,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D005947_D007511,,
770960868,false,true,5,2015-08-15T01:54:00,,No Relation,1,D010100,oxygen,D007511,ischemia,"Here we report a downregulation of GABA(A) receptor (GABA(A)R) expression, affecting both mRNA and protein levels of GABA(A)R subunits, in hippocampal neurons subjected to oxygen-glucose deprivation (OGD), an in vitro model of ischemia.",24513087_2,24513087_D010100_D007511,,
770960869,false,true,5,2015-08-14T23:17:00,,No Relation,1,D005680,GABA,D002545,brain ischemia,Similar alterations in the abundance of GABA(A)R subunits were observed in in vivo brain ischemia.,24513087_3,24513087_D005680_D002545,,
770960870,false,true,5,2015-08-15T00:03:00,,No Relation,1,D005680,GABA,D000860,OGD,"OGD reduced the interaction of surface GABA(A)R with the scaffold protein gephyrin, followed by clathrin-dependent receptor internalization.",24513087_4,24513087_D005680_D000860,,
770960871,false,true,5,2015-08-15T01:40:00,,No Relation,1,D005680,GABA,D007511,ischemic,Expression of phospho-mimetic mutant GABA(A)R _3 subunits prevented receptor internalization and protected hippocampal neurons from ischemic cell death.,24513087_6,24513087_D005680_D007511,,
770960872,false,true,5,2015-08-15T01:15:00,,Direct,0.5932,D005680,GABA,D003643,neuronal death,"The results show a key role for _3 GABA(A)R subunit dephosphorylation in the downregulation of GABAergic synaptic transmission in brain ischemia, contributing to neuronal death.",24513087_7,24513087_D005680_D003643,,
770960873,false,true,5,2015-08-14T23:13:00,'_3 GABA(A)R subunit' and not just 'GABA',No Relation,0.5885,D005680,GABA,D002545,brain ischemia,"The results show a key role for _3 GABA(A)R subunit dephosphorylation in the downregulation of GABAergic synaptic transmission in brain ischemia, contributing to neuronal death.",24513087_7,24513087_D005680_D002545,,
770960874,false,true,5,2015-08-15T01:47:00,,No Relation,1,D005680,GABA,D002545,brain ischemia,GABA(A)R phosphorylation might be a therapeutic target to preserve synaptic inhibition in brain ischemia.,24513087_8,24513087_D005680_D002545,,
770960875,false,true,5,2015-08-14T23:35:00,,No Relation,1,C045645,cilostazol,D008209,lymphedema,"In this study, we investigated whether cilostazol has the potential to proliferate lymphatic vessels and to improve lymphatic function using human lymphatic endothelial cells (LECs) and mouse lymphedema models.",24517869_3,24517869_C045645_D008209,,
770960876,false,true,5,2015-08-14T22:36:00,,No Relation,0.6165,C045645,cilostazol,D008209,lymphedema,"After oral administration of cilostazol, tail lymphedema was examined in this mouse model.",24517869_7,24517869_C045645_D008209,,
770960877,false,true,5,2015-08-15T00:25:00,,No Relation,1,C045645,cilostazol,D008209,lymphedema,Oral administration of cilostazol also decreased lymphedema in a tail of wild type mice.,24517869_11,24517869_C045645_D008209,,
770960878,false,true,5,2015-08-14T23:05:00,,No Relation,0.8069,C045645,Cilostazol,D008209,lymphedema,Cilostazol promoted growth of human LECs and improved lymph flow and lymphedema in two different mouse lymphedema models.,24517869_12,24517869_C045645_D008209,,
770960879,false,true,5,2015-08-14T23:40:00,,No Relation,1,C045645,cilostazol,D008209,lymphedema,These results suggest that cilostazol would be a promising agent for the treatment of lymphedema.,24517869_13,24517869_C045645_D008209,,
770960880,false,true,5,2015-08-14T23:11:00,,No Relation,0.8002,C445361,Restylane,D004342,hypersensitivity,No inflammatory or hypersensitivity reactions to Restylane occurred.,24529939_9,24529939_C445361_D004342,,
770960881,false,true,5,2015-08-14T22:56:00,,No Relation,1,C445361,Restylane,D004342,hypersensitivity,This represents the largest series to date using Restylane and no hypersensitivity or granulomatous reactions were observed.,24529939_12,24529939_C445361_D004342,,
770960882,false,true,5,2015-08-14T22:49:00,,No Relation,1,D005947,glucose,D008659,metabolic syndrome,"The broad-ranging effects of FXE may be due to a unique compositional profile that could be useful to prevent the metabolic syndrome, characterized by obesity, insulin resistance, glucose intolerance, hypertriglyceridemia and elevated blood pressure.",24573510_7,24573510_D005947_D008659,,
770960883,false,true,5,2015-08-15T00:59:00,,No Relation,1,D005947,glucose,D009765,obesity,"The broad-ranging effects of FXE may be due to a unique compositional profile that could be useful to prevent the metabolic syndrome, characterized by obesity, insulin resistance, glucose intolerance, hypertriglyceridemia and elevated blood pressure.",24573510_7,24573510_D005947_D009765,,
770960884,false,true,5,2015-08-14T22:44:00,,No Relation,1,D005947,glucose,D015228,hypertriglyceridemia,"The broad-ranging effects of FXE may be due to a unique compositional profile that could be useful to prevent the metabolic syndrome, characterized by obesity, insulin resistance, glucose intolerance, hypertriglyceridemia and elevated blood pressure.",24573510_7,24573510_D005947_D015228,,
770960885,false,true,5,2015-08-14T23:54:00,,No Relation,0.8205,D005947,glucose,D018149,glucose intolerance,"The broad-ranging effects of FXE may be due to a unique compositional profile that could be useful to prevent the metabolic syndrome, characterized by obesity, insulin resistance, glucose intolerance, hypertriglyceridemia and elevated blood pressure.",24573510_7,24573510_D005947_D018149,,
770960886,false,true,5,2015-08-14T22:47:00,,No Relation,1,D003907,dexamethasone,D020434,alveolar nerve,A solution of dexamethasone 4 mg/1 mL was drawn into a syringe and poured directly on the distal segment of the exposed inferior alveolar nerve during splitting and 1 mL was poured on the same nerve immediately before the start of fixation.,24576440_6,24576440_D003907_D020434,,
770960887,false,true,5,2015-08-15T02:42:00,,No Relation,1,D003907,dexamethasone,D020434,alveolar nerve,Local application of dexamethasone on the exposed inferior alveolar nerve during BSSO is not recommended.,24576440_10,24576440_D003907_D020434,,
770960888,false,true,5,2015-08-14T22:43:00,,Direct,1,D001241,aspirin,D012141,respiratory disease,Clinical course of patients with aspirin-exacerbated respiratory disease: can we predict the prognosis?,24624912_0,24624912_D001241_D012141,,
770960889,false,true,5,2015-08-14T23:33:00,,No Relation,0.6079,D001241,aspirin,D012141,respiratory disease,This study aimed to identify prognostic factors of aspirin-exacerbated respiratory disease by comparing clinical and genetic data with the clinical course.,24624912_1,24624912_D001241_D012141,,
770960890,false,true,5,2015-08-15T01:06:00,,Direct,0.7883,D001241,aspirin,D012141,respiratory disease,Baseline FEV and lower lung function after treatment were clinical factors indicating a poor prognosis of aspirin-exacerbated respiratory disease.,24624912_6,24624912_D001241_D012141,,
770960891,false,true,5,2015-08-14T23:30:00,,Direct,0.6118,D001241,aspirin,D008171,lower lung function,Baseline FEV and lower lung function after treatment were clinical factors indicating a poor prognosis of aspirin-exacerbated respiratory disease.,24624912_6,24624912_D001241_D008171,,
770960892,false,true,5,2015-08-15T02:14:00,,Direct,0.8137,D001241,aspirin,D004342,bronchial hypersensitivity,The G allele of CCR3 -520T>G was associated with persistent bronchial hypersensitivity to aspirin.,24624912_7,24624912_D001241_D004342,,
770960893,false,true,5,2015-08-14T22:42:00,,No Relation,0.7963,C055162,clopidogrel,D034381,Decreased MAADP,"Decreased MAADP (odds ratio [OR] 0.94), increased percent inhibition of platelets by clopidogrel (OR 1.03), and lower body mass index (BMI) (OR 0.78) were significantly associated with elevated CTD.",24630471_10,24630471_C055162_D034381,,
770960894,false,true,5,2015-08-15T01:34:00,,No Relation,1,D015282,octreotide,D002915,Chylous ascites,"Chylous ascites after a living-donor liver graft, effectively treated in a child with octreotide.",24635821_0,24635821_D015282_D002915,,
770960895,false,true,5,2015-08-15T01:47:00,,No Relation,1,D004164,bisphosphonates,D009362,metastasis,Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs.,24641358_0,24641358_D004164_D009362,,
770960896,false,true,5,2015-08-14T22:40:00,,No Relation,1,D004164,bisphosphonates,D009369,breast cancer,Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs.,24641358_0,24641358_D004164_D009369,,
770960897,false,true,5,2015-08-14T22:52:00,,Direct,0.8138,D002945,cisplatin,D004487,apoptotic cytotoxicity,"In lung cancer cells, knockdown of RIP1 substantially increased cisplatin-induced apoptotic cytotoxicity, which was associated with robust JNK activation.",24675421_3,24675421_D002945_D004487,,
770960898,false,true,5,2015-08-15T00:02:00,,No Relation,0.6242,D002945,cisplatin,D008175,lung cancer,"In lung cancer cells, knockdown of RIP1 substantially increased cisplatin-induced apoptotic cytotoxicity, which was associated with robust JNK activation.",24675421_3,24675421_D002945_D008175,,
770960899,false,true,5,2015-08-14T23:05:00,,Direct,0.5937,D002945,cisplatin,D004487,cytotoxicity,Knockdown of miR-940 restored MKP1 expression and attenuated cisplatin-induced JNK activation and cytotoxicity.,24675421_7,24675421_D002945_D004487,,
770960900,false,true,5,2015-08-14T22:32:00,,Direct,0.607,D002945,cisplatin,D004487,cytotoxicity,"Importantly, ectopic expression of MKP1 effectively attenuated cisplatin-induced JNK activation and cytotoxicity.",24675421_8,24675421_D002945_D004487,,
770960901,false,true,5,2015-08-15T02:23:00,,No Relation,1,D000111,NAC/N-acetylcysteine,D019966,substance abuse disorders,To conduct the first systematic literature review of clinical trials of N-acetylcysteine (NAC) for the treatment of substance abuse disorders and addictive behaviors.,24676047_1,24676047_D000111_D019966,,
770960902,false,true,5,2015-08-15T01:35:00,,No Relation,1,D000111,NAC/N-acetylcysteine,D001523,addictive behaviors,To conduct the first systematic literature review of clinical trials of N-acetylcysteine (NAC) for the treatment of substance abuse disorders and addictive behaviors.,24676047_1,24676047_D000111_D001523,,
770960903,false,true,5,2015-08-15T01:11:00,,No Relation,1,D000111,NAC,D001523,addictive behaviors,"The inclusion criteria for the review were clinical trials that used NAC in the treatment of a disorder related to substance use and/or addictive behaviors, limited to texts in English, Spanish, or French.",24676047_3,24676047_D000111_D001523,,
770960904,false,true,5,2015-08-14T22:33:00,,No Relation,1,D003042,cocaine,D002189,cannabis dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D003042_D002189,,
770960905,false,true,5,2015-08-15T02:57:00,,No Relation,1,D000111,NAC,D009293,addiction,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D000111_D009293,,
770960906,false,true,5,2015-08-14T23:37:00,Both terms being part of different diseases,No Relation,1,D008694,methamphetamine,D005715,pathological gambling,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D008694_D005715,,
770960907,false,true,5,2015-08-14T23:11:00,,No Relation,1,D008694,methamphetamine,D002189,cannabis dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D008694_D002189,,
770960908,false,true,5,2015-08-14T22:34:00,,No Relation,0.8045,D009538,nicotine,D019966,dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D009538_D019966,,
770960909,false,true,5,2015-08-14T23:42:00,"There might be a connection, abstract is suspenseful.",No Relation,0.6092,D000111,NAC,D005715,pathological gambling,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D000111_D005715,,
770960910,false,true,5,2015-08-15T02:29:00,,No Relation,1,D003042,cocaine,D005715,pathological gambling,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D003042_D005715,,
770960911,false,true,5,2015-08-14T23:53:00,,No Relation,0.8096,D000111,NAC,D019966,dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D000111_D019966,,
770960912,false,true,5,2015-08-15T01:58:00,,No Relation,1,D009538,nicotine,D002189,cannabis dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D009538_D002189,,
770960913,false,true,5,2015-08-14T23:15:00,,No Relation,1,D003042,cocaine,D009293,addiction,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D003042_D009293,,
770960914,false,true,5,2015-08-15T00:59:00,,No Relation,0.8102,D000111,NAC,D002189,cannabis dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D000111_D002189,,
770960915,false,true,5,2015-08-14T23:37:00,,No Relation,0.8105,D008694,methamphetamine,D019966,dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D008694_D019966,,
770960916,false,true,5,2015-08-14T23:35:00,,No Relation,1,D009538,nicotine,D005715,pathological gambling,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D009538_D005715,,
770960917,false,true,5,2015-08-14T22:31:00,,No Relation,0.6048,D009538,nicotine,D009293,addiction,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D009538_D009293,,
770960918,false,true,5,2015-08-14T23:17:00,,Direct,0.781,D003042,cocaine,D019966,dependence,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D003042_D019966,,
770960919,false,true,5,2015-08-14T23:03:00,,Direct,0.7896,D008694,methamphetamine,D009293,addiction,"These studies evaluated the role of NAC in cocaine dependence (three studies), cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction (one study), and pathological gambling (one study).",24676047_6,24676047_D008694_D009293,,
770960920,false,true,5,2015-08-15T02:13:00,,No Relation,1,D000111,NAC,D002189,cannabis dependence,"The studies analyzed suggest a potential role for NAC in the treatment of addiction, especially of cocaine and cannabis dependence.",24676047_8,24676047_D000111_D002189,,
770960921,false,true,5,2015-08-14T22:43:00,,No Relation,1,D003042,cocaine,D002189,cannabis dependence,"The studies analyzed suggest a potential role for NAC in the treatment of addiction, especially of cocaine and cannabis dependence.",24676047_8,24676047_D003042_D002189,,
770960922,false,true,5,2015-08-15T01:45:00,,No Relation,1,D000111,NAC,D009293,addiction,"The studies analyzed suggest a potential role for NAC in the treatment of addiction, especially of cocaine and cannabis dependence.",24676047_8,24676047_D000111_D009293,,
770960923,false,true,5,2015-08-14T23:51:00,,Direct,0.6075,D003042,cocaine,D009293,addiction,"The studies analyzed suggest a potential role for NAC in the treatment of addiction, especially of cocaine and cannabis dependence.",24676047_8,24676047_D003042_D009293,,
770960924,false,true,5,2015-08-15T01:11:00,,No Relation,1,D014640,vancomycin,D016470,bacteremia,Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci.,24679566_0,24679566_D014640_D016470,,
770960925,false,true,5,2015-08-15T01:34:00,,No Relation,1,D014640,vancomycin,D016470,bacteremia,This study aimed to evaluate a different methodology for addressing the evolution of nosocomial bacteremia by vancomycin-resistant enterococci (VRE) in a hospital setting.,24679566_1,24679566_D014640_D016470,,
770960926,false,true,5,2015-08-14T23:03:00,,No Relation,0.58,D014640,vancomycin,D016470,bacteremia,Thirty cases of VRE bacteremia and 274 cases of vancomycin-susceptible enterococci (VSE) bacteremia were identified.,24679566_3,24679566_D014640_D016470,,
770960927,false,true,5,2015-08-15T01:18:00,,No Relation,1,C548956,paliperidone palmitate,D006212,hallucinations,"Our study suggests that risperidone long-acting injection and paliperidone palmitate long-acting injection may be useful in the treatment of DD patients, specifically those with nonprominent hallucinations.",24681811_11,24681811_C548956_D006212,,
770960928,false,true,5,2015-08-15T01:14:00,,No Relation,1,D018967,risperidone,D006212,hallucinations,"Our study suggests that risperidone long-acting injection and paliperidone palmitate long-acting injection may be useful in the treatment of DD patients, specifically those with nonprominent hallucinations.",24681811_11,24681811_D018967_D006212,,
770960929,false,true,5,2015-08-14T23:02:00,,No Relation,0.7869,D005947,glucose,D003929,diabetes,We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with multiple daily insulin injection (MDI) therapy.,24716820_1,24716820_D005947_D003929,,
770960930,false,true,5,2015-08-15T01:43:00,,No Relation,1,D005947,glucose,D020773,multiple daily insulin injection/MDI,We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with multiple daily insulin injection (MDI) therapy.,24716820_1,24716820_D005947_D020773,,
770960931,false,true,5,2015-08-14T23:13:00,Used as treatment.,No Relation,1,C056493,imiquimod,D018327,LM,Reflectance confocal microscopy (RCM) is a noninvasive method that has not been validated for monitoring the treatment of LM with imiquimod.,24725478_2,24725478_C056493_D018327,,
770960932,false,true,5,2015-08-14T23:11:00,,No Relation,1,C056493,imiquimod,D018327,LM,We sought to evaluate the use of invivo RCM to accurately monitor the response of LM to nonsurgical treatment with topical imiquimod.,24725478_3,24725478_C056493_D018327,,
770960933,false,true,5,2015-08-14T22:53:00,,No Relation,1,C056493,imiquimod,D018327,LM,Invivo RCM evaluation was useful in accurately monitoring the response of LM to nonsurgical treatment with topical imiquimod in patients when surgery is contraindicated.,24725478_11,24725478_C056493_D018327,,
770960934,false,true,5,2015-08-15T00:46:00,,No Relation,1,C097613,imatinib,D046152,Gastrointestinal stromal tumor,"A PubMed search using the phrases 'Gastrointestinal stromal tumor', 'imatinib', 'c-kit'.",24749828_3,24749828_C097613_D046152,,
770960935,false,true,5,2015-08-15T01:23:00,,No Relation,1,D014859,warfarin,D011183,postoperative complications,"Three groups: continuation (CW), discontinuation (DW) and case-matched control (C) not on warfarin therapy were compared for operative details and postoperative complications.",24756918_5,24756918_D014859_D011183,,
770960936,false,true,5,2015-08-14T22:58:00,Used theraputically.,No Relation,0.5918,D014859,warfarin,D011183,postoperative complications,Maintenance of warfarin therapy during the perioperative period for open inguinal herniorrhaphy results in equivalent operative times and postoperative complications as discontinuation.,24756918_12,24756918_D014859_D011183,,
770960937,false,true,5,2015-08-15T00:01:00,,No Relation,1,C076946,donepezil,D000544,Alzheimer's disease,"Drugs that are used to treat Alzheimer's disease include the acetyl cholinesterase inhibitors (ACHIs) donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine.",24777654_1,24777654_C076946_D000544,,
770960938,false,true,5,2015-08-15T01:43:00,,No Relation,1,D005702,galantamine,D000544,Alzheimer's disease,"Drugs that are used to treat Alzheimer's disease include the acetyl cholinesterase inhibitors (ACHIs) donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine.",24777654_1,24777654_D005702_D000544,,
770960939,false,true,5,2015-08-15T01:15:00,,No Relation,1,D008559,memantine,D000544,Alzheimer's disease,"Drugs that are used to treat Alzheimer's disease include the acetyl cholinesterase inhibitors (ACHIs) donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine.",24777654_1,24777654_D008559_D000544,,
770960940,false,true,5,2015-08-15T00:38:00,,No Relation,1,C072506,rivastigmine,D000544,Alzheimer's disease,"Drugs that are used to treat Alzheimer's disease include the acetyl cholinesterase inhibitors (ACHIs) donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine.",24777654_1,24777654_C072506_D000544,,
770960941,false,true,5,2015-08-15T02:18:00,,No Relation,1,D016202,NMDA,D000544,Alzheimer's disease,"Drugs that are used to treat Alzheimer's disease include the acetyl cholinesterase inhibitors (ACHIs) donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine.",24777654_1,24777654_D016202_D000544,,
770960942,false,true,5,2015-08-14T22:51:00,,Direct,0.6221,D008559,memantine,D001919,bradycardia,Little is known about the cardiovascular effects of memantine but there have been reports of bradycardia and reduced cardiovascular survival associated with its use.,24777654_8,24777654_D008559_D001919,,
770960943,false,true,5,2015-08-14T23:43:00,,No Relation,1,D012459,salicylate,D001249,bronchial asthma,"It is the drug of choice in patients that cannot be treated with non-steroidal anti-inflammatory drugs (NSAID), such as people with bronchial asthma, peptic ulcer disease, hemophilia, salicylate-sensitized people, children under 12 years of age, pregnant or breastfeeding women.",24779190_2,24779190_D012459_D001249,,
770960944,false,true,5,2015-08-14T22:36:00,,No Relation,1,D012459,salicylate,D014456,ulcer disease,"It is the drug of choice in patients that cannot be treated with non-steroidal anti-inflammatory drugs (NSAID), such as people with bronchial asthma, peptic ulcer disease, hemophilia, salicylate-sensitized people, children under 12 years of age, pregnant or breastfeeding women.",24779190_2,24779190_D012459_D014456,,
770960945,false,true,5,2015-08-14T22:36:00,,No Relation,1,D012459,salicylate,D006467,hemophilia,"It is the drug of choice in patients that cannot be treated with non-steroidal anti-inflammatory drugs (NSAID), such as people with bronchial asthma, peptic ulcer disease, hemophilia, salicylate-sensitized people, children under 12 years of age, pregnant or breastfeeding women.",24779190_2,24779190_D012459_D006467,,
770960946,false,true,5,2015-08-15T02:29:00,,No Relation,1,C115070,ranirestat,D003929,diabetic neuropathy,Evaluation of ranirestat for the treatment of diabetic neuropathy.,24785785_0,24785785_C115070_D003929,,
770960947,false,true,5,2015-08-15T02:02:00,,No Relation,0.7877,C115070,ranirestat,D003929,diabetic,The objective of this evaluation is to summarize and provide expert opinion on the status of ranirestat with an emphasis on its pharmacokinetics in the context of its potential effects to prevent/treat diabetic complications.,24785785_5,24785785_C115070_D003929,,
770960948,false,true,5,2015-08-14T23:19:00,No connection is implied between the terms.,No Relation,1,C115070,ranirestat,D003929,diabetic neuropathy/diabetic,"A qualitative systematic literature search of PubMed through November 2013 using MeSH terms - aldose reductase inhibitors, diabetic neuropathy, AS-3201, ranirestat, diabetic complications and pharmacokinetics/pharmacodynamics - identified relevant publications limited to human and rodent (mouse and rat) and English-language studies.",24785785_6,24785785_C115070_D003929,,
770960949,false,true,5,2015-08-15T02:05:00,,No Relation,1,C115070,ranirestat,D001167,neuropathy,Trials in subjects with newly diagnosed neuropathy along with the identification of objective biomarkers/measurements of efficacy will be critical in identifying the real value and effect of ranirestat.,24785785_10,24785785_C115070_D001167,,
770960950,false,true,5,2015-08-14T23:30:00,,No Relation,0.7797,D006854,hydrocortisone,D003480,Cushing's syndrome,A high prevalence of psychological morbidity and maladaptive personality as well as impaired quality of life (QoL) is observed in patients with and without hydrocortisone dependency following (cured) Cushing's syndrome.,24801589_1,24801589_D006854_D003480,,
770960951,false,true,5,2015-08-14T23:05:00,,Direct,0.6096,D006854,hydrocortisone,D009771,compulsivity,"However, there was a strong and consistent positive association between the daily hydrocortisone dose and prevalence of maladaptive personality traits (i.e. identity problems, cognitive distortion, compulsivity, restricted expression, callousness, oppositionality, rejection, conduct problems, social avoidance, narcissism, and insecure attachment, all P<0.05).",24801589_8,24801589_D006854_D009771,,
770960952,false,true,5,2015-08-15T00:53:00,,Direct,0.622,D006854,hydrocortisone,D003072,cognitive distortion,"However, there was a strong and consistent positive association between the daily hydrocortisone dose and prevalence of maladaptive personality traits (i.e. identity problems, cognitive distortion, compulsivity, restricted expression, callousness, oppositionality, rejection, conduct problems, social avoidance, narcissism, and insecure attachment, all P<0.05).",24801589_8,24801589_D006854_D003072,,
770960953,false,true,5,2015-08-14T22:51:00,,Direct,0.8061,D006854,hydrocortisone,D003866,depression,"There was also a strong relation between the mean daily hydrocortisone dose and both psychological morbidity (i.e. depression, P<0.05) and QoL impairments (i.e. general health perception, several measures of physical functioning, and vitality, all P<0.05).",24801589_9,24801589_D006854_D003866,,
770960954,false,true,5,2015-08-15T02:05:00,,Direct,0.5914,D006854,hydrocortisone,D034381,QoL impairments,"There was also a strong relation between the mean daily hydrocortisone dose and both psychological morbidity (i.e. depression, P<0.05) and QoL impairments (i.e. general health perception, several measures of physical functioning, and vitality, all P<0.05).",24801589_9,24801589_D006854_D034381,,
770960955,false,true,5,2015-08-15T02:33:00,,Direct,1,D011078,Polychlorinated biphenyls/PCBs,D065626,NAFLD/non-alcoholic fatty liver disease,"Polychlorinated biphenyls (PCBs) are persistent environmental toxicants, present in 100% ofU.S. adults and dose-dependently associated with obesity and non-alcoholic fatty liver disease (NAFLD).",24812009_1,24812009_D011078_D065626,,
770960956,false,true,5,2015-08-15T00:21:00,,Direct,1,D011078,Polychlorinated biphenyls/PCBs,D009765,obesity,"Polychlorinated biphenyls (PCBs) are persistent environmental toxicants, present in 100% ofU.S. adults and dose-dependently associated with obesity and non-alcoholic fatty liver disease (NAFLD).",24812009_1,24812009_D011078_D009765,,
770960957,false,true,5,2015-08-14T23:15:00,,No Relation,0.7974,D011078,PCBs,D065626,NAFLD,PCBs are predicted to interact with receptors previously implicated in xenobiotic/energy metabolism and NAFLD.,24812009_2,24812009_D011078_D065626,,
770960958,false,true,5,2015-08-14T22:53:00,,No Relation,1,C026987,Aroclor 1260,D006528,hepatoma,"This study evaluates Aroclor 1260, a PCB mixture with congener composition mimicking that of human adipose tissue, and selected congeners, as potential ligands for these receptors utilizing human hepatoma-derived (HepG2) and primate-derived (COS-1) cell lines, and primary human hepatocytes.",24812009_4,24812009_C026987_D006528,,
770960959,false,true,5,2015-08-14T23:43:00,,No Relation,0.8024,C511514,Poly-SNO-HSA,D009369,tumors,We have previously demonstrated that poly-nitric oxide (NO) conjugated human serum albumin (Poly-SNO-HSA) has the potential to be a DDS carrier capable of accumulating NO in tumors.,24846171_2,24846171_C511514_D009369,,
770960960,false,true,5,2015-08-15T02:21:00,,No Relation,1,C511514,Poly-SNO-HSA,D009369,tumor,"We observed that pegylation enhanced the stability of Poly-SNO-HSA both in vitro and in vivo, and that dimerization of Poly-SNO-HSA enhanced the antitumor activity via more efficient delivery of NO in Colon 26 tumor-bearing mice.",24846171_5,24846171_C511514_D009369,,
770960961,false,true,5,2015-08-14T23:05:00,,No Relation,1,C511514,Poly-SNO-HSA,D009369,tumors,"These data suggest that pegylation and dimerization of Poly-SNO-HSA are very important tuners to optimize NO stability and accumulation, and thereby effect, in tumors.",24846171_7,24846171_C511514_D009369,,
770960962,false,true,5,2015-08-14T22:31:00,,No Relation,1,D011092,polyethylene glycol,D009369,cancer,"Thus, polyethylene glycol-Poly-SNO-HSA dimer seems to be a very appealing and safe NO carrier and thereby a strong candidate as an antitumor drug in future development of cancer therapeutics.",24846171_8,24846171_D011092_D009369,,
770960963,false,true,5,2015-08-14T23:11:00,,No Relation,1,C511514,Poly-SNO-HSA,D009369,cancer,"Thus, polyethylene glycol-Poly-SNO-HSA dimer seems to be a very appealing and safe NO carrier and thereby a strong candidate as an antitumor drug in future development of cancer therapeutics.",24846171_8,24846171_C511514_D009369,,
770960964,false,true,5,2015-08-15T00:38:00,,No Relation,1,D005231,PUFAs,D050197,atherosclerosis,The beneficial effects of fish and n-3 polyunsaturated fatty acids (PUFAs) consumption on atherosclerosis have been reported in numerous epidemiological studies.,24850465_1,24850465_D005231_D050197,,
770960965,false,true,5,2015-08-14T23:01:00,,No Relation,0.8154,D005231,PUFAs,D003920,T2DM,Twenty-three postmenopausal women with T2DM were assigned to two four-week periods of either a fish-based diet (n-3 PUFAs  3.0 g/day) or a control diet in a randomized crossover design.,24850465_4,24850465_D005231_D003920,,
770960966,false,true,5,2015-08-14T23:48:00,,No Relation,1,D005227,fatty acids,D006940,hyperemia,Endothelial function was measured with reactive hyperemia using strain-gauge plethysmography and compared with the serum levels of fatty acids and their metabolites.,24850465_5,24850465_D005227_D006940,,
770960967,false,true,5,2015-08-14T23:53:00,,No Relation,0.6106,D018943,Anthracyclines,D066126,cardiotoxicity,"Anthracyclines are important anticancer drugs, but their use is limited by acute and chronic cardiotoxicity.",24862616_1,24862616_D018943_D066126,,
770960968,false,true,5,2015-08-14T22:57:00,,Direct,0.4128,D018943,anthracycline,D066126,cardiotoxicity,We assessed whether early 3D-strain analysis could predict later anthracycline-induced cardiotoxicity.,24862616_5,24862616_D018943_D066126,,
770960969,false,true,5,2015-08-15T00:23:00,,Direct,1,D018943,anthracycline,D066126,cardiotoxicity,"Cumulative anthracycline dose at 12 weeks, LVEF, 3DGLS and TnT were predictors of the later development of cardiotoxicity on univariate logistic regression.",24862616_11,24862616_D018943_D066126,,
770960970,false,true,5,2015-08-15T01:27:00,,Direct,1,D018943,anthracycline,D066126,cardiotoxicity,3DGLS seems to be a good predictor of the future development of anthracycline-induced cardiotoxicity.,24862616_14,24862616_D018943_D066126,,
770960971,false,true,5,2015-08-15T02:49:00,,No Relation,1,C540278,enzalutamide,D011471,prostate cancer,The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment.,25048254_1,25048254_C540278_D011471,,
770960972,false,true,5,2015-08-14T22:41:00,,No Relation,1,C089740,abiraterone,D011471,prostate cancer,The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment.,25048254_1,25048254_C089740_D011471,,
770960973,false,true,5,2015-08-15T02:33:00,,No Relation,1,D000728,androgen,D013734,AR/androgen receptor,"Both drugs were designed to further suppress androgen receptor (AR) signaling, which is restored following first-line androgen deprivation therapies.",25048254_2,25048254_D000728_D013734,,
770960974,false,true,5,2015-08-15T01:53:00,,No Relation,0.8037,C540278,enzalutamide,D013734,AR,"Resistance to enzalutamide and abiraterone, however, is again marked by a return of AR signaling, indicating a remarkable ""addiction"" of prostate cancer cells to the AR pathway.",25048254_3,25048254_C540278_D013734,,
770960975,false,true,5,2015-08-14T23:15:00,,No Relation,0.6144,C089740,abiraterone,D013734,AR,"Resistance to enzalutamide and abiraterone, however, is again marked by a return of AR signaling, indicating a remarkable ""addiction"" of prostate cancer cells to the AR pathway.",25048254_3,25048254_C089740_D013734,,
770960976,false,true,5,2015-08-14T22:51:00,,No Relation,1,C540278,enzalutamide,D011471,prostate cancer,"Resistance to enzalutamide and abiraterone, however, is again marked by a return of AR signaling, indicating a remarkable ""addiction"" of prostate cancer cells to the AR pathway.",25048254_3,25048254_C540278_D011471,,
770960977,false,true,5,2015-08-15T01:56:00,,No Relation,1,C089740,abiraterone,D011471,prostate cancer,"Resistance to enzalutamide and abiraterone, however, is again marked by a return of AR signaling, indicating a remarkable ""addiction"" of prostate cancer cells to the AR pathway.",25048254_3,25048254_C089740_D011471,,
770960978,false,true,5,2015-08-14T23:58:00,,No Relation,1,C540278,enzalutamide,D013734,AR/androgen receptor,"Among these, the androgen receptor splice variants (AR-Vs), particularly variant 7 (AR-V7), have been implicated in resistance to enzalutamide and abiraterone in preclinical studies, and they cannot be targeted by currently available AR-directed drugs.",25048254_5,25048254_C540278_D013734,,
770960979,false,true,5,2015-08-15T00:17:00,,No Relation,1,C089740,abiraterone,D013734,AR/androgen receptor,"Among these, the androgen receptor splice variants (AR-Vs), particularly variant 7 (AR-V7), have been implicated in resistance to enzalutamide and abiraterone in preclinical studies, and they cannot be targeted by currently available AR-directed drugs.",25048254_5,25048254_C089740_D013734,,
770960980,false,true,5,2015-08-15T00:21:00,,No Relation,1,D000728,androgen,D013734,AR/androgen receptor,"Among these, the androgen receptor splice variants (AR-Vs), particularly variant 7 (AR-V7), have been implicated in resistance to enzalutamide and abiraterone in preclinical studies, and they cannot be targeted by currently available AR-directed drugs.",25048254_5,25048254_D000728_D013734,,
770960981,false,true,5,2015-08-14T23:00:00,,No Relation,1,C089740,abiraterone,D013734,AR/androgen receptor,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_C089740_D013734,,
770960982,false,true,5,2015-08-14T22:33:00,,No Relation,1,D000728,androgen,D011471,prostate cancer,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_D000728_D011471,,
770960983,false,true,5,2015-08-14T23:22:00,,No Relation,1,C540278,enzalutamide,D011471,prostate cancer,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_C540278_D011471,,
770960984,false,true,5,2015-08-14T23:34:00,,No Relation,1,C540278,enzalutamide,D013734,AR/androgen receptor,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_C540278_D013734,,
770960985,false,true,5,2015-08-14T23:43:00,,No Relation,1,C089740,abiraterone,D011471,prostate cancer,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_C089740_D011471,,
770960986,false,true,5,2015-08-15T01:50:00,,No Relation,1,D000728,androgen,D013734,AR/androgen receptor,"In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.",25048254_7,25048254_D000728_D013734,,
770960987,false,true,5,2015-08-15T00:46:00,,No Relation,0.8048,D015725,fluconazole,D058387,candidemia,"Prior exposure to fluconazole before candidemia (22.3 vs. 11.6 %, p < 0.001) and fungemia due to Candida glabrata (13.1 vs. 7.8 %, p = 0.03) were more frequent in period 2, as was the proportion of patients receiving an echinocandin as primary therapy (18.0 vs. 5.9 %, p < 0.001).",25082359_5,25082359_D015725_D058387,,
770960988,false,true,5,2015-08-14T22:36:00,,No Relation,1,D015725,fluconazole,D016469,fungemia,"Prior exposure to fluconazole before candidemia (22.3 vs. 11.6 %, p < 0.001) and fungemia due to Candida glabrata (13.1 vs. 7.8 %, p = 0.03) were more frequent in period 2, as was the proportion of patients receiving an echinocandin as primary therapy (18.0 vs. 5.9 %, p < 0.001).",25082359_5,25082359_D015725_D016469,,
770960989,false,true,5,2015-08-14T23:17:00,,No Relation,1,D054714,echinocandins,D058387,candidemia,The use of echinocandins as primary therapy for candidemia appears to be associated with better outcomes.,25082359_9,25082359_D054714_D058387,,
770960990,false,true,5,2015-08-15T00:13:00,,No Relation,1,C504072,carbosilane,D015658,HIV,Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides.,25114528_0,25114528_C504072_D015658,,
770960991,false,true,5,2015-08-15T01:20:00,,No Relation,1,C504072,carbosilane,D015658,HIV,"Thereby, new nanosystems, such as carbosilane dendrimers, have been shown to be safe and effective compounds against HIV with great potential as topical microbicides.",25114528_5,25114528_C504072_D015658,,
770960992,false,true,5,2015-08-15T01:16:00,,No Relation,1,C504072,carbosilane,D015658,HIV-1 infection,We evaluated various combinations of anionic carbosilane dendrimers with sulfated (G3-S16) and naphthyl sulfonated (G2-NF16) ended groups with different ARVs against HIV-1 infection.,25114528_7,25114528_C504072_D015658,,
770960993,false,true,5,2015-08-14T23:33:00,,No Relation,1,C096918,tenofovir,D015658,HIV,"The G3-S16 and G2-NF16 dendrimers showed a synergistic or additive activity profile with zidovudine, efavirenz, and tenofovir in the majority of the combinations tested against the X4 and R5 tropic HIV-1 in cell lines, as well as in human primary cells.",25114528_8,25114528_C096918_D015658,,
770960994,false,true,5,2015-08-14T22:54:00,,No Relation,1,D015215,zidovudine,D015658,HIV,"The G3-S16 and G2-NF16 dendrimers showed a synergistic or additive activity profile with zidovudine, efavirenz, and tenofovir in the majority of the combinations tested against the X4 and R5 tropic HIV-1 in cell lines, as well as in human primary cells.",25114528_8,25114528_D015215_D015658,,
770960995,false,true,5,2015-08-15T00:48:00,,No Relation,1,C098320,efavirenz,D015658,HIV,"The G3-S16 and G2-NF16 dendrimers showed a synergistic or additive activity profile with zidovudine, efavirenz, and tenofovir in the majority of the combinations tested against the X4 and R5 tropic HIV-1 in cell lines, as well as in human primary cells.",25114528_8,25114528_C098320_D015658,,
770960996,false,true,5,2015-08-14T22:49:00,,No Relation,1,C504072,carbosilane,D015658,HIV,"Therefore, the combination of ARVs and polyanionic carbosilane dendrimers enhances the antiviral potency of the individual compounds, and our findings support further clinical research on combinational approaches as potential microbicides to block the sexual transmission of HIV-1.",25114528_9,25114528_C504072_D015658,,
770960997,false,true,5,2015-08-14T22:47:00,,Direct,0.8049,C400082,Bortezomib,D001925,encephalopathy,Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.,25130124_0,25130124_C400082_D001925,,
770960998,false,true,5,2015-08-15T00:06:00,,Direct,1,C400082,bortezomib,D054038,PRES,We herein present a case of PRES that occurred after 33 days of high-dose bortezomib treatment and propose both overwhelmed cerebral autoregulation and toxin-mediated blood-brain barrier damage as the underlying mechanisms based on the imaging findings.,25130124_2,25130124_C400082_D054038,,
770960999,false,true,5,2015-08-15T00:40:00,,No Relation,1,C400082,bortezomib,D006973,hypertension,A favorable recovery was observed two days after achieving stringent hypertension control and withholding bortezomib.,25130124_3,25130124_C400082_D006973,,
770961000,false,true,5,2015-08-14T22:50:00,,No Relation,0.6069,C400082,bortezomib,D054038,PRES,"With explicit clinical and imaging features, this case highlights the need for early recognition of PRES during the clinical course of bortezomib therapy.",25130124_5,25130124_C400082_D054038,,
770961001,false,true,5,2015-08-15T00:31:00,,No Relation,1,D003520,cyclophosphamide,D006086,graft-versus-host disease,Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.,25267759_0,25267759_D003520_D006086,,
770961002,false,true,5,2015-08-15T01:46:00,,No Relation,0.7904,C024352,fludarabine,D006086,graft-versus-host disease,Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.,25267759_0,25267759_C024352_D006086,,
770961003,false,true,5,2015-08-14T22:40:00,,No Relation,1,D002066,busulfan,D006086,graft-versus-host disease,Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.,25267759_0,25267759_D002066_D006086,,
770961004,false,true,5,2015-08-14T22:34:00,,No Relation,0.7946,D002066,busulfan,D006086,graft-versus-host disease/GVHD,"The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies.",25267759_1,25267759_D002066_D006086,,
770961005,false,true,5,2015-08-15T00:26:00,,No Relation,1,C024352,fludarabine,D006086,graft-versus-host disease/GVHD,"The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies.",25267759_1,25267759_C024352_D006086,,
770961006,false,true,5,2015-08-14T22:53:00,,No Relation,1,D003520,cyclophosphamide,D006086,graft-versus-host disease/GVHD,"The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies.",25267759_1,25267759_D003520_D006086,,
770961007,false,true,5,2015-08-15T01:13:00,,Direct,0.7943,C009250,sevoflurane,D014474,unconsciousness,Neurophysiological correlates of sevoflurane-induced unconsciousness.,25296108_0,25296108_C009250_D014474,,
770961008,false,true,5,2015-08-15T01:44:00,,Direct,1,D015742,propofol,D014474,unconsciousness,Recent studies of anesthetic-induced unconsciousness in humans have focused predominantly on the intravenous drug propofol and have identified anterior dominance of alpha rhythms and frontal phase-amplitude coupling patterns as neurophysiological markers.,25296108_1,25296108_D015742_D014474,,
770961009,false,true,5,2015-08-15T00:01:00,,Direct,1,D015742,propofol,D014474,unconsciousness,"However, it is unclear whether the correlates of propofol-induced unconsciousness are generalizable to inhaled anesthetics, which have distinct molecular targets and which are used more commonly in clinical practice.",25296108_2,25296108_D015742_D014474,,
770961010,false,true,5,2015-08-14T22:37:00,,Direct,0.6106,C009250,sevoflurane,D014474,unconsciousness,"The authors recorded 64-channel electroencephalograms in healthy human participants during consciousness, sevoflurane-induced unconsciousness, and recovery (n = 10; n = 7 suitable for analysis).",25296108_3,25296108_C009250_D014474,,
770961011,false,true,5,2015-08-15T00:44:00,,Direct,0.5975,C009250,sevoflurane,D014474,unconsciousness,"At concentrations sufficient for unconsciousness, sevoflurane did not result in a consistent anteriorization of alpha power; the relationship between low-frequency phase and alpha amplitude in the frontal cortex did not undergo characteristic transitions.",25296108_6,25296108_C009250_D014474,,
770961012,false,true,5,2015-08-14T22:42:00,,Direct,0.6055,C009250,sevoflurane,D014474,unconsciousness,"Furthermore, a reversible disruption of anterior-posterior phase relationships in the alpha bandwidth was identified as a correlate of sevoflurane-induced unconsciousness.",25296108_8,25296108_C009250_D014474,,
770961013,false,true,5,2015-08-14T22:48:00,,No Relation,1,C009250,sevoflurane,D006316,cross-frequency patterns,"In humans, sevoflurane-induced unconsciousness is not correlated with anteriorization of alpha and related cross-frequency patterns, but rather by a disruption of phase-amplitude coupling in the parietal region and phase-phase relationships across the cortex.",25296108_9,25296108_C009250_D006316,,
770961014,false,true,5,2015-08-15T02:01:00,,Direct,0.6064,C009250,sevoflurane,D014474,unconsciousness,"In humans, sevoflurane-induced unconsciousness is not correlated with anteriorization of alpha and related cross-frequency patterns, but rather by a disruption of phase-amplitude coupling in the parietal region and phase-phase relationships across the cortex.",25296108_9,25296108_C009250_D014474,,
770961015,false,true,5,2015-08-14T22:46:00,,Direct,0.8042,D024505,tocopherol,D007249,inflammation,Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular risk.,25313576_0,25313576_D024505_D007249,,
770961016,false,true,5,2015-08-14T22:56:00,,No Relation,0.7894,D024505,tocopherol,D007249,inflammation,"In the present study, we examined the relationship between dietary patterns, circulating carotenoid and tocopherol concentrations, and biomarkers of chronic low-grade systemic inflammation in a 10-year longitudinal study of Scottish postmenopausal women.",25313576_2,25313576_D024505_D007249,,
770961017,false,true,5,2015-08-15T01:03:00,,No Relation,1,D024505,tocopherols,C567296,carotenoids,"Diet was assessed by FFQ (n 1682) and blood was collected for the analysis of serum high-sensitivity C-reactive protein (hs-CRP), IL-6, serum amyloid A, E-selectin, lipid profile and dietary biomarkers (carotenoids, tocopherols and retinol).",25313576_5,25313576_D024505_C567296,,
770961018,false,true,5,2015-08-14T23:02:00,,No Relation,1,D014801,retinol,C567296,carotenoids,"Diet was assessed by FFQ (n 1682) and blood was collected for the analysis of serum high-sensitivity C-reactive protein (hs-CRP), IL-6, serum amyloid A, E-selectin, lipid profile and dietary biomarkers (carotenoids, tocopherols and retinol).",25313576_5,25313576_D014801_C567296,,
770961019,false,true,5,2015-08-15T01:56:00,,Direct,0.5808,D016202,N-methyl-D-aspartate,D003072,cognitive impairment,Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis.,25384024_0,25384024_D016202_D003072,,
770961020,false,true,5,2015-08-14T23:36:00,,No Relation,1,D016202,N-methyl-D-aspartate,D009103,multiple sclerosis,Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis.,25384024_0,25384024_D016202_D009103,,
770961021,false,true,5,2015-08-14T23:08:00,,No Relation,1,D003520,cyclophosphamide,D003072,cognitive deficits,"Treatment with different immunotherapies, including cyclophosphamide and natalizumab, did not improve her cognitive deficits, necessitating admission to a nursing home at age 39 years.",25384024_4,25384024_D003520_D003072,,
770961022,false,true,5,2015-08-14T22:42:00,,No Relation,1,D016202,N-methyl-D-aspartate,D004660,encephalitis,"During a thorough reevaluation at age 43 years, analysis of current and stored cerebrospinal fluid and serum samples demonstrated an intrathecal synthesis of IgG antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor, that is, the characteristic laboratory finding of anti-N-methyl-D-aspartate receptor encephalitis.",25384024_5,25384024_D016202_D004660,,
770961023,false,true,5,2015-08-14T23:23:00,,No Relation,1,D008942,mitoxantrone,D003072,cognitive impairment,"Although the patient initially stabilized under therapy with corticosteroids, plasma exchange, and mitoxantrone, severe cognitive impairment persisted and she eventually died from the sequelae of her disease.",25384024_6,25384024_D008942_D003072,,
770961024,false,true,5,2015-08-14T23:05:00,,No Relation,1,D008942,mitoxantrone,D006013,her disease,"Although the patient initially stabilized under therapy with corticosteroids, plasma exchange, and mitoxantrone, severe cognitive impairment persisted and she eventually died from the sequelae of her disease.",25384024_6,25384024_D008942_D006013,,
770961025,false,true,5,2015-08-14T22:48:00,,No Relation,0.7942,D000305,corticosteroids,D003072,cognitive impairment,"Although the patient initially stabilized under therapy with corticosteroids, plasma exchange, and mitoxantrone, severe cognitive impairment persisted and she eventually died from the sequelae of her disease.",25384024_6,25384024_D000305_D003072,,
770961026,false,true,5,2015-08-15T01:35:00,,No Relation,1,D000305,corticosteroids,D006013,her disease,"Although the patient initially stabilized under therapy with corticosteroids, plasma exchange, and mitoxantrone, severe cognitive impairment persisted and she eventually died from the sequelae of her disease.",25384024_6,25384024_D000305_D006013,,
770961027,false,true,5,2015-08-15T01:45:00,,No Relation,1,D017294,ondansetron,D004630,ED/emergency department,"To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes).",25454931_1,25454931_D017294_D004630,,
770961028,false,true,5,2015-08-15T00:20:00,,No Relation,1,D017294,ondansetron,D003922,T1DM/type 1 diabetes mellitus,"To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes).",25454931_1,25454931_D017294_D003922,,
770961029,false,true,5,2015-08-14T23:03:00,,No Relation,1,D017294,ondansetron,D005067,illness,"To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes).",25454931_1,25454931_D017294_D005067,,
770961030,false,true,5,2015-08-15T01:51:00,,No Relation,0.8098,D017294,ondansetron,D014839,vomiting,"To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes).",25454931_1,25454931_D017294_D014839,,
770961031,false,true,5,2015-08-14T22:37:00,ED stands for Emergency Department and therefore shouldn't be a disease. :-),No Relation,0.802,D017294,Ondansetron,D004630,ED,Ondansetron usage increased from 0% to 67% of ED encounters between 2002 and 2011.,25454931_5,25454931_D017294_D004630,,
770961032,false,true,5,2015-08-14T22:38:00,,No Relation,1,D017294,ondansetron,D003922,T1DM,"Over time, along with increasing ondansetron use, there have been reductions in admissions, length of stay, and IVF administration in children with T1DM.",25454931_12,25454931_D017294_D003922,,
770961033,false,true,5,2015-08-15T00:36:00,,No Relation,1,D007213,indomethacin,D010195,pancreatitis,Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?.,25474427_0,25474427_D007213_D010195,,
770961034,false,true,5,2015-08-15T01:59:00,,No Relation,1,D007213,indomethacin,D006470,bleeding,Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?.,25474427_0,25474427_D007213_D006470,,
770961035,false,true,5,2015-08-15T01:16:00,,No Relation,1,D007213,indomethacin,D010195,pancreatitis,Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP) but its impact on bleeding after biliary sphincterotomy (BABES) and cardiovascular mortality has not been extensively studied.,25474427_2,25474427_D007213_D010195,,
770961036,false,true,5,2015-08-14T23:40:00,,No Relation,0.8137,D007213,indomethacin,D006470,bleeding,Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP) but its impact on bleeding after biliary sphincterotomy (BABES) and cardiovascular mortality has not been extensively studied.,25474427_2,25474427_D007213_D006470,,
770961037,false,true,5,2015-08-14T23:35:00,,Direct,0.5759,D003474,curcumin,D012509,Ras,Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells.,25492214_0,25492214_D003474_D012509,,
770961038,false,true,5,2015-08-14T23:02:00,,No Relation,0.5932,D003474,curcumin,C535607,AGS,Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells.,25492214_0,25492214_D003474_C535607,,
770961039,false,true,5,2015-08-14T22:33:00,,No Relation,1,D003474,curcumin,D013272,gastric carcinoma,Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells.,25492214_0,25492214_D003474_D013272,,
770961040,false,true,5,2015-08-15T01:04:00,,No Relation,0.6214,D003474,Curcumin,D013272,gastric carcinoma,"Curcumin, the biologically active compound from the rhizome of Curcuma longa, could inhibit cell growth and induce apoptosis in gastric carcinoma.",25492214_1,25492214_D003474_D013272,,
770961041,false,true,5,2015-08-14T23:02:00,,No Relation,1,D003474,curcumin,D013272,gastric carcinoma,"However, the underlying mechanism of curcumin on gastric carcinoma cells still needs further investigation.",25492214_2,25492214_D003474_D013272,,
770961042,false,true,5,2015-08-15T00:00:00,,No Relation,0.7843,D003474,curcumin,C535607,AGS,"In this study, morphological observation indicated that curcumin inhibited the proliferation of AGS cells in a dose-dependent manner.",25492214_3,25492214_D003474_C535607,,
770961043,false,true,5,2015-08-14T22:59:00,,No Relation,0.7989,D003474,curcumin,C535607,AGS,"According to the flow cytometric analysis, curcumin treatment resulted in G2/M arrest in AGS cells, accompanied with an increased expression of cyclin B1 and a decreased expression of cyclin D1.",25492214_4,25492214_D003474_C535607,,
770961044,false,true,5,2015-08-15T00:41:00,,No Relation,1,D003474,curcumin,C535607,AGS,"Meanwhile, the activities of caspase-3, -8, and -9 were also enhanced in curcumin-treated AGS cells.",25492214_6,25492214_D003474_C535607,,
770961045,false,true,5,2015-08-15T00:48:00,,Direct,0.5885,D003474,curcumin,D012509,rat sarcoma/Ras,"Furthermore, downregulation of rat sarcoma (Ras) and upregulation of extracellular-signal-regulated kinase (ERK) were also observed in AGS cells treated with curcumin by Western blot.",25492214_8,25492214_D003474_D012509,,
770961046,false,true,5,2015-08-15T01:42:00,,No Relation,1,D003474,curcumin,C535607,AGS,"Furthermore, downregulation of rat sarcoma (Ras) and upregulation of extracellular-signal-regulated kinase (ERK) were also observed in AGS cells treated with curcumin by Western blot.",25492214_8,25492214_D003474_C535607,,
770961047,false,true,5,2015-08-14T22:54:00,,No Relation,0.801,D003474,curcumin,D012509,Ras,"The results suggested that curcumin inhibited the growth of the AGS cells and induced apoptosis through the activation of Ras/ERK signaling pathway and downstream caspase cascade, and curcumin might be a potential target for the treatment of gastric carcinoma.",25492214_10,25492214_D003474_D012509,,
770961048,false,true,5,2015-08-15T00:34:00,,No Relation,1,D003474,curcumin,C535607,AGS,"The results suggested that curcumin inhibited the growth of the AGS cells and induced apoptosis through the activation of Ras/ERK signaling pathway and downstream caspase cascade, and curcumin might be a potential target for the treatment of gastric carcinoma.",25492214_10,25492214_D003474_C535607,,
770961049,false,true,5,2015-08-14T23:10:00,"Not sure on this one, there is connection, but i lack medical knowledge to determine is it cause of cure.",No Relation,0.7812,D003474,curcumin,D013272,gastric carcinoma,"The results suggested that curcumin inhibited the growth of the AGS cells and induced apoptosis through the activation of Ras/ERK signaling pathway and downstream caspase cascade, and curcumin might be a potential target for the treatment of gastric carcinoma.",25492214_10,25492214_D003474_D013272,,
770961050,false,true,5,2015-08-15T00:00:00,,No Relation,1,D000666,amphotericin B,D007898,Indian visceral leishmaniasis,Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.,25510715_0,25510715_D000666_D007898,,
770961051,false,true,5,2015-08-15T02:18:00,,No Relation,1,D000666,amphotericin B,D007898,visceral leishmaniasis,Liposomal amphotericin B is an effective and safe alternative for the treatment of visceral leishmaniasis in the Indian subcontinent.,25510715_1,25510715_D000666_D007898,,
770961052,false,true,5,2015-08-15T01:22:00,,No Relation,1,C060506,sphingosine-1-phosphate,D011695,allergic,The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses.,25512083_0,25512083_C060506_D011695,,
770961053,false,true,5,2015-08-14T22:55:00,,No Relation,0.8042,C060506,sphingosine-1-phosphate,D011695,allergic,We used a highly specific neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JTE-013 to study the signaling contributions of S1P and S1PR2 to MC- and IgE-dependent airway allergic responses in mice within minutes after antigen challenge.,25512083_3,25512083_C060506_D011695,,
770961054,false,true,5,2015-08-14T22:56:00,,No Relation,1,C471998,JTE-013,D011695,allergic,We used a highly specific neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JTE-013 to study the signaling contributions of S1P and S1PR2 to MC- and IgE-dependent airway allergic responses in mice within minutes after antigen challenge.,25512083_3,25512083_C471998_D011695,,
770961055,false,true,5,2015-08-14T23:13:00,,No Relation,1,D004967,estrogen,D006560,labial adhesions,Comparison of estrogen and betamethasone in the topical treatment of labial adhesions in prepubertal girls.,25552168_0,25552168_D004967_D006560,,
770961056,false,true,5,2015-08-14T23:37:00,,No Relation,1,D001623,betamethasone,D006560,labial adhesions,Comparison of estrogen and betamethasone in the topical treatment of labial adhesions in prepubertal girls.,25552168_0,25552168_D001623_D006560,,
770961057,false,true,5,2015-08-14T22:55:00,,No Relation,1,D004967,estrogen,D006560,labial adhesions,To compare estrogen and betamethasone in the topical treatment of labial adhesions in prepubertal girls.,25552168_1,25552168_D004967_D006560,,
770961058,false,true,5,2015-08-14T22:51:00,,No Relation,1,D001623,betamethasone,D006560,labial adhesions,To compare estrogen and betamethasone in the topical treatment of labial adhesions in prepubertal girls.,25552168_1,25552168_D001623_D006560,,
770961059,false,true,5,2015-08-14T22:42:00,,No Relation,1,D001623,Betamethasone,D006560,labial adhesions,Betamethasone cream with petroleum ointment is a safe and effective primary therapy for prepubertal labial adhesions.,25552168_9,25552168_D001623_D006560,,
770961060,false,true,5,2015-08-14T22:59:00,,No Relation,1,C065179,atorvastatin,D058729,peripheral arterial disease,High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.,25595417_0,25595417_C065179_D058729,,
770961061,false,true,5,2015-08-15T01:48:00,,No Relation,1,D019821,simvastatin,D058729,peripheral arterial disease,High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.,25595417_0,25595417_D019821_D058729,,
770961062,false,true,5,2015-08-14T23:37:00,,No Relation,1,C065179,atorvastatin,D009203,myocardial infarction,"In the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial, 8888 post-myocardial infarction patients were randomised to high-dose or usual-dose statin therapy (atorvastatin 80mg/day vs simvastatin 20-40mg/day).",25595417_2,25595417_C065179_D009203,,
770961063,false,true,5,2015-08-14T23:05:00,,No Relation,1,D019821,simvastatin,D009203,myocardial infarction,"In the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial, 8888 post-myocardial infarction patients were randomised to high-dose or usual-dose statin therapy (atorvastatin 80mg/day vs simvastatin 20-40mg/day).",25595417_2,25595417_D019821_D009203,,
770961064,false,true,5,2015-08-15T01:57:00,,No Relation,1,D019821,statins,D058729,PAD,"We investigated the effect of high-dose versus usual-dose statins on the pre-specified outcome PAD incidence, and additionally performed a posthoc analysis of the efficacy of high-dose statins in reducing CVD risk among patients with PAD.",25595417_3,25595417_D019821_D058729,,
770961065,false,true,5,2015-08-14T23:34:00,,No Relation,1,D019821,statins,D002318,CVD,"We investigated the effect of high-dose versus usual-dose statins on the pre-specified outcome PAD incidence, and additionally performed a posthoc analysis of the efficacy of high-dose statins in reducing CVD risk among patients with PAD.",25595417_3,25595417_D019821_D002318,,
770961066,false,true,5,2015-08-15T00:14:00,,No Relation,0.5882,C065179,atorvastatin,D058729,PAD,"During a median follow-up of 4.8years, 94 patients (2.2%) receiving atorvastatin and 135 patients (3.2%) receiving simvastatin developed PAD (HR=0.70, 95% CI 0.53 to 0.91; p=0.007).",25595417_4,25595417_C065179_D058729,,
770961067,false,true,5,2015-08-15T01:18:00,,Direct,1,D019821,simvastatin,D058729,PAD,"During a median follow-up of 4.8years, 94 patients (2.2%) receiving atorvastatin and 135 patients (3.2%) receiving simvastatin developed PAD (HR=0.70, 95% CI 0.53 to 0.91; p=0.007).",25595417_4,25595417_D019821_D058729,,
770961068,false,true,5,2015-08-14T23:36:00,,No Relation,1,C065179,atorvastatin,D058729,PAD,"In PAD patients, major coronary events occurred in fewer patients in the atorvastatin group (14.4%) than in the simvastatin group (20.1%), but the difference did not reach statistical significance.",25595417_6,25595417_C065179_D058729,,
770961069,false,true,5,2015-08-14T22:49:00,,No Relation,1,D019821,simvastatin,D058729,PAD,"In PAD patients, major coronary events occurred in fewer patients in the atorvastatin group (14.4%) than in the simvastatin group (20.1%), but the difference did not reach statistical significance.",25595417_6,25595417_D019821_D058729,,
770961070,false,true,5,2015-08-15T02:15:00,,No Relation,1,C065179,atorvastatin,D058729,PAD,High-dose statin therapy with atorvastatin significantly reduced the incidence of PAD compared with usual-dose statin therapy with simvastatin.,25595417_9,25595417_C065179_D058729,,
770961071,false,true,5,2015-08-14T22:59:00,,No Relation,1,D019821,simvastatin,D058729,PAD,High-dose statin therapy with atorvastatin significantly reduced the incidence of PAD compared with usual-dose statin therapy with simvastatin.,25595417_9,25595417_D019821_D058729,,
770961072,false,true,5,2015-08-14T23:51:00,,No Relation,1,C065179,atorvastatin,D058729,PAD,Patients with a history of PAD at baseline were at higher risk of future coronary events and this risk was reduced by high-dose atorvastatin treatment.,25595417_10,25595417_C065179_D058729,,
770961073,false,true,5,2015-08-14T23:15:00,,No Relation,0.8151,D008691,methadone,D010146,pain,Out-of-hospital mortality among patients receiving methadone for noncancer pain.,25599329_0,25599329_D008691_D010146,,
770961074,false,true,5,2015-08-14T23:43:00,,No Relation,1,D008691,methadone,D010146,pain,Growing methadone use in pain management has raised concerns regarding its safety relative to other long-acting opioids.,25599329_1,25599329_D008691_D010146,,
770961075,false,true,5,2015-08-15T02:19:00,,Direct,0.7835,D008691,Methadone hydrochloride,D001145,ventricular arrhythmias,Methadone hydrochloride may increase the risk for lethal respiratory depression related to accidental overdose and life-threatening ventricular arrhythmias.,25599329_2,25599329_D008691_D001145,,
770961076,false,true,5,2015-08-15T01:48:00,,No Relation,0.6184,D008691,Methadone hydrochloride,D062787,overdose,Methadone hydrochloride may increase the risk for lethal respiratory depression related to accidental overdose and life-threatening ventricular arrhythmias.,25599329_2,25599329_D008691_D062787,,
770961077,false,true,5,2015-08-15T00:04:00,,Direct,1,D008691,Methadone hydrochloride,D012131,respiratory depression,Methadone hydrochloride may increase the risk for lethal respiratory depression related to accidental overdose and life-threatening ventricular arrhythmias.,25599329_2,25599329_D008691_D012131,,
770961078,false,true,5,2015-08-15T01:14:00,,No Relation,1,D008691,methadone,D010146,pain,To compare the risk of out-of-hospital death in patients receiving methadone for noncancer pain with that in comparable patients receiving sustained-release (SR) morphine sulfate.,25599329_3,25599329_D008691_D010146,,
770961079,false,true,5,2015-08-15T01:53:00,,No Relation,0.6142,D008691,methadone,D003643,death,To compare the risk of out-of-hospital death in patients receiving methadone for noncancer pain with that in comparable patients receiving sustained-release (SR) morphine sulfate.,25599329_3,25599329_D008691_D003643,,
770961080,false,true,5,2015-08-14T23:45:00,,No Relation,1,D008691,methadone,D009369,cancer,"The cohort included patients receiving morphine SR or methadone who were aged 30 to 74 years, did not have cancer or another life-threatening illness, and were not in a hospital or nursing home.",25599329_5,25599329_D008691_D009369,,
770961081,false,true,5,2015-08-14T23:13:00,'Did not' being the key term.,No Relation,1,D009020,morphine,D009369,cancer,"The cohort included patients receiving morphine SR or methadone who were aged 30 to 74 years, did not have cancer or another life-threatening illness, and were not in a hospital or nursing home.",25599329_5,25599329_D009020_D009369,,
770961082,false,true,5,2015-08-14T23:03:00,,Direct,1,D008691,methadone,D003643,death,"After control for study covariates, patients receiving methadone had a 46% increased risk of death during the follow-up period, with an adjusted hazard ratio (HR) of 1.46 (95% CI, 1.17-1.83; P<.001), resulting in 72 (95% CI, 27-130) excess deaths per 10000 person-years of follow-up.",25599329_12,25599329_D008691_D003643,,
770961083,false,true,5,2015-08-14T22:55:00,,No Relation,0.8046,D009020,morphine,D003643,death,"Methadone doses of 20 mg/d or less, the lowest dose quartile, were associated with an increased risk of death (HR,1.59; 95% CI, 1.01-2.51, P=.046) relative to a comparable dose of morphine SR (<60 mg/d).",25599329_13,25599329_D009020_D003643,,
770961084,false,true,5,2015-08-15T00:34:00,,Direct,1,D008691,Methadone,D003643,death,"Methadone doses of 20 mg/d or less, the lowest dose quartile, were associated with an increased risk of death (HR,1.59; 95% CI, 1.01-2.51, P=.046) relative to a comparable dose of morphine SR (<60 mg/d).",25599329_13,25599329_D008691_D003643,,
770961085,false,true,5,2015-08-14T22:40:00,,No Relation,0.7974,D008691,methadone,D010146,pain,"The increased risk of death observed for patients receiving methadone in this retrospective cohort study, even for low doses, supports recommendations that it should not be a drug of first choice for noncancer pain.",25599329_14,25599329_D008691_D010146,,
770961086,false,true,5,2015-08-15T01:49:00,,Direct,1,D008691,methadone,D003643,death,"The increased risk of death observed for patients receiving methadone in this retrospective cohort study, even for low doses, supports recommendations that it should not be a drug of first choice for noncancer pain.",25599329_14,25599329_D008691_D003643,,
770961087,false,true,5,2015-08-15T02:12:00,,No Relation,1,D014443,tyrosine,D008175,lung cancer,Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.,25701783_0,25701783_D014443_D008175,,
770961088,false,true,5,2015-08-14T22:35:00,,No Relation,1,D002945,cisplatin,D008175,lung cancer,Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.,25701783_0,25701783_D002945_D008175,,
770961089,false,true,5,2015-08-14T22:33:00,,No Relation,1,D002945,cisplatin,D009369,cancer,"We therefore introduce a potential combinatorial therapy composed of p38 inhibition and cisplatin to block the activation of EGFR, therefore inducing cancer cell death and apoptosis.",25701783_6,25701783_D002945_D009369,,
770961090,false,true,5,2015-08-15T00:55:00,,No Relation,1,D002945,cisplatin,D003643,death,"We therefore introduce a potential combinatorial therapy composed of p38 inhibition and cisplatin to block the activation of EGFR, therefore inducing cancer cell death and apoptosis.",25701783_6,25701783_D002945_D003643,,
